[
    {
        "id": "5bc844fc-e852-4270-bfaf-36ea9eface3d",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "statement_text": "All the primary trial participants do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  in conrast all the secondary trial subjects receive these ",
        "statement_nums": [
            "IV  in conrast all the secondary trial subjects receive these",
            "All the primary trial participants do not receive"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Diagnostic (FLT PET) Patients with early stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan  Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo FLT PET Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen  INTERVENTION 1: Arm A Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO INTERVENTION 2: Arm B ",
            "Patients receive capecitabine and lapatinib ditosylate as in arm I  Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  cixutumumab: Given IV  lapatinib ditosylate: Given PO and capecitabine: Given PO"
        ],
        "premise_nums": [
            "stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start",
            "PO and capecitabine: Given PO INTERVENTION 2: Arm B",
            "Analysis: Correlative studies - Ki67 staining of the tumor tissue in the",
            "once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in",
            "emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo",
            "endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan",
            "oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on"
        ]
    },
    {
        "id": "86b7cb3d-6186-4a04-9aa6-b174ab764eed",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial",
            "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 4 to 5 grams per deciliter are eligible"
        ],
        "label": "Contradiction",
        "premise_text": [
            "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL "
        ],
        "premise_nums": [
            "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL"
        ]
    },
    {
        "id": "dbed5471-c2fc-45b5-b26f-430c9fa37a37",
        "primaryId": "NCT00093145",
        "secondaryId": "NCT00703326",
        "statement_text": "Heart-related adverse events were recorded in both the primary trial and the secondary trial ",
        "statement_nums": [
            "recorded in both the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction 0/752 (0.00%) "
        ],
        "premise_nums": [
            "(3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction",
            "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac"
        ]
    },
    {
        "id": "20c35c89-8d23-4be3-b603-ac0ee0f3b4de",
        "primaryId": "NCT01097642",
        "statement_text": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial ",
        "statement_nums": [
            "breast carcinoma (T1 N1 M1) are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients with histologic confirmation of invasive breast carcinoma  Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast cancer are eligible  "
        ],
        "premise_nums": [
            "Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast"
        ]
    },
    {
        "id": "f17cb242-419d-4f5d-bfa4-41494ed5ac0e",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "statement_text": "Laser Therapy is in each cohort of the primary trial and the secondary trial  along with neoadjuvant chemotherapy ",
        "statement_nums": [
            "each cohort of the primary trial and the secondary trial  along with neoadjuvant"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  INTERVENTION 2: Part B Abemaciclib: HR+  HER2- Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET)  Participants may continue to receive treatment until discontinuation criteria are met  "
        ],
        "premise_nums": [
            "treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual",
            "200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as",
            "HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle",
            "drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was",
            "A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of",
            "receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every"
        ]
    },
    {
        "id": "fc5c4554-7ce9-4c16-b374-a3cd9d15b021",
        "primaryId": "NCT00971945",
        "secondaryId": "NCT01027416",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "to participate in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study Inclusion Criteria: The patient must consent to be in the study and must have signed an approved consent form conforming to institutional guidelines The patient must be 18 years or older  Core biopsy should definitively demonstrate invasive carcinoma  Invasive carcinoma should be ER-apha receptor positive The tumor should be approximately at least 1 cm  to account for variability in imaging and imaging occult disease (physical exam  mammography  ultrasound)  We recognize that from time to time because of this variation  there might not be enough tissue available for analysis after surgical excision but this will allow the greatest opportunity to capture as many eligible patients as possible  Patients in whom surgical excision of the tumor is part of standard of care management ECOG score of 0 or 1 Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery) Consent to participate in DBBR (RPCI only) Exclusion Criteria: ",
            "Male patients are not eligible for this studyFemale patients with inoperable tumors or women with stage 4 disease diagnosed on CT  PET  PET/CT or bone scan  Patients with diagnosis by FNA cytology only Pregnant or lactating women Prior therapy for breast cancer  including irradiation  chemo- immuno- and/or hormonal therapy Patients receiving any hormonal therapy  e.g  ovarian hormonal replacement therapy  infertility medications etc.  are not eligible Nonmalignant systemic disease (cardiovascular  renal  hepatic  etc.) that would preclude the patient from being subjected to surgical excision Psychiatric or addictive disorders that would preclude obtaining informed consent Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis  stroke  TIA  or pulmonary embolism Women with non-invasive disease or microinvasion are not eligible  Women undergoing neoadjuvant chemotherapy are not eligible women currently on tamoxifen and raloxifene for prevention are not eligible Patients shall not receive any herbal/alternative therapies such as flaxseed or soy products or black cohosh  Patients with a known mutation in p53 (Li Fraumeni Syndrome) "
        ],
        "premise_nums": [
            "of care management ECOG score of 0 or 1 Negative serum or urine beta-hCG",
            "excision but this will allow the greatest opportunity to",
            "inoperable tumors or women with stage 4 disease diagnosed on CT  PET",
            "are not eligible Patients shall not receive any herbal/alternative therapies",
            "tumor should be approximately at least 1 cm  to account for",
            "institutional guidelines The patient must be 18 years or older  Core biopsy should"
        ]
    },
    {
        "id": "96b77cdd-aa9f-4770-8447-8a04d9ca5da7",
        "primaryId": "NCT00633750",
        "statement_text": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial ",
        "statement_nums": [
            "Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed axillary lymph node metastases (N2) "
        ],
        "premise_nums": [
            "stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed"
        ]
    },
    {
        "id": "c73faed2-371b-4238-bf7d-293fae380203",
        "primaryId": "NCT00003404",
        "secondaryId": "NCT00711529",
        "statement_text": "the primary trial and the secondary trial have Hypnotherapy based interventions  the secondary trial also used pain medication in its intervention ",
        "statement_nums": [
            "the primary trial and the secondary trial have Hypnotherapy based interventions"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Adjuvant Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision  Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  "
        ],
        "premise_nums": [
            "Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the",
            "Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision",
            "the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)",
            "the study will undergo individually three one-hour sessions with"
        ]
    },
    {
        "id": "8765009d-ffc4-4395-ab7a-11ecdfd43a40",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial",
        "statement_nums": [
            "breast cancer with an ECOG of 0, she is eligible for the primary",
            "woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal "
        ],
        "premise_nums": [
            "Must be female with histologically confirmed breast cancer Stage",
            "and/or PR positive ECOG Performance Status 0-1 Postmenopausal"
        ]
    },
    {
        "id": "0ad7293d-df35-42e8-881d-f2afc3f7d3fd",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of brachytherapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "Only patients in the primary trial receive 40.5 Gy of brachytherapy  patients in the",
            "in the primary trial receive 40.5 Gy of brachytherapy  patients in the secondary trial receive no radiotherapy whatsoever"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  "
        ],
        "premise_nums": [
            "to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity",
            "Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform",
            "Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7"
        ]
    },
    {
        "id": "83b83400-1439-462d-bba3-42817b5b1fa1",
        "primaryId": "NCT00777049",
        "statement_text": "Most of the cases of CHF in the primary trial  were in cohort 1.",
        "statement_nums": [
            "of CHF in the primary trial  were in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%)"
        ]
    },
    {
        "id": "17a821f8-5e68-4bf7-ac01-3f96ddfc5187",
        "primaryId": "NCT02964234",
        "statement_text": "Patients eligible for the primary trial must live in the USA ",
        "statement_nums": [
            "Patients eligible for the primary trial must live in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence in Pilsen  Little Village  East Side or South Chicago; "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence"
        ]
    },
    {
        "id": "d76d6c7f-ba39-483c-a89e-152af5ae2878",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT ",
        "statement_nums": [
            "Patients in group 1 of the secondary trial and the primary trial do not receive the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) "
        ],
        "premise_nums": [
            "to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity",
            "injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity",
            "Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform",
            "Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7"
        ]
    },
    {
        "id": "65f3e755-3e23-4e84-a218-87922759094d",
        "primaryId": "NCT01669343",
        "secondaryId": "NCT00146172",
        "statement_text": "the primary trial administers letrozole for 28 days  whereas the secondary trial administers is intervention over 4 cycles of 21 days ",
        "statement_nums": [
            "secondary trial administers is intervention over 4 cycles of 21 days  whereas the secondary trial administers is intervention over"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Post-menopausal Women Using Adjuvant Letrozole Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  Part B In overweight/obese participants who completed Part A  provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd",
            "standard of care letrozole use for 28 days; measure blood levels of"
        ]
    },
    {
        "id": "d3590771-806b-4754-a455-38113bfedfca",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate colon and liver function  and must not be currently receiving amiodarone or have received amiodarone in the last 28 day  Renal function is not relevant for inclusion ",
        "statement_nums": [
            "Candidates for the primary trial must have adequate colon",
            "have received amiodarone in the last 28 day  Renal function is"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: The following criteria are to be checked at the time of study entry  The patients may only be included in the study if ALL of the following statements are FULLFILLED: The patient (male or female) is at least 18 years old at the time of signature of the informed consent form  Written informed consent has been obtained from the patient prior to the performance of any protocol-specific procedure  The patient is diagnosed with confirmed invasive breast cancer with stage IV disease  Note: If the metastatic disease is restricted to a solitary lesion  its neoplastic nature should be confirmed by cytology or histology  The patient has documented disease progression or relapse following at least one prior standard therapy with trastuzumab (alone or in combination with chemotherapy)  Patients with prior lapatinib use are eligible  Furthermore  The administration of the chemotherapeutic agent(s) should have been stopped for at least 28 days by the time of the first ASCI administration  The administration of trastuzumab alone could be maintained after chemotherapy  but the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration  ",
            "The patient will not be given trastuzumab during the trial For metastatic patients whose disease is ER+ and/or PR+ the following criteria should be met: Patients with visceral disease that requires chemotherapy (eg.  patients with liver or lung metastases)  Rapidly progressing or life threatening disease  as determined by the investigator  Patients who received hormonal therapy and are no longer benefiting from this therapy  A tumor lesion from the patient biopsied before or during screening shows either: Overexpression of the HER2 protein  as determined by immunohistochemistry (IHC  with result IHC 3+) or Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e  at least 8 copies)  Note: Overexpression/amplification measurements must be performed on a metastatic lesion in all cases where such a lesion is sufficiently easily accessible  If however such a biopsy is not possible  then these measurements can be performed on the primary tumor  Use of the primary tumor is to be documented and justified  ",
            "Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification has been done -if available-may be requested  These may be used to retrospectively carry out part of the translational research (i.e  analysis of EGF receptor activity and of the presence of immune effector cells  refer to Section 7).The patient has at least one measurable lesion according to RECIST criteria  The patient has ECOG status of 0 or 1. The patient has adequate bone marrow reserve as indicated by: White blood cell count greater than /= 3,000/mm3. Neutrophil count greater than /= 1,500/mm3. Platelet count greater than /= 100,000/mm3. Hemoglobin levels greater than /= 10.0 g/dl  The patient has adequate renal function as shown by the creatinine levels (i.e  within the normal range)  The patient has adequate hepatic function as shown by serum bilirubin levels i.e: Serum bilirubin levels within the normal limits  ",
            "Both AST and ALT levels smaller than 1.5 times the ULN  Note: However  for patients with liver metastasis  a serum bilirubin level smaller than 1.5 times the ULN and both AST and ALT levels smaller than 3 times the ULN will be accepted The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility  If the patient is female  she must be of non-childbearing potential  i.e  have a current tubal ligation  hysterectomy  ovariectomy or be post-menopausal  or if she is of childbearing potential  she must practice adequate contraception for 30 days prior to treatment  have a negative pregnancy test and continue such precautions for two months after completion of the study treatment  ",
            "Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable  as mentioned in the product label) for example abstinence  combined or progestogen oral contraceptives  injectable progestogen  implants of levonorgestrel  oestrogenic vaginal ring  percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS)  vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent) For azoospermia  \"documented\" refers to the outcome of the investigator's/ designee's medical examination of the subject or review of the subject's medical history for study eligibility  as obtained via a verbal interview with the subject or from the subject's medical records  ",
            "Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles  menses  and implies the loss of reproductive potential by ovarian failure  A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g  greater than 45 years Able to swallow and retain oral medication  In the view of the investigator  the patient can and will comply with the requirements of the protocol  Exclusion Criteria: The following criteria should be checked at the time of study entry  If any apply  the patient must not be included in the study: The patient has received greater than 300 mg/m2 doxorubicin (cumulative dose) or greater than 600 mg/m2 epirubicin (cumulative dose)  The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration  (See also section 5.3.2.). The patient has received any investigational or non-registered product (drug or vaccine) other than the study treatment(s) within 30 days preceding the first dose of study treatment  or planned use during the study period  ",
            "The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening The patient requires concomitant treatment with systemic corticosteroids or any immunosuppressive agents  The use of prednisone  or equivalent  smaller than 0.5 mg/kg/day (absolute maximum 40 mg/day)  or inhaled corticosteroids or topical steroids is permitted  The patient has a malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Patients with ulcerative colitis  The patient has known coronary artery disease  arrhythmia requiring treatment  clinically significant valvular disease  cardiomegaly on chest X-ray  ventricular hypertrophy (found by ECG) or previous myocardial infarction  The patient has any acute or chronic  clinically significant pulmonary  cardiovascular  hepatic or renal functional abnormality  as determined by physical examination or laboratory screening tests  ",
            "The patient has current active hepatic or biliary's disease (with exception of patients with Gilbert's syndrome  asymptomatic gallstones  liver metastases or stable chronic liver disease per investigator assessment) The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease is not an exclusion criterion)  The patient has a known family history of congenital or hereditary immunodeficiency  The patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder  The patient has a history of anaphylaxis or severe allergic reaction to vaccines or unknown allergens  The patient has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib  These include other anilinoquinazolines  such as gefitinib (Iressa)  erlotinib (Tarceva)  or other chemically related compounds or excipients  The patient is known to be positive for the Human Immunodeficiency Virus (HIV)  ",
            "The patient has (or has had) previous or concomitant malignancies at other sites except effectively treated:Non-melanoma skin cancers or carcinoma in situ of the cervix Malignancy that has been in remission for greater than 2 years and is considered highly likely to have been cured  The patient has any psychiatric or addictive disorder that may compromise her ability to give informed consent  or to comply with the trial procedures  The patient has any other condition that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with the requirements of the study  The patient is pregnant or lactating  "
        ],
        "premise_nums": [
            "(male or female) is at least 18 years old at the time of the first ASCI administration  The administration",
            "or has received amiodarone in the 6 months prior to screening The patient requires",
            "with failure rate of less than 1% per year when used consistently and",
            "three weeks before the first ASCI administration  (See also section 5.3.2.). The patient has received",
            "count greater than /= 3,000/mm3. Neutrophil count greater than /= 1,500/mm3. Platelet count greater than /= 100,000/mm3.",
            "a metastatic lesion in all cases where such a lesion",
            "been in remission for greater than 2 years and is considered highly likely to",
            "dose) or greater than 600 mg/m2 epirubicin (cumulative dose)  The patient has received greater than 300 mg/m2 doxorubicin (cumulative dose) or",
            "be performed on the primary tumor  Use of the",
            "the study treatment(s) within 30 days preceding the first dose of study",
            "(male or female) is at least 18 years old at the time of signature",
            "solitary lesion  its neoplastic nature should be confirmed",
            "The patient has ECOG status of 0 or 1. The patient has adequate bone",
            "appropriate age e.g  greater than 45 years Able to swallow and retain oral medication",
            "Gilbert's syndrome  asymptomatic gallstones  liver metastases or",
            "effector cells  refer to Section 7).The patient has at least one measurable lesion according to",
            "The patient has received greater than 300 mg/m2 doxorubicin (cumulative dose) or greater than 600 mg/m2 epirubicin (cumulative dose)  The patient",
            "she must practice adequate contraception for 30 days prior to treatment  have a",
            "as determined by FISH (at least 4 fold i.e  at least 8 copies)  Note: Overexpression/amplification measurements",
            "female) is at least 18 years old at the time of signatureceived greater than 300 mg/m2 doxorubicin (cumulative dose) or greater than 600",
            "AST and ALT levels smaller than 3 times the ULN will be accepted The",
            "or equivalent  smaller than 0.5 mg/kg/day (absolute maximum 40 mg/day)  or inhaled corticosteroids or",
            "or has received amiodarone in the 6 months prior to screening The patient has ECOG status of 0 or 1. The patient has",
            "A practical definition accepts menopause after 1 year without menses with an appropriate clinical",
            "A practical definition accepts menopause after 1 year without menses with and ALT levels smaller than 1.5 times the ULN  Note: However"
        ]
    },
    {
        "id": "941b960f-8d57-4830-9d4c-8e96765ba76c",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "statement_text": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient ",
        "statement_nums": [
            "primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Bevacizumab Fulvestrant "
        ],
        "premise_nums": [
            "will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment",
            "Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET)",
            "the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab"
        ]
    },
    {
        "id": "f79a9011-0a68-4255-a40f-5d73af412bf0",
        "primaryId": "NCT01425268",
        "secondaryId": "NCT01373671",
        "statement_text": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial  and not used in either of the study groups in the secondary trial ",
        "statement_nums": [
            "study groups in the secondary trial",
            "CO2 is utilised as part of the intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only"
        ]
    },
    {
        "id": "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "statement_text": "There were no completed suicides in either the primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial ",
        "statement_nums": [
            "primary trial or the secondary trial  however there was one attempt in cohort 1 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) ",
            "Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) "
        ],
        "premise_nums": [
            "Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54",
            "1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%)",
            "In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal",
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal",
            "(0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "(0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54",
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116",
            "Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%)",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure",
            "Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%)",
            "Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54",
            "Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115",
            "Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115",
            "myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116",
            "Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115",
            "(0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54",
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54"
        ]
    },
    {
        "id": "57f3a264-9119-4931-9f9c-9cb20e945973",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course ",
        "statement_nums": [
            "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 2: Placebo With Paclitaxel Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS "
        ],
        "premise_nums": [
            "Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the",
            "expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this",
            "orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks"
        ]
    },
    {
        "id": "589e2f5b-9286-465b-8162-bb1549cd5ece",
        "primaryId": "NCT00305448",
        "statement_text": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "At least 4 patients in both cohorts of the primary trial achieved either complete response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response  Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number ",
            "Unit of Measure: percentage of participants 17.6"
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 51 Measure Type: Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization",
            "mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 17."
        ]
    },
    {
        "id": "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7",
        "primaryId": "NCT01390064",
        "statement_text": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [
            "both Cohorts of the primary trial receive their treatment via"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule "
        ],
        "premise_nums": [
            "VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination",
            "ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51",
            "the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope",
            "administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination"
        ]
    },
    {
        "id": "18d9991c-ca96-4bab-93af-77654857a07f",
        "primaryId": "NCT01142661",
        "statement_text": "the primary trial does not accept patients with grade 1 alopecia ",
        "statement_nums": [
            "the primary trial does not accept patients with grade 1 alopecia"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol: Existing anti-cancer therapy-related toxicities of Grade greater than /= 2, except that alopecia and Grade 2 neuropathy are acceptable  "
        ],
        "premise_nums": [
            "2, except that alopecia and Grade 2 neuropathy are acceptable"
        ]
    },
    {
        "id": "6fb9056d-277c-4dc2-9b45-d7661bb41831",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography ",
        "statement_nums": [
            "Participant in cohort 1 of the primary trial undergo a Mammography",
            "cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)"
        ]
    },
    {
        "id": "52b23601-2276-4634-96c7-8b6e55596085",
        "primaryId": "NCT00129376",
        "statement_text": "A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat ",
        "statement_nums": [
            "single patient in the primary trial experienced a clinically significant inflammation of the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%)"
        ]
    },
    {
        "id": "95e05332-4926-4381-90a4-87941269e7bf",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "More than 5% of the primary trial participants achieved partial response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 "
        ],
        "premise_nums": [
            "Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title:",
            "up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression",
            "or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants"
        ]
    },
    {
        "id": "20d51467-b059-4f39-b636-d32f2dc692da",
        "primaryId": "NCT00054028",
        "secondaryId": "NCT02162719",
        "statement_text": "Both the primary trial and the secondary trial at least partly administer their interventions orally ",
        "statement_nums": [
            "Both the primary trial and the secondary trial at least partly administer their interventions orally"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  INTERVENTION 1: Ipatasertib and Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity  elective withdrawal from the study  or study completion or termination  "
        ],
        "premise_nums": [
            "completion of the suramin infusion the 1 hour infusion of paclitaxel will begin",
            "Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally",
            "orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity",
            "Suramin will be infused weekly over 30 minutes  Four hours after",
            "Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of"
        ]
    },
    {
        "id": "e100212f-5bef-4f84-a3c1-d18a6b3e8355",
        "primaryId": "NCT01648322",
        "secondaryId": "NCT00436566",
        "statement_text": "the primary trial has a shorter time frame than the secondary trial  both of these studies employ the same units of measure in their evaluation ",
        "statement_nums": [
            "the primary trial has a shorter time frame than the secondary trial  both of these"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Duration of Moderate Neurtopenia Post First Chemotherapy Administration Number of days In which the patient has had an absolute neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Unit of Measure: days 0.6 (1.26) Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Unit of Measure: participants 0 "
        ],
        "premise_nums": [
            "[Not Specified] Time frame: 6 months Unit of Measure: participants 0",
            "smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Unit",
            "The first of 4, 21 Day Chemotherapy Cycles Unit of Measure: days 0.6 (1.26) Outcome Measurement: Number of Patients With",
            "neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time"
        ]
    },
    {
        "id": "56d2a387-49dd-49b9-93bb-bcb092bf2714",
        "primaryId": "NCT02286843",
        "statement_text": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions ",
        "statement_nums": [
            "is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions  PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions  rather than evaluation of only single lesions by biopsy  "
        ],
        "premise_nums": [
            "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT",
            "allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which allows excellent visualization of HER2+",
            "PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows"
        ]
    },
    {
        "id": "2485a3e1-7520-47d2-b941-32ebf91e5b65",
        "primaryId": "NCT00300781",
        "statement_text": "Participants of the primary trial are assigned an intervention depending on their prior treatments ",
        "statement_nums": [
            "Participants of the primary trial are assigned an intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally",
            "40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as",
            "Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long"
        ]
    },
    {
        "id": "b97d9465-db14-43af-9451-4b824e67abb8",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "statement_text": "the primary trial and the secondary trial use different inclusion criteria for their cohorts  so patients may be eligible for one cohort  but not the other ",
        "statement_nums": [
            "the primary trial and the secondary trial use different inclusion criteria"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: (Cohort 1) Concurrent systemic cancer therapy (hormones  biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for greater than or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator  (Cohort 2) Any concurrent systemic therapy is allowed Inclusion Criteria: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization positive Patients with resistance to trastuzumab Prior taxane therapy Patients with an ECOG performance status of 0 - 2 Patients with measurable disease as per RECIST criteria Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization  Sexually active pre-menopausal women must use adequate contraceptive measures  excluding estrogen containing contraceptives  while on study; Patients must meet laboratory criteria defined in the study within 21 days prior to randomization Exclusion Criteria: ",
            "Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancerMore than three prior chemotherapy lines for advanced disease  Symptomatic CNS metastases or evidence of leptomeningeal disease  Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed greater than 8 weeks prior to randomization Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the exception of adequately treated in-situ carcinoma of the cervix uteri  basal or squamous cell carcinoma or non-melanomatous skin cancer Known hypersensitivity to any study medication Breastfeeding or pregnant "
        ],
        "premise_nums": [
            "of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the",
            "with an ECOG performance status of 0 - 2 Patients with measurable disease as per RECIST",
            "CNS metastases was completed greater than 8 weeks prior to randomization Impairment of gastrointestinal",
            "biologics or chemotherapy) is allowed if distant metastases have",
            "greater than or = 12 weeks and skin metastases are non-responsive (stable",
            "of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of",
            "criteria defined in the study within 21 days prior to randomization Exclusion Criteria:",
            "with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization",
            "bearing potential prior to enrollment within 7 days prior to randomization  Sexually active"
        ]
    },
    {
        "id": "798c0983-5265-47ea-bfcd-735738793482",
        "primaryId": "NCT02010021",
        "statement_text": "A patient has recently been receiving Tamoxifen to treat breast cancer  they are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Prior endocrine therapy for any histologically confirmed cancer is not allowed  Prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed  "
        ],
        "premise_nums": [
            "endocrine therapy for any histologically confirmed cancer is not",
            "Prior endocrine therapy that was administered 5 years ago for the prevention of breast"
        ]
    },
    {
        "id": "127e9179-6781-4b9a-abe9-080d2ffad591",
        "primaryId": "NCT02176083",
        "secondaryId": "NCT03061175",
        "statement_text": "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention ",
        "statement_nums": [
            "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Intervention Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM  Survey Administration: Ancillary studies "
        ],
        "premise_nums": [
            "dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not",
            "CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients",
            "hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients"
        ]
    },
    {
        "id": "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d",
        "primaryId": "NCT00089479",
        "secondaryId": "NCT02964234",
        "statement_text": "Agatha had her 50th birthday last week  she has a histologically confirmed adenocarcinoma of the breast  with no evidence of metastatic disease  She is eligible for the primary trial but not the secondary trial ",
        "statement_nums": [
            "Agatha had her 50th birthday last week  she has a",
            "had her 50th birthday last week  she has a histologically confirmed adenocarcinoma of the",
            "is eligible for the primary trial but not the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: female patients 18-70 years of age; Inclusion Criteria: Age 52-75 years old; "
        ],
        "premise_nums": [
            "Inclusion Criteria: female patients 18-70 years of age; Inclusion Criteria: Age 52-75 years old;"
        ]
    },
    {
        "id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
        "primaryId": "NCT01401166",
        "statement_text": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration ",
        "statement_nums": [
            "several patients in cohort 1 of the primary trial Preferred oral tablets as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
            "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 Measure Type: Number Unit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 "
        ],
        "premise_nums": [
            "Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC",
            "the IV dose was 6 mg/kg for all cycles where IV Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0",
            "via SID  and during Cycles 5 to 8, IV Herceptin was given",
            "of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0",
            "HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period",
            "HCP  The SC dose was 600 mg for all cycles where SC Herceptin was",
            "Number of Participants Analyzed: 117 Measure Type: Number Unit of Measure: percentage",
            "The SC dose was 600 mg for all cycles where SC Herceptin for up to 10 remaining cycles  Administration was performed by",
            "The SC dose was 600 mg for all cycles where SC Herceptin on Day 1 of each 3-week cycle for 18 cycles",
            "Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1",
            "received IV Herceptin for up to 10 remaining cycles  Administration was performed by"
        ]
    },
    {
        "id": "2ed770a0-fe98-4029-9511-ad04a94a1a69",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial",
            "the primary trial cohort 2 had more patients with Leukopenia than cohort 1 had more than cohort 2. Cohort 1 of the primary",
            "the primary trial cohort 2 had more patients with Leukopenia than cohort 2. Cohort 1 of the primary trial had the highest",
            "1, whereas in the secondary trial cohort 1 had more patients with Leukopenia than cohort 1, whereas in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145",
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144",
            "1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144"
        ]
    },
    {
        "id": "b4c97206-66fd-468b-8388-fac076222c10",
        "primaryId": "NCT00863655",
        "statement_text": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in",
            "7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) "
        ],
        "premise_nums": [
            "Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular",
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238"
        ]
    },
    {
        "id": "6e22d118-af77-41bd-bd47-9385779f33aa",
        "primaryId": "NCT00450723",
        "statement_text": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "PRIOR CONCURRENT THERAPY: No prior thoracic or cardiac surgery No prior ipsilateral chest tube placement Contralateral chest tube placement allowed No prior neoadjuvant chemotherapy No prior radiotherapy to the mediastinum "
        ],
        "premise_nums": [
            "Contralateral chest tube placement allowed No prior neoadjuvant chemotherapy"
        ]
    },
    {
        "id": "ccc5362a-33d0-4f1b-be46-d31729ba9194",
        "primaryId": "NCT01945775",
        "statement_text": "The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group ",
        "statement_nums": [
            "Talazoparib group of the primary trial was over a month"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause  whichever occurs first  As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements  compared to the smallest sum on study (including baseline)  the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions  evaluated as a whole  such that it is clear that treatment has failed and disease is progressing  regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions  The analysis was performed by Kaplan-Meier method  Time frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Title: Talazoparib ",
            "Arm/Group Description: Participants received talazoparib 1 mg  orally  once daily until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or sponsor's decision to terminate the trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) "
        ],
        "premise_nums": [
            "compared to the smallest sum on study (including",
            "per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target",
            "cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Description: Participants received talazoparib 1 mg  orally  once",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3)",
            "in solid tumors (RECIST) version 1.1 or death from any cause  whichever",
            "trial (up to a maximum of 70.2 months)  One cyclesions: at least a 20% increase in the sum of target",
            "until the date of first documented radiologic progressive disease per"
        ]
    },
    {
        "id": "fa530b28-9142-49f2-aa80-4d04fa532910",
        "primaryId": "NCT03765996",
        "statement_text": "Participants in group 2 of the primary trial receive taping to anastomosis regions.  but no Complex Decongestive Physiotherapy ",
        "statement_nums": [
            "Participants in group 2 of the primary trial receive taping to anastomosis"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Decongestive Physiotherapy This group received Complex Decongestive Physiotherapy  Decongestive Physiotherapy: This group received CDP  which include MLD  short-stretch bandages  lymph-reducing exercises  and skin care  MLD was applied to the anterior trunk  posterior trunk  and the base of the neck  progressing to the affected limb  Short-stretch bandages were applied in multiple layers after MLD  A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm  The fingers and the hand were wrapped in gauze  A layer of cotton was wrapped around the arm  Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand  The most compression was at the most distal points and gradually decreased proximally  Exercises were done by patients to improve mobility and enhance lymphatic flow  INTERVENTION 2: Decongestive Physiotherapy Plus Taping This group received Complex Decongestive Physiotherapy  and also applying taping to anastomosis regions  ",
            "Decongestive Physiotherapy plus taping: This group received CDP as same protocol of active comparator  In addition  taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis  The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis  For axillo-inguinal anastomosis  the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region "
        ],
        "premise_nums": [
            "arm  Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral"
        ]
    },
    {
        "id": "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 had Pyrexia ",
        "statement_nums": [
            "none of the patients in cohort 2 had Pyrexia",
            "None of the patients in cohort 1 of the primary trial had a platlet deficiency"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) ",
            "Hepatic failure 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%)",
            "Hepatic failure 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%)",
            "(0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21",
            "7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)",
            "(3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)",
            "(1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%)",
            "(1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%)",
            "Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%)",
            "(0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%)",
            "(0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21",
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain"
        ]
    },
    {
        "id": "41cf791e-ed7a-48e5-af84-eefc9fa41ba7",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  alcohol poisoning was reported as the most common event ",
        "statement_nums": [
            "the primary trial where all equally prevalent  whereas in the secondary trial  alcohol poisoning was"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9 (11.11%) ",
            "Small Bowel Obstruction1/9 (11.11%)Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29",
            "Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9",
            "Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%)",
            "Small Bowel Obstruction1/9 (11.11%)Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%)"
        ]
    },
    {
        "id": "d417aa7b-6d2c-46f8-812c-426ea60e0328",
        "primaryId": "NCT00894504",
        "statement_text": "There were only 3 adverse events in the primary trial which occurred more than twice ",
        "statement_nums": [
            "There were only 3 adverse events in the primary trial which occurred more than"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%) NAUSEA 1/71 (1.41%) VOMITING 1/71 (1.41%) CHEST PAIN 1/71 (1.41%) PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%) "
        ],
        "premise_nums": [
            "10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%)",
            "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71",
            "PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%)"
        ]
    },
    {
        "id": "2744cc0a-86e9-4764-ae1c-f10f635dc283",
        "primaryId": "NCT00171704",
        "statement_text": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months ",
        "statement_nums": [
            "Letrozole group of the primary trial had a decreased Bone",
            "Density of the Lumbar Spine after 24 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range) ",
            "Unit of Measure: Percent Change 0.37 (-6.98 to 15.21)"
        ],
        "premise_nums": [
            "2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 68 Median (Full Range)",
            "Unit of Measure: Percent Change 0.37 (-6.98 to 15.21",
            "Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change 0.37 (-6.98 to 15.",
            "Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years",
            "was the lumbar spine (L2 to L4) and the secondary scanning site was the total",
            "Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63",
            "2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range)",
            "Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years",
            "Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let",
            "daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of",
            "after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until",
            "2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar",
            "of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray",
            "2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent"
        ]
    },
    {
        "id": "2e4717fd-b349-48a3-b751-88674dfaaa18",
        "primaryId": "NCT02392611",
        "statement_text": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy  or have no standard therapy available  and cohort 2 patients must respond well to standard therapy ",
        "statement_nums": [
            "standard therapy available  and cohort 2 patients must respond well to standard therapy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  "
        ],
        "premise_nums": [
            "tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the",
            "orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD",
            "alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and"
        ]
    },
    {
        "id": "b0c65cd7-8cad-404d-8704-ee074e480f57",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion criteria  apart from the mimimum age limit of 18.",
        "statement_nums": [
            "the primary trial and the secondary trial do not have any",
            "from the mimimum age limit of 18."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer at high risk for recurrence  defined by one of the following: Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy May or may not have elevated CA 15-3 or CEA levels Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart Stage III and completed adjuvant therapy no more than 24 months ago Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy ",
            "Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissectionStage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Stage IV that is stable on hormonal therapy Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female Menopausal status: Not specified Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No clinically significant New York Heart Association class III or IV cardiac disease Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No prior seafood allergy No known prior immunodeficiency or autoimmune disease No other active cancer except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: ",
            "At least 6 weeks since prior immunotherapyNo prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior surgery Concurrent surgery for local recurrence allowed if patient remains disease free "
        ],
        "premise_nums": [
            "specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female Menopausal",
            "or may not have elevated CA 15-3 or CEA levels Stage I  II",
            "on 2 consecutive occasions at least 2 weeks apart For patients witherapy no more than 24 months ago Stage IV that is stable",
            "previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer",
            "Disease Characteristics At least 4 weeks since prior chemotherapy No concurrent chemotherapy no more than 24 months ago Stage IV that is stable",
            "times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart For patients with a significant",
            "Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not have elevated CA 15-3 or CEA levels Stage I  II",
            "a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2",
            "times ULN Cardiovascular: No clinically significant New York Heart",
            "CEA levels Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart",
            "Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline",
            "axillary dissectionStage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Recurrence in the",
            "At least 6 weeks since prior immunotherapyNo prior vaccine with",
            "Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than",
            "II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Stage IV that is stable",
            "axillary dissectionStage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Stage IV that"
        ]
    },
    {
        "id": "34a75478-e7cc-495e-86c3-d0accdaf1ddd",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "than 18, have histologically confirmed stage 4 breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months",
            "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer  ECOGsmaller than"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older "
        ],
        "premise_nums": [
            "of greater than or equal to 6 months 18 years of age or older",
            "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy",
            "IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater"
        ]
    },
    {
        "id": "47780450-1202-4934-8e50-b29416b124f5",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  and all patients in the secondary trial are administered the same dose of Tamoxifen ",
        "statement_nums": [
            "All the primary trial participants receive the same",
            "of Letrozole  and all patients in the secondary trial are administered the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  "
        ],
        "premise_nums": [
            "Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally",
            "20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function",
            "for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane",
            "parent study  IBCSG 24-02 (SOFT)  The sample size",
            "2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid",
            "Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane",
            "Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen",
            "(OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or",
            "Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily",
            "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole",
            "(OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION",
            "1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic"
        ]
    },
    {
        "id": "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c",
        "primaryId": "NCT00179309",
        "statement_text": "There were 2 cases of severe back pain observed in the primary trial ",
        "statement_nums": [
            "There were 2 cases of severe back pain observed in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other  specify -stomatitis) 0/25 (0.00%) Vomiting 1/25 (4.00%) Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Sinus tachycardia 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other  specify -stomatitis) 1/23 (4.35%) Vomiting 0/23 (0.00%) Fever 1/23 (4.35%) Injection site reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) ",
            "Activated partial thromboplastin time prolonged 1/23 (4.35%)"
        ],
        "premise_nums": [
            "reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 1/23 (4.35%)",
            "Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin",
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other",
            "reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2:",
            "(0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Sinus tachycardia",
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders -",
            "0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23",
            "time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other",
            "reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other"
        ]
    },
    {
        "id": "c5e6497a-2e2f-4663-97fd-e73ba8904b0c",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis ",
        "statement_nums": [
            "Across all cohorts of the secondary trial and the primary trial there was only a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%) ",
            "Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%)Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%) Sodium  serum-low (hyponatremia) [1]1/43 (2.33%) Thrombosis/thrombus/embolism [6]2/43 (4.65%) "
        ],
        "premise_nums": [
            "Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70",
            "Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70",
            "2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73",
            "Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea",
            "Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%)",
            "Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea",
            "2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70",
            "(0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70",
            "Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73",
            "Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73",
            "(hyponatremia) [1]1/43 (2.33%) Thrombosis/thrombus/embolism [6]2/43 (4.65%)",
            "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73",
            "Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%)Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%)"
        ]
    },
    {
        "id": "c4dd814d-f525-465f-abe1-a7975771d57e",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered Methylprednisolone 3 times per week for 6 doses ",
        "statement_nums": [
            "cohort 1 of the primary trial weighing less than 45 kg  but all participants will be administered Methylprednisolone",
            "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than",
            "trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg  but all participants"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses)  "
        ],
        "premise_nums": [
            "(For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week",
            "Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5",
            "than 1 hour; no more than 8.0 x 10^7 cells/kg will be given at 5 million units/m^2 3 times per week",
            "a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For",
            "than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses)",
            "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of",
            "mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over"
        ]
    },
    {
        "id": "cfd93077-87c5-458b-8712-e1896929309d",
        "primaryId": "NCT00924352",
        "statement_text": "One patient in the primary trial had abnormally low red blood cells  white blood cells  and platelets ",
        "statement_nums": [
            "One patient in the primary trial had abnormally low red blood cells"
        ],
        "label": "Entailment",
        "premise_text": [
            "Pancytopenia * 1/56 (1.79%) "
        ],
        "premise_nums": [
            "Pancytopenia * 1/56 (1.79%)"
        ]
    },
    {
        "id": "a3faaf85-62c6-430f-acf2-9c5992ee5221",
        "primaryId": "NCT00503906",
        "secondaryId": "NCT01142661",
        "statement_text": "The adverse events in the primary trial where all equally prevalent  whereas in the secondary trial  progression of disease was reported as the most common event ",
        "statement_nums": [
            "the primary trial where all equally prevalent  whereas in the secondary trial  progression of disease"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9 (11.11%) ",
            "Small Bowel Obstruction1/9 (11.11%)Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29",
            "Adverse Events 1: Total: 7/9 (77.78%) Febrile Neutropenia1/9 (11.11%) Neutropenia1/9 (11.11%) Tachycardia1/9 (11.11%) Hematemesis1/9",
            "Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%)",
            "Small Bowel Obstruction1/9 (11.11%)Pneumonia1/9 (11.11%) Hypokalemia1/9 (11.11%) Alcohol Poisoning1/9 (11.11%) Progressive Disease4/9 (44.44%)"
        ]
    },
    {
        "id": "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were recorded as having High blood sugar ",
        "statement_nums": [
            "than 5% of cohort 1 of the primary trial had High blood sugar  0% of the secondary trial patients were",
            "Less than 5% of cohort 1 of the primary trial had High blood sugar"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2: ",
            "Total: 22/103 (21.36%)LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) "
        ],
        "premise_nums": [
            "21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%)",
            "1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE",
            "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22",
            "OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE",
            "FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%)",
            "OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%)",
            "(0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE",
            "0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE",
            "CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA",
            "(0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101",
            "FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%)",
            "DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) Adverse Events 2:",
            "FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%)",
            "Total: 22/103 (21.36%)LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%)",
            "OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%)",
            "FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%)",
            "FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%)",
            "FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA"
        ]
    },
    {
        "id": "335936e4-9eaa-43b3-84fe-6f112c0d0226",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "statement_text": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [
            "therapy is used in all cohorts of the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Radiotherapy/Supportive Care (A) Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  "
        ],
        "premise_nums": [
            "the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated",
            "and clear margins  will receive 15 doses of radiation over three weeks",
            "whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost",
            "wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions simultaneously with a boost treatment",
            "the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive"
        ]
    },
    {
        "id": "19921113-538e-4fd2-81a6-6053f2dd6459",
        "primaryId": "NCT02622074",
        "statement_text": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptions Other: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: ",
            "Arm/Group Title: Cohort A: KNp / KACArm/Group Description: Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)  This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via intravenous (IV) infusion except for doxorubicin (A)  which was administered via IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 2 20.0% Results 2: ",
            "Arm/Group Title: Cohort B: KNpCb (Regimen 1) / KACArm/Group Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A)  which was administered via IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants ",
            "Unit of Measure: Participants 4 40.0%"
        ],
        "premise_nums": [
            "exceptions Other: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction",
            "Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 2 20.0% Results 2:",
            "1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)",
            "1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity;",
            "1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 through end of Cycle 3 and Cycle 6 Day 1",
            "Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 4 40.",
            "through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 3 and Cycle 6 Day 1",
            "Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade",
            "Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W)",
            "pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day",
            "200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A)",
            "requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade",
            "Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab",
            "followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 through end of Cycle 7 (Up to ~150 days from",
            "first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp)",
            "mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on",
            "6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each",
            "IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of",
            "Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8",
            "200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or Grade 3 non-hematologic",
            "first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once",
            "Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3",
            "Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The",
            "consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on",
            "requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48",
            "Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)",
            "Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen);",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48",
            "(Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in",
            "a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring",
            "pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on",
            "Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W)"
        ]
    },
    {
        "id": "6a013bb4-0688-4f02-96c5-062f3ca67ae1",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "In total there were 5x more adverse events in cohort 1 of the primary trial  than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%) Acute renal failure * 20/28 (0.00%) "
        ],
        "premise_nums": [
            "failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia",
            "(0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) Hospitalisation for intrapleuric chemotherapy and",
            "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%)"
        ]
    },
    {
        "id": "c103a786-0b1d-4124-aa5d-4945ded2c384",
        "primaryId": "NCT01106040",
        "secondaryId": "NCT01441596",
        "statement_text": "the primary trial and the secondary trial are not studying PFS  PBR or DLTs ",
        "statement_nums": [
            "the primary trial and the secondary trial are not studying PFS"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Concordance of Blue Dye and Lymphoseek The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek  Time frame: Surgery after injections of Lymphoseek and blue dye Outcome Measurement: Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS)  no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation "
        ],
        "premise_nums": [
            "in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of",
            "Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the",
            "extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation"
        ]
    },
    {
        "id": "2746a75c-7f01-4dc3-a05e-5c7499e75555",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "statement_text": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Evidence of metastatic involvement (stage IV disease) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past Measurable disease  defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm by conventional techniques or as greater than 10 mm by spiral CT scan  No known CNS disease Hormone receptor status not specified PATIENT CHARACTERISTICS: Inclusion criteria: Postmenopausal status not specified ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normal AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis) ",
            "Creatinine 1.5 mg/dLNot pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Exclusion criteria: Pre-existing neuropathy grade 1 Uncontrolled intercurrent illness including  but not limited to  any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Serious  non-healing wound  ulcer  or bone fracture Psychiatric illness/social situations that would limit compliance with study requirements Inadequately controlled hypertension (defined as systolic blood pressure greater than 150 mm Hg and/or diastolic blood pressure greater than 100 mm Hg on antihypertensive medications) History of hypertensive crisis or hypertensive encephalopathy New York Heart Association class II-IV congestive heart failure History of myocardial infarction or unstable angina within the past 6 months History of stroke or transient ischemic attack within the past 6 months Significant vascular disease (e.g.  aortic aneurysm  aortic dissection) Symptomatic peripheral vascular disease ",
            "Evidence of bleeding diathesis or coagulopathySignificant traumatic injury within the past 28 days History of abdominal fistula  gastrointestinal perforation  or intra-abdominal abscess within the past 6 months Proteinuria  as demonstrated by either urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein 1g History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation  paclitaxel  bevacizumab  carboplatin  albumin  drug product excipients  or chemically similar agents PRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from all prior therapy No prior chemotherapy for locally recurrent or metastatic disease Prior neoadjuvant or adjuvant chemotherapy allowed More than 1 week since prior core biopsy or other minor surgical procedure  excluding placement of a vascular access device More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy More than 4 weeks since prior radiotherapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) At least 1 year since prior taxane regimen ",
            "No other concurrent investigational agentsConcurrent anticoagulation allowed  provided the following criteria are met: Stable dose of warfarin or low molecular weight heparin INR within desired range (2-3) No evidence of active bleeding or coagulopathy No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent radiotherapy  chemotherapy  immunotherapy  or antitumor hormonal therapy "
        ],
        "premise_nums": [
            "cervix Exclusion criteria: Pre-existing neuropathy grade 1 Uncontrolled intercurrent illness including  but not",
            "a vascular access device More than 4 weeks since prior and no concurrent major",
            "concurrent investigational agentsConcurrent anticoagulation allowed  provided the following",
            "by either urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ Patients discovered to have 2+ proteinuria on dipstick urinalysis at",
            "conventional techniques or as greater than 10 mm by spiral CT scancer or  if HER-2-positive, must be unable to receive trastuzumab",
            "disease  defined as at least one lesion that can be",
            "proteinuria 2+ Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein 1g History",
            "to be recorded) as greater than 20 mm by conventional techniques or as greater than 10 mm by spiral CT scan",
            "other concurrent malignancies within the past 5 years except basal cell or as greater than 10 mm by spiral CT scan  No",
            "attack within the past 6 months Significant vascular disease (e.g.  aortic",
            "or adjuvant chemotherapy allowed More than 1 week since prior core biopsy or other",
            "Creatinine 1.5 mg/dLNot pregnant or nursing Negative pregnancy",
            "ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL",
            "3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normalignancies within the past 5 years except basal cell or squamous cell",
            "0-1 OR Karnofsky PS 70-100% Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total",
            "coagulopathySignificant traumatic injury within the past 28 days History of abdominal fistula  gastrointestinal",
            "or unstable angina within the past 6 months History of stroke or transient ischemic",
            "Total bilirubin normal AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN (unless bone",
            "Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normal AST and ALT",
            "as systolic blood pressure greater than 150 mm Hg and/or diastolic blood pressure greater than 100 mm Hg on antihypertensive medications) History of",
            "PS 70-100% Life expectancy greater than 12 weeks WBC 3,000/mcL Absolute neutrophil count 1,500/mcL Platelet count 100,000/mcL Total bilirubin normal AST",
            "IV disease) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally",
            "weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) At least 1 year since prior taxane regimen"
        ]
    },
    {
        "id": "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "statement_text": "Only White and Asian patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "eligible for both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection)  including those women with a history of previous surgery for breast cancer  radiation therapy or chemotherapy Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks  Home access to internet from stationary computer  lab top or tablet Ability to use internet Ability to read and understand Danish Exclusion Criteria: Surgery for breast cancer with immediate breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast cancer Planned use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues  seroma  hematoma Severe physical  cognitive  or psychiatric illness causing inability to follow the study protocol: i.e  severe depression  anxiety  dementia  poor physical health with likely possibility of hospitalization within the next twelve weeks  Planned hospitalization or surgery within the next twelve weeks Participation in another clinical trial with a rehabilitation or exercise intervention Inclusion Criteria: Participants can be from any racial or ethnic origin  "
        ],
        "premise_nums": [
            "radiation therapy or chemotherapy Part 2 only: Completion of surgery and",
            "Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer",
            "use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues",
            "breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast"
        ]
    },
    {
        "id": "348c9273-6aa1-43a8-840d-3cf080874669",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there were at least 2 patients with a fever ",
        "statement_nums": [
            "both cohorts of the primary trial  there were at least 2 patients with a fever"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) Adverse Events 2: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) ",
            "Thrombosis in device * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) "
        ],
        "premise_nums": [
            "Thrombosis in device * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%)",
            "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%)"
        ]
    },
    {
        "id": "9f424ebb-63b8-4930-b2c1-cd46fff4d706",
        "primaryId": "NCT01302379",
        "statement_text": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline ",
        "statement_nums": [
            "patient cohort of the primary trial had a positive median"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Insulin Insulin measured as percent change from baseline Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle Intervention Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -21.8 (-29.7 to -13.0) Results 2: Arm/Group Title: Placebo + Lifestyle Intervention Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -17.7 (-25.9 to -8.6) "
        ],
        "premise_nums": [
            "dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500",
            "dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1",
            "for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent",
            "at dinner time Weeks 2-4: 2 pills at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500",
            "dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1",
            "Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning;",
            "500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle"
        ]
    },
    {
        "id": "c1f8c7fb-22de-4501-af86-d9eb59542ae3",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 ",
            "Stable disease (SD): 8CR+PR+SD: 9 "
        ],
        "premise_nums": [
            "participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30",
            "Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed:",
            "disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of",
            "Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD):",
            "Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed:",
            "weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6",
            "+ stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at",
            "as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1:",
            "mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants",
            "mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants"
        ]
    },
    {
        "id": "6630047b-7ebc-4435-8203-cf6bbe6b6ee7",
        "primaryId": "NCT00331630",
        "statement_text": "Left ventricular ejection fraction greater than 50% is required for participation in the primary trial ",
        "statement_nums": [
            "Left ventricular ejection fraction greater than 50% is required for participation in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "LVEF 50% as measured by echocardiogram or MUGA scan "
        ],
        "premise_nums": [
            "LVEF 50% as measured by echocardiogram or MUGA"
        ]
    },
    {
        "id": "039c3fc2-f798-4d97-b904-9aa7d363eeef",
        "primaryId": "NCT00903162",
        "secondaryId": "NCT01674062",
        "statement_text": "Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "are eligible for the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix Exclusion Criteria: Any other malignancy in the last 5 years  except for basal cell cancer or cancer in situ of the cervix "
        ],
        "premise_nums": [
            "cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in",
            "Any other malignancy in the last 5 years  except for basal"
        ]
    },
    {
        "id": "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f",
        "primaryId": "NCT00121134",
        "statement_text": "the primary trial requires participants to have undergone PTR ",
        "statement_nums": [
            "the primary trial requires participants to have"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must have completed definitive resection of primary tumor with adequate excision of gross disease  "
        ],
        "premise_nums": [
            "completed definitive resection of primary tumor with adequate excision of"
        ]
    },
    {
        "id": "f8028143-35d1-4cc3-895a-acb577db4715",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD ",
        "statement_nums": [
            "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40",
            "cohort 1 in the primary trial and all participants of cohort 1 in the primary trial and all participants"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days "
        ],
        "premise_nums": [
            "1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days"
        ]
    },
    {
        "id": "907f7e56-b6ec-4a43-bf3a-14f93c644bc1",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial",
            "female patient over the age of 18 suffering from chronic viral hepatitis would be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic"
        ]
    },
    {
        "id": "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "developing breast cancer within the next 5 years and within her lifetime by the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group "
        ],
        "premise_nums": [
            "Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group"
        ]
    },
    {
        "id": "a41bf7b0-9a09-4ce0-8832-f13758581f20",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) ",
            "CATARACT 1/201 (0.50%)OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) "
        ],
        "premise_nums": [
            "CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%)OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%)",
            "2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202",
            "NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%)",
            "NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202",
            "61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202",
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE",
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202",
            "(0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%)",
            "NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201",
            "CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201",
            "NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201",
            "CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202",
            "NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%)",
            "CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA",
            "1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA"
        ]
    },
    {
        "id": "609ddd08-ebd5-4661-be43-874b65dbfe52",
        "primaryId": "NCT03273426",
        "secondaryId": "NCT01091168",
        "statement_text": "Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "be eligible for the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC) who received NAC with detectable lesion / clip marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete response on MRI with informed consent Exclusion Criteria: Multifocal cancer Residual microcalcification Contralateral breast cancer Concurrent serious uncontrolled medical disorder  "
        ],
        "premise_nums": [
            "Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy",
            "marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete"
        ]
    },
    {
        "id": "b6ac985d-87ae-4e0f-83e1-38033c1db5cc",
        "primaryId": "NCT00322348",
        "secondaryId": "NCT00429572",
        "statement_text": "the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status ",
        "statement_nums": [
            "the primary trial and the secondary trial use ECOG to evaluate"
        ],
        "label": "Contradiction",
        "premise_text": [
            "World Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2 "
        ],
        "premise_nums": [
            "Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2"
        ]
    },
    {
        "id": "43ff9425-5e6e-4a85-a8ca-0c0c67a96623",
        "primaryId": "NCT00431067",
        "statement_text": "More than 5% of the primary trial participants achieved Objective Response (OR) ",
        "statement_nums": [
            "More than 5% of the primary trial participants achieved Objective Response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response (OR) Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria   Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants 4 "
        ],
        "premise_nums": [
            "Time frame: From first dose of study medication to response measurement  up to 34 month Results 1: Arm/Group Title:",
            "up to 34 month Results 1: Arm/Group Title: Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression",
            "or undue toxicity  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: Participants"
        ]
    },
    {
        "id": "b3ccde30-cdfc-4e18-aee0-8b3a921dde39",
        "primaryId": "NCT00470301",
        "statement_text": "Every patient in the primary trial is given tipifarnib PO  along with paclitaxel  doxorubicin hydrochloride and acyclophosphamide IV  but only a subset of participants undergo axillary lymph node dissection ",
        "statement_nums": [
            "Every patient in the primary trial is given tipifarnib PO"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I See Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV pegfilgrastim: Given SC conventional surgery: surgical procedures performed on patients axillary lymph node dissection: correlative study "
        ],
        "premise_nums": [
            "Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin"
        ]
    },
    {
        "id": "8697a59e-0f1c-452a-b15a-6d24e2df387f",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "statement_text": "None of the patients in the primary trial or the secondary trial committed suicide ",
        "statement_nums": [
            "the patients in the primary trial or the secondary trial committed suicide"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) "
        ],
        "premise_nums": [
            "Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%)",
            "1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%)",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32",
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32"
        ]
    },
    {
        "id": "4ab74186-5f4e-4139-af05-d4a9871a251d",
        "primaryId": "NCT02721147",
        "statement_text": "Stephanie has been living with her husband for 31 years  she is eligible for the primary trial ",
        "statement_nums": [
            "been living with her husband for 31 years  she is eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Has a partner or spouse who is greater than 21 Lives with a romantic partner greater than 6 months "
        ],
        "premise_nums": [
            "or spouse who is greater than 21 Lives with a romantic partner greater than 6 months"
        ]
    },
    {
        "id": "082ee581-f420-4892-b098-ce82c6ad0210",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial were cardiac related ",
        "statement_nums": [
            "events recorded in the primary trial were cardiac related"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%) Diabetes decompensation * 0/45 (0.00%) Diarrhea * [2]0/45 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%) Pancreatitis * [4]1/45 (2.22%) Febrile neutropenia * [2]3/45 (6.67%) Adverse Events 2: Total: 0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00%) Diabetes decompensation * 0/46 (0.00%) ",
            "Diarrhea * [2]0/46 (0.00%)Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%) Pancreatitis * [4]0/46 (0.00%) Febrile neutropenia * [2]0/46 (0.00%) Infection pulmonary/ Upper airway NOS * [5]0/46 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%)",
            "Diarrhea * [2]0/46 (0.00%)Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%)"
        ]
    },
    {
        "id": "7bf084eb-873a-4011-9b98-3a899ee582ee",
        "primaryId": "NCT00982319",
        "statement_text": "Pre and Post menopausal women can enter the primary trial  as long as they do not have prior hormone replacement therapy ",
        "statement_nums": [
            "women can enter the primary trial  as long as"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female 18 + years of age Confirmed diagnosis of DCIS on core or excisional/incisional biopsy and scheduled for definitive surgery Pre or Post menopausal women reporting no use of hormone replacement therapy  tamoxifen or raloxifene within the prior 6 months to eligibility screening "
        ],
        "premise_nums": [
            "tamoxifen or raloxifene within the prior 6 months to eligibility screening"
        ]
    },
    {
        "id": "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a",
        "primaryId": "NCT01575522",
        "secondaryId": "NCT00181363",
        "statement_text": "the primary trial and the secondary trial are testing completely different modalities of interventions  but utilising the same 21 day cycle ",
        "statement_nums": [
            "interventions  but utilising the same 21 day cycle",
            "the primary trial and the secondary trial are testing completely different"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position "
        ],
        "premise_nums": [
            "PTEN loss  and PI3K mutation analysis by FISH and IHC",
            "collection at baseline and periodically during study for c-Met",
            "receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position"
        ]
    },
    {
        "id": "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with ERBB2 positive tumors are eligible for the primary trial ",
        "statement_nums": [
            "Patients with ERBB2 positive tumors are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. "
        ],
        "premise_nums": [
            "centralized FISH testing prior to day 1.",
            "(FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)"
        ]
    },
    {
        "id": "f6c85ce8-e0fc-4186-a961-6207dd4cacd2",
        "primaryId": "NCT01268150",
        "statement_text": "Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "Most patients in the primary trial treated with Eribulin Mesylate"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) The ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)  based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Targeted lesions were assessed by computed tomography (CT) and magnetic resonance imaging (MRI) which were then assessed by the investigator based on RECIST  CR was defined as the disappearance of all target lesions  PR was defined as at least 30% decrease in the sum of diameters of target lesions  taking as reference baseline sum diameters  Possible CR and PR had to be confirmed no fewer than 4 weeks after the initial response assessment  A brain and bone scan was performed by CT/MRI within 1 week after confirmation of a response to ensure no new metastases  To be assigned a status of CR or PR  changes in tumor measurements had to be confirmed by repeat evaluations  to be performed not fewer than 4 weeks after the response criteria were first met  ORR = CR + PR Time frame: Cycle 1 (Day 1) until first evidence of disease progression  assessed up to the data cutoff date (30 Aug 2013) up to 2.5 years Results 1: ",
            "Arm/Group Title: Eribulin MesylateArm/Group Description: Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle  Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: Percentage of participants 28.6 "
        ],
        "premise_nums": [
            "the response criteria were first met  ORR = CR",
            "the data cutoff date (30 Aug 2013) up to 2.5 years Results 1:",
            "intravenous (IV) infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle  Overall Number of Participants",
            "to be confirmed no fewer than 4 weeks after the initial response assessment",
            "PR was defined as at least 30% decrease in the sum of diameters",
            "Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: Percentage of participants 28.6",
            "MesylateArm/Group Description: Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days",
            "scan was performed by CT/MRI within 1 week after confirmation of a response to",
            "PR was defined as at least 30% decrease in the sum of participants with best overall response (BOR) of confirmed complete",
            "Days 1 and 8 of each 3-week cycle  Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: Percentage"
        ]
    },
    {
        "id": "5bdd61d9-aadf-4944-afe3-a04242d9c2b2",
        "primaryId": "NCT02321527",
        "statement_text": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial ",
        "statement_nums": [
            "with a diameter of less than 4 cm are included in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Ipsilateral biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or Mammography  "
        ],
        "premise_nums": [
            "biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or"
        ]
    },
    {
        "id": "b8ce7d6a-d707-48e0-816c-de7ac3a63823",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial",
            "Fiona's sister  who is 34 years old was diagnosed with a ductal"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  "
        ],
        "premise_nums": [
            "under the age of 60 or multiple second degree relatives with breast cancer under the age of 60 or multiple second degree relatives",
            "breast cancer under the age of 60 or multiple second degree relatives with breast"
        ]
    },
    {
        "id": "53d88010-e7d7-41c7-b20d-6328c8e507d1",
        "primaryId": "NCT01498458",
        "statement_text": "For some adverse event types in the primary trial  there were no recorded cases ",
        "statement_nums": [
            "event types in the primary trial  there were no"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%)"
        ]
    },
    {
        "id": "8257bf5c-fae6-44c0-a86d-293746fdc468",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "statement_nums": [
            "Hepatic encephalopathy and Pneumonia than cohort 2.",
            "Cohort 1 of the primary trial had more cases of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/26 (19.23%) Febrile neutropenia 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Nausea 1/26 (3.85%) Pancreatitis 1/26 (3.85%) Vomiting 2/26 (7.69%) Pain 0/26 (0.00%) Pneumonia 0/26 (0.00%) Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) Hepatic encephalopathy 1/26 (3.85%) Adverse Events 2: Total: 4/13 (30.77%) Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%) Nausea 0/13 (0.00%) Pancreatitis 0/13 (0.00%) Vomiting 0/13 (0.00%) ",
            "Pain 1/13 (7.69%)Pneumonia 1/13 (7.69%) Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) Ammonia increased 0/13 (0.00%) Hepatic encephalopathy 0/13 (0.00%) "
        ],
        "premise_nums": [
            "5/26 (19.23%) Febrile neutropenia 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 1/13 (7.69%) Nausea 0/13 (0.00%) Pancreatitis 0/13 (0.00%) Vomiting 0/13",
            "Hepatic encephalopathy 1/26 (3.85%) Adverse Events 2: Total: 4/13 (30.77%) Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%)",
            "infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) Hepatic encephalopathy 1/26 (3.85%) Adverse Events 2:",
            "Pneumonia 0/26 (0.00%) Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 0/13 (0.00%) Ammonia increased 0/13 (0.00%) Hepatic encephalopathy 0/13",
            "infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) Ammonia increased 0/13 (0.00%) Hepatic encephalopathy 0/13 (0.00%)",
            "Pneumonia 0/26 (0.00%) Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) Hepatic encephalopathy 1/26",
            "Adverse Events 1: Total: 5/26 (19.23%) Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%)",
            "vertebral fracture 1/26 (3.85%) Ammonia increased 1/26 (3.85%) Hepatic encephalopathy 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Nausea 1/26",
            "Hepatic encephalopathy 1/26 (3.85%) Adverse Events 2: Total: 4/13 (30.77%) Febrile neutropenia 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "Febrile neutropenia 1/13 (7.69%) Abdominal pain 1/13 (7.69%) Constipation 1/13 (7.69%)Pneumonia 1/13 (7.69%) Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture"
        ]
    },
    {
        "id": "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial  but excluded from the secondary trial ",
        "statement_nums": [
            "Patients with HER2 positive breast tumors are eligible for the primary trial  but excluded from"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting "
        ],
        "premise_nums": [
            "evidence of unresectable  locally recurrent  or metastatic",
            "disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH)"
        ]
    },
    {
        "id": "974225b7-9089-499c-9550-0a7207fd28b2",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "statement_text": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study  whereas in the secondary trial  all patients receive Radiation Therapy ",
        "statement_nums": [
            "The intervention for the primary trial does not require patients",
            "whereas in the secondary trial  all patients receive Radiation Therapy"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  INTERVENTION 2: Arm 2: Enhanced Usual Care (Surgical Care Booklet) ",
            "Investigators recruited patients scheduled for plastic/reconstruction consultation  Investigators identified patients who completed or scheduled a mastectomy  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home  Patients were randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with American Society of Plastic Surgeons booklet \"Breast Reconstruction.\" They were asked to answer a survey  After the appointment  the team collected information about consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
            "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
            "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed "
        ],
        "premise_nums": [
            "gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The",
            "40.5 Gy to the breast and 48.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Gy to the breast and 48.0 Gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm",
            "participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed",
            "patients scheduled for a plastic/reconstruction consult  Investigators identified",
            "recruited patients scheduled for plastic/reconstruction consultation  Investigators identified",
            "breast with a Friday boost of 2.0 Gy to the tumor bed  for",
            "A study team member called the patient to determine",
            "with a daily concomitant boost of 0.5 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "40.5 Gy to the breast and 46.5 gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2:",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks",
            "to come to their scheduled appointment 30 minutes early to meet a coordinator or",
            "bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)",
            "making  Patient participation was approximately 30 minutes  INTERVENTION 2: Arm",
            "The overall dose will be 40.5 Gy to the breast with a Friday boost of 2.0 Gy to the tumor"
        ]
    },
    {
        "id": "6f533f52-c8e4-4983-8968-69af03a9e34a",
        "primaryId": "NCT01506609",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial ",
        "statement_nums": [
            "Patients with cytologically confirmed breast cancer",
            "not eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast"
        ]
    },
    {
        "id": "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "statement_text": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial ",
        "statement_nums": [
            "percentage of patients with at least partial response than either cohort of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants Who Had a Tumor Response  According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions  taking as reference the baseline sum LD) response  Time frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months after end of treatment  Results 1: Arm/Group Title: Caelyx  Docetaxel  Trastuzumab Arm/Group Description: Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end of this stage  based on the number of cardiac events  subjects will proceed to a second stage or restart with a lower dose of Caelyx  Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: Participants Participants who had a complete tumor response: 2 Participants who had a partial tumor response: 13 ",
            "Participants who did not have a tumor response: 11Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study  Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane Alone ",
            "Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks) Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) "
        ],
        "premise_nums": [
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will",
            "a complete tumor response: 2 Participants who had a partial tumor response:",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane",
            "percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8,",
            "Time frame: Week 09, Week 18, at the end of each patient's",
            "Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane",
            "8, and 15 at 28-day intervals  Abraxane will be administered as a 10 mg/kg loading dose followed by 5 mg/kg",
            "Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day",
            "docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1)",
            "evaluated for response every 2 cycles (every 8 weeks) Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: Participants",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will be evaluated for response every 2 cycles (every 8 weeks) Overall",
            "Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered",
            "either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Abraxane at 100 mg/m2 X 3 doses on Days 1,",
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "have a tumor response: 11Outcome Measurement: Objective Response Rate Patient",
            "frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months",
            "will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6",
            "Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day",
            "progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days",
            "tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then",
            "5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will be evaluated for response every 8 weeks  Patients with disease"
        ]
    },
    {
        "id": "34ee4f66-e6f7-458c-964c-12fa730a9d56",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies "
        ],
        "premise_nums": [
            "therapy and continuing until 1 week after completion of radiation therapy and continuing until 1 week after completion of radiation",
            "curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and",
            "studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply curcumin-based gel topically TID approximately every 4-6"
        ]
    },
    {
        "id": "9b0451fe-f760-46d3-b555-0a9b83546e73",
        "primaryId": "NCT00087152",
        "secondaryId": "NCT00203502",
        "statement_text": "the primary trial recorded half as many patients vomiting as the secondary trial ",
        "statement_nums": [
            "the primary trial recorded half as many",
            "patients vomiting as the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%)"
        ]
    },
    {
        "id": "b9304415-073d-476e-a056-cb2a747d56fa",
        "primaryId": "NCT00021255",
        "statement_text": "Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin  cyclophosphamide  Herceptin and docetaxel during Cycle 5 of the study ",
        "statement_nums": [
            "Herceptin and docetaxel during Cycle 5 of the study",
            "Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin  cyclophosphamide"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 2: AC Followed by Docetaxel + Herceptin (AC→TH) Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles)  After completion of the last cycle of chemotherapy  Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose  "
        ],
        "premise_nums": [
            "IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV bolus Injection on Day 1 of every 3 weeks for",
            "starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg",
            "4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg",
            "mg/m² IV bolus Injection on Day 1 of every 3 weeks for all subsequent cycles ( total 4",
            "IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on",
            "of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV",
            "bolus Injection on Day 1 of every 3 weeks for 4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of",
            "of chemotherapy  Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose",
            "IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from",
            "IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for 4 cycles  Herceptin 4"
        ]
    },
    {
        "id": "6e365e33-16b8-43e1-99b5-49dfed6f7b13",
        "primaryId": "NCT00316199",
        "statement_text": "Only Chinese women with stage 4 or Unresectable  locally recurrent cancer breast cancer are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "Only Chinese women with stage 4 or Unresectable  locally recurrent cancer breast cancer"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer  Unresectable  locally recurrent breast cancer or stage IV disease  "
        ],
        "premise_nums": [
            "of Chinese origin with histologically or cytologically proven diagnosis"
        ]
    },
    {
        "id": "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "statement_nums": [
            "and Paclitaxel than those in cohort 2.",
            "Participants of cohort 1 in the primary trial received more Dasatinib and"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 ",
            "Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days "
        ],
        "premise_nums": [
            "followed by a rest period of 7 days  Dasatinib 100mg was repeated on Day 1 of a 28-day cycle until radiographic or",
            "I  the first cycle lasted 38 days  INTERVENTION 2: Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2",
            "Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression",
            "treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and",
            "phase I  the first cycle lasted 38 days  INTERVENTION 2: Phase",
            "dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of",
            "a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest",
            "cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was",
            "followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)",
            "weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a"
        ]
    },
    {
        "id": "5919a080-2f0d-4c3b-9b03-10df80b2e680",
        "primaryId": "NCT01007942",
        "statement_text": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort ",
        "statement_nums": [
            "adverse event in the primary trial which affected more than 10% of a particular patient cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 30/280 (10.71%)"
        ]
    },
    {
        "id": "b351a091-d5fb-49f9-a864-5c89c6316b1b",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed PR+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter TO PARTICIPATE in the primary trial ",
        "statement_nums": [
            "Patients must have histologically or cytologically confirmed PR+",
            "with Primary tumor greater than 2 cm in diameter TO PARTICIPATE in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ "
        ],
        "premise_nums": [
            "Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor",
            "cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound",
            "Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or",
            "situ hybridization (FISH) + when IHC 2+"
        ]
    },
    {
        "id": "d5ca2086-8404-42d1-bf45-5370f3d4e8e8",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "statement_text": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial ",
        "statement_nums": [
            "of hemorrhaging in the primary trial than in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac * 1/15 (6.67%) Diarrhea * 1/15 (6.67%) Duodenal hemorrhage * 1/15 (6.67%) Fatigue * 1/15 (6.67%) Fever * 1/15 (6.67%) Sudden death NOS * 1/15 (6.67%) Sepsis * 1/15 (6.67%) Skin infection * 1/15 (6.67%) Neutrophil count decreased * 1/15 (6.67%) Platelet count decreased * 1/15 (6.67%) Adverse Events 1: Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) ",
            "Pericardial effusion 0/258 (0.00%)Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%) "
        ],
        "premise_nums": [
            "Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral",
            "(1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224",
            "pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%)",
            "(0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224",
            "Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral",
            "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac *",
            "(1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 1: Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia",
            "neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224",
            "(26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence",
            "(0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224",
            "Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation",
            "neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224",
            "(28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%)",
            "pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%)Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper",
            "Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation",
            "Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral",
            "(1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia",
            "1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224"
        ]
    },
    {
        "id": "4c038972-20a9-4031-a1cd-ba00e9dd0908",
        "primaryId": "NCT00410813",
        "secondaryId": "NCT00617539",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily  The opposite was true in the secondary trial ",
        "statement_nums": [
            "In the primary trial  Dasatinib  70",
            "PFS than Dasatinib  100 mg  Daily  The opposite",
            "was true in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed  unequivocal progression of non-measurable disease  the appearance of any new lesion/site  death due to disease without prior documentation of progression and without symptomatic deterioration  development of one or more new bone lesions from baseline  or symptomatic deterioration related to disease progression  Time from date of registration to date of first documentation of progression or symptomatic deterioration  or death due to any cause  Patients last known to be alive and progression-free are censored at last date of contact  Time frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100 mg  Daily Arm/Group Description: Dasatinib  100 mg PO daily until progression of disease Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib  70 mg  Twice Daily Arm/Group Description: Dasatinib  70 mg PO twice daily until progression of disease Overall Number of Participants Analyzed: 38 ",
            "Median (95% Confidence Interval)Unit of Measure: weeks 15.3 (8.7 to 20.1) Outcome Measurement: Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS Imaging was performed at 8-week intervals to assess response to treatment  Patients with known or suspected leptomeningeal disease were deemed to have a complete response if CSF cytology converted to negative (if positive at baseline) and all meningeal enhancement or nodularity of brain and/or spine MRI resolved  A modified RECIST 1.0 criteria was used to assess CNS response for patients with new or progressing brain metastases  In this modified RECIST criteria  CNS lesions smaller than 1cm were not considered measurable  but were considered evaluable for response and progression  Progressive disease for patients with lesions smaller than 1 cm was defined as follows: growth of a lesion from less than or equal to 5 mm to greater than or equal to 10mm; or  growth of a 6-9 mm lesion by at least 5 mm in the case of non-target parenchymal brain metastases  ",
            "Time frame: Baseline scan prior to study entry was performed within 14 days of cycle 1 day 1, then every 8 weeks from then until disease progression or up to 2 yearsResults 1: Arm/Group Title: Irinotecan and Temozolomide Arm/Group Description: irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 and days 15-21 of a 28 day cycle Overall Number of Participants Analyzed: 30 Measure Type: Count of Participants Unit of Measure: Participants 2 6.7% "
        ],
        "premise_nums": [
            "days 1-7 and days 15-21 of a 28 day cycle Overall Number of Participants Analyzed: 30 Measure Type: Count of Participants Unit of",
            "the CNS Imaging was performed at 8-week intervals to assess response to treatment",
            "Number of Participants Analyzed: 30 Measure Type: Count of Participants Unit of Measure: Participants 2 6.7%",
            "with lesions smaller than 1 cm was defined as follows: growth of a 6-9 mm lesion by at least 5 mm",
            "cycle 1 day 1, then every 8 weeks from then until disease progression or up to 2 yearsResults 1: Arm/Group Title: Irinotecan",
            "frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100 mg/m2 on days 1-7 and days 15-21 of a 28 day",
            "contact  Time frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100",
            "Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 15.3 (8.7 to 20.1) Outcome Measurement: Number of Patients",
            "criteria  CNS lesions smaller than 1cm were not considered measurable lesions over the smallest sum observed  unequivocal",
            "until disease progression or up to 2 yearsResults 1: Arm/Group Title: Irinotecany cause  Patients last known to be alive and",
            "MRI resolved  A modified RECIST 1.0 criteria was used to assess CNS response",
            "entry was performed within 14 days of cycle 1 day 1, then every 8 weeks from then until disease progression or",
            "Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib",
            "with lesions smaller than 1 cm was defined as follows: growth of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib",
            "125 mg/m2 on days 1 and 15 of a 28 day cycle temozolomide orally for seven days at",
            "Progression-free Survival RECIST progression defined as 20% increase in the sum of longest",
            "to greater than or equal to 10mm; or  growth of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib",
            "registration to date of first documentation of progression or symptomatic",
            "and 15 of a 28 day cycle temozolomide orally for seven days 1-7 and days 15-21 of a 28 day cycle Overall Number",
            "to greater than or equal to 10mm; or  growth of a 6-9 mm lesion by at least 5 mm",
            "RECIST progression defined as 20% increase in the sum of longestarting dose of 125 mg/m2 on days 1 and 15 of a",
            "Arm/Group Description: Dasatinib  100 mg PO daily until progression of disease",
            "days at a starting dose of 100 mg/m2 on days 1-7 and days 15-21 of a 28 day cycle Overall Number"
        ]
    },
    {
        "id": "82d6275a-97e6-4d13-84eb-5f7c2585db8b",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "statement_text": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure ",
        "statement_nums": [
            "patient cohorst of the primary trial and the secondary trial there was only a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199 (0.50%) PANCYTOPENIA 1/199 (0.50%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) NEUTROPENIA 2/198 (1.01%) ",
            "PANCYTOPENIA 1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: ",
            "Total: 2/6 (33.33%)Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) "
        ],
        "premise_nums": [
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "PANCYTOPENIA 1/199 (0.50%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199",
            "Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "PANCYTOPENIA 1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198",
            "PANCYTOPENIA 1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) NEUTROPENIA 2/198",
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "Total: 2/6 (33.33%)Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%)",
            "PANCYTOPENIA 1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1:",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse",
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) NEUTROPENIA 2/198 (1.01%)",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199",
            "(0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "(0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse",
            "1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2:",
            "CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%)",
            "MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199",
            "(0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "(0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%)",
            "Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "(0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198",
            "ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199",
            "Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "1/198 (0.51%)ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199",
            "Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%)",
            "MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198",
            "ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia",
            "1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199",
            "Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "2/6 (33.33%)Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)"
        ]
    },
    {
        "id": "286e74e5-74ed-4d42-b32d-f1398c514d37",
        "primaryId": "NCT01125566",
        "statement_text": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "one participant in the primary trial receiving an oral treatment",
            "once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months",
            "tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  Progression of disease was determined if at least 1 of the following criteria applied: At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions ",
            "Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 monthsResults 1: Arm/Group Title: Afatinib + Vinorelbine (AV) Arm/Group Description: Participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of each course  The treatment was administered in treatment courses of 28 days  For Afatinib  a protocol-defined dose-reduction scheme was to be followed if a participant experienced certain pre-specified adverse events  From 26 April 2013, any participant who had been randomised to the AV arm stopped treatment  had the option to switch to Trastuzamb + Vinorelbine  Overall Number of Participants Analyzed: 339 Median (Inter-Quartile Range) ",
            "Unit of Measure: Months 5.49 (3.55 to 9.07)"
        ],
        "premise_nums": [
            "Trastuzamb + Vinorelbine  Overall Number of Participants Analyzed: 339 Median (Inter-Quartile Range)",
            "was administered in treatment courses of 28 days  For Afatinib",
            "tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2",
            "in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of",
            "Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of Measure: Months 5.49 (3.55 to 9.",
            "10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of each course  The treatment was",
            "adverse events  From 26 April 2013, any participant who had been randomised",
            "disease was determined if at least 1 of the following criteria applied: At least a 20% increase in the sum of the",
            "taking as reference the smallest SoD recorded since the",
            "in the SoD of at least 5 mm Appearance of 1 or data cut-off (08Jun2013); Up to 34 monthsResults 1: Arm/Group Title: Afatinib",
            "RECIST 1.1 based endpoints (08Jun2013) were considered  Progression of disease was determined if at least 1 of the following criteria applied:",
            "in the SoD of at least 5 mm Appearance of 1 or death whichever occurs first  Assessed by investigator according"
        ]
    },
    {
        "id": "634642da-db6d-49cc-a999-67f46e91dbca",
        "primaryId": "NCT01237327",
        "secondaryId": "NCT00030823",
        "statement_text": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria ",
        "statement_nums": [
            "the primary trial and the secondary trial do not have any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer at high risk for recurrence  defined by one of the following: Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy May or may not have elevated CA 15-3 or CEA levels Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart Stage III and completed adjuvant therapy no more than 24 months ago Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection ",
            "Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months agoStage IV that is stable on hormonal therapy Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female Menopausal status: Not specified Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No clinically significant New York Heart Association class III or IV cardiac disease Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No prior seafood allergy No known prior immunodeficiency or autoimmune disease No other active cancer except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine with any of the antigens in this study Chemotherapy: See Disease Characteristics ",
            "At least 4 weeks since prior chemotherapyNo concurrent chemotherapy Endocrine therapy: See Disease Characteristics Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics At least 4 weeks since prior surgery Concurrent surgery for local recurrence allowed if patient remains disease free "
        ],
        "premise_nums": [
            "specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Male or female Menopausal",
            "or may not have elevated CA 15-3 or CEA levels Stage I  II",
            "on 2 consecutive occasions at least 2 weeks apart For patients witherapy no more than 24 months agoStage IV that is stable on",
            "previously participated in study 971-ONC-0028-080. DISEASE CHARACTERISTICS: Diagnosis of breast cancer",
            "times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart For patients with a significant",
            "Previous participation in study 971-ONC-0028-080. Exclusion Criteria: Subjects who had not have elevated CA 15-3 or CEA levels Stage I  II",
            "a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2",
            "Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago Recurrence in the",
            "times ULN Cardiovascular: No clinically significant New York Heart",
            "Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months agoStage IV that is",
            "Lymphocyte count at least 500/mm^3 WBC at least 3,000/mm^3 Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline",
            "At least 4 weeks since prior chemotherapyNo concurrent chemotherapy Endocrine",
            "CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior vaccine",
            "Hepatic: AST no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 1.5 times ULN Renal: Creatinine no greater than",
            "surgery for local recurrence allowed if patient remains disease  but have rising CA 15-3 or CEA levels Rising",
            "completed adjuvant therapy no more than 24 months agoStage IV that is free of all known disease after eradication by"
        ]
    },
    {
        "id": "a529e364-2da7-4067-acb6-9fb2f0adf08b",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial ",
        "statement_nums": [
            "T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; "
        ],
        "premise_nums": [
            "Must be 4 weeks since all of the following treatments (recovered",
            "toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy;"
        ]
    },
    {
        "id": "317e00ae-9d17-4f85-8787-602cc2548fdb",
        "primaryId": "NCT00004092",
        "statement_text": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "No histologically proven bone marrow metastasis "
        ],
        "premise_nums": [
            "No histologically proven bone marrow metastasis"
        ]
    },
    {
        "id": "de955acc-ce0e-4416-9884-644a06971603",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "statement_text": "Cohort 2 of the primary trial and the secondary trial are test groups ",
        "statement_nums": [
            "Cohort 2 of the primary trial and the secondary trial are test groups"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  "
        ],
        "premise_nums": [
            "four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and",
            "three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting"
        ]
    },
    {
        "id": "4956f0d0-4df4-4de3-9a46-6073927485c3",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "statement_text": "the secondary trial has more patients cohorts than the primary trial ",
        "statement_nums": [
            "the secondary trial has more patients cohorts than the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Electronic Brachytherapy Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System  Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using Iridium-192, but was FDA cleared for use prior to commencing study enrollment using an electronic source  INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule "
        ],
        "premise_nums": [
            "Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System",
            "(SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300",
            "of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination",
            "Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51",
            "used by physicians using Iridium-192, but was FDA cleared for use",
            "Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination"
        ]
    },
    {
        "id": "70dd1a42-6e40-4880-80a8-45dfd4941ce4",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration ",
        "statement_nums": [
            "the primary trial uses a 3 week cycle for SB-715992 administration"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  "
        ],
        "premise_nums": [
            "Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for",
            "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib"
        ]
    },
    {
        "id": "85f43677-b680-4127-b1da-7e1cc966e4b2",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "statement_text": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi ",
        "statement_nums": [
            "Not all subjects in the primary trial will be adminstered 4-8 mCi Tc-99m sestamibi"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Overall Population Each subject served as",
            "breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi"
        ]
    },
    {
        "id": "4cccea8a-22ae-4813-96df-b902850f4991",
        "primaryId": "NCT01783444",
        "secondaryId": "NCT03136367",
        "statement_text": "Women of any age can participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "can participate in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Key Inclusion Criteria: - Women with locally advanced  recurrent  or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)  Measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above  Key Exclusion Criteria: - Patients who received more than one chemotherapy line  Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane  mTOR inhibitors  PI3K inhibitors or AKT inhibitors  Inclusion Criteria: Assigned female at birth; 18 years and older; "
        ],
        "premise_nums": [
            "mTOR inhibitors  PI3K inhibitors or AKT inhibitors  Inclusion",
            "or mixed (lytic + blastic) in the absence of",
            "Criteria: - Women with locally advanced  recurrent",
            "Measurable disease defined as at least one lesion 10 mm by CT or MRI that can",
            "one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic",
            "Assigned female at birth; 18 years and older;"
        ]
    },
    {
        "id": "8574ecd7-4da7-49b0-a273-de495bc1fee7",
        "primaryId": "NCT00951665",
        "statement_text": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial",
        "statement_nums": [
            "adverse events for patients in cohort 1 of the primary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) "
        ],
        "premise_nums": [
            "cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%)",
            "0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%)",
            "(0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device",
            "Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown",
            "1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure"
        ]
    },
    {
        "id": "01b82c51-dd3d-430b-9523-0e93a9eb9c1a",
        "primaryId": "NCT00950300",
        "secondaryId": "NCT00615901",
        "statement_text": "the primary trial recorded a multitude of patients with chest pain  whereas the secondary trial observed only one patient with abdominal pain ",
        "statement_nums": [
            "pain  whereas the secondary trial observed only one patient",
            "the primary trial recorded a multitude of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%)"
        ]
    },
    {
        "id": "93149dfc-667b-48d3-a46d-ad48b15e701f",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events ",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial recorded exactly the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) ",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%)",
            "Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39",
            "Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94",
            "Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%)",
            "(2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%)",
            "0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%)",
            "Oedema peripheral 1/94 (1.06%) Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic"
        ]
    },
    {
        "id": "d080eec7-412f-4a44-8c56-91e0ec459acc",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks ",
        "statement_nums": [
            "II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice",
            "the primary trial is a phase II"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  "
        ],
        "premise_nums": [
            "The duration of treatment will be 4 weeks",
            "phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All"
        ]
    },
    {
        "id": "fd18a599-f94a-478a-975f-854a4210ccad",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is only a single day after removal of the drains ",
        "statement_nums": [
            "primary trial has a 5 year long intervention  the duration of the secondary trial is only a single",
            "the primary trial has a 5 year long intervention  the duration of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  ",
            "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  "
        ],
        "premise_nums": [
            "Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg",
            "20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function",
            "orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen",
            "parent study  IBCSG 24-02 (SOFT)  The sample size",
            "25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for",
            "will be examined by ultrasonography INTERVENTION 2: Double Drain Insertion of double"
        ]
    },
    {
        "id": "ac9ca070-80b2-4913-97d8-06d1b90fcfce",
        "primaryId": "NCT01797120",
        "secondaryId": "NCT02005887",
        "statement_text": "the secondary trial and the primary trial both have a placebo arm and a test arm ",
        "statement_nums": [
            "the secondary trial and the primary trial both have a placebo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 2: Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles)  If no evidence of disease progression after 12 cycles  unblind and continue same dose and schedule until progression or unacceptable toxicity  Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles  Placebo manufactured to mimic everolimus tablet  INTERVENTION 1: Arm A: Triptorelin + Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 2: Arm B: Degarelix + Letrozol ",
            "Arm B: Degarelix 240 mg s.c  on day 1 of cycle 1, followed by 80 mg s.c  on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cyclesDegarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment  followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles "
        ],
        "premise_nums": [
            "every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles",
            "skin given as two injections of 120 mg on the first day 1 of cycles 2 to 6 + letrozole 2.5 mg every",
            "for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 of cycle 1, followed by 80 mg s.c",
            "s.c  on day 1 of cycles 2 to 6 + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg",
            "Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of cycle 1, followed by 80 mg s.c  on day",
            "2.5 mg orally every day for 6 cycles INTERVENTION 2: Arm B: Degarelix 240 mg s.c  on day 1 of",
            "(1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 2: Arm B: Degarelix + Letrozol",
            "cycle 1, followed by 80 mg s.c  on day 1 of cycles 2 to 6 + letrozole 2.5 mg every",
            "Arm B: Degarelix 240 mg s.c  on day 1 of cycles 2 to 6 + letrozole 2.5 mg every",
            "(1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cyclesDegarelix: Degarelix 240 mg injected under the skin given as",
            "1 of cycle 1, followed by 80 mg s.c  on day 1 of cycles 2 to 6 + letrozole 2.5",
            "240 mg s.c  on day 1 of cycle 1, followed by injection of 80 mg on day 1 of cycles 2",
            "for 6 cyclesDegarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day",
            "+ letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6",
            "no evidence of disease progression after 12 cycles  unblind and continue",
            "day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into",
            "2 to 6 + letrozole 2.5 mg every day orally for 6 cyclesDegarelix: Degarelix 240 mg injected under the skin given as",
            "cycle 1, followed by 80 mg s.c  on day 1 of cycle 1, followed by 80 mg s.c  on day",
            "3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin:",
            "Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle",
            "1 of cycle 1, followed by 80 mg s.c  on day 1 of cycle 1, followed by 80 mg s.c",
            "(1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cyclesDegarelix: Degarelix 240 mg injected under the skin given as",
            "(1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle",
            "for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 of cycles 2 to 6 + letrozole 2.5",
            "day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cyclesDegarelix: Degarelix 240 mg injected",
            "skin given as two injections of 120 mg on the first day of treatment  followed"
        ]
    },
    {
        "id": "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21",
        "primaryId": "NCT00082810",
        "statement_text": "Throughout the duration of the primary trial  pariticpants receive increasing doses of Fulvestrant ",
        "statement_nums": [
            "the duration of the primary trial  pariticpants receive increasing"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28",
            "mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in",
            "on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of"
        ]
    },
    {
        "id": "5152d810-7669-4fb2-a66b-a0a1d6026af5",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "statement_text": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure  and use a 6 month time frame ",
        "statement_nums": [
            "the secondary trial and the primary trial both use Pathologic complete",
            "outcome measure  and use a 6 month time frame"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (CR + PR + SD greater than 6 Months)  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease greater than 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer  This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline through end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs  Placebo for PIK3CA Mutant Cohort ",
            "Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy  or who did not receive surgery for any reason  or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate Time frame: After 24 weeks of treatment "
        ],
        "premise_nums": [
            "end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR)",
            "ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression",
            "Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and",
            "had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline",
            "+ PR + SD greater than 6 Months)  To determine the",
            "reason  or received antineoplastic treatment other than study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR)"
        ]
    },
    {
        "id": "3fa8b747-b48d-4fb4-995d-38a23c64ccb3",
        "primaryId": "NCT02069093",
        "statement_text": "2 of the patients in the primary trial were either symptomatic  but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences ",
        "statement_nums": [
            "2 of the patients in the primary trial were either symptomatic",
            "but able to swallow a modified diet; symptomatic"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 = minimal symptoms  normal diet; grade 2 = symptomatic  but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without food or drink (NPO) for one hour after administration of the mouthwash  Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations  Overall Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 ",
            "Stomatitis grade greater than or equal 2: Not evaluable: 1"
        ],
        "premise_nums": [
            "or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater",
            "daily (qid) orally for 2 minutes each for 8 weeks  Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational",
            "consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash",
            "Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 =",
            "Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: Not evaluable:",
            "Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations",
            "aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening"
        ]
    },
    {
        "id": "b9c294c3-93b7-4681-be02-285f9e5cd867",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "statement_text": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort ",
        "statement_nums": [
            "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast",
            "and clear margins  will receive 15 doses of radiation over three weeks",
            "whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost",
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three",
            "wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions simultaneously with a boost treatment",
            "times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive"
        ]
    },
    {
        "id": "9df90d78-d857-4e1d-a650-e47f7b6b68d6",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone  at a higher frequency  than cohort 1,",
        "statement_nums": [
            "Cohort 2 of the primary trial receive a higher frequency  than cohort 1,",
            "Cohort 2 of the primary trial receive a higher dose"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV",
            "25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to",
            "IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants",
            "mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin",
            "INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV"
        ]
    },
    {
        "id": "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe",
        "primaryId": "NCT03098550",
        "statement_text": "There results section indicates there were no patients in the primary trial with 0 adverse events ",
        "statement_nums": [
            "no patients in the primary trial with 0 adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
            "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab +",
            "Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0%",
            "Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title:",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41",
            "16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of",
            "16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure",
            "cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 30 days post last dose (up to 34 months)"
        ]
    },
    {
        "id": "92ac6e0c-8427-454d-9218-36eda1c580a7",
        "primaryId": "NCT01653964",
        "secondaryId": "NCT02660788",
        "statement_text": "The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them ",
        "statement_nums": [
            "The interventions in the primary trial and the secondary trial are so different that"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter "
        ],
        "premise_nums": [
            "Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm",
            "breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1:"
        ]
    },
    {
        "id": "f0aff1fc-4a67-4b28-a974-a4a67a5c930f",
        "primaryId": "NCT00733408",
        "statement_text": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "There was over 14 weeks difference in Progression-free Survival between the",
            "maximum PFS in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results  Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years Results 1: Arm/Group Title: Tx (Chemo  MoAb  and Enzyme Inhibitor) ",
            "Arm/Group Description: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity MAINTENANCE THERAPY: Patients achieving complete response  partial response  or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity  paclitaxel albumin-stabilized nanoparticle formulation: Given IV bevacizumab: Given IV erlotinib hydrochloride: Given PO Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1) "
        ],
        "premise_nums": [
            "receive bevacizumab IV over 30-90 minutes once every 14 or 21 days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on",
            "A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel-",
            "Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1)",
            "receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO",
            "be used  A 95% confidence interval for the median PFS",
            "any cause  assessed up to 8 years Results 1: Arm/Group Title: Tx (Chemo",
            "However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median",
            "days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days",
            "Treatment repeats every 28 days for 6 courses in the absence of Measure: Months 9.1 (7.2 to 11.1)",
            "or greater (regardless of whether the 95% confidence interval for the mediand bevacizumab IV over 30-90 minutes on days 1 and 15.",
            "registration to date of first documentation of progression or symptomatic",
            "days 1, 8, and 15 and bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6",
        "primaryId": "NCT00121836",
        "secondaryId": "NCT00256243",
        "statement_text": "Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part ",
        "statement_nums": [
            "for participation of the primary trial or the secondary trial will not be made"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Women greater than or equal 18 years of age HER2-negative metastatic breast cancer Previous adjuvant chemotherapy or hormonal treatment greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment with chemotherapy  an anti-angiogenic agent  or a biologic therapy for advanced or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy Central nervous system metastases Other malignancy within last 5 years  except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix Serious concurrent infection All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  "
        ],
        "premise_nums": [
            "greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment",
            "system metastases Other malignancy within last 5 years  except cured basal",
            "or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient",
            "greater than or equal 18 years of age HER2-negative metastatic breast cancer Radiation therapy within 4 weeks of study treatment start or insufficient"
        ]
    },
    {
        "id": "96ab702d-cfe1-48fb-b348-a7c7b8db3f16",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months ",
        "statement_nums": [
            "Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) Analysis of the primary endpoint  PFS  will be performed using Cox regression with treatment group as a single covariate  Time frame: From randomization to the earliest date of documentation of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group Description: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO Overall Number of Participants Analyzed: 19 Median (95% Confidence Interval) Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6) "
        ],
        "premise_nums": [
            "of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group",
            "(PFS) Analysis of the primary endpoint  PFS  will",
            "once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Participants Analyzed: 19 Median (95% Confidence Interval) Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6)",
            "oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on"
        ]
    },
    {
        "id": "95154c62-9f79-4d80-90fd-2f61612285b0",
        "primaryId": "NCT01095003",
        "secondaryId": "NCT01702571",
        "statement_text": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache ",
        "statement_nums": [
            "In total more than 5 patients in the primary trial and the secondary trial experienced Earache"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2: Total: 85/383 (22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) ",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) Adverse Events 1: Total: 427/2002 (21.33%) ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ANAEMIA 0/181 (0.00%) ",
            "BONE MARROW FAILURE 0/181 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC ARREST 0/181 (0.00%) CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181 (0.00%) "
        ],
        "premise_nums": [
            "INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC",
            "(0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002",
            "INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC",
            "THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002",
            "(5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2:",
            "(0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181 (0.00%)",
            "Adverse Events 2: Total: 85/383 (22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%)",
            "NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC ARREST 0/181",
            "(0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ANAEMIA 0/181",
            "CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ANAEMIA 0/181 (0.00%)",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383",
            "(0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2:",
            "Total: 427/2002 (21.33%) ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383",
            "Abdominal pain 3/383 (0.78%) Adverse Events 1: Total: 427/2002 (21.33%) ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION",
            "NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%) ANGINA PECTORIS 1/2002 (0.05%) CARDIAC",
            "(0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) Adverse Events 1: Total: 427/2002",
            "MARROW FAILURE 0/181 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%)",
            "(0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2:",
            "ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%)",
            "Adverse Events 2: Total: 36/181 (19.89%) ANAEMIA 0/181 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383",
            "anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%)",
            "CARDIAC ARREST 1/2002 (0.05%) CARDIAC FAILURE 1/2002 (0.05%) CARDIAC TAMPONADE 1/2002 (0.05%) Adverse Events 2: Total: 36/181 (19.89%) ANAEMIA 0/181",
            "CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383",
            "(27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Abdominal pain 3/383 (0.78%) Adverse Events 1: Total: 427/2002",
            "4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris",
            "(5.52%) ACUTE CORONARY SYNDROME 1/181 (0.55%) ANGINA PECTORIS 0/181 (0.00%) CARDIAC ARREST 0/181 (0.00%) CARDIAC FAILURE 0/181 (0.00%) CARDIAC TAMPONADE 0/181",
            "ANAEMIA 13/2002 (0.65%) BONE MARROW FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 0/181 (0.00%) FEBRILE NEUTROPENIA 0/181 (0.00%) THROMBOCYTOPENIA 10/181 (5.52%)",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383",
            "FAILURE 1/2002 (0.05%) DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%) FEBRILE NEUTROPENIA 1/2002 (0.05%) THROMBOCYTOPENIA 11/2002 (0.55%) ACUTE CORONARY SYNDROME 3/2002 (0.15%)"
        ]
    },
    {
        "id": "2f6243a9-af40-426d-9a6a-a5c5708cf1b4",
        "primaryId": "NCT00721630",
        "secondaryId": "NCT00364611",
        "statement_text": "the primary trial and the secondary trial recorded the exact same number of cases of nausea ",
        "statement_nums": [
            "the primary trial and the secondary trial recorded the exact same"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%)"
        ]
    },
    {
        "id": "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "statement_text": "Patients in the primary trial will not be made to take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously like those in the secondary trial ",
        "statement_nums": [
            "Patients in the primary trial will not be made",
            "like those in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy  FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2), and post therapy (within 3 weeks prior to surgery  FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography: Undergo 18F-FLT PET/CT Computed Tomography: Undergo 18F-FLT PET/CT Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  ",
            "Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal  INTERVENTION 2: MYL-1401O Trastuzumab + Taxane Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior PR  CR at cycle 9 (week 24) proceed to Herceptin©",
            "Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject",
            "weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If",
            "1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice)",
            "Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice)",
            "and post therapy (within 3 weeks prior to surgery  FLT-3). Patients",
            "FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2),",
            "weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint",
            "9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once",
            "INTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously",
            "neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography:",
            "or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject",
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to"
        ]
    },
    {
        "id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
        "primaryId": "NCT02630693",
        "statement_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "A 30% of patients in the primary trial suffered a life-threatening reaction"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) ",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) "
        ],
        "premise_nums": [
            "2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general",
            "(2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites",
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90",
            "general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%)",
            "1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders",
            "general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%)",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%)",
            "9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general",
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89",
            "hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2:",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia",
            "1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders",
            "2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%)"
        ]
    },
    {
        "id": "d72ecaae-c132-480c-af5e-87c58dd26082",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "statement_text": "The only adverse event observed in Patients from both the secondary trial and the primary trial  was Endocervical cancer ",
        "statement_nums": [
            "Patients from both the secondary trial and the primary trial  was Endocervical cancer"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) ",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) "
        ],
        "premise_nums": [
            "1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%)",
            "Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%)",
            "(0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%)",
            "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary",
            "0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69",
            "(0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69",
            "2: Total: 17/66 (25.76%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244",
            "neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69",
            "14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69",
            "(0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69",
            "1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia",
            "1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69",
            "1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular",
            "(1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer"
        ]
    },
    {
        "id": "80245791-4a95-4682-bd5f-856694c9f52f",
        "primaryId": "NCT00721409",
        "secondaryId": "NCT02413320",
        "statement_text": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial",
        "statement_nums": [
            "Patients with HER2 negative tumours are eligible for the primary trial but not for the",
            "are eligible for the primary trial but not for the secondary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Inoperable estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients with newly diagnosed stage I (Tgreater than 1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy "
        ],
        "premise_nums": [
            "estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients",
            "newly diagnosed stage I (Tgreater than 1cm), II or III triple"
        ]
    },
    {
        "id": "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  to be able to speak a specific language or to be above a certain height threshold ",
        "statement_nums": [
            "the secondary trial and the primary trial do not require participants"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion criteria: Female patients greater than or equal 18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer Locally advanced or metastatic disease Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients  must have failed prior trastuzumab treatment Investigator-confirmed diagnosis of Inflammatory Breast Cancer Must have biopsiable disease Exclusion criteria: Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population) Must not have received prior vinorelbine treatment INCLUSION CRITERIA: Postmenopausal female  Postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy  In unclear cases  (e.g  50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with follicle stimulating hormone (FSH) greater than 35 U/L  Elevated risk for developing invasive breast cancer by virtue of one of the following criteria: ",
            "Gail Model risk of greater than or equal to 1.7% over 5 years from study entry  (This is the same minimum level of risk required for a subject to be eligible for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial) Lobular neoplasia  Atypical ductal hyperplasia  DCIS (ductal carcinoma in situ) that has been previously treated with mastectomy or lumpectomy and radiation  +/- tamoxifen  Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2 gene mutation  The BRCAPRO and Couch model will both be used to asses this risk  If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will meet eligibility criteria  Prior stage I or II breast cancer at least 2 years out from treatment for invasive disease and no prior use of aromatase inhibitors  ",
            "Subjects should be willing to abstain from use of hormonal therapies (e.g  tamoxifen  hormone replacement therapy  oral contraceptive pills  hormone-containing intrauterine devices (IUDs)  E-string is acceptable)  Venlafaxine will be offered as supportive care for women with menopausal symptoms Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her options and has signed the informed consent document  Baseline dual-emission x-ray absorptiometry (DEXA) scan with bone mineral density (BMD) T-score greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin greater than or equal to 11 g/dl  Creatinine less than 1.5 times the upper limits of normal  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times upper limit of normal  No investigational agent for the past 30 days  ",
            "If history of cancer (other than squamous or basal cell skin cancers)  subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment EXCLUSION CRITERIA: Current or recent chronic use (within 3 months) of hormonal medications  e.g  oral contraceptive pills  hormone replacement therapy  tamoxifen  raloxifene  IUD with progestins or corticosteroids  (Subjects on chronic topical or inhaled steroids will be eligible for the study.) Current use of phenytoin  carbamazepine  rifampin due to increased estrogen metabolism  History of clotting or bleeding disorder  History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane (e.g  anastrozole  letrozole  formestane)  Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements  "
        ],
        "premise_nums": [
            "of greater than or equal to 1.7% over 5 years from study entry  (This is",
            "Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her",
            "of cancer directed treatment in the 2 years preceding enrollment EXCLUSION CRITERIA: Current or",
            "as no menses for at least 12 months or bilateral oophorectomy  In unclear",
            "directed treatment in the 2 years preceding enrollment EXCLUSION CRITERIA: Current or aspartate aminotransferase (AST) less than 2.5 times upper limit of",
            "aspartate aminotransferase (AST) less than 2.5 times upper limit of normal  No investigational agent for the past 30 days",
            "Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2",
            "T-score greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin",
            "can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients",
            "with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer at least 2 years out from treatment for invasive disease",
            "disorder  History of allergic reactions attributed to compounds",
            "greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin greater than or equal to 11 g/dl  Creatinine less than",
            "If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will",
            "follicle stimulating hormone (FSH) greater than 35 U/L  Elevated risk for developing",
            "or II breast cancer at least 2 years out from treatment for invasive disease",
            "cases  (e.g  50 year old who has had hysterectomy) chemical"
        ]
    },
    {
        "id": "f0da58e6-e937-41ac-b53a-d46ec8a28d11",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily ",
        "statement_nums": [
            "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  "
        ],
        "premise_nums": [
            "Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily"
        ]
    },
    {
        "id": "5a74a63a-3912-44f0-9e83-4e6b678cbe90",
        "primaryId": "NCT02685566",
        "secondaryId": "NCT03076190",
        "statement_text": "the primary trial and the secondary trial have the same number of study groups  and are both testing the effectiveness of Full-Field Digital Mammography ",
        "statement_nums": [
            "the primary trial and the secondary trial have the same number"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 2: Full-Field Digital Mammography (FFDM) Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group "
        ],
        "premise_nums": [
            "Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group",
            "Plus DBT: FujiFilm Aspire Cristalle System  This endpoint"
        ]
    },
    {
        "id": "43f03ba4-ef03-4f57-b059-3d9267f0dcf8",
        "primaryId": "NCT00325234",
        "statement_text": "Patients under the age of 18, wanting to participate in the primary trial  must discontinue any Antitumoral hormonal treatment prior to study entry  and have a life expectancy of more than 3 months ",
        "statement_nums": [
            "a life expectancy of more than 3 months",
            "Patients under the age of 18, wanting to participate in the primary trial  must discontinue any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Antitumoral hormonal treatment must be discontinued prior to enrollment  Estimated life expectancy of at least 3 months  Female participants must be at least 18 years of age  "
        ],
        "premise_nums": [
            "Estimated life expectancy of at least 3 months  Female participants must be at least 18 years of age"
        ]
    },
    {
        "id": "6e106caf-2522-4022-898d-64b82093d77a",
        "primaryId": "NCT02413320",
        "statement_text": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer  are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "Females over the age of 20 with no prior chemotherapy with therapeutic intent"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: No prior chemotherapy  endocrine therapy or radiation therapy with therapeutic intent for this cancer Female subjects age 18 - 70 years "
        ],
        "premise_nums": [
            "for this cancer Female subjects age 18 - 70 years"
        ]
    },
    {
        "id": "7f8a918c-fab8-4129-8178-0cda7d0441e1",
        "primaryId": "NCT00021255",
        "statement_text": "Cohort 2 of the primary trial recieves Doxorubicin  cyclophosphamide  Herceptin and docetaxel throughout the cycles of the study ",
        "statement_nums": [
            "Cohort 2 of the primary trial recieves Doxorubicin  cyclophosphamide"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: AC Followed by Docetaxel + Herceptin (AC→TH) Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles)  After completion of the last cycle of chemotherapy  Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose  "
        ],
        "premise_nums": [
            "IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV bolus Injection on Day 1 of every 3 weeks for",
            "starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg",
            "4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg",
            "mg/m² IV bolus Injection on Day 1 of every 3 weeks for all subsequent cycles ( total 4",
            "IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on",
            "of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV",
            "bolus Injection on Day 1 of every 3 weeks for 4 cycles  Herceptin 4 mg/kg IV infusion on Day 1 of",
            "of chemotherapy  Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose",
            "IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from",
            "IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for 4 cycles  Herceptin 4"
        ]
    },
    {
        "id": "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d",
        "primaryId": "NCT01125566",
        "statement_text": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months ",
        "statement_nums": [
            "At least 400 participants in the primary trial receiving an oral treatment",
            "once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months",
            "tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as time from randomisation to disease progression or death whichever occurs first  Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve (\"respond\")  stay the same (\"stabilize\") or worsen (\"progress\") during treatment  Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered  Progression of disease was determined if at least 1 of the following criteria applied: At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started  together with an absolute increase in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of existing non-target lesions ",
            "Time frame: From randomization (07Sep2010) until disease progression  death or data cut-off (08Jun2013); Up to 34 monthsResults 1: Arm/Group Title: Afatinib + Vinorelbine (AV) Arm/Group Description: Participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of each course  The treatment was administered in treatment courses of 28 days  For Afatinib  a protocol-defined dose-reduction scheme was to be followed if a participant experienced certain pre-specified adverse events  From 26 April 2013, any participant who had been randomised to the AV arm stopped treatment  had the option to switch to Trastuzamb + Vinorelbine  Overall Number of Participants Analyzed: 339 Median (Inter-Quartile Range) ",
            "Unit of Measure: Months 5.49 (3.55 to 9.07)"
        ],
        "premise_nums": [
            "Trastuzamb + Vinorelbine  Overall Number of Participants Analyzed: 339 Median (Inter-Quartile Range)",
            "was administered in treatment courses of 28 days  For Afatinib",
            "tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2",
            "in the SoD of at least 5 mm Appearance of 1 or more new lesions Unequivocal progression of",
            "Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of Measure: Months 5.49 (3.55 to 9.",
            "10 minutes intravenous infusion of Vinorelbine 25 mg/meter^2 (meter=m) on days 1, 8, 15, and 22 of each course  The treatment was",
            "adverse events  From 26 April 2013, any participant who had been randomised",
            "disease was determined if at least 1 of the following criteria applied: At least a 20% increase in the sum of the",
            "taking as reference the smallest SoD recorded since the",
            "in the SoD of at least 5 mm Appearance of 1 or data cut-off (08Jun2013); Up to 34 monthsResults 1: Arm/Group Title: Afatinib",
            "RECIST 1.1 based endpoints (08Jun2013) were considered  Progression of disease was determined if at least 1 of the following criteria applied:",
            "in the SoD of at least 5 mm Appearance of 1 or death whichever occurs first  Assessed by investigator according"
        ]
    },
    {
        "id": "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "statement_text": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial ",
        "statement_nums": [
            "be included in the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Active infection or unexplained fever greater than 38.5°C during screening  Inclusion Criteria: Tissue diagnosis of a breast carcinoma The oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen Have acceptable organ function within 14 days of enrollment defined as: liver function: total bilirubin  AST and ALT within normal institutional limits kidney function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) - formula: (140 - age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written informed consent indicating an understanding of the investigational nature of the study Agrees not to consume grapefruit juice while on the study Exclusion Criteria: Known allergy to enalapril Taking any known P450 cytochrome inducers or inhibitors Taking any herbal supplements while on the study or the week prior to receiving doxorubicin Taking an ace-inhibitor or angiotensin receptor blocker Pregnant or lactating  Enalapril is Pregnancy Categories C (first trimester) and D (second and third trimesters) "
        ],
        "premise_nums": [
            "acceptable organ function within 14 days of enrollment defined as: liver function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for",
            "function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) -",
            "infection or unexplained fever greater than 38.5°C during screening  Inclusion",
            "age) x weight x .85 divided by (sCr x 72) At leastudy Exclusion Criteria: Known allergy to enalapril Taking any",
            "regimen Have acceptable organ function within 14 days of enrollment defined as: liver function:",
            "study Exclusion Criteria: Known allergy to enalapril Taking any known P450 cytochrome inducers or inhibitors Taking any herbal",
            "age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written",
            "is Pregnancy Categories C (first trimester) and D (second and third trimesters)"
        ]
    },
    {
        "id": "505afbf8-b2b4-4b12-99c5-e0feef473248",
        "primaryId": "NCT00577122",
        "secondaryId": "NCT01923168",
        "statement_text": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure  and they do not use the same time frame ",
        "statement_nums": [
            "the secondary trial and the primary trial do not both use"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (CR + PR + SD greater than 6 Months)  To determine the clinical benefit rate (Complete Response + Partial Response + Stable Disease greater than 6 months) per Response Evaluation Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer  This will show the percent of patients who had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline through end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs  Placebo for PIK3CA Mutant Cohort ",
            "Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy  or who did not receive surgery for any reason  or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate Time frame: After 24 weeks of treatment "
        ],
        "premise_nums": [
            "end of study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR)",
            "ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression",
            "Criteria in Solid tumors (RECIST version 1.0). of MPA monotherapy and",
            "had Clinical Benefit and the Exact 95% Confidence Interval  Time frame: baseline",
            "+ PR + SD greater than 6 Months)  To determine the",
            "reason  or received antineoplastic treatment other than study  up to 3 years Outcome Measurement: Pathological Complete Response (pCR)"
        ]
    },
    {
        "id": "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5",
        "primaryId": "NCT01816594",
        "secondaryId": "NCT02222337",
        "statement_text": "Patients with histologically confirmed  newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [
            "histologically confirmed  newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial  but may still",
            "be eligible for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish Exclusion Criteria: Inability to understand spoken English and/or Spanish and/or Cognitive impairment that precludes informed consent (determined by the PIs or Co-Investigators who are mental health professionals)  "
        ],
        "premise_nums": [
            "participate  Caregivers: a primary caregiver for a Latina breast"
        ]
    },
    {
        "id": "2e540abd-06e3-483d-bd69-6eb5d2275e9e",
        "primaryId": "NCT01830933",
        "secondaryId": "NCT01224678",
        "statement_text": "Patients in the primary trial and the secondary trial are administered daily oral medication ",
        "statement_nums": [
            "Patients in the primary trial and the secondary trial are administered daily oral"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Usual Care Usual Care is the comparison Clinic Patients  where there is no change in their standard or usual care  INTERVENTION 2: BreastCARE Intervention Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk  Intervention Patient Report  Once the patient completes the BreastCare Computer survey  the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk  This report will be printed and given to the patients before she meets with her doctor  BreastCARE : The physician will receive a physician report that contains information similar to the patient report  Patients receive oral vitamin D (2000 IU) once daily for 12 months  "
        ],
        "premise_nums": [
            "receive oral vitamin D (2000 IU) once daily for 12 months"
        ]
    },
    {
        "id": "d905f4cb-32aa-41b8-8f61-40578d8ea9ae",
        "primaryId": "NCT00274469",
        "statement_text": "No less than 2 patients from either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "No less than 2 patients from either cohorts of the primary trial felt nauseous"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%)"
        ]
    },
    {
        "id": "45510043-7931-493b-8251-41b0be9aabbd",
        "primaryId": "NCT00232505",
        "statement_text": "There were 2 instances of patients with Atrial tachycardia in the primary trial ",
        "statement_nums": [
            "There were 2 instances of patients with Atrial tachycardia in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify  __) * [1]0/31 (0.00%) Cardiac General - Other (Specify  __) * [2]0/31 (0.00%) Left ventricular diastolic dysfunction * 0/31 (0.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2: Total: 8/25 (32.00%) Edema: limb * 1/25 (4.00%) Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%) Cardiac General - Other (Specify  __) * [1]1/25 (4.00%) Cardiac General - Other (Specify  __) * [2]0/25 (0.00%) ",
            "Left ventricular diastolic dysfunction * 1/25 (4.00%)Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%) "
        ],
        "premise_nums": [
            "tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%)",
            "ventricular diastolic dysfunction * 1/25 (4.00%)Supraventricular and nodal arrhythmia - Atrial",
            "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify"
        ]
    },
    {
        "id": "5275a332-46c1-4941-8850-26a8033012e3",
        "primaryId": "NCT00981305",
        "statement_text": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial  as long as they are over the age of 20.",
        "statement_nums": [
            "are eliglbe for the primary trial  as long as",
            "they are over the age of 20."
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: breast cancer survivors over 20 years-old "
        ],
        "premise_nums": [
            "Inclusion Criteria: breast cancer survivors over 20 years-old"
        ]
    },
    {
        "id": "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0",
        "primaryId": "NCT01129622",
        "secondaryId": "NCT01156987",
        "statement_text": "the secondary trial and the primary trial both used MRI and Letrozole for their interventions ",
        "statement_nums": [
            "the secondary trial and the primary trial both used MRI and"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: "
        ],
        "premise_nums": [
            "healthy volunteers will be first screened for MRI contraindications",
            "(baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive"
        ]
    },
    {
        "id": "b02f43d7-44bb-4219-9a08-fd70e7cc9b87",
        "primaryId": "NCT01004744",
        "statement_text": "Patients must have a confirmed Postmenopausal status  defined as a lack of menses for over a year  if they are to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Postmenopausal status defined as cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month) "
        ],
        "premise_nums": [
            "cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month)"
        ]
    },
    {
        "id": "ec97c90e-f904-4cf2-9567-8525edf747cf",
        "primaryId": "NCT03196635",
        "secondaryId": "NCT01943916",
        "statement_text": "the primary trial and the secondary trial are both evaluating patient assisted imaging interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial are both evaluating patient"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  "
        ],
        "premise_nums": [
            "Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two",
            "evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study"
        ]
    },
    {
        "id": "7a129a1e-20d9-4f5a-a921-d30957460e27",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "statement_text": "the secondary trial and the primary trial do not test the same modalities of cancer treatments ",
        "statement_nums": [
            "the secondary trial and the primary trial do not test the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Plus Capecitabine Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 2: Trastuzumab Plus Capecitabine Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 1: Behavioral Dietary Intervention ",
            "Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and",
            "was taken with food or within 30 minutes after food  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered",
            "caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  and at least 2 weeks after radiation therapy)",
            "Beginning 2-4 weeks after completion of lumpectomy  patients",
            "IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received",
            "undergo radiation therapy QD 5 days a week for 6 weeks Behaviorally twice daily  12 hours apart)  for 14 days",
            "reduce caloric intake by 25% of their normal diet  Patients undergo radiation therapy QD 5 days a week for 6",
            "every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast",
            "was taken with food or within 30 minutes after food  Participants received a daily dose of 5 tablets of lapatinib (1250 mg)",
            "was taken with food or within 30 minutes after food  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered",
            "was taken with food or within 30 minutes after food  Participants received study",
            "also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days",
            "Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same",
            "days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy",
            "modifications to reduce caloric intake by 25% of their normal diet  Patients",
            "Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted",
            "receive food diaries to complete for 7-10 days  Dietary counselors then give",
            "Participants also received capecitabine 2000 mg/m^2) per day (divided and administereduce caloric intake by 25% of their normal diet  Patients",
            "radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo"
        ]
    },
    {
        "id": "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4",
        "primaryId": "NCT01566721",
        "statement_text": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "statement_nums": [
            "both cohorts of the primary trial is less than 1%",
            "Percentage of Participants With At Least 1 Adverse Event (AE) During the primary trial is less than 1%"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: Arm/Group Title: Cohort A: SC Herceptin by Needle/Syringe Arm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: ",
            "Arm/Group Title: Cohort B: SC Herceptin by SIDArm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP  Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants with at least 1 AE during the treatment period",
            "Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC",
            "planned to receive a total of 18 cycles of SC Herceptin as 600 mg every 3 weeks for a total of",
            "planned to receive a total of 18 cycles of SC Herceptin by an assisted administration as 600 mg every 3 weeks for",
            "pre-filled SID  The first administration was performed by an",
            "reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results",
            "planned to receive a total of 18 cycles of SC Herceptin  An AE",
            "Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2:",
            "Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period"
        ]
    },
    {
        "id": "a1c99d5b-d53a-4195-ad5f-5e1b48c22078",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "statement_text": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial  no robust comparisons"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Adverse Events 1: Total: 6/8"
        ]
    },
    {
        "id": "0203435e-03a0-4c41-afdf-6c497d8908c1",
        "primaryId": "NCT00331630",
        "statement_text": "Men with Left ventricular ejection fraction greater than 50% are excluded from participating in the primary trial ",
        "statement_nums": [
            "Left ventricular ejection fraction greater than 50% are excluded from participating in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "LVEF 50% as measured by echocardiogram or MUGA scan Male or female "
        ],
        "premise_nums": [
            "LVEF 50% as measured by echocardiogram or MUGA"
        ]
    },
    {
        "id": "e6388dc2-b096-467d-8b70-fd5346dd581a",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "statement_nums": [
            "event in both the primary trial and the secondary trial was 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%) Cardiac General - Other 2/2240 (0.09%) Endocrine - Other 1/2240 (0.04%) Ocular - Other 1/2240 (0.04%) Colitis 2/2240 (0.09%) Diarrhea 1/2240 (0.04%) Dysphagia 1/2240 (0.04%) Gastritis 1/2240 (0.04%) Adverse Events 1: Total: 6 Agranulocytosis 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%) Neutropenia 1/42 (2.38%) Thrombocytopenia 1/42 (2.38%) ",
            "Cardio-respiratory arrest 0/42 (0.00%)Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Fatigue 1/42 (2.38%) Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%) "
        ],
        "premise_nums": [
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%)",
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%)",
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%)",
            "effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%)",
            "effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61",
            "effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%)",
            "(1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "Cardio-respiratory arrest 0/42 (0.00%)Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%)",
            "neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61",
            "neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "(3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%)"
        ]
    },
    {
        "id": "93511e52-1c12-4dee-858e-13b10793e2a6",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "statement_text": "the secondary trial exclusively uses radiotherapy in its intervention  whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [
            "Cell Transplants on the first day of the study",
            "the secondary trial exclusively uses radiotherapy in",
            "intervention  whereas the primary trial gives its patient cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: High-dose Chemotherapy Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  Stem Cell Transplant : Stem Cell Transplant on Day 0. Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. "
        ],
        "premise_nums": [
            "receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell",
            "days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3",
            "days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses",
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with",
            "20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa",
            "higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium",
            "dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP."
        ]
    },
    {
        "id": "0b9aa7e8-5912-44db-b9b0-6a84df769e19",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions in the primary trial ",
        "statement_nums": [
            "sinus reactions in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 21/107 (19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107 (0.00%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 0/107 (0.00%) ",
            "Abdominal strangulated hernia * 1/107 (0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) "
        ],
        "premise_nums": [
            "Abdominal strangulated hernia * 1/107 (0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%)",
            "10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107",
            "(19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%)",
            "(0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia",
            "Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107",
            "(20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%)"
        ]
    },
    {
        "id": "570ab6bb-b23c-4955-b6b0-d756d1b69c0e",
        "primaryId": "NCT00756717",
        "statement_text": "Patients with cytologically confirmed  metastatic  early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial ",
        "statement_nums": [
            "Patients with cytologically confirmed  metastatic",
            "cancer with an Allred score of 3 are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory  and is not metastatic  - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy  "
        ],
        "premise_nums": [
            "Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that"
        ]
    },
    {
        "id": "0a17a404-ed1d-4c31-a192-509b68198ea8",
        "primaryId": "NCT00717405",
        "statement_text": "There was a dental adverse event in the primary trial ",
        "statement_nums": [
            "adverse event in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth loss * 1/52 (1.92%) Hyperthermia * 1/52 (1.92%) Malaise * 1/52 (1.92%) Pyrexia * 1/52 (1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%) "
        ],
        "premise_nums": [
            "(9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth",
            "(1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%)",
            "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%)"
        ]
    },
    {
        "id": "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial require participants to practice"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Group I (SparkPeople Program) Participants receive training on how to use the SparkPeople website  self-monitor their diet using the SparkPeople tool  and to self-monitor their activity daily using the Fitbit monitoring device  Participants receive weekly motivational reminders to log into the website for 3 months via email  text  or phone  based on patient preference (active phase)  Participants then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention: Use SparkPeople web-based program Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants receive the weight loss handout and a Fitbit activity monitor  After 6 months  participants receive the SparkPeople treatment  Exercise Intervention: Use Fitbit monitor Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group "
        ],
        "premise_nums": [
            "to log into the website for 3 months via email  text  or",
            "Wear Fitbit activity monitoring device INTERVENTION 1: Arm 1: Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group",
            "then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention:",
            "Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants"
        ]
    },
    {
        "id": "e8b86ef4-3ce8-4d81-a632-f30672c80ff5",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "statement_text": "Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres  whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [
            "Patients in the primary trial receive an Infusion of",
            "whereas in the secondary trial subjects are implanted with"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Definity Infusion Infusion of Definity (Perflutren Lipid Microspheres) Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  "
        ],
        "premise_nums": [
            "infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix",
            "tissue expander during the first stage of breast reconstruction",
            "Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix"
        ]
    },
    {
        "id": "879f2f14-38a8-419a-bae0-e62ed81eb9dd",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.",
        "statement_nums": [
            "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd"
        ]
    },
    {
        "id": "2ec46285-dd0c-4420-b9f6-e44a1ac74f20",
        "primaryId": "NCT01752907",
        "secondaryId": "NCT01940497",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial ",
        "statement_nums": [
            "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) ",
            "Abdominal pain 1/151 (0.66%)Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) ",
            "Neutropenia 0/20 (0.00%)Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Intervertebral disc protrusion 1/20 (5.00%) "
        ],
        "premise_nums": [
            "(1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151",
            "(10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive",
            "(0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Intervertebral disc protrusion 1/20 (5.00%)",
            "1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture",
            "1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151",
            "neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%)",
            "Abdominal pain 1/151 (0.66%)Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%)",
            "(1.99%) Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia",
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/20 (0.00%)Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%)",
            "Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation",
            "(13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive",
            "5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149",
            "(0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95",
            "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation",
            "failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%)",
            "(0.66%) Nausea 1/151 (0.66%) Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation",
            "Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation",
            "(1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2:",
            "neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149",
            "fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Nausea 1/151 (0.66%) Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia",
            "(0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "Abdominal pain 1/151 (0.66%)Diarrhoea 3/151 (1.99%) Dyspepsia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151",
            "(0.66%) Nausea 1/151 (0.66%) Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation",
            "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation",
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac",
            "0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Intervertebral disc protrusion",
            "Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 0/20 (0.00%)Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%)",
            "(0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%)",
            "1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%)",
            "(0.00%) Pryexia 0/20 (0.00%) Anaphylactic shock 0/20 (0.00%) Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%)",
            "1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151",
            "Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia",
            "(0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%)",
            "disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation"
        ]
    },
    {
        "id": "65f22210-47dd-4865-99e2-ddd414dddb08",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years ",
        "statement_nums": [
            "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7%",
            "to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of",
            "2 years for the primary analysis + 3 additional years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg",
            "came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg",
            "2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization",
            "Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7%",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "statement_text": "INR of 1.35 is enough for participation in the primary trial and the secondary trial ",
        "statement_nums": [
            "INR of 1.35 is enough for participation in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  "
        ],
        "premise_nums": [
            "ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion",
            "International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female"
        ]
    },
    {
        "id": "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial crashed their motorbike ",
        "statement_nums": [
            "One patient in cohort 2 of the primary trial crashed their motorbike"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) "
        ],
        "premise_nums": [
            "1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537",
            "0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537",
            "(0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%)"
        ]
    },
    {
        "id": "0aa3c085-b9c6-4918-a5d0-eabc55bdd177",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%)"
        ]
    },
    {
        "id": "333c2723-e2e8-4c68-9591-36b7f169ff26",
        "primaryId": "NCT00828074",
        "statement_text": "A higher percentage of cohort 1 of the primary trial showed signs of fever  compared to cohort 2.",
        "statement_nums": [
            "cohort 1 of the primary trial showed signs of fever  compared to cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%)"
        ]
    },
    {
        "id": "1fa01b9a-1288-404c-ad58-8dcf3db3264c",
        "primaryId": "NCT00477464",
        "statement_text": "59% of Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "or stable disease for at least 6 months",
            "59% of Arm A of the primary trial achieved a best overall"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number ",
            "Unit of Measure: percentage of participants 59"
        ],
        "premise_nums": [
            "Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily",
            "was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day",
            "6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib",
            "Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was",
            "twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants",
            "\"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the",
            "progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 Arm/Group Description: Participants took lapatinib",
            "Unit of Measure: percentage of participants 59",
            "who achieved a best overall response classified as a complete",
            "or stable disease for at least 6 months (24 weeks)  A \"complete response\""
        ]
    },
    {
        "id": "ed272c3f-37a1-4db7-8990-bf226f8c9822",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "statement_text": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial ",
        "statement_nums": [
            "of Diplopia in the primary trial as anemia in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) ",
            "Vomiting 0/6 (0.00%)Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) NEUTROPENIA 0/2 (0.00%) PANCYTOPENIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) ",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) PANCYTOPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) "
        ],
        "premise_nums": [
            "Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER",
            "Vomiting 0/6 (0.00%)Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2",
            "Hepatic failure [1]0/6 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%)",
            "Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%)",
            "(0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6",
            "(0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%)",
            "CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "(0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%)",
            "Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%)",
            "PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "(0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "(0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER",
            "1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "(0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "(0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1"
        ]
    },
    {
        "id": "b1497cf4-6b06-4227-b679-19e2ac5fb5c3",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS)  9 weeks after the start of treatment ",
        "statement_nums": [
            "the primary trial studies the effects of",
            "(CNS) Progression-free Survival(PFS)  9 weeks after the start of treatment"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT "
        ],
        "premise_nums": [
            "the time of best overall response  The response criteria",
            "2009). Time frame: 9 weeks from the start of the treatment"
        ]
    },
    {
        "id": "6b86f306-f989-4676-8f5e-c4c8a6aa4258",
        "primaryId": "NCT00470847",
        "statement_text": "the primary trial participants will receive either Lapatinib  WBRT or Herceptin ",
        "statement_nums": [
            "the primary trial participants will receive either"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lapatinib,Whole Brain Radiation,Herceptin Lapatinib before and during Whole Brain Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly "
        ],
        "premise_nums": [
            "Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly"
        ]
    },
    {
        "id": "0e8e4a92-b104-4192-ad36-33b683f94216",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial ",
        "statement_nums": [
            "difference in the results from the 9 mg and 18 mg group in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+ Subjects To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD  Time frame: 24 weeks Results 1: Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: participants 16 Results 2: ",
            "Arm/Group Title: GTx-024 18 mgArm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants 15 "
        ],
        "premise_nums": [
            "mgArm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether",
            "Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+",
            "SD  Time frame: 24 weeks Results 1: Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024",
            "Arm/Group Title: GTx-024 18 mgArm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily",
            "clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants",
            "daily to a total dose of 18 mg GTx-024: To determine whether either or both",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "or stable disease) according to RECIST 1.1, in subjects with estrogen"
        ]
    },
    {
        "id": "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "statement_text": "the primary trial has a topical intervention  whereas the secondary trial has both oral and IV interventions ",
        "statement_nums": [
            "the primary trial has a topical intervention  whereas the secondary trial has both oral and"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm A  INTERVENTION 1: Afatinib Monotherapy Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Afatinib and Paclitaxel or Vinorelbine Combination Therapy Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy "
        ],
        "premise_nums": [
            "area (breast or chest wall) for the duration of",
            "Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2:",
            "once daily at a dose of 40 milligram (mg) film-coated tablets until progression of",
            "Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous",
            "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to",
            "have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to",
            "for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once daily at a dose of 40 milligram (mg) film-coated tablets until"
        ]
    },
    {
        "id": "03a8a787-2bf3-43e5-9c9e-7bd9c3278751",
        "primaryId": "NCT00171704",
        "statement_text": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years ",
        "statement_nums": [
            "Letrozole group of the primary trial had a decreased Bone",
            "Density of the Lumbar Spine after 3 years"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range) ",
            "Unit of Measure: Percent Change 0.37 (-6.98 to 15.21)"
        ],
        "premise_nums": [
            "2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 68 Median (Full Range)",
            "Unit of Measure: Percent Change 0.37 (-6.98 to 15.21",
            "Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change 0.37 (-6.98 to 15.",
            "Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years",
            "was the lumbar spine (L2 to L4) and the secondary scanning site was the total",
            "Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63",
            "2.5 mg q.d  orally for 3 years  Overall Number of Participants Analyzed: 68 Median (Full Range)",
            "Time frame: Baseline  24 months Results 1: Arm/Group Title: Letrozole Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years",
            "Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent Change -4.63 (-14.21 to 4.32) Results 2: Arm/Group Title: Tam-Let",
            "daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d  orally for 3 years  Overall Number of",
            "after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until",
            "2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar",
            "of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray",
            "2.5 mg once daily (q.d.)orally for 5 years Overall Number of Participants Analyzed: 63 Median (Full Range) Unit of Measure: Percent"
        ]
    },
    {
        "id": "7d7a9a69-533a-4480-b2e7-aa59eb8a738b",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial  than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "6x higher in the HER2-positive group in the primary trial  than in the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months  Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles ",
            "Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1,Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) "
        ],
        "premise_nums": [
            "partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on",
            "by IV on day 1 of each 21 day cycle  Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage",
            "Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2",
            "lesions and PR is at least a 30% decrease in the sum of longest",
            "Baseline  Cycle 2 Day 1,Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until",
            "is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of",
            "60 mg tablet daily of each 21 day cycle  Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage",
            "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesions and PR is at least a 30% decrease in the",
            "for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily percentage of participants 14 (.4 to 58)",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort",
            "by IV on day 1 of each 21 day cycle  Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage",
            "or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated",
            "MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )"
        ]
    },
    {
        "id": "c6fc8336-7c74-443e-9548-3bbafe21fc37",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "In total Less than 10% of patients in the primary trial either had a disease"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane ",
            "Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 "
        ],
        "premise_nums": [
            "completing 2.5 years to 3 years of tamoxifen  participants were to complete a total of 5 years endocrine therapy Overall Number",
            "(Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events",
            "or Death) From Baseline up to 2.75 Years Number of events (disease relapse or",
            "(Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events",
            "were to complete a total of 5 years endocrine therapy Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events",
            "Baseline (Month 0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to",
            "0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall",
            "Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by"
        ]
    },
    {
        "id": "522ca0ec-aeb0-4083-a274-ab58c2cddb8a",
        "primaryId": "NCT03210220",
        "secondaryId": "NCT00290745",
        "statement_text": "Unlike the primary trial  the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices ",
        "statement_nums": [
            "Unlike the primary trial  the secondary trial does not test Gonadotrophin-releasing"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Pecs Group Ultrasound guided pectoral nerve block is performed right after induction  before surgery  The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery  and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle   INTERVENTION 2: Control Group There is no block  INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy "
        ],
        "premise_nums": [
            "a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor",
            "and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of"
        ]
    },
    {
        "id": "46d65581-7a0a-423b-907e-662c1f5843cc",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) "
        ],
        "premise_nums": [
            "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%)"
        ]
    },
    {
        "id": "f4ea6e98-75e1-43a0-8202-548bb7ceb66c",
        "primaryId": "NCT02413008",
        "secondaryId": "NCT02725801",
        "statement_text": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks  whereas the interventions for the secondary trial are only apllied once ",
        "statement_nums": [
            "the interventions for the secondary trial are only apllied once",
            "The intervention in the primary trial requires patients to receive"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: 0.005% Estriol Vaginal Gel Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction "
        ],
        "premise_nums": [
            "inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3:",
            "of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION"
        ]
    },
    {
        "id": "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP for patients in cohort one of the primary trial is NA ",
        "statement_nums": [
            "cohort one of the primary trial is NA"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time to Progression (TTP) Time to progression is defined as the time from treatment start until objective tumor progression  Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion  progression of existing non-target lesions  or the appearance of 1 or more new lesions  The median time to progression is the parameter used to describe TTP  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29 months  Results 1: Arm/Group Title: Capecitabine and Fulvestrant Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg  Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA) "
        ],
        "premise_nums": [
            "as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a",
            "as 1000 mg po AM and 500 mg po PM in patients with a body weight of 80 kg  Fulvestrant will be",
            "Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the",
            "basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients",
            "lesions  or the appearance of 1 or more new lesions  The median",
            "will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28",
            "500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days",
            "mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of",
            "frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29",
            "Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA)",
            "and at a total dose of 2000 mg given as 1000 mg po bid"
        ]
    },
    {
        "id": "932728c5-2e7f-401f-be64-e90597ff2ce2",
        "primaryId": "NCT00129935",
        "statement_text": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "more cases of embolisms in cohort 2 of the primary trial than cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) ",
            "CNS cerebrovascular ischemia * [3]1/715 (0.14%)Heart Failure * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%) "
        ],
        "premise_nums": [
            "[1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%)",
            "Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin",
            "(0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes *",
            "CNS cerebrovascular ischemia * [3]1/715 (0.14%)Heart Failure * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%)",
            "111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669",
            "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin"
        ]
    },
    {
        "id": "54ad9406-852c-40fc-bd0e-8e7e81eacc71",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "statement_nums": [
            "a participant of the primary trial to have a Time",
            "to Reach Maximum Plasma Concentration of 16, 17 or 20"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose "
        ],
        "premise_nums": [
            "2, 4, 6, 8, 12, 24 hours postdose",
            "plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3."
        ]
    },
    {
        "id": "7021a4a9-b474-4568-a3b8-015a50c9d9cc",
        "primaryId": "NCT00201760",
        "secondaryId": "NCT00127933",
        "statement_text": "Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial ",
        "statement_nums": [
            "to participate in the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Eligibility Criteria: Must have invasive metastatic breast cancer Tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology)or positive FISH Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer  "
        ],
        "premise_nums": [
            "breast cancer Tumor must be Her 2/neu 3+ by IHC (must be confirmed",
            "Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer Tumor must be Her 2/neu 3+ by IHC (must"
        ]
    },
    {
        "id": "3e2dda3a-815f-4681-a470-009d9f9b30d6",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device",
        "statement_nums": [
            "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Sole Method patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days INTERVENTION 2: Boost patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx) INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: ",
            "Negative PressurePhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  "
        ],
        "premise_nums": [
            "/ day (separated by at least 6 hours) Delivered in 5 consecutive working days INTERVENTION 2: Boost patients will be treated",
            "or DCIS Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions",
            "at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx) INTERVENTION 1: Manual Lymph Drainage",
            "lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch:"
        ]
    },
    {
        "id": "1a293e7c-691f-4f93-bab8-6bf5d9b3f904",
        "primaryId": "NCT01653964",
        "secondaryId": "NCT02660788",
        "statement_text": "The interventions in the primary trial and the secondary trial are similar  as they are testing the same medication  however they are not using the same doses ",
        "statement_nums": [
            "The interventions in the primary trial and the secondary trial are similar  as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter "
        ],
        "premise_nums": [
            "Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm",
            "breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  INTERVENTION 1:"
        ]
    },
    {
        "id": "a87e6e20-c7d0-4941-9933-204fab99b299",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment ",
        "statement_nums": [
            "Less than 1/3 participants in the primary trial treated with Lapatinib achieved",
            "1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks) Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of",
            "Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate",
            "frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab",
            "Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg",
            "or death from any cause following 12 weeks of treatment  Disease progression is",
            "Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab",
            "Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12:",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "6c3427a8-27a1-459c-9fbc-175649210868",
        "primaryId": "NCT01940497",
        "statement_text": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "more allergic reactions observed in cohort 1 of the primary trial than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) ",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)",
            "(0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%)",
            "(0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%)",
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "(0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia",
            "Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia",
            "3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "(1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2:",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion"
        ]
    },
    {
        "id": "883bec6a-bce2-4e60-9304-49a056e66df7",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin smaller than 1.2 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin smaller than 1.2 x ULN are eligilbe",
            "100,000/¬¨¬µl and total bilirubin smaller than 1.2 x ULN are eligilbe for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  "
        ],
        "premise_nums": [
            "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5"
        ]
    },
    {
        "id": "8720143a-2611-4502-a5ee-da4e641df918",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "statement_text": "There were no cases of extravasation in either the primary trial or the secondary trial ",
        "statement_nums": [
            "extravasation in either the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Memory impairment * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) ",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) "
        ],
        "premise_nums": [
            "(0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%)",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%)",
            "(0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%)",
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24",
            "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24",
            "1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2:",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%)"
        ]
    },
    {
        "id": "0fdda7a2-4119-40a7-84f3-6c5c6077df49",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No",
            "No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention"
        ]
    },
    {
        "id": "e7eae332-6b6a-41e0-aa31-86a781fd373f",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial ",
        "statement_nums": [
            "as cases of Dyspnea in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%)"
        ]
    },
    {
        "id": "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide ",
        "statement_nums": [
            "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  "
        ],
        "premise_nums": [
            "High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO)",
            "mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)",
            "daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)"
        ]
    },
    {
        "id": "c09b9f7c-2d22-4c44-a79d-32929530dd9e",
        "primaryId": "NCT01735175",
        "secondaryId": "NCT01216319",
        "statement_text": "the secondary trial and the primary trial are both testing Biodesign interventions ",
        "statement_nums": [
            "the secondary trial and the primary trial are both testing Biodesign"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive LA-EP2006 s.c  post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 2: Neulasta® During each chemotherapy cycle eligible patients receive Neulasta® s.c  post chemotherapy application  Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder "
        ],
        "premise_nums": [
            "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive",
            "application  INTERVENTION 2: Neulasta® During each chemotherapy cycle",
            "post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive"
        ]
    },
    {
        "id": "6f143256-52e4-40b7-950c-5c892f8632b9",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Event-free Survival Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer Arm/Group Description: See Detailed Description  tamoxifen citrate: Given orally busulfan: Given orally thiotepa: Given IV melphalan: Given IV aldesleukin: Given SC sargramostim: Given SC peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF Overall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of Measure: Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1% "
        ],
        "premise_nums": [
            "GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for",
            "radiotherapy after completion of IL-2/GM-CSF Overall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of",
            "Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1%"
        ]
    },
    {
        "id": "d2718f05-1d35-4c84-a054-06a3fe4a0a9c",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  and must meet some specific size conditions ",
        "statement_nums": [
            "be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  and must meet"
        ],
        "label": "Entailment",
        "premise_text": [
            "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam "
        ],
        "premise_nums": [
            "mm on CT scan (5 mm sections) Lesion greater than or equal 10 mm on CT scan (5 mm sections)",
            "CT scan or MRI (10 mm sections) Lesion greater than or equal 1 unidimensionally measurable lesion  including greater than",
            "sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal",
            "greater than or equal 1 of the following: Lesion greater than or equal 1 unidimensionally measurable lesion  including greater than",
            "mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10",
            "following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal",
            "greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or",
            "mm on CT scan (5 mm sections) Lesion greater than or equal 1 of the following: Lesion greater than or"
        ]
    },
    {
        "id": "7f49cafd-3a27-4fc8-872d-914b9176442e",
        "primaryId": "NCT01427933",
        "statement_text": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial ",
        "statement_nums": [
            "adverse event for patients in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 26/69 (37.68%) Anaemia 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac failure congestive 1/69 (1.45%) Cardiac tamponade 1/69 (1.45%) Pericardial effusion 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Ascites 2/69 (2.90%) Colitis 1/69 (1.45%) Gastritis 1/69 (1.45%) Gastritis erosive 1/69 (1.45%) "
        ],
        "premise_nums": [
            "Pericardial effusion 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Ascites 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest",
            "Adverse Events 1: Total: 26/69 (37.68%) Anaemia 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac",
            "neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac tamponade 1/69 (1.45%) Pericardial effusion 1/69 (1.45%) Abdominal pain 1/69",
            "4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac failure congestive 1/69 (1.45%) Gastritis 1/69 (1.45%) Gastritis erosive 1/69 (1.45%)",
            "Total: 26/69 (37.68%) Anaemia 2/69 (2.90%) Febrile neutropenia 3/69 (4.35%) Neutropenia 4/69 (5.80%) Cardiac arrest 1/69 (1.45%) Cardiac failure congestive"
        ]
    },
    {
        "id": "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "are observed in patients from cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%)"
        ]
    },
    {
        "id": "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8",
        "primaryId": "NCT00428922",
        "secondaryId": "NCT00499083",
        "statement_text": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago  are not eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "radiotherapy for the treatment of stage 4 cancer over 5 years ago  are not eligible for"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ hybridization)+ Age 18 years No prior trastuzumab  except as given in the adjuvant or neoadjuvant setting  No prior chemotherapy in the metastatic setting  Exclusion Criteria: CNS (central nervous system) metastases Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating women Major surgical procedure  open biopsy  non-healing wounds  or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study  No prior chemotherapy or radiotherapy "
        ],
        "premise_nums": [
            "Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating",
            "Inclusion Criteria: Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ",
            "or significant traumatic injury within 28 days prior to starting study or anticipation",
            "needle aspirations or core biopsies within 7 days prior to start of study"
        ]
    },
    {
        "id": "4ab00376-83a4-467e-8a1e-6b8b1643a8f0",
        "primaryId": "NCT00365599",
        "secondaryId": "NCT01771666",
        "statement_text": "Black men with and ECOG smaller than =2, with ANC greater than 1.5 x 10^9/L, PLT greater than 100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "statement_nums": [
            "than =2, with ANC greater than 1.5 x 10^9/L, PLT greater than 100 x 10^9/L and no prior history of blood",
            "are eligible for the primary trial but excluded from the secondary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Patients must have acceptable organ function  as defined by the following laboratory parameters: white blood count (WBC) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)  Creatinine smaller than 1.8 mg/dl (Creatinine clearance greater than 60 ml/min)  Both men and women of all races and ethnic groups are eligible for this trial  Patient with a history of blood clots are not eligible  Inclusion Criteria: Women of 18 years of age or older  "
        ],
        "premise_nums": [
            "Cooperative Oncology Group (ECOG) performance status 0-2. Patients must have acceptable organ function",
            "aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)  Creatinine smaller than 1.8 mg/dl (Creatinine clearance greater than 60",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than",
            "than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT)",
            "eligible  Inclusion Criteria: Women of 18 years of age or older",
            "100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)",
            "greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl",
            "absolute neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than",
            "x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than"
        ]
    },
    {
        "id": "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "statement_text": "None of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different heart related issues ",
        "statement_nums": [
            "the patients in the primary trial were recorded as having"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1: Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%) ",
            "Anaemia 2/49 (4.08%)Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) "
        ],
        "premise_nums": [
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%)",
            "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%)",
            "(0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%)",
            "ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "(4.08%)Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49",
            "(0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%)",
            "Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49",
            "Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1:",
            "(0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%)",
            "Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52",
            "Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1:",
            "Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir",
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%)",
            "effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac",
            "Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "(0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%)"
        ]
    },
    {
        "id": "407369fa-92ba-4994-8a0f-d372995f3241",
        "primaryId": "NCT02699983",
        "secondaryId": "NCT00994279",
        "statement_text": "Neither the primary trial or the secondary trial require participants to practice yoga ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial require participants to practice"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Group I (SparkPeople Program) Participants receive training on how to use the SparkPeople website  self-monitor their diet using the SparkPeople tool  and to self-monitor their activity daily using the Fitbit monitoring device  Participants receive weekly motivational reminders to log into the website for 3 months via email  text  or phone  based on patient preference (active phase)  Participants then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention: Use SparkPeople web-based program Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants receive the weight loss handout and a Fitbit activity monitor  After 6 months  participants receive the SparkPeople treatment  Exercise Intervention: Use Fitbit monitor Activity Monitoring Device: Wear Fitbit activity monitoring device INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group "
        ],
        "premise_nums": [
            "to log into the website for 3 months via email  text  or",
            "Wear Fitbit activity monitoring device INTERVENTION 1: Arm 1: Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group",
            "then enter the maintenance phase for 3 months without reminders  Behavioral Dietary Intervention:",
            "Wear Fitbit activity monitoring device INTERVENTION 2: Group II (Wait List) Participants"
        ]
    },
    {
        "id": "59fd53e4-b38c-4018-bafc-6fd7f7becebe",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels ",
        "statement_nums": [
            "1 patient in the primary trial suffered from a blood"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) Dyspnea 2/31 (6.45%) "
        ],
        "premise_nums": [
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) Dyspnea",
            "(3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%)",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain",
            "(3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain",
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain",
            "limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb",
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain",
            "(3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31"
        ]
    },
    {
        "id": "c17eaeab-4e99-4cc4-8681-ae6ccddba572",
        "primaryId": "NCT01926886",
        "statement_text": "There were no cases of Cellulitis  Nausea or Anaemia in the primary trial ",
        "statement_nums": [
            "or Anaemia in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%)",
            "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%)"
        ]
    },
    {
        "id": "621d06ac-12dd-42c2-a012-15c1d94a4f0b",
        "primaryId": "NCT00952692",
        "statement_text": "Candidates for the primary trial must have adequate renal and hepatic function  and must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "statement_nums": [
            "Candidates for the primary trial must have adequate renal",
            "or have received amiodarone in the 6"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: The patient has adequate renal function as shown by the creatinine levels (i.e  within the normal range)  The patient has adequate hepatic function as shown by serum bilirubin levels i.e: Exclusion Criteria: The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening  "
        ],
        "premise_nums": [
            "or has received amiodarone in the 6 months prior to screening"
        ]
    },
    {
        "id": "021e79d2-ce70-43cf-aac9-fa8d4c8d3770",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed  these are pneumonia  urinary tract and Athlete's foot ",
        "statement_nums": [
            "In the primary trial patient cohort  3 different types of infections are observed"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41",
            "(4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia",
            "Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41",
            "Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41"
        ]
    },
    {
        "id": "06aa0fbc-fe49-4715-88cc-507646f6323f",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga  whereas cohort 2 abstained from yoga ",
        "statement_nums": [
            "the primary trial is that cohort 1 participated in a Hatha yoga  whereas cohort 2 abstained from yoga"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  "
        ],
        "premise_nums": [
            "in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also"
        ]
    },
    {
        "id": "21947261-bbef-4d3a-adda-02bb4a91a3ca",
        "primaryId": "NCT00754325",
        "secondaryId": "NCT00399529",
        "statement_text": "the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast ",
        "statement_nums": [
            "the secondary trial and the primary trial both accept patients with"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Inclusion Criteria: Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH)  Prior adjuvant Trastuzumab therapy is permitted  Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Histologically confirmed hormone receptor positive",
            "Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is"
        ]
    },
    {
        "id": "71daae7c-3ee5-4451-91e2-273d8ff55aae",
        "primaryId": "NCT00617942",
        "secondaryId": "NCT00388726",
        "statement_text": "the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial ",
        "statement_nums": [
            "events compared to the primary trial",
            "the secondary trial had a lower total"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%)"
        ]
    },
    {
        "id": "7d22937b-9823-45fa-a914-261f993e4d64",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient developed issues with their vision ",
        "statement_nums": [
            "Throughout the primary trial  one patient developed"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Ileus 1/214 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) ",
            "Diarrhoea 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) "
        ],
        "premise_nums": [
            "0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214",
            "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "Diarrhoea 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%)",
            "Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%)",
            "(12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%)",
            "failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%)",
            "failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)",
            "fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%)",
            "(0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)",
            "fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213"
        ]
    },
    {
        "id": "507a4189-4905-4752-8348-d715a5ce3962",
        "primaryId": "NCT01940497",
        "statement_text": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "statement_nums": [
            "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Vomiting 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%) Pryexia 0/20 (0.00%) ",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)",
            "(0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%)",
            "(0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Pryexia 0/95 (0.00%) Anaphylactic shock 1/95 (1.05%) Gastroenteritis 0/95 (0.00%)",
            "Adverse Events 1: Total: 5/95 (5.26%) Febrile neutropenia 0/95 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20",
            "0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "(0.00%) Neutropenia 0/95 (0.00%) Atrial fibrillation 0/95 (0.00%) Pleuropericarditis 0/95 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%)",
            "fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia",
            "Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2: Total: 3/20 (15.00%) Febrile neutropenia",
            "3/20 (15.00%) Febrile neutropenia 0/20 (0.00%) Neutropenia 0/20 (0.00%) Atrial fibrillation 1/20 (5.00%) Pleuropericarditis 1/20 (5.00%) Vomiting 0/20",
            "(1.05%) Gastroenteritis 0/95 (0.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2:",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 0/20 (0.00%) Tibia fracture 0/20 (0.00%)",
            "Anaphylactic shock 0/20 (0.00%)Gastroenteritis 1/20 (5.00%) Fibula fracture 1/95 (1.05%) Tibia fracture 1/95 (1.05%) Intervertebral disc protrusion"
        ]
    },
    {
        "id": "24001e83-6a8c-4f67-9c24-55dc285c4cc2",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo ",
        "statement_nums": [
            "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 8.33 (0.79) "
        ],
        "premise_nums": [
            "fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue",
            "Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of",
            "of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2",
            "Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile",
            "fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 -",
            "It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1",
            "Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day"
        ]
    },
    {
        "id": "d179396d-94fe-465f-a4f1-e7c3291a0a9a",
        "primaryId": "NCT00513695",
        "statement_text": "filgrastim is the only drug in the primary trial given by subcutaneous injection ",
        "statement_nums": [
            "only drug in the primary trial given by subcutaneous injection"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Neoadjuvant Chemotherapy Before Surgery) Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity  Beginning within 3 weeks of completion of sunitinib malate and paclitaxel  patients receive doxorubicin IV once weekly for 15 weeks  cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients undergo surgery  sunitinib malate: Given PO paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO filgrastim: Given SC therapeutic conventional surgery: Undergo surgery laboratory biomarker analysis: Correlative studies flow cytometry: Correlative studies "
        ],
        "premise_nums": [
            "unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients",
            "cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of",
            "and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression"
        ]
    },
    {
        "id": "4b893eeb-80a4-4a83-8df5-b5c668ce55b1",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "statement_text": "More patients in the secondary trial suffered from oedema in their limbs  compared to patients in the primary trial ",
        "statement_nums": [
            "More patients in the secondary trial suffered from oedema in",
            "to patients in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%) Left ventricular systolic dysfunction * 1/56 (1.79%) Dehydration * 1/56 (1.79%) Diarrhea * 1/56 (1.79%) Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%) Sodium  serum-low (hyponatremia) * 1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) ",
            "Nausea 2/70 (2.86%)Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%)",
            "- Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70",
            "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70",
            "Nausea 2/70 (2.86%)Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%)",
            "Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) *"
        ]
    },
    {
        "id": "44cd16f5-6638-4d82-9121-1941eb8ce4b5",
        "primaryId": "NCT00448279",
        "statement_text": "In total there were more adverse events in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "were more adverse events in cohort 1 of the primary trial  than in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia * 0/28 (0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%) Acute renal failure * 20/28 (0.00%) "
        ],
        "premise_nums": [
            "failure * 21/26 (3.85%) Adverse Events 2: Total: 1/28 (3.57%) Febrile neutropenia",
            "(0.00%) Gastric volvulus * 21/28 (3.57%) General Malaise * 20/28 (0.00%) Hospitalisation for intrapleuric chemotherapy and",
            "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%)"
        ]
    },
    {
        "id": "50ac2c53-3b63-4507-8712-41f8c257b4da",
        "primaryId": "NCT01697345",
        "secondaryId": "NCT00513292",
        "statement_text": "Fluorouracil  epirubicin  and cyclophosphamide (FEC) are used in both cohorts of the secondary trial  but not in cohort 1 of the primary trial ",
        "statement_nums": [
            "both cohorts of the secondary trial  but not in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: FSFI Total Score (Pretest) Administered to participants prior to starting vaginal testosterone therapy  INTERVENTION 1: FEC-75 Then Paclitaxel/Trastuzumab ",
            "Patients receive Fluorouracil  epirubicin  and cyclophosphamide (FEC) comprising fluorouracil IV  epirubicin hydrochloride IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesINTERVENTION 2: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 ",
            "Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and trastuzumab  patients receive FEC comprising fluorouracil IV  epirubicin IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive trastuzumab IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab as in arm I  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studies"
        ],
        "premise_nums": [
            "and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive",
            "IV once weekly for an additional 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of FEC and trastuzumab",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once weekly for 12 weeks  Beginning 7 days",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "laboratory biomarker analysis: Correlative studiesINTERVENTION 2: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75",
            "undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once every 3 weeks for up to 52 weeks",
            "undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks",
            "patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given"
        ]
    },
    {
        "id": "14607d45-9aef-458d-89cc-d47c62c23322",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "statement_text": "A patient with Histologically confirmed triple-negative breast cancer  with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial",
            "A patient with Histologically confirmed triple-negative breast cancer"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative  progesterone receptor (PR)-negative  and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease History of autoimmune disease Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously  are progressive  or require any type of therapy (e.g.  radiation  surgery  or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose History of clinically significant cardiac dysfunction Inclusion Criteria: Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II  Exclusion Criteria: Ductal carcinoma in situ (DCIS; stage 0 cancer)  Advanced or distant metastatic stage  Receiving any neoadjuvant therapy  History of receiving any antibiotics within prior 3 months  History of immunodeficiency  Having a remote infection  History of reaction to study antibiotics  Denial of signing the consent form  "
        ],
        "premise_nums": [
            "control symptoms from brain metastases within 30 days prior to first study treatment dose History of",
            "and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast",
            "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative",
            "of receiving any antibiotics within prior 3 months  History of immunodeficiency"
        ]
    },
    {
        "id": "d2961e96-bd3b-4994-aa7e-2b310eb6204e",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "At least 1 participant in the primary trial showed signs of poor"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%)"
        ]
    },
    {
        "id": "8a5d7285-f4be-4e50-9057-19f74bcc410b",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W "
        ],
        "premise_nums": [
            "Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W"
        ]
    },
    {
        "id": "512990dd-45d2-4b31-b571-66735ff02308",
        "primaryId": "NCT00394251",
        "statement_text": "There were 4 different adverse events  for which 0 cases were recorded in cohort 1.",
        "statement_nums": [
            "There were 4 different adverse events  for which 0 cases were recorded in cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%) Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac",
            "Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%)",
            "failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure",
            "(7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98",
            "failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%)"
        ]
    },
    {
        "id": "383db144-4bcd-4ebc-989c-b6ae7d282026",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial  ",
        "statement_nums": [
            "more common in patients from cohort 2 of the secondary trial  than cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 2: Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Extrasystoles 0/10 (0.00%) Nausea 0/10 (0.00%) ",
            "Abdominal pain 0/10 (0.00%)Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown cause 0/10 (0.00%) Thrombosis in device 0/10 (0.00%) "
        ],
        "premise_nums": [
            "(1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 2:",
            "abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 2: Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia",
            "Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Extrasystoles 0/10 (0.00%)Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown",
            "Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Death - unknown cause 0/10 (0.00%) Thrombosis in device",
            "0/10 (0.00%) Death - unknown cause 0/10 (0.00%) Thrombosis in device 0/10 (0.00%)",
            "5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%) Extrasystoles 0/10 (0.00%)",
            "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83",
            "Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%)",
            "Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 2:",
            "Adverse Events 2: Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%) Thrombocytopenia 1/10 (10.00%) Cardiac failure congestive 0/10 (0.00%)",
            "2: Total: 5/10 (50.00%) Febrile neutropenia 0/10 (0.00%) Neutropenia 0/10 (0.00%)Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown",
            "(2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 2:",
            "Abdominal pain 0/10 (0.00%)Constipation 0/10 (0.00%) Gastrointestinal haemorrhage 0/10 (0.00%) Death - unknown cause 0/10 (0.00%) Thrombosis in device"
        ]
    },
    {
        "id": "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73",
        "primaryId": "NCT00951665",
        "statement_text": "Most patients in cohort 1 of the primary trial died of unknown causes ",
        "statement_nums": [
            "Most patients in cohort 1 of the primary trial died of unknown causes"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) "
        ],
        "premise_nums": [
            "cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%)",
            "0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%)",
            "(0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device",
            "Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown",
            "1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Nausea 1/26 (3.85%) Abdominal pain 0/26 (0.00%) Constipation 0/26 (0.00%)",
            "Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure"
        ]
    },
    {
        "id": "b7caad28-5fb2-4eb6-845e-8315cff97318",
        "primaryId": "NCT00896649",
        "statement_text": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial  neither is Adequate organ function or a particular racial or ethnic background ",
        "statement_nums": [
            "for patients in the primary trial  neither is Adequate"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion criteria: DISEASE CHARACTERISTICS: Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue At high-risk for breast cancer PATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian PRIOR CONCURRENT THERAPY: None specified Exclusion criteria: No history of breast cancer  palpable breast mass  abnormal nipple discharge  or other focal complaints warranting diagnostic mammogram "
        ],
        "premise_nums": [
            "the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue"
        ]
    },
    {
        "id": "73c37b9c-e7ba-4c90-b26e-23b7a65509c4",
        "primaryId": "NCT00005957",
        "statement_text": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative "
        ],
        "premise_nums": [
            "breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or",
            "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of"
        ]
    },
    {
        "id": "cdba382e-894b-4f79-a8e2-ff818746adc5",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered adverse events ",
        "statement_nums": [
            "100% of patients in the primary trial suffered adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 "
        ],
        "premise_nums": [
            "Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg",
            "Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5",
            "Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont",
            "Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg",
            "from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg",
            "frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group",
            "screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane"
        ]
    },
    {
        "id": "0093175a-38cb-4f63-b391-709ac48158b8",
        "primaryId": "NCT00971737",
        "secondaryId": "NCT00392392",
        "statement_text": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial  but not for the primary trial ",
        "statement_nums": [
            "Patients with tumors overexpressing HER-2 are eligible for the secondary trial  but not for"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer "
        ],
        "premise_nums": [
            "breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV",
            "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the",
            "disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer"
        ]
    },
    {
        "id": "19106207-4fa2-4cc4-8e22-6e5330bf05ce",
        "primaryId": "NCT00846027",
        "statement_text": "None of the adverse events recorded for the primary trial occurred more than once ",
        "statement_nums": [
            "events recorded for the primary trial occurred more than once"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Dehydration 1/82 (1.22%) Diarrhoea 1/82 (1.22%) "
        ],
        "premise_nums": [
            "1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%)",
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left",
            "(1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%)"
        ]
    },
    {
        "id": "a015685e-f744-4bb2-a6d3-893f081d6dcc",
        "primaryId": "NCT02597452",
        "secondaryId": "NCT01929395",
        "statement_text": "the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively ",
        "statement_nums": [
            "the primary trial and the secondary trial both use 21 day cycles for their interventions up to"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Intelligent Breast Exam  iBE Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment  No return visit required for participation  intelligent Breast Exam  iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual  If the patient is selected to participate in the inter-rater reliability portion of the study  the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit  INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) "
        ],
        "premise_nums": [
            "clinical breast exams twice sequentially performed by two different"
        ]
    },
    {
        "id": "b9578bae-6640-4ef1-ba2c-899b45c602ee",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "All patients in the primary trial had to drink 4 cups of water  either Alkaline Water"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  "
        ],
        "premise_nums": [
            "for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing",
            "arm I  Patients also drink 8 ounces of distilled water within"
        ]
    },
    {
        "id": "405369ef-d216-4d81-a04f-46f36f466a19",
        "primaryId": "NCT01416389",
        "statement_text": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "statement_nums": [
            "infections and lumbar fractures than cohort 2.",
            "Cohort 1 of the primary trial had more cases of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Urinary tract infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Adverse Events 2: Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 0/13 (0.00%) "
        ],
        "premise_nums": [
            "infection 1/26 (3.85%) Lumbar vertebral fracture 1/26 (3.85%) Adverse Events 2: Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture",
            "Adverse Events 2: Urinary tract infection 0/13 (0.00%) Lumbar vertebral fracture 1/26 (3.85%) Adverse Events 2: Urinary tract infection 0/13 (0.00%)"
        ]
    },
    {
        "id": "e424c65e-7c6f-43a4-95e4-6beb705d9903",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "cohort 1 of the primary trial",
            "higher percent of patients in cohort 1 of the secondary trial experienced stomatitis  than"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%)"
        ]
    },
    {
        "id": "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1",
        "primaryId": "NCT01466270",
        "statement_text": "The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group ",
        "statement_nums": [
            "The the primary trial placebo group had a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Retention Retention is the percentage of participants who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group Description: Patients receive donepezil hydrochloride PO QD  donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 71.0 (8.3) Results 2: Arm/Group Title: Arm II Arm/Group Description: Patients receive placebo PO QD  Placebo: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 80.7 (7.2) "
        ],
        "premise_nums": [
            "donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage",
            "who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group"
        ]
    },
    {
        "id": "6843daf8-8136-4973-9bf2-62a622d5a890",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [
            "whereas in the secondary trial the interventions are randomly"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 2: Breast Cancer Patients Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 1: Hydrophor (Group A) ",
            "Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily  starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Hydrophor application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Hydrophor within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area INTERVENTION 2: MediHoney (Group B) ",
            "Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily  starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Medihoney application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Medihoney within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area "
        ],
        "premise_nums": [
            "onset of RT and continuing until 2 weeks after the final RT session or",
            "healthy volunteers will be first screened for MRI contraindications",
            "agents in the irradiated area INTERVENTION 2: MediHoney (Group B)",
            "should not apply the Hydrophor within 4 hours of receiving RT  Patients should",
            "is healed (whichever is first)  Medihoney application should not apply the Hydrophor within 4 hours of receiving RT",
            "should not apply the Medihoney within 4 hours of receiving RT  Patients should",
            "is healed (whichever is first)  Hydrophor application should not apply the Medihoney within 4 hours of receiving RT"
        ]
    },
    {
        "id": "2687b547-c225-4838-bbcd-99212a74d815",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events ",
        "statement_nums": [
            "Patients in the primary trial and the secondary trial did not have any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%) Diarrhea 1/25 (4.00%) Nausea 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19 (5.26%) Fracture [1]1/19 (5.26%) Hip Fracture [1]1/19 (5.26%) Headache [2]1/19 (5.26%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19",
            "Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1:",
            "duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue",
            "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%)",
            "Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting"
        ]
    },
    {
        "id": "fadf7710-6e4d-49d6-82fc-4f3137b5e26b",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "is observed in patients from cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%)"
        ]
    },
    {
        "id": "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5",
        "primaryId": "NCT00074152",
        "statement_text": "All of the adverse event cases in the primary trial occurred in patients from cohort 2.",
        "statement_nums": [
            "event cases in the primary trial occurred in patients from cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%) ",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) "
        ],
        "premise_nums": [
            "(0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%)",
            "mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77",
            "ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "(0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85",
            "Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%)",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening",
            "Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection"
        ]
    },
    {
        "id": "6c0896ac-db42-45b4-a6e2-620a27fd321a",
        "primaryId": "NCT01439945",
        "statement_text": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide ",
        "statement_nums": [
            "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  "
        ],
        "premise_nums": [
            "High Dose Magnesium Oxide (1200 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO)",
            "mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)",
            "daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)"
        ]
    },
    {
        "id": "3a80ba8a-265f-4931-a9a8-b7e00e372599",
        "primaryId": "NCT00432172",
        "statement_text": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "events recorded in the primary trial occurred in patients from cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%) Diabetes decompensation * 0/45 (0.00%) Diarrhea * [2]0/45 (0.00%) Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%) Pancreatitis * [4]1/45 (2.22%) Febrile neutropenia * [2]3/45 (6.67%) Adverse Events 2: Total: 0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00%) Diabetes decompensation * 0/46 (0.00%) ",
            "Diarrhea * [2]0/46 (0.00%)Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%) Pancreatitis * [4]0/46 (0.00%) Febrile neutropenia * [2]0/46 (0.00%) Infection pulmonary/ Upper airway NOS * [5]0/46 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 5/45 (11.11%) Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%) Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%)",
            "Diarrhea * [2]0/46 (0.00%)Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%)"
        ]
    },
    {
        "id": "df4b98f2-7ca9-4855-8d94-d62407ff8535",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "statement_text": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group ",
        "statement_nums": [
            "the primary trial only has one test cohort whereas the secondary trial has both a test"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education "
        ],
        "premise_nums": [
            "The decision support workshop will be 2 hours in duration on the morning of",
            "answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education"
        ]
    },
    {
        "id": "5d2542fa-5482-4aff-af29-80875a0a9dcc",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "statement_text": "the primary trial records instances of Rectal Hemorrhage within its patient cohort  whereas the secondary trial records Vaginal hemorrhages ",
        "statement_nums": [
            "the primary trial records instances of Rectal",
            "cohort  whereas the secondary trial records Vaginal hemorrhages"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) ",
            "Arrhythmia Ventricular 0/1634 (0.00%)Cardiomyopathy 1/1634 (0.06%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%)",
            "Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%)",
            "Arrhythmia Ventricular 0/1634 (0.00%)Cardiomyopathy 1/1634 (0.06%)",
            "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44",
            "infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders",
            "Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total:"
        ]
    },
    {
        "id": "5f4880ac-1ce2-4b89-841b-a9918720b6ea",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial patients must satisfy all",
            "following conditions; alkaline phosphatase smaller than 2 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10",
            "aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL"
        ],
        "label": "Entailment",
        "premise_text": [
            "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL AST smaller than 2 times upper limit of normal (ULN) Alkaline phosphatase smaller than 2 times ULN "
        ],
        "premise_nums": [
            "g/dL AST smaller than 2 times upper limit of normal (ULN) Alkaline phosphatase smaller than 2 times ULN",
            "(AST) must be less than/equal to 1.5 x ULN for the lab  Platelet",
            "10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL AST smaller than 2 times upper limit of normal",
            "alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate",
            "count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to"
        ]
    },
    {
        "id": "b3aabfaa-23cb-4a75-8416-761d8574f0a4",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO ",
        "statement_nums": [
            "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  "
        ],
        "premise_nums": [
            "the dose may be escalated to 50 mg",
            "Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated"
        ]
    },
    {
        "id": "f697c2d8-e0dd-476e-8ff4-dffe053076f8",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "statement_nums": [
            "Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than",
            "which achieved a pCR rate of 45%"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel  Time frame: Week 26 Results 1: Arm/Group Title: Trastuzumab ",
            "Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants were treated with trastuzumab in a 2-week run-in period  On Day 14, a second core needle biopsy was performed  followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib ",
            "Arm/Group Description: Participants received lapatinib alone (1250 mg orally [PO] once daily [QD])  Participants were treated with lapatinib in a 2-week run-in period  On Day 14, a second core needle biopsy was performed  followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 45.0 "
        ],
        "premise_nums": [
            "trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of",
            "mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15)",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib",
            "Day 8, and Day 15) in combination with lapatinib Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage",
            "Day 1 of Week 2 and weekly thereafter)  Participants were treated with lapatinib in a 2-week run-in period  On",
            "followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil",
            "cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day",
            "mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number",
            "were treated with lapatinib in a 2-week run-in period  On Day 14, a second core needle biopsy",
            "followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU",
            "Time frame: Week 26 Results 1: Arm/Group Title: Trastuzumab",
            "epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib Overall",
            "1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants were treated",
            "chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500",
            "the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and",
            "Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number of Participants Analyzed: 26",
            "were treated with trastuzumab in a 2-week run-in period  On Day 14, a second core needle biopsy",
            "Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the",
            "the lymph nodes  26 weeks of therapy comprised the 2-week run-in period  On Day 14, a second core needle biopsy",
            "4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of therapy comprised the 2-week run-in phase  12 weeks of",
            "4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib",
            "mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants received lapatinib alone (1250 mg orally [PO] once daily [QD])",
            "trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, Day 8, and Day 15) in combination with lapatinib Overall",
            "weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80"
        ]
    },
    {
        "id": "f2c0f753-1775-42af-94f0-b87b20156e65",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "statement_text": "the primary trial and the secondary trial do not use chemotherapy  radiotherapy or mammography in their interventions",
        "statement_nums": [
            "the primary trial and the secondary trial do not use chemotherapy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  "
        ],
        "premise_nums": [
            "Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2:",
            "in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also",
            "meeting decided whether to recall the woman or not"
        ]
    },
    {
        "id": "17b31c1d-db62-4628-b390-02da22512079",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or sensory neuropathy"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; "
        ],
        "premise_nums": [
            "that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that"
        ]
    },
    {
        "id": "2e6e1044-8b4a-41f7-8319-85fc5bba4482",
        "primaryId": "NCT00574145",
        "secondaryId": "NCT03167359",
        "statement_text": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial ",
        "statement_nums": [
            "Radiotherapy is used in all cohorts of the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Radiotherapy/Supportive Care (A) Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  "
        ],
        "premise_nums": [
            "the duration of their radiotherapy INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated",
            "and clear margins  will receive 15 doses of radiation over three weeks",
            "whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost",
            "wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions simultaneously with a boost treatment",
            "the duration of their radiotherapy INTERVENTION 2: Control ARM (B) Patients receive"
        ]
    },
    {
        "id": "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "statement_text": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial ",
        "statement_nums": [
            "was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) ",
            "Abdominal Pain Lower 1/40 (2.50%)Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) "
        ],
        "premise_nums": [
            "NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia",
            "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486",
            "Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%)",
            "COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%)",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%)",
            "INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION",
            "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION",
            "(0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION",
            "(0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION",
            "INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486",
            "ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION"
        ]
    },
    {
        "id": "b3bd3522-8731-448a-bade-a5a350697a98",
        "primaryId": "NCT01421472",
        "statement_text": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream ",
        "statement_nums": [
            "Over 9 patients in the primary trial suffered from adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%)"
        ]
    },
    {
        "id": "8607e8c1-6e99-49be-a63e-e707856c805a",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead ",
        "statement_nums": [
            "Each patient in the primary trial receives 3 different drugs  whereas in the secondary",
            "patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients are given supportive-expressive"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  "
        ],
        "premise_nums": [
            "death  whichever occurred first  Taxane chemotherapy was docetaxel",
            "Afatinib 50 mg orally from Day 1 to Day 21 of eachemotherapy once of every 3 weeks per treatment cycle until predefined study",
            "plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day"
        ]
    },
    {
        "id": "1c26e1a7-9d77-46ff-b1c6-179ece7c190f",
        "primaryId": "NCT03252431",
        "statement_text": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time ",
        "statement_nums": [
            "both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy  Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) ",
            "Unit of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.45) "
        ],
        "premise_nums": [
            "were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled",
            "on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196",
            "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy",
            "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) Results",
            "was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy  Time frame: The",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe",
            "Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group",
            "4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation)",
            "(0.51)Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group",
            "Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 Eligible subjects were randomized in a 1:1"
        ]
    },
    {
        "id": "0a156ee2-eb90-40d2-9802-27b9b4a42ff3",
        "primaryId": "NCT00191789",
        "statement_text": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice ",
        "statement_nums": [
            "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) Fatigue 1/65 (1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%) "
        ],
        "premise_nums": [
            "Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%)",
            "(1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%)",
            "(1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65"
        ]
    },
    {
        "id": "82895f11-37bf-4d03-8de2-84818d93cce0",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event reports ",
        "statement_nums": [
            "the primary trial and the secondary trial have entirely different adverse"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS * 1/17 (5.88%) Constipation * 1/17 (5.88%) Adverse Events 1: Total: 19/51 (37.25%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51 (0.00%) Dysphagia 1/51 (1.96%) Abdominal pain 0/51 (0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) ",
            "Leukopenia 0/50 (0.00%)Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) "
        ],
        "premise_nums": [
            "failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%)",
            "failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive",
            "(0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%)",
            "(0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51",
            "(2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive",
            "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS *",
            "(0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%)",
            "Leukopenia 0/50 (0.00%)Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive",
            "(2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51 (0.00%) Dysphagia 1/51 (1.96%)",
            "neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter",
            "2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive",
            "Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51"
        ]
    },
    {
        "id": "f94643de-7122-4a58-972d-b0bb7e59d441",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "statement_text": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0.",
        "statement_nums": [
            "primary trial had a total of 3 patients experiencing Pancreatic Cancer  the secondary trial had 0."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) ",
            "Sinus tachycardia 1/1408 (0.07%)Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) ",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) "
        ],
        "premise_nums": [
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris",
            "(0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)",
            "(0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)",
            "(27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.07%) Nausea 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris",
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%)",
            "Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408",
            "Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%)",
            "(0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "(6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%)"
        ]
    },
    {
        "id": "1485315b-3169-42a3-a672-6f7963d49a51",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis ",
        "statement_nums": [
            "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Omega-3 Fatty Acid) Patients receive omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 2: Arm II (Placebo) Patients receive placebo PO daily for 7-14 days  placebo: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies "
        ],
        "premise_nums": [
            "Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of",
            "therapy and continuing until 1 week after completion of radiation therapy and continuing until 1 week after completion of radiation",
            "laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6",
            "curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and",
            "omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis:"
        ]
    },
    {
        "id": "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee",
        "primaryId": "NCT03371732",
        "statement_text": "patients with Karnofsky Index = 72 are eligible for the primary trial ",
        "statement_nums": [
            "with Karnofsky Index = 72 are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). "
        ],
        "premise_nums": [
            "use  (Karnofsky Index greater than 70).",
            "Inclusion Criteria : women with primary breast cancer  without ongoing",
            "An AUDIT-C score greater than 1 or more than one cigarette smoked per"
        ]
    },
    {
        "id": "426196d8-44ab-4c5c-8f81-5cb12345ad69",
        "primaryId": "NCT00899574",
        "secondaryId": "NCT01007942",
        "statement_text": "the primary trial uses different inclusion criteria for its cohorts  the secondary trial only uses one set on inclusion criteria for all cohorts ",
        "statement_nums": [
            "on inclusion criteria for all cohorts",
            "the primary trial uses different inclusion criteria",
            "its cohorts  the secondary trial only uses one set"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: (Cohort 1) Concurrent systemic cancer therapy (hormones  biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for greater than or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator  (Cohort 2) Any concurrent systemic therapy is allowed Inclusion Criteria: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization positive Patients with resistance to trastuzumab Prior taxane therapy Patients with an ECOG performance status of 0 - 2 Patients with measurable disease as per RECIST criteria Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization  Sexually active pre-menopausal women must use adequate contraceptive measures  excluding estrogen containing contraceptives  while on study; Patients must meet laboratory criteria defined in the study within 21 days prior to randomization Exclusion Criteria: ",
            "Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancerMore than three prior chemotherapy lines for advanced disease  Symptomatic CNS metastases or evidence of leptomeningeal disease  Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed greater than 8 weeks prior to randomization Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the exception of adequately treated in-situ carcinoma of the cervix uteri  basal or squamous cell carcinoma or non-melanomatous skin cancer Known hypersensitivity to any study medication Breastfeeding or pregnant "
        ],
        "premise_nums": [
            "of cardiac dysfunction Any malignancy within 5 years prior to randomization  with the",
            "with an ECOG performance status of 0 - 2 Patients with measurable disease as per RECIST",
            "CNS metastases was completed greater than 8 weeks prior to randomization Impairment of gastrointestinal",
            "biologics or chemotherapy) is allowed if distant metastases have",
            "greater than or = 12 weeks and skin metastases are non-responsive (stable",
            "of oral everolimus Peripheral neuropathy grade 2 at randomization Active cardiac disease History of",
            "criteria defined in the study within 21 days prior to randomization Exclusion Criteria:",
            "with curative intent  HER2+ status defined as IHC 3+ staining or in situ hybridization",
            "bearing potential prior to enrollment within 7 days prior to randomization  Sexually active"
        ]
    },
    {
        "id": "bcf433b6-4029-4d00-9ccf-d8d94f1722d8",
        "primaryId": "NCT00365365",
        "secondaryId": "NCT00005908",
        "statement_text": "the primary trial and the secondary trial only recorded one type of acute adverse event ",
        "statement_nums": [
            "the primary trial and the secondary trial only recorded one type"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 23/78 (29.49%) Febrile neutropenia * 4/78 (5.13%) Neutropenia * 1/78 (1.28%) Thrombocytopenia * 0/78 (0.00%) Acute coronary syndrome * 1/78 (1.28%) Cardiac failure congestive * 1/78 (1.28%) Myocardial infarction * 1/78 (1.28%) Cardiomyopathy * 0/78 (0.00%) Abdominal pain * 1/78 (1.28%) Diarrhoea * 1/78 (1.28%) Upper gastrointestinal haemorrhage * 1/78 (1.28%) Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) ",
            "Nausea 1/30 (3.33%)Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) "
        ],
        "premise_nums": [
            "neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%)",
            "(3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30",
            "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%)",
            "Nausea 1/30 (3.33%)Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30",
            "Adverse Events 1: Total: 23/78 (29.49%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%)"
        ]
    },
    {
        "id": "1268edfc-cce2-4f07-9fbb-392341b7f399",
        "primaryId": "NCT01605396",
        "statement_text": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months ",
        "statement_nums": [
            "Exemestane group of the primary trial had a median PFS of over 5 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) PFS was defined as the time from randomization to progressive disease  or death  whichever occurs first  Response was assessed according to RECIST 1.1 by BICR  According to RECIST 1.1, progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions  taking as reference the nadir SOD and an absolute increase of greater than 5 mm in the SOD  or the appearance of new lesions  PFS was analyzed using the Kaplan-Meier method and median PFS (95% confidence interval [CI]) in weeks was reported for each treatment arm  Per protocol  participants remained on assigned treatment until disease progression  Participants who discontinued study treatment for reasons other than disease progression continued to be assessed by imaging until objective documentation of progression  All participants (including participants who discontinued study treatment) were followed for survival until investigator notification to discontinue  Time frame: From Day 1 through last post-study efficacy follow-up (up to ~19 months) Results 1: ",
            "Arm/Group Title: Ridaforolimus + Dalotuzumab + ExemestaneArm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 40 Median (95% Confidence Interval) Unit of Measure: Weeks 23.29 (8.71 to 38.43) "
        ],
        "premise_nums": [
            "Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on",
            "an absolute increase of greater than 5 mm in the SOD  or the",
            "discontinue  Time frame: From Day 1 through last post-study efficacy follow-up (up to",
            "Participants Analyzed: 40 Median (95% Confidence Interval) Unit of Measure: Weeks 23.29 (8.71 to 38.43)",
            "(IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or",
            "mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus",
            "disease (PD) was defined as a 20% relative increase in the sum of",
            "death  whichever occurs first  Response was assessed according to RECIST 1.1 by BICR  According to RECIST 1.1,",
            "+ ExemestaneArm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously",
            "method and median PFS (95% confidence interval [CI]) in weeks was defined as a 20% relative increase in the sum of"
        ]
    },
    {
        "id": "58ccfd13-aa6d-4604-bf3d-c69270fe50d2",
        "primaryId": "NCT01276041",
        "statement_text": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term ",
        "statement_nums": [
            "1 patient in the primary trial died in an event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) "
        ],
        "premise_nums": [
            "- Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70",
            "(2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%)",
            "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70"
        ]
    },
    {
        "id": "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249",
        "primaryId": "NCT00182793",
        "secondaryId": "NCT00509769",
        "statement_text": "The majority of patients in the primary trial and the secondary trial experienced an adverse event ",
        "statement_nums": [
            "of patients in the primary trial and the secondary trial experienced an adverse event"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 24/32 (75.00%) Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%) "
        ],
        "premise_nums": [
            "(0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112",
            "Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%)",
            "Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112",
            "stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112",
            "Adverse Events 1: Total: 24/32 (75.00%) Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage",
            "(0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112"
        ]
    },
    {
        "id": "8c84c96f-1635-40dc-839b-fc937ed566a2",
        "primaryId": "NCT01105312",
        "statement_text": "Patients with measurable diseases are only eligible for phase 2 of the primary trial ",
        "statement_nums": [
            "diseases are only eligible for phase 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for phase II study "
        ],
        "premise_nums": [
            "study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for"
        ]
    },
    {
        "id": "7b48355e-3b9c-4cca-b7fa-1cbd612d1523",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients ",
        "statement_nums": [
            "was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202",
            "fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202",
            "neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac"
        ]
    },
    {
        "id": "3d188d93-13c6-48f3-b231-dcdeef81080e",
        "primaryId": "NCT00617539",
        "statement_text": "Presence of Extracranial metastases is part of the exclusion critera for the primary trial ",
        "statement_nums": [
            "exclusion critera for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain Extracranial metastases allowed "
        ],
        "premise_nums": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast"
        ]
    },
    {
        "id": "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV "
        ],
        "premise_nums": [
            "Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel -",
            "1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly",
            "1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly",
            "Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg",
            "20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort"
        ]
    },
    {
        "id": "2206dc2a-93da-4c11-b110-81f9c39af807",
        "primaryId": "NCT00101400",
        "statement_text": "A female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin greater than 1.6 x ULN are eligilbe for the primary trial ",
        "statement_nums": [
            "Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin greater than 1.6 x ULN are eligilbe for the primary",
            "female with Hemoglobin greater than 10.0 g/dl  Absolute neutrophil count 1,733/mm3, platelet count = 100,000/¬¨¬µl and total bilirubin greater than 1.6",
            "100,000/¬¨¬µl and total bilirubin greater than 1.6 x ULN are eligilbe for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5 x the upper limit of normal  "
        ],
        "premise_nums": [
            "Hemoglobin greater than 9.0 g/dl Absolute neutrophil count (ANC) greater than 1,500/mm3 Platelet count = 100,000/µl Total bilirubin =1.5"
        ]
    },
    {
        "id": "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd",
        "primaryId": "NCT02006979",
        "statement_text": "Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines ",
        "statement_nums": [
            "one cohort of the primary trial needs to receive manual"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Exercise an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines "
        ],
        "premise_nums": [
            "an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines",
            "for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of"
        ]
    },
    {
        "id": "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104",
        "primaryId": "NCT00849472",
        "statement_text": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [
            "than a dozen the primary trial participants are classified as"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen  axillary nodes  or sentinel node identified after neoadjuvant chemotherapy  Time frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results 1: Arm/Group Title: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
            "Arm/Group Description: Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants Analyzed: 93 Measure Type: Number Unit of Measure: Participants 16 "
        ],
        "premise_nums": [
            "the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results",
            "resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants",
            "each day  either 1 hour before or 2 hours after a meal) taken daily and",
            "[mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed",
            "the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants Analyzed: 93",
            "the same oral dose 4-6 weeks after surgery and was continued daily and continuing until 7 days before surgery  Pazopanib was resumed",
            "with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for",
            "(WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800",
            "Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at"
        ]
    },
    {
        "id": "87987ebb-6799-4d1d-8529-d33c6b7799f8",
        "primaryId": "NCT00548184",
        "statement_text": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response",
            "study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Pathologic Assessment After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy  Pathologic complete response: no invasive cancer in the residual breast  Near pathologic complete response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants Analyzed: 64 Measure Type: Number Unit of Measure: participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic response: 30 "
        ],
        "premise_nums": [
            "response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab",
            "After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or",
            "Number of Participants Analyzed: 64 Measure Type: Number Unit of Measure: participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic",
            "participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic response: 30",
            "study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants"
        ]
    },
    {
        "id": "bf94f208-a29b-4d8f-92a7-3cb8241ce344",
        "primaryId": "NCT00097721",
        "secondaryId": "NCT00896649",
        "statement_text": "Black women cannot take part in the secondary trial or the primary trial ",
        "statement_nums": [
            "take part in the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy) Patients must have measurable disease by the RECIST criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan  or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a cytological or histological confirmation of breast carcinoma is required  Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well  Patients must have progressed within six months of the last dose of chemotherapy  or experienced disease progression while receiving chemotherapy for advanced/metastatic disease  Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months ",
            "Adequate renal function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and Gault formulaAdequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion)  and platelet count 100 x 10^9/L Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN) Patients willing and able to complete the FACT-B questionnaire  Analgesic Diary  Pain VAS  and the tumor-related symptomatic assessment Patients willing and able to comply with the study protocol for the duration of the study A sample from the diagnostic biopsy (paraffin block) must be available Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice ",
            "Exclusion Criteria:Patients who have received chemotherapy  radiation  hormonal therapy  or Herceptin within 2 weeks of E7389 treatment start Radiation therapy encompassing greater than 10% of marrow Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator Prior treatment with Mitomycin C or nitrosoureas Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment  including the use of oxygen Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389 Patients with meningeal carcinomatosis Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted ",
            "Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test  Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator  Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Severe /uncontrolled intercurrent illness/infection Significant cardiovascular impairment (history of congestive heart failure greater than NYHA grade II  unstable angina or myocardial infarction within the past six months  or serious cardiac arrhythmia) Patients with organ allografts Patients with known positive HIV status Patients who have had a prior malignancy  other than carcinoma in situ of the cervix  or non-melanoma skin cancer  unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrence Patients with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative Patients who participated in a prior E7389 clinical trial ",
            "Patients with other significant disease or disorders that  in the Investigator's opinion  would exclude the patient from the studyPATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian "
        ],
        "premise_nums": [
            "radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance",
            "at least one diameter (at least 10 mm in longest diameter (LD) by spiral",
            "discontinued from corticosteroids for at least two weeks before starting treatment with E7389 Patients with meningeal carcinomatosis Patients who require",
            "must measure at least 20 mm in LD  If a single",
            "or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and aspartate transaminase (AST) 3 times the upper limits of normal (ULN)",
            "function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and",
            "must be amenorrheic for at least 12 months to be considered of non-childbearing potential",
            "(in the case of liver metastases 5 x ULN) Patients willing and able to",
            "malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of",
            "hormonal therapy  or Herceptin within 2 weeks of E7389 treatment start Radiation therapy encompassing greater than 10% of marrow Failure to recover",
            "with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B",
            "(CT) scan  or at least 20 mm by standard techniques; If the only",
            "or transfusion)  and platelet count 100 x 10^9/L Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine",
            "participated in a prior E7389 clinical trial",
            "of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in",
            "absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it",
            "six months of the last dose of chemotherapy  or transfusion)  and platelet count 100 x 10^9/L Adequate liver function",
            "Criteria: Female patients with histologically or cytologically confirmed carcinoma",
            "is deemed to be clinically significant by the studyPATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds",
            "Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months"
        ]
    },
    {
        "id": "c68f6822-24fa-44b5-bf63-c272a8031fab",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have either AST or ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "either AST or ALT smaller than 1.5 ULN to participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; "
        ],
        "premise_nums": [
            "aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN;",
            "higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase",
            "Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in",
            "serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5"
        ]
    },
    {
        "id": "54a459cf-f01a-4abc-a8cf-0efebc01c694",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "statement_text": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "statement_nums": [
            "the primary trial and the secondary trial recorded none of the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac failure * 1/50 (2.00%) Diarrhoea * 1/50 (2.00%) Gastritis * 1/50 (2.00%) Nausea * 1/50 (2.00%) Oesophagitis * 1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Drug hypersensitivity * 1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482 (0.00%) Thrombocytopenia 2/482 (0.41%) ",
            "Anaemia 28/482 (1.66%)Disseminated intravascular coagulation 21/482 (0.21%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) Neutropenia 20/482 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482",
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac",
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) Neutropenia 20/482 (0.00%)",
            "1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%)",
            "1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482"
        ]
    },
    {
        "id": "d97ebc59-ab4b-462a-9057-12f4fc46df56",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [
            "Patients in the primary trial receive vorinostat at the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity  vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO gene expression analysis: Correlative studies INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  ",
            "Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  "
        ],
        "premise_nums": [
            "gene expression analysis: Correlative studies INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO)",
            "Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week",
            "an Urgent Safety Measure in August 2012 due to a large proportion of patients",
            "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole",
            "myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day",
            "a day (od) in the morning 1 hour after eating  on a continuous",
            "(od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given",
            "Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography:",
            "OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression",
            "the morning  One cycle is 28 days  Treatment is given",
            "surface area  administered orally (PO) once a day  and 15mg/m2 of Methotrexate orally once a week"
        ]
    },
    {
        "id": "2e4c7d0b-f1a2-4204-bac3-7445852fd916",
        "primaryId": "NCT01727011",
        "secondaryId": "NCT01420146",
        "statement_text": "the primary trial and the secondary trial interventions involve a variety of scans  such as CT  PET  MRI and dosimetry",
        "statement_nums": [
            "the primary trial and the secondary trial interventions involve a variety"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: IPAS Once the patient recorded in the trial  and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk  the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate  delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm "
        ],
        "premise_nums": [
            "delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium"
        ]
    },
    {
        "id": "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691",
        "primaryId": "NCT01928186",
        "secondaryId": "NCT00684983",
        "statement_text": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine  oral lapatinib ditosylate or cixutumumab IV  however cohort 2 of the secondary trial receive all of these ",
        "statement_nums": [
            "the primary trial participants and cohort 1 participants in the secondary trial receive all of these",
            "or cixutumumab IV  however cohort 2 of the secondary trial receive all of these"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Diagnostic (FLT PET) Patients with early stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan  Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo FLT PET Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen  INTERVENTION 1: Arm A Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO INTERVENTION 2: Arm B ",
            "Patients receive capecitabine and lapatinib ditosylate as in arm I  Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  cixutumumab: Given IV  lapatinib ditosylate: Given PO and capecitabine: Given PO"
        ],
        "premise_nums": [
            "stage  ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start",
            "PO and capecitabine: Given PO INTERVENTION 2: Arm B",
            "Analysis: Correlative studies - Ki67 staining of the tumor tissue in the",
            "once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Patients also receive cixutumumab IV over 1-1½ hours on days 1, 8, and 15. Courses repeat every 21 days in",
            "emission tomography) scanning procedure: [F18] fluorothymidine  Positron Emission Tomography: Undergo",
            "endocrine treatment  The surgery follows 1-7 days after the second FLT PET scan",
            "oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on"
        ]
    },
    {
        "id": "4546c169-cc5c-4e03-bcce-31d491ed18e0",
        "primaryId": "NCT01989676",
        "statement_text": "the primary trial only records cardiovasuclar adverse events ",
        "statement_nums": [
            "the primary trial only records cardiovasuclar adverse"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia * 1/349 (0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349 (0.00%) Cardio-respiratory arrest * 2/349 (0.57%) Cardiovascular insufficiency * 0/349 (0.00%) "
        ],
        "premise_nums": [
            "(0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349",
            "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia"
        ]
    },
    {
        "id": "1bb3badf-41c6-4741-90f0-367473ce254d",
        "primaryId": "NCT00612560",
        "statement_text": "children and illiterate adults are not able to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to read and write English "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to"
        ]
    },
    {
        "id": "87953ba3-3e94-421c-b426-b716562b8b5d",
        "primaryId": "NCT02806544",
        "secondaryId": "NCT00605267",
        "statement_text": "A patient with stage 2B   pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "A patient with stage 2B   pathologically confirmed PR positive breast",
            "elgible for both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Clinical locally advance breast cancer (Stage IIB or III) Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Clinical locally advance breast cancer (Stage",
            "Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and",
            "or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive"
        ]
    },
    {
        "id": "847b4dbe-428f-431c-8916-2a9c0c80cce4",
        "primaryId": "NCT00686127",
        "secondaryId": "NCT01129622",
        "statement_text": "dosages are specified in the intervention section of the secondary trial and the primary trial",
        "statement_nums": [
            "intervention section of the secondary trial and the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo Patch Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  "
        ],
        "premise_nums": [
            "(baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive",
            "Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo"
        ]
    },
    {
        "id": "9c00b318-0a3a-43c9-a6cd-2983c07be393",
        "primaryId": "NCT00232505",
        "statement_text": "There were no instances of patients with abnormal heart rates in the primary trial ",
        "statement_nums": [
            "heart rates in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify  __) * [1]0/31 (0.00%) Cardiac General - Other (Specify  __) * [2]0/31 (0.00%) Left ventricular diastolic dysfunction * 0/31 (0.00%) Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/31 (0.00%) Adverse Events 2: Total: 8/25 (32.00%) Edema: limb * 1/25 (4.00%) Neutrophils/granulocytes (ANC/AGC) * 0/25 (0.00%) Cardiac General - Other (Specify  __) * [1]1/25 (4.00%) Cardiac General - Other (Specify  __) * [2]0/25 (0.00%) ",
            "Left ventricular diastolic dysfunction * 1/25 (4.00%)Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%) "
        ],
        "premise_nums": [
            "tachycardia/Paroxysmal Atrial Tachycardia * 0/25 (0.00%)",
            "ventricular diastolic dysfunction * 1/25 (4.00%)Supraventricular and nodal arrhythmia - Atrial",
            "Adverse Events 1: Total: 3/31 (9.68%) Edema: limb * 2/31 (6.45%) Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%) Cardiac General - Other (Specify"
        ]
    },
    {
        "id": "cbfe14a5-5169-4de3-b69f-13b489be949a",
        "primaryId": "NCT02597452",
        "secondaryId": "NCT01929395",
        "statement_text": "the primary trial and the secondary trial do not use cyclical interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial do not use cyclical"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Intelligent Breast Exam  iBE Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment  No return visit required for participation  intelligent Breast Exam  iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual  If the patient is selected to participate in the inter-rater reliability portion of the study  the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit  INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) "
        ],
        "premise_nums": [
            "clinical breast exams twice sequentially performed by two different"
        ]
    },
    {
        "id": "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b",
        "primaryId": "NCT00325598",
        "statement_text": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in Gy has a huge effect ",
        "statement_nums": [
            "Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial  the increase in"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40 Gy) Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 "
        ],
        "premise_nums": [
            "of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The",
            "Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40",
            "Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36",
            "(40 Gy) Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall",
            "be deemed infeasible if more than 4 patients cannot be given treatment because her"
        ]
    },
    {
        "id": "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "statement_text": "There were more patients with hypotension in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "more patients with hypotension in cohort 1 of the primary trial  than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%) Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) "
        ],
        "premise_nums": [
            "Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21",
            "Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%)",
            "Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%)"
        ]
    },
    {
        "id": "eae76b80-107c-4469-b06f-73d5f7a4c1d5",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
            "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization  Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol  Exclusion Criteria: ",
            "Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded; ",
            "Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies);Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). Exclusion Criteria : Patients who currently use substances for which a second-line care is already committed  ",
            "Patients with a Karnofsky index smaller than 70."
        ],
        "premise_nums": [
            "An AUDIT-C score greater than 1 or more than one cigarette smoked per",
            "Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination",
            "CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin",
            "uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at",
            "count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at leastudy  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or",
            "for patients of childbearing potential within 2-weeks (preferably 7 days) prior",
            "with a Karnofsky index smaller than 70.",
            "Previous (less than 5 years) or current history of",
            "or idiosyncrasy to drugs chemically related to trastuzumab Emtansine",
            "comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing",
            "higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase",
            "study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina",
            "use  (Karnofsky Index greater than 70). Exclusion Criteria : Patients who currently use substances",
            "ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple",
            "comply with the protocol Inclusion Criteria : women with primary breast cancer: Primary tumor greater than 1 cm diameter  measured by",
            "women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or",
            "Serum total bilirubin 2 x upper limit of normal (ULN)"
        ]
    },
    {
        "id": "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e",
        "primaryId": "NCT00347919",
        "statement_text": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 "
        ],
        "premise_nums": [
            "their response at Week 12 was unknown or missing  Response was",
            "as a greater than or equal 20% increase in target lesions  Participants",
            "Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall",
            "Progressive Disease at Week 12 in Cohort 1 The percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1",
            "Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage",
            "Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease"
        ]
    },
    {
        "id": "91cf53f9-7233-49ee-a619-c027f6db67ac",
        "primaryId": "NCT00605267",
        "statement_text": "Only men can be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  "
        ],
        "premise_nums": [
            "positive women  aged 20 years and over  with operable and"
        ]
    },
    {
        "id": "78894316-fc7d-4d61-a2d4-9ea369bfce20",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea ",
        "statement_nums": [
            "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Erysipelas 2/167 (1.20%) Bacterial diarrhoea 1/167 (0.60%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Erysipelas 2/167 (1.20%) Bacterial diarrhoea 1/167 (0.60%)"
        ]
    },
    {
        "id": "889e6622-1614-4f6c-a47c-e7caad6e154f",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial had the same number",
            "anaemia and Neutropenia  but Cohort 1 had 1 more case of Leukopenia than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50"
        ]
    },
    {
        "id": "4577d986-d7e5-4b5d-9852-b944a6f7f252",
        "primaryId": "NCT01740323",
        "secondaryId": "NCT00127205",
        "statement_text": "the secondary trial and the primary trial accept patients in the same age range ",
        "statement_nums": [
            "the secondary trial and the primary trial accept patients in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female breast cancer patients over the age of 18 will be recruited for this study  Patients enrolled in the study will meet standard criteria for whole breast XRT  PATIENT CHARACTERISTICS: Age 18 and over "
        ],
        "premise_nums": [
            "cancer patients over the age of 18 will be recruited for this study",
            "PATIENT CHARACTERISTICS: Age 18 and over the age of 18 will be recruited for this study"
        ]
    },
    {
        "id": "e83b56ba-d129-4cde-976d-2865e67ef4a3",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "statement_text": "the primary trial studies tumours response  whereas the secondary trial investigates changes in Bone Mineral Density ",
        "statement_nums": [
            "the primary trial studies tumours response  whereas the secondary trial investigates changes in Bone"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions  Any pathological lymph node must have reduction in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of target lesions from baseline sum diameters  Progressive Disease (PD): smaller than /= 20% increase in the sum of the diameters of target lesions  from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions  The appearance of one or more new lesions* denotes disease progression  Stable Disease (SD): Neither sufficient decrease or increase  Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions  Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions  Progressive Disease (PD): Substantial  unequivocal progression of existing non-target lesions  ",
            "Time frame: from time of First treatment to week 24Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months "
        ],
        "premise_nums": [
            "sum on study with at least a 5 mm absolute increase in the sum of",
            "in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of",
            "by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance",
            "time of First treatment to week 24Outcome Measurement: Lumbar Spine Bone Mineral",
            "Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane",
            "(PD): smaller than /= 20% increase in the sum of the",
            "Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy",
            "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate",
            "Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST"
        ]
    },
    {
        "id": "eee75423-9a61-4a57-8baf-8f91b9562486",
        "primaryId": "NCT01705691",
        "statement_text": "The majority of patients in the primary trial suffered from Kidney stones ",
        "statement_nums": [
            "of patients in the primary trial suffered from Kidney stones"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/19 (15.79%) Febrile neutropenia 1/19 (5.26%) Colitis 1/19 (5.26%) Pain in extremity 0/19 (0.00%) Nephrolithiasis 0/19 (0.00%) Pulmonary embolism 1/19 (5.26%) Dyspnoea 0/19 (0.00%) Haematoma 0/19 (0.00%) Adverse Events 2: Total: 4/30 (13.33%) Febrile neutropenia 1/30 (3.33%) Colitis 0/30 (0.00%) Pain in extremity 1/30 (3.33%) Nephrolithiasis 1/30 (3.33%) Pulmonary embolism 0/30 (0.00%) Dyspnoea 1/30 (3.33%) Haematoma 1/30 (3.33%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 4/30 (13.33%) Febrile neutropenia 1/30 (3.33%) Colitis 1/19 (5.26%) Pain in extremity 0/19 (0.00%) Nephrolithiasis 0/19 (0.00%)",
            "Colitis 1/19 (5.26%) Pain in extremity 0/19 (0.00%) Nephrolithiasis 0/19 (0.00%) Haematoma 0/19 (0.00%) Adverse Events 2: Total: 4/30 (13.33%) Febrile neutropenia",
            "Adverse Events 1: Total: 3/19 (15.79%) Febrile neutropenia 1/19 (5.26%) Colitis 0/30 (0.00%) Pain in extremity 1/30 (3.33%) Nephrolithiasis 1/30 (3.33%)",
            "(0.00%) Haematoma 0/19 (0.00%) Adverse Events 2: Total: 4/30 (13.33%) Febrile neutropenia 1/30 (3.33%) Colitis 0/30 (0.00%) Pain in extremity 1/30 (3.33%)",
            "1: Total: 3/19 (15.79%) Febrile neutropenia 1/19 (5.26%) Colitis 1/19 (5.26%) Pain in extremity 0/19 (0.00%) Nephrolithiasis 0/19 (0.00%) Pulmonary embolism"
        ]
    },
    {
        "id": "9e046221-7d4b-4681-a374-96793350927d",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort ",
        "statement_nums": [
            "Group 1 of the secondary trial has a higher ORR",
            "Letrozole cohort of the primary trial and the trastuzumab cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) Results 2: Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
            "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 "
        ],
        "premise_nums": [
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given",
            "percentage of subjects 28.6 (14.6 to 46.3) Results 2: Arm/Group Title: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed:",
            "NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage",
            "NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage",
            "Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102",
            "for a period of at least one month; Partial Response (PR)  at least a 30% decrease in the sum of",
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole",
            "the date of the first documented disease progression or date",
            "Results 2: Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed:",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "Partial Response (PR)  at least a 30% decrease in the sum of the",
            "Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of",
            "for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of",
            "Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Response Rate (ORR) was defined",
            "Response (PR)  at least a 30% decrease in the sum of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until",
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2",
            "Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement:",
            "partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT:"
        ]
    },
    {
        "id": "5448c6b8-244c-4a42-bbef-e1a1a2e254e2",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "statement_text": "Cyclophosphamide  Doxil and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [
            "were used in the secondary trial intervention  but not in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cabozantinib Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV "
        ],
        "premise_nums": [
            "once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 30-90 minutes weekly or every 3 weeks at the discretion of",
            "Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at",
            "was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the",
            "oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every"
        ]
    },
    {
        "id": "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2",
        "primaryId": "NCT00429572",
        "secondaryId": "NCT02455453",
        "statement_text": "pre-menopausal patients are excluded from the secondary trial  but eligible for the primary trial ",
        "statement_nums": [
            "are excluded from the secondary trial  but eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Recurrent or residual metastatic breast carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor  No major organ dysfunction or active infection Exclusion Criteria: None Inclusion Criteria: Patient must be postmenopausal defined as meeting one or more of the following: "
        ],
        "premise_nums": [
            "carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen",
            "performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible"
        ]
    },
    {
        "id": "8d450d42-4eb1-4edb-be76-b2885964aa90",
        "primaryId": "NCT01506609",
        "secondaryId": "NCT00656019",
        "statement_text": "Patients with cytologically confirmed breast cancer  who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial  but are eligible for the primary trial ",
        "statement_nums": [
            "Patients with cytologically confirmed breast cancer",
            "not eligible for the secondary trial  but are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent  INCLUSION CRITERIA: Undergoing core needle biopsy for a breast abnormality suspicious for breast cancer  Has undergone a core needle biopsy demonstrating breast cancer and has not yet had any further therapy  provided the core needle biopsy is available for analysis  No prior therapy for breast cancer within the past 5 years  18 years of age or older  Ability to understand and the willingness to sign a written informed consent document  EXCLUSION CRITERIA: History of parathyroid disease  hypercalcemia  or kidney stones  Supplemental vitamin D other than from a standard multiple vitamin or from standard formulations of calcium and vitamin D (eg  calcium citrate with vitamin D) within the prior 6 months  History of renal failure requiring dialysis or kidney transplantation  Pregnant or nursing Receiving supplemental calcium greater than 1200 mg calcium per day during study  Initial treatment of breast cancer will not be with breast-conserving surgery or mastectomy  Locally-advanced breast cancer Plans for neoadjuvant chemotherapy  hormonal therapy  or other systemic therapy Plans for preoperative radiation therapy ",
            "Plans for breast cancer surgery  and does not allow for at least 10 days of vitamin D intervention Any condition potentially interfering with subjects ability to comply with taking study medication  Any medical condition that would potentially interfere with vitamin D absorption  such as celiac sprue  ulcerative colitis  Current participation in another research study that would increase risk to subject  in the opinion of the investigators "
        ],
        "premise_nums": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast",
            "nursing Receiving supplemental calcium greater than 1200 mg calcium per day during study",
            "for breast cancer within the past 5 years  18 years of age or older  Ability",
            "and does not allow for at least 10 days of vitamin D intervention Any condition",
            "with vitamin D) within the prior 6 months  History of renal"
        ]
    },
    {
        "id": "a7232387-b266-4bfb-8df8-ca9789188500",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ",
            "ATRIAL FIBRILLATION 0/24 (0.00%)APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) "
        ],
        "premise_nums": [
            "NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%)",
            "PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2:",
            "2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%)",
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "(0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%)"
        ]
    },
    {
        "id": "2e317381-2704-4d06-a793-1d2b29139969",
        "primaryId": "NCT01959490",
        "statement_text": "In total only one participant of the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "one participant of the primary trial did not achieve Pathological"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants ",
            "Unit of Measure: Participants 4 80.0%Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0%",
            "90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in",
            "8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression",
            "chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression",
            "or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of",
            "or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of Participants Analyzed: 5 Measure Type: Count of Participants",
            "840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is",
            "run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in"
        ]
    },
    {
        "id": "030316a2-fb48-469d-9c55-04cdc9a37fb6",
        "primaryId": "NCT00559507",
        "statement_text": "the primary trial participants are given saracatinib PO every single day of the study duration ",
        "statement_nums": [
            "the primary trial participants are given saracatinib"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  "
        ],
        "premise_nums": [
            "Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression"
        ]
    },
    {
        "id": "2c723e02-14d8-4a80-a95f-517e904bbbad",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year  but several patients had a PFS of less than 1 month ",
        "statement_nums": [
            "No participants of the primary trial had a Progression Free Survival over 1 year  but several patients",
            "had a PFS of less than 1 month"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death  whichever occurred first  Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff  For PD or death with a missing interval immediately preceding the event  progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval  Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment  Time frame: From the date of randomization to the date of disease progression (PD) or death  whichever occurred first (up to 8.4 years) Results 1: Arm/Group Title: Standard of Care (SOC) Arm/Group Description: Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion  Overall Number of Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin Alfa ",
            "Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week Overall Number of Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 7.6) "
        ],
        "premise_nums": [
            "(SC) once a week Overall Number of Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months",
            "death  whichever occurred first  Participants who had not",
            "were censored at the last disease assessment prior to the",
            "Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin",
            "Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin",
            "Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a",
            "whichever occurred first (up to 8.4 years) Results 1: Arm/Group"
        ]
    },
    {
        "id": "8befa03f-c3da-4950-8d27-491ea06b51ed",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "statement_text": "Patients' appetites were not affected in the primary trial  but at least one was affected in the secondary trial ",
        "statement_nums": [
            "not affected in the primary trial  but at least one was affected in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%) Medical device complication * 1/33 (3.03%) Cellulitis * 1/33 (3.03%) Sepsis * 1/33 (3.03%) Hip fracture * 1/33 (3.03%) Back pain * 1/33 (3.03%) Menorrhagia * 1/33 (3.03%) Thrombosis * 1/33 (3.03%) Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) ",
            "DEHYDRATION 4/48 (8.33%)DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) "
        ],
        "premise_nums": [
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48",
            "NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "DEHYDRATION 4/48 (8.33%)DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48",
            "Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53",
            "(27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%)",
            "(0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%)",
            "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48",
            "Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%)",
            "ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53",
            "(2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%)",
            "Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%)",
            "VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53"
        ]
    },
    {
        "id": "32424458-a3e2-440a-9693-6a2f8d4aaddb",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the",
            "Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR)"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study  Overall Number of Participants Analyzed: 39 Measure Type: Number ",
            "Unit of Measure: percentage of patients 28 (14.9 to 45.0)Results 2: Arm/Group Title: Abraxane Alone Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) "
        ],
        "premise_nums": [
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will",
            "will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "8, and 15 at 28-day intervals  Abraxane will be administered as a 10 mg/kg loading dose followed by 5 mg/kg",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1)",
            "basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0)Results 2: Arm/Group Title: Abraxane Alone",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Abraxane at 100 mg/m2 X 3 doses on Days 1,",
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the",
            "at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered",
            "will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21",
            "progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab",
            "tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then",
            "5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients",
            "Number of Participants Analyzed: 39 Measure Type: Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage"
        ]
    },
    {
        "id": "a2b25229-c003-49c3-8b0b-94b68f756d3c",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial did not record any skin infections in their patients ",
        "statement_nums": [
            "the primary trial did not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/4 (50.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy  malaise) 1/4 (25.00%) Pain - Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation 0/3 (0.00%) Dehydration 0/3 (0.00%) Fatigue (asthenia  lethargy  malaise) 0/3 (0.00%) Pain - Back 0/3 (0.00%) Urinary tract infection 0/3 (0.00%) Dyspnea (shortness of breath) 0/3 (0.00%) ",
            "Pericardial effusion 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%) "
        ],
        "premise_nums": [
            "of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin",
            "0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin",
            "skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy",
            "0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation",
            "Pericardial effusion 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin",
            "Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of"
        ]
    },
    {
        "id": "728721c4-6376-4ab8-9e4a-af8596bd1ab3",
        "primaryId": "NCT00852930",
        "secondaryId": "NCT02308020",
        "statement_text": "Laser Therapy is only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this ",
        "statement_nums": [
            "only used in cohort 1 of the primary trial  neither cohort of the secondary trial make use of this"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  INTERVENTION 2: Part B Abemaciclib: HR+  HER2- Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET)  Participants may continue to receive treatment until discontinuation criteria are met  "
        ],
        "premise_nums": [
            "treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual",
            "200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as",
            "HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle",
            "drainage: therapist administered massage therapy INTERVENTION 1: Part A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was",
            "A Abemaciclib: HR+  HER2+ Breast Cancer Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of",
            "receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every"
        ]
    },
    {
        "id": "c7151ad6-bcac-48e1-ba1e-e6f56a043804",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "statement_text": "the primary trial and the secondary trial both record cases of Cholecystitis ",
        "statement_nums": [
            "the primary trial and the secondary trial both record cases of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) ",
            "Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) "
        ],
        "premise_nums": [
            "failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%)",
            "increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular",
            "failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased",
            "intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%)",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2:",
            "Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24",
            "increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33",
            "Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%)",
            "Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%)"
        ]
    },
    {
        "id": "4f71e33c-4f0f-4952-bb03-52402be5f9f4",
        "primaryId": "NCT02015676",
        "statement_text": "There is 1 case (1.45%) of thrombocytopenia in the primary trial ",
        "statement_nums": [
            "There is 1 case (1.45%) of thrombocytopenia in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%) Acute febrile neutrophilic dermatosis * 1/69 (1.45%) Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69 (1.45%) Intestinal obstruction NOS * 1/69 (1.45%) Diarrhoea NOS * 2/69 (2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69 (1.45%) "
        ],
        "premise_nums": [
            "(2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69",
            "Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69",
            "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%)"
        ]
    },
    {
        "id": "ef675459-a7d9-4ea1-8963-c95682c38d15",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 "
        ],
        "premise_nums": [
            "Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic",
            "clinically negative axillary nodes (N0) M0"
        ]
    },
    {
        "id": "f9df9e45-eb68-4257-801e-b086a89374b8",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine  paclitaxel  abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial ",
        "statement_nums": [
            "Female Patients with LVEF greater than 50%, who have previously undergone",
            "still eligible for the primary trial but are excluded from the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Prospectively confirmed HER2-positive (i.e.  IHC 3+ or IHC 2+ and gene amplified by fluorescence in situ hybridization [FISH] positive) as assessed on primary tumor and/or metastatic site Documented progression of unresectable  locally advanced  or mBC  determined by the investigator Left ventricular ejection fraction (LVEF) greater than /= 50% by echocardiogram (ECHO) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 A negative serum Beta-Human Chorionic Gonadotropin (Beta-HCG) test for women of childbearing potential (premenopausal or not meeting the definition of postmenopausal i.e  greater than /= 12 months of amenorrhea)  and women who have not undergone surgical sterilization (i.e.  absence of ovaries and/or uterus) ",
            "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate non-hormonal methods of contraception  including at least one method with a failure rate of smaller than 1% per year  during the treatment period and for at least 7 months after the last dose of study drugFor men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm  With female partners of childbearing potential  men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of smaller than 1% per year during the treatment period and for at least 7 months plus 90 days (a spermatogenesis cycle) after the last dose of study drug  Men must refrain from donating sperm during this same period  With pregnant female partners  men must remain abstinent or use a condom during the treatment period and for at least 7 months after the last dose of study drug  Exclusion Criteria: Prior treatment with trastuzumab emtansine ",
            "Prior treatment with lapatinib or lapatinib with capecitabine or non-comparable biologic or biosimilar of trastuzumabPeripheral neuropathy of Grade greater than /= 3 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE [version 4.03]) History of other malignancy within the previous 5 years  except for appropriately treated carcinoma in situ of the cervix  non-melanoma skin carcinoma  Stage 1 uterine cancer  synchronous or previously diagnosed HER2-positive breast cancer  or cancers with a similar curative outcome as those mentioned above History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to enrollment except hormone therapy  which can be given up to 7 days prior to enrollment; recovery of treatment-related toxicity consistent with other eligibility criteria History of exposure to cumulative doses of anthracyclines  as defined in the protocol History of radiation therapy within 14 days of enrollment ",
            "Brain metastases that are untreated  symptomatic  or require therapy to control symptoms  as well as a history of radiation  surgery  or other therapy  including steroids  to control symptoms from brain metastases within 2 months (60 days) before enrollmentCNS only disease History of a decrease in LVEF to smaller than 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment History of symptomatic chronic heart failure (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment History of myocardial infarction or unstable angina within 6 months of enrollment Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy Current severe  uncontrolled systemic disease Pregnancy or lactation ",
            "Concurrent  serious  uncontrolled infections or current known infection with human immunodeficiency virus (HIV) or active hepatitis B and/or hepatitis C  For patients who are known carriers of hepatitis B virus (HBV)  active hepatitis B infection must be ruled out  based on negative serologic testing and/or determination of HBV DNA viral load per local guidelinesPresence of conditions that could affect gastrointestinal absorption: malabsorption syndrome  resection of the small bowel or stomach  and ulcerative colitis History of intolerance (such as Grade 3-4 infusion reaction) or known hypersensitivity to trastuzumab or murine proteins or any component of the product Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  ",
            "Any N No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL, ",
            "Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization  Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol  Exclusion Criteria: Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix  Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  ",
            "Preexisting peripheral neuropathy grade 2Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded; Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; ",
            "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components;Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol "
        ],
        "premise_nums": [
            "Preexisting peripheral neuropathy grade 2Known history of uncontrolled or",
            "Exclusion Criteria: Previous (less than 5 years) or current history of",
            "lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl",
            "expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a",
            "uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at",
            "a prior malignancy diagnosed more than 5 years prior to randomization may enter the",
            "10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: Serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase",
            "progression of unresectable  locally advanced  or mBC",
            "or symptomatic angina  clinically significant arrhythmias  congestive",
            "a failure rate of smaller than 1% per year  during the treatment",
            "Oncology Group (ECOG) performance status of 0 or 1 A negative serum Beta-Human Chorionic",
            "treatment period and for at least 7 months after the last dose of study drugFor men:",
            "neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: Serum total",
            "limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: Serum",
            "Hepatic status: Serum total bilirubin 2 x upper limit of normalignancy diagnosed more than 5 years prior to randomization may enter the",
            "higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase",
            "and for at least 7 months plus 90 days (a spermatogenesis cycle) after the last",
            "positive) as assessed on primary tumor and/or metastatic site Documented",
            "which can be given up to 7 days prior to enrollment; recovery of treatment-related",
            "protocol History of radiation therapy within 14 days of enrollment",
            "control symptoms from brain metastases within 2 months (60 days) before enrollmentCNS only disease",
            "ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple",
            "of other malignancy within the previous 5 years  except for appropriately",
            "History of intolerance (such as Grade 3-4 infusion reaction) or known hypersensitivity to trastuzumab",
            "3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,",
            "women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or",
            "100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: Serum total bilirubin 2 x upper limit of normal (ULN)",
            "Grade greater than /= 3 per the National Cancer Institute's Common Terminology",
            "Inclusion Criteria: Prospectively confirmed HER2-positive (i.e.  IHC 3+ or idiosyncrasy to drugs chemically related to trastuzumab Emtansine",
            "greater than /= 12 months of amenorrhea)  and women who",
            "hormonal contraceptives are not allowed) Signed informed consent form",
            "neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobintolerance (such as Grade 3-4 infusion reaction) or known hypersensitivity to trastuzumab",
            "decrease in LVEF to smaller than 40% or symptomatic congestive heart failure (CHF)",
            "(LVEF) greater than /= 50% by echocardiogram (ECHO) Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor"
        ]
    },
    {
        "id": "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e",
        "primaryId": "NCT00319254",
        "statement_text": "the primary trial did not use overall response rate  tumour response rate or progression-free survival rate as its outcome measurement ",
        "statement_nums": [
            "the primary trial did not use overall response rate  tumour response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  "
        ],
        "premise_nums": [
            "of study treatment to first documentation of objective tumor progression",
            "experienced progression or death by Week 16 is reported",
            "first dose of study medication plus 1) divided by 7. Tumor progression was determined from"
        ]
    },
    {
        "id": "958721dc-e374-4fd1-abb9-071add70bde3",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg ",
        "statement_nums": [
            "the results of the primary trial the MTD of paclitaxel is approximately is 120 mg"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel  [Not Specified] Time frame: Through completion of Phase I  up to 1 year Results 1: Arm/Group Title: Dasatinib and Paclitaxel Arm/Group Description: The phase I portion is a standard  three-patient per cohort  dose escalation schedule will be used  Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel  The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel  Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days  according to the following schedule: Dasatinib 120MG PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle  ",
            "The trial will initially test the combination of weekly paclitaxel and dasatinib given PO  once daily   continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule  5 days on and 2 days off  omitting dasatinib the day prior and the day of administration of paclitaxel Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg of dasatinib 120 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg/m2 given intravenously over 1 hour on day 1, 8, and 15",
            "continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort",
            "The trial will initially test the combination of Phase I  up to 1 year Results 1: Arm/Group Title:",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg of dasatinib 120",
            "PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a",
            "I  up to 1 year Results 1: Arm/Group Title: Dasatinib and 15 of a 28 day cycle",
            "be used  Between 6 and 54 patients will likely be necessary",
            "a different schedule  5 days on and 2 days off  omitting dasatinib the day",
            "A treatment cycle will consist of 28 days  according to the following schedule: Dasatinib 120MG PO once daily  Weekly"
        ]
    },
    {
        "id": "19c0b2c7-e45c-4740-b25d-f6e738b59893",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia ",
        "statement_nums": [
            "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%)"
        ]
    },
    {
        "id": "7bcfca9e-1b09-45d4-8165-cb6ac96b8815",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "statement_text": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial ",
        "statement_nums": [
            "the secondary trial recorded more total occurences",
            "adverse events than the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120 (0.00%) Large intestine polyp 0/120 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%) ",
            "Oesophagitis 1/122 (0.82%)Large intestine polyp 0/122 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) ",
            "Lymphadenopathy 0/269 (0.00%)Acute myocardial infarction 0/269 (0.00%) Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) "
        ],
        "premise_nums": [
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254",
            "Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease",
            "injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy",
            "Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 0/269 (0.00%)Acute myocardial infarction 0/269 (0.00%) Angina pectoris 3/269",
            "block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%)",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254",
            "(0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade",
            "(0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120 (0.00%) Large intestine polyp 0/120 (0.00%) Death 1/120 (0.83%)",
            "(0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%)",
            "myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%)",
            "Lymphadenopathy 0/269 (0.00%)Acute myocardial infarction 0/269 (0.00%) Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269",
            "Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)",
            "(0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle",
            "Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%)",
            "0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis",
            "2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122",
            "30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites",
            "1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%)",
            "1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120",
            "Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%)",
            "Oesophagitis 1/122 (0.82%)Large intestine polyp 0/122 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%)",
            "1/122 (0.82%)Large intestine polyp 0/122 (0.00%) Death 1/122 (0.82%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122",
            "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular",
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%)",
            "injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122",
            "disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%)",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "myocardial infarction 0/269 (0.00%) Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269",
            "disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia",
            "Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade",
            "block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%)",
            "Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)"
        ]
    },
    {
        "id": "e3a8be03-20e4-460d-9ebc-f958a515ac45",
        "primaryId": "NCT01095003",
        "statement_text": "Less than 5 patients in the primary trial experienced Earache ",
        "statement_nums": [
            "Less than 5 patients in the primary trial experienced Earache"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2: Total: 85/383 (22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 0/383 (0.00%) Neutropenia 1/383 (0.26%) ",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%) "
        ],
        "premise_nums": [
            "Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383",
            "(1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Abdominal pain 3/383 (0.78%)",
            "(27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Abdominal pain 3/383 (0.78%)",
            "Total: 107/383 (27.94%) Anaemia 4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383",
            "(22.19%) Anaemia 3/383 (0.78%) Febrile neutropenia 2/383 (0.52%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383",
            "Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383",
            "(1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383",
            "Ear pain 0/383 (0.00%) Abdominal distension 1/383 (0.26%) Abdominal pain 6/383 (1.57%) Adverse Events 2: Total: 85/383 (22.19%) Anaemia 3/383",
            "4/383 (1.04%) Febrile neutropenia 7/383 (1.83%) Haemoytique anaemia 0/383 (0.00%) Leukopenia 1/383 (0.26%) Neutropenia 6/383 (1.57%) Thrombocytopenia 2/383 (0.52%) Anginal pectoris",
            "(0.00%) Cardiomyopathy 1/383 (0.26%) Ear pain 1/383 (0.26%) Abdominal distension 0/383 (0.00%) Abdominal pain 3/383 (0.78%)",
            "Thrombocytopenia 1/383 (0.26%)Anginal pectoris 0/383 (0.00%) Cardiomyopathy 1/383 (0.26%) Cardiomyopathy 0/383 (0.00%) Ear pain 0/383 (0.00%) Abdominal distension 1/383"
        ]
    },
    {
        "id": "f1096271-3160-4483-9246-ba0d96735efb",
        "primaryId": "NCT01118624",
        "statement_text": "Less than 5% of the primary trial participants achieved CR or PR ",
        "statement_nums": [
            "Less than 5% of the primary trial participants achieved CR or"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Tumor response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients achieving a CR or PR is considered in the overall response  Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks)  or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended  Results 1: Arm/Group Title: Pralatrexate Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants 1 "
        ],
        "premise_nums": [
            "is considered in the overall response  Time frame: Assessed",
            "response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients",
            "Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks and nor more than every 12 weeks (+/- 1 week) if",
            "drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants",
            "of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if"
        ]
    },
    {
        "id": "329b6871-2edc-4142-a4af-e7f8cef118ee",
        "primaryId": "NCT00004888",
        "statement_text": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events ",
        "statement_nums": [
            "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy Results 1: Arm/Group Title: Arm I: Doxorubicin and Taxotere ",
            "Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx  168 days): 4 Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 "
        ],
        "premise_nums": [
            "dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while",
            "after cycle 8 (~168 days)  and 30 or equal 10% but smaller than 20% of baseline value  Grade",
            "of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx  168 days): 4",
            "PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered",
            "8 (approx 168 days): 4 Grade 2 After 30 days or more days after last cycle of induction therapy Results",
            "4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more",
            "(approx  168 days): 4 Grade 1 After 30 days or more days after last cycle of induction therapy Results",
            "of LVEF greater than or equal 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline",
            "Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after",
            "different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of",
            "more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168",
            "Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  168 days): 4 Grade 1 After 30 days or more",
            "IV followed by docetaxel 60 mg/m^2 IV  one hour after cycle 8 (~168 days)  and 30 or",
            "was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was",
            "8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84",
            "more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168",
            "8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84",
            "is LVEF below LLN (50%) or decline of LVEF greater than or equal 10% but smaller than 20% of baseline",
            "Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or",
            "(approx  84 days): 2 Grade 1 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more",
            "4 (~84 days)  after cycle 8 (~168 days)  and 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour",
            "Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx"
        ]
    },
    {
        "id": "67522762-9423-4e3d-bf75-247f84ba7f05",
        "primaryId": "NCT00365417",
        "secondaryId": "NCT00853996",
        "statement_text": "To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than = 1.5 x ULN and Hemoglobin greater than 10 g/dL ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial patients must satisfy all",
            "following conditions; alkaline phosphatase smaller than 2.5 x ULN  aspartate aminotransferase smaller than",
            "x ULN and Hemoglobin greater than 10 g/dL"
        ],
        "label": "Contradiction",
        "premise_text": [
            "The following criteria for evidence of adequate hepatic function must be met: alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab  Platelet count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to 10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL AST smaller than 2 times upper limit of normal (ULN) Alkaline phosphatase smaller than 2 times ULN "
        ],
        "premise_nums": [
            "g/dL AST smaller than 2 times upper limit of normal (ULN) Alkaline phosphatase smaller than 2 times ULN",
            "(AST) must be less than/equal to 1.5 x ULN for the lab  Platelet",
            "10 g/dL  Platelets greater than 100,000/mm^3 Hemoglobin greater than 10 g/dL AST smaller than 2 times upper limit of normal",
            "alkaline phosphatase must be less than 2.5 x ULN for the lab; and aspartate",
            "count must be greater than/equal to 100,000/mm^3. Hemoglobin must be greater than/equal to"
        ]
    },
    {
        "id": "efd37946-54f3-4813-b63d-6d7df6123677",
        "primaryId": "NCT02630693",
        "statement_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection ",
        "statement_nums": [
            "A total of 3 patients in the primary trial suffered a life-threatening reaction"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 0/89 (0.00%) ",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) "
        ],
        "premise_nums": [
            "2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general",
            "(2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites",
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Vomiting 0/90",
            "general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%)",
            "1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders",
            "general disorders  administration site conditions 1/89 (1.12%) Other hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%)",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%)",
            "9/90 (10.00%) Febrile neutropenia 2/90 (2.22%) Ascites 0/90 (0.00%) Nausea 0/90 (0.00%) Death NOS 1/90 (1.11%) Fever 0/90 (0.00%) Other general",
            "Adverse Events 1: Total: 9/90 (10.00%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Nausea 1/89 (1.12%) Vomiting 1/89",
            "hepatobiliary disorders 1/90 (1.11%) Lung infection 2/90 (2.22%) Sepsis 2/90 (2.22%) Spinal fracture 0/90 (0.00%) Adverse Events 2:",
            "Lung infection 0/89 (0.00%)Sepsis 1/89 (1.12%) Spinal fracture 0/90 (0.00%) Adverse Events 2: Total: 12/89 (13.48%) Febrile neutropenia",
            "1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%) Other general disorders  administration site conditions 0/90 (0.00%) Other hepatobiliary disorders",
            "2: Total: 12/89 (13.48%) Febrile neutropenia 0/89 (0.00%) Ascites 1/89 (1.12%) Vomiting 1/89 (1.12%) Death NOS 2/89 (2.25%) Fever 1/89 (1.12%)"
        ]
    },
    {
        "id": "dcf62f43-04b7-4acb-b444-2d805238a8b1",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group ",
        "statement_nums": [
            "Pathological Response than the CT-P6 and ZA group",
            "Herceptin group in the primary trial had a higher percentage"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes  Regardless of Ductal Carcinoma in Situ (DCIS) Subject who went through Neoadjuvant period completely (24 weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response  will be assessed using resected bio-specimens collected in breast and axilla during a surgery  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title: CT-P6 ",
            "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248 Measure Type: Number Unit of Measure: percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Title: Herceptin ",
            "Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68) "
        ],
        "premise_nums": [
            "weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period",
            "FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 2 through 8 (3-week cycles)  Patients also received",
            "percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg",
            "Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title:",
            "75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8.",
            "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion",
            "Number of Participants Analyzed: 248 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)",
            "through 8. After a total of 8 treatment cycles of the neoadjuvant period  The primary endpoint  Pathological complete response",
            "75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment",
            "1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also",
            "CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by",
            "cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 8. After a total of 8 treatment cycles of the neoadjuvant",
            "received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through",
            "6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through",
            "6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage",
            "surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248",
            "will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response",
            "Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)",
            "an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on",
            "Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received"
        ]
    },
    {
        "id": "83dc7b9a-b863-4f81-88fb-763afc3b79e8",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  and half the subjects in the secondary trial must take a weekly tablet ",
        "statement_nums": [
            "the subjects in the secondary trial must take a weekly"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training ",
            "Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise"
        ],
        "premise_nums": [
            "pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting",
            "lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual"
        ]
    },
    {
        "id": "d446920a-2b8e-4452-b9f2-17d2771dbb07",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is Neutropenia ",
        "statement_nums": [
            "most common adverse event in cohort 1 of the primary trial is Neutropenia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%)",
            "1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%)",
            "21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree"
        ]
    },
    {
        "id": "aa710138-bf2a-4a7f-8014-4513fa1f448b",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events ",
        "statement_nums": [
            "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%)"
        ]
    },
    {
        "id": "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "statement_text": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "Patients must be doing less than 2 hours of physical exercise per week to",
            "be doing less than 2 hours of physical exercise per week to participate in the primary trial  however  this",
            "a requirement for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria: The patient has provided written informed consent with HIPAA authorization before participating in the study  as has his/her responsible caregiver  if applicable  The patient is a candidate for surgical intervention  with lymph node mapping being a part of the surgical plan  The patient is at least 18 years of age at the time of consent  The patient has an ECOG performance status of Grade 0 - 2 [8]. The patient has a clinical negative node status at the time of study entry  If of child bearing potential  the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek  has been surgically sterilized  or has been postmenopausal for at least 1 year  The patient is currently not participating in another investigational drug study  Melanoma Patients The patient has a diagnosis of primary melanoma  Breast Cancer Patients The patient has a diagnosis of primary breast cancer  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Exclusion Criteria: The patient is pregnant or lactating; ",
            "The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e.  all patients should be any T,N0,M0);The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V  Melanoma Patients The patient has a tumor with a Breslow depth less than 0.75mm.; Patients that have had preoperative chemotherapy  immunotherapy or radiation therapy; Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin; Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma; Patients who have undergone a wide excision for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation  free flap or skin graft of any type)  Breast Cancer Patients The patient has bilateral primary breast cancers or multiple tumors within their breast; ",
            "Patients that have had prior surgical procedures such as breast implants  reduction mammoplasty or axillary surgery;Patients scheduled for bilateral mastectomy for any reason; Patients that have had preoperative radiation therapy to the affected breast or axilla "
        ],
        "premise_nums": [
            "has a diagnosis of primary melanoma  Breast Cancer Patients",
            "has a negative pregnancy test within 72 hours prior to administration of Lymphoseek",
            "for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation",
            "an ECOG performance status of Grade 0 - 2 [8]. The patient is at least 18 years of age at the time of",
            "with a Breslow depth less than 0.75mm.; Patients that have had",
            "breast implants  reduction mammoplasty or axillary surgery;Patients scheduled",
            "lymph nodes (i.e.  all patients should be any T,N0,M0);The patient has a known hypersensitivity to",
            "with truncal or extremity primary melanoma who has had a",
            "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria:"
        ]
    },
    {
        "id": "6a71c114-2e38-4d57-8f8b-8252d9c62cbe",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial  and 0 cases of heart failure ",
        "statement_nums": [
            "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial  and 0 cases"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%)"
        ]
    },
    {
        "id": "4333aaa3-dbe4-4275-a982-881fe25c96c0",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity  doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally filgrastim: Given SC paclitaxel albumin-stabilized nanoparticle formulation: Given IV trastuzumab: Given IV laboratory biomarker analysis: Correlative studies quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "Given IV cyclophosphamide: Given orally filgrastim: Given SC paclitaxel",
            "once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in",
            "unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel",
            "doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once a week for 1 year in the absence of disease progression",
            "nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of",
            "toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year",
            "chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on",
            "filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression"
        ]
    },
    {
        "id": "d605b820-2915-4b19-b9cd-ca7850645f83",
        "primaryId": "NCT00357110",
        "statement_text": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "Only 6 patients in cohort 1 of the primary trial had Varicose Veins"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Varicose Vein 1/6 (16.67%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Varicose Vein 1/6 (16.67%)"
        ]
    },
    {
        "id": "d6de70df-d113-4bc8-9d3b-b71f31937ebe",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) "
        ],
        "premise_nums": [
            "deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)"
        ]
    },
    {
        "id": "9f897b29-7cfa-414c-8cf6-212a68ec2216",
        "primaryId": "NCT03346161",
        "secondaryId": "NCT01000662",
        "statement_text": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions  they are only testing effectiveness of consultations ",
        "statement_nums": [
            "Neither the secondary trial or the primary trial require patients to undergo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  INTERVENTION 2: Arm 2: Enhanced Usual Care (Surgical Care Booklet) ",
            "Investigators recruited patients scheduled for plastic/reconstruction consultation  Investigators identified patients who completed or scheduled a mastectomy  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home  Patients were randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with American Society of Plastic Surgeons booklet \"Breast Reconstruction.\" They were asked to answer a survey  After the appointment  the team collected information about consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
            "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  ",
            "Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed "
        ],
        "premise_nums": [
            "gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The",
            "40.5 Gy to the breast and 48.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Gy to the breast and 48.0 Gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm",
            "participation was approximately 30 minutes INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed",
            "patients scheduled for a plastic/reconstruction consult  Investigators identified",
            "recruited patients scheduled for plastic/reconstruction consultation  Investigators identified",
            "breast with a Friday boost of 2.0 Gy to the tumor bed  for",
            "A study team member called the patient to determine",
            "with a daily concomitant boost of 0.5 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "gy to the tumor bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "40.5 Gy to the breast and 46.5 gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy to the breast and 46.5 gy to the tumor bed INTERVENTION 2:",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks",
            "to come to their scheduled appointment 30 minutes early to meet a coordinator or",
            "bed INTERVENTION 2: ARM 2 Weekly Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy",
            "for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)",
            "making  Patient participation was approximately 30 minutes  INTERVENTION 2: Arm",
            "The overall dose will be 40.5 Gy to the breast with a Friday boost of 2.0 Gy to the tumor"
        ]
    },
    {
        "id": "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed much better than the test group  as a lower PFS is ideal ",
        "statement_nums": [
            "The the primary trial placebo group performed much"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause  Time frame: From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months) Results 1: Arm/Group Title: Exemestane 25 mg + Placebo Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25 mg + Entinostat 5 mg ",
            "Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36) "
        ],
        "premise_nums": [
            "or death up to primary completion date (Median follow-up 6",
            "Sponsor  whichever occurred first Overall Number of Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25",
            "orally once per week on Days 1, 8, 15 and 22 of Measure: months 4.28 (3.26 to 5.36)",
            "orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of",
            "Sponsor  whichever occurred first Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months",
            "orally once per week on Days 1, 8, 15 and 22 of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane",
            "Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25",
            "Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36)",
            "Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per"
        ]
    },
    {
        "id": "4606f64f-64cc-4d73-a8be-75701c97008d",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Plasma transfusion ",
        "statement_nums": [
            "A patient in cohort 2 of the primary trial received a Plasma transfusion"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Total: 17/181 (9.39%) Disseminated intravascular coagulation 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics 0/181 (0.00%) Transfusion: pRBCs 1/181 (0.55%) Arrhythmia supraventricular 1/181 (0.55%) Cardiac disorder 0/181 (0.00%) Edema 0/181 (0.00%) Left ventricular failure 1/181 (0.55%) Myocardial ischemia 0/181 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 17/181 (9.39%) Disseminated intravascular coagulation 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics",
            "Total: 17/181 (9.39%) Disseminated intravascular coagulation 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics 0/181 (0.00%) Transfusion: pRBCs",
            "Transfusion: pRBCs 1/181 (0.55%) Arrhythmia supraventricular 1/181 (0.55%) Cardiac disorder 0/181 (0.00%) Febrile neutropenia 1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics",
            "1/181 (0.55%) Hemoglobin decreased 13/181 (7.18%) Lymphatics 0/181 (0.00%) Transfusion: pRBCs 1/181 (0.55%) Arrhythmia supraventricular 1/181 (0.55%) Cardiac disorder 0/181"
        ]
    },
    {
        "id": "40bef815-18ed-4db5-8108-9a1cdbdd0a13",
        "primaryId": "NCT00478257",
        "statement_text": "Adequate Hematologic  Hepatic and renal function is not necessary for participating in the primary trial  However  being pregnant is required ",
        "statement_nums": [
            "for participating in the primary trial  However  being"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - "
        ],
        "premise_nums": [
            "anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast"
        ]
    },
    {
        "id": "5c676007-9ea4-4f80-82dd-89293237cb07",
        "primaryId": "NCT00319254",
        "statement_text": "the primary trial did not use overall response rate  tumour response rate or preference score as its outcome measurement ",
        "statement_nums": [
            "the primary trial did not use overall response rate  tumour response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  "
        ],
        "premise_nums": [
            "of study treatment to first documentation of objective tumor progression",
            "experienced progression or death by Week 16 is reported",
            "first dose of study medication plus 1) divided by 7. Tumor progression was determined from"
        ]
    },
    {
        "id": "a6682883-ace7-4d83-a35c-956928fdc75a",
        "primaryId": "NCT01325428",
        "secondaryId": "NCT00073073",
        "statement_text": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity  sex  height or to be able to speak a specific language ",
        "statement_nums": [
            "the secondary trial and the primary trial do not require participants"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion criteria: Female patients greater than or equal 18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer Locally advanced or metastatic disease Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients  must have failed prior trastuzumab treatment Investigator-confirmed diagnosis of Inflammatory Breast Cancer Must have biopsiable disease Exclusion criteria: Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population) Must not have received prior vinorelbine treatment INCLUSION CRITERIA: Postmenopausal female  Postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy  In unclear cases  (e.g  50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with follicle stimulating hormone (FSH) greater than 35 U/L  Elevated risk for developing invasive breast cancer by virtue of one of the following criteria: ",
            "Gail Model risk of greater than or equal to 1.7% over 5 years from study entry  (This is the same minimum level of risk required for a subject to be eligible for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial) Lobular neoplasia  Atypical ductal hyperplasia  DCIS (ductal carcinoma in situ) that has been previously treated with mastectomy or lumpectomy and radiation  +/- tamoxifen  Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2 gene mutation  The BRCAPRO and Couch model will both be used to asses this risk  If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will meet eligibility criteria  Prior stage I or II breast cancer at least 2 years out from treatment for invasive disease and no prior use of aromatase inhibitors  ",
            "Subjects should be willing to abstain from use of hormonal therapies (e.g  tamoxifen  hormone replacement therapy  oral contraceptive pills  hormone-containing intrauterine devices (IUDs)  E-string is acceptable)  Venlafaxine will be offered as supportive care for women with menopausal symptoms Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her options and has signed the informed consent document  Baseline dual-emission x-ray absorptiometry (DEXA) scan with bone mineral density (BMD) T-score greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin greater than or equal to 11 g/dl  Creatinine less than 1.5 times the upper limits of normal  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times upper limit of normal  No investigational agent for the past 30 days  If history of cancer (other than squamous or basal cell skin cancers)  subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment  EXCLUSION CRITERIA: ",
            "Current or recent chronic use (within 3 months) of hormonal medications  e.g  oral contraceptive pills  hormone replacement therapy  tamoxifen  raloxifene  IUD with progestins or corticosteroids  (Subjects on chronic topical or inhaled steroids will be eligible for the study.) Current use of phenytoin  carbamazepine  rifampin due to increased estrogen metabolism History of clotting or bleeding disorder  History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane (e.g  anastrozole  letrozole  formestane)  Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements  "
        ],
        "premise_nums": [
            "of greater than or equal to 1.7% over 5 years from study entry  (This is",
            "Cooperative Oncology Group (ECOG) performance status 0-1. Subject has been counseled regarding her",
            "of cancer directed treatment in the 2 years preceding enrollment  EXCLUSION CRITERIA:",
            "as no menses for at least 12 months or bilateral oophorectomy  In unclear",
            "follicle stimulating hormone (FSH) greater than 35 U/L  Elevated risk for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial) Lobular neoplasia",
            "Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2",
            "T-score greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin",
            "can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1) For trastuzumab pre-treated patients",
            "with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer at least 2 years out from treatment for invasive disease",
            "disorder  History of allergic reactions attributed to compounds",
            "greater than or equal to 2.5 at antero posterior (AP) spine  Hemoglobin greater than or equal to 11 g/dl  Creatinine less than",
            "If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model  she will",
            "follicle stimulating hormone (FSH) greater than 35 U/L  Elevated risk for developing",
            "or aspartate aminotransferase (AST) less than 2.5 times upper limit of cancer directed treatment in the 2 years preceding enrollment  EXCLUSION",
            "No investigational agent for the past 30 days  If history of greater than or equal to 1.7% over 5 years from",
            "or II breast cancer at least 2 years out from treatment for invasive disease",
            "cases  (e.g  50 year old who has had hysterectomy) chemical"
        ]
    },
    {
        "id": "1a271e29-477b-4819-a472-5c7c7df99e70",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "statement_text": "2 cases of hematolysis were recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "were recorded in the primary trial  none in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 9/157 (5.73%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Cataract 0/157 (0.00%) Diplopia 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%) ",
            "Tinnitus 1/157 (0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION 1/168 (0.60%) "
        ],
        "premise_nums": [
            "Tinnitus 1/157 (0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157",
            "(0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin",
            "Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%)",
            "Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION",
            "Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%)",
            "decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157",
            "(0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS",
            "(0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA",
            "Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157",
            "Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2:",
            "Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%)",
            "Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157",
            "decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157",
            "(0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%)",
            "Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157"
        ]
    },
    {
        "id": "060e833e-384f-48f0-8e56-ebd95f55f221",
        "primaryId": "NCT01926886",
        "statement_text": "There were no cases of Cellulitis  Vertigo or Anaemia in the primary trial ",
        "statement_nums": [
            "or Anaemia in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%)",
            "Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%)"
        ]
    },
    {
        "id": "ac193d32-156e-48bf-bc6b-d613691f869c",
        "primaryId": "NCT01166763",
        "statement_text": "the primary trial only recorded three types of adverse events ",
        "statement_nums": [
            "the primary trial only recorded three types"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30 (3.33%) Flank pain * [3]1/30 (3.33%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30"
        ]
    },
    {
        "id": "d79173da-5e59-4150-99bd-f1c20118dddc",
        "primaryId": "NCT00503750",
        "statement_text": "All participants of the primary trial must have recently undergone either an echocardiography ",
        "statement_nums": [
            "All participants of the primary trial must have recently undergone"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction"
        ]
    },
    {
        "id": "a5af6d2b-4cea-40aa-acdc-59fab5362b3e",
        "primaryId": "NCT00635050",
        "statement_text": "Patients with Breast cancers that have estrogen receptors are included in the primary trial ",
        "statement_nums": [
            "are included in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients with node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible  "
        ],
        "premise_nums": [
            "node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low",
            "risk (defined as a score of 0-17) on an Oncotype DX profile are"
        ]
    },
    {
        "id": "7e89b190-b8f7-4281-b0f1-0e65dcebf402",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  "
        ],
        "premise_nums": [
            "with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B:",
            "mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600"
        ]
    },
    {
        "id": "6036d341-9c6a-49fc-a2f4-19c0e2399f4c",
        "primaryId": "NCT01565083",
        "statement_text": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial ",
        "statement_nums": [
            "tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%)"
        ]
    },
    {
        "id": "a84afa25-2741-4a08-9e6c-4049f5feca48",
        "primaryId": "NCT01790932",
        "statement_text": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial  if this treatment ended over 5 years prior ",
        "statement_nums": [
            "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial  if this treatment",
            "are eligible for the primary trial  if this treatment ended over 5 years prior"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Have received previous treatment with PI3K inhibitors "
        ],
        "premise_nums": [
            "received previous treatment with PI3K inhibitors"
        ]
    },
    {
        "id": "09e4c746-642a-4a5d-a267-25258a3f2ec0",
        "primaryId": "NCT01669343",
        "secondaryId": "NCT00146172",
        "statement_text": "the primary trial and the secondary trial do not have the same duration of intervention administration ",
        "statement_nums": [
            "the primary trial and the secondary trial do not have the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Post-menopausal Women Using Adjuvant Letrozole Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants Letrozole: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  Part B In overweight/obese participants who completed Part A  provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period  INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd",
            "standard of care letrozole use for 28 days; measure blood levels of"
        ]
    },
    {
        "id": "99855d11-e2e4-4a0e-b40e-2264ff128ac5",
        "primaryId": "NCT02502864",
        "statement_text": "the primary trial recorded the same number of occurences for every type of adverse event ",
        "statement_nums": [
            "the primary trial recorded the same number"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9 (11.11%) Sepsis * 1/9 (11.11%) Urinary tract infection * 1/9 (11.11%) Syncope * 1/9 (11.11%) Anxiety * 1/9 (11.11%) Thromboembolic event * 1/9 (11.11%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9"
        ]
    },
    {
        "id": "54fe69c7-5a67-49b1-8bc5-c975133e2bb7",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine ",
        "statement_nums": [
            "Patients in the primary trial receive a lower dose",
            "by IV than the secondary trial patients receive of ado-trastuzumab"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  PI3K inhibitor BYL719: Given PO Ado-trastuzumab emtansine: Given IV Pharmacological study: Correlative studies Laboratory biomarker analysis: Optional correlative studies "
        ],
        "premise_nums": [
            "250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1).",
            "-1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over",
            "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time",
            "INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on",
            "time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone",
            "and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression",
            "PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat"
        ]
    },
    {
        "id": "76362fd3-3a07-4aa3-a072-b9075d2ea791",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment) ",
        "statement_nums": [
            "single patient in the primary trial suffered from Congestive Heart"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months  Overall Number of Participants Analyzed: 109 Measure Type: Number Unit of Measure: participants 0 "
        ],
        "premise_nums": [
            "daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for",
            "repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib",
            "[Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL Arm/Group Description:",
            "lapatinib (TL)) for a total of 12 months  Overall Number of Participants Analyzed: 109 Measure Type: Number Unit of Measure: participants",
            "x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab"
        ]
    },
    {
        "id": "064b39e9-e9d8-4c51-a76a-ad150bb127f1",
        "primaryId": "NCT00878709",
        "secondaryId": "NCT02447003",
        "statement_text": "the primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had 0.",
        "statement_nums": [
            "primary trial had a total of 3 patients experiencing pancreas related adverse events  the secondary trial had"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Vertigo 0/1408 (0.00%) Diarrhoea 22/1408 (1.56%) Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 1/1408 (0.07%) ",
            "Sinus tachycardia 1/1408 (0.07%)Tachycardia 1/1408 (0.07%) Vertigo 1/1408 (0.07%) Diarrhoea 1/1408 (0.07%) Vomiting 1/1408 (0.07%) Nausea 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170 (0.59%) Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) ",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) "
        ],
        "premise_nums": [
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris",
            "(0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)",
            "(0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)",
            "(27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.07%) Nausea 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris",
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Colitis 1/170",
            "(0.59%) Myocarditis 1/170 (0.59%) Pericardial effusion 2/170 (1.18%) Pericarditis 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%)",
            "Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "Vomiting 12/1408 (0.85%) Nausea 4/1408 (0.28%) Abdominal pain 2/1408 (0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "Adverse Events 1: Total: 103/1408 (7.32%) Anaemia 1/1408 (0.07%) Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408",
            "Angina pectoris 1/1408 (0.07%) Myocardial infarction 1/1408 (0.07%) Atrial fibrillation 0/1408 (0.00%) Sinus tachycardia 0/1408 (0.00%) Tachycardia 0/1408 (0.00%)",
            "(0.14%) Pancreatitis 2/1408 (0.14%) Adverse Events 2: Total: 85/1408 (6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408",
            "Constipation 1/170 (0.59%) Diarrhoea 0/170 (0.00%) Gastroenteritis eosinophilic 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170",
            "(6.04%) Anaemia 1/1408 (0.07%) Angina pectoris 0/1408 (0.00%) Myocardial infarction 1/1408 (0.07%) Abdominal pain 0/1408 (0.00%) Pancreatitis 1/1408 (0.07%) Adverse Events",
            "Intestinal obstruction 0/170 (0.00%)Adverse Events 2: Total: 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Adverse Events 1: Total: 46/170 (27.06%) Anaemia 1/170 (0.59%) Febrile neutropenia 1/170 (0.59%) Cardiac tamponade 1/170 (0.59%) Myocarditis 1/170 (0.59%)"
        ]
    },
    {
        "id": "67a628d7-d883-44b9-b351-901f20fd5d0a",
        "primaryId": "NCT00429182",
        "secondaryId": "NCT00429507",
        "statement_text": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study ",
        "statement_nums": [
            "Cell Transplants on the first day of the study",
            "the secondary trial and the primary trial give their patient cohorts"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: High-dose Chemotherapy Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  Stem Cell Transplant : Stem Cell Transplant on Day 0. Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion  INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. "
        ],
        "premise_nums": [
            "receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell",
            "days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3",
            "days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses",
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with",
            "20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  Thiotepa",
            "higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium",
            "dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP."
        ]
    },
    {
        "id": "78c60212-28f7-4306-9f63-549be04687b2",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events  Leukopenia and Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "Anaemia  occurred in more than 1% of patient in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264 (0.04%) "
        ],
        "premise_nums": [
            "8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264",
            "bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia",
            "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia *"
        ]
    },
    {
        "id": "a72e1259-50be-48e5-bdf8-296040cbf7ce",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "statement_text": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial ",
        "statement_nums": [
            "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are",
            "excluded from both the secondary trial but eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) "
        ],
        "premise_nums": [
            "Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN)",
            "AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in"
        ]
    },
    {
        "id": "19cfd511-8582-4116-8d51-7ec4a6221022",
        "primaryId": "NCT03366428",
        "statement_text": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of smaller than 60ms.",
        "statement_nums": [
            "baseline in QTcF of smaller than 60m",
            "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1% Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% "
        ],
        "premise_nums": [
            "QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The",
            "3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received",
            "(IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49",
            "Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days)",
            "3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants Unit of",
            "greater than 30 ms: 3 6.1% Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0%",
            "days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "3f012bd3-bb89-414b-9dd9-35cef524a69a",
        "primaryId": "NCT00820170",
        "statement_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg ",
        "statement_nums": [
            "with weekly paclitaxel is approximately is 120 mg",
            "the results of the primary trial the MTD of dasatinib"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel  [Not Specified] Time frame: Through completion of Phase I  up to 1 year Results 1: Arm/Group Title: Dasatinib and Paclitaxel Arm/Group Description: The phase I portion is a standard  three-patient per cohort  dose escalation schedule will be used  Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel  The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel  Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days  according to the following schedule: Dasatinib 120MG PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle  ",
            "The trial will initially test the combination of weekly paclitaxel and dasatinib given PO  once daily   continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule  5 days on and 2 days off  omitting dasatinib the day prior and the day of administration of paclitaxel Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg of dasatinib 120 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg/m2 given intravenously over 1 hour on day 1, 8, and 15",
            "continuously  In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort",
            "The trial will initially test the combination of Phase I  up to 1 year Results 1: Arm/Group Title:",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: mg of dasatinib 120",
            "PO once daily  Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a",
            "I  up to 1 year Results 1: Arm/Group Title: Dasatinib and 15 of a 28 day cycle",
            "be used  Between 6 and 54 patients will likely be necessary",
            "a different schedule  5 days on and 2 days off  omitting dasatinib the day",
            "A treatment cycle will consist of 28 days  according to the following schedule: Dasatinib 120MG PO once daily  Weekly"
        ]
    },
    {
        "id": "5eafb3a1-473a-4270-848d-173e5dca9466",
        "primaryId": "NCT02600923",
        "statement_text": "Patients with Leukemia  Hepatitis or Cataracts cannot be included in the primary trial ",
        "statement_nums": [
            "be included in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or metastatic disease)  Women who are not of childbearing potential  ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice)  HER2-negative breast cancer based on local laboratory results (test as per local practice or local guidelines)  Patients must be appropriate candidates for letrozole therapy  Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Adequate bone marrow function  Adequate liver function Adequate renal function  Exclusion Criteria: Known hypersensitivity to letrozole  or any of its excipients  or to any palbociclib excipients  Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry  Prior treatment with any CDK inhibitor  Previous participation in a palbociclib clinical study  Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation  ",
            "QTc greater than 480 msec; history of QT syndrome  Brugada syndrome or known history of QTc prolongation  or Torsade de Pointes High cardiovascular risk  including  but not limited to recent myocardial infarction  severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment  Diagnosis of any second invasive malignancy within the last 3 years prior to enrollment  Note: patients with adequately treated basal cell or squamous cell skin cancer  a history of intraepithelial neoplasia or in situ disease (eg  carcinoma in situ of the cervix or melanoma in situ) may enter  Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  brain metastases are permitted  Other severe acute or chronic medical or psychiatric conditions  Patients who are investigational site staff members directly involved in the conduct of the study and their family members  site staff members otherwise supervised by the investigator  or patients who are Pfizer employees directly involved in the conduct of the study  "
        ],
        "premise_nums": [
            "QTc greater than 480 msec; history of QT syndrome",
            "Cooperative Oncology Group (ECOG) performance status 0-2. Adequate bone marrow function  Adequate",
            "Previously treated and clinically stable  brain metastases",
            "second invasive malignancy within the last 3 years prior to enrollment  Note: patients",
            "involving investigational drug(s) within 2 weeks prior to study entry and/or during",
            "per local practice)  HER2-negative breast cancer based on local laboratory",
            "inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry  Prior"
        ]
    },
    {
        "id": "ed956644-5228-4915-b706-1cedb0462577",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "statement_text": "the primary trial participants are treated with hypnosis  this is not used at all in the secondary trial ",
        "statement_nums": [
            "is not used at all in the secondary trial",
            "the primary trial participants are treated with"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  "
        ],
        "premise_nums": [
            "Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2:",
            "the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)",
            "the study will undergo individually three one-hour sessions with"
        ]
    },
    {
        "id": "02158762-9490-46a1-b494-0589885fd4ce",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any cardiac related adverse events ",
        "statement_nums": [
            "the primary trial does not record any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%) ",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%) "
        ],
        "premise_nums": [
            "Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia",
            "Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458",
            "Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%)",
            "39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction",
            "2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458",
            "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221",
            "Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%)",
            "neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial",
            "Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2:",
            "Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%)",
            "(0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia"
        ]
    },
    {
        "id": "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "statement_text": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial ",
        "statement_nums": [
            "fistula enterovesical than the secondary trial",
            "the primary trial had a higher occurrence"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia 1/50 (2.00%) Arrythmia 1/50 (2.00%) Ileus 1/50 (2.00%) Nausea 1/50 (2.00%) Pain-Abdominal 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%) Arthralgia 1/50 (2.00%) "
        ],
        "premise_nums": [
            "Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%)",
            "(2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%)",
            "Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%)",
            "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia"
        ]
    },
    {
        "id": "7ec286e9-f519-41da-848d-a0bc5a50c0ee",
        "primaryId": "NCT00686127",
        "secondaryId": "NCT01129622",
        "statement_text": "dosages are specified in the intervention section of the secondary trial  whereas for the primary trial these are not made clear ",
        "statement_nums": [
            "intervention section of the secondary trial  whereas for the primary trial these are not made"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo Patch Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  "
        ],
        "premise_nums": [
            "(baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive",
            "Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  INTERVENTION 2: Placebo"
        ]
    },
    {
        "id": "d0af59a9-04ae-4922-97eb-dc29f5bc44e3",
        "primaryId": "NCT00256698",
        "secondaryId": "NCT03573804",
        "statement_text": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions  however they both require trained Radiologists on site for evaluation ",
        "statement_nums": [
            "the primary trial and the secondary trial use completely different drugs"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Fulvestrant + Anastrozole Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented "
        ],
        "premise_nums": [
            "Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated",
            "number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated"
        ]
    },
    {
        "id": "5d4cbb15-ea50-4394-b1b9-ab4553b5b275",
        "primaryId": "NCT00509587",
        "statement_text": "Patients in the primary trial receive oral pazopanib once daily every day  continuing until disease progression or unacceptable toxicity ",
        "statement_nums": [
            "Patients in the primary trial receive oral pazopanib once"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Pazopanib Hydrochloride) Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  pazopanib hydrochloride: Given orally pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression",
            "pazopanib hydrochloride: Given orally pharmacological study: Correlative studies"
        ]
    },
    {
        "id": "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8",
        "primaryId": "NCT00777049",
        "statement_text": "All 4 of the CHF cases in the primary trial  were in cohort 1.",
        "statement_nums": [
            "All 4 of the CHF cases in the primary trial  were in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Cardiac failure congestive 1/32 (3.13%) Adverse Events 2: Cardiac failure congestive 0/20 (0.00%)"
        ]
    },
    {
        "id": "78a5162d-140a-4631-b776-5c284446b5ec",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "statement_text": "the primary trial and the secondary trial have entirely different adverse event profiles ",
        "statement_nums": [
            "the primary trial and the secondary trial have entirely different adverse"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia 24/36 (11.11%) Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) "
        ],
        "premise_nums": [
            "Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36",
            "Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia",
            "Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot",
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%)",
            "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36",
            "Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36"
        ]
    },
    {
        "id": "633ef768-9e9b-4336-9142-8d4ce7ee2342",
        "primaryId": "NCT01026142",
        "secondaryId": "NCT00846027",
        "statement_text": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial ",
        "statement_nums": [
            "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary",
            "systolic dysfunction in the primary trial than in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular systolic dysfunction 1/82 (1.22%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1:",
            "1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular"
        ]
    },
    {
        "id": "7c5b29bc-ac37-48bb-abb1-a102174f79ef",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs  administered orally from Day 1 to Day 21",
        "statement_nums": [
            "different drugs  administered orally from Day 1 to Day 21",
            "2 of the primary trial receive 50mg of different drugs  administered orally from Day 1 to Day"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day"
        ]
    },
    {
        "id": "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a",
        "primaryId": "NCT00708214",
        "statement_text": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole ",
            "Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) "
        ],
        "premise_nums": [
            "Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New",
            "Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s)",
            "Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment",
            "Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib",
            "further disease progression  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage",
            "Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71)",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was",
            "Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline",
            "50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 7",
            "1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5",
            "1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5",
            "an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib",
            "Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole"
        ]
    },
    {
        "id": "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "statement_text": "the primary trial recorded many more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [
            "the primary trial recorded many more seizures than the secondary trial  despite having less"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%) Atrial fibrillation * 1/490 (0.20%) Cardiomyopathy * 1/490 (0.20%) Coronary artery disease * 0/490 (0.00%) Pericardial effusion * 0/490 (0.00%) Adverse Events 2: Total: 99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 1/488 (0.20%) Febrile neutropenia * 2/488 (0.41%) ",
            "Neutropenia * 1/488 (0.20%)Thrombocytopenia * 1/488 (0.20%) Angina pectoris * 1/488 (0.20%) Atrial fibrillation * 0/488 (0.00%) Cardiomyopathy * 0/488 (0.00%) Coronary artery disease * 1/488 (0.20%) Pericardial effusion * 2/488 (0.41%) "
        ],
        "premise_nums": [
            "99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%)",
            "of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%)",
            "Neutropenia * 1/488 (0.20%)Thrombocytopenia * 1/488 (0.20%) Angina pectoris",
            "(0.20%) Atrial fibrillation * 0/488 (0.00%) Cardiomyopathy * 0/488 (0.00%) Coronary",
            "(0.20%) Pericardial effusion * 2/488 (0.41%)",
            "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease *"
        ]
    },
    {
        "id": "e852619c-312a-470f-8b77-149e79f69a3f",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups ",
        "statement_nums": [
            "In both the secondary trial and the primary trial the test cohorts produced"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS was defined as the interval from study entry until disease progression or death resulting from any cause  which ever occurred first  Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria)  Time frame: Interval from randomization until disease progression or death  whichever occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm II (Placebo) Arm/Group Description: Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
            "Unit of Measure: months 3.8 (3.8 to 5.6)Outcome Measurement: Number of Participants With Overall Response (OR)  Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR)  Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was done at Wk 4 and every 4 weeks thereafter  OR was evaluated when the skin and RECIST assessments coincided  Per RECIST  CR is the disappearance of all target and non-target lesions; PR is at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions  taking as a reference the baseline sum LD  Cutaneous disease contained non-measurable and measurable skin disease  which was assessed by skin assessment tools  Time frame: Baseline until disease progression/recurrence was documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo ",
            "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD) Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Arm/Group Description: Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 17 "
        ],
        "premise_nums": [
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants With Overall Response (OR)  Defined as",
            "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching",
            "in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions RECIST-based response assessment was done at Wk 4 and every 4 weeks thereafter  OR",
            "Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval)",
            "lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall",
            "occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib)",
            "Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of",
            "which ever occurred first  Progression is defined as a 20% increase in the sum of longest",
            "I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500",
            "each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg",
            "documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm",
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm",
            "done at Wk 4 and every 4 weeks thereafter  OR wassessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib)",
            "non-target lesions; PR is at least a 30 percent (%) decrease in the",
            "(250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146",
            "(500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course",
            "PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and",
            "done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was"
        ]
    },
    {
        "id": "27160f45-e4cb-48be-8cf2-c23ced4578c0",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total ",
        "statement_nums": [
            "both cohorts of the primary trial was Anaphylaxis  which affected more than 10 patients in total"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) "
        ],
        "premise_nums": [
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse",
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 2/2788 (0.07%) Nervous system disorders - Other",
            "Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other",
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal",
            "Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal",
            "Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal",
            "Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse",
            "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other",
            "- Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and",
            "specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%)",
            "Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) Nervous system disorders - Other",
            "- Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and"
        ]
    },
    {
        "id": "e4b65e9f-10f6-4424-95d2-837e29587a63",
        "primaryId": "NCT00754325",
        "secondaryId": "NCT00399529",
        "statement_text": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast ",
        "statement_nums": [
            "the secondary trial and the primary trial both accept patients with",
            "secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC) Inclusion Criteria: Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH)  Prior adjuvant Trastuzumab therapy is permitted  Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Histologically confirmed hormone receptor positive",
            "Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is"
        ]
    },
    {
        "id": "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. "
        ],
        "premise_nums": [
            "of metastatic disease in at least one regional lymph node",
            "any T stage is allowed as long as the N stage is 1 and M stage is 0."
        ]
    },
    {
        "id": "7796fe1b-1952-4339-90f3-47b051ebe927",
        "primaryId": "NCT01432886",
        "statement_text": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days ",
        "statement_nums": [
            "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Results 1: Arm/Group Title: E7389 With Weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously weekly  with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously tri-weekly  with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 "
        ],
        "premise_nums": [
            "the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants",
            "Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly",
            "(E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously",
            "dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6",
            "dose of 8 mg/kg followed by 6 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6"
        ]
    },
    {
        "id": "c7df7b38-068b-48a8-b805-b8ebb3e854e6",
        "primaryId": "NCT01086605",
        "secondaryId": "NCT00570921",
        "statement_text": "the primary trial and the secondary trial do not record any of the same adverse events ",
        "statement_nums": [
            "the primary trial and the secondary trial do not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) ",
            "Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) "
        ],
        "premise_nums": [
            "failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Edema limbs 0/24",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%)",
            "increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular",
            "failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Aspartate aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "Adverse Events 2: Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased",
            "intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%)",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 0/24 (0.00%) Ejection fraction decreased 1/24 (4.17%) Adverse Events 2:",
            "Total: 9/22 (40.91%) Disseminated intravascular coagulation 1/22 (4.55%) Death NOS 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "Ejection fraction decreased 1/22 (4.55%)Adverse Events 1: Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24",
            "increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33",
            "Death NOS 1/22 (4.55%) Edema limbs 1/22 (4.55%) Fatigue 1/22 (4.55%) Hepatic failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%)",
            "failure 0/22 (0.00%) Alanine aminotransferase increased 0/22 (0.00%) Aspartate aminotransferase increased 1/24 (4.17%) Blood bilirubin increased 0/24 (0.00%) Ejection fraction decreased",
            "(0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%)",
            "Death NOS 0/24 (0.00%) Edema limbs 0/24 (0.00%) Fatigue 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%)",
            "Total: 3/24 (12.50%) Disseminated intravascular coagulation 0/24 (0.00%) Death NOS 0/24 (0.00%) Hepatic failure 1/24 (4.17%) Alanine aminotransferase increased 1/24 (4.17%)"
        ]
    },
    {
        "id": "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106",
        "primaryId": "NCT03283553",
        "secondaryId": "NCT02679755",
        "statement_text": "the primary trial and the secondary trial have a different number of cohorts ",
        "statement_nums": [
            "the primary trial and the secondary trial have a different number"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  INTERVENTION 1: Palbociclib+Letrozole India Cohort Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information INTERVENTION 2: Palbociclib+Letrozole Australia Cohort ",
            "Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information"
        ],
        "premise_nums": [
            "a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received",
            "7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing",
            "Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle",
            "7 days off treatment ofr each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing",
            "with its local prescribing information INTERVENTION 2: Palbociclib+Letrozole Australia Cohort",
            "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda"
        ]
    },
    {
        "id": "fd15ddaf-1abc-4551-a5b3-08217b975e36",
        "primaryId": "NCT02321527",
        "statement_text": "Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial ",
        "statement_nums": [
            "with a diameter of more than 70mm are included in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Ipsilateral biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or Mammography  "
        ],
        "premise_nums": [
            "biopsy-proven invasive breast cancer smaller than 5 cm in maximal dimension by Ultrasound or"
        ]
    },
    {
        "id": "067f4671-0720-4980-a0fa-8d01d31daa9a",
        "primaryId": "NCT00054132",
        "secondaryId": "NCT01421017",
        "statement_text": "As the primary trial and the secondary trial use very similar outcome metrics  we can easily compare and contrast across their results ",
        "statement_nums": [
            "As the primary trial and the secondary trial use very similar outcome"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Level of EGFR Expression Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT "
        ],
        "premise_nums": [
            "the time of best overall response  The response criteria",
            "on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+",
            "2009). Time frame: 9 weeks from the start of the treatment"
        ]
    },
    {
        "id": "026e7eb7-37fd-4aae-b74f-dacf905db262",
        "primaryId": "NCT02366130",
        "secondaryId": "NCT01262027",
        "statement_text": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial  ",
        "statement_nums": [
            "trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia 24/36 (11.11%) Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) "
        ],
        "premise_nums": [
            "Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36",
            "Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Hot Flashes 25/36 (13.89%) AST/ALT elevation 211/36 (30.56%) Arthralgia",
            "Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot",
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%)",
            "Adverse Events 1: Total: 28/36 (77.78%) Lymphocytopenia 210/36 (27.78%) Neutropenia 29/36 (25.00%) Anemia 26/36 (16.67%) Thrombocytopenia 24/36 (11.11%) Hyperglycemia 27/36",
            "Hyperglycemia 27/36 (19.44%) Nausea 213/36 (36.11%) Diarrhea 211/36 (30.56%) Fatigue 215/36 (41.67%) Flu-like symptoms 26/36 (16.67%) Hot Flashes 25/36"
        ]
    },
    {
        "id": "a79fc503-215f-40d4-9cc1-e101cec3a9c9",
        "primaryId": "NCT02878057",
        "statement_text": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial ",
        "statement_nums": [
            "able to carry on all pre-disease performance without restriction are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) performance status of 0-1."
        ]
    },
    {
        "id": "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "statement_text": "There were no cases of cardiac tamponade in the primary trial or the secondary trial ",
        "statement_nums": [
            "cardiac tamponade in the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) Vomiting 1/32 (3.13%) ",
            "Fatigue 1/32 (3.13%)Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) Fatigue 0/20 (0.00%) "
        ],
        "premise_nums": [
            "pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23",
            "(3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32",
            "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "(0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32",
            "fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%)",
            "(0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20",
            "(0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%)",
            "Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2:",
            "Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20",
            "pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3",
            "Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%)",
            "Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive",
            "(3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20",
            "1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1:",
            "Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) Vomiting 1/32 (3.13%)",
            "heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive",
            "(0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive"
        ]
    },
    {
        "id": "ccb703ea-df18-451b-8db8-ed0e510a4c0f",
        "primaryId": "NCT03592121",
        "secondaryId": "NCT01439711",
        "statement_text": "Unlike the secondary trial  the primary trial does not specify a specific dosage or frequency for its intervention ",
        "statement_nums": [
            "Unlike the secondary trial  the primary trial does not specify a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. "
        ],
        "premise_nums": [
            "both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply to both nipple/areola regions approximately 1 hour prior to sexual activity",
            "MRI for disease evaluation at months 3 and 6.",
            "hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at",
            "MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will",
            "prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola",
            "prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy",
            "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply"
        ]
    },
    {
        "id": "56cd4492-3884-4b2a-a000-7c859d86f6f5",
        "primaryId": "NCT00284180",
        "statement_text": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [
            "both cohorts of the primary trial a total of two"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11 (9.09%) Vomiting 0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus [1]0/21 (0.00%) Nausea 1/21 (4.76%) Ileus 0/21 (0.00%) Dehydration 1/21 (4.76%) Vomiting 1/21 (4.76%) Pain NOS [2]0/21 (0.00%) Pain - abdomen 1/21 (4.76%) ",
            "Fracture [3]1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%) "
        ],
        "premise_nums": [
            "(0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11",
            "Fracture [3]1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%)",
            "(0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%)",
            "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11",
            "0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus",
            "CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21"
        ]
    },
    {
        "id": "08b79e0d-5e97-45fb-ac83-0096b56f714b",
        "primaryId": "NCT01492101",
        "statement_text": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy ",
        "statement_nums": [
            "less than 1% of either cohort of the primary trial was effect by either"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) Coagulopathy *0/406 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) Coagulopathy *0/406 (0.00%)"
        ]
    },
    {
        "id": "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b",
        "primaryId": "NCT01466270",
        "statement_text": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group ",
        "statement_nums": [
            "The the primary trial placebo group had a over 10% higher mean retention than the donepezil"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Retention Retention is the percentage of participants who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group Description: Patients receive donepezil hydrochloride PO QD  donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 71.0 (8.3) Results 2: Arm/Group Title: Arm II Arm/Group Description: Patients receive placebo PO QD  Placebo: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage of participants 80.7 (7.2) "
        ],
        "premise_nums": [
            "donepezil hydrochloride: Given PO Overall Number of Participants Analyzed: 31 Mean (Standard Error) Unit of Measure: percentage",
            "who stay in the study for 24 weeks  Time frame: 24 Weeks Results 1: Arm/Group Title: Arm I Arm/Group"
        ]
    },
    {
        "id": "6d549a9b-47bf-4369-962b-2759cfd7051e",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "statement_text": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD ",
        "statement_nums": [
            "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Pharmacokinetics (PK) of Oral Itraconazole To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group Title: Itraconazole Arm/Group Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) Week 2 6-OH Itraconazole Concentration: 454.8 (429.3) Week 4 6-OH Itraconazole Concentration: 501.6 (502.6) Outcome Measurement: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) ",
            "To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose  Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD Time frame: From date of first dose to 30 days after termination  the longest 163 weeks "
        ],
        "premise_nums": [
            "frame: From date of first dose to 30 days after termination  the longest 163 weeks",
            "Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) Week 2 6-OH",
            "levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group",
            "or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL",
            "frame: From date of first dose to 30 days aftermination  the longest 163 weeks",
            "Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Dose-escalation conducted using standard 3+3 model to determine maximum",
            "levels at steady state at weeks 2 and 4. Time frame: pre-dose  Dose-escalation conducted using standard 3+3 model to determine maximum",
            "Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting"
        ]
    },
    {
        "id": "596f20cf-299d-40a3-881a-cdd49bcb21f6",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "statement_text": "Participants with HER2- primary breast tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "are eligible for the secondary trial and the primary trial",
            "Participants with HER2- primary breast tumors  confirmed by"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent  Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast Hormone receptor status: Not specified "
        ],
        "premise_nums": [
            "confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization",
            "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma"
        ]
    },
    {
        "id": "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb",
        "primaryId": "NCT03066947",
        "statement_text": "At least one patient in the primary trial suffered from Gastroesophageal reflux disease ",
        "statement_nums": [
            "one patient in the primary trial suffered from Gastroesophageal reflux"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/24 (33.33%) Restrictive Cardiomyopathy * 21/24 (4.17%) Palpitations * 21/24 (4.17%) GERD * 21/24 (4.17%) Fever * 21/24 (4.17%) Sepsis * 1/24 (4.17%) Urinary Tract Infection * 21/24 (4.17%) Influenza A * 21/24 (4.17%) Dehydration * 21/24 (4.17%) Hyponatremia * 21/24 (4.17%) Worsening of Hypercalcemia * 21/24 (4.17%) Bone Pain * 21/24 (4.17%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/24 (33.33%) Restrictive Cardiomyopathy * 21/24 (4.17%) Palpitations * 21/24 (4.17%) GERD"
        ]
    },
    {
        "id": "d4b2d877-34af-4944-84f7-046e22c2854e",
        "primaryId": "NCT01781299",
        "statement_text": "all subjects in the primary trial must undergo a minor surgery ",
        "statement_nums": [
            "all subjects in the primary trial must undergo a minor"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS "
        ],
        "premise_nums": [
            "expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this"
        ]
    },
    {
        "id": "d3ca3729-2795-4cd5-9968-666781d17fac",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "cohorts 1 and 2 of the primary trial recorded a different number"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab ",
            "Overall Number of Participants Analyzed: 120Measure Type: Number Unit of Measure: percentage of participants 2.5 (0.5 to 7.1) "
        ],
        "premise_nums": [
            "Overall Number of Participants Analyzed: 120Measure Type: Number Unit of Measure:",
            "symptomatic diastolic dysfunction  223 treated patients were included in the analysis",
            "Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment",
            "treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry",
            "Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm",
            "every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group",
            "Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.5 (0.5 to 7.1)"
        ]
    },
    {
        "id": "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104",
        "primaryId": "NCT01752907",
        "statement_text": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial ",
        "statement_nums": [
            "There were 0 observed cases of Tibia or Fibula fractures in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) ",
            "Diarrhoea 3/151 (1.99%)Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%) "
        ],
        "premise_nums": [
            "(10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive",
            "(10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%)",
            "1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149",
            "(1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151",
            "(13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation 0/151 (0.00%) Cardiac failure congestive",
            "fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149",
            "failure congestive 0/149 (0.00%) Abdominal pain 0/149 (0.00%) Diarrhoea 2/149 (1.34%) Dyspepsia 0/149 (0.00%) Gastritis haemorrhagic 0/149 (0.00%) Nausea 2/149 (1.34%)",
            "fibrillation 0/151 (0.00%) Cardiac failure congestive 1/151 (0.66%) Abdominal pain 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151",
            "Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation",
            "neutropenia 7/149 (4.70%) Neutropenia 1/149 (0.67%) Pancytopenia 1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Abdominal pain 0/149",
            "Diarrhoea 3/151 (1.99%)Dyspepsia 1/151 (0.66%) Gastritis haemorrhagic 1/151 (0.66%) Nausea 1/151 (0.66%)",
            "Adverse Events 1: Total: 16/149 (10.74%) Anaemia 0/149 (0.00%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151 (0.00%) Atrial fibrillation",
            "1/149 (0.67%) Atrial fibrillation 2/149 (1.34%) Cardiac failure congestive 0/149 (0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151",
            "(0.00%) Nausea 2/149 (1.34%) Adverse Events 2: Total: 20/151 (13.25%) Anaemia 1/151 (0.66%) Febrile neutropenia 4/151 (2.65%) Neutropenia 2/151 (1.32%) Pancytopenia 0/151"
        ]
    },
    {
        "id": "b98c7a50-ed79-41ff-9733-fff143f630be",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "statement_text": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial ",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded the same number",
            "instances of Neutropenic fever as Cohort 1 of the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%)"
        ]
    },
    {
        "id": "47aa5686-75af-4ed8-b4ff-715b458ce40a",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "statement_text": "laboratory biomarker analysis is used in the secondary trial and the primary trial ",
        "statement_nums": [
            "is used in the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Supportive Care (Dakin's Solution  Radiation Therapy) Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied topically radiation therapy: Undergo radiation therapy questionnaire administration: Ancillary studies laboratory biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant",
            "solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied"
        ]
    },
    {
        "id": "e89fdc93-d624-4ba7-aa64-574a278e982b",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "statement_text": "the primary trial investigates a novel chemotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [
            "the primary trial investigates a novel chemotherapy",
            "treatment  whereas the secondary trial is testing a type"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone  After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity  INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  ",
            "Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  "
        ],
        "premise_nums": [
            "controlled group in the first stage of intervention Following are",
            "a half-structured interview and lasting for 20-25 minutes each session  Clinical management will",
            "then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker)  and at least a 5-HT3 antagonist and dexamethasone",
            "and dexamethasone  After completion of 24 weekly trastuzumab doses (induction therapy) beginning one week after the 24th weekly dose  Trastuzumab",
            "(PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)",
            "treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a",
            "28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day",
            "were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after",
            "were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV)",
            "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical",
            "by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6",
            "then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent"
        ]
    },
    {
        "id": "1739541a-2d3f-4a13-b956-769a1cbed4d7",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in cohort 1 of the primary trial was diagnosed with a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) "
        ],
        "premise_nums": [
            "1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2:",
            "cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection",
            "Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney",
            "0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60",
            "2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis",
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60",
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney",
            "1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58"
        ]
    },
    {
        "id": "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9",
        "primaryId": "NCT02187744",
        "statement_text": "One patient in the primary trial suffered from sepsis  due to the presence of an implanted device ",
        "statement_nums": [
            "One patient in the primary trial suffered from sepsis"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Device related sepsis 1/113 (0.88%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Device related sepsis 1/113 (0.88%)"
        ]
    },
    {
        "id": "206fc00c-2c34-42bc-8fca-44be696e03c9",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles for each cohort  1 for cohort 1 and 4 for cohort 2.",
        "statement_nums": [
            "Both cohorts of the primary trial receive identical interventions; Pegylated",
            "diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC and the number of cycles",
            "for each cohort  1 for cohort 1 and 4 for cohort 2.",
            "Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days   the differences"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) INTERVENTION 2: Cohort C - Pegylated Irinotecan to Treat mBC Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  ",
            "Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)"
        ],
        "premise_nums": [
            "Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) INTERVENTION 2: Cohort C",
            "Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will",
            "irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression"
        ]
    },
    {
        "id": "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "Sunitinib group of the primary trial than for the Docetaxel",
            "Median (95% Confidence Interval) Progression-Free Survival (PFS) was"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)  Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3) ",
            "Investigator's assessment: 8.2 (7.3 to 8.6)Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) "
        ],
        "premise_nums": [
            "Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3)",
            "Independent radiology assessment: 8.6 (8.2 to 10.3)",
            "(mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square",
            "absence of sunitinib)  Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: months",
            "Investigator's assessment: 8.2 (7.3 to 8.6)Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants",
            "docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)  Overall Number of Participants Analyzed: 296",
            "absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)",
            "Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of",
            "Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of",
            "Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for",
            "to date of the first documentation of objective tumor progression",
            "every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence",
            "by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2)",
            "3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of sunitinib)  Overall Number of Participants Analyzed: 296"
        ]
    },
    {
        "id": "83cef795-d4a8-486c-8ac1-34a9acee9672",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial ",
        "statement_nums": [
            "breast cancer and an ECOG between 1-2 are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria "
        ],
        "premise_nums": [
            "Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria"
        ]
    },
    {
        "id": "b3cee7a6-cec1-4676-974d-7cfb3ccd9919",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "statement_text": "the primary trial recorded one patient with a catheter-related complication  whereas in the secondary trial none where observed ",
        "statement_nums": [
            "the primary trial recorded one patient with",
            "whereas in the secondary trial none where observed"
        ],
        "label": "Entailment",
        "premise_text": [
            "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) Fatigue 1/65 (1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%) "
        ],
        "premise_nums": [
            "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia",
            "Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%)",
            "(1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%)",
            "cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia",
            "site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65"
        ]
    },
    {
        "id": "007de11b-4265-4695-b18e-e0d6909a347a",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "statement_text": "Patients with HER2 positive tumors are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "be included in the secondary trial",
            "Patients with HER2 positive tumors are excluded from the primary trial  but may be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances  "
        ],
        "premise_nums": [
            "to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation",
            "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to"
        ]
    },
    {
        "id": "ce621235-b584-439b-bb11-ab2fa04c3195",
        "primaryId": "NCT01869764",
        "secondaryId": "NCT02556632",
        "statement_text": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire ",
        "statement_nums": [
            "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Omega-3 Fatty Acid) Patients receive omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 2: Arm II (Placebo) Patients receive placebo PO daily for 7-14 days  placebo: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies "
        ],
        "premise_nums": [
            "Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of",
            "therapy and continuing until 1 week after completion of radiation therapy and continuing until 1 week after completion of radiation",
            "laboratory biomarker analysis: Correlative studies INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6",
            "curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and",
            "omega-3 fatty acid PO daily for 7-14 days  omega-3 fatty acid: Given PO laboratory biomarker analysis:"
        ]
    },
    {
        "id": "f358f023-2393-44eb-9535-3f0e1851318d",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "statement_text": "the secondary trial and the primary trial both use irradiation techniques in their studies ",
        "statement_nums": [
            "the secondary trial and the primary trial both use irradiation techniques"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: 4D Conformal Image-Guided Partial Breast RT This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  "
        ],
        "premise_nums": [
            "the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda",
            "partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided"
        ]
    },
    {
        "id": "0e963b25-0d2b-4fc6-89c6-1eb068bc092e",
        "primaryId": "NCT00470301",
        "statement_text": "Every patient in the primary trial is given tipifarnib PO  along with paclitaxel  doxorubicin hydrochloride and acyclophosphamide IV ",
        "statement_nums": [
            "Every patient in the primary trial is given tipifarnib PO"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I See Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given IV pegfilgrastim: Given SC conventional surgery: surgical procedures performed on patients axillary lymph node dissection: correlative study "
        ],
        "premise_nums": [
            "Detailed Description tipifarnib: Given orally paclitaxel: Given IV doxorubicin"
        ]
    },
    {
        "id": "390b08d3-e147-47f9-82d7-0643b8d5c8ae",
        "primaryId": "NCT00733408",
        "statement_text": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial ",
        "statement_nums": [
            "maximum PFS in the primary trial",
            "There was just under 8 weeks difference in Progression-free Survival between the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results  Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years Results 1: Arm/Group Title: Tx (Chemo  MoAb  and Enzyme Inhibitor) ",
            "Arm/Group Description: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity MAINTENANCE THERAPY: Patients achieving complete response  partial response  or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity  paclitaxel albumin-stabilized nanoparticle formulation: Given IV bevacizumab: Given IV erlotinib hydrochloride: Given PO Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1) "
        ],
        "premise_nums": [
            "receive bevacizumab IV over 30-90 minutes once every 14 or 21 days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on",
            "A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel-",
            "Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: Months 9.1 (7.2 to 11.1)",
            "receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO",
            "be used  A 95% confidence interval for the median PFS",
            "any cause  assessed up to 8 years Results 1: Arm/Group Title: Tx (Chemo",
            "However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median",
            "days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days",
            "Treatment repeats every 28 days for 6 courses in the absence of Measure: Months 9.1 (7.2 to 11.1)",
            "or greater (regardless of whether the 95% confidence interval for the mediand bevacizumab IV over 30-90 minutes on days 1 and 15.",
            "registration to date of first documentation of progression or symptomatic",
            "days 1, 8, and 15 and bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "2570cb04-4edd-48c9-b634-9f2e086469de",
        "primaryId": "NCT00994279",
        "secondaryId": "NCT00545077",
        "statement_text": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial ",
        "statement_nums": [
            "Between both the primary trial and the secondary trial Bevacizumab is only administered"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm 1: Yoga Intervention Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Bevacizumab Fulvestrant "
        ],
        "premise_nums": [
            "will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment",
            "Yoga Intervention Yoga: Yoga sessions INTERVENTION 2: Arm 2: Educational Wellness Group Education: Educational Wellness Group INTERVENTION 1: Arm A: Endocrine Therapy (ET)",
            "the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab"
        ]
    },
    {
        "id": "f6a7e279-b923-45e3-8ad5-e81e17c0a682",
        "primaryId": "NCT00270894",
        "statement_text": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments  Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 "
        ],
        "premise_nums": [
            "(6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks",
            "cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75",
            "Subjects Able to Complete greater than 85% of the Planned Dose on Schedule",
            "for 4 treatments  Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage",
            "(100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 treatments  Overall Number of Participants Analyzed: 30"
        ]
    },
    {
        "id": "3d82851c-f302-4988-bd78-232583e04e96",
        "primaryId": "NCT02511730",
        "secondaryId": "NCT00193206",
        "statement_text": "Patients with prior chemotherapy are eligible for the primary trial  but excluded from the secondary trial ",
        "statement_nums": [
            "are eligible for the primary trial  but excluded from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  Inclusion Criteria: No prior chemotherapy for breast cancer "
        ],
        "premise_nums": [
            "Female subjects participating in FMSU004A protocol with known clinical status Exclusion"
        ]
    },
    {
        "id": "5c9f5916-37d3-4f6f-977b-be70204cf57c",
        "primaryId": "NCT01819233",
        "statement_text": "All the primary trial participants have the same number of calories in their diets throughout the duration of the study ",
        "statement_nums": [
            "All the primary trial participants have the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks  Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients",
            "receive food diaries to complete for 7-10 days  Dietary counselors then give",
            "reduce caloric intake by 25% of their normal diet  Patients undergo radiation therapy QD 5 days a week for 6",
            "caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  and at least 2 weeks after radiation therapy)",
            "modifications to reduce caloric intake by 25% of their normal diet  Patients",
            "radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo"
        ]
    },
    {
        "id": "0c5f2498-4c10-4e51-8915-d86b37b08156",
        "primaryId": "NCT01156987",
        "secondaryId": "NCT02234479",
        "statement_text": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis  whereas in the secondary trial the interventions are randomly assigned ",
        "statement_nums": [
            "whereas in the secondary trial the interventions are randomly"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 2: Breast Cancer Patients Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: INTERVENTION 1: Hydrophor (Group A) ",
            "Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily  starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Hydrophor application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Hydrophor within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area INTERVENTION 2: MediHoney (Group B) ",
            "Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily  starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first)  Medihoney application should include the entire treatment area  including the axillae and shoulder/back area in patients treated with modified radical mastectomy  To avoid possible build-up effects  patients should not apply the Medihoney within 4 hours of receiving RT  Patients should wash the application area daily with perfume-free soap and tap water  Patients will be asked to refrain from using other topical agents in the irradiated area "
        ],
        "premise_nums": [
            "onset of RT and continuing until 2 weeks after the final RT session or",
            "healthy volunteers will be first screened for MRI contraindications",
            "agents in the irradiated area INTERVENTION 2: MediHoney (Group B)",
            "should not apply the Hydrophor within 4 hours of receiving RT  Patients should",
            "is healed (whichever is first)  Medihoney application should not apply the Hydrophor within 4 hours of receiving RT",
            "should not apply the Medihoney within 4 hours of receiving RT  Patients should",
            "is healed (whichever is first)  Hydrophor application should not apply the Medihoney within 4 hours of receiving RT"
        ]
    },
    {
        "id": "c54dc963-671a-4384-8b1f-d8058a832131",
        "primaryId": "NCT00545688",
        "statement_text": "There were no patients with paranasal sinus reactions  or Left ventricular dysfunction in the primary trial ",
        "statement_nums": [
            "ventricular dysfunction in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 21/107 (19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107 (0.00%) Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%) Cardiac failure congestive * 0/107 (0.00%) Diarrhoea * 0/107 (0.00%) ",
            "Abdominal strangulated hernia * 1/107 (0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) "
        ],
        "premise_nums": [
            "Abdominal strangulated hernia * 1/107 (0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%)",
            "10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Diarrhoea * 2/107 (1.87%) Abdominal strangulated hernia * 0/107",
            "(19.63%) Febrile neutropenia * 10/107 (9.35%) Neutropenia * 1/107 (0.93%) Left ventricular dysfunction * 0/107 (0.00%) Angina pectoris * 0/107 (0.00%)",
            "(0.93%)Duodenal ulcer haemorrhage * 0/107 (0.00%) Pyrexia * 1/107 (0.93%) Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia",
            "Adverse Events 2: Total: 22/107 (20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107",
            "(20.56%) Febrile neutropenia * 8/107 (7.48%) Neutropenia * 6/107 (5.61%) Left ventricular dysfunction * 3/107 (2.80%) Angina pectoris * 1/107 (0.93%)"
        ]
    },
    {
        "id": "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 32 patients in the primary trial had Diarrhoea ",
        "statement_nums": [
            "A total of 32 patients in the primary trial had Diarrhoea"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) ",
            "Diarrhoea 32/416 (7.69%)Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) "
        ],
        "premise_nums": [
            "0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive",
            "(0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416",
            "Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213",
            "Diarrhoea 32/416 (7.69%)Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%)",
            "Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416",
            "fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%)",
            "(0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac",
            "Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416"
        ]
    },
    {
        "id": "91adb350-ab20-41a6-944d-c13b55cf33f2",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded none ",
        "statement_nums": [
            "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Adverse Events 2: Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) ",
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%) "
        ],
        "premise_nums": [
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%)",
            "Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "(0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680",
            "neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "(0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile",
            "11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680",
            "Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%)",
            "0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%)",
            "(0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Adverse Events 2: Total: 86/688 (12.50%) Hemoglobin 15/688"
        ]
    },
    {
        "id": "78949f1f-6738-4220-a233-e7831902e6f3",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "statement_nums": [
            "Neither the primary trial or the secondary trial are measuring Dose Limiting",
            "primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)  A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication  Lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE Time frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
            "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months "
        ],
        "premise_nums": [
            "following first dose of BYL719 that is determined to be at least possibly related to study medication",
            "Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)",
            "a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will",
            "Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes",
            "A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia)",
            "following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death",
            "is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of",
            "Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's",
            "has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM",
            "experienced during the first 21 days following first dose of BYL719 that baseline and after 4 months of treatment; The most common CYP2D6",
            "4 Life-threatening or disabling AE Grade 5 Death related to AE Time frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement:"
        ]
    },
    {
        "id": "135311d8-c579-4568-913e-937be00dde7e",
        "primaryId": "NCT00390455",
        "secondaryId": "NCT00558103",
        "statement_text": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups ",
        "statement_nums": [
            "secondary trial and the primary trial the test cohorts achieved better overall response than the control groups",
            "In both the secondary trial and the primary trial the test cohorts achieved"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS was defined as the interval from study entry until disease progression or death resulting from any cause  which ever occurred first  Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria)  Time frame: Interval from randomization until disease progression or death  whichever occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm II (Placebo) Arm/Group Description: Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
            "Unit of Measure: months 3.8 (3.8 to 5.6)Outcome Measurement: Number of Participants With Overall Response (OR)  Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR)  Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was done at Wk 4 and every 4 weeks thereafter  OR was evaluated when the skin and RECIST assessments coincided  Per RECIST  CR is the disappearance of all target and non-target lesions; PR is at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions  taking as a reference the baseline sum LD  Cutaneous disease contained non-measurable and measurable skin disease  which was assessed by skin assessment tools  Time frame: Baseline until disease progression/recurrence was documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo ",
            "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD) Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Arm/Group Description: Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 17 "
        ],
        "premise_nums": [
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants With Overall Response (OR)  Defined as",
            "Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching",
            "in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions RECIST-based response assessment was done at Wk 4 and every 4 weeks thereafter  OR",
            "Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval)",
            "lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  Overall",
            "occurs first  assessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib)",
            "Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: participants 11 Results 2: Arm/Group Title: Cohort 1: Lapatinib",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of",
            "which ever occurred first  Progression is defined as a 20% increase in the sum of longest",
            "I (Lapatinib) Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500",
            "each subsequent course  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg",
            "documented  assessed for up to 66 weeks Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo",
            "800 mg (2 x 400 mg tablets) QD  Overall Number of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm",
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: months 4.7 (3.7 to 5.7) Results 2: Arm/Group Title: Arm",
            "done at Wk 4 and every 4 weeks thereafter  OR wassessed up to 5 years Results 1: Arm/Group Title: Arm I (Lapatinib)",
            "non-target lesions; PR is at least a 30 percent (%) decrease in the",
            "(250 mg) of course 1 and on day 1 (250 mg)of each subsequent course  Overall Number of Participants Analyzed: 146",
            "(500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course",
            "PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and",
            "done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter  Cutaneous disease assessment was"
        ]
    },
    {
        "id": "0984431d-4997-41dc-9ba4-07134568c3fa",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim  whereas both cohorts in the secondary trial receive some ",
        "statement_nums": [
            "both cohorts in the secondary trial receive some"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
            "Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors  subcutaneous pegfilgrastim (6 mg) or filgrastim  could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2."
        ],
        "premise_nums": [
            "Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "(600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was",
            "Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day",
            "dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles",
            "a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for",
            "2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this",
            "1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks;",
            "neutropenia occurred that recovered to Grade 2.",
            "once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day",
            "every 3 weeks; Vorinostat 200 mg of SAHA orally twice a days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin"
        ]
    },
    {
        "id": "d9dc4a6d-a913-46ac-b0aa-d50823ff2305",
        "primaryId": "NCT00662129",
        "statement_text": "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial ",
        "statement_nums": [
            "1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial",
            "Patients with Platelet count over 100,000/mm¬¨‚â•, ANC smaller than 1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible"
        ],
        "label": "Entailment",
        "premise_text": [
            "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL "
        ],
        "premise_nums": [
            "PATIENT CHARACTERISTICS: ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL"
        ]
    },
    {
        "id": "9d9ab190-cdcf-4320-b69a-12f2dad9dba9",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "statement_text": "the secondary trial and the primary trial use non comparable evaluation metrics  and significantly different time frames ",
        "statement_nums": [
            "the secondary trial and the primary trial use non comparable evaluation"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Time frame: At 48 weeks "
        ],
        "premise_nums": [
            "confirmed CR or PR by week 48. Time frame: At 48 weeks",
            "two determinations of CR at least 4 weeks apart before progression are required",
            "dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of",
            "PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with"
        ]
    },
    {
        "id": "89fdf182-7474-4e70-baf7-03c8920c4ff3",
        "primaryId": "NCT01385137",
        "secondaryId": "NCT00593346",
        "statement_text": "Placebo treatment is used in cohort 2 of the secondary trial  but there is only a test group in the primary trial ",
        "statement_nums": [
            "test group in the primary trial",
            "Placebo treatment is used in cohort 2 of the secondary trial  but there is"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  "
        ],
        "premise_nums": [
            "times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each",
            "oral placebo BID or TID for 24 weeks in the absence of",
            "3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours",
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three",
            "will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum"
        ]
    },
    {
        "id": "9f2fd0cc-af87-433d-9d2f-6235591d6cb1",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [
            "Monitoring Committee was highest in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST)  CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs)  PR for TLs is defined as a greater than or equal 30% decrease in the sum of the longest diameter (LD) of TLs  taking as a reference the Baseline sum LD  For non-TLs  it is defined as the persistence of greater than or equal 1 non-TL and no new TLs or non-TLs  Time frame: From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: Arm/Group Title: Letrozole + Placebo Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants CR: 2 ",
            "PR: 58Results 2: Arm/Group Title: Letrozole + Lapatinib Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: percentage of participants CR: 12 PR: 54 "
        ],
        "premise_nums": [
            "From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: Arm/Group Title: Letrozole + Placebo",
            "tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once",
            "as a greater than or equal 30% decrease in the sum of the",
            "orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage",
            "persistence of greater than or equal 1 non-TL and no new TLs or non-TLs",
            "Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered",
            "PR: 58Results 2: Arm/Group Title: Letrozole +",
            "as the disappearance of all target lesions (TLs) and non-TLs"
        ]
    },
    {
        "id": "90364098-7e9a-47be-ab2e-f66958cfb09d",
        "primaryId": "NCT02413008",
        "secondaryId": "NCT02725801",
        "statement_text": "The interventions in the primary trial and the secondary trial are applied daily for a period of several months ",
        "statement_nums": [
            "The interventions in the primary trial and the secondary trial are applied daily for"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: 0.005% Estriol Vaginal Gel Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction "
        ],
        "premise_nums": [
            "inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3:",
            "of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration INTERVENTION"
        ]
    },
    {
        "id": "021c3f62-8067-49e3-9d4b-c7641feb2548",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "statement_text": "The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [
            "the interventions in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 ",
            "Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days "
        ],
        "premise_nums": [
            "followed by a rest period of 7 days  Dasatinib 100mg was repeated on Day 1 of a 28-day cycle until radiographic or",
            "Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression",
            "Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel",
            "treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and",
            "pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment was repeated on Day 1 of a 28-day cycle until",
            "a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest",
            "Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at",
            "followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)",
            "once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks",
            "phase I  the first cycle lasted 38 days",
            "patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose"
        ]
    },
    {
        "id": "6893c9b4-d3a3-47a8-ada9-8aef67de2375",
        "primaryId": "NCT01702571",
        "statement_text": "Patients with incurable and unresectable Breast Cancer are eligible for the primary trial  unless it is metastatic ",
        "statement_nums": [
            "are eligible for the primary trial  unless it is"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Documented progression of incurable  unresectable  LABC  or mBC  defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy "
        ],
        "premise_nums": [
            "recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy"
        ]
    },
    {
        "id": "b88cde11-ae29-48e8-832b-4b9cb2596c30",
        "primaryId": "NCT00859651",
        "statement_text": "Helen had stage III ovarian cancer 2 years prior  from which she is still recovering  she is excluded from the primary trial ",
        "statement_nums": [
            "is excluded from the primary trial",
            "Helen had stage III ovarian cancer 2 years prior  from which she is"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Other prior malignancy  The following is allowed: adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  adequately treated stage I or II cancer from which the participant is currently in complete remission  or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years  "
        ],
        "premise_nums": [
            "the participant has been disease-free for 5 years",
            "The following is allowed: adequately treated basal cell"
        ]
    },
    {
        "id": "ebe7078c-fd8b-439a-b1f5-7bd482071ead",
        "primaryId": "NCT02472964",
        "secondaryId": "NCT00089661",
        "statement_text": "the primary trial studies changes in tumour diameter  whereas the secondary trial investigates changes in heart failure rate ",
        "statement_nums": [
            "diameter  whereas the secondary trial investigates changes in heart",
            "the primary trial studies changes in tumour"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions  Any pathological lymph node must have reduction in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of target lesions from baseline sum diameters  Progressive Disease (PD): smaller than /= 20% increase in the sum of the diameters of target lesions  from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions  The appearance of one or more new lesions* denotes disease progression  Stable Disease (SD): Neither sufficient decrease or increase  Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions  Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions  Progressive Disease (PD): Substantial  unequivocal progression of existing non-target lesions  ",
            "Time frame: from time of First treatment to week 24Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months "
        ],
        "premise_nums": [
            "sum on study with at least a 5 mm absolute increase in the sum of",
            "in short axis to smaller than 10 mm.Partial Response (PR): greater than /= 30% decrease sum of the diameters of",
            "by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST 1.1: Complete Response (CR): Disappearance",
            "time of First treatment to week 24Outcome Measurement: Lumbar Spine Bone Mineral",
            "Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane",
            "(PD): smaller than /= 20% increase in the sum of the",
            "Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy",
            "Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate",
            "Plus Taxane in the ITT1 Population Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria  Per RECIST"
        ]
    },
    {
        "id": "d0b9c11c-50f2-4803-a96c-fff3ca90cf36",
        "primaryId": "NCT02312622",
        "statement_text": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between the cohorts is the type of cancers that patients are diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC ",
        "statement_nums": [
            "diagnosed with  cohort 1 is NSCLC  whereas cohort 2 is mBC",
            "Both cohorts of the primary trial receive identical interventions; Pegylated",
            "Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle)  the difference between"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cohort A - Pegylated Irinotecan to Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) INTERVENTION 2: Cohort C - Pegylated Irinotecan to Treat mBC Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity  Pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) "
        ],
        "premise_nums": [
            "Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle) INTERVENTION 2: Cohort C",
            "Treat NSCLC Patients with non-small cell lung carinoma (NSCLC) will",
            "irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression"
        ]
    },
    {
        "id": "b620e1c5-69c4-4c30-9006-faa346200b60",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Trastuzumab  a type of chemotherapy ",
        "statement_nums": [
            "the primary trial is investigating Cognitive behavioural",
            "in contrast the secondary trial studies Trastuzumab  a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT each session  ",
            "CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months)  and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress  patients' cognitive and behavioral response to stress  Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  "
        ],
        "premise_nums": [
            "controlled group in the first stage of intervention  Following",
            "40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as",
            "Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long",
            "receive standardized CBT treatment regularly for 9 sessions(once per week in the second and third months)  and each session",
            "INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT",
            "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical",
            "receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a",
            "a half-structured interview and lasting for 20-25 minutes each session  Clinical management will",
            "stage (the third session to the 8th session): clarification of sources"
        ]
    },
    {
        "id": "0900325b-6ecd-46f1-b3f1-a2ce1605d151",
        "primaryId": "NCT00325598",
        "statement_text": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial  the increase in Gy has no notable effect ",
        "statement_nums": [
            "results or cohort size between cohort 1 and 2 of the primary trial  the increase in"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her  Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36 Gy) Arm/Group Description: 36 Gy in 9 fractions BID x 4 1/2 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40 Gy) Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 "
        ],
        "premise_nums": [
            "of Participants Achieving a Dosimetrically Satisfactory Treatment Plan -The",
            "Number of Participants Analyzed: 50 Measure Type: Number Unit of Measure: percentage of participants 100 Results 2: Arm/Group Title: Cohort 2 (40",
            "Time frame: Within 1 year of protocol registration Results 1: Arm/Group Title: Cohort 1 (36",
            "(40 Gy) Arm/Group Description: 40 Gy in 10 fractions BID over 5 treatment days Partial Breast Irradiation (PBI) Overall",
            "be deemed infeasible if more than 4 patients cannot be given treatment because her"
        ]
    },
    {
        "id": "6f10e1f3-1197-464e-b574-d697fb49331d",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "statement_text": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial  However  only patients with stage 1-2 breast cancer are eligible for the primary trial  and patients with stage 3-4 are eligilbe for the secondary trial ",
        "statement_nums": [
            "eligible for both the primary trial and the secondary trial  and patients with stage 3-4 are eligilbe for the",
            "only patients with stage 1-2 breast cancer are eligible for the primary trial and the secondary trial  However  only",
            "trial  and patients with stage 3-4 are eligilbe for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer "
        ],
        "premise_nums": [
            "or IV erbB2 (HER2) positive breast cancer",
            "a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage"
        ]
    },
    {
        "id": "cbf91beb-829b-488f-8e80-3b08b891a181",
        "primaryId": "NCT03592121",
        "secondaryId": "NCT01439711",
        "statement_text": "the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis ",
        "statement_nums": [
            "the secondary trial and the primary trial both require their patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. "
        ],
        "premise_nums": [
            "both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply to both nipple/areola regions approximately 1 hour prior to sexual activity",
            "MRI for disease evaluation at months 3 and 6.",
            "hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at",
            "MRI Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will",
            "prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola",
            "prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 1: Letrozole + MRI Protocol Therapy",
            "INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply"
        ]
    },
    {
        "id": "985df98b-b397-4dbc-8fad-43ada30927d7",
        "primaryId": "NCT00254592",
        "statement_text": "Patients needing active supportive care can participate in the primary trial ",
        "statement_nums": [
            "can participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must have a performance status of 0-2 by Zubrod criteria "
        ],
        "premise_nums": [
            "must have a performance status of 0-2 by Zubrod criteria"
        ]
    },
    {
        "id": "0d4fdeef-89b2-463b-8252-66fa51d9ce8c",
        "primaryId": "NCT00356811",
        "secondaryId": "NCT00296036",
        "statement_text": "The the secondary trial intervention is applied to the palms and soles twice daily  the primary trial participants are not administered any medication on the skin of the hands or feet  but rather onto the breast or chest wall ",
        "statement_nums": [
            "twice daily  the primary trial participants are not administered",
            "The the secondary trial intervention is applied to",
            "the breast or chest wall"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  "
        ],
        "premise_nums": [
            "Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a",
            "and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated",
            "a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6",
            "with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and"
        ]
    },
    {
        "id": "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response ",
        "statement_nums": [
            "(FASN) Expression in the primary trial treated with Minocycline Hydrochloride",
            "27.6% of Patients Who Have Fatty Acid"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: Arm/Group Title: High Dose Omeprazole Treatment Arm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) "
        ],
        "premise_nums": [
            "Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3)",
            "positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression",
            "will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: Arm/Group Title: High Dose Omeprazole"
        ]
    },
    {
        "id": "494c1f01-5a2d-409e-b614-5871f408fbe6",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial group A has a higher percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B ",
        "statement_nums": [
            "percentage of patients with greater than 25% increase in tumor area at 3 months after treatment than group B",
            "In the primary trial group A has a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
            "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 "
        ],
        "premise_nums": [
            "progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area",
            "to have progression free survival at 3 months after treatment  Progression free is",
            "frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group",
            "free is define as smaller than 25% increase in tumor area  PFS",
            "dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants",
            "as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be"
        ]
    },
    {
        "id": "17881072-2517-483f-9c03-1edad21a58cf",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "statement_text": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial ",
        "statement_nums": [
            "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) ",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%) ",
            "Thrombocytopenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) "
        ],
        "premise_nums": [
            "Thrombocytopenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%)",
            "myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%)",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia",
            "(0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%)",
            "Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia",
            "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%)",
            "(0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "2: Total: 7/42 (16.67%) Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%)",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%)",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "(2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%)"
        ]
    },
    {
        "id": "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7",
        "primaryId": "NCT00093795",
        "statement_text": "Patients with cancer cells that have metastasised into less than 3 lymph nodes  with at least one larger than 2mm, cannot enter the primary trial ",
        "statement_nums": [
            "that have metastasised into less than 3 lymph nodes  with at least one larger than 2mm, cannot enter the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: By pathologic evaluation  ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)  "
        ],
        "premise_nums": [
            "node dissection and with more than 3 positive axillary lymph nodes)"
        ]
    },
    {
        "id": "da6ce3a9-b653-47b2-9271-f831e4de3f19",
        "primaryId": "NCT00912340",
        "statement_text": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.",
        "statement_nums": [
            "Less patients in cohort 2 of the primary trial had an unusual amount",
            "around the lungs than in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%)"
        ]
    },
    {
        "id": "66979ae5-a709-4adf-9067-287f0f92b9e2",
        "primaryId": "NCT00828074",
        "statement_text": "A higher number of cohort 2 participants from the primary trial experienced fever  compared to cohort 1.",
        "statement_nums": [
            "A higher number of cohort 2 participants from the primary trial experienced fever  compared"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Fever * 2/41 (4.88%) Adverse Events 2: Fever * 0/5 (0.00%)"
        ]
    },
    {
        "id": "0af6799b-655f-4b8b-a192-ce8dcbb2fcff",
        "primaryId": "NCT02692755",
        "statement_text": "Only Black women are eligible for the primary trial  as long as they do not have uncontrolled or symptomatic brain metastases ",
        "statement_nums": [
            "are eligible for the primary trial  as long as"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Self-identified Black  African or African American women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) Exclusion Criteria: Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  as per Investigator's judgment  brain metastases are permitted  "
        ],
        "premise_nums": [
            "African or African American women of 18 years of age with proven diagnosis of",
            "adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)",
            "inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases"
        ]
    },
    {
        "id": "46ac8a9f-77ab-40cf-9421-64aad4ae6976",
        "primaryId": "NCT00537771",
        "secondaryId": "NCT00354640",
        "statement_text": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD ",
        "statement_nums": [
            "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days "
        ],
        "premise_nums": [
            "1: Arimidex Group Anastrozole(ARIMIDEX): 1 mg once daily oral dose INTERVENTION 1: anastrozole : 1 milligram tablet PO QD for 14 days"
        ]
    },
    {
        "id": "d2b7253b-0654-4bb1-a9a4-b203714d64f9",
        "primaryId": "NCT00445458",
        "secondaryId": "NCT00950742",
        "statement_text": "the primary trial and the secondary trial measure the DLT of their respective interventions  using the same time frame ",
        "statement_nums": [
            "the primary trial and the secondary trial measure the DLT of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel Dose Limiting Toxicity in subjects with solid tumors treated with neratinib  administered daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days "
        ],
        "premise_nums": [
            "Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose",
            "and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants",
            "days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28",
            "daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time"
        ]
    },
    {
        "id": "9a896e4a-ae6b-468c-a7c0-32c1514c0b48",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and more than 30% of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of",
            "Less than 5% of patients undergoing the intervention in the primary trial had adverse events",
            "adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 2: Total: 8/25 (32.00%)",
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%)"
        ]
    },
    {
        "id": "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4",
        "primaryId": "NCT00356811",
        "secondaryId": "NCT00296036",
        "statement_text": "The the secondary trial intervention is applied to the palms and soles twice daily  the primary trial participants are not administered any medication topically ",
        "statement_nums": [
            "The the secondary trial intervention is applied to",
            "twice daily  the primary trial participants are not administered any medication topically"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: Urea/Lactic Acid Cream Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily  INTERVENTION 2: Placebo Cream Patients receive placebo cream applied to palms and soles twice daily  "
        ],
        "premise_nums": [
            "Lapatinib Plus Paclitaxel Participants received lapatinib 1500 mg orally OD with paclitaxel  administered as a 1-hour IV infusion at a",
            "and 15 (±2 days) of a 28-day treatment cycle for at least 6 months  Participants were treated",
            "a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6",
            "with paclitaxel  administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and"
        ]
    },
    {
        "id": "0931065d-35e4-4f82-8ef6-ac6db900127a",
        "primaryId": "NCT00290732",
        "secondaryId": "NCT02748213",
        "statement_text": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial  but not the primary trial ",
        "statement_nums": [
            "skin and the chest wall are eligible for the secondary trial  but not the"
        ],
        "label": "Entailment",
        "premise_text": [
            "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy "
        ],
        "premise_nums": [
            "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive"
        ]
    },
    {
        "id": "70912726-ba1b-47ef-9005-9584c8caf559",
        "primaryId": "NCT00853996",
        "statement_text": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model   and no Family history consistent with hereditary breast cancer  are eligible for the primary trial ",
        "statement_nums": [
            "developing breast cancer within the next 5 years by the Gail model",
            "are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Gail risk greater than or equal 1.7% and/or relative risk greater than or equal 3 times that for 5-year age group Family history consistent with hereditary breast cancer  as indicated by 1 of the following criteria: "
        ],
        "premise_nums": [
            "relative risk greater than or equal 3 times that for 5-year age group Family history consistent with",
            "breast cancer  as indicated by 1 of the following criteria:"
        ]
    },
    {
        "id": "6743f85c-8318-49cc-acba-94aeb1f57130",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "statement_nums": [
            "the longest PFS was in cohort 2.",
            "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival [Not Specified] Time frame: From the date of randomization to date of first documented disease progression (i.e.  the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause  if before progression  assessed up to 39 months  Results 1: Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine) Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
            "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
            "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) "
        ],
        "premise_nums": [
            "Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered ( 2 tablets ) orally twice daily (approximately every",
            "Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95)",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will be administered ( 2 tablets ) orally twice daily (approximately every",
            "and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30",
            "Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally",
            "Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately",
            "Capecitabine will be administered orally at a dose of Measure: Days 81 (48 to 95)",
            "be administered (400 mg; 2 tablets x 200 mg) orally twice daily  within 30 minutes after a meal  for 14",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered orally at a dose of 1,000 mg/m2 twice daily",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will before progression  assessed up to 39 months  Results 1: Arm/Group",
            "randomization to date of first documented disease progression (i.e.",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a",
            "Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo will be administered (400 mg; 2 tablets x 200",
            "Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo"
        ]
    },
    {
        "id": "ddffa26d-2581-477a-955c-ebf0c2ab0f97",
        "primaryId": "NCT00784849",
        "secondaryId": "NCT02104895",
        "statement_text": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial  but not at all in the primary trial ",
        "statement_nums": [
            "both cohorts of the secondary trial  but not at all in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) "
        ],
        "premise_nums": [
            "Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel",
            "using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional"
        ]
    },
    {
        "id": "f1a45b47-498d-45c8-b6d9-6c8f035da30b",
        "primaryId": "NCT01201265",
        "statement_text": "1 patient in the primary trial was affected by Sepsis ",
        "statement_nums": [
            "1 patient in the primary trial was affected by Sepsis"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) "
        ],
        "premise_nums": [
            "5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal",
            "5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40",
            "Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40",
            "Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40",
            "Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40"
        ]
    },
    {
        "id": "a5272c37-0e32-42db-a44a-d17df7bd70ff",
        "primaryId": "NCT00179309",
        "statement_text": "There were no pain related adverse events observed in the primary trial ",
        "statement_nums": [
            "events observed in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other  specify -stomatitis) 0/25 (0.00%) Vomiting 1/25 (4.00%) Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Sinus tachycardia 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other  specify -stomatitis) 1/23 (4.35%) Vomiting 0/23 (0.00%) Fever 1/23 (4.35%) Injection site reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) ",
            "Activated partial thromboplastin time prolonged 1/23 (4.35%)"
        ],
        "premise_nums": [
            "reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 1/23 (4.35%)",
            "Fever 0/25 (0.00%) Injection site reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin",
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders - Other",
            "reaction 1/25 (4.00%) Catheter related infection 0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2:",
            "(0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Sinus tachycardia",
            "Adverse Events 1: Total: 3/25 (12.00%) Anemia 0/25 (0.00%) Sinus tachycardia 0/25 (0.00%) Pericardial effusion 1/25 (4.00%) Gastrointestinal disorders -",
            "0/25 (0.00%) Activated partial thromboplastin time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23",
            "time prolonged 0/25 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) Anemia 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other",
            "reaction 1/23 (4.35%) Catheter related infection 1/23 (4.35%) Pericardial effusion 0/23 (0.00%) Gastrointestinal disorders - Other"
        ]
    },
    {
        "id": "4c67a7b4-36fa-4c20-a15a-122609550973",
        "primaryId": "NCT00201773",
        "statement_text": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events  She is eligible for the primary trial",
        "statement_nums": [
            "is eligible for the primary",
            "breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events",
            "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Must be female with histologically confirmed breast cancer Stage II-IV disease ER and/or PR positive ECOG Performance Status 0-1 Postmenopausal "
        ],
        "premise_nums": [
            "Must be female with histologically confirmed breast cancer Stage",
            "and/or PR positive ECOG Performance Status 0-1 Postmenopausal"
        ]
    },
    {
        "id": "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)",
            "the primary trial results show that Zoledronic"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid Upfront ",
            "Arm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) Unit of Measure: Percentage of BMD 1.955 (3.3658) Results 2: Arm/Group Title: Zoledronic Acid Delayed-start ",
            "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) "
        ],
        "premise_nums": [
            "4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) Unit of Measure: Percentage",
            "Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) Bone mineral",
            "Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward",
            "non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward  Time frame:",
            "daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin",
            "Data prior to month 6 were not carried forward  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid Upfront",
            "study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800",
            "carried forward to month 12. Data prior to month 6 were carried forward to month 12. Data prior to month 6",
            "Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD))  Missing data at month 12 were imputed by using the",
            "Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 256",
            "Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall",
            "BMD))  Missing data at month 12 were imputed by using the upfront arm received Zoledronic Acid 4 mg i.v  on Day",
            "month 12. Data prior to month 6 were not carried forward to month 12. Data prior to month 6 were",
            "mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants",
            "Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the",
            "carried forward to month 12. Data prior to month 6 were started on zoledronic acid 4 mg i.v  and for",
            "asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6",
            "Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every",
            "2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall"
        ]
    },
    {
        "id": "ac997ae1-7e48-48e2-af9e-f7e289622250",
        "primaryId": "NCT00798135",
        "secondaryId": "NCT01209195",
        "statement_text": "the primary trial and the secondary trial investigate different outcome measures for different interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial investigate different outcome measures"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Pharmacokinetics (PK) of Oral Itraconazole To determine the pharmacokinetics (PK) of oral itraconazole in patients with MBC by measuring mean trough plasma levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group Title: Itraconazole Arm/Group Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) Week 2 6-OH Itraconazole Concentration: 454.8 (429.3) Week 4 6-OH Itraconazole Concentration: 501.6 (502.6) Outcome Measurement: Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT) ",
            "To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose  Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD Time frame: From date of first dose to 30 days after termination  the longest 163 weeks "
        ],
        "premise_nums": [
            "frame: From date of first dose to 30 days after termination  the longest 163 weeks",
            "Deviation) Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8) Week 4 Intraconazole Concentration: 305.8 (334.8) Week 2 6-OH",
            "levels at steady state at weeks 2 and 4. Time frame: pre-dose at Weeks 2 and 4 Results 1: Arm/Group",
            "or unacceptable toxicities  Overall Number of Participants Analyzed: 12 Mean (Standard Deviation) Unit of Measure: ng/mL",
            "frame: From date of first dose to 30 days aftermination  the longest 163 weeks",
            "Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose  Dose-escalation conducted using standard 3+3 model to determine maximum",
            "levels at steady state at weeks 2 and 4. Time frame: pre-dose  Dose-escalation conducted using standard 3+3 model to determine maximum",
            "Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting"
        ]
    },
    {
        "id": "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month  the patient with the longest OS was in cohort 1.",
        "statement_nums": [
            "The difference in median Overall Survival (OS) of Patients between",
            "the longest OS was in cohort 1.",
            "two cohort of the primary trial was less than one"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) of Patients To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC)  Overall survival is defined as the time from the date of randomization to the date of death from any cause  Patients will be followed until their date of death or until final database closure  Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis  Time frame: Within 3 years from study start Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle  Overall Number of Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2: ",
            "Arm/Group Title: Treatment of Physician's Choice (TPC)Arm/Group Description: In Group B  TPC will be administered per standard of care  Patients randomized to TPC will receive single-agent IV chemotherapy  limited to choice of one of the following 7 agents: eribulin  ixabepilone  vinorelbine  gemcitabine  paclitaxel  docetaxel  or nab-paclitaxel  Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4) "
        ],
        "premise_nums": [
            "choice of one of the following 7 agents: eribulin  ixabepilone",
            "145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of Measure: months 7.5 (5.8 to 10.4)",
            "Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4)",
            "or nab-paclitaxel  Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months",
            "Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level",
            "145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle  Overall Number",
            "once every 21 days (q21d) with OS of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with",
            "Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2:",
            "Time frame: Within 3 years from study start Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A",
            "Outcome Measurement: Overall Survival (OS) of Patients To"
        ]
    },
    {
        "id": "441c0760-ca4a-4f1d-864e-a77395fd1f18",
        "primaryId": "NCT00399802",
        "statement_text": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "Type I Collagen than the Odanacatib 5 mg group",
            "Lapatinib group of the primary trial had a smaller Percentage Change From Baseline"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) Unit of Measure: Percentage change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) Unit of Measure: Percentage change -77 (-82 to -71) "
        ],
        "premise_nums": [
            "Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of",
            "5 mg tablet for 4 weeks and a single IV infusion of ZA 4 mg at the start of treatment and",
            "Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame:",
            "for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) Unit of Measure: Percentage",
            "change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a",
            "Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone",
            "Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks  Overall Number of Participants Analyzed: 14",
            "Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a"
        ]
    },
    {
        "id": "fbe60029-8944-4e12-b4b2-3413037a10cc",
        "primaryId": "NCT00723125",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery ",
        "statement_nums": [
            "57% of patients in cohort 1 of the primary trial had Pathological Complete Response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks ",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 "
        ],
        "premise_nums": [
            "over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x",
            "mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV",
            "over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit",
            "frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes",
            "1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort",
            "mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10",
            "mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes",
            "over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over",
            "10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin",
            "over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes",
            "over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed:",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV",
            "omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants",
            "5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14",
            "10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV",
            "with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV over 30-60 minutes q2weeks x 34 weeks",
            "over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks",
            "1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12",
            "cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on",
            "60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes",
            "x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes",
            "over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle",
            "1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10",
            "mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
        ]
    },
    {
        "id": "fe1782aa-a871-4608-a7cb-8f83b7f76d8a",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "statement_text": "Gemcitabine is not used in the primary trial  and used only in cohort 2 of the secondary trial ",
        "statement_nums": [
            "not used in the primary trial  and used only in cohort 2 of the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Experimental cyclophosphamide: chemotherapy doxorubicin hydrochloride: chemotherapy adjuvant therapy: chemotherapy radiation therapy: chemotherapy INTERVENTION 1: Arm A: Nab-Paclitaxel + Gemcitabine Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment INTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin ",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment "
        ],
        "premise_nums": [
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment",
            "Gemcitabine Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment",
            "Days 1 and 8 in each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "unacceptable toxicity  required palliative radiotherapy or surgical intervention",
            "participant to continue on treatment INTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin",
            "by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants",
            "8 by IV administration of each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and",
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8"
        ]
    },
    {
        "id": "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b",
        "primaryId": "NCT02364388",
        "secondaryId": "NCT01425268",
        "statement_text": "There is no overlap in treatments used in the primary trial and the secondary trial ",
        "statement_nums": [
            "treatments used in the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 2: Saline Tissue Expansion Saline Tissue Expansion inflated by needle injections of saline Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline  "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue"
        ]
    },
    {
        "id": "4dc22366-3ff3-41c8-aa4c-7342d7b7085d",
        "primaryId": "NCT00263588",
        "statement_text": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate ",
        "statement_nums": [
            "The majority of the primary trial subjects either had Progressive"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: The Number of Participants With Central Nervous System (CNS) Best Overall Response Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population) Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was CNS objective response rate  A CNS objective response was defined as either a Complete response (CR) or Partial response (PR)  as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI)  provided there was no progression of systemic disease outside of the CNS  increasing steroid requirements  or worsening of Neurological signs and symptoms (NSS) A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions  with no new or progressive CNS or non-CNS lesions  no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms Time frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A ",
            "Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settingsOverall Number of Participants Analyzed: 94 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 6 6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  Overall Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 9 6.3% Stable disease (SD): 46 32.2% ",
            "Progressive disease (PD): 70 49.0%Unknown: 18 12.6% "
        ],
        "premise_nums": [
            "breast cancer  The primary indicator of drug efficacy was defined as a 50% volumetric reduction in sum of CNS",
            "progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was",
            "0.0% Partial response (PR): 9 6.3% Stable disease (SD): 46 32.2%",
            "B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of",
            "Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort",
            "Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing",
            "baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A",
            "response rate was defined as a 50% volumetric reduction in sum of CNS",
            "6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B",
            "Nervous System (CNS) Best Overall Response Summary of CNS Objective",
            "Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of"
        ]
    },
    {
        "id": "196c2132-c735-4b79-bf03-3a830fcaf0fc",
        "primaryId": "NCT00645333",
        "secondaryId": "NCT00006110",
        "statement_text": "the primary trial records several central nervous system related adverse events in its patients  whereas the secondary trial does not ",
        "statement_nums": [
            "the primary trial records several central nervous",
            "patients  whereas the secondary trial does not"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) "
        ],
        "premise_nums": [
            "microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle",
            "of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%)",
            "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia",
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe"
        ]
    },
    {
        "id": "72619b0a-57c2-465c-8428-72019b59f8ae",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Cardiac failure occurred in cohort 2.",
        "statement_nums": [
            "In the primary trial  all cases of Enteritis  Vertigo",
            "and Cardiac failure occurred in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133 (0.75%) Constipation 1/133 (0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Vertigo 1/67 (1.49%) ",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%) "
        ],
        "premise_nums": [
            "intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Abdominal pain 2/67 (2.99%)",
            "Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67",
            "Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133",
            "(0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67",
            "Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133",
            "Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67",
            "Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133",
            "Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%)"
        ]
    },
    {
        "id": "b8663fa7-585a-4cd9-afd2-89e8e1a58b82",
        "primaryId": "NCT02732119",
        "statement_text": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial ",
        "statement_nums": [
            "heart twice in the last month and he is therefore excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Clinically significant  uncontrolled heart disease and/or recent cardiac events  "
        ],
        "premise_nums": [
            "Exclusion Criteria: Clinically significant  uncontrolled heart"
        ]
    },
    {
        "id": "7c92d075-ba9d-45b5-9834-83b09d2753bc",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "statement_text": "the primary trial and the secondary trial both administer treatments to their patients through IV ",
        "statement_nums": [
            "the primary trial and the secondary trial both administer treatments to"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity  Four weeks after the last combination dose  patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity  Patients achieving PD or clinical benefit (CR  PR  or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody MEDI4736: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  "
        ],
        "premise_nums": [
            "Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg",
            "anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days",
            "Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to",
            "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody",
            "with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks for up to 18 additional doses in the absence of disease",
            "Four weeks after the last combination dose  patients continue",
            "Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time",
            "with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody MEDI4736: Given IV Laboratory Biomarker Analysis: Correlative",
            "(MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour on day 1. Treatment repeats every 28 days",
            "time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone"
        ]
    },
    {
        "id": "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8",
        "primaryId": "NCT00411788",
        "statement_text": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks  until today  she will be eligible for the primary trial next Tuesday ",
        "statement_nums": [
            "ketoconazole to treat athlete's foot for 6 weeks  until today",
            "be eligible for the primary trial next Tuesday"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Use of any of these medications within 4 weeks; cyclosporine  diltiazen  ketoconazole  rifampin  fluconazole  delavirdine  nicardipine  pioglitazone  and sulfonamides  erythromycin  clarithromycin  itraconazole  erythromycin  metoclopramide  nevirapine  phenobarbital  phenytoin  indinavir  fosamprenavir  nefazadone  St Johns Wort  "
        ],
        "premise_nums": [
            "of any of these medications within 4 weeks; cyclosporine  diltiazen"
        ]
    },
    {
        "id": "9a346aac-46c2-4a50-8f3a-309b3b7bc295",
        "primaryId": "NCT00382785",
        "secondaryId": "NCT00784849",
        "statement_text": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide  Biopsies or Mometasone in their intervention ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial use Low Dose Magnesium"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support in a peer-led format INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes "
        ],
        "premise_nums": [
            "Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel",
            "INTERVENTION 1: Moderated Group one 12-week online support group led by a",
            "1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support"
        ]
    },
    {
        "id": "949d79e0-95db-47a2-802a-6280c0255923",
        "primaryId": "NCT02132949",
        "secondaryId": "NCT01111825",
        "statement_text": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood ",
        "statement_nums": [
            "patient cohorts of the primary trial and the secondary trial there was only a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199 (0.50%) PANCYTOPENIA 1/199 (0.50%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) ",
            "NEUTROPENIA 2/198 (1.01%)PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) ",
            "Chest pain 0/8 (0.00%)Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) "
        ],
        "premise_nums": [
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%)Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia",
            "(0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199",
            "(33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%)Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia",
            "MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8",
            "CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse",
            "Chest pain 0/8 (0.00%)Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) BONE MARROW FAILURE 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "NEUTROPENIA 2/198 (1.01%)PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199",
            "(0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "(0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199",
            "Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%)",
            "NEUTROPENIA 2/198 (1.01%)PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "(0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "(0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "(1.01%)PANCYTOPENIA 1/198 (0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%)",
            "Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "MARROW FAILURE 0/198 (0.00%) FEBRILE NEUTROPENIA 27/198 (13.64%) LEUKOPENIA 0/198 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "(0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1:",
            "0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198 (33.33%) AGRANULOCYTOSIS 0/198 (0.00%) ANAEMIA 0/198 (0.00%) BONE MARROW",
            "Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199 (0.50%) FEBRILE NEUTROPENIA 11/199 (5.53%) LEUKOPENIA 1/199 (0.50%) NEUTROPENIA 1/199",
            "(0.51%) ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%) ATRIAL FLUTTER 0/198 (0.00%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2:",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "(33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia",
            "MYOCARDIAL INFARCTION 1/199 (0.50%) ATRIAL FLUTTER 1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 2: Total: 66/198",
            "ATRIAL THROMBOSIS 1/198 (0.51%) CARDIAC FAILURE 4/198 (2.02%) Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia",
            "1/199 (0.50%) ATRIAL THROMBOSIS 0/199 (0.00%) CARDIAC FAILURE 3/199 (1.51%) Adverse Events 1: Total: 56/199 (28.14%) AGRANULOCYTOSIS 1/199 (0.50%) ANAEMIA 1/199",
            "Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Polycythaemia 0/6 (0.00%) Acute coronary syndrome 0/6 (0.00%) Vertigo 0/6 (0.00%)Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%)Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia"
        ]
    },
    {
        "id": "6e080a1e-a03e-4547-a7c4-c9d5a80de977",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders ",
        "statement_nums": [
            "Patients participating in the primary trial and the secondary trial experienced serious eye disorders"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/3 (33.33%) Pericardial effusion [1]0/3 (0.00%) Abdominal muscle wall hemorrhage [2]0/3 (0.00%) Dehydration [3]0/3 (0.00%) Gastroenteritis 0/3 (0.00%) Dehydration 0/3 (0.00%) Vomiting [4]0/3 (0.00%) Colonic perforation [5]0/3 (0.00%) Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 0/3 (0.00%) Adverse Events 2: Total: 2/3 (66.67%) Pericardial effusion [1]0/3 (0.00%) Abdominal muscle wall hemorrhage [2]0/3 (0.00%) Dehydration [3]0/3 (0.00%) Gastroenteritis 0/3 (0.00%) Dehydration 0/3 (0.00%) Vomiting [4]0/3 (0.00%) ",
            "Colonic perforation [5]0/3 (0.00%)Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 1/3 (33.33%) Adverse Events 1: Total: 148/1755 (8.43%) Anaemia * 1/1755 (0.06%) Neutropenia * 0/1755 (0.00%) Thrombocytopenia * 0/1755 (0.00%) Thrombocytopenic purpura * 1/1755 (0.06%) Acute cardiac event * 1/1755 (0.06%) Aortic valve incompetence * 1/1755 (0.06%) Arrhythmia * 1/1755 (0.06%) Atrial fibrillation * 1/1755 (0.06%) Cardiac failure * 0/1755 (0.00%) Cardiac tamponade * 0/1755 (0.00%) Adverse Events 2: Total: 64/868 (7.37%) Anaemia * 2/868 (0.23%) Neutropenia * 2/868 (0.23%) ",
            "Thrombocytopenia * 1/868 (0.12%)Thrombocytopenic purpura * 0/868 (0.00%) Acute cardiac event * 0/868 (0.00%) Aortic valve incompetence * 0/868 (0.00%) Arrhythmia * 1/868 (0.12%) Atrial fibrillation * 0/868 (0.00%) Cardiac failure * 1/868 (0.12%) Cardiac tamponade * 1/868 (0.12%) "
        ],
        "premise_nums": [
            "Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 0/3 (0.00%) Adverse Events 2: Total: 2/3 (66.67%) Pericardial effusion",
            "Adverse Events 1: Total: 1/3 (33.33%) Pericardial effusion [1]0/3 (0.00%) Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3",
            "Colonic perforation [5]0/3 (0.00%)Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 1/3",
            "Colonic perforation [5]0/3 (0.00%) Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 1/3",
            "Thrombocytopenia * 1/868 (0.12%)Thrombocytopenic purpura * 0/868 (0.00%) Acute cardiac event * 0/868",
            "Lung infection 0/3 (0.00%) Wound infection 1/3 (33.33%) Adverse Events 1: Total: 1/3 (33.33%) Pericardial effusion [1]0/3 (0.00%) Abdominal",
            "(0.00%)Abdominal pain 0/3 (0.00%) Chemical meningitis 0/3 (0.00%) Lung infection 0/3 (0.00%) Wound infection 1/3 (33.33%) Adverse Events 1:",
            "Adverse Events 2: Total: 2/3 (66.67%) Pericardial effusion [1]0/3 (0.00%) Abdominal muscle wall hemorrhage [2]0/3 (0.00%) Dehydration [3]0/3",
            "0/3 (0.00%) Wound infection 1/3 (33.33%) Adverse Events 1: Total: 148/1755 (8.43%) Anaemia * 1/1755 (0.06%) Neutropenia * 0/1755 (0.00%) Thrombocytopenia",
            "Lung infection 0/3 (0.00%) Wound infection 0/3 (0.00%) Adverse Events 2: Total: 2/3 (66.67%) Pericardial effusion [1]0/3 (0.00%) Abdominal",
            "tamponade * 0/1755 (0.00%) Adverse Events 2: Total: 64/868 (7.37%) Anaemia * 2/868 (0.23%) Neutropenia * 2/868 (0.23%)"
        ]
    },
    {
        "id": "d7fa4f81-e108-491f-9b08-c147a33863e8",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication orally and intraveinously ",
        "statement_nums": [
            "Patients receiving intervention 1 of the primary trial  will be administered medication orally and intraveinously"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² "
        ],
        "premise_nums": [
            "day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day",
            "mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14",
            "3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of",
            "vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B :",
            "Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration",
            "iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle followed by 1 week of rest  vinflunine:",
            "day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B :",
            "twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine:",
            "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each"
        ]
    },
    {
        "id": "f24afb09-ea65-457f-9f9b-0db3cc3101ac",
        "primaryId": "NCT00849472",
        "statement_text": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes ",
        "statement_nums": [
            "Two dozen the primary trial participants are classified as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen  axillary nodes  or sentinel node identified after neoadjuvant chemotherapy  Time frame: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results 1: Arm/Group Title: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib ",
            "Arm/Group Description: Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants Analyzed: 93 Measure Type: Number Unit of Measure: Participants 16 "
        ],
        "premise_nums": [
            "the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry) Results",
            "resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants",
            "each day  either 1 hour before or 2 hours after a meal) taken daily and",
            "[mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed",
            "the same oral dose 4-6 weeks after surgery and was continued daily for 6 months Overall Number of Participants Analyzed: 93",
            "the same oral dose 4-6 weeks after surgery and was continued daily and continuing until 7 days before surgery  Pazopanib was resumed",
            "with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for",
            "(WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800",
            "Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at"
        ]
    },
    {
        "id": "3cd79df2-e6dd-41dd-b819-4d993b5f7aed",
        "primaryId": "NCT00403130",
        "statement_text": "There were no cases of Leukopenia  Epitasis or Arrhythmia observed in patients participating in the primary trial ",
        "statement_nums": [
            "patients participating in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral arterial ischemia * 1/26 (3.85%) Thrombosis * [1]1/26 (3.85%) Weakness * 1/26 (3.85%) Pain * [2]2/26 (7.69%) Febrile neutropenia * 1/26 (3.85%) Aspartate Aminotransferase * [3]1/26 (3.85%) Syncope * 1/26 (3.85%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral"
        ]
    },
    {
        "id": "d2d6f646-5881-42a2-b965-0c6f79e89463",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  the study physician can still decide to let them participate ",
        "statement_nums": [
            "results from this are more than 2 standard deviations below normal  the study"
        ],
        "label": "Entailment",
        "premise_text": [
            "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician "
        ],
        "premise_nums": [
            "normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the"
        ]
    },
    {
        "id": "428d5165-560b-4783-8c4b-5fd3a3289cab",
        "primaryId": "NCT00022672",
        "statement_text": "There were no patients in either cohort of the primary trial with a PFS exceeding one year ",
        "statement_nums": [
            "either cohort of the primary trial with a PFS exceeding"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations  Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion  For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required  PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death  Kaplan Meier estimates of PFS are presented  Time frame: 24 Months  End of Study (Up to 5 years) Results 1: Arm/Group Title: Trastuzumab + Anastrozole ",
            "Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes  followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase Overall Number of Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 4.8 (3.7 to 7) End of Study: 5.8 (4.6 to 8.3) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: 1 mg oral dose of anastrozole every day for 24 Months in the Main phase  In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes  followed by weekly doses of 2 mg/kg iv over 30 minutes  Overall Number of Participants Analyzed: 104 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1 to 4.5) "
        ],
        "premise_nums": [
            "in the Extension Phase Overall Number of Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months",
            "Number of Participants Analyzed: 104 Median (95% Confidence Interval) Unit of",
            "Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90",
            "identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions",
            "followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day",
            "could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over",
            "Months 24 Months: 4.8 (3.7 to 7) End of Study: 5.8 (4.6 to 8.3) Results 2: Arm/Group Title: Anastrozole",
            "an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions",
            "End of Study (Up to 5 years) Results 1: Arm/Group Title:",
            "Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1 to 4.5)",
            "Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1",
            "centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an"
        ]
    },
    {
        "id": "6e7df2e4-11b3-4183-aefc-760f85809515",
        "primaryId": "NCT02536794",
        "secondaryId": "NCT00712985",
        "statement_text": "the primary trial and the secondary trial both administer Zometa to their patients through IV  although in different doses ",
        "statement_nums": [
            "the primary trial and the secondary trial both administer Zometa to"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity  Four weeks after the last combination dose  patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity  Patients achieving PD or clinical benefit (CR  PR  or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody MEDI4736: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  "
        ],
        "premise_nums": [
            "Correlative studies Tremelimumab: Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg",
            "anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days",
            "Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to",
            "INTERVENTION 1: Treatment (MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody",
            "with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks for up to 18 additional doses in the absence of disease",
            "Four weeks after the last combination dose  patients continue",
            "Given IV INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time",
            "with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks  Anti-B7H1 Monoclonal Antibody MEDI4736: Given IV Laboratory Biomarker Analysis: Correlative",
            "(MEDI4736, Tremelimumab) Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour on day 1. Treatment repeats every 28 days",
            "time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone"
        ]
    },
    {
        "id": "45e6b4b6-ca31-4318-936e-5b27cbca47a2",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months ",
        "statement_nums": [
            "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  Time frame: up to 3 months from start of treatment Results 1: Arm/Group Title: Letrozole + MRI Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) "
        ],
        "premise_nums": [
            "MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed:",
            "disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic",
            "Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a",
            "(FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from",
            "at baseline  For V3 the raw change in the volume will",
            "t-tests  Time frame: up to 3 months from start of treatment Results 1: Arm/Group Title: Letrozole + MRI",
            "Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more",
            "each patient and a mean and 95% confidence interval will be constructed using",
            "the sum over all measureable lesions on the MRI for disease evaluation at months 3 and 6. Overall Number of"
        ]
    },
    {
        "id": "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment  but is administered much more often ",
        "statement_nums": [
            "the primary trial treament last for a shorter period of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks "
        ],
        "premise_nums": [
            "plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be",
            "CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified",
            "CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks",
            "Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1:",
            "a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of",
            "Hz  and to automatically turn off at the end of 1 hour  Patients use their"
        ]
    },
    {
        "id": "50d119f6-a657-4619-918e-7617ac57f052",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 1 of the primary trial reported one case of AML ",
        "statement_nums": [
            "Cohort 1 of the primary trial reported one case of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) "
        ],
        "premise_nums": [
            "failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%)",
            "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%)",
            "Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%)"
        ]
    },
    {
        "id": "e436827b-10db-4179-bf8f-07786ee6145b",
        "primaryId": "NCT01009918",
        "statement_text": "There are no racial criteria for entry into the primary trial  however there are gender criteria ",
        "statement_nums": [
            "for entry into the primary trial  however there are"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted)  Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up  Taxanes are permitted  Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy  Pertuzumab may be used in conjunction with trastuzumab  Left Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate renal function for administration of trastuzumab-containing chemotherapy regimen  Sitting systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute Not pregnant or breastfeeding Female patients of childbearing potential  who are sexually active  must have a negative pregnancy test before starting the study Both men and women must be willing to use effective contraception during the study  Teratogenicity is documented for both active study agents Able to swallow capsules EXCLUSION CRITERIA: Patients with metastatic disease Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen ",
            "Current treatment with angiotensin converting enzyme (ACE) inhibitors  angiotensin receptor blockers (ARBs)  such as losartan  β-blockers or digoxinKnown cardiac history: heart failure  myocardial infarction  radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors or β-blockers History of bronchial asthma or related bronchospastic conditions Hereditary or idiopathic angioedema History of severe hypersensitivity reactions to drugs or other causes  i.e  bee stings This protocol does not exclude patients who are participating on other investigational studies  Refer to the local IRB guidelines  "
        ],
        "premise_nums": [
            "systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute Not pregnant or breastfeeding Female patients",
            "given with or after primary chemotherapy  Pertuzumab may be",
            "Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate",
            "radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors",
            "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant",
            "potential  who are sexually active  must have"
        ]
    },
    {
        "id": "d63706f1-4fb8-488d-8f86-c1a19df341d4",
        "primaryId": "NCT00944047",
        "secondaryId": "NCT00228943",
        "statement_text": "Patients with tumors underexpressing HER2 are excluded from the primary trial  but may be included in the secondary trial ",
        "statement_nums": [
            "Patients with tumors underexpressing HER2 are excluded from the primary trial  but may be",
            "be included in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to provide informed consent Reporting daily hot flashes Able to read  write  and speak English Postmenopausal to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation  chemotherapy) for non-metastatic breast cancer  These criteria allow inclusion of women successfully treated for recurrent breast cancer since there is no known reason to exclude them  Menopausal status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users  Exclusion Criteria: Exclusion criteria are current depression  history of migraines or hepatitis  abnormal chemistry profile (e.g.  sodium  potassium  glucose)  or a positive urine drug screen for illegal substances  "
        ],
        "premise_nums": [
            "to limit sample variability (greater than 12 months amenorrhea) Greater then 1 month but smaller than 5 years post-treatment (surgery  radiation",
            "Inclusion Criteria: HER-2/neu 1+ or 2+ by immunohistochemistry Inclusion Criteria: At least 18 years of age Willing and able to"
        ]
    },
    {
        "id": "ab357056-67a7-4227-966d-8c96eb1640fd",
        "primaryId": "NCT02694029",
        "statement_text": "Candidates for the primary trial are expected to be capable of holding their breath for half a minute ",
        "statement_nums": [
            "Candidates for the primary trial are expected to be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patient must be able to maintain a 30 second breath hold  "
        ],
        "premise_nums": [
            "must be able to maintain a 30 second breath hold"
        ]
    },
    {
        "id": "0359eef3-6339-485e-95bc-0cb6fa7bcd12",
        "primaryId": "NCT00635050",
        "statement_text": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients with node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible  "
        ],
        "premise_nums": [
            "node-negative  ER or PR-positive tumors 4 cm in size whose tumors are low",
            "risk (defined as a score of 0-17) on an Oncotype DX profile are"
        ]
    },
    {
        "id": "57ef3c6c-b4e1-4302-b423-aa9faca21200",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "statement_text": "the primary trial and the secondary trial do not use the same route of administration for their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial do not use the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Vaccine Therapy+ex Vivo-expanded T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later  patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion  Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations  Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals  HER-2/neu peptide vaccine: Given ID leukapheresis: Undergo leukapheresis ex vivo-expanded HER2-specific T cells: Given IV cyclophosphamide: Given IV sargramostim: Given ID laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy No comparison group  All enrolled participants were expected to undergo PET guided biopsy  "
        ],
        "premise_nums": [
            "booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals",
            "T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2",
            "laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy No comparison day 1. Treatment repeats every 7-10 days for up to",
            "IV over 30 minutes on day 1. Treatment repeats every 7-10 days 1, 8, and 15. Beginning 2 weeks later  patients",
            "and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days"
        ]
    },
    {
        "id": "29d5779b-c228-4b82-9ca8-075beadae879",
        "primaryId": "NCT00091442",
        "statement_text": "There were more cases of Febrile neutropenia than eukopenia observed in the primary trial  but less cases of Febrile neutropenia than Neutropenia ",
        "statement_nums": [
            "eukopenia observed in the primary trial  but less cases"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%)"
        ]
    },
    {
        "id": "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3",
        "primaryId": "NCT00291694",
        "statement_text": "the route of administration for both interventions in the primary trial is a topical skin cream ",
        "statement_nums": [
            "both interventions in the primary trial is a topical skin"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months "
        ],
        "premise_nums": [
            "receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized"
        ]
    },
    {
        "id": "f4c7dae5-012f-4f05-b5ba-da072fe1359c",
        "primaryId": "NCT01674062",
        "statement_text": "One patient in the primary trial was observed suffering from Enteritis ",
        "statement_nums": [
            "One patient in the primary trial was observed suffering from"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 12/66 (18.18%) Palpitations * 1/66 (1.52%) Haematemesis * 1/66 (1.52%) Performance status decreased * 1/66 (1.52%) Hepatic failure * 1/66 (1.52%) Cellulitis * 1/66 (1.52%) Device related infection * 1/66 (1.52%) Pneumonia * 1/66 (1.52%) Pneumonia pneumococcal * 1/66 (1.52%) Femur fracture * 0/66 (0.00%) Hypokalaemia * 1/66 (1.52%) Back pain * 2/66 (3.03%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 12/66 (18.18%) Palpitations * 1/66 (1.52%) Haematemesis * 1/66 (1.52%) Performance",
            "(1.52%) Femur fracture * 0/66 (0.00%) Hypokalaemia * 1/66 (1.52%) Back pain * 2/66 (3.03%)"
        ]
    },
    {
        "id": "927bbb75-37da-4b75-9483-252d31a0fd98",
        "primaryId": "NCT01067976",
        "secondaryId": "NCT00941330",
        "statement_text": "Unlike the secondary trial  the primary trial does not provide a duration of cycles or any dosages in the intervention section ",
        "statement_nums": [
            "Unlike the secondary trial  the primary trial does not provide a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: CMRM vs UMRM [Not Specified] INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  "
        ],
        "premise_nums": [
            "with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B:",
            "mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600"
        ]
    },
    {
        "id": "80a5cdbc-0721-41b6-af1a-28e3f46557ce",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had a cardiac related adverse event ",
        "statement_nums": [
            "1 patient in the primary trial had a cardiac related"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) ",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) "
        ],
        "premise_nums": [
            "Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%)",
            "Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial",
            "(0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570",
            "flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial",
            "Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573",
            "Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573",
            "Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570",
            "1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%)",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570"
        ]
    },
    {
        "id": "af710d36-8062-4412-8d11-1c57a14b5e5a",
        "primaryId": "NCT00217672",
        "secondaryId": "NCT00110084",
        "statement_text": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial ",
        "statement_nums": [
            "the primary trial had three times the",
            "fistula enterovesical as the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia 1/50 (2.00%) Arrythmia 1/50 (2.00%) Ileus 1/50 (2.00%) Nausea 1/50 (2.00%) Pain-Abdominal 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%) Arthralgia 1/50 (2.00%) "
        ],
        "premise_nums": [
            "Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%)",
            "(2.00%) Vomiting 1/50 (2.00%) Bronchial infection 1/50 (2.00%) Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%)",
            "Sepsis 1/50 (2.00%) Neutropenia 2/50 (4.00%) Platelet count decreased 1/50 (2.00%) Dehydration 1/50 (2.00%)",
            "Adverse Events 1: fistula enterovesical 1/74 (1.35%) Adverse Events 1: Total: 11/50 (22.00%) Anemia 3/50 (6.00%) Febrile neutropenia"
        ]
    },
    {
        "id": "c91c7dc1-17b7-4475-9aec-38999a18a306",
        "primaryId": "NCT00717405",
        "statement_text": "There were several patients who contracted Pneumonia in the primary trial ",
        "statement_nums": [
            "contracted Pneumonia in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth loss * 1/52 (1.92%) Hyperthermia * 1/52 (1.92%) Malaise * 1/52 (1.92%) Pyrexia * 1/52 (1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%) "
        ],
        "premise_nums": [
            "(9.62%) Febrile neutropenia * 6/52 (11.54%) Leukopenia * 6/52 (11.54%) Atrial tachycardia * 1/52 (1.92%) Vomiting * 1/52 (1.92%) Tooth",
            "(1.92%) Impaired healing * 3/52 (5.77%) Inflammation * 1/52 (1.92%)",
            "Adverse Events 1: Total: 20/52 (38.46%) Febrile bone marrow aplasia * 5/52 (9.62%) Febrile neutropenia * 6/52 (11.54%)"
        ]
    },
    {
        "id": "5357ce66-7f7b-4ffd-926c-f6116f5a2e20",
        "primaryId": "NCT00243503",
        "secondaryId": "NCT00448279",
        "statement_text": "the primary trial and the secondary trial observed a different number of adverse events in their patients ",
        "statement_nums": [
            "the primary trial and the secondary trial observed a different number"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 25/60 (41.67%) Anaemia * 1/60 (1.67%) Febrile neutropenia * 2/60 (3.33%) Idiopathic thrombocytopenic purpura * 1/60 (1.67%) Thrombocytopenia * 3/60 (5.00%) Cardiac failure * 1/60 (1.67%) Cardiac failure acute * 1/60 (1.67%) Cardiogenic shock * 1/60 (1.67%) Left ventricular dysfunction * 1/60 (1.67%) Anal fistula * 1/60 (1.67%) Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%) Acute renal failure * 21/26 (3.85%) "
        ],
        "premise_nums": [
            "(3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%) Hospitalisation for intrapleuric chemotherapy and",
            "Adverse Events 1: Total: 4/26 (15.38%) Febrile neutropenia * 1/26 (3.85%) Gastric volvulus * 20/26 (0.00%) General Malaise * 21/26 (3.85%)",
            "(1.67%) Febrile neutropenia * 2/60 (3.33%) Idiopathic thrombocytopenic purpura * 1/60 (1.67%) Thrombocytopenia * 3/60 (5.00%) Cardiac failure * 1/60 (1.67%)"
        ]
    },
    {
        "id": "2c53e14a-719c-4994-9090-73f9bddb60ba",
        "primaryId": "NCT00615901",
        "secondaryId": "NCT00829166",
        "statement_text": "the primary trial recorded more seizures than the secondary trial  despite having less than one tenth the number of patients in its total cohort ",
        "statement_nums": [
            "the primary trial recorded more seizures than the secondary trial  despite having less"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%) Atrial fibrillation * 1/490 (0.20%) Cardiomyopathy * 1/490 (0.20%) Coronary artery disease * 0/490 (0.00%) Pericardial effusion * 0/490 (0.00%) Adverse Events 2: Total: 99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 1/488 (0.20%) Febrile neutropenia * 2/488 (0.41%) ",
            "Neutropenia * 1/488 (0.20%)Thrombocytopenia * 1/488 (0.20%) Angina pectoris * 1/488 (0.20%) Atrial fibrillation * 0/488 (0.00%) Cardiomyopathy * 0/488 (0.00%) Coronary artery disease * 1/488 (0.20%) Pericardial effusion * 2/488 (0.41%) "
        ],
        "premise_nums": [
            "99/488 (20.29%) Anaemia * 1/488 (0.20%) Anaemia of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%)",
            "of malignant disease * 0/490 (0.00%) Febrile neutropenia * 0/490 (0.00%) Thrombocytopenia * 4/490 (0.82%) Angina pectoris * 0/490 (0.00%)",
            "Neutropenia * 1/488 (0.20%)Thrombocytopenia * 1/488 (0.20%) Angina pectoris",
            "(0.20%) Atrial fibrillation * 0/488 (0.00%) Cardiomyopathy * 0/488 (0.00%) Coronary",
            "(0.20%) Pericardial effusion * 2/488 (0.41%)",
            "Adverse Events 1: Seizure 1/38 (2.63%) Adverse Events 1: Total: 92/490 (18.78%) Anaemia * 1/490 (0.20%) Anaemia of malignant disease *"
        ]
    },
    {
        "id": "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a",
        "primaryId": "NCT00089999",
        "statement_text": "In total more participants in the primary trial had no tumor Response  than partial response  and only 3 patients had a complete response ",
        "statement_nums": [
            "more participants in the primary trial had no tumor Response",
            "than partial response  and only 3 patients had a complete response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR)  as Assessed by the Independent Review Committee (IRC) ",
            "OR is defined as the number of participants achieving either a confirmed CR or PR  per Response Evaluation Criteria in Solid Tumors (RECIST  v 1.0). Best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence  CR is defined as the disappearance of all target lesions (TLs) and non-TLs  PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs  taking as a reference the Baseline sum LD and no PD  or complete resolution of TLs and the persistence of one or more non-TL(s)  as assessed by the IRC  PD is defined as at least a 20% increase in the sum of the LD of TLs  taking as a reference the smallest sum LD recorded since the treatment started or the appearance of greater than or equal 1 new lesions or unequivocal progression of existing non-TLs  Responses were confirmed at subsequent assessments made greater than or equal 28 days after the original response  Participants with an unknown or missing response are treated as non-responders Time frame: From the date of the first dose of investigational product to the first documented evidence of a confirmed CR or PR (up to Study Week 103) Results 1: ",
            "Arm/Group Title: Lapatinib 1500 mg QDArm/Group Description: Participants received lapatinib 1500 mg orally QD  Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason  After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule  until disease progression  provided the treatment was tolerated  Overall Number of Participants Analyzed: 69 Measure Type: Number Unit of Measure: Participants CR: 0 PR: 15 Results 2: Arm/Group Title: Lapatinib 500 mg BID Arm/Group Description: Participants received lapatinib 500 mg orally BID  Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason  After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule  until disease progression  provided the treatment was tolerated  Overall Number of Participants Analyzed: 69 Measure Type: Number Unit of Measure: Participants CR: 0 PR: 18 "
        ],
        "premise_nums": [
            "is defined as at least a 20% increase in the sum of the",
            "assessments made greater than or equal 28 days after the original response  Participants",
            "appearance of greater than or equal 1 new lesions or unequivocal progression of existing",
            "BID Arm/Group Description: Participants received lapatinib 500 mg orally BID  Treatment was continued for 12 weeks or until disease progression or withdrawal",
            "PR is defined as at least a 30% decrease in the sum of the",
            "PR is defined as at least a 30% decrease in the date of the first dose of investigational product to",
            "or PR (up to Study Week 103) Results 1:",
            "greater than or equal 28 days after the original response  Participants With a Best Overall Response (OR) of Confirmed Complete",
            "2: Arm/Group Title: Lapatinib 500 mg BID Arm/Group Description: Participants received lapatinib 1500 mg orally QD  Treatment was continued",
            "for another reason  After Week 12, participants with clinical benefit had the",
            "as the disappearance of all target lesions (TLs) and non-TLs"
        ]
    },
    {
        "id": "bfb617c8-51ae-4ab2-be05-6346daad5437",
        "primaryId": "NCT00820222",
        "secondaryId": "NCT01819233",
        "statement_text": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets  while completing food diaries ",
        "statement_nums": [
            "the secondary trial and the primary trial interventions both require subjects"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Plus Capecitabine Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 2: Trastuzumab Plus Capecitabine Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days  every 21 days  Capecitabine was taken with food or within 30 minutes after food  Participants received study medication until disease progression  unacceptable toxicity  or participant withdrawal  INTERVENTION 1: Behavioral Dietary Intervention ",
            "Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received capecitabine 2500 mg/m^2 per day (divided and",
            "was taken with food or within 30 minutes after food  Participants also received capecitabine 2000 mg/m^2) per day (divided and administered",
            "caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  and at least 2 weeks after radiation therapy)",
            "Beginning 2-4 weeks after completion of lumpectomy  patients",
            "IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks  Participants also received",
            "undergo radiation therapy QD 5 days a week for 6 weeks Behaviorally twice daily  12 hours apart)  for 14 days",
            "reduce caloric intake by 25% of their normal diet  Patients undergo radiation therapy QD 5 days a week for 6",
            "every day  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast",
            "was taken with food or within 30 minutes after food  Participants received a daily dose of 5 tablets of lapatinib (1250 mg)",
            "was taken with food or within 30 minutes after food  Participants also received capecitabine 2500 mg/m^2 per day (divided and administered",
            "was taken with food or within 30 minutes after food  Participants received study",
            "also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily  12 hours apart)  for 14 days",
            "Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same",
            "days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy",
            "modifications to reduce caloric intake by 25% of their normal diet  Patients",
            "Patients undergo radiation therapy QD 5 days a week for 6 weeks Behavioral dietary intervention: Receive caloric restricted",
            "receive food diaries to complete for 7-10 days  Dietary counselors then give",
            "Participants also received capecitabine 2000 mg/m^2) per day (divided and administereduce caloric intake by 25% of their normal diet  Patients",
            "radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo"
        ]
    },
    {
        "id": "18fcd396-cb03-4e80-bb2d-ee03c12ba32a",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "case of pregnancy  in cohort 1 of the secondary trial and the primary trial there was only one"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) ",
            "THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) ",
            "Diarrhoea 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) "
        ],
        "premise_nums": [
            "Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79",
            "Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76",
            "Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased",
            "(0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145",
            "Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79",
            "Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%)",
            "inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76",
            "ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%)",
            "Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION",
            "inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76",
            "Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%)",
            "PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2:",
            "THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1:",
            "(0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2:",
            "(1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2:",
            "Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular",
            "CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144",
            "Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular",
            "status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79",
            "status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144",
            "Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79"
        ]
    },
    {
        "id": "694c5820-ebb6-4271-8685-a0b51c637f7f",
        "primaryId": "NCT00038103",
        "statement_text": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [
            "alone cohort of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Subjects With Clinical Benefit Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation  Includes subjects with complete response (CR)  partial response (PR)  and long term disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV) Results 1: Arm/Group Title: Exemestane (Exemestane Alone) Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants 24 Results 2: Arm/Group Title: Combination (Exemestane + Celecoxib) Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants 24 "
        ],
        "premise_nums": [
            "exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants",
            "16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last",
            "Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter",
            "exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants",
            "disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks",
            "weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)",
            "exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number"
        ]
    },
    {
        "id": "b87abb47-13b6-4dbe-9cfd-e63075b676aa",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
            "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 "
        ],
        "premise_nums": [
            "at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally",
            "defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the",
            "daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Day 1 at the starting dose of 37.5 mg/day",
            "1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was",
            "those that persist on repeat evaluation 4 weeks after initial documentation of response",
            "of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19",
            "of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE",
            "administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for",
            "lesions  PR is defined as 30% decrease in sum of the longest",
            "Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants",
            "Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is",
            "Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of",
            "2, every 6 weeks after Cycle 2, and at the end of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR):"
        ]
    },
    {
        "id": "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed under a year ago  are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "Patients who received over 5 years of anastrozole therapy  completed under"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago "
        ],
        "premise_nums": [
            "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.",
            "part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago"
        ]
    },
    {
        "id": "23df2cc2-6aae-4251-a8a7-e2f5a65f176a",
        "primaryId": "NCT02149524",
        "statement_text": "None of the adverse events which occurred in the primary trial were not GI related ",
        "statement_nums": [
            "which occurred in the primary trial were not GI related"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) ",
            "Cardiac failure congestive 3/437 (0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) "
        ],
        "premise_nums": [
            "(0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%)",
            "(0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438",
            "(0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%)",
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia",
            "neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia",
            "(0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia",
            "Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure",
            "Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia",
            "Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia",
            "Cardiac failure congestive 3/437 (0.69%)Supraventricular tachycardia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%)",
            "58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure"
        ]
    },
    {
        "id": "58c58b68-fc9a-438c-8a85-9233dde714c9",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort ",
        "statement_nums": [
            "Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Response Rate (ORR) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Title: Cohort 1: HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 45 Measure Type: Number ",
            "Unit of Measure: percentage of participants 35.6 (24 to 49)Results 2: Arm/Group Title: Cohort 2: TNBC Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage of participants 13.2 (5 to 26) "
        ],
        "premise_nums": [
            "days 1 and 8 of each 21 day cycle Participants remained on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance",
            "Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on",
            "evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months",
            "for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage",
            "lesions and PR is at least a 30% decrease in the sum of longest",
            "HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle",
            "months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days",
            "on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Title:",
            "Outcome Measurement: Overall Response Rate (ORR) ORR was",
            "Number of Participants Analyzed: 45 Measure Type: Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage",
            "on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and PR is at least a 30% decrease in the sum of"
        ]
    },
    {
        "id": "843778c6-a320-49a1-93a0-5dc6239b822a",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis ",
        "statement_nums": [
            "adverse events in the primary trial where Infection and Stomatitis"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) "
        ],
        "premise_nums": [
            "1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "(1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%)",
            "Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81",
            "Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "(1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)"
        ]
    },
    {
        "id": "a5486f80-69e5-4a5a-8435-f82f39cddf85",
        "primaryId": "NCT00080301",
        "statement_text": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial  than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 127/368 (34.51%) ANAEMIA 3/368 (0.82%) LEUKOPENIA 0/368 (0.00%) NEUTROPENIA 0/368 (0.00%) COAGULOPATHY 3/368 (0.82%) LYMPHADENOPATHY 0/368 (0.00%) THROMBOCYTOPENIA 2/368 (0.54%) BONE MARROW FAILURE 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ATRIAL FLUTTER 0/368 (0.00%) CARDIAC ARREST 0/368 (0.00%) Adverse Events 2: Total: 151/369 (40.92%) ANAEMIA 11/369 (2.98%) LEUKOPENIA 6/369 (1.63%) NEUTROPENIA 18/369 (4.88%) COAGULOPATHY 0/369 (0.00%) ",
            "LYMPHADENOPATHY 1/369 (0.27%)THROMBOCYTOPENIA 7/369 (1.90%) BONE MARROW FAILURE 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%) ATRIAL FLUTTER 1/369 (0.27%) CARDIAC ARREST 1/369 (0.27%) "
        ],
        "premise_nums": [
            "1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)THROMBOCYTOPENIA 7/369 (1.90%) BONE MARROW FAILURE 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369",
            "Total: 127/368 (34.51%) ANAEMIA 3/368 (0.82%) LEUKOPENIA 0/368 (0.00%) NEUTROPENIA 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)",
            "Adverse Events 1: Total: 127/368 (34.51%) ANAEMIA 3/368 (0.82%) LEUKOPENIA 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)",
            "NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%) ATRIAL FLUTTER 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)",
            "NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ATRIAL FLUTTER 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)",
            "MARROW FAILURE 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ATRIAL FLUTTER 0/368 (0.00%) CARDIAC ARREST 0/368",
            "INTRAVASCULAR COAGULATION 1/369 (0.27%) ATRIAL FLUTTER 1/369 (0.27%) CARDIAC ARREST 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)",
            "NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%) ATRIAL FLUTTER 0/368 (0.00%) CARDIAC ARREST 0/368 (0.00%) Adverse Events 2:",
            "Adverse Events 2: Total: 151/369 (40.92%) ANAEMIA 11/369 (2.98%) LEUKOPENIA 6/369 (1.63%) NEUTROPENIA 18/369 (4.88%) COAGULOPATHY 0/369 (0.00%)",
            "LYMPHADENOPATHY 0/368 (0.00%) THROMBOCYTOPENIA 2/368 (0.54%) BONE MARROW FAILURE 0/368 (0.00%) FEBRILE NEUTROPENIA 4/368 (1.09%) DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)",
            "LYMPHADENOPATHY 1/369 (0.27%)THROMBOCYTOPENIA 7/369 (1.90%) BONE MARROW FAILURE 1/369 (0.27%) FEBRILE NEUTROPENIA 15/369 (4.07%) DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)",
            "CARDIAC ARREST 0/368 (0.00%) Adverse Events 2: Total: 151/369 (40.92%) ANAEMIA 11/369 (2.98%) LEUKOPENIA 6/369 (1.63%) NEUTROPENIA 18/369 (4.88%) COAGULOPATHY 0/369"
        ]
    },
    {
        "id": "c2c60b25-f255-48ba-bcb7-2bcd2de4315d",
        "primaryId": "NCT00171314",
        "statement_text": "There are four types of adverse events in the primary trial  for which no occurences are recorded ",
        "statement_nums": [
            "adverse events in the primary trial  for which no"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) "
        ],
        "premise_nums": [
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block",
            "myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254",
            "(18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle",
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%)",
            "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%)",
            "Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease",
            "block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%)"
        ]
    },
    {
        "id": "a8167a90-8ccf-4024-a4cc-8c1b047fd548",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "statement_text": "the primary trial and the secondary trial do not employ the same route of administration for their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial do not employ the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent  INTERVENTION 2: PD-0332991 125 mg: Dose Escalation Cohort ",
            "In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent "
        ],
        "premise_nums": [
            "oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg",
            "oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg",
            "regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single oral dose",
            "period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for",
            "oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg",
            "Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before",
            "capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of",
            "days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single",
            "PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each",
            "days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single",
            "oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg"
        ]
    },
    {
        "id": "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression ",
        "statement_nums": [
            "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression "
        ],
        "premise_nums": [
            "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression"
        ]
    },
    {
        "id": "277f5d17-36cc-44c5-9b94-7e052f2bdb2c",
        "primaryId": "NCT01067976",
        "secondaryId": "NCT00941330",
        "statement_text": "Unlike the secondary trial  the primary trial only provides the duration of cycles and drug doses in the intervention section ",
        "statement_nums": [
            "Unlike the secondary trial  the primary trial only provides the duration"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: CMRM vs UMRM [Not Specified] INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  "
        ],
        "premise_nums": [
            "with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B:",
            "mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600"
        ]
    },
    {
        "id": "fcb195de-2143-44d8-8c46-136104554e2d",
        "primaryId": "NCT01492101",
        "statement_text": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia  but just over 5% of cohort 1 patients suffered from Coagulopathy ",
        "statement_nums": [
            "by Pancytopenia  but just over 5% of cohort 1 patients suffered from Coagulopathy",
            "There less than 1% of either cohort of the primary trial was effect by Pancytopenia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Pancytopenia *2/425 (0.47%) Coagulopathy *1/425 (0.24%) Adverse Events 2: Pancytopenia *0/406 (0.00%)"
        ]
    },
    {
        "id": "70337af9-3d4a-44bc-bbfa-0d97ea88553c",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "Patients must have at least 3 prior treatments with trastuzumab to be eligible"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  "
        ],
        "premise_nums": [
            "may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based"
        ]
    },
    {
        "id": "a289f67c-ff56-44a9-b3da-152fb0d20271",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "statement_text": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "Only 1 respiratory adverse event was recorded across the",
            "duration of both the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) Gastroenteritis 1/6 (16.67%) Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) ",
            "Anemia 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) Gastroenteritis 0/52 (0.00%) Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%)",
            "tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32",
            "duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%)",
            "1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1:",
            "Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo",
            "0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) Gastroenteritis 0/52 (0.00%)",
            "Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%)",
            "Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%)",
            "Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%)",
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32"
        ]
    },
    {
        "id": "683b9885-4027-4108-b37e-61255611538a",
        "primaryId": "NCT02692755",
        "statement_text": "Asian  white british and white irish women are eligible for the primary trial  as long as they do not have uncontrolled or symptomatic brain metastases ",
        "statement_nums": [
            "are eligible for the primary trial  as long as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Self-identified Black  African or African American women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) Exclusion Criteria: Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases  Previously treated and clinically stable  as per Investigator's judgment  brain metastases are permitted  "
        ],
        "premise_nums": [
            "African or African American women of 18 years of age with proven diagnosis of",
            "adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)",
            "inhibitors or inducers of CYP3A4 Active uncontrolled or symptomatic brain metastases"
        ]
    },
    {
        "id": "a47e048a-56aa-49e0-9903-563f53797b6e",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2.",
        "statement_nums": [
            "Cohorts 1 of the primary trial recieves Bevacizumab at a",
            "higher frequency and dose than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks "
        ],
        "premise_nums": [
            "3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks",
            "8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every",
            "4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15",
            "mg/m² twice-daily  days 1-14, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every",
            "intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every"
        ]
    },
    {
        "id": "f5477a02-dde7-44c8-80b5-2cdb9fa66f23",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "statement_text": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia * 0/260 (0.00%) Bundle branch block right * 0/260 (0.00%) Pericardial effusion * 0/260 (0.00%) Cardiopulmonary failure * 0/260 (0.00%) Aplasia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: Total: 71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle branch block right * 1/267 (0.37%) ",
            "Pericardial effusion * 5/267 (1.87%)Cardiopulmonary failure * 1/267 (0.37%) Aplasia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%) Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea  pain 1/74 (1.35%) hemorrhage/bleeding 2/74 (2.70%) "
        ],
        "premise_nums": [
            "Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea",
            "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia",
            "71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle",
            "vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea",
            "enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%)",
            "Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia",
            "discomfort * 1/267 (0.37%) Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74",
            "Pericardial effusion * 5/267 (1.87%)Cardiopulmonary failure * 1/267 (0.37%) Aplasia * 1/267 (0.37%) Eye",
            "(0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: Total: 71/267 (26.59%) Anaemia *",
            "Adverse Events 2: Total: 71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia"
        ]
    },
    {
        "id": "4dfbdeba-cae0-48b2-a38d-07338512904e",
        "primaryId": "NCT03076190",
        "secondaryId": "NCT03196635",
        "statement_text": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions ",
        "statement_nums": [
            "applied in either the primary trial or the secondary trial interventions"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  "
        ],
        "premise_nums": [
            "evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study",
            "Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two",
            "My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA"
        ]
    },
    {
        "id": "62489179-bb30-4b96-a904-ea907dd05e23",
        "primaryId": "NCT01097460",
        "secondaryId": "NCT01009918",
        "statement_text": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF)  Number of Patients who experienced a cardiotoxicity  Time frame: 2 years Results 1: Arm/Group Title: Arm I Lisinopril Arm/Group Description: Patients receive oral lisinopril once daily  lisinopril: Given orally Overall Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants 45 29.6% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants 45 29.6%",
            "[Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin",
            "Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and",
            "in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation",
            "or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants",
            "+ Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111",
            "Unit of Measure: participants 16 Outcome Measurement: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment Reduction in incidence of"
        ]
    },
    {
        "id": "45891239-bb78-4f83-8306-8edceb8247fe",
        "primaryId": "NCT01011946",
        "statement_text": "All patients in the primary trial must have a bilateral breast mammography prior to study entry ",
        "statement_nums": [
            "All patients in the primary trial must have a bilateral"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e  lumpectomy)  Exclusion Criteria: Children (smaller than 18 years old) Pregnant or Lactating women Diabetic patients (Type I or II) Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM Patients who have NOT undergone a standard of care bilateral breast MRI at UC  "
        ],
        "premise_nums": [
            "Exclusion Criteria: Children (smaller than 18 years old) Pregnant or Lactating women Diabetic",
            "Inclusion Criteria: Women 18-75 years old with newly diagnosed breast cancer",
            "node procedure using radioactive Tc-99m within 24 hours of PEM Patients who have NOT"
        ]
    },
    {
        "id": "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3",
        "primaryId": "NCT00258349",
        "secondaryId": "NCT01328249",
        "statement_text": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat  whereas both cohorts in the secondary trial receive some of both ",
        "statement_nums": [
            "both cohorts in the secondary trial receive some of both"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day  daily for 14 days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin Mesylate With Filgrastim as Needed Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors  subcutaneous pegfilgrastim (6 mg) or filgrastim  could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2. "
        ],
        "premise_nums": [
            "(60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles",
            "neutropenia occurred that recovered to Grade 2.",
            "regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day",
            "once on Day 1, infused over 90 minutes  every 3 weeks; Vorinostat 200 mg of SAHA orally twice a day",
            "(IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was",
            "2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this",
            "a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "1: Vorinostat +Trastuzumab Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes  every 3 weeks;",
            "a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for",
            "every 3 weeks; Vorinostat 200 mg of SAHA orally twice a days out of a 21-day cycle INTERVENTION 1: Cohort 1: Eribulin"
        ]
    },
    {
        "id": "91f23b55-38b6-41c4-af30-baa15e989aa7",
        "primaryId": "NCT00371254",
        "statement_text": "Patients must have eceptorsestrogen receptor (ER) -  progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer  aswell as not having Dysphagia ",
        "statement_nums": [
            "and human epidermal growth factor receptor 2 (HER2) - non metastatic breast"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: recurrent or progressive locally advanced  or 'triple negative' metastatic breast cancer Exclusion Criteria: Unable to take oral medication "
        ],
        "premise_nums": [
            "Criteria: recurrent or progressive locally advanced  or 'triple"
        ]
    },
    {
        "id": "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d",
        "primaryId": "NCT00374322",
        "statement_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients ",
        "statement_nums": [
            "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants (Par.) With Any Recurrence of the Initial Disease  Second Primary Cancer  Contralateral Breast Cancer  or Death (Disease-free Survival [DFS]) ",
            "DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence  a second primary cancer  or death from any cause  The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer  including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin  melanoma in situ  carcinoma in situ of the cervix  or lobular carcinoma in situ of the breast); death from any cause without a prior event  Par  who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored  Par  who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed ",
            "Time frame: From randomization until date of the first occurrence of an objective disease recurrence  a second primary cancer  or death from any cause (assessed up to 6 years; 1 year of treatment  5 years of follow-up [median of 5.3 years for final analysis])Results 1: Arm/Group Title: Lapatinib 1500 mg Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily  Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer  withdrawal from study treatment due to unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 1571 Measure Type: Number Unit of Measure: Participants Any recurrence or death: 252 Censored  New Anti-cancer Agent/Radiotherapy: 1 Censored  Follow-up Ended: 1318 Results 2: Arm/Group Title: Placebo Arm/Group Description: Participants received matching placebo orally once daily  Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer  withdrawal from study treatment due to unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 1576 Measure Type: Number Unit of Measure: Participants Any recurrence or death: 290 ",
            "Censored  New Anti-cancer Agent/Radiotherapy: 1Censored  Follow-up Ended: 1285 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 1576 Measure Type: Number Unit of Measure: Participants",
            "1: Arm/Group Title: Lapatinib 1500 mg Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily  Treatment",
            "(follow-up ongoing) at the last visit date available at which",
            "Any recurrence or death: 252 Censored  New Anti-cancer Agent/Radiotherapy: 1",
            "was continued for a maximum of 12 months or until disease recurrence  a second primary cancer  or death from",
            "the date of the first occurrence of an objective disease",
            "Number of Participants Analyzed: 1571 Measure Type: Number Unit of Measure: Participants",
            "from any cause (assessed up to 6 years; 1 year of treatment  5 years of follow-up [median of 5.3 years"
        ]
    },
    {
        "id": "a2d489d5-3677-43ef-b03a-33d571c0c3b2",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  as long as they do not have uncontrolled Hypertension ",
        "statement_nums": [
            "be included in the primary trial  but can be",
            "be entered into the secondary trial  as long as"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Body mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or III disease  Measurable disease by physical examinations or diagnostic breast imaging (mammography  ultrasonography or MR)  Pre-treatment core or incisional biopsy  Patients may not have had definitive primary surgery  Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined in the protocol  Exclusion Criteria: Prior radiation therapy  cytotoxic therapy or systemic therapy for breast cancer  Prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry  Metastatic (Stage IV) breast cancer Patients who have had only a pre-treatment fine needle aspiration (FNA) are excluded  Current therapeutic treatment on another clinical trial with an investigational agent  ",
            "Any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolusOngoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal 2, atrial fibrillation of any grade  or QTc interval greater than 450 msec for males or greater than 470 msec for females  Hypertension that cannot be controlled by medications  Current treatment with therapeutic doses of any anti-coagulant  Prophylactic use of anticoagulants is allowed  Known human immunodeficiency virus (HIV) infection  Pregnancy or breastfeeding  All female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication  Other severe acute or chronic medical or psychiatric condition  or laboratory abnormality that would impart  in the judgment of the investigator  excess risk associated with study participation or study drug administration  or which  in the judgment of the investigator  would make the patient inappropriate for entry into this study  "
        ],
        "premise_nums": [
            "breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or",
            "Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined",
            "or QTc interval greater than 450 msec for males or greater than 470 msec for females  Hypertension that cannot",
            "pregnancy test prior to first day of study medication",
            "Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0",
            "(BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast",
            "mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria:",
            "CTCAE grade greater than or equal 2, atrial fibrillation of any grade",
            "Any of the following within the 6 months prior to starting study treatment: -myocardial",
            "use of anticoagulants is allowed  Known human immunodeficiency"
        ]
    },
    {
        "id": "943ff737-4edd-4dbd-a3c9-213e3e0234d8",
        "primaryId": "NCT00423917",
        "secondaryId": "NCT00082641",
        "statement_text": "the primary trial and the secondary trial both report cases of confusion in their patient cohorts ",
        "statement_nums": [
            "the primary trial and the secondary trial both report cases of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%)",
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 2: Confusion 0/12 (0.00%)"
        ]
    },
    {
        "id": "be50c45f-ec51-40c8-904f-ffc200d39d9d",
        "primaryId": "NCT01042938",
        "statement_text": "Only patients capable of understanding english are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)  "
        ],
        "premise_nums": [
            "to complete assessment forms (all assessment forms are in English)"
        ]
    },
    {
        "id": "f53c8212-6da8-470f-a392-1bb037ed90e8",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all  or a placebo ",
        "statement_nums": [
            "secondary trial and the primary trial either include no treatment at all  or a placebo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue  Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
            "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  "
        ],
        "premise_nums": [
            "with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone",
            "with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If",
            "injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone",
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly",
            "local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to"
        ]
    },
    {
        "id": "7b7e6e8b-aa62-4fcd-af1e-c243995243d1",
        "primaryId": "NCT02622074",
        "statement_text": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "many patients with DLT in cohort 2 of the primary trial than in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The following events  if considered to be study-treatment-related by the Investigator  were considered a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or Grade 3 non-hematologic  non-hepatic organ toxicity  with exceptions Other: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction of study treatment during the DLT evaluation period  Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen); Each cycle was 21 days  Results 1: ",
            "Arm/Group Title: Cohort A: KNp / KACArm/Group Description: Participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)  This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via intravenous (IV) infusion except for doxorubicin (A)  which was administered via IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 2 20.0% Results 2: ",
            "Arm/Group Title: Cohort B: KNpCb (Regimen 1) / KACArm/Group Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments were administered via IV infusion except for doxorubicin (A)  which was administered via IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants ",
            "Unit of Measure: Participants 4 40.0%"
        ],
        "premise_nums": [
            "exceptions Other: Any treatment delays for 14 days due to unresolved toxicity; Grade 5 treatment-related adverse event (AE); A dose reduction",
            "Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 2 20.0% Results 2:",
            "1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)",
            "1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "6 in Cycles 2-5 on Day 1 (Q3W). This was followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity;",
            "1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 through end of Cycle 3 and Cycle 6 Day 1",
            "Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of Measure: Participants 4 40.",
            "through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 3 and Cycle 6 Day 1",
            "Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp)",
            "lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade",
            "Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This was followed by",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W)",
            "pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day",
            "200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A)",
            "requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade",
            "Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab",
            "followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 through end of Cycle 7 (Up to ~150 days from",
            "first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp)",
            "mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on",
            "6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each",
            "IV injection  Each cycle was 21 days  Overall Number of Participants Analyzed: 10 Measure Type: Count of Participants Unit of",
            "Time frame: Cycle 1 Day 1 through end of Cycle 3 and Cycle 6 Day 1 through end of Cycle 7",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8",
            "200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 3 asymptomatic hepatic toxicities lasting 7 days; or Grade 3 non-hematologic",
            "first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each",
            "pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once",
            "Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48 hours  or Grade 3",
            "Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) The",
            "consisted of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on",
            "requiring platelet transfusion  or Grade 3 thrombocytopenia with bleeding Non-hematologic: Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48",
            "Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW)",
            "Day 1 through end of Cycle 7 (Up to ~150 days from first dose of first combination regimen);",
            "Grade 4; or Grade 4 thrombocytopenia requiring platelet transfusion  or Grade 4 toxicity; Grade 3 symptomatic hepatic toxicities lasting greater than 48",
            "(Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in",
            "a DLT: Hematologic: Grade 4 neutropenia lasting 8 days; Febrile neutropenia Grade 3 or Grade 4; or Grade 4 thrombocytopenia requiring",
            "pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on",
            "Description: Participants first received KNpCb Regimen 1 which consisted of: pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W)"
        ]
    },
    {
        "id": "74a53536-bb9d-4c64-9280-679d7b660cdd",
        "primaryId": "NCT02162719",
        "statement_text": "the primary trial does not investigate the effects of its intervention on patient tpCR ",
        "statement_nums": [
            "the primary trial does not investigate the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS was defined as the time from randomization to the first occurrence of disease progression  as determined by investigator review of tumor assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study treatment regimen) from any cause  whichever occurred first  Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016) "
        ],
        "premise_nums": [
            "(Clinical Cut Off Date: 07 June 2016)",
            "from randomization to the first occurrence of disease progression",
            "Time frame: Baseline up to 30 days after the last dose",
            "assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study"
        ]
    },
    {
        "id": "6b35c306-a699-44f2-8606-a58d58fc18f3",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases ",
        "statement_nums": [
            "6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "(0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%)",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%)",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%)",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction"
        ]
    },
    {
        "id": "62f50fe5-a83d-4f07-9dc7-8f495254d398",
        "primaryId": "NCT00784849",
        "secondaryId": "NCT02104895",
        "statement_text": "Breast breast irradiation is used in some form for both cohorts of the secondary trial  but not at all in the primary trial ",
        "statement_nums": [
            "both cohorts of the secondary trial  but not at all in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional whole breast irradiation (WBI) Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI) INTERVENTION 2: Partial Breast Irradiation (APBI) Accelerated partial breast irradiation (APBI) Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT) "
        ],
        "premise_nums": [
            "Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel",
            "using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes INTERVENTION 1: Whole Breast Irradiation (WBI) Conventional"
        ]
    },
    {
        "id": "edcae553-8a0a-45d2-a0fa-4db68608ef03",
        "primaryId": "NCT00121134",
        "statement_text": "the primary trial requires participants to have a primary tumor greater than 5cm in longest dimension ",
        "statement_nums": [
            "the primary trial requires participants to have a primary tumor greater than 5cm in longest dimension"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must have completed definitive resection of primary tumor with adequate excision of gross disease  "
        ],
        "premise_nums": [
            "completed definitive resection of primary tumor with adequate excision of"
        ]
    },
    {
        "id": "a1b3667f-bfa5-426a-975a-20ed350c12c0",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month ",
        "statement_nums": [
            "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle "
        ],
        "premise_nums": [
            "(Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week",
            "cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week",
            "(Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-weekly for 3 weeks of each 4-week cycle"
        ]
    },
    {
        "id": "903617fa-7c40-45ac-a03c-498f51879408",
        "primaryId": "NCT02915744",
        "statement_text": "The difference in median  maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month ",
        "statement_nums": [
            "maximum and minimum Overall Survival (OS) of Patients between",
            "two cohort of the primary trial was less than one"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) of Patients To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC)  Overall survival is defined as the time from the date of randomization to the date of death from any cause  Patients will be followed until their date of death or until final database closure  Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis  Time frame: Within 3 years from study start Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle  Overall Number of Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2: ",
            "Arm/Group Title: Treatment of Physician's Choice (TPC)Arm/Group Description: In Group B  TPC will be administered per standard of care  Patients randomized to TPC will receive single-agent IV chemotherapy  limited to choice of one of the following 7 agents: eribulin  ixabepilone  vinorelbine  gemcitabine  paclitaxel  docetaxel  or nab-paclitaxel  Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4) "
        ],
        "premise_nums": [
            "choice of one of the following 7 agents: eribulin  ixabepilone",
            "145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of Measure: months 7.5 (5.8 to 10.4)",
            "Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.5 (5.8 to 10.4)",
            "or nab-paclitaxel  Overall Number of Participants Analyzed: 86 Median (95% Confidence Interval) Unit of Measure: months",
            "Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A  NKTR-102 will be administered at a dose level",
            "145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle  Overall Number",
            "once every 21 days (q21d) with OS of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with",
            "Participants Analyzed: 92 Median (95% Confidence Interval) Unit of Measure: months 7.8 (6.1 to 10.2) Results 2:",
            "Time frame: Within 3 years from study start Results 1: Arm/Group Title: NKTR-102 Arm/Group Description: In Group A",
            "Outcome Measurement: Overall Survival (OS) of Patients To"
        ]
    },
    {
        "id": "9436e18a-a055-41c3-980f-bf451b4da7ee",
        "primaryId": "NCT00171314",
        "statement_text": "There are four types of adverse events in the primary trial  for which one occurence is recorded ",
        "statement_nums": [
            "adverse events in the primary trial  for which one"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) "
        ],
        "premise_nums": [
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block",
            "myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254",
            "(18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle",
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%)",
            "Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%)",
            "Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease",
            "block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%)"
        ]
    },
    {
        "id": "f57403d9-7278-481e-bcb9-066bf31b6158",
        "primaryId": "NCT01201265",
        "secondaryId": "NCT00932373",
        "statement_text": "1 patient in the primary trial was affected by Sepsis  and several were affected in the secondary trial ",
        "statement_nums": [
            "1 patient in the primary trial was affected by Sepsis",
            "were affected in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Adverse Events 1: Total: 1/3 (33.33%) Pain 0/3 (0.00%) Cellulitis 0/3 (0.00%) Influenza 0/3 (0.00%) Osteomyelitis 0/3 (0.00%) Pneumonia 0/3 (0.00%) Humerus Fracture 0/3 (0.00%) Brain Oedema 0/3 (0.00%) Cerebral Haemorrhage 0/3 (0.00%) ",
            "Convulsion 0/3 (0.00%)Dysarthria 0/3 (0.00%) Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: Total: 1/1 (100.00%) Pain 0/1 (0.00%) Cellulitis 0/1 (0.00%) Influenza 0/1 (0.00%) Osteomyelitis 0/1 (0.00%) Pneumonia 0/1 (0.00%) Humerus Fracture 0/1 (0.00%) Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Dysarthria 0/1 (0.00%) Hepatic Encephalopathy 0/1 (0.00%) Confusional State 0/1 (0.00%) Dyspnoea 0/1 (0.00%) "
        ],
        "premise_nums": [
            "Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Pneumonia 0/1 (0.00%) Humerus Fracture 0/1 (0.00%) Brain Oedema 0/1",
            "Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Pneumonia 0/3 (0.00%) Humerus Fracture 0/3 (0.00%) Brain Oedema 0/3",
            "Brain Oedema 0/3 (0.00%) Cerebral Haemorrhage 0/3 (0.00%)Dysarthria 0/3 (0.00%) Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal",
            "Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: Total: 1/1 (100.00%) Pain 0/1",
            "Brain Oedema 0/1 (0.00%) Cerebral Haemorrhage 0/1 (0.00%) Convulsion 0/1 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: Total: 1/1 (100.00%) Pain 0/1",
            "2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%)",
            "0/3 (0.00%)Dysarthria 0/3 (0.00%) Hepatic Encephalopathy 0/3 (0.00%) Confusional State 0/3 (0.00%) Dyspnoea 1/3 (33.33%) Adverse Events 2: Total: 1/1",
            "Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40",
            "Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Adverse Events 1: Total: 1/3 (33.33%) Pain 0/3 (0.00%) Cellulitis 0/3",
            "(5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) Disease Progression 6/40 (15.00%) Fatigue 1/40 (2.50%)",
            "Adverse Events 1: Total: 1/3 (33.33%) Pain 0/3 (0.00%) Cellulitis 0/3 (0.00%) Influenza 0/3",
            "Brain Oedema 0/3 (0.00%) Cerebral Haemorrhage 0/3 (0.00%) Pneumonia 0/3 (0.00%) Humerus Fracture 0/3 (0.00%) Brain Oedema 0/3"
        ]
    },
    {
        "id": "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "statement_text": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events ",
        "statement_nums": [
            "Patients in the primary trial and the secondary trial did not suffer from"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) Vomiting * [1]1/63 (1.59%) Acute Pharyngitis * 1/63 (1.59%) Infection * 3/63 (4.76%) Neutrophil count decreased * [1]1/63 (1.59%) Pneumonitis/pulmonary infiltrates * [3]1/63 (1.59%) "
        ],
        "premise_nums": [
            "leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1:",
            "(19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) Vomiting",
            "(0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post",
            "Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63",
            "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis"
        ]
    },
    {
        "id": "0f0e5a8e-3972-46c2-84dd-7436e82a9787",
        "primaryId": "NCT00291135",
        "secondaryId": "NCT00291694",
        "statement_text": "The duration of treatment in the primary trial is half as long as in the secondary trial  but twice as frequent ",
        "statement_nums": [
            "of treatment in the primary trial is half as long as in the secondary trial  but twice as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months "
        ],
        "premise_nums": [
            "1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib",
            "mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo"
        ]
    },
    {
        "id": "420e4977-ce75-4fab-99e0-3e7db837d521",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "to Disease Progression the primary trial was over 21 days in the Docetaxel Plus Capecitabine group"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time to Disease Progression (Initial Treatment) Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment  Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: ",
            "Arm/Group Title: Docetaxel Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins  Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) "
        ],
        "premise_nums": [
            "Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a",
            "mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, intravenous  day 1 every 21 days  Treatment continues until",
            "21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until",
            "21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a",
            "Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05)",
            "crossover treatment begins  Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05)",
            "or 2) date of last contact for participants alive without",
            "Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until",
            "and the date of first documented disease progression or the",
            "due to study disease (up to 82 months) Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "d07b4a30-e74f-468a-8420-7ade791d372d",
        "primaryId": "NCT00096356",
        "statement_text": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "statement_nums": [
            "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients",
            "compared to a placebo by about 8%"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile of Mood States - fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 - CoQ10 & Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day  Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2 - Placebo & Vitamin E Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 114 Least Squares Mean (Standard Error) Unit of Measure: units on a scale 8.33 (0.79) "
        ],
        "premise_nums": [
            "fatigue scale  It ranges from 0 to 28; higher values indicate greater fatigue",
            "Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses Overall Number of Participants Analyzed: 122 Least Squares Mean (Standard Error) Unit of",
            "of Measure: units on a scale 6.96 (0.71) Results 2: Arm/Group Title: Arm 2",
            "Measurement: Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization POMS-F is the Profile",
            "fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1 -",
            "It ranges from 0 to 28; higher values indicate greater fatigue  Time frame: 24 weeks Results 1: Arm/Group Title: Arm 1",
            "Vitamin E Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day"
        ]
    },
    {
        "id": "412b2743-8f76-494a-af97-f7bf9541a890",
        "primaryId": "NCT02536339",
        "secondaryId": "NCT00371345",
        "statement_text": "At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial ",
        "statement_nums": [
            "patients from both the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Parainfluenzae virus infection 1/39 (2.56%) Adverse Events 1: PNEUMONIA 1/70 (1.43%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Parainfluenzae virus infection 1/39 (2.56%) Adverse Events 1: PNEUMONIA 1/70 (1.43%)"
        ]
    },
    {
        "id": "e1fa68ac-42b4-4223-a362-a89c43562e06",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [
            "adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%)",
            "lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac",
            "lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected",
            "1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7",
            "3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101",
            "count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7"
        ]
    },
    {
        "id": "6f5570c0-4114-47ee-9611-b2e4be91cf9a",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "statement_text": "2 patients in the primary trial suffer from DVT  0 in the secondary trial ",
        "statement_nums": [
            "2 patients in the primary trial suffer from DVT  0 in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Deep vein thrombosis 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) Hypertension *1/30 (3.33%) Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) "
        ],
        "premise_nums": [
            "Deep vein thrombosis 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other",
            "Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%)"
        ]
    },
    {
        "id": "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "statement_nums": [
            "Intervention 2 of the primary trial resulted in a lower",
            "change in tumor diameter than intervention 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: percent change -1.4 (11.9) "
        ],
        "premise_nums": [
            "Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd",
            "receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent",
            "here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description:",
            "receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 46"
        ]
    },
    {
        "id": "6495c223-f7d9-459f-8c57-66a2caac5ee4",
        "primaryId": "NCT02581839",
        "statement_text": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 16 weeks ",
        "statement_nums": [
            "All participants in the primary trial had a Central Nervous",
            "Survival (PFS) greater than or equal 16 weeks"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) The study team will assess the percent of participants without CNS progression at 3 months  The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS  Response and progression by MR were evaluated using WHO/modified McDonald's criteria  Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate Eribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate ",
            "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the discretion of the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at the discretion of the treating physician Overall Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7) "
        ],
        "premise_nums": [
            "subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and",
            "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the",
            "Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate Arm/Group",
            "the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at",
            "and every 12 weeks after cycles 4+ while on study eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes",
            "MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate",
            "PFS and estimate the PFS and 95% confidence interval (CI) of the PFS",
            "Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12",
            "dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day",
            "Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7)",
            "is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI",
            "of participants without CNS progression at 3 months  The study team"
        ]
    },
    {
        "id": "eb61fee2-30fc-42f9-80bd-4d73d6af592c",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "statement_text": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [
            "the secondary trial and the primary trial are evaluating interventions associated"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  "
        ],
        "premise_nums": [
            "to come to their scheduled appointment 30 minutes early to meet a coordinator or",
            "reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool)",
            "patients scheduled for a plastic/reconstruction consult  Investigators identified",
            "A study team member called the patient to determine",
            "making  Patient participation was approximately 30 minutes"
        ]
    },
    {
        "id": "79c698bf-a756-4a73-8075-38c3c5eb7a04",
        "primaryId": "NCT00091832",
        "statement_text": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) ",
        "statement_nums": [
            "Both cohorts of the primary trial in a negative (mean)"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14) "
        ],
        "premise_nums": [
            "2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of",
            "Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)",
            "Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W",
            "from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr)",
            "Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:",
            "Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14)",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent",
            "From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)",
            "of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Measure: Percent change -52.87 (95.14)",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:",
            "Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:"
        ]
    },
    {
        "id": "f7be0a6e-6c63-473e-af00-df009f3d7d46",
        "primaryId": "NCT00571987",
        "statement_text": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [
            "from entry to the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or calcification BIRADS classification IV location of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal Carcinoma Grade I-III on final pathology Good general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or supraclavicular lymph nodes If prior non-breast malignancy  must have greater than 5 year disease-free survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants Multicentric disease or bilateral disease Lesions greater than 5 cm in diameter Lesions smaller than 1.0 cm from the skin Previous prior radiation to the breast Need for mastectomy Diffuse microcalcifications (as determined by the Investigator) "
        ],
        "premise_nums": [
            "general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or",
            "of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal",
            "radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or",
            "survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants",
            "disease Lesions greater than 5 cm in diameter Lesions smaller than 1.0 cm from the skin Previous prior radiation",
            "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study"
        ]
    },
    {
        "id": "6f686de9-f110-4be0-9cd8-1ceb0ce6f073",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily",
            "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I Low Dose DHEA Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD)  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 2: Arm II High Dose DHEA Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  "
        ],
        "premise_nums": [
            "receive 30 mg duloxetine orally for 7 days  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "1 week  then 60 mg daily x 4 weeks  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days"
        ]
    },
    {
        "id": "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480",
        "primaryId": "NCT01004744",
        "statement_text": "Patients must have a confirmed pregnancy by positive Hcg test  if they are to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Postmenopausal status defined as cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month) "
        ],
        "premise_nums": [
            "cessation of menses for greater than 1 year or FSH greater than 20 mIU/mL (within the past month)"
        ]
    },
    {
        "id": "ffa913b7-9875-458e-8a28-476f9e788bb0",
        "primaryId": "NCT02463032",
        "statement_text": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial ",
        "statement_nums": [
            "There was less than a 5% difference in the Percentage of Participants",
            "Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+ Subjects To estimate the clinical benefit rate (defined as complete response  partial response  or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD  Time frame: 24 weeks Results 1: Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 50 Measure Type: Number ",
            "Unit of Measure: participants 16Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants 15 "
        ],
        "premise_nums": [
            "daily to a total dose of 9 mg GTx-024: To determine whether either or both",
            "Benefit Rate  in Centrally Confirmed Androgen Receptor (AR)+",
            "SD  Time frame: 24 weeks Results 1: Arm/Group Title: GTx-024 9 mg Arm/Group Description: Drug: GTx-024 GTx-024",
            "16Results 2: Arm/Group Title: GTx-024 18 mg Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily",
            "clinical benefit rate  Overall Number of Participants Analyzed: 52 Measure Type: Number Unit of Measure: participants",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "or stable disease) according to RECIST 1.1, in subjects with estrogen"
        ]
    },
    {
        "id": "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 different types of infections ",
        "statement_nums": [
            "the primary trial records a total of 7 different types of infections"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) "
        ],
        "premise_nums": [
            "(0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123"
        ]
    },
    {
        "id": "d8e47fe7-be41-4f74-881b-a80cd3a1e95f",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "statement_text": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [
            "intervention sections of the primary trial and the secondary"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  INTERVENTION 2: All Study Participants: Technologist Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Technologist-Controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site  INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  ",
            "This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate) INTERVENTION 2: Full-Field Digital Mammography (FFDM) Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  "
        ],
        "premise_nums": [
            "Plus DBT: FujiFilm Aspire Cristalle System",
            "performance in non-cancer cases (recall rate) and in cancer cases"
        ]
    },
    {
        "id": "e77e15a3-d851-4174-80c3-7b5156e7f987",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "statement_text": "the primary trial and the secondary trial do not use any of the same drugs in their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial do not use any"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment Schedule (Weekly) Arm C  Docetaxel and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm D  Paclitaxel and Gemcitabine (Weekly): Paclitaxel: 80 mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 2: Treatment Schedule (3 Weekly) ",
            "Arm A  Docetaxel and Gemcitabine (3 Weekly):Docetaxel: 75 mg/m²  60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm B  Paclitaxel and Gemcitabine (3 Weekly): Paclitaxel: 175 mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) ",
            "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO gene expression analysis: Correlative studies "
        ],
        "premise_nums": [
            "Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles",
            "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole",
            "mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every",
            "mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine",
            "Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography:",
            "and Gemcitabine (Weekly): Paclitaxel: 80 mg/m²  IV infusion over approximately 1 hour  Days 1, 8,",
            "Gemcitabine (3 Weekly): Paclitaxel: 175 mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every",
            "1 only  to be given 30 min prior to Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to",
            "Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15, followed by Gemcitabine  repeated every",
            "and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be",
            "until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion over approximately 3 hours followed by Gemcitabine  repeated every",
            "and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion over approximately 3 hours followed by Gemcitabine  repeated every",
            "OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression",
            "until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "IV infusion on Days 1 and 8, repeated every 21 days for CRs or PRs; 6 cycles for SD; or until PD",
            "Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles",
            "prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles",
            "and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1 and 8, repeated every 21 days for",
            "8, and 15 to be given 30 minutes prior to Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion",
            "Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles",
            "1 only  to be given 30 min prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles",
            "8, and 15 to be given 30 minutes prior to Gemcitabine (3 Weekly): Paclitaxel: 175 mg/m²  IV infusion over approximately",
            "mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every",
            "until PD  Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for",
            "1 only  to be given 30 min prior to Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and",
            "Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs;",
            "until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for",
            "until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for"
        ]
    },
    {
        "id": "c003dd08-af3b-44cc-b31c-6fbdadfa1d83",
        "primaryId": "NCT01806259",
        "statement_text": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years ",
        "statement_nums": [
            "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg Arm/Group Description: Active drug to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 80 83.3% Results 2: Arm/Group Title: NaCl 0.9% 3mL Arm/Group Description: Ketorolac 30 mg IV Overall Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7%",
            "to be compared with placebo Ketorolac 30 mg IV Overall Number of Participants Analyzed: 96 Measure Type: Count of Participants Unit of",
            "2 years for the primary analysis + 3 additional years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg",
            "came first  assessed up to 5 years) Time frame: 5 years Results 1: Arm/Group Title: Ketorolac 30 mg",
            "2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization",
            "Number of Participants Analyzed: 107 Measure Type: Count of Participants Unit of Measure: Participants 96 89.7%",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "8ddf49c7-316e-4c7c-b2dd-423182a37612",
        "primaryId": "NCT00455533",
        "secondaryId": "NCT00767520",
        "statement_text": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death  in cohort 1 of the secondary trial ",
        "statement_nums": [
            "and unexpected death  in cohort 1 of the secondary trial and the primary trial there was only one"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) LEUKOCYTOSIS 1/145 (0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144 (0.00%) NEUTROPENIA 0/144 (0.00%) LEUKOCYTOSIS 0/144 (0.00%) THROMBOCYTOPENIA 0/144 (0.00%) FEBRILE NEUTROPENIA 1/144 (0.69%) ",
            "THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) ",
            "Diarrhoea 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) "
        ],
        "premise_nums": [
            "Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79",
            "Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76",
            "Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76 (1.32%) Dysphagia 0/76 (0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased",
            "(0.69%) THROMBOCYTOPENIA 1/145 (0.69%) FEBRILE NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145",
            "Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79",
            "Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79 (0.00%) Dysphagia 1/79 (1.27%)",
            "inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76",
            "ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%)",
            "Total: 17/145 (11.72%) ANAEMIA 0/145 (0.00%) LEUKOPENIA 2/145 (1.38%) NEUTROPENIA 1/145 (0.69%) THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION",
            "inflammation 0/76 (0.00%) Performance status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%)Vomiting 2/76 (2.63%) Abdominal pain 1/76 (1.32%) Colonic obstruction 1/76",
            "Sudden death 1/79 (1.27%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular dysfunction 0/76 (0.00%)",
            "PURPURA 0/145 (0.00%) DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2:",
            "THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1:",
            "(0.00%) Nausea 1/76 (1.32%) Mucosal inflammation 0/76 (0.00%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2:",
            "(1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2:",
            "Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 1: Total: 22/79 (27.85%) Anaemia 0/79 (0.00%) Right ventricular",
            "CARDIAC FAILURE 1/145 (0.69%) ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144",
            "Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Nausea 1/79 (1.27%) Mucosal inflammation 1/79 (1.27%) Performance status decreased",
            "1/144 (0.69%) CARDIAC FAILURE 0/144 (0.00%) ATRIAL FIBRILLATION 0/144 (0.00%) Adverse Events 2: Total: 13/76 (17.11%) Anaemia 1/76 (1.32%) Right ventricular",
            "status decreased 0/76 (0.00%) Sudden death 0/76 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79",
            "status decreased 1/79 (1.27%) Sudden death 1/79 (1.27%) Adverse Events 2: Total: 11/144 (7.64%) ANAEMIA 1/144 (0.69%) LEUKOPENIA 0/144",
            "Anaemia 0/79 (0.00%) Right ventricular dysfunction 1/79 (1.27%) Diarrhoea 1/79 (1.27%) Vomiting 2/79 (2.53%) Abdominal pain 0/79 (0.00%) Colonic obstruction 0/79"
        ]
    },
    {
        "id": "d9e41be5-1e37-4dff-b51a-166576f351d0",
        "primaryId": "NCT01498458",
        "statement_text": "For all adverse event types in the primary trial  at least one case was recorded ",
        "statement_nums": [
            "For all adverse event types in the primary trial  at least one case was recorded"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%)"
        ]
    },
    {
        "id": "ee2287bd-af76-4232-9575-d371fe3257dc",
        "primaryId": "NCT00544167",
        "statement_text": "Every adverse event in the primary trial occurred once ",
        "statement_nums": [
            "adverse event in the primary trial occurred once"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI 1/45 (2.22%) Pancreatitis 1/45 (2.22%) Infection - pneumonia 1/45 (2.22%) Infection - Streptococcus 1/45 (2.22%) Abcess of Bartholin's cyst 1/45 (2.22%) "
        ],
        "premise_nums": [
            "arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI",
            "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular"
        ]
    },
    {
        "id": "e5495b51-5f42-4e97-80ec-c215652bd3ab",
        "primaryId": "NCT00675259",
        "secondaryId": "NCT01875367",
        "statement_text": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial ",
        "statement_nums": [
            "with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion: HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: Breast cancer patients with tumors HER 2-negative. "
        ],
        "premise_nums": [
            "HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: Breast cancer patients with tumors HER 2-negative."
        ]
    },
    {
        "id": "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d",
        "primaryId": "NCT00612560",
        "statement_text": "children and illiterate adults are able to take part in the primary trial  unless they are can read and write in italian ",
        "statement_nums": [
            "take part in the primary trial  unless they are"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to read and write English "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 18 and 85 years Exclusion Criteria: Inability to"
        ]
    },
    {
        "id": "9ae51f9c-8544-4764-b731-e4efe9ae0ba6",
        "primaryId": "NCT00452673",
        "statement_text": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy  Time frame: Day 1 to 30 days post last dose Results 1: Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine ",
            "Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID  Participants were treated at each dose level (DL) for minimum of 21 days before accrual to the next DL  Rules for dose escalation: If 0 dose level toxicity (DLT) was observed in the first 3 participants in a cohort  the next higher cohort was opened to accrual  If 1 DLT was observed in the first 3 participants in a cohort  then 3 additional participants were studied  If 0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)  the next higher cohort was opened for accrual  If greater than or equal 2 DLT was observed in up to 6 subjects  then the maximum tolerated dose (MTD) was exceeded and the next lower DL was defined as the MTD  If 0 DLT was observed in 6 participants in a cohort and the next higher DL exceeded the MTD  then intermediate DLs would be studied  Once the MTD was determined  additional participants were enrolled into that dose group Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: participants 1 "
        ],
        "premise_nums": [
            "a cohort  then 3 additional participants were studied  If 0 DLT was observed in 6 participants in a cohort and",
            "(DLT) was observed in the first 3 participants in a cohort  then 3 additional participants were studied  If 0",
            "Time frame: Day 1 to 30 days post last dose Results 1: Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine",
            "of study drug through at least 30 days after the last dose level (DL) for minimum of 21 days before accrual to the",
            "were studied  If 0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)",
            "0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)  the next",
            "Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily",
            "dose level (DL) for minimum of 21 days before accrual to the next DL",
            "study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which",
            "Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral",
            "If 0 DLT was observed in 6 participants in a cohort and the next",
            "if it occurred in the first 21 days and was at least possibly related",
            "of study drug through at least 30 days after the last dose  until resolution of",
            "3, or of Grade 2 which required interruption of treatment for greater than or equal 2 DLT was observed in up to 6",
            "into that dose group Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: participants",
            "If greater than or equal 2 DLT was observed in up to 6 subjects  then the maximum",
            "3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which",
            "3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory"
        ]
    },
    {
        "id": "5b1915da-1819-4504-81bd-3f44a83b5e95",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial recorded three times as",
            "many cases of Leukopenia as cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%)"
        ]
    },
    {
        "id": "edb1e4c0-7669-4b8c-878b-ea8ca060c350",
        "primaryId": "NCT00074152",
        "statement_text": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "statement_nums": [
            "Only 2 of the adverse event cases in the primary trial occurred in patients from"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%) ",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) "
        ],
        "premise_nums": [
            "(0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%)",
            "mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Adverse Events 1: Total: 0/77 (0.00%) Neutropenia [1]0/77 (0.00%) Left ventricular dysfunction 0/77 (0.00%) Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77",
            "ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "(0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2: Total: 12/85 (14.12%) Neutropenia [1]1/85",
            "Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Colitis 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Neutropenia [1]1/85 (1.18%) Left ventricular dysfunction 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis 1/85 (1.18%)",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "neuropathy 1/85 (1.18%) Endometrial mucosa thinkening 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Endometrial mucosa thinkening",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Febrile neutropenia 3/85 (3.53%)",
            "Pulmonary/upper respiratory infection 1/85 (1.18%)Diverticulitis 1/85 (1.18%) Motor neuropathy 1/85 (1.18%) Cardiac ischemia 2/85 (2.35%) Gastrointestinal pain 1/85 (1.18%) Colitis",
            "neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection 0/77 (0.00%) Diverticulitis 0/77 (0.00%) Motor neuropathy 0/77 (0.00%) Endometrial mucosa thinkening",
            "Cardiac ischemia 0/77 (0.00%) Gastrointestinal pain 0/77 (0.00%) Colitis 0/77 (0.00%) Febrile neutropenia 0/77 (0.00%) Pulmonary/upper respiratory infection"
        ]
    },
    {
        "id": "915939cf-7813-43e7-b503-e14a7eb4e568",
        "primaryId": "NCT00429299",
        "statement_text": "Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2.",
        "statement_nums": [
            "one cohort in the primary trial is administered trastuzumab 600 mg/m^2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: CT Plus Trastuzumab Participants received chemotherapy (CT)  which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks  followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration  The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first paclitaxel course  Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2: CT Plus Lapatinib 1500 mg ",
            "Participants received CT  which included paclitaxel 80 mg/m^2 weekly for 12 weeks  followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration  Treatments were administered for 26 weeks prior to surgery Following Independent Data Monitoring Committee (IDMC) recommendations  lapatinib doses were reduced to 1250 mg/day orally on an empty stomach  "
        ],
        "premise_nums": [
            "two weeks after the last CT administration  The first dose of trastuzumab was administered",
            "weeks  followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days",
            "three weeks after the last CT administration  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2:",
            "lapatinib doses were reduced to 1250 mg/day orally on an empty stomach",
            "chemotherapy (CT)  which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks  followed by intravenous",
            "IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses",
            "were given weekly at 2 mg/kg IV for 30 minutes  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2:",
            "CT administration  The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60",
            "600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants",
            "dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first",
            "IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty",
            "600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty stomach throughout"
        ]
    },
    {
        "id": "126c1169-b375-4f89-95b2-52e971d19565",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious ",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded no deaths and"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) "
        ],
        "premise_nums": [
            "Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%)",
            "2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%)",
            "Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%)",
            "(1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal",
            "(1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal",
            "Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96"
        ]
    },
    {
        "id": "11235250-3627-427e-aae9-099507484456",
        "primaryId": "NCT00284180",
        "statement_text": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues ",
        "statement_nums": [
            "Across all three cohorts of the primary trial a total of two"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11 (9.09%) Vomiting 0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus [1]0/21 (0.00%) Nausea 1/21 (4.76%) Ileus 0/21 (0.00%) Dehydration 1/21 (4.76%) Vomiting 1/21 (4.76%) Pain NOS [2]0/21 (0.00%) Pain - abdomen 1/21 (4.76%) ",
            "Fracture [3]1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%) "
        ],
        "premise_nums": [
            "(0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11",
            "Fracture [3]1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%)",
            "(0.00%) Fracture [3]0/11 (0.00%) Progressive Disease 1/11 (9.09%) CNS Ischemia 1/11 (9.09%) Respiratory Failure 0/11 (0.00%) Hypoxia 1/11 (9.09%)",
            "Adverse Events 1: Total: 5/11 (45.45%) Diabetes insipidus [1]1/11 (9.09%) Nausea 0/11 (0.00%) Ileus 1/11 (9.09%) Dehydration 1/11",
            "0/11 (0.00%) Pain NOS [2]2/11 (18.18%) Pain - abdomen 0/11 (0.00%) Hypoxia 1/11 (9.09%) Adverse Events 2: Total: 8/21 (38.10%) Diabetes insipidus",
            "CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21 (4.76%) Hypoxia 1/21 (4.76%)Progressive Disease 1/21 (4.76%) CNS Ischemia 1/21 (4.76%) Respiratory Failure 1/21"
        ]
    },
    {
        "id": "8a9f2247-7c51-44be-910b-5091d9abb2ea",
        "primaryId": "NCT00236899",
        "secondaryId": "NCT01153672",
        "statement_text": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts  but only the secondary trial utilises positron emission tomography ",
        "statement_nums": [
            "the primary trial and the secondary trial both administer Paclitaxel and"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment Schedule (Weekly) Arm C  Docetaxel and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm D  Paclitaxel and Gemcitabine (Weekly): Paclitaxel: 80 mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  ",
            "Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD INTERVENTION 2: Treatment Schedule (3 Weekly) Arm A  Docetaxel and Gemcitabine (3 Weekly): Docetaxel: 75 mg/m²  60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  Arm B  Paclitaxel and Gemcitabine (3 Weekly): ",
            "Paclitaxel: 175 mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD  INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity  vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO ",
            "exemestane: Given POgene expression analysis: Correlative studies "
        ],
        "premise_nums": [
            "Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine:",
            "60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine  repeated every",
            "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole",
            "21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD INTERVENTION",
            "mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15, followed by Gemcitabine  repeated every",
            "mg/m²  IV infusion over approximately 1 hour  Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine",
            "Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography:",
            "or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1, 8, and 15 repeated every",
            "Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or",
            "1 only  to be given 30 min prior to Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine:",
            "Days 1, 8, and 15, followed by Gemcitabine  repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles",
            "for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles",
            "and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 to be",
            "OR exemestane PO QD for 6 weeks  Courses repeat every 28 days for 10 cycles for CRs or PRs; 6 cycles",
            "Paclitaxel: 175 mg/m²  IV infusion over approximately 1 hour  Days 1, 8,",
            "IV infusion on Days 1 and 8, repeated every 21 days for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine:",
            "and Gemcitabine (Weekly): Docetaxel: 30 mg/m²  30-60 min IV infusion over approximately 3 hours followed by Gemcitabine  repeated every",
            "OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression",
            "or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for",
            "Docetaxel: 75 mg/m²  60 min IV infusion on Day 1 only  to be given 30 min prior to Gemcitabine",
            "to be given 30 min prior to Gemcitabine  repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles",
            "Gemcitabine (3 Weekly): Docetaxel: 75 mg/m²  60 min IV infusion on Days 1 and 8, repeated every 21 days for",
            "Docetaxel: 30 mg/m²  30-60 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for",
            "8, and 15 to be given 30 minutes prior to Gemcitabine (3 Weekly): Docetaxel: 75 mg/m²  60 min IV infusion",
            "for CRs or PRs; 6 cycles for SD; or until PD INTERVENTION 2: Treatment Schedule (3 Weekly) Arm",
            "15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles",
            "for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion",
            "8, and 15 to be given 30 minutes prior to Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8,",
            "for CRs or PRs; 6 cycles for SD; or until PD  Gemcitabine: 800 mg/m²  30 min IV infusion",
            "and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine:",
            "Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine  repeated every 28 days (weekly) for 10 cycles",
            "Gemcitabine: 800 mg/m²  30 min IV infusion on Days 1, 8, and 15, followed by Gemcitabine  repeated every",
            "Days 1, 8, and 15, followed by Gemcitabine  repeated every 21 days (tri-weekly) for 10 cycles",
            "for CRs or PRs; 6 cycles for SD; or until PD Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and",
            "30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles",
            "mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine  repeated every 28 days (weekly) for 10 cycles for CRs",
            "until PD  Gemcitabine: 800 mg/m²  30 min IV infusion over approximately 3 hours followed by Gemcitabine  repeated every",
            "mg/m²  IV infusion over approximately 3 hours followed by Gemcitabine: 1250 mg/m²  30 min IV infusion on Days 1 and",
            "30-60 min IV infusion on Days 1, 8, and 15 to be given 30 min prior to Gemcitabine  repeated every",
            "IV infusion on Days 1 and 8, repeated every 21 days for SD; or until PD INTERVENTION 2: Treatment Schedule (3 Weekly) Arm",
            "until PD  Gemcitabine: 1000 mg/m²  30 min IV infusion on Days 1 and 8, repeated every 21 days for"
        ]
    },
    {
        "id": "7e283897-4d9e-4353-8331-00f8db16cc7e",
        "primaryId": "NCT00038467",
        "statement_text": "The patient groups in the primary trial each receive different oral medication  either Tamoxifen or Exemestane ",
        "statement_nums": [
            "patient groups in the primary trial each receive different oral"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  "
        ],
        "premise_nums": [
            "who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally",
            "received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants",
            "3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per"
        ]
    },
    {
        "id": "54b15068-023b-4e60-bb82-2a22512fda62",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "statement_text": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [
            "be eligible for the secondary trial",
            "are excluded from the primary trial but may still be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "No prior or currently active autoimmune disease* requiring management with systemic immunosuppression  including any of the following: Systemic lupus erythematosus Inclusion Criteria: Written informed consent and ability to follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC); Metastatic BC (stage IV according to TNM classification version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ; Documented results of oestrogen and progesterone receptors expression analysis; Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy - 20 weeks or more from the moment of randomization; Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone metastasis as the only measurable tumour are not eligible for the trial; ",
            "Patients of childbearing potential must implement reliable contraceptive measures during the study treatment  starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug Exclusion Criteria: Previous anticancer therapy for metastatic BC  including cytotoxic chemotherapy  or previous anticancer therapy with signal transduction inhibitors (e.g  lapatinib)  biological drugs (e.g  trastuzumab  bevacizumab)  experimental (not approved for BC therapy) anticancer drugs  Any previous hormonal therapy is allowed; Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy; Surgery  radiation therapy  use of any experimental medications within 4 weeks (28 days) prior to randomization; Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil  hypersensitivity to dexamethasone  diphenhydramine  ranitidine/cimetidine  recombinant murine proteins  contrast agents or excipients of study medications; ",
            "BC metastases in central nervous system  progressing or clinically manifested (e.g  cerebral oedema  spinal cord injury)  with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification  unstable angina pectoris  myocardial infarction) within 12 months prior to randomization; Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet  physical exercise); Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper limit of normal (ULN); Bilirubin level 1.5 × ULN; ",
            "Asparagine transferase (AST) and alanine transferase (ALT) levels 2.5 × ULN (5 × ULN for patients with liver metastases);Alkaline phosphatase level 5 × ULN; Pregnancy or lactation; Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening  except curatively treated intraductal carcinoma in situ  curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; Conditions limiting patient's adherence to protocol requirements (dementia  neurologic or psychiatric disorders  drug addiction  alcoholism and others); Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; Concomitant participation in other clinical trials  previous participation in other clinical trials within 30 days before entering into the trial  previous participation in the same trial; Acute or active chronic infections; Hepatitis C virus  hepatitis B virus  HIV or syphilis infections; Obstacles in intravenous administration of study drugs "
        ],
        "premise_nums": [
            "treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;Cardiovascular system pathology (congestive",
            "patients with liver metastases);Alkaline phosphatase level 5 × ULN; Pregnancy or lactation;",
            "including contralateral breast cancer revealed within 5 years prior to screening  except curatively",
            "participation in other clinical trials within 30 days before entering into the trial",
            "ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper",
            "by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in",
            "myocardial infarction) within 12 months prior to randomization; Uncontrolled hypertension comprising",
            "size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone",
            "previous hormonal therapy is allowed; Disease progression within 6 months after adjuvant and/or neoadjuvant",
            "000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper limit of normal (ULN); Bilirubin level 1.5 × ULN;",
            "use of any experimental medications within 4 weeks (28 days) prior to randomization; Hypersensitivity",
            "Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy -",
            "follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC);",
            "despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental",
            "1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy - 20 weeks or more from the moment of",
            "version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed",
            "Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5",
            "other clinical trials within 30 days before entering into the trial and until 6 months after the last administration of the"
        ]
    },
    {
        "id": "78764961-52be-4235-a2b7-e581497d0099",
        "primaryId": "NCT00900627",
        "statement_text": "The two groups in the primary trial receive the same drug treatment  but different doses ",
        "statement_nums": [
            "two groups in the primary trial receive the same drug"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle "
        ],
        "premise_nums": [
            "mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each",
            "weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part",
            "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8",
            "160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931"
        ]
    },
    {
        "id": "e09fe98c-ec5c-49cf-9f49-92ba8824e82e",
        "primaryId": "NCT03708393",
        "secondaryId": "NCT03456427",
        "statement_text": "The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment ",
        "statement_nums": [
            "The interventions in the primary trial and the secondary trial require active participation from"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  "
        ],
        "premise_nums": [
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted"
        ]
    },
    {
        "id": "a83d98c9-e3da-4449-878b-5fa2f3bee8cf",
        "primaryId": "NCT01277757",
        "statement_text": "the primary trial is not testing a novel Physiotherapy or radiotherapy intervention ",
        "statement_nums": [
            "the primary trial is not testing a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28 days  "
        ],
        "premise_nums": [
            "orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28",
            "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting"
        ]
    },
    {
        "id": "f559cacb-30e7-47cf-9ac6-5929c1a508f7",
        "primaryId": "NCT00493649",
        "secondaryId": "NCT01201265",
        "statement_text": "There were no MRSA infections in either the secondary trial or the primary trial ",
        "statement_nums": [
            "infections in either the secondary trial or the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) DEHYDRATION 5/486 (1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal Pain Lower 1/40 (2.50%) ",
            "Disease Progression 6/40 (15.00%)Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) "
        ],
        "premise_nums": [
            "Disease Progression 6/40 (15.00%)Fatigue 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%)",
            "NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40 (12.50%) Pericardial Effusion 1/40 (2.50%) Abdominal",
            "(0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486",
            "FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) BOWEL PERFORATION 1/486 (0.21%) COLITIS 1/486 (0.21%)",
            "(1.03%) DIARRHEA 5/486 (1.03%) GASTRIC INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1:",
            "Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40 (2.50%) Pyrexia 3/40 (7.50%) Septic Shock 1/40 (2.50%) Streptococcal Infection 1/40",
            "NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) Adverse Events 1: Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486",
            "Adverse Events 1: Total: 17/40 (42.50%) Anaemia 2/40 (5.00%) Febrile Neutropenia 3/40 (7.50%) Neutropenia 2/40 (5.00%) Thrombocytopenia 5/40",
            "INFLAMMATION 1/486 (0.21%) NAUSEA 3/486 (0.62%) NAUSEA AND VOMITING 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486",
            "FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486",
            "Total: 51/486 (10.49%) ANEMIA 1/486 (0.21%) NEUTROPENIA 4/486 (0.82%) FIBRILLATION ATRIAL 1/486 (0.21%) ABDOMINAL PAIN 2/486 (0.41%) BLOATING 1/486 (0.21%)"
        ]
    },
    {
        "id": "79362f6d-ef2c-4b93-8719-be361d0b5acc",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and",
            "not eligible for the primary trial  but may be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male "
        ],
        "premise_nums": [
            "Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability"
        ]
    },
    {
        "id": "54918996-1b4d-48bd-a0ca-13d8e259767b",
        "primaryId": "NCT02650193",
        "secondaryId": "NCT00656669",
        "statement_text": "Patients with Class III obesity cannot be included in the primary trial  but can be entered into the secondary trial  even if they have uncontrolled Hypertension ",
        "statement_nums": [
            "be included in the primary trial  but can be",
            "be entered into the secondary trial  even if they"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Body mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or III disease  Measurable disease by physical examinations or diagnostic breast imaging (mammography  ultrasonography or MR)  Pre-treatment core or incisional biopsy  Patients may not have had definitive primary surgery  Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined in the protocol  Exclusion Criteria: Prior radiation therapy  cytotoxic therapy or systemic therapy for breast cancer  Prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry  Metastatic (Stage IV) breast cancer Patients who have had only a pre-treatment fine needle aspiration (FNA) are excluded  Current therapeutic treatment on another clinical trial with an investigational agent  ",
            "Any of the following within the 6 months prior to starting study treatment: -myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolusOngoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal 2, atrial fibrillation of any grade  or QTc interval greater than 450 msec for males or greater than 470 msec for females  Hypertension that cannot be controlled by medications  Current treatment with therapeutic doses of any anti-coagulant  Prophylactic use of anticoagulants is allowed  Known human immunodeficiency virus (HIV) infection  Pregnancy or breastfeeding  All female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication  Other severe acute or chronic medical or psychiatric condition  or laboratory abnormality that would impart  in the judgment of the investigator  excess risk associated with study participation or study drug administration  or which  in the judgment of the investigator  would make the patient inappropriate for entry into this study  "
        ],
        "premise_nums": [
            "breast with operable or inoperable stage 1c (primary tumor greater than 1.0 cm)  II or",
            "Male or female  18 years of age or older  ECOG performance status 0 or 1. Adequate organ function as defined",
            "or QTc interval greater than 450 msec for males or greater than 470 msec for females  Hypertension that cannot",
            "pregnancy test prior to first day of study medication",
            "Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor greater than 1.0",
            "(BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria: Patients must have histologically-confirmed adenocarcinoma of the breast",
            "mass index (BMI) of 19 to 40 kg/m^2   inclusive Inclusion Criteria:",
            "CTCAE grade greater than or equal 2, atrial fibrillation of any grade",
            "Any of the following within the 6 months prior to starting study treatment: -myocardial",
            "use of anticoagulants is allowed  Known human immunodeficiency"
        ]
    },
    {
        "id": "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5",
        "primaryId": "NCT00679341",
        "secondaryId": "NCT00201851",
        "statement_text": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events ",
        "statement_nums": [
            "Patients in the secondary trial and those in the primary trial did not share any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) ",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) "
        ],
        "premise_nums": [
            "1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%)",
            "Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69 (0.00%) Vomiting 1/69 (1.45%) Chills 1/69 (1.45%) Oedema peripheral 0/69 (0.00%) Pyrexia 1/69 (1.45%)",
            "(0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia",
            "Intestinal obstruction 1/66 (1.52%)Vomiting 0/66 (0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%)",
            "Adverse Events 1: Total: 14/69 (20.29%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary",
            "0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69 (1.45%) Intestinal obstruction 0/69",
            "(0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69",
            "2: Total: 17/66 (25.76%) Febrile neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244",
            "neutropenia 6/66 (9.09%) Anaemia 1/66 (1.52%) Atrial fibrillation 1/66 (1.52%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69 (1.45%) Abdominal pain 1/69",
            "14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular extrasystoles 1/69",
            "(0.00%) Chills 0/66 (0.00%) Oedema peripheral 1/66 (1.52%) Pyrexia 0/66 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69",
            "1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Pyrexia 1/69 (1.45%) Adverse Events 2: Total: 17/66 (25.76%) Febrile neutropenia",
            "1/66 (1.52%) Supraventricular extrasystoles 0/66 (0.00%) Abdominal pain 0/66 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69",
            "1: Total: 14/69 (20.29%) Febrile neutropenia 0/69 (0.00%) Anaemia 0/69 (0.00%) Atrial fibrillation 1/69 (1.45%) Cardiopulmonary failure 0/69 (0.00%) Supraventricular",
            "(1.52%) Pyrexia 0/66 (0.00%) Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer"
        ]
    },
    {
        "id": "52c8361f-75dc-45f1-a35c-79180a22b931",
        "primaryId": "NCT02015676",
        "statement_text": "There are no recorded cases of thrombocytopenia in the primary trial ",
        "statement_nums": [
            "of thrombocytopenia in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%) Acute febrile neutrophilic dermatosis * 1/69 (1.45%) Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69 (1.45%) Intestinal obstruction NOS * 1/69 (1.45%) Diarrhoea NOS * 2/69 (2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69 (1.45%) "
        ],
        "premise_nums": [
            "(2.90%) Febrile neutropenia * 12/69 (17.39%) Mucosal inflammation NOS * 1/69",
            "Cardiac failure NOS * 2/69 (2.90%) Ejection fraction decreased * 1/69",
            "Adverse Events 1: Total: 26/69 (37.68%) Thrombophlebitis * 1/69 (1.45%) Anaemia NOS * 1/69 (1.45%)"
        ]
    },
    {
        "id": "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year  however several patients in arm B survived longer than a year ",
        "statement_nums": [
            "control group of the primary trial had a median Overall Survival of less than a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Survival The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up  For patients who have not died  survival duration will be censored at the date of last contact or last follow-up or the date of last news  Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country  Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months 9.3 (7.5 to 10.9) "
        ],
        "premise_nums": [
            "Outcome Measurement: Overall Survival The main endpoint of",
            "date of death or last follow-up  For patients who",
            "Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group",
            "Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months"
        ]
    },
    {
        "id": "db8ffa86-bf52-47bb-89f7-42e7ae47b84d",
        "primaryId": "NCT01271725",
        "statement_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group ",
        "statement_nums": [
            "In the primary trial The Percentage of Participants",
            "(OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 Objective response according to RECIST v1.1. Best overall response of confirmed complete response (CR) or confirmed partial response (PR) recorded since first administration of trial medication and until the earliest of disease progression  death or start of next treatment in each part separately  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR  Percentage of participants with OR along with exact 95% Confidence Interval by Clopper and Pearson is presented  Time frame: From the initial dose of study drug until 28 days after end of the treatment period  up to 1562 days Results 1: Arm/Group Title: Afatinib Monotherapy ",
            "Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated Overall Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage of participants 18 (10 to 28) Results 2: Arm/Group Title: Afatinib and Paclitaxel or Vinorelbine Combination Therapy Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: Percentage of participants 31 (17 to 48) "
        ],
        "premise_nums": [
            "of study drug until 28 days after end of the treatment period  up to 1562 days Results 1: Arm/Group Title: Afatinib Monotherapy",
            "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of",
            "Patients could have dose reduced if 40 mg was not tolerated Overall Number of",
            "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of",
            "have dose reduced if 40 mg was not tolerated Overall Number of study drug until 28 days after end of the treatment period",
            "Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage of participants 31 (17 to 48)",
            "have dose reduced if 40 mg was not tolerated Overall Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage",
            "participants with OR along with exact 95% Confidence Interval by Clopper and Pearson",
            "initial dose of study drug until 28 days after end of the treatment period",
            "Solid Tumours Version (RECIST) 1.1 Objective response according to RECIST v1.1. Best overall response of confirmed complete response",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once daily at a dose of 40 milligram (mg) film-coated tablets until",
            "participants 18 (10 to 28) Results 2: Arm/Group Title: Afatinib and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or"
        ]
    },
    {
        "id": "5a01d00f-8601-4c17-b814-be87e63b0d8a",
        "primaryId": "NCT02392611",
        "statement_text": "the primary trial cohorts are not seperated based on patient characteristics ",
        "statement_nums": [
            "the primary trial cohorts are not seperated"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  "
        ],
        "premise_nums": [
            "tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the",
            "orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD",
            "alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and"
        ]
    },
    {
        "id": "3b0440e6-cf85-4236-8a1d-2e3572143946",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events ",
        "statement_nums": [
            "Patients in the primary trial experienced a only one"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/50 (20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction 1/48 (2.08%) Tachycardia 1/48 (2.08%) ",
            "Intestinal obstruction 0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48 (2.08%) "
        ],
        "premise_nums": [
            "(20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "(0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "(0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "Intestinal obstruction 0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48",
            "(0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48",
            "(0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48",
            "(0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction"
        ]
    },
    {
        "id": "6f342205-ef33-482a-b74a-74644537538b",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "Patients must be older than 18, female  have one or more",
            "more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  "
        ],
        "premise_nums": [
            "Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2"
        ]
    },
    {
        "id": "5b63fffb-0a75-414f-8744-5fea78395f28",
        "primaryId": "NCT00950742",
        "statement_text": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 1: Arm/Group Title: Afatinib 20mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  This group includes patients from the dose-escalation cohort and from the expansion cohort  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Participants 4 "
        ],
        "premise_nums": [
            "with DLT in the first cycle (28 days) for the",
            "received continuous daily dosing with Afatinib 20mg film-coated tablets and once",
            "section  Time frame: 28 days Results 1: Arm/Group Title: Afatinib 20mg +",
            "the expansion cohort  Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Participants"
        ]
    },
    {
        "id": "9e655973-7d1d-4528-8394-a9cbcf0b978f",
        "primaryId": "NCT02279108",
        "secondaryId": "NCT00943670",
        "statement_text": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had",
            "excluded from both the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically proved infiltrating breast cancer (ductal  lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion  (High grade with necrosis  radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal or multifocal but in same quarter Size smaller than 5cm clinically palpable or not Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed informed consent by patient or legally responsable authority Patient registered to a social security system No surgical contra-indication Exclusion Criteria: Mammary carcinoma recurrence Previous same side mammary reduction Previous lumpectomy Contra-indication to surgery Pregnant or breast feeding patient Denial of participation Inclusion Criteria: Histologically documented  locally advanced  or metastatic breast cancer; measurable and/or non-measureable but evaluable disease is permitted HER2-positive disease History of prior trastuzumab therapy Life expectancy 90 days as assessed by the investigator ",
            "Negative urine pregnancy test 72 hours prior to Cycle 1 Day 1 for all women of childbearing potentialFor patients of childbearing potential  agreement to use one highly effective form of contraception or two effective forms of contraception for the duration of the study treatment(s) and for 4 months after the last dose of T-DM1 or 6 months after the last dose of pertuzumab  if applicable Exclusion Criteria: Any chemotherapy  hormonal therapy  radiotherapy  immunotherapy  or biologic therapy for the treatment of breast cancer within 2 weeks of the first study treatment Prior T-DM1 or pertuzumab therapy History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to trastuzumab Grade 2 (based on National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v3) peripheral neuropathy at the time of or within 3 weeks prior to the first study treatment ",
            "Brain metastases that are untreated or progressive or have required any type of therapy  including radiation  surgery  and/or steroids  to control symptoms from brain metastases within 60 days prior to the first study treatmentHistory of cardiac disease  unstable angina  symptomatic congestive heart failure (CHF) (Class II per the New York Heart Associate [NYHA] guidelines)  myocardial infarction  or ventricular arrhythmia 6 months prior to Cycle 1, Day 1 Implantable pacemaker or automatic implantable cardioverter defibrillator Congenital long QT syndrome or family history of long QT syndrome Current uncontrolled hypertension Current treatment with medications that alter cardiac conduction (e.g.  digitalis  beta-blockers  or calcium channel blockers) or medications that are generally accepted to have a risk of causing torsades de pointes (TdP) Current known active infection with human immunodeficiency virus (HIV)  hepatitis B virus  or hepatitis C virus ",
            "Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment  or anticipation of the need for major surgery during the course of study treatment"
        ],
        "premise_nums": [
            "myocardial infarction  or ventricular arrhythmia 6 months prior to Cycle 1, Day 1 Implantable pacemaker or automatic implantable cardioverter defibrillator",
            "radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal",
            "control symptoms from brain metastases within 60 days prior to the first study treatmentHistory of cardiac disease",
            "of breast cancer within 2 weeks of the first study treatment Prior medications that are generally accepted to have a",
            "in same quarter Size smaller than 5cm clinically palpable or not",
            "first study treatment Prior T-DM1 or pertuzumab therapy History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to",
            "Negative urine pregnancy test 72 hours prior to Cycle 1 Day 1 for all women of childbearing potentialFor patients",
            "trastuzumab therapy Life expectancy 90 days as assessed by the investigator ventricular arrhythmia 6 months prior to Cycle 1, Day 1",
            "the treatment of breast cancer within 2 weeks of the first study treatment(s) and for 4 months after the last dose of T-DM1",
            "Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed",
            "evaluable disease is permitted HER2-positive disease History of prior trastuzumab therapy Life expectancy 90 days as assessed by the investigator",
            "from brain metastases within 60 days prior to the first study treatmentHistory of intolerance (such as Grade 3-4 infusion reaction) and/or adverse",
            "History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to trastuzumab Grade 2 (based on National Cancer Institute"
        ]
    },
    {
        "id": "ea62355f-aab9-4796-8658-746c0b669ca7",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "statement_text": "There is no placebo or control group in the primary trial  in the secondary trial  Suramin acts as placebo ",
        "statement_nums": [
            "control group in the primary trial  in the secondary trial  Suramin acts as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects  Exemestane: exemestane 25 mg by mouth (PO) every day for two years Calcium carbonate: calcium carbonate 1200 mg PO every day x 2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  "
        ],
        "premise_nums": [
            "2 years Vitamin D: Vitamin D 400 international units PO every day and vitamin D 400 IU PO every day Initially",
            "PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after",
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for",
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will",
            "2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will",
            "completion of the suramin infusion the 1 hour infusion of paclitaxel will begin"
        ]
    },
    {
        "id": "55eaae8d-611c-4dbb-b162-de664902e059",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "statement_nums": [
            "cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
            "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Small Intestinal Obstruction 1/31 (3.23%) Adverse Events 2: Small Intestinal Obstruction 0/31 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Small Intestinal Obstruction 1/31 (3.23%) Adverse Events 2: Small Intestinal Obstruction 0/31 (0.00%)"
        ]
    },
    {
        "id": "c3438bb2-4a49-4f14-ae50-a46fb48d0208",
        "primaryId": "NCT00485953",
        "secondaryId": "NCT00068601",
        "statement_text": "the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified ",
        "statement_nums": [
            "cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously "
        ],
        "premise_nums": [
            "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication",
            "Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing",
            "Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before"
        ]
    },
    {
        "id": "8f505cec-6ad4-4142-a861-1771e3ae5cdd",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle ",
        "statement_nums": [
            "on days for a total of 13 days every 28 day cycle",
            "the primary trial participants apply topical imiquimod"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies "
        ],
        "premise_nums": [
            "to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in",
            "Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions",
            "toxicity  imiquimod: Given topically Abraxane: Given IV laboratory",
            "on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of"
        ]
    },
    {
        "id": "8f4f9793-041d-448b-9da8-b0c787a875bb",
        "primaryId": "NCT00478257",
        "statement_text": "Adequate Hematologic  Hepatic and renal function is not necessary for participating in the primary trial ",
        "statement_nums": [
            "for participating in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - "
        ],
        "premise_nums": [
            "anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast"
        ]
    },
    {
        "id": "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1",
        "primaryId": "NCT01735175",
        "secondaryId": "NCT01216319",
        "statement_text": "the secondary trial is testing a surgical intervention  unlike the primary trial ",
        "statement_nums": [
            "the secondary trial is testing a surgical",
            "intervention  unlike the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive LA-EP2006 s.c  post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 2: Neulasta® During each chemotherapy cycle eligible patients receive Neulasta® s.c  post chemotherapy application  Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks  During each chemotherapy cycle pegfilgrastim is injected s.c  post chemotherapy application  INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder "
        ],
        "premise_nums": [
            "INTERVENTION 1: LA-EP2006 During each chemotherapy cycle eligible patients receive",
            "application  INTERVENTION 2: Neulasta® During each chemotherapy cycle",
            "post chemotherapy application  LA-EP2006: Eligible patients are scheduled to receive"
        ]
    },
    {
        "id": "61d56c2a-089f-4fa3-9e97-3a9007576077",
        "primaryId": "NCT00376597",
        "statement_text": "the primary trial do not receive any intervention by IV  orally or by surgery during the study ",
        "statement_nums": [
            "intervention by IV  orally or by surgery during",
            "the primary trial do not receive any"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Lymphedema Education) Six weeks after surgery  patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials  Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm II (Lymphedema Education  Physical Therapy) Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I  Patients also complete a personalized physical therapy intervention  receive a refrigerator magnet  and a 15-minute video that reinforces information and exercises  "
        ],
        "premise_nums": [
            "are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm",
            "complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are",
            "a refrigerator magnet  and a 15-minute video that reinforces information and exercises"
        ]
    },
    {
        "id": "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41",
        "primaryId": "NCT00411788",
        "statement_text": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks  until today  she will not be eligible for the primary trial for the next month ",
        "statement_nums": [
            "ketoconazole to treat athlete's foot for 6 weeks  until today",
            "be eligible for the primary trial for the next month"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Use of any of these medications within 4 weeks; cyclosporine  diltiazen  ketoconazole  rifampin  fluconazole  delavirdine  nicardipine  pioglitazone  and sulfonamides  erythromycin  clarithromycin  itraconazole  erythromycin  metoclopramide  nevirapine  phenobarbital  phenytoin  indinavir  fosamprenavir  nefazadone  St Johns Wort  "
        ],
        "premise_nums": [
            "of any of these medications within 4 weeks; cyclosporine  diltiazen"
        ]
    },
    {
        "id": "bad4d3e7-a05a-44fd-937a-c94a23655c03",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "Cohort 2 patients in the primary trial receive naproxen at the",
            "same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  "
        ],
        "premise_nums": [
            "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks",
            "a day (BID) for 5 days in each of the 4 cycles  beginning on the",
            "pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles",
            "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant"
        ]
    },
    {
        "id": "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "statement_text": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial ",
        "statement_nums": [
            "of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) ",
            "Small Intestinal Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) "
        ],
        "premise_nums": [
            "Small Intestinal Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)",
            "embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41",
            "1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1:",
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41",
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41",
            "Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%)",
            "Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1:",
            "27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion",
            "Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)"
        ]
    },
    {
        "id": "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "statement_text": "Prior exposure to exemestane is not allowed for patients in the secondary trial  however  the primary trial may accept patients despite this ",
        "statement_nums": [
            "to exemestane is not allowed for patients in the secondary trial  however  the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; No contraindications for primary chemotherapy; Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; ",
            "If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation;Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy; Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  Exclusion Criteria: Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa)  or any agent known to inhibit FGFRs  "
        ],
        "premise_nums": [
            "Inclusion Criteria Pathologically confirmed diagnosis of invasive",
            "normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional",
            "be a candidate for primary systemic (neoadjuvant) therapy and for",
            "study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy",
            "of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II);",
            "neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or",
            "been disease free for less than 5 years  Exclusion Criteria: Prior",
            "one year  OR surgically sterile  OR not",
            "function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits;"
        ]
    },
    {
        "id": "a29e6a86-65f3-4565-93e2-81f49fa837e4",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or depression ",
        "statement_nums": [
            "Unlike the secondary trial  the primary trial does not record any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ * 1/35 (2.86%) Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%) Vomiting 1/41 (2.44%) Pain 3/41 (7.32%) Allergic reaction 1/41 (2.44%) Infections and infestations - Other  specify: [1]1/41 (2.44%) Vascular access complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%) "
        ],
        "premise_nums": [
            "specify: [1]1/41 (2.44%) Vascular access complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%)",
            "Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%)",
            "complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%)",
            "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ *"
        ]
    },
    {
        "id": "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049",
        "primaryId": "NCT00418457",
        "statement_text": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphine Other cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality "
        ],
        "premise_nums": [
            "by the attending surgeon to present 25% two-year mortality",
            "believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy",
            "dissection (anticipated removal of at least five nodes) Written informed consent",
            "18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia"
        ]
    },
    {
        "id": "34bb7f09-3b2b-464f-96df-c8d80b1206fc",
        "primaryId": "NCT03190083",
        "secondaryId": "NCT01805089",
        "statement_text": "All cancer stages are accepted for the primary trial and the secondary trial ",
        "statement_nums": [
            "are accepted for the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: New diagnosis of breast cancer New diagnosis if a previous breast cancer patient with negative surgical margins Patients willing to sign a written informed consent form Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer Not currently receiving chemotherapy or hormonal therapy Postmenopausal "
        ],
        "premise_nums": [
            "lobular carcinoma in situ or stages 1-3 breast cancer Not currently receiving chemotherapy or"
        ]
    },
    {
        "id": "e9824c27-bb70-4707-9599-ff20281f873e",
        "primaryId": "NCT00357110",
        "statement_text": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins ",
        "statement_nums": [
            "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Varicose Vein 1/6 (16.67%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Varicose Vein 1/6 (16.67%)"
        ]
    },
    {
        "id": "43fcba9b-4edd-433d-86a7-370cbbf56853",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "statement_text": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial  was lower than the median time for patients in the secondary trial ",
        "statement_nums": [
            "from randomization until the first documented sign of disease progression",
            "to any cause for all participants in the primary trial  was lower than",
            "for patients in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) PFS was defined as the time from randomization until the first documented sign of disease progression or death due to any cause  Time frame: Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title: Trastuzumab + Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) ",
            "Unit of Measure: weeks 8.1 (7.6 to 9.0)Outcome Measurement: Time to Progression as Evaluated by the Investigator Time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer  The investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress (Response Evaluation Criteria in Solid Tumors [RECIST] Criteria: target lesion (TL)  at least a 20% increase in the sum of largest diameter (LD) of TLs or the appearance of one or more new lesions; non-TL (NTL)  the appearance of one or more new lesions and/or unequivocal progression of existing NTLs)  TTP was assessed in participants who died due to breast cancer or progressed  as assessed by the investigator  as well as in those who were censored and completed follow-up and those who were censored but are still being followed  For censored participants (those without a documented date of disease progression/death due to breast cancer)  the date of the last radiographic assessment was used  ",
            "Time frame: Randomization until the date of disease progression or death (average of 26 weeks)Results 1: Arm/Group Title: Lapatinib With Paclitaxel Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 29.0 (13.9 to 46.9) Results 2: Arm/Group Title: Placebo With Paclitaxel Arm/Group Description: Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 288 ",
            "Median (Inter-Quartile Range)Unit of Measure: weeks 22.9 (12.0 to 38.3) "
        ],
        "premise_nums": [
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 29.0 (13.9 to 46.9) Results 2: Arm/Group Title: Placebo",
            "daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the date of the last radiographic assessment was used",
            "30 minutes weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval)",
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 22.9 (12.0 to 38.3)",
            "orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV",
            "Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with",
            "Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 8.1 (7.6 to 9.0)Outcome Measurement: Time to Progression as",
            "Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 22.9 (12.0 to 38.3)",
            "Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 29.0 (13.9 to 46.9) Results 2: Arm/Group Title: Placebo",
            "weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a",
            "disease progression or death (average of 26 weeks)Results 1: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1",
            "target lesion (TL)  at least a 20% increase in the sum of largest",
            "30 minutes weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure:",
            "weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks",
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0)Outcome Measurement: Time to Progression as",
            "death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title:",
            "of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1"
        ]
    },
    {
        "id": "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial  compared to cohort 2.",
        "statement_nums": [
            "any cause was higher in cohort 1 of the primary trial  compared to cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: Arm/Group Title: Chemotherapy Arm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) "
        ],
        "premise_nums": [
            "Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7)",
            "Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the",
            "Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall",
            "Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: Arm/Group Title: Chemotherapy",
            "Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group"
        ]
    },
    {
        "id": "36a5357f-0c5f-4c64-a56a-a84aab165a16",
        "primaryId": "NCT01727011",
        "secondaryId": "NCT01420146",
        "statement_text": "the primary trial and the secondary trial interventions involve a variety of scans  such as CT  PET and dosimetry",
        "statement_nums": [
            "the primary trial and the secondary trial interventions involve a variety"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: IPAS Once the patient recorded in the trial  and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk  the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate  delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm "
        ],
        "premise_nums": [
            "delivering a total dose of 16 Gy in one fraction IPAS INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium"
        ]
    },
    {
        "id": "c876167f-fe1e-4c3b-9183-dd3c1069ed0b",
        "primaryId": "NCT00024102",
        "statement_text": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion ",
        "statement_nums": [
            "A patient in cohort 2 of the primary trial received a Packed red"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Transfusion: pRBCs 1/181 (0.55%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Transfusion: pRBCs 1/181 (0.55%)"
        ]
    },
    {
        "id": "d6989b67-ae99-4c2a-a67d-c2285cc57058",
        "primaryId": "NCT00191152",
        "statement_text": "The longest Time to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group ",
        "statement_nums": [
            "to Disease Progression the primary trial was over 11 months in the Docetaxel Plus Capecitabine group"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time to Disease Progression (Initial Treatment) Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment  Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) Results 2: ",
            "Arm/Group Title: Docetaxel Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until progression of disease  at which time crossover treatment begins  Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05) "
        ],
        "premise_nums": [
            "Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a",
            "mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, intravenous  day 1 every 21 days  Treatment continues until",
            "21 days plus capecitabine 1000 mg/m2, by mouth twice a day  days 1-14 every 21 days  Treatment continues until",
            "21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a",
            "Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05)",
            "crossover treatment begins  Overall Number of Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 236 Median (95% Confidence Interval) Unit of Measure: months 8.88 (7.37 to 11.05)",
            "or 2) date of last contact for participants alive without",
            "Plus CapecitabineArm/Group Description: docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until",
            "and the date of first documented disease progression or the",
            "due to study disease (up to 82 months) Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1",
        "primaryId": "NCT00320385",
        "secondaryId": "NCT00075270",
        "statement_text": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS ",
        "statement_nums": [
            "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) PFS was defined as the time from randomization until the first documented sign of disease progression or death due to any cause  Time frame: Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title: Trastuzumab + Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with Trastuzumab infusion at a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before or after breakfast  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement: ",
            "Time to Progression as Evaluated by the InvestigatorTime to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer  The investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress (Response Evaluation Criteria in Solid Tumors [RECIST] Criteria: target lesion (TL)  at least a 20% increase in the sum of largest diameter (LD) of TLs or the appearance of one or more new lesions; non-TL (NTL)  the appearance of one or more new lesions and/or unequivocal progression of existing NTLs)  TTP was assessed in participants who died due to breast cancer or progressed  as assessed by the investigator  as well as in those who were censored and completed follow-up and those who were censored but are still being followed  For censored participants (those without a documented date of disease progression/death due to breast cancer)  the date of the last radiographic assessment was used  Time frame: Randomization until the date of disease progression or death (average of 26 weeks) Results 1: Arm/Group Title: Lapatinib With Paclitaxel ",
            "Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal Overall Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 29.0 (13.9 to 46.9) Results 2: Arm/Group Title: Placebo With Paclitaxel Arm/Group Description: Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 288 Median (Inter-Quartile Range) Unit of Measure: weeks 22.9 (12.0 to 38.3) "
        ],
        "premise_nums": [
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement:",
            "Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the",
            "Number of Participants Analyzed: 288 Median (Inter-Quartile Range) Unit of Measure: weeks 29.0 (13.9 to 46.9) Results 2: Arm/Group Title: Placebo",
            "a loading dose of 4 milligrams/kilogram (mg/kg) body weight intravenously (IV) over 90 minutes on Day 1, followed by 2 mg/kg IV",
            "target lesion (TL)  at least a 20% increase in the date of the last radiographic assessment was used",
            "Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib",
            "Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1 hour before",
            "Lapatinib Arm/Group Description: Participants received Lapatinib 1000 milligram (mg) tablets orally daily 1 hour before or after breakfast along with",
            "Day 1, followed by 2 mg/kg IV over 30 minutes weekly  in a 4 week cycle  Overall Number of Participants",
            "Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 8.1 (7.6 to 9.0) Outcome Measurement:",
            "30 minutes weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of",
            "Number of Participants Analyzed: 291 Median (Inter-Quartile Range) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib",
            "Number of Participants Analyzed: 288 Median (Inter-Quartile Range) Unit of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib",
            "Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the",
            "target lesion (TL)  at least a 20% increase in the sum of largest",
            "from randomization until the first documented sign of disease progression or death (average of 26 weeks) Results 1: Arm/Group Title:",
            "weekly  in a 4 week cycle  Overall Number of Participants Analyzed: 146 Median (95% Confidence Interval) Unit of Measure: weeks",
            "death due to any cause or 30 days after last dose (up to 216 weeks) Results 1: Arm/Group Title:",
            "of Measure: weeks 12.0 (8.1 to 16.0) Results 2: Arm/Group Title: Lapatinib Arm/Group Description: Participants received Lapatinib 1500 mg tablets orally daily 1"
        ]
    },
    {
        "id": "886d3280-bc44-4a58-a5ba-66b018210332",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was just over a year ",
        "statement_nums": [
            "any patient in the primary trial  was just over",
            "of study treatment to first documentation of objective tumor progression"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time to Tumor Progression (TTP) Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer  whichever comes first  TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind) Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 247 (208 to 265) Results 2: ",
            "Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind)Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Participants with disease progression after consent were continued to open-label phase  Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247) "
        ],
        "premise_nums": [
            "Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of Measure: days 215 (191 to 247)",
            "toxicity  or for 2 cycles after complete response  Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of",
            "Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247)",
            "first dose of study medication plus 1. Tumor progression was determined from study treatment  assessed every 9 weeks up to 129 weeks",
            "starting from Day 1 of Cycle 1, in cycles of 3 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel",
            "Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks",
            "intolerable toxicity  or for 2 cycles after complete response  Participants with",
            "Time frame: Phase 2 double-blind baseline until tumor progression or death",
            "Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of Measure: days 247 (208 to 265) Results 2:",
            "Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247)",
            "3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of",
            "of study treatment to first documentation of objective tumor progression",
            "from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel"
        ]
    },
    {
        "id": "03dcb6d9-efae-40ec-87ee-68ef89424498",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "statement_text": "There were more cases of deteriorating mental health in the primary trial than the secondary trial ",
        "statement_nums": [
            "mental health in the primary trial than the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%) General body pain 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) ",
            "Cardiac failure congestive 0/24 (0.00%)Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) "
        ],
        "premise_nums": [
            "failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%)",
            "Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2:",
            "leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%)",
            "failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2:",
            "Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)",
            "Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)",
            "Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 0/24 (0.00%)Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%)",
            "leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%)",
            "(0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder",
            "worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110",
            "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26"
        ]
    },
    {
        "id": "b881b717-1c8a-41b8-9554-6ed9e8ee7c77",
        "primaryId": "NCT00193206",
        "statement_text": "the primary trial records a total of 7 patients suffering from various infections ",
        "statement_nums": [
            "the primary trial records a total of 7 patients suffering from various infections"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 22/123 (17.89%) Cardiac Ischemia/Infarction [1]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123 (0.81%) Weakness 1/123 (0.81%) Pain - Liver 1/123 (0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Infection - Vein [5]2/123 (1.63%) Infection - Pneumonia 1/123 (0.81%) "
        ],
        "premise_nums": [
            "(0.81%) Infection - Skin [3]3/123 (2.44%) Infection - Gastrointestinal [4]1/123 (0.81%) Pain - Chest 2/123 (1.63%) Dehydration 2/123 (1.63%) Death [2]1/123"
        ]
    },
    {
        "id": "20530faf-addb-47bf-896d-b9666e149223",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
        "statement_nums": [
            "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%)"
        ]
    },
    {
        "id": "52557c9f-f771-4f31-bb71-01f87f9f5821",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeks Measurable disease by RECIST 1.1 Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: ",
            "Serum bilirubin 1.5 X upper limit of normal (ULN);Adequate renal function as defined by a serum creatinine 1.5 x ULN AST  ALT  and alkaline phosphatase 3 × ULN except for: Patients with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment Female subjects of childbearing age must have a negative serum pregnancy test at study entry  Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease Major surgery within 4 weeks prior to first dose of STA-9090 Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material  ",
            "History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80)Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation) Women who are pregnant or lactating Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements Other medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication Prior treatment with an HSP90 inhibitor persistent adverse events of prior therapies that are greater than 1 grade 1 in severity ",
            "history of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgeryhistory of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics "
        ],
        "premise_nums": [
            "and Polysorbate 80)Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline Treatment with chronic immunosuppressants",
            "as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined",
            "Female patients must be at least 18 years of age Pathologically confirmed diagnosis of",
            "1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL Adequate hepatic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin",
            "therapy (excluding Hormonal therapy) 3 weeks Measurable disease by RECIST 1.1 Central nervous system metastases are permitted if",
            "Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of measurable disease Major surgery within 4 weeks prior to first dose",
            "of measurable disease Major surgery within 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status",
            "Serum bilirubin 1.5 X upper limit of normal (ULN);Adequate renal",
            "hormonal therapy) Patients with HER2+ disease must have received prior treatment",
            "Serum bilirubin 1.5 X upper limit of measurable disease Major surgery within 4 weeks prior to first dose",
            "Prior treatment with an HSP90 inhibitor persistent adverse events of prior therapies that are greater than 1 grade 1 in severity",
            "Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with",
            "History of severe (grade 3 or 4) allergic or hypersensitivity reactions to",
            "with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's",
            "for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New",
            "defined by a serum creatinine 1.5 x ULN AST  ALT  and clinically stable for at least 4 weeks prior to first dose",
            "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast",
            "Polyethylene glycol [PEG] 300 and Polysorbate 80)Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than",
            "angina pectoris  angioplasty or coronary bypass surgeryhistory",
            "and clinically stable for at least 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status",
            "Female patients must be at least 18 years of age Pathologically confirmedications  or Grade 2 or greater left bundle branch block New"
        ]
    },
    {
        "id": "11472413-533f-45f9-9aac-c46bca318aab",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the median PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "and Paclitaxel for a duration of 18 months or until death  and the",
            "for this group was just under 7 and a half months",
            "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel Arm/Group Description: Starting sunitinib doses of 25 mg daily  After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator  Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted  Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) "
        ],
        "premise_nums": [
            "the date of the first documentation of objective tumor progression",
            "Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted",
            "Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months",
            "been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted  Overall Number",
            "to 80 or 90 mg/m^2 upon recovery was permitted  Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of",
            "randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel",
            "of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator"
        ]
    },
    {
        "id": "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0",
        "primaryId": "NCT00191854",
        "statement_text": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial",
        "statement_nums": [
            "be included in the primary",
            "need to have a Her2neu positive tumours or a measurable"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female patients with histological or cytological proven diagnosis of breast cancer Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease Adequate organ function Exclusion Criteria: Prior chemotherapy for metastatic disease Previous radiation therapy is allowed but must not have included whole pelvis radiation Known or suspected brain metastasis  Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study  at the discretion of the investigator Concurrent administration of any other tumor therapy  including cytotoxic chemotherapy  hormonal therapy and immunotherapy (including trastuzumab (Herceptin)) Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder  including seizures or dementia "
        ],
        "premise_nums": [
            "Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or",
            "Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology",
            "Previous radiation therapy is allowed but must not have"
        ]
    },
    {
        "id": "6446f085-c6b0-43ce-82ed-16d6952b549e",
        "primaryId": "NCT00880022",
        "secondaryId": "NCT00916578",
        "statement_text": "Only patients in cohort 2 of the primary trial undergo Trunk compression  However all patients in the secondary trial are treated with Trunk compression ",
        "statement_nums": [
            "all patients in the secondary trial are treated with Trunk compression  However all patients in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm Compression Only [Not Specified] INTERVENTION 2: Arm  Trunck and Chest Compression [Not Specified] INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  "
        ],
        "premise_nums": [
            "Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the",
            "Radiation therapy doses will be 50-57 Gy to the initial clinical target volume",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy doses will be 50-57 Gy to the initial clinical target volume"
        ]
    },
    {
        "id": "db90c9d8-b289-48e2-a7df-f41620b3feab",
        "primaryId": "NCT00110084",
        "secondaryId": "NCT01961544",
        "statement_text": "the primary trial and the secondary trial both reported cases of sepsis in their patients ",
        "statement_nums": [
            "the primary trial and the secondary trial both reported cases of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%)"
        ]
    },
    {
        "id": "c15309b3-eb08-4d46-94ef-e4a504a111db",
        "primaryId": "NCT03708393",
        "secondaryId": "NCT03456427",
        "statement_text": "The intervention in the primary trial is carried out by either a doctor  radiographer or a sonographer  whereas one of the interventions in the secondary trial requires active participation from the patient ",
        "statement_nums": [
            "the interventions in the secondary trial requires active participation from",
            "The intervention in the primary trial is carried out by"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  "
        ],
        "premise_nums": [
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: All Study Participants: Patient Assisted"
        ]
    },
    {
        "id": "4885cd77-628c-4b8f-8345-6bce2165938c",
        "primaryId": "NCT02964234",
        "secondaryId": "NCT00246090",
        "statement_text": "Patients eligible for the primary trial and the secondary trial must live in the USA ",
        "statement_nums": [
            "Patients eligible for the primary trial and the secondary trial must live in the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence in Pilsen  Little Village  East Side or South Chicago; Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast  Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis  Patients with locally advanced or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer  at least one of which was administered for treatment of locally advanced or metastatic disease  Prior therapy must be documented by the following criteria prior to entry onto study: Regimens must have included an anthracycline (eg  doxorubicin  epirubicin)  a taxane (eg  paclitaxel  docetaxel) and capecitabine in any combination or order  One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy  Patients with human epidermal growth factor receptor 2 (HER2/neu) over-expressing tumors must additionally have been treated with trastuzumab  Patients with estrogen receptor-expressing tumors may have additionally been treated with estrogen-specific therapy  ",
            "Prior hormonal therapy  biological therapy  (eg  trastuzumab  bevacizumab)  or immunotherapy  is not to be counted as one of the 2 to 5 prior chemotherapy regimens allowed  However  hormonal therapy must be discontinued one week before administration of E7389, and biological therapy must be discontinued two weeks before E7389 administration Patients who are being treated with bisphosphonates when they enter the study are allowed to continue the medication as long as the dosing does not change  In case a change in dosing is deemed necessary  the case needs to be discussed with the Sponsor  Progression on or within six months of the last regimen for advanced disease  documented by the following: The dates of treatment  doses  outcome of therapy and the reason for discontinuation of prior anthracycline  taxane  capecitabine  and trastuzumab therapy must be provided  Prior to entry onto the study  information ensuring that the last therapy fulfills eligibility criteria is required  which includes progression while receiving this last prior chemotherapy regimen  or within six months of receiving that therapy  ",
            "Chemotherapy medication administration sheets or other official medical/hospital records indicating type and dates of chemotherapy must be available for inspection  and one of the following as a reason for discontinuation of medication is required: radiographic evidence of progression  or doctor's office or hospitalization notes documenting radiologic progression  clinically documented increase in tumor burden  and/or increase in tumor-specific markers Patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter [LD] by spiral computer tomography [CT] scan)  or at least 20 mm by standard techniques  If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a biopsy or aspiration with cytological or histological confirmation of the diagnosis of breast carcinoma is required  Resolution of all chemotherapy or radiation-related toxicities to less than Grade 2 severity  except for stable sensory neuropathy Grade 2 and alopecia  Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of 3 months  ",
            "Adequate renal function as evidenced by serum creatinine 2.0 mg/dL or calculated creatinine clearance 40 mL/minute (min) per the Cockcroft and Gault formula Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L hemoglobin 10.0 g/dL (acceptable if it is corrected by therapeutic intervention or transfusional support)  and platelet count 100 x 10^9/L. Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN)  unless there are bone metastases  in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase  Willing and able to complete the European Organization for Research on the Treatment of Cancer (EORTC) quality of life assessment  Analgesic Diary  and Pain Visual Analog Scale (VAS)  Willing and able to comply with the study protocol for the duration of the study  ",
            "Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria: Patients must not have received chemotherapy  radiation  or biologic therapy within two weeks  hormonal therapy within one week  or trastuzumab within three weeks  before E7389 treatment start  Patients must not have received radiation therapy encompassing greater than 30% of marrow (a lesion that has been irradiated cannot be used as a target lesion  unless it has progressed after the irradiation)  Patients must not have pre-existing neuropathy greater than Grade 2. Patients must not have participated in a prior E7389 clinical trial  "
        ],
        "premise_nums": [
            "transfusional support)  and platelet count 100 x 10^9/L. Adequate liver function as evidenced by serum creatinine 2.0 mg/dL or calculated creatinine",
            "documenting radiologic progression  clinically documented increase in tumor",
            "must measure at least 20 mm in LD  If a single",
            "Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of",
            "Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; Residence",
            "be counted as one of the 2 to 5 prior chemotherapy regimens allowed  However  hormonal",
            "absolute neutrophil count (ANC) 1.5 x 10^9/L hemoglobin 10.0 g/dL (acceptable if it is corrected",
            "except for stable sensory neuropathy Grade 2 and alopecia  Age greater than or equal 18 years  Eastern Cooperative Oncology",
            "[CT] scan)  or at least 20 mm by standard techniques  If the",
            "function as evidenced by serum creatinine 2.0 mg/dL or calculated creatinine clearance 40 mL/minute (min) per the Cockcroft and",
            "(in the case of liver metastases 5 x ULN)  unless there are bone",
            "have pre-existing neuropathy greater than Grade 2. Patients must not have participated in a prior E7389 clinical trial",
            "Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of 3 months",
            "or calculated creatinine clearance 40 mL/minute (min) per the Cockcroft and aspartate transaminase (AST) 3 times the upper limits of normal (ULN)",
            "at least one diameter (at least 10 mm in longest diameter [LD] by spiral",
            "week before administration of E7389, and biological therapy must be discontinued two weeks before E7389 administration Patients who are being treated with",
            "Criteria: Female patients with histologically or cytologically confirmed carcinoma",
            "case of liver metastases 5 x ULN)  unless there are bone diameter (at least 10 mm in longest diameter [LD] by spiral",
            "received radiation therapy encompassing greater than 30% of marrow (a lesion that has",
            "six months of the last regimen for advanced disease who have received at least two (and not more than"
        ]
    },
    {
        "id": "8809cc5e-36d5-4f7e-b06d-b1915a421f71",
        "primaryId": "NCT00759785",
        "statement_text": "Only one adverse event  a Breast abscess  is observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "is observed in patients from cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/25 (4.00%) Diarrhoea 0/25 (0.00%) Breast abscess 0/25 (0.00%) Breast cellulitis 0/25 (0.00%) Syncope 1/25 (4.00%)"
        ]
    },
    {
        "id": "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1",
        "primaryId": "NCT00908791",
        "secondaryId": "NCT00297596",
        "statement_text": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial  unless they have an ECOGgreater than 2.",
        "statement_nums": [
            "ineligible for both the secondary trial and the primary trial  unless they have"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: All study patients must have histologically confirmed invasive adenocarcinoma of the breast  Their breast cancer must be resectable clinical stage I or II breast cancer as defined by the current AJCC TNM Staging System (Greene FL  Page DL  Fleming ID  et al.: editors  AJCC cancer staging manual  6th edition  New York: Springer; 2002). All patients must be able to and give informed consent indicating they are aware of the investigational nature of this treatment  prior to entry into the study  All subjects must be Age greater than 18 years  All subject must have adequate hepatic and renal function documented prior to study entry to include: hepatic transaminases (AST or ALT) 1.5 times the upper limits of normal  total bilirubin 1.5 times the upper limits of normal  serum creatinine 1.5 times the upper limit of normal or eCRCl 60 mL/min  Exclusion criteria: Patients who have received prior or be receiving radiation therapy for their breast cancer will be excluded  Patients who have received prior chemotherapy or receiving chemotherapy or hormonal therapy for their breast cancer will not be included  ",
            "Women must be surgically sterilized or post-menopausal or women of childbearing potential must be using an adequate method of contraception  Women of childbearing potential must be using at least one of the following: oral  implanted  injectable contraceptive hormones  or mechanical products such as an intrauterine device or barrier methods (diaphragm  condoms  spermicides) to prevent pregnancy or practicing abstinence or have a partner that is sterile (e.g.  vasectomy)  Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of study therapy  Women who are pregnant or breast-feeding and women of childbearing potential not using an adequate method of birth control will be excluded Patients with gastrointestinal abnormalities including: inability to take oral medication  requirement for intravenous alimentation  or prior surgical procedures affecting nutrient /drug absorption will be excluded  ",
            "A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded  Significant cardiac disease  including uncontrolled high blood pressure  unstable angina  and congestive heart failure  myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be excluded  Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded Inclusion Criteria: Dementia or significantly altered mental status that would interfere with proper consenting  "
        ],
        "premise_nums": [
            "potential must be using at least one of the following: oral",
            "myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be",
            "serum or urine pregnancy test within 72 hours prior to start of normal or eCRCl 60 mL/min  Exclusion criteria: Patients who",
            "subjects must be Age greater than 18 years  All subject must",
            "of normal  total bilirubin 1.5 times the upper limits of normal  serum creatinine 1.5 times the upper limit of normal or",
            "of normal  total bilirubin 1.5 times the upper limits of normal  total bilirubin 1.5 times the upper limits",
            "serum or urine pregnancy test within 72 hours prior to start of normal  total bilirubin 1.5 times the upper limits of normal",
            "serum or urine pregnancy test within 72 hours prior to start of study therapy",
            "of normal  serum creatinine 1.5 times the upper limit of normal or eCRCl 60 mL/min  Exclusion criteria: Patients who",
            "Women must be surgically sterilized or post-menopausal or"
        ]
    },
    {
        "id": "ca27db58-14c4-4889-95b1-69be9c10a07a",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "statement_text": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial ",
        "statement_nums": [
            "where found in the primary trial than in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%) Neutropenia 1/52 (1.92%) Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%) Diarrhoea 1/52 (1.92%) Adverse Events 1: Total: 14/54 (25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%) ",
            "Pericardial effusion 1/54 (1.85%)Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Vomiting 0/20 (0.00%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%)",
            "Pericardial effusion 1/54 (1.85%)Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%)",
            "Vomiting 0/20 (0.00%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20",
            "failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20",
            "2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%)",
            "Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20",
            "Pericardial effusion 1/54 (1.85%)Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2:",
            "Adverse Events 1: Total: 14/54 (25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54",
            "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac",
            "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%)",
            "(25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive",
            "6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) Cardiac failure congestive 1/54 (1.85%)Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%)"
        ]
    },
    {
        "id": "3c482d5e-bfad-4a46-9e98-ba9967f2d900",
        "primaryId": "NCT00903162",
        "secondaryId": "NCT01674062",
        "statement_text": "Patients with BCC are excluded from the primary trial and the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix Exclusion Criteria: Any other malignancy in the last 5 years  except for basal cell cancer or cancer in situ of the cervix "
        ],
        "premise_nums": [
            "cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in",
            "Any other malignancy in the last 5 years  except for basal"
        ]
    },
    {
        "id": "48ccd744-abf1-4e98-bc86-8ecd625e6279",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial ",
        "statement_nums": [
            "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be",
            "be eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease "
        ],
        "premise_nums": [
            "metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab",
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally"
        ]
    },
    {
        "id": "dce5d9c8-7da6-4732-b969-c492c876cdca",
        "primaryId": "NCT01783444",
        "statement_text": "Women of any age can participate in the primary trial ",
        "statement_nums": [
            "can participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Key Inclusion Criteria: - Women with locally advanced  recurrent  or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)  Measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above  Key Exclusion Criteria: - Patients who received more than one chemotherapy line  Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane  mTOR inhibitors  PI3K inhibitors or AKT inhibitors  "
        ],
        "premise_nums": [
            "or mixed (lytic + blastic) in the absence of",
            "Criteria: - Women with locally advanced  recurrent",
            "Measurable disease defined as at least one lesion 10 mm by CT or MRI that can",
            "mTOR inhibitors  PI3K inhibitors or AKT inhibitors",
            "one dimension (CT scan slice thickness 5 mm) OR Bone lesions: lytic"
        ]
    },
    {
        "id": "1882de62-2df2-4b73-a3d2-81811f85f661",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy ",
        "statement_nums": [
            "diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity  cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) "
        ],
        "premise_nums": [
            "patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of",
            "Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression",
            "or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5)",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 14 courses in the absence of disease progression"
        ]
    },
    {
        "id": "161c852e-a42c-47c2-ab6a-2b7bd6a4b934",
        "primaryId": "NCT00325234",
        "statement_text": "Patients wanting to participate in the primary trial  must discontinue any Antitumoral hormonal treatment  and must have a life expectancy of more than 3 months ",
        "statement_nums": [
            "to participate in the primary trial  must discontinue any",
            "a life expectancy of more than 3 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Antitumoral hormonal treatment must be discontinued prior to enrollment  Estimated life expectancy of at least 3 months  "
        ],
        "premise_nums": [
            "Estimated life expectancy of at least 3 months"
        ]
    },
    {
        "id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia  a rare coagulation disorder ",
        "statement_nums": [
            "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 81/353 (22.95%) Febrile neutropenia * 13/353 (3.68%) Anaemia * 21/353 (0.28%) Neutropenia * 25/353 (1.42%) Thrombocytopenia * 20/353 (0.00%) Hypercoagulation * 21/353 (0.28%) Leukopenia * 21/353 (0.28%) Atrial fibrillation * 1/353 (0.28%) Cardiac failure * 0/353 (0.00%) Cardiac failure congestive * 0/353 (0.00%) Myocardial infarction * 1/353 (0.28%) "
        ],
        "premise_nums": [
            "(22.95%) Febrile neutropenia * 13/353 (3.68%) Anaemia * 21/353 (0.28%) Neutropenia * 25/353 (1.42%) Thrombocytopenia * 20/353 (0.00%) Hypercoagulation"
        ]
    },
    {
        "id": "0701ac32-45b3-4199-aa20-a71080ce9bf6",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "statement_text": "There are no cases of Vertigo in the primary trial or the primary trial ",
        "statement_nums": [
            "of Vertigo in the primary trial or the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%) Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4 (0.00%) Diarrhoea 0/4 (0.00%) Nausea 0/4 (0.00%) Vomiting 0/4 (0.00%) Disease progression 0/4 (0.00%) Influenza 0/4 (0.00%) Nasopharyngitis 0/4 (0.00%) Lumbar vertebral fracture 0/4 (0.00%) Hyponatraemia 0/4 (0.00%) Ataxia 0/4 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4",
            "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%)"
        ]
    },
    {
        "id": "866876f5-68de-44bd-b58a-e4b590aa4b39",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention  in the secondary trial patients must use a fitbit ",
        "statement_nums": [
            "primary trial must undergo at least one MRI during the intervention  in the secondary trial patients must use a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  "
        ],
        "premise_nums": [
            "Active Living counseling program consists of 12 weekly group educational sessions  These sessions",
            "number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will",
            "a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects",
            "number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated"
        ]
    },
    {
        "id": "b4304362-1cb4-4606-9de4-03935ad509f1",
        "primaryId": "NCT00370552",
        "statement_text": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "statement_nums": [
            "There 55 more Participants With Best Tumor Response of",
            "or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity  ",
            "Overall Number of Participants Analyzed: 46Measure Type: Number Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6) "
        ],
        "premise_nums": [
            "Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered",
            "still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was",
            "to be infused over 90 minutes for the first dose  and 15 of a 28-day cycle until disease progression or unacceptable",
            "Number of Participants Analyzed: 46Measure Type: Number Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6)",
            "1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable",
            "months  then every 3 months until disease progression Results 1: Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV",
            "evidence of target lesions; PR=At least 30% reduction in the sum of the",
            "90 minutes for the first dose  and if well tolerated for 60 minutes  for the second",
            "Bevacizumab to be infused over 90 minutes for the first dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab",
            "mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 3-hour IV infusion on Day 1 of",
            "IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2",
            "While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of",
            "to be infused over 90 minutes for the first dose  and then every 8 weeks to 12 months  then every 3",
            "mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable",
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone",
            "progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered",
            "progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of",
            "to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16",
            "Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg",
            "Overall Number of Participants Analyzed: 46Measure Type: Number Unit of Measure:"
        ]
    },
    {
        "id": "9cddd86a-4340-4918-b000-7e6e593a3f7f",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "statement_text": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None DISEASE CHARACTERISTICS: Histologically or cytologically confirmed infiltrating breast cancer Clinical evidence of metastatic disease Measurable disease  defined as at least one measurable lesion per RECIST criteria No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal masses that are not confirmed and followed by imaging techniques Cystic lesions Patients with HER-2/neu positive tumors  must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumab No evidence of active brain metastasis  including leptomeningeal involvement  on MRI or CT scan CNS metastasis controlled by prior surgery and/or radiotherapy allowed Must be asymptomatic for 2 months with no evidence of progression prior to study entry Hormone receptor status not specified ",
            "PATIENT CHARACTERISTICS:Menopausal status not specified Life expectancy 12 weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN Total bilirubin 1.5 times ULN Creatinine 1.5 mg/dL Urine protein:creatinine ratio smaller than 1 or urinalysis smaller than 1+ protein Patients discovered to have 1+ proteinuria at baseline must demonstrate 24-hour urine protein smaller than 1 g Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 30 days after completion of study therapy Able to complete questionnaires alone or with assistance No peripheral neuropathy greater than grade 1 No history of allergy or hypersensitivity to albumin-bound paclitaxel  paclitaxel  gemcitabine hydrochloride  bevacizumab  albumin  drug product excipients  or chemically similar agents No stage III or IV invasive  non-breast malignancy within the past 5 years ",
            "No other active malignancy  except nonmelanoma skin cancer or carcinoma in situ of the cervixPatient must not be receiving other specific treatment for a prior malignancy No uncontrolled hypertension (i.e.  blood pressure [BP] greater than 160/90 mm Hg on 2 occasions at least 5 minutes apart) Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is smaller than 140/90 mm Hg on any new regimen for 3 different observations in 14 days No bleeding diathesis or uncontrolled coagulopathy No hemoptysis within the past 6 months No prior arterial or venous thrombosis within the past 12 months No history of cerebrovascular accident No history of hypertensive crisis or hypertensive encephalopathy No abdominal fistula or gastrointestinal perforation within the past 6 months No serious non-healing wound  ulcer  or fracture No clinically significant cardiac disease  defined as any of the following: Congestive heart failure Symptomatic coronary artery disease Unstable angina Cardiac arrhythmias not well controlled with medication Myocardial infarction within the past 12 months ",
            "No comorbid systemic illnesses or other severe concurrent disease which  in the judgment of the investigator  would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimensPRIOR CONCURRENT THERAPY: See Disease Characteristics No prior chemotherapy for metastatic disease May have received one prior adjuvant chemotherapy regimen Prior neoadjuvant chemotherapy allowed More than 6 months since prior adjuvant or neoadjuvant taxane (i.e.  docetaxel or paclitaxel) therapy Prior hormonal therapy in either adjuvant or metastatic setting allowed More than 4 weeks since prior radiotherapy (except if to a non-target lesion only  or single dose radiation for palliation) Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug More than 2 weeks since prior and no concurrent acetylsalicylic acid  anticoagulants  or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid) ",
            "More than 6 weeks since prior major surgery  chemotherapy  or immunologic therapyMore than 1 week since prior minor surgery (e.g.  core biopsy) Placement of a vascular access device within 7 days is allowed More than 3 months since prior neurosurgery No concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed "
        ],
        "premise_nums": [
            "BP is smaller than 140/90 mm Hg on any new regimen Prior neoadjuvant chemotherapy allowed More than 6 months",
            "pressure [BP] greater than 160/90 mm Hg on 2 occasions at least 5 minutes apart) Patients who have recently started",
            "performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL AST and ALT 2.5 times upper limit of normal (ULN) Alkaline",
            "weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL AST and ALT 2.5 times upper limit of",
            "chemotherapy  or immunologic therapyMore than 1 week since prior minor surgery (e.g.",
            "Hemoglobin 9.0 g/dL AST and ALT 2.5 times upper limit of a vascular access device within 7 days is allowed More than",
            "BP is smaller than 140/90 mm Hg on any new regimen for 3 different observations in 14 days No bleeding diathesis or",
            "disease  defined as at least one measurable lesion per RECIST",
            "1+ proteinuria at baseline must demonstrate 24-hour urine protein smaller than 1 g Not pregnant or nursing Negative pregnancy",
            "agents (except for once-daily 81 mg acetylsalicylic acid)",
            "9.0 g/dL AST and ALT 2.5 times upper limit of normal (ULN) Alkaline phosphatase 2.5 times ULN Total bilirubin 1.5 times ULN",
            "Hg on any new regimen for 3 different observations in 14 days No bleeding diathesis or uncontrolled coagulopathy",
            "1+ proteinuria at baseline must demonstrate 24-hour urine protein smaller than 1 or urinalysis smaller than 1+ protein Patients discovered to have",
            "No peripheral neuropathy greater than grade 1 No history of allergy or hypersensitivity to",
            "radiotherapy allowed Must be asymptomatic for 2 months with no evidence of progression prior",
            "limit of normal (ULN) Alkaline phosphatase 2.5 times ULN Total bilirubin 1.5 times ULN Creatinine 1.5 mg/dL Urine protein:creatinine ratio smaller than",
            "use effective contraception during and for 30 days after completion of study therapy Able",
            "not specified Life expectancy 12 weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL AST and ALT 2.5 times",
            "3 different observations in 14 days No bleeding diathesis or uncontrolled coagulopathy No hemoptysis within the past 6 months No prior arterial or",
            "regimen Prior neoadjuvant chemotherapy allowed More than 6 months since prior adjuvant or neoadjuvant taxane",
            "CHARACTERISTICS:Menopausal status not specified Life expectancy 12 weeks ECOG performance status 0-1 ANC 1,500/mm³ Platelet count 100,000/mm³ Hemoglobin 9.0 g/dL AST",
            "Cystic lesions Patients with HER-2/neu positive tumors  must have received",
            "of a vascular access device within 7 days is allowed More than 6 weeks since prior major surgery  chemotherapy",
            "small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions"
        ]
    },
    {
        "id": "c3f01101-2259-4677-add1-1b1f48a0202b",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.",
        "statement_nums": [
            "affected by adverse events in cohort 2 the primary trial is more than 1000."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) "
        ],
        "premise_nums": [
            "related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea",
            "Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract",
            "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal",
            "Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%)",
            "Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea",
            "Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%)"
        ]
    },
    {
        "id": "33b827a0-ada5-4204-abb8-d5239ea16f0b",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group ",
        "statement_nums": [
            "In the primary trial There was less than 3 days difference between the maximum recorded TTP"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole ",
            "Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months 11.1 (10.8 to 16.6) "
        ],
        "premise_nums": [
            "tablet each of anastrozole 1 mg and exemestane placebo were orally administeredition)  Time frame: Up to 2008 days of the treatment Results",
            "bone metastasis only  at least 25% increase in the measurable lesions compared to the smallest SLD since the study",
            "Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months from randomization to first documentation of objective tumor progression",
            "Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months 11.1 (10.8 to 16.6)",
            "tablet each of exemestane 25 mg and anastrozole placebo were orally administeredition)  Time frame: Up to 2008 days of the treatment Results",
            "Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole",
            "edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane Arm/Group Description:",
            "2008 days of the treatment Results 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were",
            "Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 11.1 (10.8 to 16.6)",
            "expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the"
        ]
    },
    {
        "id": "22bff413-a1bd-419b-b19b-2157dedc9948",
        "primaryId": "NCT00802945",
        "secondaryId": "NCT01231659",
        "statement_text": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort ",
        "statement_nums": [
            "ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: Up to 2 years  Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) Results 2: Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) ",
            "Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 "
        ],
        "premise_nums": [
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102 given",
            "percentage of subjects 28.6 (14.6 to 46.3) Results 2: Arm/Group Title: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed:",
            "NKTR-102 given on a q14 day schedule Overall Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage",
            "NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage",
            "Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) Results 1: Arm/Group Title: NKTR-102 14 Day Arm/Group Description: NKTR-102: NKTR-102",
            "for a period of at least one month; Partial Response (PR)  at least a 30% decrease in the sum of",
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole",
            "the date of the first documented disease progression or date",
            "Results 2: Arm/Group Title: NKTR-102 21 Days Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule Overall Number of Participants Analyzed:",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "Partial Response (PR)  at least a 30% decrease in the sum of the",
            "Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of",
            "for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  at least a 30% decrease in the sum of",
            "Day Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule Overall Response Rate (ORR) was defined",
            "Response (PR)  at least a 30% decrease in the sum of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until",
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2",
            "Number of Participants Analyzed: 35 Measure Type: Number Unit of Measure: percentage of subjects 35 (14.6 to 46.3) Outcome Measurement:",
            "partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT:"
        ]
    },
    {
        "id": "2ea80a50-0db3-4ff2-8ca0-71eb048649f7",
        "primaryId": "NCT01875367",
        "statement_text": "More than 3 patients in the primary trial had a common cold ",
        "statement_nums": [
            "More than 3 patients in the primary trial had a common cold"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related infection (Bacteriemia) 0/81 (0.00%) Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%) Hematuria 1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Catheter related infection (Bacteriemia) 1/85 (1.18%) Lack of strength in left leg 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%) Hematuria 0/85 (0.00%) ",
            "Nodule in left breast 1/85 (1.18%)"
        ],
        "premise_nums": [
            "1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) Fever",
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Catheter related",
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related",
            "0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%)",
            "10/85 (11.76%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85",
            "1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%)",
            "Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81"
        ]
    },
    {
        "id": "3b1bdc19-62cd-4ff1-9e30-424e124342f3",
        "primaryId": "NCT02425891",
        "secondaryId": "NCT00593827",
        "statement_text": "the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame ",
        "statement_nums": [
            "the secondary trial and the primary trial both measure PFS of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants PFS was defined as the time from randomization to the occurrence of disease progression  as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause  whichever occurred first  Time frame: Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months  Computed using Kaplan-Meier estimates  Time frame: From the date of randomization to 6-months on study "
        ],
        "premise_nums": [
            "From the date of randomization to 6-months on study",
            "Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants",
            "Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression",
            "who neither progressed nor died before 6 months  Computed using Kaplan-Meier"
        ]
    },
    {
        "id": "a44cd0d1-92b3-4add-badf-b8dd5a324138",
        "primaryId": "NCT01466972",
        "secondaryId": "NCT01446159",
        "statement_text": "the primary trial recorded one patient with congestive heart failure  the secondary trial did not record any ",
        "statement_nums": [
            "the primary trial recorded one patient with",
            "heart failure  the secondary trial did not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%)"
        ]
    },
    {
        "id": "291bb67e-f02f-49d4-b967-29cc9f5098c4",
        "primaryId": "NCT01738438",
        "secondaryId": "NCT00331552",
        "statement_text": "Cyclophosphamide  Cabozantinib and Trastuzumab were used in the secondary trial intervention  but not in the primary trial ",
        "statement_nums": [
            "were used in the secondary trial intervention  but not in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cabozantinib Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV "
        ],
        "premise_nums": [
            "once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 30-90 minutes weekly or every 3 weeks at the discretion of",
            "Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at",
            "was given at a dose of 60 mg orally once per day for 21 day cycles  Treatment continued in the",
            "oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every"
        ]
    },
    {
        "id": "55704a1f-eab2-44ea-a6de-8df508a28066",
        "primaryId": "NCT00274768",
        "secondaryId": "NCT00654836",
        "statement_text": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Evidence of metastatic involvement (stage IV disease) Locally recurrent or metastatic disease "
        ],
        "premise_nums": [
            "involvement (stage IV disease) Locally recurrent or metastatic disease"
        ]
    },
    {
        "id": "6e1955b8-e6fa-42b2-a498-7ada9e733304",
        "primaryId": "NCT01593020",
        "secondaryId": "NCT00834678",
        "statement_text": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "excluded from both the secondary trial and the primary trial",
            "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in the presence of documented liver metastases) "
        ],
        "premise_nums": [
            "Criteria: AST or ALT greater than 2.5 times the upper limit of normal (ULN)",
            "AST or ALT greater than 2.5 times the upper limit of normal (ULN) ALT and AST 2.5 times ULN ( 5 times ULN in"
        ]
    },
    {
        "id": "8a6397e9-84cd-4a2e-ac6a-b56ee355d862",
        "primaryId": "NCT00004092",
        "statement_text": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "No histologically proven bone marrow metastasis "
        ],
        "premise_nums": [
            "No histologically proven bone marrow metastasis"
        ]
    },
    {
        "id": "8b5f946c-71d9-42cd-aa9a-1d3a4845c460",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their hormone status  Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [
            "cohort B is ER/PR +HER2- BC Patients  in contrast the primary trial designates specific interventions to"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cohort A: Triple-negative Breast Cancer Patients Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients Patients with hormone receptor positive (ER and/or PR positive)  HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy "
        ],
        "premise_nums": [
            "treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual",
            "2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients Patients with hormone",
            "therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via"
        ]
    },
    {
        "id": "8f0aff7f-0d9e-498b-bcb6-05e6d309724c",
        "primaryId": "NCT01852032",
        "secondaryId": "NCT01118624",
        "statement_text": "the secondary trial administers placebo tablets at twice the rate of the primary trial  but less than half the dose ",
        "statement_nums": [
            "the rate of the primary trial  but less than",
            "the secondary trial administers placebo tablets at"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Breast Cancer Patients Tomosynthesis Breast Scanning is done and breast CT Scanning is done  INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks"
        ]
    },
    {
        "id": "b7936bbc-f0c0-444c-a199-2db323c30396",
        "primaryId": "NCT00313170",
        "secondaryId": "NCT00305448",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4) Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) Outcome Measurement: Objective Response Rate (ORR) ",
            "An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number ",
            "Unit of Measure: percentage of participants 17.6"
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg",
            "Number of Participants Analyzed: 51 Measure Type: Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization",
            "up to data cut-off (19th march 2008) Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg",
            "been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group",
            "mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45",
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 17.",
            "partial response (PR - at least 30% decrease in the sum of diameters",
            "were to be followed up every 12 weeks for progression  defined by response"
        ]
    },
    {
        "id": "6d6625ec-26b7-4157-a38c-87c770201323",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "statement_text": "Lidoderm products are used in intervention arm 1 of the secondary trial  and a Siemens product is used in arm 1 of the primary trial",
        "statement_nums": [
            "products are used in intervention arm 1 of the secondary trial  and a Siemens"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  "
        ],
        "premise_nums": [
            "Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day",
            "scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.):"
        ]
    },
    {
        "id": "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210",
        "primaryId": "NCT01305941",
        "statement_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial  meaning their cancer is Histologically-confirmed as being triple-positive ",
        "statement_nums": [
            "to participate in the primary trial  meaning their cancer is Histologically-confirmed as being triple-positive"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (greater than /=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy  stereotactic radiosurgery  gamma knife  or equivalent)  Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible  "
        ],
        "premise_nums": [
            "brain lesion (greater than /=5 mm on radiographic imaging) after receipt of",
            "of the breast with at least one progressive and/or new metastatic",
            "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in",
            "clinical assay on either primary or metastatic tumor) adenocarcinoma of"
        ]
    },
    {
        "id": "c94ad26b-1f5e-4446-a4fe-bb949c5dc561",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "statement_text": "Patients must have BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial ",
        "statement_nums": [
            "mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution AST(GPT): within twice a normal upper value in an institution BUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: ",
            "Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intentMeasurable disease as per RECIST  Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy  Prior treatment with an anthracycline and a taxane in the neoadjuvant  adjuvant or metastatic disease settings  Exclusion Criteria: Histology of inflammatory carcinoma with no other measurable disease  Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease  Brain metastases  spinal cord compression  or carcinomatous meningitis  or leptomeningeal disease  ",
            "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting"
        ],
        "premise_nums": [
            "normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's",
            "Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater",
            "Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater",
            "(World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than",
            "Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 organs Performance Status (World Health Organization :WHO) 0-2 Functions below are",
            "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/",
            "= Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria:",
            "organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs:",
            "Histologically- or cytologically-proven diagnosis of"
        ]
    },
    {
        "id": "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment ",
        "statement_nums": [
            "30% of the primary trial participants had an increased level of CECs after 42 days of treatment"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 "
        ],
        "premise_nums": [
            "patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate)",
            "or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage",
            "Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression",
            "of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated",
            "CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI",
            "40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3"
        ]
    },
    {
        "id": "5c00f992-5066-42f2-88d7-566b8b9104b5",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity   whereas those in cohort 2 did not experience any Acute Toxicities ",
        "statement_nums": [
            "On average cohort 1 participants in the primary trial had an increased Rate",
            "whereas those in cohort 2 did not experience any Acute Toxicities"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) "
        ],
        "premise_nums": [
            "Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent",
            "of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo",
            "1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123",
            "Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit",
            "123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results",
            "Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy"
        ]
    },
    {
        "id": "4c0ffc50-5cb2-4574-b954-335d142edbe4",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial ",
        "statement_nums": [
            "not eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Chronic use of drugs that cause QTc prolongation  Patients must discontinue use of these drugs 7 days prior to the start of study treatment  "
        ],
        "premise_nums": [
            "must discontinue use of these drugs 7 days prior to the start of study"
        ]
    },
    {
        "id": "4e3379b9-f971-4ab6-8846-c395f1162bf2",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "statement_text": "Skin infections were more common in patients in cohort 1 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "more common in patients in cohort 1 of the secondary trial  than in cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 1: Skin infection * 2/41 (4.88%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 1: Skin infection"
        ]
    },
    {
        "id": "adf3bb50-ec36-467a-987a-f33c10380c60",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "statement_text": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) performance status of 0 or 1",
            "Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese"
        ]
    },
    {
        "id": "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1",
        "primaryId": "NCT01875367",
        "statement_text": "One patient in the primary trial suffered a cerebral infarction ",
        "statement_nums": [
            "One patient in the primary trial suffered a cerebral infarction"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related infection (Bacteriemia) 0/81 (0.00%) Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%) Hematuria 1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Catheter related infection (Bacteriemia) 1/85 (1.18%) Lack of strength in left leg 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%) Hematuria 0/85 (0.00%) ",
            "Nodule in left breast 1/85 (1.18%)"
        ],
        "premise_nums": [
            "1/81 (1.23%) Nodule in left breast 0/81 (0.00%) Adverse Events 2: Total: 10/85 (11.76%) Heart failure 1/85 (1.18%) Fever",
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Catheter related",
            "Adverse Events 1: Total: 2/81 (2.47%) Heart failure 0/81 (0.00%) Fever 1/81 (1.23%) Cold 0/81 (0.00%) Catheter related",
            "0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81 (0.00%) Stroke 0/81 (0.00%)",
            "10/85 (11.76%) Heart failure 1/85 (1.18%) Fever 0/85 (0.00%) Cold 1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85",
            "1/85 (1.18%) Ostenecrosis produced by biphosphonates 1/85 (1.18%) Gastric cancer 1/85 (1.18%) Stroke 1/85 (1.18%)",
            "Lack of strength in left leg 0/81 (0.00%) Ostenecrosis produced by biphosphonates 0/81 (0.00%) Gastric cancer 0/81"
        ]
    },
    {
        "id": "03cb39e4-1d21-47e5-9b09-ebe508eb2a17",
        "primaryId": "NCT00477464",
        "statement_text": "59 patients from Arm A of the primary trial achieved a best overall response  classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months ",
        "statement_nums": [
            "or stable disease for at least 6 months",
            "59 patients from Arm A of the primary trial achieved a best overall"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Response (Independent Reviewer-assessed) CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks)  A \"complete response\" is defined as the disappearance of all target or non-target lesions  \"partial response\" and \"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the sum of the longest diameter of target lesions  and \"stable disease\" as neither \"partial response\" nor \"disease progression.\" Time frame: Baseline  every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 Arm/Group Description: Participants took lapatinib and capecitabine  Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants Analyzed: 51 Measure Type: Number ",
            "Unit of Measure: percentage of participants 59"
        ],
        "premise_nums": [
            "Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily",
            "was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day",
            "6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib",
            "Lapatinib was orally administered at 1250 milligrams (mg) once daily  Capecitabine was",
            "twice daily on the first day through the fourteenth day of each 21-day cycle  Overall Number of Participants",
            "\"disease progression\" as at least a 30% decrease and at least a 20% increase  respectively  in the",
            "progression (up to Week 119) Results 1: Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 Arm/Group Description: Participants took lapatinib",
            "Unit of Measure: percentage of participants 59",
            "who achieved a best overall response classified as a complete",
            "or stable disease for at least 6 months (24 weeks)  A \"complete response\""
        ]
    },
    {
        "id": "dca6ba74-441e-482f-b667-6c45800ed8c1",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle  for a total of 6 courses  unless death occurs  ",
        "statement_nums": [
            "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle  for a total"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies "
        ],
        "premise_nums": [
            "receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of"
        ]
    },
    {
        "id": "aeecc244-13a9-4944-858e-27ef49585e90",
        "primaryId": "NCT01702571",
        "statement_text": "Patients with incurable and unresectable Locally Advanced Breast Cancer are eligible for the primary trial ",
        "statement_nums": [
            "with incurable and unresectable Locally Advanced Breast Cancer are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Documented progression of incurable  unresectable  LABC  or mBC  defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy "
        ],
        "premise_nums": [
            "recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy"
        ]
    },
    {
        "id": "741ca5eb-4737-4a35-a9fd-4235d6552b4f",
        "primaryId": "NCT01256008",
        "secondaryId": "NCT00300781",
        "statement_text": "the primary trial is investigating Cognitive behavioural therapy  a type of psychotherapy  in contrast the secondary trial studies Neratinib  a type of chemotherapy ",
        "statement_nums": [
            "the primary trial is investigating Cognitive behavioural",
            "in contrast the secondary trial studies Neratinib  a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical management treatment only each session  Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT each session  ",
            "CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months)  and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress  patients' cognitive and behavioral response to stress  Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  "
        ],
        "premise_nums": [
            "controlled group in the first stage of intervention  Following",
            "40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as",
            "Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long",
            "receive standardized CBT treatment regularly for 9 sessions(once per week in the second and third months)  and each session",
            "INTERVENTION 2: Stage 1 CBT The experimental group will receive CBT",
            "INTERVENTION 1: Stage 1 Clinical Management The group will receive clinical",
            "receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a",
            "a half-structured interview and lasting for 20-25 minutes each session  Clinical management will",
            "stage (the third session to the 8th session): clarification of sources"
        ]
    },
    {
        "id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "statement_nums": [
            "Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin",
            "Gemcitabine group of the primary trial had a median Kaplan-Meier"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment  PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir  Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm C Results 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
            "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) Results 2: Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin ",
            "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 8.3 (5.7 to 10.6) "
        ],
        "premise_nums": [
            "Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 8.3 (5.7 to 10.6)",
            "Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in",
            "8 by IV administration of each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "Days 1 and 8 in each 21-day treatment cycle  Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months",
            "Days 1 and 8 in each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by",
            "8 by IV administration of each 21-day treatment cycle  Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months",
            "unacceptable toxicity  required palliative radiotherapy or surgical intervention",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment",
            "length of time on study was 31 months for Arm A  34 months for Arm B and 35 months",
            "randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A",
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed",
            "for Arm A  34 months for Arm B and 35 months for Arm C Results 1: Arm/Group Title: Arm A: Nab-Paclitaxel",
            "is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and",
            "Progressive Disease- is at least a 20% increase in the sum of diameters"
        ]
    },
    {
        "id": "1a112ed3-8318-493b-8973-10de01794892",
        "primaryId": "NCT00382018",
        "secondaryId": "NCT03012477",
        "statement_text": "Between the patients in the primary trial and the secondary trial  only a single one suffered from sepsis ",
        "statement_nums": [
            "the patients in the primary trial and the secondary trial  only a single"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161 (0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64 (1.56%) Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161",
            "Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%)",
            "(0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64"
        ]
    },
    {
        "id": "6044590d-0f89-4a6e-8be7-54ca0c0327d9",
        "primaryId": "NCT00003404",
        "secondaryId": "NCT00711529",
        "statement_text": "the primary trial does not have a Hypnotherapy based intervention  and the secondary trial does not have a Radiotherapy intervention ",
        "statement_nums": [
            "the primary trial does not have a",
            "intervention  and the secondary trial does not have a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Adjuvant Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision  Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  "
        ],
        "premise_nums": [
            "Adjuvant Radiotherapy: Adjuvant radiation therapy INTERVENTION 1: Hypnotherapy Patients randomized to the",
            "Radiotherapy Adjuvant radiation was started within 12 weeks of local excision or breast re-excision",
            "the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)",
            "the study will undergo individually three one-hour sessions with"
        ]
    },
    {
        "id": "8d3378f7-caaf-4654-b12a-382a0e911eb1",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "Patients with a platelet count of 50 x 109/l are not eligible for the primary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit "
        ],
        "premise_nums": [
            "phosphatase less or equal to 1.5 x upper normal limit   Serum",
            "equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 100 x 109/l, Serum bilirubin less than",
            "cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal",
            "neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than",
            "blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or"
        ]
    },
    {
        "id": "f701473d-e034-4a06-9829-d20cc483162c",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant ",
        "statement_nums": [
            "the primary trial and the secondary trial have non comparable results"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as number of consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4 neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results  ",
            "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years"
        ],
        "premise_nums": [
            "A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel-",
            "any cause  assessed up to 8",
            "consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4",
            "neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival",
            "be used  A 95% confidence interval for the median PFS",
            "However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median",
            "registration to date of first documentation of progression or symptomatic",
            "of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "3889cecd-aa2d-4f58-857e-11d7209f9cf4",
        "primaryId": "NCT00450866",
        "statement_text": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than cohort 2.",
        "statement_nums": [
            "patients with progression free survival at 3 months after treatment  than cohort 2.",
            "primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment  than",
            "In the primary trial a cohort 1 has a higher percentage of patients with"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Central Nervous System (CNS) Progression-free Survival(PFS) The number of patients that are documented to have progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area  PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death  Time frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group A Arm/Group Description: Group A: Patients with progressive  radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT)  Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: participants 12 Results 2: Arm/Group Title: Epothilone B: Group B ",
            "Arm/Group Description: Group B: an exploratory cohort of patients  with either leptomeningeal metastases (LMD) or unirradiated  asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants 2 "
        ],
        "premise_nums": [
            "progression free survival at 3 months after treatment  Progression free is define as smaller than 25% increase in tumor area",
            "to have progression free survival at 3 months after treatment  Progression free is",
            "frame: 3 months after treatment Results 1: Arm/Group Title: Epothilone B: Group",
            "free is define as smaller than 25% increase in tumor area  PFS",
            "dose of 10 mg/m2 (q3weeks) with actual body weight Overall Number of Participants Analyzed: 10 Measure Type: Number Unit of Measure: participants",
            "as a single intravenous infusion over 20 minutes  once every 3 weeks  Patupilone will be"
        ]
    },
    {
        "id": "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051",
        "primaryId": "NCT00338286",
        "statement_text": "No participants of the primary trial had a Progression Free Survival over 1 year ",
        "statement_nums": [
            "No participants of the primary trial had a Progression Free Survival over 1 year"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death  whichever occurred first  Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff  For PD or death with a missing interval immediately preceding the event  progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval  Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment  Time frame: From the date of randomization to the date of disease progression (PD) or death  whichever occurred first (up to 8.4 years) Results 1: Arm/Group Title: Standard of Care (SOC) Arm/Group Description: Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion  Overall Number of Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin Alfa ",
            "Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week Overall Number of Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 7.6) "
        ],
        "premise_nums": [
            "(SC) once a week Overall Number of Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months",
            "death  whichever occurred first  Participants who had not",
            "were censored at the last disease assessment prior to the",
            "Participants Analyzed: 1048 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin",
            "Participants Analyzed: 1050 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (7.1 to 7.6) Results 2: Arm/Group Title: Epoetin",
            "Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a",
            "whichever occurred first (up to 8.4 years) Results 1: Arm/Group"
        ]
    },
    {
        "id": "cb023dbc-3e99-4c32-a857-7f8d49ef5a96",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts ",
        "statement_nums": [
            "the secondary trial reported more cases of",
            "Haematemesis  but the primary trial had more total cases"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 58/305 (19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA * 1/305 (0.33%) DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%) DIASTOLIC DYSFUNCTION * 1/305 (0.33%) PERICARDIAL EFFUSION * 1/305 (0.33%) Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA * 0/304 (0.00%) ",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%) DIASTOLIC DYSFUNCTION * 0/304 (0.00%) PERICARDIAL EFFUSION * 0/304 (0.00%) Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) "
        ],
        "premise_nums": [
            "(19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA",
            "neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%)",
            "DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%)",
            "ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%)",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA",
            "12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA",
            "Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA",
            "31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%)",
            "2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%)"
        ]
    },
    {
        "id": "1d0ce237-70eb-45b4-9c77-f0b70d410387",
        "primaryId": "NCT00193180",
        "statement_text": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial ",
        "statement_nums": [
            "female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic liver disease "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 18 years or older Exclusion Criteria: Known chronic"
        ]
    },
    {
        "id": "93290529-38b1-444b-9ac8-fa32b98821c5",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "statement_text": "Patients wanting to take part in the secondary trial must be at a specific location  this is not necessary for the primary trial ",
        "statement_nums": [
            "take part in the secondary trial must be at a",
            "not necessary for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Eligibility Criteria: Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma  Histologic confirmation shall be by either core needle biopsy or incisional biopsy  Punch biopsy is allowed if invasive breast cancer is documented  Patients must meet one of the criteria defined below (indicate one): a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment  b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  Physical examination  chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration  Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible  Patients with hypertension or age greater than 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal  ",
            "Patients must have a serum creatinine and bilirubin the institutional upper limit of normal  and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) 2x the institutional upper limit of normal  These tests must have been performed within 90 days prior to registration Patients must have an Absolute neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration  Patients must have a performance status of 0-2 by Zubrod criteria Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen  Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method  A urine pregnancy test is required for women of childbearing potential  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  Inclusion Criteria: Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology at MSKCC  "
        ],
        "premise_nums": [
            "a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an",
            "be women with a histologically confirmed diagnosis of locally",
            "b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  Physical examination",
            "1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration Patients must have",
            "must have a performance status of 0-2 by Zubrod criteria Pregnant or nursing women",
            "tumor assessment must be performed within 90 days prior to registration  Patients with",
            "with hypertension or age greater than 60 years must have a Multiple Gated Acquisition",
            "neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed"
        ]
    },
    {
        "id": "dad5ecc6-afcf-496c-8193-778a100c0318",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA) ",
        "statement_nums": [
            "are excluded from the primary trial  as these constitute",
            "Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or"
        ],
        "label": "Entailment",
        "premise_text": [
            "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine "
        ],
        "premise_nums": [
            "with a Cobb angle greater than 15 degrees at the lumbar spine"
        ]
    },
    {
        "id": "63ec91be-7e12-431e-84b0-ca401bfb157b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "statement_text": "the primary trial recorded 2.38% more total adverse events than the secondary trial",
        "statement_nums": [
            "the primary trial recorded 2.38% more total adverse events than the secondary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%)"
        ]
    },
    {
        "id": "fd5af11f-7270-49d5-924a-755ff399c463",
        "primaryId": "NCT00373256",
        "statement_text": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death  and the mean PFS for this group was just under 7 and a half months ",
        "statement_nums": [
            "and Paclitaxel for a duration of 18 months or until death  and the",
            "for this group was just under 7 and a half months",
            "the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS = (first event date minus randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5) "
        ],
        "premise_nums": [
            "Title: Sunitinib + Paclitaxel Overall Number of Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months",
            "Participants Analyzed: 242 Median (95% Confidence Interval) Unit of Measure: Months 7.4 (6.9 to 8.5)",
            "the date of the first documentation of objective tumor progression",
            "randomization date +1) divided by 30.4 Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18",
            "randomization through Day 1 and every 8 weeks thereafter up to 18 months or death Results 1: Arm/Group Title: Sunitinib + Paclitaxel"
        ]
    },
    {
        "id": "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276",
        "primaryId": "NCT02186015",
        "statement_text": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol ",
        "statement_nums": [
            "cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Cholecalciferol Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks  INTERVENTION 2: No",
            "No Cholecalciferol Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention"
        ]
    },
    {
        "id": "6a5ee728-7db9-4ec0-b98c-0500e9a6187e",
        "primaryId": "NCT00924352",
        "statement_text": "One patient in the primary trial had abnormally low levels of AST  ALT and ANC ",
        "statement_nums": [
            "One patient in the primary trial had abnormally low levels of AST"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 11/56 (19.64%) Febrile Neutropenia * 3/56 (5.36%) Neutropenia * 1/56 (1.79%) Pancytopenia * 1/56 (1.79%) Atrial Fibrillation * 1/56 (1.79%) Coronary Artery Disease * 1/56 (1.79%) Constipation * 1/56 (1.79%) Chest Pain * 1/56 (1.79%) Non-Cardiac Chest Pain * 1/56 (1.79%) Edema due to Cardiac Disease * 1/56 (1.79%) Cellulitis * 1/56 (1.79%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 11/56 (19.64%) Febrile Neutropenia * 3/56 (5.36%) Neutropenia * 1/56 (1.79%) Pancytopenia * 1/56 (1.79%) Atrial"
        ]
    },
    {
        "id": "a495df61-260d-479c-8d5f-d586f295c672",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups  receiving a placebo tablet PO BID ",
        "statement_nums": [
            "Cohort 2 of the secondary trial and the primary trial are control groups"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control ",
            "Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR Control: Web-based resource lists and text-based study adherence reminders "
        ],
        "premise_nums": [
            "reminders  At completion of the 24 weeks of follow up  they will",
            "minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of",
            "prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship",
            "reproductive health and study adherence INTERVENTION 2: Control"
        ]
    },
    {
        "id": "917afeec-5152-4424-89e3-7f3ffad6378f",
        "primaryId": "NCT01105650",
        "statement_text": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg  but all participants will be administered IL-2 3 times per week for 6 doses ",
        "statement_nums": [
            "less of IL-2, than participants over 45 kg  but all participants will be administered IL-2",
            "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than",
            "the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm 1: CsA Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5 days)  Cyclophosphamide: Administered intravenously  60 mg/kg  days -5 and -4. Cyclosporine (CsA): Administered intravenously  1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given  Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses)  "
        ],
        "premise_nums": [
            "(For patients weighing less than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week",
            "Fludarabine: Administered intravenously  25 mg/m^2, days -6 through -2 (5",
            "than 1 hour; no more than 8.0 x 10^7 cells/kg will be given at 5 million units/m^2 3 times per week",
            "a week for a total of 6 doses  beginning 4 hours after NK cell infusion  (For",
            "than 45 kilograms  IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses)",
            "Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of",
            "mg/kg for target dose range of 150-250 ng/mL day -3 through day +14 Natural Killer cells: Administered by infusion over"
        ]
    },
    {
        "id": "f5aa1aa3-7be3-4518-8cc5-df2394e70e96",
        "primaryId": "NCT02244580",
        "secondaryId": "NCT01901146",
        "statement_text": "Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial ",
        "statement_nums": [
            "accepted by both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Estrogen receptor (ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry "
        ],
        "premise_nums": [
            "(ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease Known estrogen receptor (ER) and"
        ]
    },
    {
        "id": "45338f7c-5aaa-40fb-8503-7c943e1f3a29",
        "primaryId": "NCT03584009",
        "statement_text": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally ",
        "statement_nums": [
            "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a",
            "participants who were administered an additional 800mg of Venetoclax orally"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Defined as Complete Response (CR)  Partial Response (PR) or Stable Disease (SD) Lasting greater than or equal 24 Weeks  as Determined by the Investigator According to RECIST v1.1 Clinical Benefit was defined as CR  PR  or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline  as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: CR  Disappearance of all target lesions; PR  PR greater than or equal 30% decrease in the sum of diameters of target lesions (TL) taking as reference the baseline sum of diameters; SD  neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD)  PDgreater than or equal 20% increase in the sum of diameters of TL taking as reference the smallest sum on study(Nadir)  In addition to the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm. ",
            "Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)Results 1: Arm/Group Title: Venetoclax + Fulvestrant Arm/Group Description: Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days)  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 11.8 (4.44 to 23.87) Results 2: Arm/Group Title: Fulvestrant Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days)  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 13.7 (5.70 to 26.26) "
        ],
        "premise_nums": [
            "addition to the relative increase of 20% sum must have demonstrate an absolute",
            "(PD)  PDgreater than or equal 20% increase in the sum of diameters",
            "Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent",
            "PR greater than or equal 30% decrease in the sum of diameters",
            "Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 11.8 (4.44 to 23.87) Results 2: Arm/Group Title: Fulvestrant",
            "the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm.",
            "(RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or",
            "Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 13.7 (5.70 to 26.26)",
            "PR  or SD lasting more than equal to 24 weeks from randomization in participants with measurable",
            "6 months after the last participant is enrolled into the study (up to approximately 23 months)Results 1: Arm/Group Title: Venetoclax",
            "15 of Cycle 1 and Day 1 of subsequent cycles (Cycle lengthe relative increase of 20% sum must have demonstrate an absolute",
            "Investigator According to RECIST v1.1 Clinical Benefit was defined as CR  Disappearance of all target lesions; PR  PR",
            "Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent"
        ]
    },
    {
        "id": "0964be32-f9e7-49ec-ad22-b030d483702a",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally ",
        "statement_nums": [
            "secondary trial  the primary trial does not administer any medication orally"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  "
        ],
        "premise_nums": [
            "disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as",
            "receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell",
            "who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily",
            "received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants",
            "dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi)",
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with",
            "3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per"
        ]
    },
    {
        "id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
        "primaryId": "NCT01527487",
        "statement_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial  as Psychological illnesses are not permitted ",
        "statement_nums": [
            "not eligible for the primary trial  as Psychological illnesses"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed invasive adenocarcinoma of the breast  Primary palpable disease confined to the breast and axilla on physical examination (clinical Stage II or III disease)  For patients without clinically suspicious axillary adenopathy  the primary must be greater than 2 cm in diameter by physical examination or imaging studies (clinical T2-3, N0-2, M0). For patients with clinically suspicious axillary adenopathy  the primary breast tumor can be any size (clinical T1-3, N1-2, M0). Patients who have had axillary node dissection and have pN3a (i.e  10 involved axillary nodes) are also eligible  Patients entering the trial after undergoing an axillary node dissection will be eligible if they meet other entry criteria  Estrogen receptor (ER) and progesterone receptor (PR) status in the primary tumor known or pending at the time of study registration  Resolution of all acute effects of surgical procedures to grade 1. For patients who had or will have  a sentinel node and/or axillary node dissection  completion at least 1 week prior to the initiation of study treatment with a well-healed wound is required  ",
            "Bilateral  synchronous breast cancer is allowed if both primary tumors are HER2-negative and at least one meets the specified qualifying tumor or nodal inclusion criteria Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2. Patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available  and at the time of future surgical procedure(s) for correlative testing  If tissue is not available  the patient will still be eligible for enrollment to the study  No evidence of metastatic disease  as documented by complete staging workup 8 weeks prior to initiation of study treatment  No prior treatment for this breast cancer with the exception of criterion #3. HER2-negative tumor status defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in situ hybridization) or SISH (Silver in situ hybridization) negative (defined by ratio smaller than 2.2) Adequate hematologic function defined as: Absolute neutrophil count (ANC) 1500/μL Hemoglobin (Hgb) 10 g/dL Platelets 100,000/uL Adequate liver function defined as: ",
            "Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x the upper limit of normal (ULN)Total bilirubin the institutional ULN Adequate renal function defined as: Serum creatinine 1.5 mg/dL x ULN OR calculated creatinine clearance 50 mL/min by the Cockcroft-Gault method: GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL) Other laboratory testing: Serum magnesium the institutional lower limit of normal (LLN) Serum potassium the institutional LLN Female and 18 years of age  Negative serum pregnancy test within smaller than 7 days prior to initial trial treatment  Female patients who are not of child-bearing potential  and female patients of child-bearing potential who agree to use adequate contraceptive measures that are approved by their study physician while receiving study treatment and continuing for 3 weeks after the last dose of study drug treatment  who are not breastfeeding  and who have a negative serum pregnancy test prior to start of dosing  Willingness and ability to comply with trial and follow-up procedures  Ability to understand the nature of this trial and give written informed consent  Exclusion Criteria: ",
            "Clinical T4 lesions  including inflammatory breast cancer  Clinical N3 involvement (e.g.  ipsilateral  infraclavicular  supraclavicular  and internal mammary nodes) Peripheral neuropathy (motor or sensory) greater than grade 1 according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Patient has received radiotherapy for treatment of previous cancer that included 30% of major bone marrow containing areas (e.g.  pelvis  lumbar  spine)  Known or suspected allergy or hypersensitivity to any of the study drugs (i.e.  eribulin  cyclophosphamide  docetaxel) or known hypersensitivity to polysorbate 80. Patients with acute or chronic liver or renal disease or pancreatitis  Known diagnosis of human immunodeficiency virus (HIV)  Hepatitis B (HBV) or Hepatitis C (HCV)  ",
            "Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene  tamoxifen or other selective estrogen receptor modulator (SERM)  Patients must have discontinued use of such agents prior to beginning study treatment  However  use of GNRH agonists for the purpose of fertility preservation or suppression of heavy menses is permitted (see Section 5.4.1).Patient has any of the following cardiac diseases currently or within the last 6 months: Left Ventricular Ejection Fraction (LVEF) smaller than 45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) Heart rate-corrected QT interval (QTc) greater than 480 ms on screening electrocardiogram (ECG) (using Bazett's formula) Unstable angina pectoris Congestive heart failure (New York Heart Association [NYHA] Grade 2 Acute myocardial infarction Conduction abnormality not controlled with pacemaker or medication Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)  ",
            "Valvular disease with significant compromise in cardiac functionChronic use of drugs that cause QTc prolongation  Patients must discontinue use of these drugs 7 days prior to the start of study treatment  Presence of other active cancers  or history of treatment for invasive cancer 5 years  Patients with stage I cancer who have received definitive local treatment at least 3 years previously  and are considered unlikely to recur are eligible  All patients with previously treated in situ carcinoma (i.e  non-invasive) are eligible  as are patients with history of non-melanoma skin cancer  Patients may not receive any other investigational or anti-cancer treatments while participating in this trial  Psychological  familial  sociological  or geographical conditions that do not permit compliance with the protocol  Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol  "
        ],
        "premise_nums": [
            "axillary adenopathy  the primary must be greater than 2 cm in diameter by physical examination or",
            "the Cockcroft-Gault method: GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL) Other laboratory testing:",
            "heavy menses is permitted (see Section 5.4.1).Patient has any of the primary must be greater than 2 cm in diameter by physical",
            "Known or suspected allergy or hypersensitivity to any",
            "effects of surgical procedures to grade 1. For patients who had or",
            "receiving study treatment and continuing for 3 weeks after the last dose of study drug treatment",
            "is allowed if both primary tumors are HER2-negative and at least one meets the specified qualifying",
            "be any size (clinical T1-3, N1-2, M0). Patients who have had",
            "(ECOG) Performance Status (PS) score of 0-2. Patients entering this study must be",
            "Inclusion Criteria: Histologically confirmed invasive adenocarcinoma of",
            "history of treatment for invasive cancer 5 years  Patients with stage",
            "received definitive local treatment at least 3 years previously  and are considered unlikely",
            "(Hgb) 10 g/dL Platelets 100,000/uL Adequate liver function defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ or IHC 3+ confirmed as",
            "Heart Association [NYHA] Grade 2 Acute myocardial infarction Conduction abnormality not controlled",
            "exception of criterion #3. HER2-negative tumor status defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ or IHC 3+ confirmed as",
            "(ANC) 1500/μL Hemoglobin (Hgb) 10 g/dL Platelets 100,000/uL Adequate liver function defined as: Serum creatinine 1.5 mg/dL x ULN OR calculated creatinine",
            "and aspartate aminotransferase (AST) 2.5 x the upper limit of normal (ULN)Total",
            "have pN3a (i.e  10 involved axillary nodes) are also eligible",
            "(motor or sensory) greater than grade 1 according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Patient has",
            "serum pregnancy test within smaller than 7 days prior to initial trial treatment",
            "must discontinue use of these drugs 7 days prior to the start of study",
            "or imaging studies (clinical T2-3, N0-2, M0). For patients with clinically",
            "3 weeks after the last dose of study drug treatment and continuing for 3 weeks after the last dose of study",
            "0-1+ or IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence institutional LLN Female and 18 years of age  Negative serum pregnancy",
            "potassium the institutional LLN Female and 18 years of age  Negative serum pregnancy",
            "defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in",
            "function defined as: Serum creatinine 1.5 mg/dL x ULN OR calculated creatinine clearance 50 mL/min by the Cockcroft-Gault method: GRF =(140-age)",
            "rate-corrected QT interval (QTc) greater than 480 ms on screening electrocardiogram (ECG) (using Bazett's",
            "3 weeks after the last dose of study drug treatment of previous cancer that included 30% of major bone marrow containing",
            "as documented by complete staging workup 8 weeks prior to initiation of study treatment",
            "breast cancer  Clinical N3 involvement (e.g.  ipsilateral  infraclavicular",
            "test within smaller than 7 days prior to initial trial treatment of previous cancer that included 30% of major bone marrow containing",
            "x ULN OR calculated creatinine clearance 50 mL/min by the Cockcroft-Gault method: GRF =(140-age) x (weight/kg) x (0.85 if female)"
        ]
    },
    {
        "id": "94cd9451-35a4-4035-a7de-2d385f771607",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 2 of the primary trial fainted ",
        "statement_nums": [
            "1/42 patients in cohort 2 of the primary trial fainted"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%)"
        ]
    },
    {
        "id": "18310f83-54ca-4530-92f1-7c41419ab69e",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "statement_nums": [
            "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) ",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) "
        ],
        "premise_nums": [
            "0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain",
            "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%)",
            "death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)",
            "Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)",
            "(6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and",
            "Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%)",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)"
        ]
    },
    {
        "id": "4fa6b99e-0e70-465d-8b24-b728979b3689",
        "primaryId": "NCT00567190",
        "statement_text": "There was the same number of anemic patinets in both cohorts of the primary trial ",
        "statement_nums": [
            "both cohorts of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%)"
        ]
    },
    {
        "id": "85210693-996a-4ab9-92f4-62060571da21",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "a heart rate of at most 50 beats per minute are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm "
        ],
        "premise_nums": [
            "English or Spanish speaking women age 18 Heart Rate greater than 60 bpm"
        ]
    },
    {
        "id": "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia ",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial recorded the same number"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) "
        ],
        "premise_nums": [
            "0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT",
            "SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%)",
            "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse"
        ]
    },
    {
        "id": "6a37e999-4b7e-4654-b9ac-7776a0720040",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "statement_text": "1 patient in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "1 patient in the secondary trial developed an eating disorder",
            "this happening in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: ",
            "Total: 9/46 (19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) "
        ],
        "premise_nums": [
            "Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia",
            "Total: 9/46 (19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46",
            "Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "(19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)",
            "Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%)",
            "neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia",
            "Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia",
            "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%)",
            "gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%)",
            "Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)"
        ]
    },
    {
        "id": "a625ff4b-9c91-4ab8-a78b-df833d15759a",
        "primaryId": "NCT00423917",
        "secondaryId": "NCT00082641",
        "statement_text": "the primary trial and the secondary trial both report cases of confusion in all their patient cohorts ",
        "statement_nums": [
            "the primary trial and the secondary trial both report cases of",
            "primary trial and the secondary trial both report cases of confusion in all their patient cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 1: Confusion 1/11 (9.09%) Adverse Events 2: Confusion 0/12 (0.00%)",
            "Adverse Events 1: Confusion 1/33 (3.03%) Adverse Events 2: Confusion 0/12 (0.00%)"
        ]
    },
    {
        "id": "b25e7c40-a1db-4ae7-9613-0f65ddb4c040",
        "primaryId": "NCT00082641",
        "statement_text": "At least one patient in the primary trial suffered from a life threatening bone fracture ",
        "statement_nums": [
            "one patient in the primary trial suffered from a life"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/11 (45.45%) Nausea 1/11 (9.09%) Vomiting 1/11 (9.09%) Fever 1/11 (9.09%) skin infection [1]1/11 (9.09%) Hip fracture 0/11 (0.00%) Confusion 1/11 (9.09%) Adverse Events 2: Total: 1/12 (8.33%) Nausea 0/12 (0.00%) Vomiting 0/12 (0.00%) Fever 0/12 (0.00%) skin infection [1]0/12 (0.00%) Hip fracture 1/12 (8.33%) Confusion 0/12 (0.00%) "
        ],
        "premise_nums": [
            "(0.00%) Confusion 1/11 (9.09%) Adverse Events 2: Total: 1/12 (8.33%) Nausea 0/12 (0.00%) Vomiting 0/12 (0.00%) Fever 0/12",
            "Adverse Events 1: Total: 5/11 (45.45%) Nausea 1/11 (9.09%) Vomiting 1/11 (9.09%) Fever 1/11",
            "skin infection [1]0/12 (0.00%) Hip fracture 1/12 (8.33%) Confusion 0/12 (0.00%) Confusion 1/11 (9.09%) Adverse Events 2: Total: 1/12 (8.33%) Nausea 0/12"
        ]
    },
    {
        "id": "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f",
        "primaryId": "NCT00856492",
        "statement_text": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia ",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded no deaths and"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%) "
        ],
        "premise_nums": [
            "Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%)",
            "2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96 (0.00%)",
            "Total: 22/96 (22.92%) Anemia 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal pain 1/96 (1.04%) Dysphagia 1/96 (1.04%)",
            "(1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal",
            "(1.04%) Dysphagia 1/96 (1.04%) Mucositis oral 1/96 (1.04%) Nausea 1/96 (1.04%) Febrile neutropenia 4/96 (4.17%) Heart failure 1/96 (1.04%) Abdominal",
            "Nausea 1/96 (1.04%) Vomiting 2/96 (2.08%) Death NOS 0/96 (0.00%) Pain 1/96 (1.04%) Catheter related infection 1/96 (1.04%) Enterocolitis infectious 0/96"
        ]
    },
    {
        "id": "c0ddffa9-4a88-4ee1-8525-a77e887c3d85",
        "primaryId": "NCT01268150",
        "statement_text": "The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group ",
        "statement_nums": [
            "Mesylate group in the primary trial had a higher proportion"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) The ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)  based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Targeted lesions were assessed by computed tomography (CT) and magnetic resonance imaging (MRI) which were then assessed by the investigator based on RECIST  CR was defined as the disappearance of all target lesions  PR was defined as at least 30% decrease in the sum of diameters of target lesions  taking as reference baseline sum diameters  Possible CR and PR had to be confirmed no fewer than 4 weeks after the initial response assessment  A brain and bone scan was performed by CT/MRI within 1 week after confirmation of a response to ensure no new metastases  To be assigned a status of CR or PR  changes in tumor measurements had to be confirmed by repeat evaluations  to be performed not fewer than 4 weeks after the response criteria were first met  ORR = CR + PR Time frame: Cycle 1 (Day 1) until first evidence of disease progression  assessed up to the data cutoff date (30 Aug 2013) up to 2.5 years ",
            "Results 1:Arm/Group Title: Eribulin Mesylate Arm/Group Description: Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days 1 and 8 of each 3-week cycle  Overall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: Percentage of participants 28.6 "
        ],
        "premise_nums": [
            "the response criteria were first met  ORR = CR",
            "Arm/Group Description: Eribulin mesylate at 1.4 mg/m^2 was administered as and 8 of each 3-week cycle  Overall Number of Participants",
            "to be confirmed no fewer than 4 weeks after the initial response assessment",
            "PR was defined as at least 30% decrease in the sum of diameters",
            "Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: Percentage of participants 28.6",
            "scan was performed by CT/MRI within 1 week after confirmation of a response to",
            "PR was defined as at least 30% decrease in the sum of participants with best overall response (BOR) of confirmed complete",
            "Results 1:Arm/Group Title: Eribulin Mesylate Arm/Group Description: Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion",
            "the data cutoff date (30 Aug 2013) up to 2.5 years",
            "Eribulin mesylate at 1.4 mg/m^2 was administered as an intravenous (IV) infusion over 2 to 5 minutes on Days 1 and"
        ]
    },
    {
        "id": "64ea58e5-e28f-42bc-818e-31bbf347080c",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial  but may still be eligible for the secondary trial ",
        "statement_nums": [
            "be eligible for the secondary trial",
            "are excluded from the primary trial  but may still"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0. Histologically or cytologically confirmed adenocarcinoma of the breast Stage III or IV disease Primary or recurrent disease Invasive lobular carcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered from prior primary therapy Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including  but not limited to  surgery  chemotherapy  and radiotherapy within the past 36 months Must have at least one undissected axillary and/or inguinal lymph node basin No history of brain metastases Hormone receptor status Estrogen receptor-positive or -negative tumor PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal status not specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL ",
            "Hemoglobin A1c smaller than 7%AST and ALT 2.5 x upper limit of normal (ULN) Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN HIV negative Hepatitis C negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known or suspected allergies to any component of the vaccine No active infection requiring antibiotics No New York Heart Association class III or IV heart disease No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement  except the following: Laboratory evidence of autoimmune disease (e.g.  positive ANA titer) without symptoms Clinical evidence of vitiligo Other forms of depigmenting illness Mild arthritis requiring nonsteroidal antiinflammatory drugs No medical contraindication or potential problem that would preclude study participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy More than 4 weeks since prior and no concurrent allergy desensitization injections ",
            "More than 4 weeks since prior parenteral  oral  or inhaled corticosteroidsNo concurrent inhaled steroids (e.g.  Advair® or triamcinolone acetonide) Prior or concurrent topical corticosteroids allowed More than 4 weeks since prior and no concurrent growth factors (e.g.  epoetin alfa  darbepoetin alfa  or pegfilgrastim) More than 4 weeks since prior and no concurrent other investigational medication More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents Prior and concurrent hormonal therapy (e.g.  tamoxifen  raloxifene  toremifene  fulvestrant  letrozole  anastrozole  or exemestane) allowed No prior vaccination with any synthetic peptides in this protocol Vaccines for infectious disease (e.g.  influenza) allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy for acute conditions not related to breast cancer allowed No concurrent illegal drugs "
        ],
        "premise_nums": [
            "specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL",
            "or concurrent topical corticosteroids allowed More than 4 weeks since prior parenteral  oral",
            "or concurrent topical corticosteroids allowed More than 4 weeks prior to or 2 weeks after study vaccine Short term therapy",
            "must have undergone prior antineoplastic therapy including  but",
            "PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than or equal 2 motor or sensorial neurotoxicity by the National",
            "Toxicity Criteria (NCICTC) v-2.0. Histologically or cytologically confirmed adenocarcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered",
            "participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery More than 4 weeks since prior parenteral  oral",
            "specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than or equal 2 motor or sensorial neurotoxicity by the National",
            "Hemoglobin A1c smaller than 7%AST and ALT 2.5 x upper limit of normal (ULN) Bilirubin",
            "limit of normal (ULN) Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN HIV negative Hepatitis C negative",
            "PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal",
            "allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy",
            "Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National"
        ]
    },
    {
        "id": "7a0f4365-9775-4f1d-a1c7-4630b41b43ea",
        "primaryId": "NCT01905592",
        "statement_text": "the primary trial only defines intervention dosage for cohort 2.",
        "statement_nums": [
            "the primary trial only defines intervention dosage for cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine)  until progression or unacceptable toxicity develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops "
        ],
        "premise_nums": [
            "1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies",
            "develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression"
        ]
    },
    {
        "id": "64dcb690-ef14-4cf2-85e5-670eb0645d7f",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial ",
        "statement_nums": [
            "of 18, whose last period was 2 weeks prior are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  "
        ],
        "premise_nums": [
            "and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation",
            "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2",
            "1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of"
        ]
    },
    {
        "id": "cacd1b1b-510e-421b-9adb-c5715f281794",
        "primaryId": "NCT01566721",
        "statement_text": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "statement_nums": [
            "trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Participants were planned to receive a total of 18 cycles of SC Herceptin  An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin  Examples included unfavorable/unintended signs and symptoms  new or exacerbated disease  recurrence of intermittent condition  deterioration in laboratory value or other clinical test  or adverse procedure-related events  The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results 1: Arm/Group Title: Cohort A: SC Herceptin by Needle/Syringe Arm/Group Description: Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe  Overall Number of Participants Analyzed: 1864 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2: ",
            "Arm/Group Title: Cohort B: SC Herceptin by SIDArm/Group Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC Herceptin was administered from a pre-filled SID  The first administration was performed by an HCP  Subsequent doses were self-administered by participants who were willing and judged competent by the HCP  Overall Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 89.0 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants with at least 1 AE during the treatment period",
            "Description: Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles  Each dose of SC",
            "planned to receive a total of 18 cycles of SC Herceptin as 600 mg every 3 weeks for a total of",
            "planned to receive a total of 18 cycles of SC Herceptin by an assisted administration as 600 mg every 3 weeks for",
            "pre-filled SID  The first administration was performed by an",
            "reported  Time frame: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year) Results",
            "planned to receive a total of 18 cycles of SC Herceptin  An AE",
            "Number of Participants Analyzed: 709 Measure Type: Number Unit of Measure: percentage of participants 88.6 Results 2:",
            "Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period"
        ]
    },
    {
        "id": "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a",
        "primaryId": "NCT02502864",
        "statement_text": "The maximum number of occurences for an adverse event in the primary trial was 3.",
        "statement_nums": [
            "adverse event in the primary trial was 3."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9 (11.11%) Sepsis * 1/9 (11.11%) Urinary tract infection * 1/9 (11.11%) Syncope * 1/9 (11.11%) Anxiety * 1/9 (11.11%) Thromboembolic event * 1/9 (11.11%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/9 (33.33%) Fatigue * 1/9 (11.11%) Non-cardiac chest pain * 1/9"
        ]
    },
    {
        "id": "7926bfa3-cf49-4589-8143-0a0826336b67",
        "primaryId": "NCT01401166",
        "statement_text": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration ",
        "statement_nums": [
            "All patients in cohort 1 of the primary trial had a Preferred Method"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants by Preferred Method of Drug Administration The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant  Participants were asked  \"All things considered  which method of administration did you prefer?\" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported  Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin ",
            "Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1 to 4 of the crossover period  SC Herceptin was administered via SID  and during Cycles 5 to 8, IV Herceptin was given  In the continuation period  participants received IV Herceptin for up to 10 remaining cycles  Administration was performed by HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP  The SC dose was 600 mg for all cycles where SC Herceptin was given  and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given Overall Number of Participants Analyzed: 117 Measure Type: Number Unit of Measure: percentage of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0 "
        ],
        "premise_nums": [
            "Time frame: Week 24 Results 1: Arm/Group Title: Cohort 1: SC",
            "the IV dose was 6 mg/kg for all cycles where IV Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0",
            "via SID  and during Cycles 5 to 8, IV Herceptin was given",
            "of participants SC Herceptin: 95.7 IV Herceptin: 4.3 No Preference: 0.0",
            "HCP  Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period",
            "HCP  The SC dose was 600 mg for all cycles where SC Herceptin was",
            "Number of Participants Analyzed: 117 Measure Type: Number Unit of Measure: percentage",
            "The SC dose was 600 mg for all cycles where SC Herceptin for up to 10 remaining cycles  Administration was performed by",
            "The SC dose was 600 mg for all cycles where SC Herceptin on Day 1 of each 3-week cycle for 18 cycles",
            "Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles  During Cycles 1",
            "received IV Herceptin for up to 10 remaining cycles  Administration was performed by"
        ]
    },
    {
        "id": "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "statement_text": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts  On the other hand  the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib ",
        "statement_nums": [
            "the primary trial does not explicitly state",
            "other hand  the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib ",
            "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  "
        ],
        "premise_nums": [
            "1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe",
            "treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly",
            "will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days",
            "mg/m2 orally BID 14 of every 21 days  Treatment cycles will be paired with LBH589 and will range in dose from 825",
            "orally twice daily for 14 days out of every 21 days  Treatment cycles will be 21 days in length  Once",
            "orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib",
            "With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be administered orally twice daily for 14 days out of every 21",
            "be administered orally twice daily for 14 days out of every 21 days",
            "treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin",
            "days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the"
        ]
    },
    {
        "id": "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "statement_text": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial ",
        "statement_nums": [
            "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%)"
        ]
    },
    {
        "id": "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9",
        "primaryId": "NCT01269346",
        "secondaryId": "NCT01597193",
        "statement_text": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total number of adverse events ",
        "statement_nums": [
            "Cohort 1 of the primary trial and Cohort 1 of the secondary trial have the same total"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 15/52 (28.85%) Adverse Events 1: Total: 2/7 (28.57%)"
        ]
    },
    {
        "id": "1aee22c7-96f2-4ea6-909a-48741f87ba07",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) ",
            "Acute coronary syndrome 0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) "
        ],
        "premise_nums": [
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "(0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "(0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:"
        ]
    },
    {
        "id": "d677707e-9ca9-4801-8fcd-7960a9f4f30a",
        "primaryId": "NCT00513695",
        "statement_text": "paclitaxel is the only drug in the primary trial given by IV ",
        "statement_nums": [
            "only drug in the primary trial given by IV"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Neoadjuvant Chemotherapy Before Surgery) Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity  Beginning within 3 weeks of completion of sunitinib malate and paclitaxel  patients receive doxorubicin IV once weekly for 15 weeks  cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients undergo surgery  sunitinib malate: Given PO paclitaxel: Given IV doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO filgrastim: Given SC therapeutic conventional surgery: Undergo surgery laboratory biomarker analysis: Correlative studies flow cytometry: Correlative studies "
        ],
        "premise_nums": [
            "unacceptable toxicity  Beginning 3-6 weeks after completion of chemotherapy  patients",
            "cyclophosphamide PO once daily for 15 weeks  and filgrastim SC on days 2-7 for 16 weeks in the absence of",
            "and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression"
        ]
    },
    {
        "id": "5335a9c9-bae1-42e9-9428-eb0eded62d7f",
        "primaryId": "NCT03252145",
        "secondaryId": "NCT00904033",
        "statement_text": "None of the subjects in the primary trial are required to injest any pills  whereas both cohorts of the secondary trial must take a weekly tablet ",
        "statement_nums": [
            "both cohorts of the secondary trial must take a weekly",
            "the subjects in the primary trial are required to injest"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid  INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training ",
            "Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise"
        ],
        "premise_nums": [
            "pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting",
            "lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb Manual"
        ]
    },
    {
        "id": "e6c0f7af-b549-4aad-8f3c-15f367a04a50",
        "primaryId": "NCT01307891",
        "statement_text": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group ",
        "statement_nums": [
            "Tigatuzumab group of the primary trial has 10% more patients with either Complete Response",
            "the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR)"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study  Overall Number of Participants Analyzed: 39 Measure Type: Number ",
            "Unit of Measure: percentage of patients 28 (14.9 to 45.0)Results 2: Arm/Group Title: Abraxane Alone Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) "
        ],
        "premise_nums": [
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will",
            "will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "8, and 15 at 28-day intervals  Abraxane will be administered as a 10 mg/kg loading dose followed by 5 mg/kg",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1)",
            "basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 28 (14.9 to 45.0)Results 2: Arm/Group Title: Abraxane Alone",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Abraxane at 100 mg/m2 X 3 doses on Days 1,",
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the",
            "at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered",
            "will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21",
            "progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab",
            "tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then",
            "5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients",
            "Number of Participants Analyzed: 39 Measure Type: Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage"
        ]
    },
    {
        "id": "1fc3aeac-3bc0-4a47-8222-ea267a822804",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile bone marrow aplasia in the primary trial ",
        "statement_nums": [
            "marrow aplasia in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/284 (0.00%) Arrhythmia * 21/284 (0.35%) Atrial fibrillation * 1/284 (0.35%) Coronary artery disease * 20/284 (0.00%) Left ventricular dysfunction * 21/284 (0.35%) Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%) Neutropenia * 20/92 (0.00%) Leukopenia * 20/92 (0.00%) Anaemia * 20/92 (0.00%) Thrombocytopenia * 20/92 (0.00%) ",
            "Myocardial infarction * 20/92 (0.00%)Arrhythmia * 20/92 (0.00%) Atrial fibrillation * 0/92 (0.00%) Coronary artery disease * 20/92 (0.00%) Left ventricular dysfunction * 20/92 (0.00%) "
        ],
        "premise_nums": [
            "23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/92 (0.00%)Arrhythmia * 20/92 (0.00%) Atrial fibrillation",
            "(27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia",
            "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia",
            "dysfunction * 21/284 (0.35%) Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%)"
        ]
    },
    {
        "id": "9e664bcb-38cc-4ca6-9738-28d96248b7f2",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily ",
        "statement_nums": [
            "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily "
        ],
        "premise_nums": [
            "1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily"
        ]
    },
    {
        "id": "1b8403ac-7eb3-41cb-8b7e-a89af3492805",
        "primaryId": "NCT02924883",
        "statement_text": "In the primary trial  all cases of Enteritis  Vertigo and Anaemia occurred in cohort 2.",
        "statement_nums": [
            "In the primary trial  all cases of Enteritis  Vertigo",
            "the primary trial  all cases of Enteritis  Vertigo and Anaemia occurred in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133 (0.75%) Constipation 1/133 (0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Vertigo 1/67 (1.49%) ",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%) "
        ],
        "premise_nums": [
            "intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67 (1.49%) Abdominal pain 2/67 (2.99%)",
            "Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67",
            "Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133",
            "(0.75%) Enteritis 0/133 (0.00%) Abdominal pain 0/133 (0.00%) Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67",
            "Total: 52/133 (39.10%) Thrombocytopenia 2/133 (1.50%) Anaemia 1/133 (0.75%) Disseminated intravascular coagulation 0/133 (0.00%) Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133",
            "Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67 (0.00%) Cardiac failure 1/67",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Constipation 0/67",
            "Atrial thrombosis 1/133 (0.75%) Cardiac failure 0/133 (0.00%) Vertigo 0/133 (0.00%) Vomiting 3/133 (2.26%) Nausea 1/133 (0.75%) Colitis 1/133",
            "Adverse Events 2: Total: 16/67 (23.88%) Thrombocytopenia 0/67 (0.00%) Anaemia 0/67 (0.00%) Disseminated intravascular coagulation 1/67 (1.49%) Atrial thrombosis 0/67",
            "Vomiting 0/67 (0.00%)Nausea 1/67 (1.49%) Colitis 0/67 (0.00%) Enteritis 1/67 (1.49%) Abdominal pain 2/67 (2.99%)"
        ]
    },
    {
        "id": "ad853675-40ed-4a65-a401-d09ac3153570",
        "primaryId": "NCT03004534",
        "statement_text": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible)  Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement Either clinically positive (N1 only) or clinically negative axillary nodes (N0) M0 "
        ],
        "premise_nums": [
            "Patient must have (according to TNM 7th edition rules): T1 with T 1.0cm, T2 or T3 by at least one radiographic",
            "clinically negative axillary nodes (N0) M0"
        ]
    },
    {
        "id": "b43bee02-cc3f-4dc8-b13f-8a93de5dc422",
        "primaryId": "NCT00493636",
        "statement_text": "Cohort 1 of the primary trial had a longer median  maximum and minimum pfs than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial had a longer median",
            "maximum and minimum pfs than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival [Not Specified] Time frame: From the date of randomization to date of first documented disease progression (i.e.  the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause  if before progression  assessed up to 39 months  Results 1: Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine) Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
            "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine) Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours) ",
            "Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30 minutes after a meal  for 14 days followed by a 7 day rest period (without capecitabine) Overall Number of Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95) "
        ],
        "premise_nums": [
            "Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered ( 2 tablets ) orally twice daily (approximately every",
            "Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 81 (48 to 95)",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will be administered ( 2 tablets ) orally twice daily (approximately every",
            "and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily  within 30",
            "Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally",
            "Participants Analyzed: 81 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately",
            "Capecitabine will be administered orally at a dose of Measure: Days 81 (48 to 95)",
            "be administered (400 mg; 2 tablets x 200 mg) orally twice daily  within 30 minutes after a meal  for 14",
            "mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered orally at a dose of 1,000 mg/m2 twice daily",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will before progression  assessed up to 39 months  Results 1: Arm/Group",
            "randomization to date of first documented disease progression (i.e.",
            "Days 1 and 8 of a 21 day cycle; Capecitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a",
            "Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo will be administered (400 mg; 2 tablets x 200",
            "Participants Analyzed: 79 Median (95% Confidence Interval) Unit of Measure: Days 103 (83 to 128) Results 2: Arm/Group Title: B (Placebo"
        ]
    },
    {
        "id": "62258901-8207-413d-913f-a04682635add",
        "primaryId": "NCT00050011",
        "statement_text": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD) ",
        "statement_nums": [
            "for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD)",
            "the primary trial results show that Zoledronic"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA)  The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader  Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method  Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid Upfront ",
            "Arm/Group Description: Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) Unit of Measure: Percentage of BMD 1.955 (3.3658) Results 2: Arm/Group Title: Zoledronic Acid Delayed-start ",
            "Arm/Group Description: In lieu of a placebo arm  which was considered unethical for this trial  a delayed start arm was used  Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture  or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6 months until disease progression (recurrence) or end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 256 Mean (Standard Deviation) Unit of Measure: Percentage of BMD -2.325 (3.9542) "
        ],
        "premise_nums": [
            "4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 253 Mean (Standard Deviation) Unit of Measure: Percentage",
            "Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) Bone mineral",
            "Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward",
            "non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward  Time frame:",
            "daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin",
            "Data prior to month 6 were not carried forward  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid Upfront",
            "study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800",
            "carried forward to month 12. Data prior to month 6 were carried forward to month 12. Data prior to month 6",
            "Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD))  Missing data at month 12 were imputed by using the",
            "Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall Number of Participants Analyzed: 256",
            "Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall",
            "BMD))  Missing data at month 12 were imputed by using the upfront arm received Zoledronic Acid 4 mg i.v  on Day",
            "month 12. Data prior to month 6 were not carried forward to month 12. Data prior to month 6 were",
            "mg) and vitamin D (400-800 IU) daily Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants",
            "Percent change = 100*((BMD at Month 12 - Baseline BMD)/Baseline BMD))  Missing data at month 12 were imputed by using the",
            "carried forward to month 12. Data prior to month 6 were started on zoledronic acid 4 mg i.v  and for",
            "asymptomatic fracture discovered at the Month 36 scheduled visit  were started on zoledronic acid 4 mg i.v  and for every 6",
            "Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every",
            "2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  Overall"
        ]
    },
    {
        "id": "d23aee47-e80f-42fe-b095-9cd81f9e0ed3",
        "primaryId": "NCT02657889",
        "statement_text": "Both the primary trial cohorts reported identical results ",
        "statement_nums": [
            "Both the primary trial cohorts reported identical results"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) DLTs are defined as: Any treatment-related Grade 3 non-hematologic clinical (non-laboratory) AE Any treatment-related Grade 3 or Grade 4 non-hematologic lab abnormality if: - Medical intervention is required to treat the patient  or - The abnormality leads to hospitalization  or - The abnormality persists for 7 days  Any treatment-related hematologic toxicity specifically defined as: - Thrombocytopenia Grade 4 for 7 days  or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days  or Grade 3 or 4 associated with infection or febrile neutropenia; - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion  Any treatment-related AE leading to niraparib dose interruption per the following criteria: - A dose interruption for a non-DLT lab abnormality lasting 14 days  - A dose in interruption per dose modification rules for nonhematologic AE leading to smaller than 80% of an intended dose being administered  Time frame: During Cycle 1, ie  during the first 21 days of treatment Results 1: Arm/Group Title: Phase 1: Niraparib 200mg + Pembrolizumab ",
            "Arm/Group Description: Niraparib 200 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 1 16.7% Results 2: Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab Arm/Group Description: Niraparib 300 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 1 16.7% "
        ],
        "premise_nums": [
            "as: Any treatment-related Grade 3 non-hematologic clinical (non-laboratory) AE Any treatment-related Grade 3 or Grade 4 non-hematologic lab abnormality if: - Medical intervention",
            "leading to smaller than 80% of an intended dose being administered  Time frame: During Cycle 1, ie  during the first",
            "Arm/Group Description: Niraparib 200 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle Overall",
            "Title: Phase 1: Niraparib 300mg + Pembrolizumab Arm/Group Description: Niraparib 300 mg/day orally (PO)  Pembrolizumab 200 mg",
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 1 16.7% Results 2: Arm/Group Title: Phase 1:",
            "for a non-DLT lab abnormality lasting 14 days  - A dose",
            "during the first 21 days of treatment Results 1: Arm/Group Title: Phase 1: Niraparib 200mg + Pembrolizumab",
            "as: - Thrombocytopenia Grade 4 for 7 days  or Grade 3 or Grade 4 non-hematologic lab abnormality if: - Medical intervention",
            "Pembrolizumab Arm/Group Description: Niraparib 300 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle Overall",
            "nonhematologic AE leading to smaller than 80% of an intended dose being administered",
            "or - The abnormality persists for 7 days  Any treatment-related hematologic",
            "intravenously (IV) on Day 1 of each 21-day cycle Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of",
            "or febrile neutropenia; - Anemia Grade 4, or Grade 3 or 4"
        ]
    },
    {
        "id": "d23eb56e-c232-4754-94aa-903bc174cb35",
        "primaryId": "NCT00524303",
        "statement_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm ",
        "statement_nums": [
            "Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel  Time frame: Week 26 Results 1: Arm/Group Title: Trastuzumab ",
            "Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants were treated with trastuzumab in a 2-week run-in period  On Day 14, a second core needle biopsy was performed  followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib ",
            "Arm/Group Description: Participants received lapatinib alone (1250 mg orally [PO] once daily [QD])  Participants were treated with lapatinib in a 2-week run-in period  On Day 14, a second core needle biopsy was performed  followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 45.0 "
        ],
        "premise_nums": [
            "trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of",
            "mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15)",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib",
            "Day 8, and Day 15) in combination with lapatinib Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage",
            "Day 1 of Week 2 and weekly thereafter)  Participants were treated with lapatinib in a 2-week run-in period  On",
            "followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil",
            "cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day",
            "mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number",
            "were treated with lapatinib in a 2-week run-in period  On Day 14, a second core needle biopsy",
            "followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU",
            "Time frame: Week 26 Results 1: Arm/Group Title: Trastuzumab",
            "epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib Overall",
            "1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants were treated",
            "chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500",
            "the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and",
            "Day 1, Day 8, and Day 15) in combination with trastuzumab Overall Number of Participants Analyzed: 26",
            "were treated with trastuzumab in a 2-week run-in period  On Day 14, a second core needle biopsy",
            "Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy A pCR in the",
            "the lymph nodes  26 weeks of therapy comprised the 2-week run-in period  On Day 14, a second core needle biopsy",
            "4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of therapy comprised the 2-week run-in phase  12 weeks of",
            "4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of Measure: percentage of participants 54.0 Results 2: Arm/Group Title: Lapatinib",
            "mg/kg on Day 1 of Week 2 and weekly thereafter)  Participants received lapatinib alone (1250 mg orally [PO] once daily [QD])",
            "trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, Day 8, and Day 15) in combination with lapatinib Overall",
            "weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80"
        ]
    },
    {
        "id": "33652443-0bb4-493e-adfe-f5032b96b13d",
        "primaryId": "NCT01808573",
        "statement_text": "the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months ",
        "statement_nums": [
            "than the study time frame of 38 months",
            "the primary trial Patients receiving Neratinib Plus"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Centrally Assessed Progression Free Survival Progression Free Survival (PFS)  Measured in Months  for Randomized Subjects of the Central Assessment  The time interval from the date of randomization until the first date on which recurrence  progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause  is documented  For subjects without recurrence  progression or death  it is censored at the last valid tumor assessment  Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Here  the time to event was reported as the restricted mean survival time  The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months  Time frame: From randomization date to recurrence  progression or death  assessed up to 38 months  The result is based on primary analysis data cut  Results 1: Arm/Group Title: Neratinib Plus Capecitabine ",
            "Arm/Group Description: neratinib 240 mg orally  once daily with food  continuously in 21 day cycles  and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle Overall Number of Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months 8.8 (7.8 to 9.8) Results 2: Arm/Group Title: Lapatinib Plus Capecitabine Arm/Group Description: lapatinib 1250 mg orally  once daily  continuously in 21 day cycles  and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle  Overall Number of Participants Analyzed: 314 Mean (95% Confidence Interval) Unit of Measure: months 6.6 (5.9 to 7.4) "
        ],
        "premise_nums": [
            "(RECIST v1.1), as a 20% increase in the sum of the survival function up to 24 months  Time frame: From",
            "Outcome Measurement: Centrally Assessed Progression Free Survival",
            "Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the",
            "daily with food  continuously in 21 day cycles  and capecitabine 2000 mg/m^2 daily in 2 evenly divided",
            "and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on",
            "a meal  taken on days 1 to 14 of each 21 day cycle Overall Number of",
            "of randomization until the first date on which recurrence",
            "is censored at the last valid tumor assessment  Progression",
            "taken on days 1 to 14 of each 21 day cycles  and capecitabine 1500 mg/m^2 daily in 2 evenly divided",
            "or death  assessed up to 38 months  The result is based on primary analysis data cut  Results",
            "Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months 8.8 (7.8 to 9.8) Results 2: Arm/Group Title: Lapatinib",
            "orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle",
            "doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21",
            "days 1 to 14 of each 21 day cycle Overall Number of Participants Analyzed: 314 Mean (95% Confidence Interval) Unit of",
            "Capecitabine Arm/Group Description: lapatinib 1250 mg orally  once daily  continuously",
            "Number of Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months"
        ]
    },
    {
        "id": "5344044c-127d-4a39-80dc-277538b5ad33",
        "primaryId": "NCT02131064",
        "statement_text": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: Arm/Group Title: TCH + P ",
            "Arm/Group Description: Participants received pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion  trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles) Overall Number of Participants Analyzed: 221 Measure Type: Number ",
            "Unit of Measure: Percentage of Participants 56.1 (49.29 to 62.76)"
        ],
        "premise_nums": [
            "period (up to a total of 18 cycles) Overall Number of Participants Analyzed: 221 Measure Type: Number",
            "resected breast specimen and all sampled ipsilateral lymph nodes (",
            "3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance",
            "period (up to a total of 18 cycles) Overall Number of Participants 56.1 (49.29 to 62.76",
            "milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received",
            "Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: Arm/Group Title:",
            "Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion q3w for rest of the cycles (12",
            "(mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg",
            "that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer",
            "Unit of Measure: Percentage of Participants 56.1 (49.29 to 62.76",
            "IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period"
        ]
    },
    {
        "id": "ed43519d-9954-4e0f-9d42-39a3ed81e4a5",
        "primaryId": "NCT00820872",
        "statement_text": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "most common adverse event in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) "
        ],
        "premise_nums": [
            "10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage",
            "Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%)",
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30",
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%)",
            "Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%)"
        ]
    },
    {
        "id": "8d2fde27-a5e8-40ee-a35d-3d4697198a4e",
        "primaryId": "NCT00929240",
        "statement_text": "There are no cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [
            "Febrile neutropenia in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/284 (0.00%) Arrhythmia * 21/284 (0.35%) Atrial fibrillation * 1/284 (0.35%) Coronary artery disease * 20/284 (0.00%) Left ventricular dysfunction * 21/284 (0.35%) Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%) Neutropenia * 20/92 (0.00%) Leukopenia * 20/92 (0.00%) Anaemia * 20/92 (0.00%) Thrombocytopenia * 20/92 (0.00%) ",
            "Myocardial infarction * 20/92 (0.00%)Arrhythmia * 20/92 (0.00%) Atrial fibrillation * 0/92 (0.00%) Coronary artery disease * 20/92 (0.00%) Left ventricular dysfunction * 20/92 (0.00%) "
        ],
        "premise_nums": [
            "23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia * 20/284 (0.00%) Myocardial infarction * 20/92 (0.00%)Arrhythmia * 20/92 (0.00%) Atrial fibrillation",
            "(27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia * 22/284 (0.70%) Thrombocytopenia",
            "Adverse Events 1: Total: 78/284 (27.46%) Febrile neutropenia * 28/284 (9.86%) Neutropenia * 217/284 (5.99%) Leukopenia * 23/284 (1.06%) Anaemia",
            "dysfunction * 21/284 (0.35%) Adverse Events 2: Total: 7/92 (7.61%) Febrile neutropenia * 0/92 (0.00%)"
        ]
    },
    {
        "id": "fc0da76b-e5b5-44e3-abaf-6231fff493c3",
        "primaryId": "NCT00676663",
        "statement_text": "The the primary trial placebo group performed worse than the test group ",
        "statement_nums": [
            "The the primary trial placebo group performed worse"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause  Time frame: From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months) Results 1: Arm/Group Title: Exemestane 25 mg + Placebo Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first  Overall Number of Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25 mg + Entinostat 5 mg ",
            "Arm/Group Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor  whichever occurred first Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36) "
        ],
        "premise_nums": [
            "or death up to primary completion date (Median follow-up 6",
            "Sponsor  whichever occurred first Overall Number of Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25",
            "orally once per week on Days 1, 8, 15 and 22 of Measure: months 4.28 (3.26 to 5.36)",
            "orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of",
            "Sponsor  whichever occurred first Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months",
            "orally once per week on Days 1, 8, 15 and 22 of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane",
            "Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 2.27 (1.81 to 3.68) Results 2: Arm/Group Title: Exemestane 25",
            "Participants Analyzed: 66 Median (95% Confidence Interval) Unit of Measure: months 4.28 (3.26 to 5.36)",
            "Description: Exemestane (Aromasin ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per"
        ]
    },
    {
        "id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
        "primaryId": "NCT00119262",
        "statement_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure ",
        "statement_nums": [
            "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Congestive Heart Failure Rate Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN)  or symptomatic diastolic dysfunction  223 treated patients were included in the analysis  Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group Title: Arm A (ddBAC greater than BT greater than B) Arm/Group Description: Dose dense bevacizumab  cyclophosphamide and doxorubicin  followed by paclitaxel and bevacizumab  followed by bevacizumab Overall Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm B (ddAC greater than BT greater than B) Arm/Group Description: Dose dense doxorubicin and cyclophosphamide  followed by paclitaxel and bevacizumab  followed by bevacizumab ",
            "Overall Number of Participants Analyzed: 120Measure Type: Number Unit of Measure: percentage of participants 2.5 (0.5 to 7.1) "
        ],
        "premise_nums": [
            "Overall Number of Participants Analyzed: 120Measure Type: Number Unit of Measure:",
            "symptomatic diastolic dysfunction  223 treated patients were included in the analysis",
            "Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment",
            "treatment  then every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry",
            "Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.9 (0.6 to 8.3) Results 2: Arm/Group Title: Arm",
            "every 3 months for smaller than 2 years and every 6 months for 2-3 years from study entry Results 1: Arm/Group",
            "Number of Participants Analyzed: 103 Measure Type: Number Unit of Measure: percentage of participants 2.5 (0.5 to 7.1)"
        ]
    },
    {
        "id": "9a31db67-e28a-4114-a308-e899f9c22813",
        "primaryId": "NCT02291913",
        "statement_text": "One patient in the primary trial suffered from an inflammation of the esophagus ",
        "statement_nums": [
            "One patient in the primary trial suffered from an inflammation"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal hemorrhage * 1/48 (2.08%) Non-Cardiac chest pain * 1/48 (2.08%) Pain * 1/48 (2.08%) Cholecystitis * 1/48 (2.08%) Diverticulitis * 1/48 (2.08%) Cellulitis * 1/48 (2.08%) Gastroenteritis * 1/48 (2.08%) "
        ],
        "premise_nums": [
            "15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal",
            "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48"
        ]
    },
    {
        "id": "f948a2d1-2e22-47c8-9345-0eb68569bd3f",
        "primaryId": "NCT00996632",
        "secondaryId": "NCT01644890",
        "statement_text": "Emily has an Inoperable breast cancer  she is eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Inoperable breast cancer Inclusion Criteria: Written informed consent of the patient signed by herself  Histologically confirmed metastatic or recurrent adenocarcinoma of the breast  Aged 20 to 74 at the time of informed consent  Exclusion Criteria: Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer  "
        ],
        "premise_nums": [
            "the breast  Aged 20 to 74 at the time of informed",
            "signed by herself  Histologically confirmed metastatic or recurrent"
        ]
    },
    {
        "id": "382747d3-69df-41be-a771-4218407ce5d3",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in",
            "whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
            "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) "
        ],
        "premise_nums": [
            "Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every",
            "4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1.Overall Number of Participants Analyzed:",
            "Intravenous (IV) 15 minute infusion every 6 months beginning when one of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group",
            "following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or",
            "15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD",
            "of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density",
            "mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following",
            "every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on",
            "of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed",
            "mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1.",
            "4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets",
            "tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group",
            "Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423",
            "All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423",
            "Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group"
        ]
    },
    {
        "id": "d05ec90a-f267-44be-aaa6-3be960a0d50c",
        "primaryId": "NCT00376688",
        "statement_text": "Most the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "Most the primary trial subjects experienced a complete",
            "stable disease (SD) for at least 24 weeks"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (Complete Response  Partial Response  or Stable Disease) Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks  Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions  taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference the smallest sum LD since the treatment started; Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits Time frame: Up to 24 months Results 1: Arm/Group Title: Treatment (Temsirolimus) ",
            "Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Temsirolimus: Given IV Overall Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7 "
        ],
        "premise_nums": [
            "stable disease (SD) for at least 24 weeks  Evaluation of target",
            "normal limits Time frame: Up to 24 months Results 1: Arm/Group Title: Treatment (Temsirolimus)",
            "Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7",
            "in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical",
            "Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the",
            "receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of"
        ]
    },
    {
        "id": "37301690-9b68-48de-b280-6307e632043e",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "statement_text": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains  ",
        "statement_nums": [
            "recorded by both the secondary trial and the primary trial is Diarrhoea and various"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection 0/75 (0.00%) Pneumonia 1/75 (1.33%) ",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) ",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) "
        ],
        "premise_nums": [
            "(1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%)",
            "Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%)",
            "(2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%)",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37",
            "(1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pyrexia 1/75",
            "(1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with",
            "1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction",
            "(1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain",
            "(0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%)",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction",
            "(1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%)",
            "0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%)",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37",
            "General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%)",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%)",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%)",
            "(2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection"
        ]
    },
    {
        "id": "3ca27248-0728-4b10-b940-6e2603acef30",
        "primaryId": "NCT00201760",
        "secondaryId": "NCT00127933",
        "statement_text": "Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial ",
        "statement_nums": [
            "to participate in the secondary trial or the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Eligibility Criteria: Must have invasive metastatic breast cancer Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer  "
        ],
        "premise_nums": [
            "Inclusion Criteria: infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer"
        ]
    },
    {
        "id": "c2da6504-96a1-4669-b609-16731a5330d3",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is ineligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "ineligible for both the secondary trial and the primary trial",
            "Ae-Cha is a 32 year old Korean woman with an inoperable"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Recent primary surgery for breast cancer Exclusion Criteria: Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) "
        ],
        "premise_nums": [
            "Inclusion Criteria: Recent primary surgery for breast cancer Exclusion"
        ]
    },
    {
        "id": "646959e4-25d0-4eb1-b7b0-2d7b1e02e132",
        "primaryId": "NCT01262027",
        "statement_text": "Less than 5% of patients in the primary trial suffered an adverse event ",
        "statement_nums": [
            "Less than 5% of patients in the primary trial suffered an adverse event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%)"
        ]
    },
    {
        "id": "0e6eebe9-46c2-4fa5-b9ed-e0997044960b",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery ",
        "statement_nums": [
            "the patients in the primary trial or the secondary trial are required to undergo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Group 2 (RS 11-25) Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or treatment Arm 2, neoadjuvant chemotherapy  INTERVENTION 1: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months  "
        ],
        "premise_nums": [
            "each day  either 1 hour before or 2 hours after a meal) taken daily and",
            "[mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed",
            "the same oral dose 4-6 weeks after surgery and was continued daily and continuing until 7 days before surgery  Pazopanib was resumed",
            "every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same",
            "(AC) (600 mg/m^2) every 21 days for 4 cycles  This was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or",
            "with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for",
            "(WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800",
            "by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given",
            "daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and"
        ]
    },
    {
        "id": "a781374c-99e1-47ee-a266-bff9267c2ed1",
        "primaryId": "NCT00950742",
        "statement_text": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities ",
        "statement_nums": [
            "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days Results 2: Arm/Group Title: Afatinib 30mg + Herceptin Arm/Group Description: Patients received continuous daily dosing with Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit  Overall Number of Participants Analyzed: 2 Measure Type: Number Unit of Measure: Participants 2 "
        ],
        "premise_nums": [
            "received continuous daily dosing with Afatinib 30mg film-coated tablets and once",
            "of clinical benefit  Overall Number of Participants Analyzed: 2 Measure Type: Number Unit of Measure: Participants",
            "with DLT in the first cycle (28 days) for the",
            "section  Time frame: 28 days Results 2: Arm/Group Title: Afatinib 30mg +"
        ]
    },
    {
        "id": "9aea5a84-bced-4441-b8b8-154c307f5a03",
        "primaryId": "NCT01151046",
        "statement_text": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort ",
        "statement_nums": [
            "Median PFS than the MM-121 cohort",
            "placebo group in the primary trial had a much lower"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) To determine whether MM-121 + exemestane was more effective than placebo + exemestane in prolonging progression-free survival  PFS was a time to event measure  and progression of disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), \"as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions\"  Progression free survival was defined as the number of months from the date of randomization to the date of death or progression  If neither death nor progression was observed during the study  PFS data was censored at the last non-progressive disease valid tumor assessment unless the patient was discontinued due to symptomatic deterioration  If this occurred  the patient was counted as having progressive disease (PD)  Time frame: Time from first dose to date of progression  the longest time frame of 79.1 weeks Results 1: Arm/Group Title: MM-121 + Exemestane ",
            "Arm/Group Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week  plus exemestane (25 mg) administered orally once per dayOverall Number of Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 15.9 (9.3 to 30.3) Results 2: Arm/Group Title: Placebo + Exemestane Arm/Group Description: Placebo and Exemestane: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week plus exemestane (25 mg) administered orally once per day Overall Number of Participants Analyzed: 59 Median (95% Confidence Interval) Unit of Measure: weeks 10.7 (8.1 to 16.1) "
        ],
        "premise_nums": [
            "Time frame: Time from first dose to date of progression",
            "the longest time frame of 79.1 weeks Results 1: Arm/Group Title: MM-121 + Exemestane",
            "exemestane (25 mg) administered orally once per dayOverall Number",
            "Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 15.9 (9.3 to 30.3) Results 2: Arm/Group Title: Placebo",
            "was censored at the last non-progressive disease valid tumor assessment",
            "Tumors Criteria (RECIST v1.1), \"as a 20% increase in the sum of the",
            "Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 10.7 (8.1 to 16.1)",
            "Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per"
        ]
    },
    {
        "id": "deb77d34-76a5-4e6e-bc9d-176cc30eca07",
        "primaryId": "NCT00917735",
        "statement_text": "One patient in cohort 2 of the primary trial died in a motorcycle crash ",
        "statement_nums": [
            "One patient in cohort 2 of the primary trial died in a motorcycle"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) "
        ],
        "premise_nums": [
            "1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537",
            "0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537",
            "(0.00%) Elevated ALT or AST enzyme 0/537 (0.00%) Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%)"
        ]
    },
    {
        "id": "bfe97430-fcec-4c4a-9621-51f6ec05d8d3",
        "primaryId": "NCT00068341",
        "statement_text": "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2.",
        "statement_nums": [
            "More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain  swelling  mastectomy site cellulitis * 0/15 (0.00%) death progressive disease * 0/15 (0.00%) divetricular abscess * 0/15 (0.00%) fever * 1/15 (6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%) hypokalemia * 0/14 (0.00%) pain  swelling  mastectomy site cellulitis * 0/14 (0.00%) death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%) ",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) "
        ],
        "premise_nums": [
            "0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%) Severe Dehydration * 1/15 (6.67%) hypokalemia * 1/15 (6.67%) pain",
            "Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15 (0.00%) Severe Dehydration * 1/15 (6.67%)",
            "death progressive disease * 1/14 (7.14%) divetricular abscess * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)",
            "Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)",
            "(6.67%) febrile neutropenia * 3/15 (20.00%) Neutropenia * 0/15 (0.00%) Adverse Events 1: Total: 6/15 (40.00%) diarrhea and dehydration * 0/15",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and",
            "Neutropenia * 0/15 (0.00%) Adverse Events 2: Total: 4/14 (28.57%) diarrhea and dehydration * 0/14 (0.00%) Severe Dehydration * 0/14 (0.00%)",
            "fever * 0/14 (0.00%)febrile neutropenia * 2/14 (14.29%) Neutropenia * 0/14 (0.00%)"
        ]
    },
    {
        "id": "568beebd-b350-4ba1-b8fc-c43f4d6ed517",
        "primaryId": "NCT01421017",
        "statement_text": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment ",
        "statement_nums": [
            "IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment",
            "the primary trial studies the effects of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Systemic Tumor Response Rates (Complete Response+Partial Response) The systemic tumor response refers to the response at the time of best overall response  The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok  et al.  2009). Time frame: 9 weeks from the start of the treatment of RT "
        ],
        "premise_nums": [
            "the time of best overall response  The response criteria",
            "2009). Time frame: 9 weeks from the start of the treatment"
        ]
    },
    {
        "id": "6bcc18b7-b063-49a1-8ab7-773636c02f1d",
        "primaryId": "NCT00076024",
        "statement_text": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial  was 191.",
        "statement_nums": [
            "any patient in the primary trial  was",
            "of study treatment to first documentation of objective tumor progression"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time to Tumor Progression (TTP) Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer  whichever comes first  TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind) Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 247 (208 to 265) Results 2: ",
            "Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind)Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of 3 weeks  Treatment was continued until disease progression  intolerable toxicity  or for 2 cycles after complete response  Participants with disease progression after consent were continued to open-label phase  Overall Number of Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247) "
        ],
        "premise_nums": [
            "Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of Measure: days 215 (191 to 247)",
            "toxicity  or for 2 cycles after complete response  Overall Number of Participants Analyzed: 112 Median (95% Confidence Interval) Unit of",
            "Participants Analyzed: 55 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247)",
            "first dose of study medication plus 1. Tumor progression was determined from study treatment  assessed every 9 weeks up to 129 weeks",
            "starting from Day 1 of Cycle 1, in cycles of 3 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel",
            "Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks",
            "intolerable toxicity  or for 2 cycles after complete response  Participants with",
            "Time frame: Phase 2 double-blind baseline until tumor progression or death",
            "Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of Measure: days 247 (208 to 265) Results 2:",
            "Participants Analyzed: 112 Median (95% Confidence Interval) Unit of Measure: days 215 (191 to 247)",
            "3 weeks  Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle  in cycles of",
            "of study treatment to first documentation of objective tumor progression",
            "from study treatment  assessed every 9 weeks up to 129 weeks Results 1: Arm/Group Title: Axitinib + Docetaxel"
        ]
    },
    {
        "id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
        "primaryId": "NCT01519700",
        "statement_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1 Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) "
        ],
        "premise_nums": [
            "either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean",
            "Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants",
            "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia",
            "Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title:",
            "of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to"
        ]
    },
    {
        "id": "81c85a29-d449-4f79-a3b3-682ba5f288ca",
        "primaryId": "NCT00190671",
        "secondaryId": "NCT00455533",
        "statement_text": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia ",
        "statement_nums": [
            "1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary",
            "cohort 1 had more than cohort 2. Cohort 2 of the primary trial cohort 2 had more patients with Leukopenia than cohort",
            "1, whereas in the secondary trial cohort 1 had more patients with Leukopenia than cohort 1, whereas in the secondary trial",
            "more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145",
            "Adverse Events 1: Leukopenia 0/42 (0.00%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144",
            "1: Leukopenia 0/42 (0.00%) Adverse Events 2: Leukopenia 2/61 (3.28%) Adverse Events 1: LEUKOPENIA 2/145 (1.38%) Adverse Events 2: LEUKOPENIA 0/144"
        ]
    },
    {
        "id": "9c48c5d6-83fd-42cc-aacc-2e888099bcdb",
        "primaryId": "NCT00338728",
        "statement_text": "Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis ",
        "statement_nums": [
            "Participants of the primary trial more Imatinib mesylate than"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Letrozole and Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle  "
        ],
        "premise_nums": [
            "for 28 days and Letrozole 2.5 mg once a day daily for 28 days and Letrozole 2.5 mg once a day",
            "Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day",
            "mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28"
        ]
    },
    {
        "id": "cea17554-6736-4b52-b76c-b3c5dc9ecb77",
        "primaryId": "NCT00503750",
        "statement_text": "All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan ",
        "statement_nums": [
            "All participants of the primary trial must have recently undergone"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Normal (greater than 50%) left ventricular ejection fraction"
        ]
    },
    {
        "id": "b250a17c-9d4d-405d-ba64-40f7eda16707",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 90 mg/m2  ",
        "statement_nums": [
            "Adverse Events  is 90 mg/m2",
            "the primary trial results indicate that the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea  vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy)  Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration  Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle  ",
            "All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg 300 "
        ],
        "premise_nums": [
            "or failure to complete all protocol specificed doses in the standard 3 + 3 phase I trial design based upon toxicity",
            "days 2, 9, and 16 of every 28-day cycle  Bevacizumab was carried out in the standard 3 + 3 phase I trial",
            "Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat",
            "Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg/m2 as 1-hour infusion on days 2, 9, and 16 of every",
            "were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtologicalso received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2,",
            "days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day",
            "a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group",
            "DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at",
            "of the 28 day cycle at 10 mg/kg dose  Vorinostat dose (200 or 300 mg BID) was assigned at the",
            "toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity",
            "administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle",
            "was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was",
            "Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the",
            "at 90 mg/m2 as 1-hour infusion on days 2, 9, and 15-17 of each 28-day cycle",
            "was carried out in the standard 3 + 3 phase I trialso received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2,",
            "Bevacizumab was administered on day 2 and day 16 of the standard 3 + 3 phase I trial design based upon toxicity"
        ]
    },
    {
        "id": "698849c5-78fa-4c15-a1dc-f44eb9c970c2",
        "primaryId": "NCT00082641",
        "statement_text": "At least one patient in the primary trial suffered from impaired mobility ",
        "statement_nums": [
            "one patient in the primary trial suffered from impaired mobility"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Hip fracture 1/12 (8.33%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Hip fracture 1/12 (8.33%)"
        ]
    },
    {
        "id": "4b4e6ac7-107c-46f4-adbb-c77c01f51935",
        "primaryId": "NCT00075764",
        "statement_text": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels ",
        "statement_nums": [
            "most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%) Cardiac-ischemia/infarction 1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%)",
            "1/337 (0.30%) Left ventricular diastolic dysfunction 0/337 (0.00%) Left ventricular systolic dysfunction 1/337 (0.30%) Restrictive cardiomyopathy 1/337 (0.30%)",
            "21/337 (6.23%) Blood/Bone Marrow-Other 0/337 (0.00%) Febrile neutropenia 0/337 (0.00%) Hemoglobin 2/337 (0.59%) Atrioventricular block - 2nd degree"
        ]
    },
    {
        "id": "2a1d9064-fde9-4645-95ab-7ddaea4ad322",
        "primaryId": "NCT00324259",
        "statement_text": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (CR Plus PR Plus SD) Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease SD is defined as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol daily (2 mg tid)  Overall Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 1 ",
            "Stable disease (SD): 8CR+PR+SD: 9 "
        ],
        "premise_nums": [
            "participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30",
            "Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed:",
            "disease (SD): 7 CR+PR+SD: 10 Results 2: Arm/Group Title: Arm 2 (30 mg Estradiol) Arm/Group Description: 30 mg of",
            "Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants Complete response (CR): 0 Partial response (PR): 3 Stable disease (SD):",
            "Arm/Group Title: Arm 1 (6 mg Estradiol) Arm/Group Description: 6 mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed:",
            "weeks  Time frame: 24 weeks after start of treatment Results 1: Arm/Group Title: Arm 1 (6",
            "+ stable disease (SD) using RECIST 1.0 CR = disappearance of all target lesions PR = at",
            "as lack of disease progression by 24 weeks  Time frame: 24 weeks after start of treatment Results 1:",
            "mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 32 Measure Type: Number Unit of Measure: participants",
            "mg of estradiol  (10 mg tid) Overall Number of Participants Analyzed: 34 Measure Type: Number Unit of Measure: participants"
        ]
    },
    {
        "id": "847de3fe-b584-4d43-b82d-93263ce88830",
        "primaryId": "NCT00509587",
        "statement_text": "Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day  continuing until disease progression or unacceptable toxicity ",
        "statement_nums": [
            "Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Pazopanib Hydrochloride) Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  pazopanib hydrochloride: Given orally pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression",
            "pazopanib hydrochloride: Given orally pharmacological study: Correlative studies"
        ]
    },
    {
        "id": "3c798991-6366-43e2-94ca-0523629930c2",
        "primaryId": "NCT00149214",
        "secondaryId": "NCT01004744",
        "statement_text": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial  but not for patients in the secondary trial ",
        "statement_nums": [
            "of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for",
            "for patients in the primary trial  but not for",
            "for patients in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Prior anthracyclines as part of prior anticancer therapy  Inclusion Criteria: No prior chemotherapy  radiation therapy  or surgery within 6 months of study entry "
        ],
        "premise_nums": [
            "radiation therapy  or surgery within 6 months of study entry"
        ]
    },
    {
        "id": "64fe54a2-8897-4324-af88-f627c1c208ed",
        "primaryId": "NCT01764022",
        "statement_text": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia ",
        "statement_nums": [
            "Cohort 2 of the primary trial recorded multiple incidents of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Anemia with trombocytopenia 1/110 (0.91%)"
        ]
    },
    {
        "id": "4eac6a2d-64cd-4289-a545-211eb835f0e9",
        "primaryId": "NCT01328249",
        "statement_text": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Feasibility The regimen was considered feasible if the participant was able to complete the eribulin portion without dose delay or reduction  Dose delay was defined as a delay due to eribulin-related adverse event (AE) for more than 2 days for subsequent doses (cycles after the initiation of full dose of eribulin  except holidays  scheduling difficulties and nonclinical logistical issues)  If a participant had more than 1 dose omission  delay or reduction due to eribulin-related AE  these events were collectively counted as one entity in the same participant  Participants were followed for approximately 3 years after the last dose of the study treatment  Feasibility rates were calculated with or without growth factor support  In both cohorts  the percentage of participants who completed the eribulin portion of the regimen without a dose omission  delay or reduction due to eribulin-related AE was estimated via the observed completion rate and an exact 90% confidence interval (CI) was constructed  Time frame: From date of first dose  up to 3 years after the last dose of study treatment  or up to approximately 4 years 2 months Results 1: Arm/Group Title: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors  subcutaneous pegfilgrastim (6 mg) or filgrastim  could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage of participants 70.4 (58.5 to 80.4) Results 2: Arm/Group Title: Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim ",
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants greater than 60 kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle Overall Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage of participants 60.0 (41.7 to 76.4) "
        ],
        "premise_nums": [
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day",
            "Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "(IV) on Day 1, of every 14-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "observed completion rate and an exact 90% confidence interval (CI) was constructed",
            "of first dose  up to 3 years after the last dose of 300 micrograms for participants 60 kg or 480 micrograms for",
            "eribulin therapy at a dose of 300 micrograms for participants 60 kg  administered subcutaneously on Days 3 and 4 and Days 10",
            "cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and",
            "dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles",
            "neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage",
            "dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 3 and 4 and Days 10 and 11 of each eribulin",
            "kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle Overall",
            "Participants were followed for approximately 3 years after the last dose of the study treatment",
            "dose of 300 micrograms for participants 60 kg or 480 micrograms for participants greater than 60 kg  administered subcutaneously on",
            "Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage of participants 60.0 (41.7 to 76.4)",
            "Participants were followed for approximately 3 years after the last dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days",
            "If a participant had more than 1 dose omission  delay or reduction due",
            "treatment  or up to approximately 4 years 2 months Results 1: Arm/Group Title: Cohort 1: Eribulin",
            "480 micrograms for participants greater than 60 kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11",
            "neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage",
            "(60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles",
            "adverse event (AE) for more than 2 days for subsequent doses (cycles after the",
            "frame: From date of first dose  up to 3 years after the last dose",
            "Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage of participants 70.4 (58.5 to 80.4) Results 2: Arm/Group Title: Cohort",
            "cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for up to approximately 4 years 2 months Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1",
        "primaryId": "NCT02435680",
        "secondaryId": "NCT01743560",
        "statement_text": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics  however they use significantly different time frames ",
        "statement_nums": [
            "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Time frame: At 48 weeks "
        ],
        "premise_nums": [
            "confirmed CR or PR by week 48. Time frame: At 48 weeks",
            "two determinations of CR at least 4 weeks apart before progression are required",
            "dose)  in line with phase 2 study design  Time frame: 4 years Outcome Measurement: Best Overall Response of",
            "PFS Results presented for all MCS110 treated patients (with and without day 8 dose)  in line with"
        ]
    },
    {
        "id": "da1e1019-adb5-47bf-8093-e03352ca9e51",
        "primaryId": "NCT01340300",
        "secondaryId": "NCT00671918",
        "statement_text": "Patients cannot do more than half an hour of physical exercise in a day  if they are to participate in the primary trial  however  this is not a requirement for the secondary trial ",
        "statement_nums": [
            "a requirement for the secondary trial",
            "to participate in the primary trial  however  this"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria: The patient has provided written informed consent with HIPAA authorization before participating in the study  as has his/her responsible caregiver  if applicable  The patient is a candidate for surgical intervention  with lymph node mapping being a part of the surgical plan  The patient is at least 18 years of age at the time of consent  The patient has an ECOG performance status of Grade 0 - 2 [8]. The patient has a clinical negative node status at the time of study entry  If of child bearing potential  the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek  has been surgically sterilized  or has been postmenopausal for at least 1 year  The patient is currently not participating in another investigational drug study  Melanoma Patients The patient has a diagnosis of primary melanoma  Breast Cancer Patients The patient has a diagnosis of primary breast cancer  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan  Exclusion Criteria: The patient is pregnant or lactating; ",
            "The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e.  all patients should be any T,N0,M0);The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V  Melanoma Patients The patient has a tumor with a Breslow depth less than 0.75mm.; Patients that have had preoperative chemotherapy  immunotherapy or radiation therapy; Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin; Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma; Patients who have undergone a wide excision for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation  free flap or skin graft of any type)  Breast Cancer Patients The patient has bilateral primary breast cancers or multiple tumors within their breast; ",
            "Patients that have had prior surgical procedures such as breast implants  reduction mammoplasty or axillary surgery;Patients scheduled for bilateral mastectomy for any reason; Patients that have had preoperative radiation therapy to the affected breast or axilla "
        ],
        "premise_nums": [
            "has a diagnosis of primary melanoma  Breast Cancer Patients",
            "has a negative pregnancy test within 72 hours prior to administration of Lymphoseek",
            "for their primary melanoma (greater than 1 cm in dimension) or complex reconstruction (rotation",
            "an ECOG performance status of Grade 0 - 2 [8]. The patient is at least 18 years of age at the time of",
            "with a Breslow depth less than 0.75mm.; Patients that have had",
            "breast implants  reduction mammoplasty or axillary surgery;Patients scheduled",
            "lymph nodes (i.e.  all patients should be any T,N0,M0);The patient has a known hypersensitivity to",
            "with truncal or extremity primary melanoma who has had a",
            "Inclusion Criteria: Less than 120 minutes of exercise per week Inclusion Criteria:"
        ]
    },
    {
        "id": "e7fb6490-1ec7-48ff-95b1-715d79faec92",
        "primaryId": "NCT01042938",
        "statement_text": "Patients must be english to participate in the primary trial ",
        "statement_nums": [
            "to participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female with a diagnosis of  non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy  Participants must be at least 21 years of age  Participants must not be pregnant  Participants can be from any racial or ethnic origin  Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment  Participants with in situ breast cancer are eligible  Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible  Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation  A time period of three weeks must elapse after chemotherapy and surgery before beginning the study  The total dose prescribed to the whole breast should be 50 Gy or greater  Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)  Participants must be able to swallow medication  Topical skin agents  e.g.  Aquaphor  Cetaphil  or other emollients  are allowed either PRN or prophylactically  Participant must give informed consent  Exclusion Criteria: ",
            "Patients with bilateral breast cancer are not eligible Patients who have had previous radiation therapy to the breast or chest are not eligible  Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible  Patients who will be receiving treatment with Herceptin (trastuzumab)  anti-coagulants  or anti-human epidermal growth factor receptor (EGFR) drugs  e.g  Iressa (gefitinib)  Erbitux (cetuximab  C225), concurrently with their radiation therapy are not eligible  Patients cannot have had breast reconstructions  implants  and/or expanders  Patients with known radiosensitivity syndromes (e.g.  Ataxia-telangiectasia) are not eligible  Patients with collagen vascular disease  vasculitis  unhealed surgical sites  or breast infections are not eligible  ",
            "Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e.  25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e.  less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e.  1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST  ALT (i.e.  greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e.  greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e.  greater than 2x ULN) "
        ],
        "premise_nums": [
            "four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation  A time",
            "PT and PTT(i.e.  1.5-2x upper level normal (ULN)); greater than or equal to Grade 2 change Hemoglobin (i.e.  25%",
            "Bilirubin (i.e.  greater than 1.5x ULN); greater than or equal to Grade 1 change in Platelets (i.e.  less than",
            "greater than or equal to Grade 1 change in Platelets (i.e.  less than 75,000/mm3); greater than or equal to Grade",
            "in Creatinine (i.e.  greater than 2x ULN)",
            "radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per",
            "or equal to Grade 2 change in PT and PTT(i.e.  1.5-2x upper level normal (ULN)); greater than",
            "in Bilirubin (i.e.  greater than 1.5x ULN); greater than or equal to Grade 1 change in Platelets (i.e.",
            "in Bilirubin (i.e.  greater than 1.5x ULN); greater than or equal to Grade 2 change Hemoglobin (i.e.  25%",
            "in Platelets (i.e.  less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e.  1.5-2x",
            "to complete assessment forms (all assessment forms are in English)",
            "whole breast should be 50 Gy or greater  Participants must be at least 21 years of age  Participants must not",
            "PT and PTT(i.e.  1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in Platelets (i.e."
        ]
    },
    {
        "id": "d5ea3443-103f-4d29-9be3-522210b84152",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "statement_text": "the primary trial and the secondary trial only record 2 of the same adverse events ",
        "statement_nums": [
            "the primary trial and the secondary trial only record 2 of the same adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%)",
            "lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia"
        ]
    },
    {
        "id": "d54cae08-3ac9-4460-bf6d-7338b45d8cd7",
        "primaryId": "NCT00193050",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial ",
        "statement_nums": [
            "must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months "
        ],
        "premise_nums": [
            "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months"
        ]
    },
    {
        "id": "608c5521-c9a6-47de-9ebf-791ce317a02d",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced an adverse event ",
        "statement_nums": [
            "All of the patients in cohort 1 of the primary trial experienced an adverse event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) "
        ],
        "premise_nums": [
            "(100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Leukopenia * 1/2 (50.00%)",
            "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%)"
        ]
    },
    {
        "id": "14a8e9e9-0a46-4537-bc07-53c786bcbe97",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "statement_text": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - "
        ],
        "premise_nums": [
            "anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast",
            "nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion"
        ]
    },
    {
        "id": "2d97bfa0-336f-4976-95e5-1262327a730b",
        "primaryId": "NCT01048099",
        "secondaryId": "NCT02502864",
        "statement_text": "the primary trial recorded 2 more total adverse events than the secondary trial",
        "statement_nums": [
            "the primary trial recorded 2 more total adverse events than the secondary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 5/14 (35.71%) Adverse Events 1: Total: 3/9 (33.33%)"
        ]
    },
    {
        "id": "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240",
        "primaryId": "NCT00003199",
        "statement_text": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients  and the worst was Stage IV Disease patients ",
        "statement_nums": [
            "Event-free Survival in the primary trial was Stage IIIB patients"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Event-free Survival Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer Arm/Group Description: See Detailed Description  tamoxifen citrate: Given orally busulfan: Given orally thiotepa: Given IV melphalan: Given IV aldesleukin: Given SC sargramostim: Given SC peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF Overall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of Measure: Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1% "
        ],
        "premise_nums": [
            "GM-CSF  Time frame: 11 years Results 1: Arm/Group Title: TX/Maintenance Therapy for",
            "radiotherapy after completion of IL-2/GM-CSF Overall Number of Participants Analyzed: 50 Measure Type: Count of Participants Unit of",
            "Participants Stage IIIB Disease: 18 participants 11 61.1% Stage IV Disease: 32 participants 9 28.1%"
        ]
    },
    {
        "id": "8c83330f-f2f3-48e1-9905-dc2ba1970c54",
        "primaryId": "NCT03765996",
        "statement_text": "Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions ",
        "statement_nums": [
            "Participants in group 2 of the primary trial receive the same Complex",
            "Decongestive Physiotherapy as those in group 1, with the addition of applying"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Decongestive Physiotherapy This group received Complex Decongestive Physiotherapy  Decongestive Physiotherapy: This group received CDP  which include MLD  short-stretch bandages  lymph-reducing exercises  and skin care  MLD was applied to the anterior trunk  posterior trunk  and the base of the neck  progressing to the affected limb  Short-stretch bandages were applied in multiple layers after MLD  A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm  The fingers and the hand were wrapped in gauze  A layer of cotton was wrapped around the arm  Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand  The most compression was at the most distal points and gradually decreased proximally  Exercises were done by patients to improve mobility and enhance lymphatic flow  INTERVENTION 2: Decongestive Physiotherapy Plus Taping This group received Complex Decongestive Physiotherapy  and also applying taping to anastomosis regions  ",
            "Decongestive Physiotherapy plus taping: This group received CDP as same protocol of active comparator  In addition  taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis  The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis  For axillo-inguinal anastomosis  the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region "
        ],
        "premise_nums": [
            "arm  Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral"
        ]
    },
    {
        "id": "4613834d-c178-475c-b9fd-c9c66d5681eb",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "statement_text": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  "
        ],
        "premise_nums": [
            "AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)",
            "50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100",
            "INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days"
        ]
    },
    {
        "id": "c1b90c18-45f4-4e28-b50a-a00b0eadc523",
        "primaryId": "NCT00290732",
        "secondaryId": "NCT02748213",
        "statement_text": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial  but not the primary trial ",
        "statement_nums": [
            "are eligible for the secondary trial  but not the primary trial",
            "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial  but not the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy "
        ],
        "premise_nums": [
            "T1-3, any N disease No inflammatory breast cancer or other T4 features Inclusion Criteria: Histologically confirmed  HER2-positive"
        ]
    },
    {
        "id": "33ef3abf-97c0-4d15-909d-258fb47ac54a",
        "primaryId": "NCT00232479",
        "statement_text": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "Only patients with HER2 positive breast carcinoma are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: HER-2 overexpressing breast cancer "
        ],
        "premise_nums": [
            "Inclusion Criteria: HER-2 overexpressing breast cancer"
        ]
    },
    {
        "id": "a381e340-18b1-4baa-91ce-0c420bcb411c",
        "primaryId": "NCT01323530",
        "secondaryId": "NCT01106040",
        "statement_text": "the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age  cancer grade and ethnicity ",
        "statement_nums": [
            "PFS of participants is partially linked to age",
            "the secondary trial and the primary trial results indicate that the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) ",
            "DLTs as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days  2) Neutropenia Grade 3 or 4 complicated by fever and/or infection (absolute neutrophil count [ANC] less than 1.0*10^9/liter [L]  fever of at least 38.5 degree celsius [°C])  3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated by bleeding and/or requiring platelet or blood transfusion  5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea  and Grade 3 or 4 vomiting or diarrhea in participants who had not received optimal treatment with antiemetic and/or antidiarrheal medication; excluding laboratory abnormalities without clinical symptoms)  6) Delayed recovery from treatment-related toxicity resulting in dose delay greater than 14 days  7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline Time frame: Cycle 1 (21 days) Outcome Measurement: Concordance of Blue Dye and Lymphoseek ",
            "The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek Time frame: Surgery after injections of Lymphoseek and blue dye "
        ],
        "premise_nums": [
            "increase of at least 2 grades from baseline Time frame: Cycle 1 as result of Grade 2 or higher treatment-related toxicity that",
            "7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher",
            "transfusion  5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea  and Grade 3 or 4 vomiting or diarrhea",
            "as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline Time frame: Cycle 1",
            "[L]  fever of at least 38.5 degree celsius [°C])  3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated",
            "resulting in dose delay greater than 14 days  7) Failure to administer at least 75 percent (%) of planned study",
            "as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days",
            "7 days  2) Neutropenia Grade 3 or 4 complicated by fever and/or infection",
            "defined as:1) Neutropenia Grade 4 that lasted at least 7 days  2) Neutropenia Grade 3 or 4 complicated by fever",
            "Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)"
        ]
    },
    {
        "id": "8e246d8f-e063-4f2e-a382-5d201a946b87",
        "primaryId": "NCT00436566",
        "statement_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "statement_nums": [
            "single patient in the primary trial suffered from Congestive Heart"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months  Overall Number of Participants Analyzed: 109 Measure Type: Number Unit of Measure: participants 0 "
        ],
        "premise_nums": [
            "daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for",
            "repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib",
            "[Not Specified] Time frame: 6 months Results 1: Arm/Group Title: AC/PTL Arm/Group Description:",
            "lapatinib (TL)) for a total of 12 months  Overall Number of Participants Analyzed: 109 Measure Type: Number Unit of Measure: participants",
            "x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab"
        ]
    },
    {
        "id": "8154bd8c-90a2-4b2f-8090-fcc89aeae30c",
        "primaryId": "NCT00097721",
        "statement_text": "Patients of any ethnicity can participate in the primary trial ",
        "statement_nums": [
            "can participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female patients with histologically or cytologically confirmed carcinoma of the breast Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy) Patients must have measurable disease by the RECIST criteria  defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan  or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node  it must measure at least 20 mm in LD  If a single lesion is identified as the target lesion  a cytological or histological confirmation of breast carcinoma is required  Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well  Patients must have progressed within six months of the last dose of chemotherapy  or experienced disease progression while receiving chemotherapy for advanced/metastatic disease  Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months ",
            "Adequate renal function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and Gault formulaAdequate bone marrow function as evidenced by absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion)  and platelet count 100 x 10^9/L Adequate liver function as evidenced by bilirubin 1.5 mg/dL and alkaline phosphatase  alanine transaminase (ALT)  and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) (in the case of liver metastases 5 x ULN) Patients willing and able to complete the FACT-B questionnaire  Analgesic Diary  Pain VAS  and the tumor-related symptomatic assessment Patients willing and able to comply with the study protocol for the duration of the study A sample from the diagnostic biopsy (paraffin block) must be available Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria: ",
            "Patients who have received chemotherapy  radiation  hormonal therapy  or Herceptin within 2 weeks of E7389 treatment startRadiation therapy encompassing greater than 10% of marrow Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator Prior treatment with Mitomycin C or nitrosoureas Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment  including the use of oxygen Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389 Patients with meningeal carcinomatosis Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted ",
            "Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test  Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator  Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Severe /uncontrolled intercurrent illness/infection Significant cardiovascular impairment (history of congestive heart failure greater than NYHA grade II  unstable angina or myocardial infarction within the past six months  or serious cardiac arrhythmia) Patients with organ allografts Patients with known positive HIV status Patients who have had a prior malignancy  other than carcinoma in situ of the cervix  or non-melanoma skin cancer  unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrence Patients with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative Patients who participated in a prior E7389 clinical trial Patients with other significant disease or disorders that  in the Investigator's opinion  would exclude the patient from the study "
        ],
        "premise_nums": [
            "radiation-related toxicities to less than grade 1 severity Age 18 years Eastern Cooperative Oncology Group (ECOG) Performance",
            "at least one diameter (at least 10 mm in longest diameter (LD) by spiral",
            "must measure at least 20 mm in LD  If a single",
            "or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and aspartate transaminase (AST) 3 times the upper limits of normal (ULN)",
            "function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine clearance 50 mL/minute (min) per the Cockcroft and",
            "must be amenorrheic for at least 12 months to be considered of non-childbearing potential",
            "(in the case of liver metastases 5 x ULN) Patients willing and able to",
            "malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of",
            "with pre-existing neuropathy greater than Grade 1 Patients with a hypersensitivity to halichondrin B",
            "(CT) scan  or at least 20 mm by standard techniques; If the only",
            "or transfusion)  and platelet count 100 x 10^9/L Adequate liver function as evidenced by serum creatinine 1.5 mg/dL or calculated creatinine",
            "hormonal therapy  or Herceptin within 2 weeks of E7389 treatment startRadiation therapy encompassing greater than 10% of marrow Failure to recover",
            "of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in",
            "absolute neutrophil count (ANC) 1.5 x 10^9/L, hemoglobin 10.0 g/dL (a hemoglobin smaller than 10.0 g/dL would be acceptable if it",
            "is deemed to be clinically significant by the study",
            "participated in a prior E7389 clinical trial Patients with other significant disease",
            "six months of the last dose of chemotherapy  or transfusion)  and platelet count 100 x 10^9/L Adequate liver function",
            "Criteria: Female patients with histologically or cytologically confirmed carcinoma",
            "Status (APPENDIX 4) of 0 or 1 Life expectancy of 3 months"
        ]
    },
    {
        "id": "537781f9-3693-479e-af22-824cdd827b9c",
        "primaryId": "NCT02657889",
        "statement_text": "the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) ",
        "statement_nums": [
            "the primary trial indicates that varying Pembrolizumab"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs) DLTs are defined as: Any treatment-related Grade 3 non-hematologic clinical (non-laboratory) AE Any treatment-related Grade 3 or Grade 4 non-hematologic lab abnormality if: - Medical intervention is required to treat the patient  or - The abnormality leads to hospitalization  or - The abnormality persists for 7 days  Any treatment-related hematologic toxicity specifically defined as: - Thrombocytopenia Grade 4 for 7 days  or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days  or Grade 3 or 4 associated with infection or febrile neutropenia; - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion  Any treatment-related AE leading to niraparib dose interruption per the following criteria: - A dose interruption for a non-DLT lab abnormality lasting 14 days  - A dose in interruption per dose modification rules for nonhematologic AE leading to smaller than 80% of an intended dose being administered  Time frame: During Cycle 1, ie  during the first 21 days of treatment Results 1: ",
            "Arm/Group Title: Phase 1: Niraparib 200mg + PembrolizumabArm/Group Description: Niraparib 200 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 1 16.7% Results 2: Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab Arm/Group Description: Niraparib 300 mg/day orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 1 16.7% "
        ],
        "premise_nums": [
            "administered  Time frame: During Cycle 1, ie  during the first 21 days of treatment Results 1:",
            "requiring platelet transfusion; - Neutropenia Grade 4 for 7 days  or Grade 3 or 4 associated with bleeding or requiring",
            "are defined as: Any treatment-related Grade 3 non-hematologic clinical (non-laboratory) AE Any treatment-related Grade 3 or Grade 4 non-hematologic lab abnormality if:",
            "orally (PO)  Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle  Overall Number of Participants",
            "leading to smaller than 80% of an intended dose being administered  Time frame: During Cycle 1, ie  during the first",
            "for a non-DLT lab abnormality lasting 14 days  - A dose",
            "Participants Unit of Measure: Participants 1 16.7% Results 2: Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab Arm/Group Description: Niraparib",
            "nonhematologic AE leading to smaller than 80% of an intended dose being administered",
            "or - The abnormality persists for 7 days  Any treatment-related hematologic",
            "Title: Phase 1: Niraparib 200mg + PembrolizumabArm/Group Description: Niraparib 200 mg/day orally (PO)  Pembrolizumab 200 mg",
            "days  or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days  or",
            "Participants Unit of Measure: Participants 1 16.7% Results 2: Arm/Group Title: Phase 1: Niraparib 200mg + PembrolizumabArm/Group Description: Niraparib 200",
            "or febrile neutropenia; - Anemia Grade 4, or Grade 3 or 4",
            "intravenously (IV) on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of"
        ]
    },
    {
        "id": "5feefe8b-ddca-4eb8-af68-d1e211963d1f",
        "primaryId": "NCT02748213",
        "statement_text": "2 patients  in cohort 1 of the primary trial was recorded as having an overactive pituitary gland ",
        "statement_nums": [
            "2 patients  in cohort 1 of the primary trial was recorded as having"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) ",
            "Pericardial effusion * 1/110 (0.91%)Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac",
            "7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse",
            "26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110",
            "Pericardial effusion * 1/110 (0.91%)Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting",
            "1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%)",
            "Vomiting * 3/112 (2.68%) Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia",
            "(46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%)"
        ]
    },
    {
        "id": "2a5d8ca7-1608-4607-b996-490fc447b593",
        "primaryId": "NCT00956813",
        "statement_text": "All the primary trial subjects are required to take the intervention tablet PO daily ",
        "statement_nums": [
            "All the primary trial subjects are required to"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily"
        ]
    },
    {
        "id": "178c50cc-49ee-4083-bc8e-b5832037498a",
        "primaryId": "NCT00258960",
        "statement_text": "4 patients in the primary trial experienced a grade 3 or above adverse event ",
        "statement_nums": [
            "4 patients in the primary trial experienced a grade 3 or above adverse event"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) "
        ],
        "premise_nums": [
            "grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related",
            "Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%)",
            "cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis",
            "grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade",
            "grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48",
            "(2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis",
            "cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48",
            "(2.08%) Catheter - related infection grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade",
            "(6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis",
            "Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48",
            "3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%)"
        ]
    },
    {
        "id": "92ace4fa-4426-4f34-af52-ee62913e60aa",
        "primaryId": "NCT01026142",
        "secondaryId": "NCT00846027",
        "statement_text": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial ",
        "statement_nums": [
            "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular systolic dysfunction 1/82 (1.22%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1:",
            "1: Left Ventricular Dysfunction 4/218 (1.83%) Adverse Events 2: Left Ventricular Dysfunction 13/228 (5.70%) Adverse Events 1: Left ventricular"
        ]
    },
    {
        "id": "7dbde84d-f1c9-4197-9d44-500fd337bebd",
        "primaryId": "NCT01823107",
        "statement_text": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events ",
        "statement_nums": [
            "At most 12 Patients implanted with a Meso BioMatrix Acellular"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Rate of Breast Related Adverse Events Investigators evaluated each subject and each reconstructed breast for the occurrence of an adverse event from the first stage of reconstruction through the final follow-up visit  A breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast  Time frame: 18 months Results 1: Arm/Group Title: Meso BioMatrix Acellular Peritoneum Matrix Arm/Group Description: All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  Overall Number of Participants Analyzed: 25 Overall Number of Units Analyzed Type of Units Analyzed: Reconstructed breasts Measure Type: NumberUnit of Measure: Reconstructed breasts affected: 12 "
        ],
        "premise_nums": [
            "adverse event from the first stage of reconstruction through the",
            "breast  Time frame: 18 months Results 1: Arm/Group Title: Meso BioMatrix Acellular",
            "Number of Participants Analyzed: 25 Overall Number of Units Analyzed Type of"
        ]
    },
    {
        "id": "824da29f-b2ff-440e-8b78-7a8291cbd6d2",
        "primaryId": "NCT02340221",
        "statement_text": "A total of 89 patients in the primary trial had Supraventricular tachycardia ",
        "statement_nums": [
            "A total of 89 patients in the primary trial had Supraventricular tachycardia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%) Colitis 0/213 (0.00%) Vomiting 1/213 (0.47%) Nausea 1/213 (0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416 (0.24%) ",
            "Diarrhoea 32/416 (7.69%)Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%) "
        ],
        "premise_nums": [
            "0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive",
            "(0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416 (0.24%) Supraventricular tachycardia 1/416",
            "Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213",
            "Diarrhoea 32/416 (7.69%)Colitis 14/416 (3.37%) Vomiting 4/416 (0.96%) Nausea 3/416 (0.72%) Enterocolitis 2/416 (0.48%)",
            "Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416",
            "fibrillation 0/213 (0.00%) Cardiac failure congestive 0/213 (0.00%) Myocardial infarction 0/213 (0.00%) Supraventricular tachycardia 0/213 (0.00%) Diarrhoea 0/213 (0.00%)",
            "(0.47%) Enterocolitis 0/213 (0.00%) Adverse Events 2: Total: 133/416 (31.97%) Pancytopenia 1/416 (0.24%) Anaemia 0/416 (0.00%) Atrial fibrillation 2/416 (0.48%) Cardiac",
            "Total: 19/213 (8.92%) Pancytopenia 0/213 (0.00%) Anaemia 1/213 (0.47%) Atrial fibrillation 2/416 (0.48%) Cardiac failure congestive 1/416 (0.24%) Myocardial infarction 1/416"
        ]
    },
    {
        "id": "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1",
        "primaryId": "NCT02748213",
        "statement_text": "1 patient  in cohort 1 of the primary trial was recorded as having an overactive thyroid gland ",
        "statement_nums": [
            "1 patient  in cohort 1 of the primary trial was recorded as having"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%) Neutropenia * 7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Coronary artery disease * 1/112 (0.89%) Left ventricular dysfunction * 1/112 (0.89%) Pericardial effusion * 0/112 (0.00%) Hyperthyroidism * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110 (0.00%) Left ventricular dysfunction * 0/110 (0.00%) ",
            "Pericardial effusion * 1/110 (0.91%)Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting * 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac",
            "7/112 (6.25%) Anaemia * 1/112 (0.89%) Cardiac failure * 1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse",
            "26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%) Coronary artery disease * 0/110",
            "Pericardial effusion * 1/110 (0.91%)Hyperthyroidism * 0/110 (0.00%) Diarrhoea * 0/110 (0.00%) Vomiting",
            "1/112 (0.89%) Diarrhoea * 5/112 (4.46%) Vomiting * 3/112 (2.68%) Adverse Events 1: Total: 52/112 (46.43%) Febrile neutropenia * 16/112 (14.29%)",
            "Vomiting * 3/112 (2.68%) Adverse Events 2: Total: 51/110 (46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia",
            "(46.36%) Febrile neutropenia * 26/110 (23.64%) Neutropenia * 7/110 (6.36%) Anaemia * 1/110 (0.91%) Cardiac failure * 0/110 (0.00%)"
        ]
    },
    {
        "id": "052ee533-7daa-4cbf-a64c-bc9a50444173",
        "primaryId": "NCT00244933",
        "statement_text": "the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events ",
        "statement_nums": [
            "the primary trial does not monitor the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19 (26.32%) Platelets 3/19 (15.79%) Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%) Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%) Dyspnea 3/19 (15.79%) "
        ],
        "premise_nums": [
            "Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19",
            "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19"
        ]
    },
    {
        "id": "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 7 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "A total of 7 patients in the primary trial were observed with either"
        ],
        "label": "Entailment",
        "premise_text": [
            "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) "
        ],
        "premise_nums": [
            "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%)"
        ]
    },
    {
        "id": "9b622b9b-3ad3-4cff-acb3-4127d0304de0",
        "primaryId": "NCT00571987",
        "statement_text": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial ",
        "statement_nums": [
            "from entry to the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or calcification BIRADS classification IV location of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal Carcinoma Grade I-III on final pathology Good general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or supraclavicular lymph nodes If prior non-breast malignancy  must have greater than 5 year disease-free survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants Multicentric disease or bilateral disease Lesions greater than 5 cm in diameter Lesions smaller than 1.0 cm from the skin Previous prior radiation to the breast Need for mastectomy Diffuse microcalcifications (as determined by the Investigator) "
        ],
        "premise_nums": [
            "general health Zubrod Performance Status of 0,1, or 2 No previous chemotherapy No palpable axillary or",
            "of abnormality greater than 1 cm from skin Ductal or Infiltrating Ductal",
            "radiologic documentation of: size 5 cm unicentric  unilateral suspicious mass or",
            "survival Exclusion Criteria: Patient smaller than 18 y/o or greater than 100 y/o Pregnant or breastfeeding Male Breast implants",
            "disease Lesions greater than 5 cm in diameter Lesions smaller than 1.0 cm from the skin Previous prior radiation",
            "Inclusion Criteria: Female  18-100 years old Not pregnant or breastfeeding Pre-study"
        ]
    },
    {
        "id": "825ba6fd-8c08-49d2-941b-3338ef01e7fd",
        "primaryId": "NCT02673918",
        "secondaryId": "NCT01042938",
        "statement_text": "African American patients are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "eligible for both the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection)  including those women with a history of previous surgery for breast cancer  radiation therapy or chemotherapy Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks  Home access to internet from stationary computer  lab top or tablet Ability to use internet Ability to read and understand Danish Exclusion Criteria: Surgery for breast cancer with immediate breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast cancer Planned use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues  seroma  hematoma Severe physical  cognitive  or psychiatric illness causing inability to follow the study protocol: i.e  severe depression  anxiety  dementia  poor physical health with likely possibility of hospitalization within the next twelve weeks  Planned hospitalization or surgery within the next twelve weeks Participation in another clinical trial with a rehabilitation or exercise intervention Inclusion Criteria: Participants can be from any racial or ethnic origin  "
        ],
        "premise_nums": [
            "radiation therapy or chemotherapy Part 2 only: Completion of surgery and",
            "Criteria: Diagnosis of breast cancer Part 1 only: Surgery for breast cancer",
            "use of chemotherapy within the next 6 weeks Surgical complications: infection  drainage issues",
            "breast reconstruction Diagnosis of primary lymphedema Metastatic or inflammatory breast"
        ]
    },
    {
        "id": "95345dbe-446f-4999-8f3e-a429b77ea554",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not explicitly required for the secondary trial ",
        "statement_nums": [
            "phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN  These conditions are not",
            "explicitly required for the secondary trial",
            "for entry to the primary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT"
        ],
        "label": "Entailment",
        "premise_text": [
            "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy Pregnant or lactating as determined by routine standard practice Personal history of breast cancer History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded) History of prior breast reduction mammoplasty surgery ",
            "History of prior breast augmentation surgeryMental condition rendering the subject unable to understand the nature  scope  and possible consequences of the study  "
        ],
        "premise_nums": [
            "Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function",
            "total bilirubin)) should be less than 2.5x upper limits of normal (ULN)",
            "of prior breast reduction mammoplasty surgery",
            "creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old Glomerular filtration rategreater than 60",
            "History of iodinated contrast allergy Pregnant or lactating as"
        ]
    },
    {
        "id": "b05fde86-4004-427f-8baf-2ea4a0a535c7",
        "primaryId": "NCT00376597",
        "statement_text": "the primary trial all undergo surgery twice  first at 2 weeks and then again a month later ",
        "statement_nums": [
            "the primary trial all undergo surgery twice  first at 2 weeks and then again a month later"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Lymphedema Education) Six weeks after surgery  patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials  Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm II (Lymphedema Education  Physical Therapy) Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I  Patients also complete a personalized physical therapy intervention  receive a refrigerator magnet  and a 15-minute video that reinforces information and exercises  "
        ],
        "premise_nums": [
            "are also contacted by telephone at 9 and 15 months  INTERVENTION 2: Arm",
            "complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months  Patients are",
            "a refrigerator magnet  and a 15-minute video that reinforces information and exercises"
        ]
    },
    {
        "id": "21e24c6c-d282-48fb-8d68-3e723458794e",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "unstable angina or a grade 4 hemorrhage within the last month",
            "be excluded from the primary trial; grade 3 infection"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  "
        ],
        "premise_nums": [
            "other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment",
            "or active infection greater than grade 2. Unstable angina (anginal symptoms at"
        ]
    },
    {
        "id": "d1e579e2-b057-43da-8a2f-64dad964b789",
        "primaryId": "NCT00821964",
        "statement_text": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle ",
        "statement_nums": [
            "other day for a total of 14 days every 28 day cycle",
            "the primary trial participants apply topical imiquimod"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Biological Therapy  Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity  imiquimod: Given topically Abraxane: Given IV laboratory biomarker analysis: Correlative studies RNA analysis: Correlative studies immunoenzyme technique: Correlative studies "
        ],
        "premise_nums": [
            "to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in",
            "Chemo) Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions",
            "toxicity  imiquimod: Given topically Abraxane: Given IV laboratory",
            "on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of"
        ]
    },
    {
        "id": "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6",
        "primaryId": "NCT00093145",
        "secondaryId": "NCT00703326",
        "statement_text": "Heart-related adverse events were recorded in the secondary trial  but not the primary trial ",
        "statement_nums": [
            "were recorded in the secondary trial  but not the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction 0/752 (0.00%) "
        ],
        "premise_nums": [
            "(3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac failure congestive 1/752 (0.13%) Left ventricular dysfunction",
            "Adverse Events 1: Supraventricular tachycardia 1/32 (3.13%) Adverse Events 1: Atrial fibrillation 1/752 (0.13%) Atrial flutter 0/752 (0.00%) Cardiac"
        ]
    },
    {
        "id": "d130c981-f602-4f17-b1cb-11a7ad632b92",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial more than 6 different types of cardiac related adverse events ",
        "statement_nums": [
            "the primary trial more than 6 different types of cardiac related adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) "
        ],
        "premise_nums": [
            "1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations",
            "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations",
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%)",
            "2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%)",
            "ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%)"
        ]
    },
    {
        "id": "c1f9982f-c4c9-48dc-887a-7ae05f508c21",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 2 cycles",
        "statement_nums": [
            "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 2"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  "
        ],
        "premise_nums": [
            "including any additional cycles beyond cycle 2. After completion of all neoadjuvant",
            "additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy",
            "the end of cycle 2 and breast ultrasounds were performed at the end of cycle 2 and breast ultrasounds were performed",
            "Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles",
            "performed at the end of cycle 2 and breast ultrasounds were performed at the"
        ]
    },
    {
        "id": "75130da8-77be-45d1-bc32-dfc97c1a1dae",
        "primaryId": "NCT02441946",
        "secondaryId": "NCT00325598",
        "statement_text": "the secondary trial has a much longer duration than the primary trial ",
        "statement_nums": [
            "the secondary trial has a much longer duration than the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration "
        ],
        "premise_nums": [
            "Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration"
        ]
    },
    {
        "id": "c71cbcd6-3786-4b90-8991-b3c6e159ae77",
        "primaryId": "NCT00975676",
        "secondaryId": "NCT00632489",
        "statement_text": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib ",
        "statement_nums": [
            "of Triptorelin as the secondary trial uses for Capecitabine and",
            "the primary trial uses the same dosage"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib ",
            "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  "
        ],
        "premise_nums": [
            "1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe",
            "treated with triptorelin plus exemestane for 5 years  INTERVENTION 1: LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly",
            "will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days",
            "mg/m2 orally BID 14 of every 21 days  Treatment cycles will be paired with LBH589 and will range in dose from 825",
            "orally twice daily for 14 days out of every 21 days  Treatment cycles will be 21 days in length  Once",
            "orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib",
            "With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be administered orally twice daily for 14 days out of every 21",
            "be administered orally twice daily for 14 days out of every 21 days",
            "treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin",
            "days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the"
        ]
    },
    {
        "id": "ed48936e-4933-437b-a7ba-e65b4c1fd276",
        "primaryId": "NCT03167359",
        "secondaryId": "NCT01385137",
        "statement_text": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial  but not the primary trial ",
        "statement_nums": [
            "is used in the secondary trial  but not the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast conserving surgery or mastectomy and clear margins  will receive 15 doses of radiation over three weeks  Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment  The boost treatment will be given on the same days as the whole breast treatment  The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions  INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "INTERVENTION 1: Participants With Stage 0-III Breast Cancer Women with Stage 0-III breast cancer  treated with breast",
            "and clear margins  will receive 15 doses of radiation over three weeks",
            "whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost",
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three",
            "wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions simultaneously with a boost treatment",
            "times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive"
        ]
    },
    {
        "id": "b01e966e-6624-4740-b477-a8bbbd8eec50",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Skin lymphangitis  Bone marrow suppression or Allergic shock ",
        "statement_nums": [
            "In contrast to the secondary trial  the primary trial did not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Large intestinal obstruction 1/132 (0.76%) Nausea 3/132 (2.27%) Adverse Events 1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone marrow suppression 1/51 (1.96%) ",
            "Allergic shock 0/51 (0.00%)Deep incisional SSI 0/51 (0.00%) "
        ],
        "premise_nums": [
            "(0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper",
            "shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone",
            "(0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper",
            "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132",
            "Allergic shock 0/51 (0.00%)Deep incisional SSI 0/51 (0.00%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "Adverse Events 1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep",
            "1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI"
        ]
    },
    {
        "id": "92acd36d-ea44-4b98-acbc-e51382233089",
        "primaryId": "NCT00820872",
        "statement_text": "Diarrhea was the most common adverse event in cohort 1 of the primary trial ",
        "statement_nums": [
            "most common adverse event in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%) Skin infection 1/30 (3.33%) Neutrophil count decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%) "
        ],
        "premise_nums": [
            "10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage",
            "Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%)",
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 2/30 (6.67%) Abdominal pain 1/30 (3.33%) Colitis 1/30 (3.33%) Diarrhea 7/30",
            "Adverse Events 1: Total: 10/30 (33.33%) Hemoglobin decreased 1/30 (3.33%) Platelet count decreased 3/30 (10.00%) Dehydration 1/30 (3.33%)",
            "Colitis 1/30 (3.33%) Diarrhea 7/30 (23.33%) Nausea 2/30 (6.67%) Rectal hemorrhage 1/30 (3.33%) Fatigue 1/30 (3.33%)"
        ]
    },
    {
        "id": "01280892-ca31-4e46-831b-a076426f65e5",
        "primaryId": "NCT01401062",
        "statement_text": "A patient who underwent T-cell transfer therapy in the past 6 months prior  and has fully recovered from the associated toxicities  would be excluded from the primary trial ",
        "statement_nums": [
            "T-cell transfer therapy in the past 6 months prior  and has fully recovered",
            "be excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy; "
        ],
        "premise_nums": [
            "Must be 4 weeks since all of the following treatments (recovered",
            "toxicity of prior treatment to Grade 1, excluding alopecia): immunotherapy;"
        ]
    },
    {
        "id": "959bd67a-1b2a-48da-ae44-211cbab4b665",
        "primaryId": "NCT00393939",
        "statement_text": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group ",
        "statement_nums": [
            "Sunitinib group of the primary trial than for the Docetaxel",
            "Median (95% Confidence Interval) Progression-Free Survival (PFS) was"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause  whichever occurred first  PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)  Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.6 (8.2 to 10.3) ",
            "Investigator's assessment: 8.2 (7.3 to 8.6)Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3) "
        ],
        "premise_nums": [
            "Independent radiology assessment: 8.3 (7.7 to 9.6) Investigator's assessment: 6.9 (6.5 to 7.3)",
            "Independent radiology assessment: 8.6 (8.2 to 10.3)",
            "(mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square",
            "absence of sunitinib)  Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: months",
            "Investigator's assessment: 8.2 (7.3 to 8.6)Results 2: Arm/Group Title: Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants",
            "docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)  Overall Number of Participants Analyzed: 296",
            "absence of docetaxel)  or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib)",
            "Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 297 Median (95% Confidence Interval) Unit of",
            "Docetaxel Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of",
            "Baseline up to Month 33 Results 1: Arm/Group Title: Docetaxel + Sunitinib Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for",
            "to date of the first documentation of objective tumor progression",
            "every 3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence",
            "by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2)",
            "3 weeks  or sunitinib 37.5 mg daily in continuous dosing (in absence of sunitinib)  Overall Number of Participants Analyzed: 296"
        ]
    },
    {
        "id": "92923765-76d4-4a27-a240-101690d9fea4",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "statement_nums": [
            "in higher dosages than Methotrexate and 6-",
            "the primary trial patients are administered cyclophosphamide"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  "
        ],
        "premise_nums": [
            "progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a",
            "an Urgent Safety Measure in August 2012 due to a large proportion of patients",
            "myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day",
            "a day (od) in the morning 1 hour after eating  on a continuous",
            "(od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given",
            "The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week",
            "6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day"
        ]
    },
    {
        "id": "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b",
        "primaryId": "NCT00429507",
        "secondaryId": "NCT00038467",
        "statement_text": "Unlike the secondary trial  the primary trial does not administer any medication orally or intravenously ",
        "statement_nums": [
            "secondary trial  the primary trial does not administer any medication orally or intravenously"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones  receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP. INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  "
        ],
        "premise_nums": [
            "disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as",
            "receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell",
            "who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily",
            "received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants",
            "dose of 153 Sm-EDTMP 7-14 days after tracer dose  Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi)",
            "INTERVENTION 1: Samarium 153-EDTMP + Stem Cell Transplant Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with",
            "3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per"
        ]
    },
    {
        "id": "5a5695e8-9b84-42ad-9f34-6dd043153943",
        "primaryId": "NCT02872103",
        "secondaryId": "NCT02995980",
        "statement_text": "Adequate renal  hepatic and blood work is required for entry to the primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT  AST  alkaline phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN ",
        "statement_nums": [
            "primary trial and the secondary trial  this includes the following criteria; hemoglobin 11.5 g/dL  aswell as ALT",
            "for entry to the primary trial and the secondary trial  this includes the",
            "phosphatase and total bilirubin smaller than 2.5xULN, and Serum creatinine should be less than 1.7x ULN"
        ],
        "label": "Contradiction",
        "premise_text": [
            "White Blood Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function (Liver function tests (ALT  AST  alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN)  Serum creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy Pregnant or lactating as determined by routine standard practice Personal history of breast cancer History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded) History of prior breast reduction mammoplasty surgery History of prior breast augmentation surgery ",
            "Mental condition rendering the subject unable to understand the nature  scope  and possible consequences of the study "
        ],
        "premise_nums": [
            "Cell count (WBC) 4.0 109/L, hemoglobin 11.5 g/dL and a platelet count 150 109/L. Demonstrate adequate renal  hepatic function",
            "total bilirubin)) should be less than 2.5x upper limits of normal (ULN)",
            "of prior breast reduction mammoplasty surgery History of prior",
            "creatinine should be less than 1.7x ULN  Inclusion Criteria: Signed informed consent At least 19 years old Glomerular filtration rategreater than 60",
            "History of iodinated contrast allergy Pregnant or lactating as"
        ]
    },
    {
        "id": "33634c51-0fb9-4de1-966d-14784bca93f8",
        "primaryId": "NCT01847001",
        "statement_text": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial ",
        "statement_nums": [
            "a heart rate of at least 60 beats per minute are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: English or Spanish speaking women age 18 Heart Rate greater than 60 bpm "
        ],
        "premise_nums": [
            "English or Spanish speaking women age 18 Heart Rate greater than 60 bpm"
        ]
    },
    {
        "id": "8e46dc77-fa36-4231-a124-0ff6392891a1",
        "primaryId": "NCT02297412",
        "secondaryId": "NCT02667626",
        "statement_text": "Cohort 2 of the secondary trial and the primary trial are control groups ",
        "statement_nums": [
            "Cohort 2 of the secondary trial and the primary trial are control groups"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Minocycline Hydrochloride) Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 2: Arm II (Placebo) Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity  INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  ",
            "Control: Web-based resource lists and text-based study adherence reminders"
        ],
        "premise_nums": [
            "reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants",
            "reminders  At completion of the 24 weeks of follow up  they will",
            "minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of",
            "prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship"
        ]
    },
    {
        "id": "d11b0673-42a9-46c0-887f-d5a9b038264f",
        "primaryId": "NCT00407888",
        "statement_text": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity ",
        "statement_nums": [
            "a week long cycle up to 12 times in the absence of disease progression",
            "Arm 1 of the primary trial receive dose-intensive chemotherapy on"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity  doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally filgrastim: Given SC paclitaxel albumin-stabilized nanoparticle formulation: Given IV trastuzumab: Given IV laboratory biomarker analysis: Correlative studies quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "Given IV cyclophosphamide: Given orally filgrastim: Given SC paclitaxel",
            "once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in",
            "unacceptable toxicity  Beginning 1 week later  patients then receive paclitaxel",
            "doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once a week for 1 year in the absence of disease progression",
            "nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of",
            "toxicity  Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year",
            "chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on",
            "filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression"
        ]
    },
    {
        "id": "e08c196a-e3f0-420b-a252-7e2818949038",
        "primaryId": "NCT03197389",
        "statement_text": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception  for the course of the study through 120 days after receiving the study medication  Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject  Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception  until 120 after receiving the study therapy  "
        ],
        "premise_nums": [
            "the course of the study through 120 days after receiving the study medication",
            "5.7.1- Contraception  until 120 after receiving the study therapy",
            "of contraception as outlined in Section 5.7.2 - Contraception  for"
        ]
    },
    {
        "id": "83511f04-e07c-438d-bf1e-f680fa49b384",
        "primaryId": "NCT01901146",
        "secondaryId": "NCT00209092",
        "statement_text": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial ",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 3/364 (0.82%) Adverse Events 1: Febrile Neutropenia *0/25 (0.00%)"
        ]
    },
    {
        "id": "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94",
        "primaryId": "NCT00290758",
        "statement_text": "There was one genitourinary adverse events recorded in the primary trial ",
        "statement_nums": [
            "events recorded in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) renal - Other * 0/64 (0.00%) Obstruction  GU: Uterus * 0/64 (0.00%) Sexual * 1/64 (1.56%) Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) Ulceration * 0/64 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62"
        ]
    },
    {
        "id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "compared to cohort 1 of the primary trial  there are more",
            "every observed adverse event in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden Death * 1/41 (2.44%) Bacterial Infection * 1/41 (2.44%) Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%)",
            "Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden"
        ]
    },
    {
        "id": "076ead15-ce03-4c33-9050-1f6eb13764a1",
        "primaryId": "NCT01490892",
        "secondaryId": "NCT02364388",
        "statement_text": "The intervention in the primary trial requires an injection and two different imaging modalities  whereas the secondary trial provides almost no details in the intervention section ",
        "statement_nums": [
            "The intervention in the primary trial requires an injection and",
            "modalities  whereas the secondary trial provides almost no details"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) INTERVENTION 1: MAESTRO Baseline "
        ],
        "premise_nums": [
            "Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging"
        ]
    },
    {
        "id": "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76",
        "primaryId": "NCT00323479",
        "secondaryId": "NCT03078751",
        "statement_text": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial ",
        "statement_nums": [
            "Pulmonary embolisms in the primary trial than the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%) General body pain 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) ",
            "Cardiac failure congestive 0/24 (0.00%)Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) "
        ],
        "premise_nums": [
            "failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%)",
            "Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2:",
            "leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%)",
            "failure congestive 1/26 (3.85%) Breast cellulitis 1/26 (3.85%) Cellulitis 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 2:",
            "Cellulitis 1/26 (3.85%) Acute myeloid leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)",
            "Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)",
            "Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 0/24 (0.00%)Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%)",
            "leukaemia 1/26 (3.85%) Seizure 0/26 (0.00%) Pulmonary embolism 1/26 (3.85%) Adverse Events 1: Total: 6/110 (5.45%) Sudden death unexplained 1/110 (0.91%)",
            "(0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110 (0.91%) Depression worsened 1/110 (0.91%) Calculus urinary bladder",
            "worsened 1/110 (0.91%) Calculus urinary bladder 1/110 (0.91%) Pneumopathy 1/110 (0.91%) Lymphangitis 1/110 (0.91%) Femur fracture 1/110 (0.91%) Parathyroid adenoma 1/110",
            "Adverse Events 1: Total: 4/26 (15.38%) Disseminated intravascular coagulation 1/26 (3.85%) Cardiac failure congestive 1/26 (3.85%) Breast cellulitis 1/26"
        ]
    },
    {
        "id": "3e1037fd-cc1e-4229-892f-95d0987d9a68",
        "primaryId": "NCT01042535",
        "statement_text": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg ",
        "statement_nums": [
            "Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg) MTD of 1-methyl-d-tryptophan (indoximod) given by mouth (PO)  twice a day (BID)  with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100 mg  200 mg  400 mg  800 mg daily (QD) then 800 mg  1,200 mg  and 1,600 mg PO BID +up to 6 fixed dose Ad.p53 DC vaccinations q2wks. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. The MTD is the highest dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients  that is  0 or 1 out of 6 patients experiences a dose limiting toxicity (DLT)  Time frame: Up to 4 weeks Results 1: Arm/Group Title: Treatment (Vaccine Therapy  1-methyl-d-tryptophan) ",
            "Arm/Group Description: Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses  Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity adenovirus-p53 transduced dendritic cell (DC) vaccine: Given intradermally (ID) 1-methyl-d-tryptophan: Given orally (PO) Laboratory biomarker analysis: Correlative studies Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: indoximod dose in mg 1600 "
        ],
        "premise_nums": [
            "to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod",
            "200 mg  400 mg  800 mg daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days",
            "indoximod dose levels (DL) (100 mg  200 mg  400 mg  800 mg daily (QD) then 800 mg",
            "1,200 mg  and 1,600 mg PO BID +up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1",
            "vaccine: Given intradermally (ID) 1-methyl-d-tryptophan: Given orally (PO) Laboratory biomarker analysis:",
            "dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients  that is",
            "day (BID)  with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used",
            "(MTD) in Milligrams (mg) MTD of 1-methyl-d-tryptophan (indoximod) given by mouth",
            "Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: indoximod dose levels (DL) (100 mg  200 mg  400",
            "(DLT)  Time frame: Up to 4 weeks Results 1: Arm/Group Title: Treatment (Vaccine Therapy",
            "with up to 6 fixed doses Ad.p53 DC vaccinations every 200 mg  400 mg  800 mg daily (QD)",
            "or 1 out of 6 patients experiences a dose limiting toxicity (DLT)  Time frame: Up to 4 weeks Results 1: Arm/Group Title:",
            "days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of",
            "This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100 mg  200 mg  400",
            "Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100",
            "every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100 mg",
            "Arm/Group Description: Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and",
            "adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for",
            "400 mg  800 mg daily (QD) then 800 mg  1,200 mg  and 1,600 mg PO",
            "then 800 mg  1,200 mg  and 1,600 mg PO BID +up to 6 fixed",
            "that is  0 or 1 out of 6 patients experiences a dose limiting toxicity (DLT)",
            "and then every 3 weeks for 6 total doses  Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on"
        ]
    },
    {
        "id": "f25adbc7-c0a0-44ed-af93-02f4bced7208",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "statement_text": "Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  "
        ],
        "premise_nums": [
            "Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression"
        ]
    },
    {
        "id": "99951bae-37c8-4299-8ec1-4577a97d0b81",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "statement_text": "the primary trial recorded cases of pleural effusion and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [
            "the primary trial recorded cases of pleural",
            "were observed in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50 (2.00%) Cholelithiasis 1/50 (2.00%) Anaphylactic reaction [1]1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) ",
            "PLEURAL EFFUSION 1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) "
        ],
        "premise_nums": [
            "1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1:",
            "PLEURAL EFFUSION 1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%)",
            "(2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH",
            "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50",
            "1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%)",
            "(2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia",
            "chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture",
            "1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%)"
        ]
    },
    {
        "id": "c789e79c-a254-4bb1-9d15-73d1726da8a6",
        "primaryId": "NCT00334802",
        "secondaryId": "NCT00167414",
        "statement_text": "There is no age limit for either the secondary trial or the primary trial  Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible ",
        "statement_nums": [
            "limit for either the secondary trial or the primary trial  Patients simply need"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically and/or cytologically confirmed breast cancer Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen To have at least one measurable region Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow  liver and renal function) Exclusion Criteria: To have interstitial pneumonia or pulmonary fibrosis To have inflammatory breast cancer Within 28 days after the latest chemotherapy or radiotherapy  14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastases with symptoms To have severe complication (cardiac infarction  infection  drug hypersensitivity or diabetes) Inclusion Criteria: Age: no limit "
        ],
        "premise_nums": [
            "anthracycline regimen To have at least one measurable region Eastern Cooperative",
            "Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow",
            "Inclusion Criteria: Histologically and/or cytologically confirmed breast",
            "days after the latest hormonal/immunotherapy or 7 days after surgery To have inflammatory breast cancer Within 28 days after the latest chemotherapy"
        ]
    },
    {
        "id": "2b182323-9357-486a-87aa-09ddc6230bf1",
        "primaryId": "NCT02481050",
        "statement_text": "There is only 1 adverse event in the primary trial that occurred more than once ",
        "statement_nums": [
            "There is only 1 adverse event in the primary trial that occurred more than"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/58 (24.14%) Constipation 1/58 (1.72%) Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Hypovolaemia 1/58 (1.72%) "
        ],
        "premise_nums": [
            "Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture",
            "Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased",
            "fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture",
            "(1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture"
        ]
    },
    {
        "id": "9681ec15-7545-455e-ac8c-1052fc199b11",
        "primaryId": "NCT02162667",
        "statement_text": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group ",
        "statement_nums": [
            "Herceptin group in the primary trial had a higher number"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes  Regardless of Ductal Carcinoma in Situ (DCIS) Subject who went through Neoadjuvant period completely (24 weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response  will be assessed using resected bio-specimens collected in breast and axilla during a surgery  Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title: CT-P6 ",
            "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248 Measure Type: Number Unit of Measure: percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Title: Herceptin ",
            "Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment  surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68) "
        ],
        "premise_nums": [
            "weeks)  will receive surgery within 3-6 weeks after last treatment of neoadjuvant period",
            "FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 2 through 8 (3-week cycles)  Patients also received",
            "percentage of responders 46.77 (40.43 to 53.19) Results 2: Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg",
            "Neo-adjuvant therapy and Surgery (up to 30 weeks) Results 1: Arm/Group Title:",
            "75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8.",
            "Arm/Group Description: Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion",
            "Number of Participants Analyzed: 248 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)",
            "through 8. After a total of 8 treatment cycles of the neoadjuvant period  The primary endpoint  Pathological complete response",
            "75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment",
            "1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also",
            "CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by",
            "cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through 8. After a total of 8 treatment cycles of the neoadjuvant",
            "received docetaxel 75 mg/m^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m^2, epirubicin 75mg/m^2, and cyclophosphamide 500mg/m^2) during Cycles 5 through",
            "6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received docetaxel 75 mg/m^2 during cycles 1 through",
            "6 weeks from the last dose of study Overall Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage",
            "surgery was performed within 3 to 6 weeks from the last dose of study Overall Number of Participants Analyzed: 248",
            "will receive surgery within 3-6 weeks after last treatment of neoadjuvant period  The primary endpoint  Pathological complete response",
            "Number of Participants Analyzed: 256 Measure Type: Number Unit of Measure: percentage of responders 50.39 (44.10 to 56.68)",
            "an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on",
            "Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles)  Patients also received"
        ]
    },
    {
        "id": "8ca512c3-72d8-4179-a63e-51d83d76445f",
        "primaryId": "NCT00256243",
        "secondaryId": "NCT00721630",
        "statement_text": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center ",
        "statement_nums": [
            "the secondary trial and the primary trial are both taking place"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Eligibility Criteria: Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma  Histologic confirmation shall be by either core needle biopsy or incisional biopsy  Punch biopsy is allowed if invasive breast cancer is documented  Patients must meet one of the criteria defined below (indicate one): a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment  b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  Physical examination  chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration  Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible  Patients with hypertension or age greater than 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal  ",
            "Patients must have a serum creatinine and bilirubin the institutional upper limit of normal  and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) 2x the institutional upper limit of normal  These tests must have been performed within 90 days prior to registration Patients must have an Absolute neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration  Patients must have a performance status of 0-2 by Zubrod criteria Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen  Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method  A urine pregnancy test is required for women of childbearing potential  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines  Inclusion Criteria: Patients with a diagnosis of invasive adenocarcinoma of the breast confirmed by histology or cytology at MSKCC  "
        ],
        "premise_nums": [
            "a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an",
            "be women with a histologically confirmed diagnosis of locally",
            "b  Stage IIIB (T4, Any N  M0) or (Any T  N3, M0) disease  Physical examination",
            "1,500/μl and a platelet count of 100,000/μl. These tests must have been performed within 90 days prior to registration Patients must have",
            "must have a performance status of 0-2 by Zubrod criteria Pregnant or nursing women",
            "tumor assessment must be performed within 90 days prior to registration  Patients with",
            "with hypertension or age greater than 60 years must have a Multiple Gated Acquisition",
            "neutrophil count (ANC) of 1,500/μl and a platelet count of 100,000/μl. These tests must have been performed"
        ]
    },
    {
        "id": "171d0a20-8943-4994-a48a-7dff124e62ee",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) "
        ],
        "premise_nums": [
            "Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)"
        ]
    },
    {
        "id": "25cc9a6e-656d-44ee-a301-93f5879407a0",
        "primaryId": "NCT01923168",
        "statement_text": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days ",
        "statement_nums": [
            "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily  "
        ],
        "premise_nums": [
            "Alpelisib + Letrozole Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily"
        ]
    },
    {
        "id": "d9b4d4aa-0094-405e-83a3-cf2978cfda38",
        "primaryId": "NCT00347919",
        "statement_text": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "statement_nums": [
            "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured  Per Response Evaluation Criteria In Solid Tumors (RECIST)  a response of PD is defined as a greater than or equal 20% increase in target lesions  Participants were also classified as having PD if their response at Week 12 was unknown or missing  Response was determined by an independent radiologist and by an investigator  Time frame: Week 12 Results 1: Arm/Group Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1 "
        ],
        "premise_nums": [
            "their response at Week 12 was unknown or missing  Response was",
            "as a greater than or equal 20% increase in target lesions  Participants",
            "Title: Cohort 1: Lapatinib 1500 mg Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day Overall",
            "Progressive Disease at Week 12 in Cohort 1 The percentage of participants Independently Evaluated: 38.9 Investigator Evaluated: 43.1",
            "Number of Participants Analyzed: 72 Measure Type: Number Unit of Measure: percentage",
            "Participants With Progressive Disease at Week 12 in Cohort 1 The percentage of participants with progressive disease"
        ]
    },
    {
        "id": "caa55802-329d-4a1f-a9a7-b99afc44fd67",
        "primaryId": "NCT00038467",
        "statement_text": "The patient groups in the primary trial each receive the same doses of different oral medication  either Tamoxifen or Exemestane ",
        "statement_nums": [
            "patient groups in the primary trial each receive the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Exemestane Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice  received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period  "
        ],
        "premise_nums": [
            "who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally",
            "received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period  INTERVENTION 2: Tamoxifen Participants",
            "3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per"
        ]
    },
    {
        "id": "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0",
        "primaryId": "NCT02525718",
        "secondaryId": "NCT02606708",
        "statement_text": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo ",
        "statement_nums": [
            "Patients in group 1 of the secondary trial and the primary trial receive the same dosage"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) "
        ],
        "premise_nums": [
            "to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity",
            "injection of saline  (2.5 mg/ml) INTERVENTION 1: Accelerated Intensity",
            "Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform",
            "Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7"
        ]
    },
    {
        "id": "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "statement_text": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients  Whereas all the primary trial participants receive the same treatment ",
        "statement_nums": [
            "In the secondary trial Her-2 neu positive breast cancer patients receive additional",
            "other patients  Whereas all the primary trial participants receive the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity  cyclophosphamide  paclitaxel  trastuzumab: Given IV "
        ],
        "premise_nums": [
            "and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "(bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or",
            "and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for 14 courses in the absence of disease progression",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel",
            "toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every"
        ]
    },
    {
        "id": "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad",
        "primaryId": "NCT02780713",
        "statement_text": "Both cohorts of the primary trial are administered the same drugs in different doses  ",
        "statement_nums": [
            "Both cohorts of the primary trial are administered the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment"
        ]
    },
    {
        "id": "ee7fe82e-de91-45c7-bd12-bff5d6c887a3",
        "primaryId": "NCT00320411",
        "statement_text": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily ",
        "statement_nums": [
            "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily "
        ],
        "premise_nums": [
            "1: Lapatinib Monotherapy Lapatinib: 1500 mg (six 250 mg tablets) orally once daily"
        ]
    },
    {
        "id": "888a8d39-3ad6-401e-acf2-cf5e01a73bf2",
        "primaryId": "NCT00266110",
        "secondaryId": "NCT00879086",
        "statement_text": "the primary trial had a much higher rate of adverse events than the secondary trial ",
        "statement_nums": [
            "adverse events than the secondary trial",
            "the primary trial had a much higher"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS * 1/17 (5.88%) Constipation * 1/17 (5.88%) Adverse Events 1: Total: 19/51 (37.25%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51 (0.00%) Dysphagia 1/51 (1.96%) Abdominal pain 0/51 (0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) ",
            "Leukopenia 0/50 (0.00%)Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) "
        ],
        "premise_nums": [
            "failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%)",
            "failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive",
            "(0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 1/50 (2.00%) Visual impairment 1/50 (2.00%) Dysphagia 0/50 (0.00%)",
            "(0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51",
            "(2.00%) Dysphagia 0/50 (0.00%) Abdominal pain 1/50 (2.00%) Chills 0/50 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive",
            "Adverse Events 1: Total: 2/17 (11.76%) Nausea * 1/17 (5.88%) Pain - Abdomen NOS *",
            "(0.00%) Chills 1/51 (1.96%) Adverse Events 2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%)",
            "Leukopenia 0/50 (0.00%)Neutropenia 1/50 (2.00%) Thrombocytopenia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive",
            "(2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51 (0.00%) Dysphagia 1/51 (1.96%)",
            "neutropenia 6/51 (11.76%) Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter",
            "2: Total: 17/50 (34.00%) Febrile neutropenia 0/50 (0.00%) Anaemia 1/50 (2.00%) Pericarditis 0/50 (0.00%) Atrial flutter 1/50 (2.00%) Cardiac failure congestive",
            "Neutropenia 1/51 (1.96%) Thrombocytopenia 0/51 (0.00%) Pericarditis 1/51 (1.96%) Atrial flutter 0/51 (0.00%) Cardiac failure congestive 0/51 (0.00%) Visual impairment 0/51"
        ]
    },
    {
        "id": "13466cbb-9f78-46ff-a983-09e2e9ad5a2c",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial presented a fever  in addition to either a cough or a sore throat ",
        "statement_nums": [
            "1 patient in the primary trial presented a fever"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Influenza like illness 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Influenza like illness 1/110 (0.91%)"
        ]
    },
    {
        "id": "0beaef44-a39a-462c-a084-d3f824857673",
        "primaryId": "NCT00374322",
        "statement_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients  however  there was less than a 30% difference in DFS rate between the two cohorts ",
        "statement_nums": [
            "there was less than a 30% difference in DFS rate between the",
            "more likely to achieve DFS at 5 years than placebo patients  however",
            "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to",
            "was less than a 30% difference in DFS rate between the primary trial results show that Participants"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants (Par.) With Any Recurrence of the Initial Disease  Second Primary Cancer  Contralateral Breast Cancer  or Death (Disease-free Survival [DFS]) ",
            "DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence  a second primary cancer  or death from any cause  The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer  including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin  melanoma in situ  carcinoma in situ of the cervix  or lobular carcinoma in situ of the breast); death from any cause without a prior event  Par  who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored  Par  who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed ",
            "Time frame: From randomization until date of the first occurrence of an objective disease recurrence  a second primary cancer  or death from any cause (assessed up to 6 years; 1 year of treatment  5 years of follow-up [median of 5.3 years for final analysis])Results 1: Arm/Group Title: Lapatinib 1500 mg Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily  Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer  withdrawal from study treatment due to unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 1571 Measure Type: Number Unit of Measure: Participants Any recurrence or death: 252 Censored  New Anti-cancer Agent/Radiotherapy: 1 Censored  Follow-up Ended: 1318 Results 2: Arm/Group Title: Placebo Arm/Group Description: Participants received matching placebo orally once daily  Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer  withdrawal from study treatment due to unacceptable toxicity  or consent withdrawal  Overall Number of Participants Analyzed: 1576 ",
            "Measure Type: NumberUnit of Measure: Participants Any recurrence or death: 290 Censored  New Anti-cancer Agent/Radiotherapy: 1 Censored  Follow-up Ended: 1285 "
        ],
        "premise_nums": [
            "until date of the first occurrence of an objective disease",
            "recurrence  a second primary cancer  or death from any cause (assessed up to 6 years; 1 year of treatment",
            "(follow-up ongoing) at the last visit date available at which",
            "Any recurrence or death: 252 Censored  New Anti-cancer Agent/Radiotherapy: 1",
            "years of follow-up [median of 5.3 years for final analysis])Results 1: Arm/Group Title: Lapatinib 1500 mg Arm/Group Description: Participants received lapatinib",
            "Censored  Follow-up Ended: 1318 Results 2: Arm/Group Title: Placebo Arm/Group Description: Participants received lapatinib 1500 milligrams (mg) orally once daily  Treatment",
            "Number of Participants Analyzed: 1571 Measure Type: Number Unit of Measure: Participants",
            "from any cause (assessed up to 6 years; 1 year of treatment  5 years of follow-up [median of 5.3 years"
        ]
    },
    {
        "id": "8e45da73-f016-4ca0-b106-a3fabc960b36",
        "primaryId": "NCT01432145",
        "statement_text": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate ",
        "statement_nums": [
            "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression  Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  "
        ],
        "premise_nums": [
            "progression  Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a",
            "an Urgent Safety Measure in August 2012 due to a large proportion of patients",
            "myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day",
            "a day (od) in the morning 1 hour after eating  on a continuous",
            "(od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given",
            "The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week",
            "6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day"
        ]
    },
    {
        "id": "37dc56a4-4756-4ab0-8055-7637bf579740",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "statement_text": "the primary trial and the secondary trial are both single arm clinical trials ",
        "statement_nums": [
            "the primary trial and the secondary trial are both single arm"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone  ",
            "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity "
        ],
        "premise_nums": [
            "therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity",
            "1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50",
            "at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab",
            "(PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)",
            "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab",
            "PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase",
            "administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker",
            "28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day",
            "were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV)",
            "150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone",
            "by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6",
            "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1:"
        ]
    },
    {
        "id": "65e370b7-7726-477e-8730-8cea734d1609",
        "primaryId": "NCT02115607",
        "secondaryId": "NCT01823107",
        "statement_text": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix ",
        "statement_nums": [
            "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate",
            "Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Definity Infusion Infusion of Definity (Perflutren Lipid Microspheres) Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction  After tissue expansion  the tissue expander was replaced with a breast implant during the second stage of reconstruction  "
        ],
        "premise_nums": [
            "infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix Acellular Peritoneum Matrix",
            "tissue expander during the first stage of breast reconstruction",
            "Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min INTERVENTION 1: Meso BioMatrix"
        ]
    },
    {
        "id": "affdd551-15e2-4a47-8c20-209cc01570ec",
        "primaryId": "NCT03012477",
        "statement_text": "One patient in the primary trial experienced a thromboembolic event  a condition associated with a high degree of morbidity and mortality  However  the most common adverse event was Diarrhea ",
        "statement_nums": [
            "One patient in the primary trial experienced a thromboembolic event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased 2/34 (5.88%) Dehydration 1/34 (2.94%) Headache 1/34 (2.94%) Thromboembolic event 1/34 (2.94%) "
        ],
        "premise_nums": [
            "Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%)",
            "Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased",
            "Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased"
        ]
    },
    {
        "id": "2152f503-4fa4-4f32-b766-a05a4c69742f",
        "primaryId": "NCT02176083",
        "secondaryId": "NCT03061175",
        "statement_text": "Neither the primary trial or NCT0306117 use chemotherapy  adverse event management courses or radiotherapy in their intervention ",
        "statement_nums": [
            "Neither the primary trial or NCT0306117 use chemotherapy  adverse event management courses"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Intervention Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM  Survey Administration: Ancillary studies "
        ],
        "premise_nums": [
            "dryness Text message management prompts INTERVENTION 2: Control Control YBCS will not",
            "CPM-DA Survey Administration: Ancillary studies INTERVENTION 2: Arm II (Usual Care) Patients",
            "hot flashes and vaginal dryness INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients"
        ]
    },
    {
        "id": "a7903e59-9620-457a-8d83-eb6eb5dd8a2b",
        "primaryId": "NCT01300351",
        "statement_text": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function ",
        "statement_nums": [
            "At least 1 participant in each cohort of the primary trial showed signs of poor"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Hepatic function abnormal * 1/109 (0.92%)"
        ]
    },
    {
        "id": "dc7e7fbe-eed9-4307-b584-30ecaeb77c95",
        "primaryId": "NCT00186121",
        "statement_text": "Patients with E2 outside the premenopausal range are ineligible for the primary trial ",
        "statement_nums": [
            "Patients with E2 outside the premenopausal range are ineligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "If tamoxifen administered within the past 3 months  plasma estradiol must be in the premenopausal range "
        ],
        "premise_nums": [
            "If tamoxifen administered within the past 3 months  plasma estradiol must"
        ]
    },
    {
        "id": "a34c6194-b6d9-49c3-8ddb-72de10c8a18c",
        "primaryId": "NCT02006979",
        "statement_text": "Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines ",
        "statement_nums": [
            "Neither cohort of the primary trial need to perform low"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Exercise an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines "
        ],
        "premise_nums": [
            "an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines",
            "for 48 hours post exercise INTERVENTION 2: Usual Care no exercise for 72 hours prior or 48 hours post each cycle of"
        ]
    },
    {
        "id": "da00532d-57a8-4fe2-a2de-acc525161fd9",
        "primaryId": "NCT01120184",
        "statement_text": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder ",
        "statement_nums": [
            "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Hypercoagulation * 21/353 (0.28%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Hypercoagulation * 21/353 (0.28%)"
        ]
    },
    {
        "id": "f90364e9-caee-4075-b444-2db1bf846d3a",
        "primaryId": "NCT02511730",
        "secondaryId": "NCT00193206",
        "statement_text": "Patients with prior chemotherapy are excluded from the secondary trial and the primary trial ",
        "statement_nums": [
            "are excluded from the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  Inclusion Criteria: No prior chemotherapy for breast cancer "
        ],
        "premise_nums": [
            "Female subjects participating in FMSU004A protocol with known clinical status Exclusion"
        ]
    },
    {
        "id": "a06d1ca5-c890-4157-b1d2-0b70fd0092bd",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) Non Cardiac-Chest pain 22/70 (2.86%) Fever 24/70 (5.71%) Skin infection 41/70 (1.43%) Neutrophil count decreased 31/70 (1.43%) "
        ],
        "premise_nums": [
            "1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Neutrophil count decreased 31/70 (1.43%)",
            "1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Non Cardiac-Chest pain 22/70 (2.86%) Fever 24/70 (5.71%) Skin infection",
            "Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%)",
            "Adverse Events 1: Total: 19/70 (27.14%) Febrile Neutropenia 24/70 (5.71%) Pericarditis 21/70 (1.43%) Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70",
            "Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) Neutrophil count decreased 31/70 (1.43%)",
            "Sinus bradycardia 21/70 (1.43%) Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Neutrophil count decreased 31/70 (1.43%)"
        ]
    },
    {
        "id": "5bc0d21d-a040-4d30-b0c7-8793cba6aba8",
        "primaryId": "NCT01091168",
        "statement_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year ",
        "statement_nums": [
            "control group of the primary trial had a median Overall Survival of less than a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Survival The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up  For patients who have not died  survival duration will be censored at the date of last contact or last follow-up or the date of last news  Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country  Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin Overall Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months 9.3 (7.5 to 10.9) "
        ],
        "premise_nums": [
            "Outcome Measurement: Overall Survival The main endpoint of",
            "date of death or last follow-up  For patients who",
            "Time frame: From baseline up to 3 years 1 month Results 2: Arm/Group Title: Alkylating Agent Arm/Group",
            "Number of Participants Analyzed: 296 Median (95% Confidence Interval) Unit of Measure: Months"
        ]
    },
    {
        "id": "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses ",
        "statement_nums": [
            "Cohort 2 in the primary trial and the secondary trial but receive daily placebo"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  "
        ],
        "premise_nums": [
            "gel applied to breasts daily for 4-10 weeks  INTERVENTION 2:",
            "(2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel"
        ]
    },
    {
        "id": "5a1358af-f51b-49f8-b1c0-99a0b108b0a2",
        "primaryId": "NCT00091442",
        "statement_text": "There were more cases of Febrile neutropenia than leukopenia observed in the primary trial  but less cases of neutropenia than leukopenia ",
        "statement_nums": [
            "leukopenia observed in the primary trial  but less cases"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Neutropenia 14/373 (3.75%) Febrile neutropenia 10/373 (2.68%) Leukopenia 1/373 (0.27%)"
        ]
    },
    {
        "id": "73d323e7-1a38-49d4-97f4-a15f1664fb3e",
        "primaryId": "NCT01439711",
        "statement_text": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months  almost 1cm3 less than average ",
        "statement_nums": [
            "3 months  almost 1cm3 less than average",
            "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI  the sum over all measureable lesions on the MRI was calculated at each time point  V3 was calculated by subtracting the total MRI FTV measured (i.e  the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline  For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests  Time frame: up to 3 months from start of treatment Results 1: Arm/Group Title: Letrozole + MRI Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a bilateral MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic centimeters -1.93 (-2.87 to -0.98) "
        ],
        "premise_nums": [
            "MRI for disease evaluation at months 3 and 6. Overall Number of Participants Analyzed:",
            "disease evaluation at months 3 and 6. Overall Number of Participants Analyzed: 68 Mean (95% Confidence Interval) Unit of Measure: cubic",
            "Therapy will consist of 6 months of letrozole  administered orally at a dose of 2.5 mg/day  Patients will have a",
            "(FTV) Change From Baseline to Month 3 (V3) Mean total MRI FTV change from",
            "at baseline  For V3 the raw change in the volume will",
            "t-tests  Time frame: up to 3 months from start of treatment Results 1: Arm/Group Title: Letrozole + MRI",
            "Baseline to Month 3 (V3) Mean total MRI FTV change from baseline to month 3 (V3): For patients with more",
            "each patient and a mean and 95% confidence interval will be constructed using",
            "the sum over all measureable lesions on the MRI for disease evaluation at months 3 and 6. Overall Number of"
        ]
    },
    {
        "id": "02dea6a3-d94f-4650-bf4f-be8fdb0a382f",
        "primaryId": "NCT02010021",
        "statement_text": "A patient has recently had an oophorectomy,they are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Prior endocrine therapy for any histologically confirmed cancer is not allowed  Prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed  "
        ],
        "premise_nums": [
            "endocrine therapy for any histologically confirmed cancer is not",
            "Prior endocrine therapy that was administered 5 years ago for the prevention of breast"
        ]
    },
    {
        "id": "4c8a124b-f015-42e2-8ad3-6168f21fe705",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "was at its highest on Day 1 of the third cycle  before T-DM1 intravenous (IV) infusion"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Change From Baseline in Mean Duration of the QTc Interval The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle  The corrected QT interval was calculated using Fridericia's correction (QTcF) from electrocardiogram (ECG) data  Each participant had triplicate QTcF intervals measured at each timepoint and the average was calculated for each patient at each timepoint  For each timepoint  a participant's corresponding baseline QTcF interval was subtracted from the average QTcF intervals to create a baseline-adjusted average QTcF interval  Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose  Results 1: Arm/Group Title: T-DM1 ",
            "Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9) "
        ],
        "premise_nums": [
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60",
            "Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle",
            "Number of Participants Analyzed: 51 Mean (Standard Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose",
            "by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg Overall Number of Participants Analyzed:",
            "Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose of 3.6 mg/kg Overall Number of Participants Analyzed: 51",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle",
            "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60",
            "Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle",
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day",
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle"
        ]
    },
    {
        "id": "d6df95f5-472f-4b14-9cd4-5d5ef238175a",
        "primaryId": "NCT00005879",
        "statement_text": "There are criteria for PRIOR CONCURRENT THERAPY  PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial ",
        "statement_nums": [
            "for entry to the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Current random fine needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a BRCAPRO risk of at least 25% Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries  must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram ",
            "Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2No active cancer (e.g.  detectable disease) Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any Performance status: Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein S  or antithrombin III No activated protein C resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No history of deep venous thrombosis not related to trauma or pregnancy No severe coronary artery disease No history of prior stroke Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other active cancer No retinal vein thrombosis No concurrent severe poorly controlled migraine No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: ",
            "Biologic therapy:At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration At least 12 months since prior chemotherapy Endocrine therapy: Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration At least 12 months since prior tamoxifen  raloxifene  or other antihormonal therapy Radiotherapy: At least 3 months since prior radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new medication that would be ingested for 1 or more months "
        ],
        "premise_nums": [
            "a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein",
            "showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal No ovarian cysts felt to",
            "medication that would be ingested for 1 or more months",
            "100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L",
            "specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any",
            "on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries",
            "must have been taken during days 1-14 of the menstrual cycle for premenopausal women",
            "modified Gail risk of at least 4% Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "modified Gail risk of at least 4% Hyperplasia without atypia but with a 10-year modified Gail risk of at least",
            "100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than",
            "Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than",
            "a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a 10-year modified Gail risk of at least",
            "use effective contraception during and for 3 months after study No other active cancer",
            "than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5",
            "pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8",
            "needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with stepwedge within past 6 months If intact uterus and/or ovaries",
            "genetic testing performed for BRCA1 and BRCA2No active cancer (e.g.  detectable",
            "Biologic therapy:At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase",
            "a BRCAPRO risk of at least 25% Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia"
        ]
    },
    {
        "id": "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age ",
        "statement_nums": [
            "A 55 year old postmenopausal patient with sarcoidosis would",
            "be excluded from the primary trial due to her age"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Confirmed diagnosis of prior operable  noninflammatory breast cancer meeting the following criteria: Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor)  determined by immunohistochemistry  after primary surgery and before commencement of prior endocrine therapy Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease Following primary surgery  eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes  but not supraclavicular nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of both When calculating 4-6 years  neoadjuvant endocrine therapy should not be included No evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) ",
            "Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range)Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range) Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-up No psychiatric  addictive  or any other disorder that compromises compliance with protocol requirements ",
            "PRIOR CONCURRENT THERAPY:See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: Neoadjuvant chemotherapy Neoadjuvant endocrine therapy Adjuvant chemotherapy Trastuzumab (Herceptin®) Ovarian ablation Gonadotropin releasing hormone analogues Lapatinib ditosylate No concurrent hormone-replacement therapy  bisphosphonates (except for treatment of bone loss)  or any other investigational agent "
        ],
        "premise_nums": [
            "Patients 56 years old or older with any evidence",
            "sequential combination of both When calculating 4-6 years  neoadjuvant endocrine",
            "nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant therapy allowed including  but not",
            "by immunohistochemistry  after primary surgery and before commencement of",
            "osteoporosis at any time during the 4-6 years of prior therapy No prior or",
            "in the postmenopausal range)Patients 55 years old or younger must have biochemical",
            "castration AND amenorrheic for greater than 3 months)",
            "CONCURRENT THERAPY:See Disease Characteristics More than 12 months since prior and no other concurrent",
            "(LHRH) analogues within the last year are eligible if they",
            "status as defined above Clinically adequate hepatic function No"
        ]
    },
    {
        "id": "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83",
        "primaryId": "NCT00982319",
        "statement_text": "Only Post menopausal women can enter the primary trial  as long as they do not have prior hormone replacement therapy ",
        "statement_nums": [
            "women can enter the primary trial  as long as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female 18 + years of age Confirmed diagnosis of DCIS on core or excisional/incisional biopsy and scheduled for definitive surgery Pre or Post menopausal women reporting no use of hormone replacement therapy  tamoxifen or raloxifene within the prior 6 months to eligibility screening "
        ],
        "premise_nums": [
            "tamoxifen or raloxifene within the prior 6 months to eligibility screening"
        ]
    },
    {
        "id": "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70",
        "primaryId": "NCT01425268",
        "secondaryId": "NCT01373671",
        "statement_text": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial  and saline is used in both of the study groups in the secondary trial ",
        "statement_nums": [
            "study groups in the secondary trial",
            "study groups in the primary trial  and saline is",
            "CO2 is utilised as part of the intervention"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "scan on Siemens MAMMOMAT Inspiration INTERVENTION 2: FFDM Only FFDM exam only"
        ]
    },
    {
        "id": "f820384b-0bf5-4f2e-96fd-2c8b13a4646c",
        "primaryId": "NCT01289353",
        "secondaryId": "NCT00429182",
        "statement_text": "the primary trial and the secondary trial share at least one drug in their chemotherapy regiment ",
        "statement_nums": [
            "the primary trial and the secondary trial share at least one drug in their chemotherapy"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Carboplatin: IV  weekly for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  "
        ],
        "premise_nums": [
            "Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6,",
            "20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion",
            "for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then"
        ]
    },
    {
        "id": "f7410166-82a7-4d15-8a04-47287ef6884c",
        "primaryId": "NCT00448591",
        "statement_text": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial ",
        "statement_nums": [
            "adverse events occurred in more than 1% of patient in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264 (0.04%) "
        ],
        "premise_nums": [
            "8/2264 (0.35%) Thrombocytopenia * 6/2264 (0.27%) Disseminated intravascular coagulation * 3/2264 (0.13%) Agranulocytosis * 1/2264 (0.04%) Bone marrow failure * 1/2264",
            "bone marrow aplasia * 14/2264 (0.62%) Anaemia * 8/2264 (0.35%) Leukopenia * 8/2264 (0.35%) Thrombocytopenia",
            "Total: 672/2264 (29.68%) Febrile neutropenia * 117/2264 (5.17%) Neutropenia * 98/2264 (4.33%) Febrile bone marrow aplasia *"
        ]
    },
    {
        "id": "80726ab0-e8e4-4c42-860b-fdedad407517",
        "primaryId": "NCT00121836",
        "statement_text": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included ",
        "statement_nums": [
            "for participation of the primary trial will still be included"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women greater than or equal 18 years of age HER2-negative metastatic breast cancer Previous adjuvant chemotherapy or hormonal treatment greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment with chemotherapy  an anti-angiogenic agent  or a biologic therapy for advanced or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy Central nervous system metastases Other malignancy within last 5 years  except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix Serious concurrent infection "
        ],
        "premise_nums": [
            "greater than or equal 1 measurable target lesion Exclusion Criteria: Previous treatment",
            "system metastases Other malignancy within last 5 years  except cured basal",
            "or metastatic cancer Radiation therapy within 4 weeks of study treatment start or insufficient",
            "greater than or equal 18 years of age HER2-negative metastatic breast cancer Radiation therapy within 4 weeks of study treatment start or insufficient"
        ]
    },
    {
        "id": "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d",
        "primaryId": "NCT02725801",
        "secondaryId": "NCT04030104",
        "statement_text": "Neither the primary trial or the secondary trial have placebo groups ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial have placebo groups"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of two-port tissue expander at time of reconstruction AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging "
        ],
        "premise_nums": [
            "tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of",
            "tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging"
        ]
    },
    {
        "id": "d42054cd-deb6-4436-941c-9e3a06c713cc",
        "primaryId": "NCT00036270",
        "statement_text": "In total Less than 10% of patients in the primary trial either had a disease relapse or died ",
        "statement_nums": [
            "In total Less than 10% of patients in the primary trial either had a disease"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) to time of observation for DFS  DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal  receptor positive  node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years  Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC)  Intercurrent death: death without disease relapse  Time frame: Baseline (Month 0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by Exemestane ",
            "Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen  participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events (disease relapse or death) 388 "
        ],
        "premise_nums": [
            "completing 2.5 years to 3 years of tamoxifen  participants were to complete a total of 5 years endocrine therapy Overall Number",
            "(Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4898 Measure Type: Number Unit of Measure: Events",
            "or Death) From Baseline up to 2.75 Years Number of events (disease relapse or",
            "(Aromasin ) 25 mg QD for 5 years  Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events",
            "were to complete a total of 5 years endocrine therapy Overall Number of Participants Analyzed: 4868 Measure Type: Number Unit of Measure: Events",
            "Baseline (Month 0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to",
            "0) up to 2.75 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years  Overall",
            "Death) From Baseline up to 2.75 Years Number of events (disease relapse or death) 352 Results 2: Arm/Group Title: Tamoxifen Followed by"
        ]
    },
    {
        "id": "0507fbf8-3557-4ace-b015-5e106b96f6a9",
        "primaryId": "NCT02041429",
        "secondaryId": "NCT00068588",
        "statement_text": "the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements ",
        "statement_nums": [
            "the primary trial and the secondary trial use Maximum Tolerated Dose"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT)  See DLT primary outcome measure for definition Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities "
        ],
        "premise_nums": [
            "(DLT)  See DLT primary outcome measure for definition Outcome",
            "Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the"
        ]
    },
    {
        "id": "49ecc5a6-89be-48b6-85c5-c809c83f5baf",
        "primaryId": "NCT00825734",
        "statement_text": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection  unstable angina or a grade 4 hemorrhage within the last month ",
        "statement_nums": [
            "unstable angina or a grade 4 hemorrhage within the last month",
            "be excluded from the primary trial; grade 1 infection"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection greater than grade 2. Unstable angina (anginal symptoms at rest) or new onset angina Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment  or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment  "
        ],
        "premise_nums": [
            "other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment",
            "or active infection greater than grade 2. Unstable angina (anginal symptoms at"
        ]
    },
    {
        "id": "68792f63-d7b5-4570-bf8e-95e4cb8094e9",
        "primaryId": "NCT00343382",
        "secondaryId": "NCT00798135",
        "statement_text": "Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole ",
        "statement_nums": [
            "lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression or unacceptable toxicities  "
        ],
        "premise_nums": [
            "Pilocarpine 2 times per day for 6 weeks  INTERVENTION 1: Itraconazole oral itraconazole 200mg a day until disease progression"
        ]
    },
    {
        "id": "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca",
        "primaryId": "NCT00483223",
        "secondaryId": "NCT00811135",
        "statement_text": "There are more cases of Intestinal perforation  Chest pain  death  Erysipelas and Pneumonia in the secondary trial than in the primary trial",
        "statement_nums": [
            "and Pneumonia in the secondary trial than in the primary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%) Hypertension 1/86 (1.16%) Adverse Events 1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%) Death * 1/88 (1.14%) Erysipelas * 1/88 (1.14%) Pneumonia * 1/88 (1.14%) "
        ],
        "premise_nums": [
            "8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%)",
            "1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%)"
        ]
    },
    {
        "id": "a1a5767f-07e7-4a33-a26f-586cf71a208d",
        "primaryId": "NCT01852032",
        "secondaryId": "NCT01118624",
        "statement_text": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial ",
        "statement_nums": [
            "intervention sections of the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Breast Cancer Patients Tomosynthesis Breast Scanning is done and breast CT Scanning is done  INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Pralatrexate Study drug 190 mg/m^2 for 2 to 4 weeks"
        ]
    },
    {
        "id": "9c80fb61-66dc-4b3d-82b9-4fb62db89422",
        "primaryId": "NCT01326481",
        "statement_text": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial ",
        "statement_nums": [
            "Deep vein thrombosis within the last 3 months are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Angina  MI  symptomatic congestive heart failure  cerebrovascular accident  transient ischemic attack  arterial embolism  pulmonary embolism  DVT  PTCA or CABG within the past 6 months "
        ],
        "premise_nums": [
            "PTCA or CABG within the past 6 months"
        ]
    },
    {
        "id": "6755a378-08bf-4e9b-a6de-166733d0307b",
        "primaryId": "NCT00181363",
        "statement_text": "The only difference between the interventions used in the primary trial is the patients location ",
        "statement_nums": [
            "interventions used in the primary trial is the patients location"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position "
        ],
        "premise_nums": [
            "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position"
        ]
    },
    {
        "id": "b7f3e657-638b-4463-9639-4fb0da2be042",
        "primaryId": "NCT00262834",
        "secondaryId": "NCT01106898",
        "statement_text": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients ",
        "statement_nums": [
            "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Vorinostat Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or biopsy)  INTERVENTION 1: Treatment (Chemotherapy With or Without Maintenance Therapy) SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity  cyclophosphamide  paclitaxel  trastuzumab: Given IV "
        ],
        "premise_nums": [
            "and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "(bid)  with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or",
            "and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for 14 courses in the absence of disease progression",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "6 doses of oral vorinostat at 300 mg twice daily (bid)  with the last dose administered by study personnel",
            "toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every"
        ]
    },
    {
        "id": "5498a85b-a086-4d5d-b677-9ae44646a382",
        "primaryId": "NCT00546156",
        "secondaryId": "NCT00398567",
        "statement_text": "There are no cases of Vertigo  Abdominal distension or Neutropenia in the primary trial or the primary trial ",
        "statement_nums": [
            "or Neutropenia in the primary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%) Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4 (0.00%) Diarrhoea 0/4 (0.00%) Nausea 0/4 (0.00%) Vomiting 0/4 (0.00%) Disease progression 0/4 (0.00%) Influenza 0/4 (0.00%) Nasopharyngitis 0/4 (0.00%) Lumbar vertebral fracture 0/4 (0.00%) Hyponatraemia 0/4 (0.00%) Ataxia 0/4 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/4 (25.00%) Vertigo 0/4 (0.00%) Abdominal adhesions 0/4 (0.00%) Abdominal distension 0/4 (0.00%) Abdominal pain 0/4",
            "Adverse Events 1: Total: 4/104 (3.85%) Neutropenia 1/104 (0.96%) Leukopenia 2/104 (1.92%) paranasal sinus reaction 1/104 (0.96%) cellulitis 1/104 (0.96%)"
        ]
    },
    {
        "id": "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd",
        "primaryId": "NCT00418457",
        "statement_text": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial ",
        "statement_nums": [
            "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Primary breast cancer without known extension beyond the breast and axillary nodes (i.e  believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify) Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent  including willingness to be randomized to morphine or regional analgesia Exclusion Criteria: Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Age smaller than 18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy  abnormal anatomy) Any contraindication to midazolam  propofol  sevoflurane  fentanyl  or morphine Other cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present 25% two-year mortality "
        ],
        "premise_nums": [
            "by the attending surgeon to present 25% two-year mortality",
            "believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy",
            "dissection (anticipated removal of at least five nodes) Written informed consent",
            "18 or greater than 85 years old Scheduled free flap reconstruction ASA Physical Status 4 Any contraindication to epidural or paravertebral anesthesia"
        ]
    },
    {
        "id": "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea",
        "primaryId": "NCT00209092",
        "secondaryId": "NCT00631852",
        "statement_text": "A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial ",
        "statement_nums": [
            "A patient with a Histologically confirmed breast cancer would",
            "be accepted for the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma  Inclusion Criteria: Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging "
        ],
        "premise_nums": [
            "invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging",
            "Inclusion Criteria: Histologically or cytologically confirmed breast"
        ]
    },
    {
        "id": "4fd10abc-81d1-44f4-825a-26e2eaeae979",
        "primaryId": "NCT02308020",
        "statement_text": "There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria ",
        "statement_nums": [
            "There were 23 participants in cohort 1 of the primary trial with a (CR) or"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) ",
            "OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria  CR is measurable target lesions  the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically  PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions  taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically  Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions  Stable disease (SD) is less than (smaller than )30% decrease relative to baseline but smaller than 20% increase in sum LD relative to nadir  Progressive disease (PD) is greater than or equal to ( ) 20% increase in sum LD relative to nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm) ",
            "Time frame: Baseline to Objective Disease Progression (Up to 36 Months)Results 1: Arm/Group Title: Part A Abemaciclib: HR+  HER2+ Breast Cancer Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  Overall Number of Participants Analyzed: 23 Measure Type: Number Unit of Measure: percentage of participants 0 "
        ],
        "premise_nums": [
            "relative to baseline but smaller than 20% increase in sum LD relative increase of 20%, 1 lesion must increase by absolute value of",
            "relative to baseline but smaller than 20% increase in sum LD relative to",
            "A Abemaciclib: HR+  HER2+ Breast Cancer Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours",
            "(CNS) target lesions for at least 4 weeks; no new lesions; no",
            "PR is at least a 30% decrease in the sum longest duration",
            "to Objective Disease Progression (Up to 36 Months)Results 1: Arm/Group Title: Part",
            "Number of Participants Analyzed: 23 Measure Type: Number Unit of Measure: percentage of participants 0",
            "nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm)",
            "receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every"
        ]
    },
    {
        "id": "a12a46de-9d3e-4c6a-becb-d43653040bf0",
        "primaryId": "NCT00089973",
        "statement_text": "the primary trial uses a 3 week cycle for SB-715992 administration  and the study lasts for 21 cycles ",
        "statement_nums": [
            "3 week cycle for SB-715992 administration  and the study lasts for 21 cycles"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib  intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles  until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent  "
        ],
        "premise_nums": [
            "Day 1 of every 21-day treatment cycle  at a dose of 18 mg/m^2. The dosing was repeated for",
            "INTERVENTION 1: SB-715992 The eligible participants were administered Ispinesib"
        ]
    },
    {
        "id": "66ee10ac-1bfe-44d6-9b91-8a2bb1983606",
        "primaryId": "NCT01017549",
        "secondaryId": "NCT01390064",
        "statement_text": "the secondary trial has 5 more patients cohorts than the primary trial ",
        "statement_nums": [
            "the secondary trial has 5 more patients cohorts than the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Electronic Brachytherapy Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System  Accelerated partial breast irradiation is the method of radiation therapy administration that has been commonly used by physicians using Iridium-192, but was FDA cleared for use prior to commencing study enrollment using an electronic source  INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule "
        ],
        "premise_nums": [
            "Radiation therapy was delivered using the 510(k) cleared Xoft Axxent System",
            "(SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300",
            "of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination",
            "Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51",
            "used by physicians using Iridium-192, but was FDA cleared for use",
            "Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination"
        ]
    },
    {
        "id": "714c540c-1fa1-47c7-ac13-1e8f056d1e31",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) "
        ],
        "premise_nums": [
            "0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn",
            "(45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before",
            "0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn",
            "day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%)",
            "Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after",
            "57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33",
            "Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia"
        ]
    },
    {
        "id": "3948b30d-934d-485c-b324-b3571e2957a3",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts",
            "adverse events in the primary trial and the secondary trial is Neutropenia with a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) Cardiac failure congestive *0/744 (0.00%) Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) ",
            "Thrombotic thrombocytopenic purpura *0/736 (0.00%)Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) Arrhythmia *2/736 (0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) "
        ],
        "premise_nums": [
            "(1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%)",
            "(0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "ischaemia *0/736 (0.00%) Arrhythmia *2/736 (0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67",
            "failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "Thrombotic thrombocytopenic purpura *0/736 (0.00%)Atrial flutter *0/736 (0.00%) Cardiac arrest",
            "1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%)",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "(0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736"
        ]
    },
    {
        "id": "45cf29ce-25f5-4719-8468-69d94893c9e7",
        "primaryId": "NCT01166763",
        "statement_text": "the primary trial recorded 4 life-threatening adverse events ",
        "statement_nums": [
            "the primary trial recorded 4 life-threatening adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30 (3.33%) Flank pain * [3]1/30 (3.33%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/30 (10.00%) Cholecystitis * [1]1/30 (3.33%) Increase in diarrhea * [2]1/30"
        ]
    },
    {
        "id": "89f84928-82a9-413e-ab25-400657002c55",
        "primaryId": "NCT01840163",
        "secondaryId": "NCT02005549",
        "statement_text": "the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy ",
        "statement_nums": [
            "the primary trial and the secondary trial do not exclude patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male Inclusion Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; prior or concurrent systemic antitumor therapy; clinically significant cardiac disease  "
        ],
        "premise_nums": [
            "Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no",
            "the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant",
            "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability"
        ]
    },
    {
        "id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
        "primaryId": "NCT00930930",
        "statement_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia ",
        "statement_nums": [
            "most frequent adverse event in cohort 1 of the primary trial was lymphopenia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96 (5.21%) ileus 1/96 (1.04%) nausea 2/96 (2.08%) vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) fatigue 2/96 (2.08%) Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) colitis 0/49 (0.00%) ",
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%) fatigue 0/49 (0.00%) "
        ],
        "premise_nums": [
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small",
            "1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small",
            "cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96",
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "(1.04%) fatigue 2/96 (2.08%) Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction",
            "(0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96",
            "vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%)",
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction",
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96"
        ]
    },
    {
        "id": "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group  however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [
            "Exemestane group in the primary trial had a better median"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical)  or death from any cause  PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI)  Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI  such as when the disease site is skin  bone marrow  or central nervous system  Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone Acetate + Prednisone ",
            "Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59) "
        ],
        "premise_nums": [
            "exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression",
            "Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane Arm/Group Description:",
            "Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59)",
            "toxicity  or death (up to 3 years)  Overall Number of Measure: Months 3.65 (2.73 to 5.59)",
            "toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months",
            "to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months",
            "toxicity  or death (up to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of",
            "time from randomization to first occurrence of disease progression (either",
            "at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in",
            "toxicity  or death (up to 3 years)  Overall Number of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone"
        ]
    },
    {
        "id": "23040754-d1ad-4660-aacf-3298aefa5dae",
        "primaryId": "NCT00777101",
        "secondaryId": "NCT00559845",
        "statement_text": "There were no depressed patients in either the primary trial or the secondary trial  however there was one suicide attempt in cohort 2 of the secondary trial ",
        "statement_nums": [
            "was one suicide attempt in cohort 2 of the secondary trial",
            "patients in either the primary trial or the secondary trial  however there was"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%) ",
            "Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) "
        ],
        "premise_nums": [
            "Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54",
            "1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%)",
            "In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal",
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal",
            "(0.86%) Diarrhoea 3/116 (2.59%) Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "(0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54",
            "Adverse Events 1: Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116",
            "Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115 (0.87%)",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure",
            "Total: 31/116 (26.72%) Neutropenia 1/116 (0.86%) Thrombocytopenia 1/116 (0.86%) Acute myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%)",
            "Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115 (0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54",
            "Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115",
            "Gingival bleeding 1/116 (0.86%) Intestinal haemorrhage 1/116 (0.86%) Nausea 2/116 (1.72%) Adverse Events 2: Total: 24/115 (20.87%) Neutropenia 1/115",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Abdominal pain 0/115 (0.00%)Ascites 0/115 (0.00%) Diarrhoea 4/115 (3.48%) Gingival bleeding 0/115 (0.00%) Intestinal haemorrhage 0/115",
            "myocardial infarction 1/116 (0.86%) Myocardial infarction 0/116 (0.00%) Pericardial effusion 0/116 (0.00%) Abdominal pain 3/116 (2.59%) Ascites 1/116 (0.86%) Diarrhoea 3/116",
            "Total: 24/115 (20.87%) Neutropenia 1/115 (0.87%) Thrombocytopenia 0/115 (0.00%) Acute myocardial infarction 0/115 (0.00%) Myocardial infarction 1/115 (0.87%) Pericardial effusion 1/115",
            "(0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(0.00%) Nausea 3/115 (2.61%) Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54",
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54"
        ]
    },
    {
        "id": "e3be834c-c311-4132-8529-d354b9e620b9",
        "primaryId": "NCT01033032",
        "statement_text": "The only adverse event recorded in the primary trial was one single case of pleural effusion ",
        "statement_nums": [
            "event recorded in the primary trial was one single case"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) "
        ],
        "premise_nums": [
            "(33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%)",
            "PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%)",
            "1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%)",
            "(0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%)",
            "1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%)"
        ]
    },
    {
        "id": "8115b5e3-e178-433b-b114-09d97daaa8d7",
        "primaryId": "NCT01326481",
        "statement_text": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial ",
        "statement_nums": [
            "Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Angina  MI  symptomatic congestive heart failure  cerebrovascular accident  transient ischemic attack  arterial embolism  pulmonary embolism  DVT  PTCA or CABG within the past 6 months "
        ],
        "premise_nums": [
            "PTCA or CABG within the past 6 months"
        ]
    },
    {
        "id": "bbcfc019-2d60-413f-88f9-04cacec55e30",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "statement_text": "There are several cardiac adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [
            "events recorded in the primary trial  but not a",
            "single one in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) ",
            "Arteriospasm coronary 1/252 (0.40%)Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) "
        ],
        "premise_nums": [
            "first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40",
            "Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217",
            "Arteriospasm coronary 1/252 (0.40%)Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2:",
            "82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217",
            "(0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first",
            "(2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%)",
            "Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217",
            "106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation",
            "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252",
            "(0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1:",
            "first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%)",
            "coronary 1/252 (0.40%)Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40",
            "Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%)",
            "Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252"
        ]
    },
    {
        "id": "e7899445-9b80-4429-b4c3-d47bd36a2347",
        "primaryId": "NCT00232479",
        "statement_text": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial ",
        "statement_nums": [
            "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: HER-2 overexpressing breast cancer "
        ],
        "premise_nums": [
            "Inclusion Criteria: HER-2 overexpressing breast cancer"
        ]
    },
    {
        "id": "2a50cc2a-281b-4bc6-9f18-6bd9686c682d",
        "primaryId": "NCT00754845",
        "statement_text": "Patients who received over 5 years of anastrozole therapy  completed 2 years prior  are eligible for the primary trial ",
        "statement_nums": [
            "anastrozole therapy  completed 2 years prior  are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.  letrozole  anastrozole  or exemestane)  either as initial therapy or after prior tamoxifen citrate  including treatment received as part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago "
        ],
        "premise_nums": [
            "Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g.",
            "part of clinical trial CAN-NCIC-MA17 Completed aromatase inhibitor therapy 2 years ago"
        ]
    },
    {
        "id": "26419cec-e256-46a7-9026-94dbe026c63d",
        "primaryId": "NCT01151046",
        "statement_text": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort ",
        "statement_nums": [
            "Median PFS than the MM-121 cohort",
            "placebo group in the primary trial had a much lower"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) To determine whether MM-121 + exemestane was more effective than placebo + exemestane in prolonging progression-free survival  PFS was a time to event measure  and progression of disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), \"as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions\"  Progression free survival was defined as the number of months from the date of randomization to the date of death or progression  If neither death nor progression was observed during the study  PFS data was censored at the last non-progressive disease valid tumor assessment unless the patient was discontinued due to symptomatic deterioration  If this occurred  the patient was counted as having progressive disease (PD)  Time frame: Time from first dose to date of progression  the longest time frame of 79.1 weeks Results 1: Arm/Group Title: MM-121 + Exemestane ",
            "Arm/Group Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week  plus exemestane (25 mg) administered orally once per dayOverall Number of Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 15.9 (9.3 to 30.3) Results 2: Arm/Group Title: Placebo + Exemestane Arm/Group Description: Placebo and Exemestane: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week plus exemestane (25 mg) administered orally once per day Overall Number of Participants Analyzed: 59 Median (95% Confidence Interval) Unit of Measure: weeks 10.7 (8.1 to 16.1) "
        ],
        "premise_nums": [
            "Time frame: Time from first dose to date of progression",
            "the longest time frame of 79.1 weeks Results 1: Arm/Group Title: MM-121 + Exemestane",
            "exemestane (25 mg) administered orally once per dayOverall Number",
            "Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 15.9 (9.3 to 30.3) Results 2: Arm/Group Title: Placebo",
            "was censored at the last non-progressive disease valid tumor assessment",
            "Tumors Criteria (RECIST v1.1), \"as a 20% increase in the sum of the",
            "Participants Analyzed: 56 Median (95% Confidence Interval) Unit of Measure: weeks 10.7 (8.1 to 16.1)",
            "Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per"
        ]
    },
    {
        "id": "f5d50d87-b419-4537-87ec-7c9d23b765db",
        "primaryId": "NCT00171340",
        "statement_text": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density  whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive change in Bone Mineral Density (within a certain patient demographic) ",
        "statement_nums": [
            "whereas Zoledronic Acid 4 mg Delayed causes a smaller  but still positive",
            "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA)  Time frame: Baseline  12 months Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed ",
            "Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or total hip  any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit  All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD -3.617 (4.2151) "
        ],
        "premise_nums": [
            "Results 1: Arm/Group Title: Zoledronic Acid 4 mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every",
            "4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1.Overall Number of Participants Analyzed:",
            "Intravenous (IV) 15 minute infusion every 6 months beginning when one of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group",
            "following occurred: BMD T-score smaller than = -2.0 SD at either the lumbar spine or",
            "15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score smaller than = -2.0 SD",
            "of the Lumbar Spine (L2-L4) at 12 Months of Therapy  Bone Mineral Density",
            "mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following",
            "every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on",
            "of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Delayed",
            "mg Upfront Arm/Group Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1.",
            "4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets",
            "tablets 2.5 mg/day for 5 years beginning on Day 1.Overall Number of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group",
            "Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423",
            "All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. Overall Number of Participants Analyzed: 423",
            "Number of Participants Analyzed: 418 Mean (Standard Deviation) Unit of Measure: Percentage change in BMD 2.208 (3.4194) Results 2: Arm/Group"
        ]
    },
    {
        "id": "f52ab54b-7a78-4449-9dfe-5fc67323e5c2",
        "primaryId": "NCT01797120",
        "statement_text": "Cohort 2 of the primary trial is only receiving placebo tablets  and no other medications ",
        "statement_nums": [
            "Cohort 2 of the primary trial is only receiving placebo"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles)  If no evidence of disease progression after 12 cycles  unblind and continue same dose and schedule until progression or unacceptable toxicity  Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles  Placebo manufactured to mimic everolimus tablet  "
        ],
        "premise_nums": [
            "all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles  Fulvestrant: Fulvestrant 500",
            "no evidence of disease progression after 12 cycles  unblind and continue",
            "cycles  Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days"
        ]
    },
    {
        "id": "c0277198-6eef-4cf3-9527-dea5d01a4000",
        "primaryId": "NCT00426556",
        "statement_text": "There were more than 3 cases of Febrile neutropenia  Leukopenia and Neutropenia across all cohorts in the primary trial ",
        "statement_nums": [
            "There were more than 3 cases of Febrile neutropenia  Leukopenia and Neutropenia across all cohorts in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia 0/17 (0.00%) Leukopenia 0/17 (0.00%) Neutropenia 0/17 (0.00%) "
        ],
        "premise_nums": [
            "1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia",
            "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6"
        ]
    },
    {
        "id": "fea87f74-c8ef-4efd-944a-053f5e5a752f",
        "primaryId": "NCT01582971",
        "statement_text": "In order to participate in the primary trial  participants must have 20/20 vision and a hiistologically confirmed  measurable  invasive breast carcinoma ",
        "statement_nums": [
            "to participate in the primary trial  participants must have 20/20 vision and a hiistologically confirmed  measurable"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age 21 Diagnosis of breast cancer  Stage III  IV  or Stage I or II with metastasis or recurrence Able to perform basic ADLs Undergoing chemotherapy and/or hormonal therapy for breast cancer Able to speak and understand English Have access to a telephone Able to hear normal conversation Cognitively oriented to time  place  and person (determined via nurse recruiter) Exclusion Criteria: Diagnosis of major mental illness on the medical record and verified by the recruiter Residing in a nursing home Bedridden Currently receiving regular reflexology Diagnosis of symptoms of deep vein thrombosis or painful foot neuropathy  which will require medical approval "
        ],
        "premise_nums": [
            "Inclusion Criteria: Age 21 Diagnosis of breast cancer  Stage III"
        ]
    },
    {
        "id": "43560d8e-0767-40ce-b2fb-1b8dda231bdf",
        "primaryId": "NCT00394251",
        "statement_text": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.",
        "statement_nums": [
            "than Pericardial effusion recorded in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%) Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 30/98 (30.61%) Coagulopathy 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac",
            "Ileus 1/98 (1.02%) Abdominal pain upper 1/98 (1.02%) Gastrointestinal haemorrhage 0/98 (0.00%)",
            "failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Febrile neutropenia 7/98 (7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure",
            "(7.14%) Pancytopenia 2/98 (2.04%) Cardiac failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98",
            "failure 0/98 (0.00%) Cardiac failure congestive 0/98 (0.00%) Pericardial effusion 0/98 (0.00%) Appendicitis perforated 1/98 (1.02%) Colitis 1/98 (1.02%)"
        ]
    },
    {
        "id": "2417fea2-7c8e-4f03-a918-c3cfcbe97425",
        "primaryId": "NCT01998906",
        "statement_text": "The same number of cases of Neutropenia  Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial ",
        "statement_nums": [
            "are observed in patients from cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia * 7/115 (6.09%) Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia * 7/115 (6.09%) Neutropenia * 1/115 (0.87%) Pancytopenia * 1/115 (0.87%)"
        ]
    },
    {
        "id": "55391bc6-41a8-4686-82d6-6814166d32b8",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial ",
        "statement_nums": [
            "Patients must have LVEF smaller than 50% to be eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation ",
            "History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death"
        ],
        "premise_nums": [
            "intent  ECOG performance status of 0 or 1 For women of childbearing potential",
            "be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled",
            "disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or",
            "have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent",
            "History of other malignancies within 5 years prior to screening  except for",
            "Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical",
            "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed"
        ]
    },
    {
        "id": "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b",
        "primaryId": "NCT00091832",
        "statement_text": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur) ",
        "statement_nums": [
            "cohort 1 of the primary trial had a negative (median)"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14) "
        ],
        "premise_nums": [
            "2: Arm/Group Title: Denosumab 30 mg Q4W Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of",
            "Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)",
            "Baseline value ) x 100. Time frame: Baseline and Week 13 Results 1: Arm/Group Title: Bisphosphonate IV Q4W",
            "from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr)",
            "Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:",
            "Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: Percent change -52.87 (95.14)",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent",
            "From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)",
            "of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title: Bisphosphonate IV Q4W Arm/Group Description: Open label bisphosphonate",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Measure: Percent change -52.87 (95.14)",
            "30 mg by subcutaneous injection every 4 weeks (Q4W) Overall Number of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:",
            "Number of Participants Analyzed: 38 Mean (Standard Deviation) Unit of Measure: Percent change -10.19 (208.84) Results 2: Arm/Group Title:"
        ]
    },
    {
        "id": "15553950-e26b-4fbb-a576-8455e6bb7b23",
        "primaryId": "NCT02122796",
        "secondaryId": "NCT01575522",
        "statement_text": "The intervention section for the primary trial does not detail the type  dosage or duration of the intervention  unlike the secondary trial ",
        "statement_nums": [
            "intervention  unlike the secondary trial",
            "intervention section for the primary trial does not detail the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Patients Undergoing Mastectomy Surgery Number of individuals having mastectomy surgery who were approached for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO "
        ],
        "premise_nums": [
            "PTEN loss  and PI3K mutation analysis by FISH and IHC",
            "collection at baseline and periodically during study for c-Met",
            "receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21"
        ]
    },
    {
        "id": "58838d25-bf87-44e7-a604-23468d67a1e3",
        "primaryId": "NCT02606708",
        "secondaryId": "NCT02504424",
        "statement_text": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy  patients in the secondary trial receive no radiotherapy whatsoever ",
        "statement_nums": [
            "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy",
            "patients in the secondary trial receive no radiotherapy whatsoever"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Accelerated Intensity Modulated Radiation Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields  A concurrent boost to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity modulated radiation therapy (AIMRT) INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  "
        ],
        "premise_nums": [
            "to the original tumor bed of 0.50 Gy will be delivered  Accelerated intensity",
            "Gy to the entire breast in 2.7 Gy/fraction x 15 fractions  Monday to Friday for 3 weeks delivered prone in uniform",
            "Therapy (AIMRT) All patients shall receive a total of 40.5 Gy to the entire breast in 2.7"
        ]
    },
    {
        "id": "02426c34-ebf9-4bd4-9d55-86fad89baf20",
        "primaryId": "NCT01959490",
        "statement_text": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response ",
        "statement_nums": [
            "In total only 20% of participants in the primary trial did not achieve Pathological"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants ",
            "Unit of Measure: Participants 4 80.0%Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0%",
            "90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in",
            "8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression",
            "chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression",
            "or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of",
            "or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of Participants Analyzed: 5 Measure Type: Count of Participants",
            "840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is",
            "run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in"
        ]
    },
    {
        "id": "9e28c807-8d88-4eea-87ee-48a42bd002ab",
        "primaryId": "NCT00618826",
        "secondaryId": "NCT02040857",
        "statement_text": "the primary trial and the secondary trial only record 4 of the same adverse events ",
        "statement_nums": [
            "the primary trial and the secondary trial only record 4 of the same adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia  lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Lymphocyte count decreased 2/162 (1.23%) Diarrhea 1/162 (0.62%) Fatigue 6/162 (3.70%) Hypertension 1/162 (0.62%)",
            "lethargy  malaise) 2/14 (14.29%) Hypertension 2/14 (14.29%) Adverse Events 1: Lymphopenia 1/14 (7.14%) Diarrhea 1/14 (7.14%) Fatigue (asthenia"
        ]
    },
    {
        "id": "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c",
        "primaryId": "NCT02953860",
        "statement_text": "Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis ",
        "statement_nums": [
            "Patients in the primary trial receive less mg of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily  Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end treatment  "
        ],
        "premise_nums": [
            "at the start of treatment and 4 weeks after the start of treatment",
            "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4",
            "start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end",
            "of care (SOC) and 160mg of Enzalutamide will be given IM on days 1, 15, 28, then every 4"
        ]
    },
    {
        "id": "9bcd40cf-8221-4383-8891-76a4bcc5c766",
        "primaryId": "NCT00756717",
        "statement_text": "Patients with cytologically confirmed  non metastatic  early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial ",
        "statement_nums": [
            "Patients with cytologically confirmed  non metastatic",
            "cancer with an Allred score of 1 are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory  and is not metastatic  - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy  "
        ],
        "premise_nums": [
            "Criteria: Patients must have histologically or cytologically confirmed early stage  ER-positive (Allred score 3), invasive breast cancer that"
        ]
    },
    {
        "id": "341156fc-9cbd-492f-8e9e-8fbf98191625",
        "primaryId": "NCT00291577",
        "statement_text": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours ",
        "statement_nums": [
            "to Reach Maximum Plasma Concentration of 6, 24 or 12 hours",
            "a participant of the primary trial to have a Time"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation  Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose "
        ],
        "premise_nums": [
            "2, 4, 6, 8, 12, 24 hours postdose",
            "plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3."
        ]
    },
    {
        "id": "44ae021e-241b-4dbf-b88f-0b9d41eab555",
        "primaryId": "NCT00201851",
        "statement_text": "There were no cases of Oesophageal spasming observed in the primary trial ",
        "statement_nums": [
            "spasming observed in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Endocervical cancer *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer",
            "Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%)"
        ]
    },
    {
        "id": "523a44a3-6b90-4be7-ab46-6b6addd7b5b9",
        "primaryId": "NCT00080301",
        "statement_text": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial  than in cohort 1.",
        "statement_nums": [
            "more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial  than in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: THROMBOCYTOPENIA 2/368 (0.54%) Adverse Events 2: THROMBOCYTOPENIA 7/369 (1.90%) "
        ],
        "premise_nums": [
            "Adverse Events 1: THROMBOCYTOPENIA 2/368 (0.54%) Adverse Events 2: THROMBOCYTOPENIA 7/369 (1.90%)"
        ]
    },
    {
        "id": "258a51ca-e1f0-4d9a-88a6-8749f4822034",
        "primaryId": "NCT03475992",
        "secondaryId": "NCT03106077",
        "statement_text": "Participants in the primary trial receive different interventions depending on their cancer hormone status  so Triple-Negative patients are seperated from HER2+ patients for example  whereas all patients in the secondary trial took the same intervention ",
        "statement_nums": [
            "patients are seperated from HER2+ patients for example  whereas all patients in the secondary trial",
            "Participants in the primary trial receive different interventions depending"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Pre-diagnosed Breast Cancer - Biopsy Confirmed Low-power microwave breast imaging system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave breast imaging system  No prior biopsy Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W "
        ],
        "premise_nums": [
            "characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave",
            "characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W",
            "system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power"
        ]
    },
    {
        "id": "83bacd68-871a-4777-ba23-1f9a3df9227d",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "statement_text": "Recurrence-free Survival  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [
            "outcome measurement in the secondary trial and Clinical Benefit Rate",
            "used in the primary trial are not synonymous"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate Clinical benefit = complete response (CR)  partial response (PR)  or stable disease (SD) lasting for at least 6 months  assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions  PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions  with non-progressive disease in non-target lesions  SD= sum of the longest diameters of target lesions decrease smaller than 30% or increase smaller than 20%, with non-progressive disease in non-target lesions  141 eligible  treated patients were included  Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2 years  every 6 months between 2-3 years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years "
        ],
        "premise_nums": [
            "years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years  every 6 months between 2-3 years,no specific requirements after",
            "2 years for the primary analysis + 3 additional years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years",
            "Time frame: assessed every 3 cycles while on treatment  assessed every 6 months between 2-3 years,no specific requirements after 3 years",
            "PR= disappearance of or at least 30% decrease in the sum of the",
            "or stable disease (SD) lasting for at least 6 months  assessed per Response",
            "came first  assessed up to 5 years) Time frame: 5 years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years",
            "included  Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2",
            "2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization",
            "in non-target lesions  141 eligible  treated patients were included  Time frame: assessed every 3 cycles while on treatment",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  in contrast thirty patients in the secondary trial had partial tumor response ",
        "statement_nums": [
            "One patient in the primary trial had a Confirmed tumor"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Proportion of Patients With Confirmed Tumor Response Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants Confirmed tumor partial response: 1 No Confirmed reponse: 20 Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 "
        ],
        "premise_nums": [
            "or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants",
            "from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr)",
            "on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group",
            "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression",
            "1 No Confirmed reponse: 20 Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent",
            "in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to",
            "Baseline value ) x 100. Time frame: Baseline and Week 13"
        ]
    },
    {
        "id": "1a451f2e-0818-4a86-8808-0e4cce700aef",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial  and only one case of anemia ",
        "statement_nums": [
            "In total there were 32 cases of Febrile neutropenia in the primary trial  and only one"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Anaemia * 1/206 (0.49%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) Anaemia * 1/215 (0.47%) "
        ],
        "premise_nums": [
            "14/206 (6.80%) Anaemia * 1/206 (0.49%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) Anaemia * 1/215 (0.47%)",
            "1: Febrile neutropenia * 14/206 (6.80%) Anaemia * 1/206 (0.49%) Adverse Events 1: Febrile neutropenia * 14/206 (6.80%)"
        ]
    },
    {
        "id": "52333afb-0e7a-4823-ae9b-746e0ce57c8c",
        "primaryId": "NCT01325207",
        "secondaryId": "NCT02429427",
        "statement_text": "Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems ",
        "statement_nums": [
            "Patients participating in the primary trial and the secondary trial experienced a variety of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Pericardial effusion [1]0/3 (0.00%) Acute cardiac event * 1/1755 (0.06%) Aortic valve incompetence * 1/1755 (0.06%) Arrhythmia * 1/1755 (0.06%) Atrial fibrillation * 1/1755 (0.06%) Cardiac failure * 0/1755 (0.00%) Cardiac tamponade * 0/1755 (0.00%) "
        ],
        "premise_nums": [
            "Pericardial effusion [1]0/3 (0.00%) Acute cardiac event * 1/1755 (0.06%) Aortic valve incompetence * 1/1755",
            "(0.06%) Cardiac failure * 0/1755 (0.00%) Cardiac tamponade * 0/1755 (0.00%)"
        ]
    },
    {
        "id": "4216b27f-4d3e-4029-9637-2e6dade15b73",
        "primaryId": "NCT00005908",
        "statement_text": "There was only one patient cohort in the primary trial ",
        "statement_nums": [
            "patient cohort in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2: "
        ],
        "premise_nums": [
            "neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%)",
            "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%)",
            "5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2:"
        ]
    },
    {
        "id": "14a32a42-424b-4b97-bae9-05f4bb2b415b",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "statement_text": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%)"
        ]
    },
    {
        "id": "4d83c630-d767-40cf-9aec-c871c6fc7f38",
        "primaryId": "NCT00030823",
        "statement_text": "Patients with stage I  II  III or IV breast cancer may be eliglbe for the primary trial ",
        "statement_nums": [
            "be eliglbe for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Stage I  II  or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Stage IV that is free of all known disease after eradication by surgery  radiotherapy  or chemotherapy Stage IV that is stable on hormonal therapy "
        ],
        "premise_nums": [
            "disease  but have rising CA 15-3 or CEA levels Stage IV that is",
            "with adjuvant chemotherapy and clinically free of identifiable disease  but have rising CA 15-3 or CEA levels Stage"
        ]
    },
    {
        "id": "4fd230f2-caf1-44d6-81f2-4f51dda6da3a",
        "primaryId": "NCT03371732",
        "statement_text": "Any patients with Karnofsky Index smaller than 80 are eligible for the primary trial ",
        "statement_nums": [
            "patients with Karnofsky Index smaller than 80 are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  An AUDIT-C score greater than 1 or more than one cigarette smoked per day  Individuals able to consent to benefit of intervention focused on substance use  (Karnofsky Index greater than 70). "
        ],
        "premise_nums": [
            "use  (Karnofsky Index greater than 70).",
            "Inclusion Criteria : women with primary breast cancer  without ongoing",
            "An AUDIT-C score greater than 1 or more than one cigarette smoked per"
        ]
    },
    {
        "id": "7a3d1ca7-8776-4ace-bbc0-107635b93583",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months ",
        "statement_nums": [
            "Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM  Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activity Overall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) ",
            "4-Month endoxifen concentration: 4 participants15.35 (5.48) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59)",
            "has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM",
            "4-Month endoxifen concentration: 4 participants15.35 (5.48)",
            "PM  Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers Arm/Group",
            "were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity"
        ]
    },
    {
        "id": "1196db61-0846-4185-afc9-dc4b2fccd059",
        "primaryId": "NCT01966471",
        "secondaryId": "NCT00981812",
        "statement_text": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial ",
        "statement_nums": [
            "excluded from both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Known hormone receptor status of the primary tumor Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy Exclusion Criteria: subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months "
        ],
        "premise_nums": [
            "receptor status of the primary tumor Adequately excised: participants must",
            "has had chemotherapy within the past 12 months"
        ]
    },
    {
        "id": "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time ",
        "statement_nums": [
            "All Participants in the primary trial and the secondary trial are receiving the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm A: Triptorelin + Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  "
        ],
        "premise_nums": [
            "every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin:",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront Participants in",
            "Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin",
            "study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800",
            "Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months",
            "Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole",
            "daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day",
            "mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants",
            "every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants"
        ]
    },
    {
        "id": "7e629f62-2981-4462-a4c1-f0cc9c24777a",
        "primaryId": "NCT00490646",
        "statement_text": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ",
            "ATRIAL FIBRILLATION 0/24 (0.00%)APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) "
        ],
        "premise_nums": [
            "NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%)",
            "PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2:",
            "2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%)",
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "Adverse Events 2: Total: 6/24 (25.00%) FEBRILE NEUTROPENIA 0/24 (0.00%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "(0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%)"
        ]
    },
    {
        "id": "c660faec-58d8-4ba9-8e18-1775b1135819",
        "primaryId": "NCT00600340",
        "statement_text": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.",
        "statement_nums": [
            "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks "
        ],
        "premise_nums": [
            "3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks",
            "8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every",
            "4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15",
            "mg/m² twice-daily  days 1-14, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every",
            "intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every"
        ]
    },
    {
        "id": "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2",
        "primaryId": "NCT03078751",
        "statement_text": "Cohort 2 of the primary trial reported one case of AML ",
        "statement_nums": [
            "Cohort 2 of the primary trial reported one case of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Total: 2/24 (8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%) "
        ],
        "premise_nums": [
            "failure congestive 0/24 (0.00%) Breast cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%)",
            "(8.33%) Disseminated intravascular coagulation 0/24 (0.00%) Cardiac failure congestive 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)",
            "cellulitis 0/24 (0.00%) Cellulitis 1/24 (4.17%) Acute myeloid leukaemia 0/24 (0.00%) Seizure 1/24 (4.17%) Pulmonary embolism 0/24 (0.00%)"
        ]
    },
    {
        "id": "3ee5742b-6bc3-400f-92eb-641384a75201",
        "primaryId": "NCT01830933",
        "secondaryId": "NCT01224678",
        "statement_text": "Patients in the primary trial do not receive any extra medication for the study  whereas in the secondary trial they are given an oral medication ",
        "statement_nums": [
            "whereas in the secondary trial they are given an"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Usual Care Usual Care is the comparison Clinic Patients  where there is no change in their standard or usual care  INTERVENTION 2: BreastCARE Intervention Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk  Intervention Patient Report  Once the patient completes the BreastCare Computer survey  the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk  This report will be printed and given to the patients before she meets with her doctor  BreastCARE : The physician will receive a physician report that contains information similar to the patient report  Patients receive oral vitamin D (2000 IU) once daily for 12 months  "
        ],
        "premise_nums": [
            "receive oral vitamin D (2000 IU) once daily for 12 months"
        ]
    },
    {
        "id": "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3",
        "primaryId": "NCT00118157",
        "secondaryId": "NCT01401959",
        "statement_text": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial ",
        "statement_nums": [
            "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in",
            "either cohort of the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally Overall Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) Outcome Measurement: Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy The percentage of patients that are without evidence of disease recurrence at the 2 year timepoint  as measured from date of first protocol treatment date to first documented disease progression date or date of death from any cause  whichever comes first  Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Time frame: Up to 2 years Results 1: Arm/Group Title: Cohort A: Triple-negative Breast Cancer Patients ",
            "Arm/Group Description: Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route Overall Number of Participants Analyzed: 53 Measure Type: Number Unit of Measure: percentage of patients 56 (42 to 69) "
        ],
        "premise_nums": [
            "and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous",
            "therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via",
            "Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) Outcome Measurement: Percentage of Patients With",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the",
            "lesions  Time frame: Up to 2 years Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib",
            "evidence of disease recurrence at the 2 year timepoint  as measured from date of first protocol treatment date to first",
            "lesions  Time frame: Up to 2 years Results 1: Arm/Group Title: Cohort A: Triple-negative",
            "oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally",
            "1 and 8 every 21 days for 6 cycles via the intravenous (IV) route Overall Number of Participants Analyzed: 53"
        ]
    },
    {
        "id": "e0b7a120-8735-413d-9a47-8508b2feffb3",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 20 the primary trial participants achieved partial response (PR) ",
        "statement_nums": [
            "Less than 20 the primary trial participants achieved partial response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2",
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants With Overall Response Rate (ORR) Overall Response",
            "for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of",
            "each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until",
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole",
            "partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT:",
            "the date of the first documented disease progression or date",
            "(PR)  greater than or equal 30% decrease in the sum of the"
        ]
    },
    {
        "id": "1393c5d9-d2be-433b-9abf-9449b46588c4",
        "primaryId": "NCT00981812",
        "statement_text": "Women who have undergone a breast enlargement procedure  and have since had the implants removed  are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: female subject is 25-100 years of age subjects has at least one breast imaging finding on mammography and/or ultrasound which is assessed as highly suggestive of malignancy and recommended to biopsy subject is able to provide informed consent Exclusion Criteria: subject is pregnant subject is actively lactating or discontinued breastfeeding less than 2 months ago subject has breast implants subject is scheduled for sentinel node procedure using radioactive Tc-99m within 24 hours of the PEM study subject has contraindications for core biopsy and other invasive procedures subject has Type I diabetes mellitus or poorly controlled Type II diabetes mellitus subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months subject has not fasted for 4-6 hours prior to the procedure and/or have a fasting blood glucose level greater than 140 mg/dl on day of PEM imaging "
        ],
        "premise_nums": [
            "Inclusion Criteria: female subject is 25-100 years of age subjects has at least one breast imaging finding on",
            "has had chemotherapy within the past 12 months subject has not fasted for 4-6 hours prior to the procedure and/or have",
            "fasting blood glucose level greater than 140 mg/dl on day of PEM imaging",
            "node procedure using radioactive Tc-99m within 24 hours of the PEM study subject has"
        ]
    },
    {
        "id": "abfa5699-2863-4319-9386-4b359f2062f2",
        "primaryId": "NCT00195013",
        "secondaryId": "NCT00620373",
        "statement_text": "Cohort 2 of the primary trial is a placebo group  the secondary trial does not have a placebo group ",
        "statement_nums": [
            "Cohort 2 of the primary trial is a placebo group  the secondary trial does not have a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Glutamine 10 grams three times a day (orally) for four days and then stop glutamine: 10 grams three times a day (orally) for four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and then stop Placebo: 10 grams three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 2: Gamma Imaging For this reporting arm  the interpretation and analysis was done with gamma imaging only  "
        ],
        "premise_nums": [
            "four days and then stop INTERVENTION 2: Placebo 10 grams three times a day (orally) for four days and",
            "three times a day (orally) for four days and then stop INTERVENTION 1: Mammography Only For this reporting"
        ]
    },
    {
        "id": "68e6a088-ab80-4a89-90d4-39308bccb1c2",
        "primaryId": "NCT00956813",
        "statement_text": "All the primary trial subjects are required to take the intervention PO daily ",
        "statement_nums": [
            "All the primary trial subjects are required to"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Flaxseed Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed  410 mg lignans,once daily"
        ]
    },
    {
        "id": "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions  however they both have placebo groups ",
        "statement_nums": [
            "the primary trial and the secondary trial have no overlap in"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Stratum 1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel  doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum 2: TCH + Bevacizumab HER2 positive participants were administered chemotherapy with docetaxel  carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  "
        ],
        "premise_nums": [
            "treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin",
            "treated with triptorelin plus exemestane for 5 years",
            "and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy",
            "+ bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of",
            "1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel",
            "therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum"
        ]
    },
    {
        "id": "08917306-11b0-44ad-8f45-9a67d7f6073e",
        "primaryId": "NCT00971737",
        "secondaryId": "NCT00392392",
        "statement_text": "Patients with a positive FISH result are eligible for the secondary trial  but not for the primary trial ",
        "statement_nums": [
            "are eligible for the secondary trial  but not for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer "
        ],
        "premise_nums": [
            "breast Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC Stage IV",
            "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the",
            "disease Inclusion Criteria: FISH+ HER2 gene amplified breast cancer"
        ]
    },
    {
        "id": "9702cb6a-bdb1-415f-bb99-3b740728a4ea",
        "primaryId": "NCT00073073",
        "secondaryId": "NCT00054028",
        "statement_text": "There are no placebo or control groups in the primary trial or the secondary trial ",
        "statement_nums": [
            "control groups in the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects  Exemestane: exemestane 25 mg by mouth (PO) every day for two years Calcium carbonate: calcium carbonate 1200 mg PO every day x 2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  "
        ],
        "premise_nums": [
            "2 years Vitamin D: Vitamin D 400 international units PO every day and vitamin D 400 IU PO every day Initially",
            "PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after",
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day for",
            "INTERVENTION 1: Exemestane exemestane 25 mg by mouth (PO) every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will",
            "2 years Vitamin D: Vitamin D 400 international units PO every day x 2 years INTERVENTION 1: Suramin and Paclitaxel Suramin will",
            "completion of the suramin infusion the 1 hour infusion of paclitaxel will begin"
        ]
    },
    {
        "id": "7afa2d1f-7922-4b09-b52a-43bd9a4788a9",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "statement_text": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial ",
        "statement_nums": [
            "than those in the secondary trial",
            "both cohorts of the primary trial had a drastically lower CNS Objective Response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Response Rate Overall Response Rate (ORR)  subjects with CR or PR by independent review in subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR)  disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions  and no new lesions  Time frame: From first dose date to progression or last tumor assessment  up to four years and six months  Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  Time frame: Baseline  24 months "
        ],
        "premise_nums": [
            "was the lumbar spine (L2 to L4) and the secondary scanning site was the total",
            "Outcome Measurement: Overall Response Rate Overall Response Rate",
            "after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until",
            "randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The",
            "date to progression or last tumor assessment  up to",
            "review in subjects with ErbB-2-positive breast cancer treated at the MTD",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray"
        ]
    },
    {
        "id": "dfd5acc2-6824-4b63-93ad-34e6a0a4c621",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has had an alcohol addiction for 15 years  resulting in Cirrhosis therefore he is likely to be excluded from the primary trial ",
        "statement_nums": [
            "be excluded from the primary trial",
            "has had an alcohol addiction for 15 years  resulting in Cirrhosis"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitors Conditions predisposing to renal failure secondary to rhabdomyolysis Recent history of heavy alcohol use as judged by the treating physician Known to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ",
            "Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements"
        ],
        "premise_nums": [
            "or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese",
            "receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1",
            "predisposing to renal failure secondary to rhabdomyolysis Recent history of"
        ]
    },
    {
        "id": "97e9967e-6525-4082-bd11-8c30e14d23fd",
        "primaryId": "NCT03273426",
        "secondaryId": "NCT01091168",
        "statement_text": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial  but are always excluded from the secondary trial ",
        "statement_nums": [
            "be eligible for the primary trial  but are always excluded from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC) who received NAC with detectable lesion / clip marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete response on MRI with informed consent Exclusion Criteria: Multifocal cancer Residual microcalcification Contralateral breast cancer Concurrent serious uncontrolled medical disorder  "
        ],
        "premise_nums": [
            "Criteria: Patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy",
            "marker on ultrasound with cT1-T3 tumors clinical and imaging complete or near-complete"
        ]
    },
    {
        "id": "d11dd4ae-28be-4ad2-a452-4374c48f08d1",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may increase OS  compared to Capecitabine alone ",
        "statement_nums": [
            "trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  may"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
            "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2:",
            "date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14",
            "Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine",
            "days  followed by 1 week of rest  Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of",
            "a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall Number of",
            "Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine",
            "twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number",
            "cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed",
            "Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02)",
            "be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product",
            "a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants",
            "Outcome Measurement: Overall Survival (OS) Overall survival was censored at the last date the patient was known",
            "Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02)",
            "of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14",
            "Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall",
            "3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID)",
            "capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral"
        ]
    },
    {
        "id": "3b6229a9-00a1-4d26-9285-6d9f6a25fd77",
        "primaryId": "NCT02273973",
        "statement_text": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea ",
        "statement_nums": [
            "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Diarrhoea 5/167 (2.99%) Erysipelas 2/167 (1.20%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Diarrhoea 5/167 (2.99%) Erysipelas 2/167 (1.20%)"
        ]
    },
    {
        "id": "9eab20ad-ffc6-473f-8087-c6c3f06f356f",
        "primaryId": "NCT00322348",
        "secondaryId": "NCT00429572",
        "statement_text": "the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status ",
        "statement_nums": [
            "the primary trial and the secondary trial use different metrics to"
        ],
        "label": "Entailment",
        "premise_text": [
            "World Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2 "
        ],
        "premise_nums": [
            "Health Organization (WHO) performance status of 0, 1, or 2 Zubrod performance status less than 2"
        ]
    },
    {
        "id": "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde",
        "primaryId": "NCT00368875",
        "statement_text": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat  as Assessed by NCI Common Terminology Criteria for Adverse Events  is 300 mg ",
        "statement_nums": [
            "the primary trial results indicate that the",
            "Adverse Events  is 300 mg"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity attributed to therapy (nausea  vomiting and diarrhea would be considered dose limiting only if not adequately controlled with therapy)  Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration  Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle  ",
            "All patients also received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg 300 "
        ],
        "premise_nums": [
            "or failure to complete all protocol specificed doses in the standard 3 + 3 phase I trial design based upon toxicity",
            "days 2, 9, and 16 of every 28-day cycle  Bevacizumab was carried out in the standard 3 + 3 phase I trial",
            "Any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat",
            "Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: mg/m2 as 1-hour infusion on days 2, 9, and 16 of every",
            "were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtologicalso received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2,",
            "days 2, 9, and 16 of every 28-day cycle  Bevacizumab was administered on day 2 and day 16 of the 28 day",
            "a DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group",
            "DLT Time frame: 28 days Results 1: Arm/Group Title: Phase I Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at",
            "of the 28 day cycle at 10 mg/kg dose  Vorinostat dose (200 or 300 mg BID) was assigned at the",
            "toxcities (DLT) were defined as grade 3-4 febrile neutropenia  thrombocytopenia and non-hemtological toxicity",
            "administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle",
            "was administered on day 2 and day 16 of the 28 day cycle at 10 mg/kg dose  Vorinostat dose escalation was",
            "Arm/Group Description: Vorinostat dose (200 or 300 mg BID) was assigned at the",
            "at 90 mg/m2 as 1-hour infusion on days 2, 9, and 15-17 of each 28-day cycle",
            "was carried out in the standard 3 + 3 phase I trialso received paclitaxel at 90 mg/m2 as 1-hour infusion on days 2,",
            "Bevacizumab was administered on day 2 and day 16 of the standard 3 + 3 phase I trial design based upon toxicity"
        ]
    },
    {
        "id": "553d7721-289e-4ab1-a9b9-7b2c939f47c1",
        "primaryId": "NCT01997333",
        "statement_text": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year ",
        "statement_nums": [
            "Free Survival for patients in cohort 1 the primary trial was 1 year"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study  Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) "
        ],
        "premise_nums": [
            "Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the",
            "and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment",
            "new lesions  The primary analysis of PFS was based",
            "Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2)",
            "9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21"
        ]
    },
    {
        "id": "01c6f82e-710d-4fa4-aa62-2d26e72f4533",
        "primaryId": "NCT00894504",
        "statement_text": "There were no adverse event in the primary trial which occurred more than 71 times ",
        "statement_nums": [
            "adverse event in the primary trial which occurred more than 71 times"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%) NAUSEA 1/71 (1.41%) VOMITING 1/71 (1.41%) CHEST PAIN 1/71 (1.41%) PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%) "
        ],
        "premise_nums": [
            "10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%) DIARRHOEA 1/71 (1.41%)",
            "Adverse Events 1: Total: 10/71 (14.08%) ATRIAL FIBRILLATION 1/71 (1.41%) CARDIAC TAMPONADE 1/71 (1.41%) PERICARDIAL EFFUSION 1/71 (1.41%) SUPRAVENTRICULAR TACHYCARDIA 1/71",
            "PNEUMONIA 1/71 (1.41%) MALIGNANT PLEURAL EFFUSION 1/71 (1.41%) HEPATIC ENCEPHALOPATHY 1/71 (1.41%)"
        ]
    },
    {
        "id": "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc",
        "primaryId": "NCT02018458",
        "secondaryId": "NCT00895414",
        "statement_text": "Patients with unexplained fever exceeding 39¬¨‚àûC are excluded from the primary trial but may be included in the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial but may be included in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Active infection or unexplained fever greater than 38.5°C during screening  Inclusion Criteria: Tissue diagnosis of a breast carcinoma The oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen Have acceptable organ function within 14 days of enrollment defined as: liver function: total bilirubin  AST and ALT within normal institutional limits kidney function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) - formula: (140 - age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written informed consent indicating an understanding of the investigational nature of the study Agrees not to consume grapefruit juice while on the study Exclusion Criteria: Known allergy to enalapril Taking any known P450 cytochrome inducers or inhibitors Taking any herbal supplements while on the study or the week prior to receiving doxorubicin Taking an ace-inhibitor or angiotensin receptor blocker Pregnant or lactating  Enalapril is Pregnancy Categories C (first trimester) and D (second and third trimesters) "
        ],
        "premise_nums": [
            "acceptable organ function within 14 days of enrollment defined as: liver function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for",
            "function: estimated Creatinine Clearance greater than 60 ml/min calculated creatinine clearance (for females) -",
            "infection or unexplained fever greater than 38.5°C during screening  Inclusion",
            "age) x weight x .85 divided by (sCr x 72) At leastudy Exclusion Criteria: Known allergy to enalapril Taking any",
            "regimen Have acceptable organ function within 14 days of enrollment defined as: liver function:",
            "study Exclusion Criteria: Known allergy to enalapril Taking any known P450 cytochrome inducers or inhibitors Taking any herbal",
            "age) x weight x .85 divided by (sCr x 72) At least 18 years old Patient must have given written",
            "is Pregnancy Categories C (first trimester) and D (second and third trimesters)"
        ]
    },
    {
        "id": "862c0bfe-10a6-453c-9ada-929dd00141a0",
        "primaryId": "NCT00295620",
        "secondaryId": "NCT03366428",
        "statement_text": "the secondary trial and the primary trial employ non comparable outcome measures ",
        "statement_nums": [
            "the secondary trial and the primary trial employ non comparable outcome"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Disease-free Survival After Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival  Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer "
        ],
        "premise_nums": [
            "Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after",
            "QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer"
        ]
    },
    {
        "id": "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f",
        "primaryId": "NCT01094184",
        "statement_text": "A patient who had an oophorectomy in the last month would not be eligible for the primary trial ",
        "statement_nums": [
            "an oophorectomy in the last month would not be eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment "
        ],
        "premise_nums": [
            "surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of"
        ]
    },
    {
        "id": "5501dae3-0d3c-4812-96c2-35ca863e24a5",
        "primaryId": "NCT00343863",
        "statement_text": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "dexamethasone IV or orally and ondansetron IV",
            "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  "
        ],
        "premise_nums": [
            "receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally"
        ]
    },
    {
        "id": "ece8e7df-790d-4e26-9c34-40cf66d2abf5",
        "primaryId": "NCT02005887",
        "secondaryId": "NCT00050011",
        "statement_text": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle  for the same duration of time ",
        "statement_nums": [
            "All Participants in the primary trial and the secondary trial are receiving the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm A: Triptorelin + Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront Participants in the upfront arm received Zoledronic Acid 4 mg i.v  on Day 1 and every 6 months until disease progression (recurrence)or the end of study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months  "
        ],
        "premise_nums": [
            "every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin:",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 1: Zoledronic Acid Upfront Participants in",
            "Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin",
            "study  Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800",
            "Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months",
            "Letrozol Arm A: Triptorelin 3.75 mg i.m  on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole",
            "daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants received Zoledronic Acid 4",
            "cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day",
            "mg) and vitamin D (400-800 IU) daily  Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants",
            "every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole : Participants received 2.5 mg daily  Zoledronic Acid : Participants"
        ]
    },
    {
        "id": "550a36e2-43bb-40af-b0c8-49498fbe2c8c",
        "primaryId": "NCT00077376",
        "secondaryId": "NCT01256008",
        "statement_text": "the primary trial investigates a novel radiotherapy treatment  whereas the secondary trial is testing a type of psychological therapy ",
        "statement_nums": [
            "treatment  whereas the secondary trial is testing a type",
            "the primary trial investigates a novel radiotherapy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone  After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity  INTERVENTION 1: Stage 1 Clinical Management ",
            "The group will receive clinical management treatment only each session Clinical Management: Clinical management is a clear contrast method of psychological therapy  which is a half-structured interview and lasting for 20-25 minutes each session  Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention  Following are major elements: Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction  Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible  "
        ],
        "premise_nums": [
            "IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered",
            "a half-structured interview and lasting for 20-25 minutes each session  Clinical management will",
            "then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker)  and at least a 5-HT3 antagonist and dexamethasone",
            "and dexamethasone  After completion of 24 weekly trastuzumab doses (induction therapy) beginning one week after the 24th weekly dose  Trastuzumab",
            "INTERVENTION 1: Stage 1 Clinical Management",
            "(PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)",
            "treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a",
            "28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day",
            "were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after",
            "were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV)",
            "controlled group in the first stage of intervention  Following",
            "by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6",
            "then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent"
        ]
    },
    {
        "id": "95869347-6c3d-4de8-a325-a9a652f11edf",
        "primaryId": "NCT02102490",
        "secondaryId": "NCT00768222",
        "statement_text": "In contrast to the secondary trial  the primary trial did not record any cases of Sinus bradycardia  Bone marrow suppression or Constipation  ",
        "statement_nums": [
            "In contrast to the secondary trial  the primary trial did not record any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Large intestinal obstruction 1/132 (0.76%) Nausea 3/132 (2.27%) Adverse Events 1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone marrow suppression 1/51 (1.96%) ",
            "Allergic shock 0/51 (0.00%)Deep incisional SSI 0/51 (0.00%) "
        ],
        "premise_nums": [
            "(0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Neutropenia 1/132 (0.76%) Sinus bradycardia 1/132 (0.76%) Tachycardia 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper",
            "shock 1/50 (2.00%) Deep incisional SSI 1/50 (2.00%) Adverse Events 2: Total: 1/51 (1.96%) Skin lymphangitis 0/51 (0.00%) Bone",
            "(0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%)",
            "1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Tachycardia 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper",
            "Adverse Events 1: Total: 33/132 (25.00%) Febrile neutropenia 1/132 (0.76%) Haematotoxicity 1/132 (0.76%) Neutropenia 1/132",
            "Allergic shock 0/51 (0.00%)Deep incisional SSI 0/51 (0.00%)",
            "pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%) Constipation 1/132 (0.76%) Abdominal pain 2/132 (1.52%) Abdominal pain upper 1/132 (0.76%)",
            "Adverse Events 1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep",
            "1: Total: 3/50 (6.00%) Skin lymphangitis 1/50 (2.00%) Bone marrow suppression 0/50 (0.00%) Allergic shock 1/50 (2.00%) Deep incisional SSI"
        ]
    },
    {
        "id": "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef",
        "primaryId": "NCT00509769",
        "statement_text": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus",
        "statement_nums": [
            "3/112 patients (2.68%) in the primary trial had Diabetes"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%) "
        ],
        "premise_nums": [
            "(0.89%) Asthenia 1/112 (0.89%) Disease progression 1/112 (0.89%) Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112",
            "Hepatotoxicity 1/112 (0.89%) Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%)",
            "Adverse Events 1: Total: 30/112 (26.79%) Thrombocytopenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112",
            "stenosis 1/112 (0.89%) Upper gastrointestinal haemorrhage 1/112 (0.89%) Asthenia 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112",
            "Cellulitis 3/112 (2.68%) Pneumonia 2/112 (1.79%) Osteomyelitis 1/112 (0.89%) Dysphagia 1/112 (0.89%) Haemorrhoidal haemorrhage 1/112 (0.89%) Oesophageal stenosis 1/112"
        ]
    },
    {
        "id": "1d4a385f-1c72-4c61-8d49-9ada0e3b716a",
        "primaryId": "NCT02556632",
        "statement_text": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study ",
        "statement_nums": [
            "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Curcumin-based Gel) Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Curcumin-based Gel: Applied topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy  Dermatologic Complications Management: Apply HPR Plus topically Laboratory Biomarker Analysis: Correlative studies Questionnaire Administration: Ancillary studies "
        ],
        "premise_nums": [
            "therapy and continuing until 1 week after completion of radiation therapy and continuing until 1 week after completion of radiation",
            "curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and",
            "studies Questionnaire Administration: Ancillary studies INTERVENTION 2: Arm II (HPR Plus) Patients apply curcumin-based gel topically TID approximately every 4-6"
        ]
    },
    {
        "id": "b15aa13a-fbd9-4b2e-9dd2-b16628084d07",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by results from cohort 2 of the primary trial  is 40 mg/m^2 orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "primary trial  is 40 mg/m^2 orally  twice daily (BID) on Days 1-3, 8-10 and 15-",
            "twice daily (BID) on Days 1-3, 8-10 and 15-17",
            "Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel",
            "supported by results from cohort 2 of the primary trial  is 40 mg/m^2 orally  twice daily (BID)"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
            "The MTD is defined as the dose range at which 1 of 6 evaluable participants experience dose limiting toxicities (DLT)  DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count smaller than 10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade 3 nausea/emesis  Grade 3 diarrhoea  Grade 3 fatigue  Grade 3 nonhematological toxicity that could be controlled to Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities Grade 2 that  in opinion of investigator  required a dose reduction or discontinuation of therapy with alisertib ",
            "Time frame: Cycle 1 (Up to 28 days)Results 1: Arm/Group Title: Alisertib + Paclitaxel (Phase 1) Arm/Group Description: Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles)  Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: mg 40 "
        ],
        "premise_nums": [
            "than 10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade",
            "weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles)  Overall Number of",
            "weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly (Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or",
            "as the dose range at which 1 of 6 evaluable participants experience dose limiting",
            "alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID) on Days 1-3, 8-10 and 15-17, combined",
            "ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID)",
            "neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following",
            "5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4",
            "with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days;",
            "Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the",
            "daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly (Days 1, 8, 15) in 28-day cycles in Phase 1",
            "cycles in Phase 1 (Up to 37 cycles)  Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: mg",
            "Time frame: Cycle 1 (Up to 28 days)Results 1: Arm/Group Title: Alisertib",
            "consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count smaller than 10,000/mm^3; 4. Grade 3 thrombocytopenia with",
            "twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly",
            "Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel"
        ]
    },
    {
        "id": "c9214d06-2733-4c78-99e5-a42015908eae",
        "primaryId": "NCT00246571",
        "statement_text": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment ",
        "statement_nums": [
            "cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology",
            "Care had a median PFS of 2.5 months by Core radiology laboratory assessment"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities  Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) ",
            "Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8)Investigator's assessment: 1.7 (1.5 to 2.6) Results 2: Arm/Group Title: Standard of Care Arm/Group Description: One of the following regimens was administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly  in a continuous regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion  Days 1 and 8 every 3 weeks  If RECIST defined progression was met  participants could receive sunitinib  37.5 mg oral capsules QD  in continuous 3-week cycles  ",
            "Overall Number of Participants Analyzed: 104Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.7 (1.7 to 2.8) Investigator's assessment: 2.5 (1.4 to 2.9) "
        ],
        "premise_nums": [
            "(DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities  Overall",
            "frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group",
            "radiology laboratory assessment: 2.7 (1.7 to 2.8) Investigator's assessment: 2.5 (1.4 to 2.9)",
            "IV infusion or 60-80 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel",
            "3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2",
            "investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80",
            "a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed",
            "regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via",
            "1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly",
            "Number of Participants Analyzed: 113 Median (95% Confidence Interval)",
            "rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities",
            "3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine",
            "administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2",
            "oral capsules QD  in continuous 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel",
            "Dose escalated to sunitinib 50 mg QD if minimal toxicities  Overall Number of Participants Analyzed: 104Median",
            "1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2",
            "sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a",
            "Overall Number of Participants Analyzed: 104Median (95% Confidence Interval) Unit of Measure: Months",
            "of study treatment to first documentation of objective tumor progression",
            "could receive sunitinib  37.5 mg oral capsules QD  in continuous 3-week cycles",
            "regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)",
            "date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined",
            "week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion  Days 1 and 8 every 3 weeks  If",
            "Title: Sunitinib Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter"
        ]
    },
    {
        "id": "a318fc31-4f28-4356-b09a-59741bb7c97a",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is not ",
        "statement_nums": [
            "communicate with women aged 51-73 years old   whereas the secondary trial is not",
            "communicate with women aged 51-73 years old   whereas the primary trial is investigating different ways"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) "
        ],
        "premise_nums": [
            "Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of",
            "Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging",
            "Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm"
        ]
    },
    {
        "id": "70ec4bc8-f8fa-4901-aa7a-2388b53960c6",
        "primaryId": "NCT00206518",
        "statement_text": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "statement_nums": [
            "for patients in the primary trial treated with Taxotere/Docetaxel were 3A and"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as: Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR) Presence of in situ carcinoma in the breast  No invasive tumor in breast and no tumor in LN (pCR) Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively greater than 75% therapeutic effect 3B: Subjectively between 50% - 75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4 No or few modification of tumoral appearance (pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel ",
            "Arm/Group Description: Chemotherapy In Arm A  patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will then be conducted  if operable  following completion of neoadjuvant treatment  This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles  For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity Taxotere/Docetaxel: Taxotere doxorubicin: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery  Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants 1: 3 2: 2 3A: 18 3B: 15 3C: 18 3D: 10 4: 3 N/A: 14 "
        ],
        "premise_nums": [
            "75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4",
            "mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery  Overall Number of Participants Analyzed: 83",
            "receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will",
            "standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles",
            "cycles before surgery  Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants",
            "using BSA = 2.0 m2. This is done in order to",
            "18 3D: 10 4: 3 N/A: 14",
            "(pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel",
            "patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated",
            "which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D,"
        ]
    },
    {
        "id": "00dc0e37-1d0b-4f53-a037-86bf9799dae6",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "statement_text": "Female patients with a womb cannot take part in either the secondary trial or the primary trial ",
        "statement_nums": [
            "part in either the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: All subjects must be female  Postmenopausal status  defined as any one of the following criteria: Documented history of bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement  Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination  Estrogen receptor and/or progesterone receptor positive disease  Patients must not have received any prior treatment for current or newly diagnosed breast cancer  Patients must have not received previous treatment with any of the study medications or similar drugs  No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years  WHO performance status of 0, 1, or 2. Adequate organ function defined as follows: Adequate renal function  defined by a serum creatinine within 3 times the upper limits of normal  ",
            "Adequate liver function  defined by total bilirubin  AST  ALT  and alkaline phosphatase within 3 times the upper limits of normal Adequate bone marrow function  defined as a WBC greater than 3.0 ml  PLT greater than 75,000/ul, Hb greater than 9 gm/l  Willing to undergo breast core biopsies as required by the study protocol  - Ability to understand and sign a written informed consent for participation in the trial  Life expectancy of at least 1 year  Exclusion Criteria: Premenopausal status  Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ  Patients with brain metastasis  WHO performance status of 3 or 4. Is judged by the investigator  uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  significant cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements  Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial  - Concurrent treatment with estrogens or progestins  Patients must stop these drugs at least two weeks prior to study entry  ",
            "Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment Platelet count less than 75,000. In the opinion of the investigator  bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections  History of hypersensitivity to castor oil  Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Patients with recurrent breast cancer  Patients with contralateral second primary breast cancers are eligible  Inclusion Criteria: To be included in this study  you must meet the following criteria: Metastatic breast cancer confirmed by biopsy No more than one prior chemotherapy regimen for metastatic breast cancer Able to perform activities of daily living with minimal assistance Adequate bone marrow  liver and kidney function Age 18 years or older Give written informed consent Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Moderate to severe peripheral neuropathy Uncontrolled blood pressure or uncontrolled heart beat irregularities Diabetes Mellitus with fasting blood sugar greater than 200 mg % Significant heart disease within the prior 6 months Severe or uncontrolled medical disease Active uncontrolled infection Known chronic liver disease Known diagnosis of HIV infection Pregnant or breast feeding females ",
            "Please note: There are additional inclusion/exclusion criteria  The study center will determine if you meet all of the criteria  If you do not qualify for the trial  study personnel will explain the reasons  If you do qualify  study personnel will explain the trial in detail and answer any questions you may have "
        ],
        "premise_nums": [
            "liver and kidney function Age 18 years or older Give written informed consent",
            "with fasting blood sugar greater than 200 mg % Significant heart disease within the prior 6 months Severe or uncontrolled medical disease Active",
            "breast cancer with a primary tumor of 3 cm or more in greatest dimension as",
            "Life expectancy of at least 1 year  Exclusion Criteria: Premenopausal",
            "or similar agents in the past 2 years  WHO performance status of 3 or 4. Is judged by the investigator",
            "or similar agents in the past 2 years  WHO performance status of 0, 1, or 2. Adequate organ",
            "Patients with contralateral second primary breast cancers are eligible",
            "metastasis  WHO performance status of 3 or 4. Is judged by the investigator",
            "defined by a serum creatinine within 3 times the upper limits of normal",
            "bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more",
            "determine if you meet all of the criteria  If",
            "ALT  and alkaline phosphatase within 3 times the upper limits of normal Adequate",
            "or investigational drug within 30 days before Day 1 of study treatment Platelet count less than 75,000. In the opinion of",
            "3.0 ml  PLT greater than 75,000/ul, Hb greater than 9 gm/l  Willing to undergo breast"
        ]
    },
    {
        "id": "a1a421cc-01c9-4afb-8f09-6b10b0ff5094",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "statement_text": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death ",
            "PATIENT CHARACTERISTICS:Age Any age "
        ],
        "premise_nums": [
            "intent  ECOG performance status of 0 or 1 For women of childbearing potential",
            "lactation History of other malignancies within 5 years prior to screening  except for",
            "disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or",
            "or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with",
            "have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent",
            "Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical",
            "conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life"
        ]
    },
    {
        "id": "9316ef0d-55b0-4547-88ae-887e0132a263",
        "primaryId": "NCT00246571",
        "statement_text": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment ",
        "statement_nums": [
            "Care had a median PFS of 2.7months by Core radiology laboratory assessment",
            "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause  PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from adverse event (AE) data (where the outcome was \"Death\")  Time frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter referred to as sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities  Overall Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months Core radiology laboratory assessment: 2.0 (1.5 to 2.8) ",
            "Investigator's assessment: 1.7 (1.5 to 2.6)Results 2: Arm/Group Title: Standard of Care Arm/Group Description: One of the following regimens was administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly  in a continuous regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion  Days 1 and 8 every 3 weeks  If RECIST defined progression was met  participants could receive sunitinib  37.5 mg oral capsules QD  in continuous 3-week cycles  Overall Number of Participants Analyzed: 104 Median (95% Confidence Interval) ",
            "Unit of Measure: Months Core radiology laboratory assessment: 2.7 (1.7 to 2.8)Investigator's assessment: 2.5 (1.4 to 2.9) "
        ],
        "premise_nums": [
            "(DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities  Overall",
            "frame: Baseline  every 6 weeks until disease progression or death (up to 3 years from first dose) Results 1: Arm/Group",
            "mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2 via IV infusion every 3 weeks; paclitaxel 175-200 mg/m^2 via",
            "every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; paclitaxel 80-90 mg/m^2 weekly  in a continuous",
            "every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly  expressed in 3-week cycles;",
            "Investigator's assessment: 1.7 (1.5 to 2.6)Results 2: Arm/Group Title: Standard of",
            "investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80",
            "a continuous regimen  expressed in 3-week cycles  1-week treatment rests and dose reductions allowed",
            "regimen expressed in 3-week cycles or 3 weeks of treatment followed by 1 week of rest; gemcitabine 800-1250 mg/m^2 via",
            "1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral weekly",
            "rests and dose reductions allowed for dose-limiting toxicity (DLT)  Dose escalated to sunitinib 50 mg QD if minimal toxicities",
            "investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3",
            "3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80 mg/m^2 oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine",
            "administered (at investigator's discretion): oral capecitabine 1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2",
            "every 3 weeks; paclitaxel 175-200 mg/m^2 via IV infusion every 3 weeks; vinorelbine 25-30 mg/m^2 rapid IV infusion or 60-80",
            "1000-1250 mg/m^2 BID Days 1-14, every 3 weeks; vinorelbine 25-30 mg/m^2 oral weekly  expressed in 3-week cycles; docetaxel 75-100 mg/m^2",
            "sunitinib]) oral capsules  37.5 milligrams (mg) once daily (QD) in a",
            "of study treatment to first documentation of objective tumor progression",
            "radiology laboratory assessment: 2.7 (1.7 to 2.8)Investigator's assessment: 2.5 (1.4 to 2.9)",
            "date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined",
            "week of rest; gemcitabine 800-1250 mg/m^2 via IV infusion  Days 1 and 8 every 3 weeks  If",
            "Title: Sunitinib Arm/Group Description: SU011248 (Sutent [sunitinib malate  hereafter",
            "Number of Participants Analyzed: 113 Median (95% Confidence Interval) Unit of Measure: Months",
            "could receive sunitinib  37.5 mg oral capsules QD  in continuous 3-week cycles  Overall Number of Participants Analyzed: 104"
        ]
    },
    {
        "id": "5d815fac-c66c-43fe-9ac8-a352b6e47a5b",
        "primaryId": "NCT01929395",
        "secondaryId": "NCT01857882",
        "statement_text": "the primary trial and the secondary trial are both utilising test and control groups in their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial are both utilising test"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Phase 1: Addition of Supine MRI to Conventional Imaging Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI) INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education "
        ],
        "premise_nums": [
            "The decision support workshop will be 2 hours in duration on the morning of",
            "answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education"
        ]
    },
    {
        "id": "7b9fdeaa-5cb7-4453-b174-07b44bb58234",
        "primaryId": "NCT00127205",
        "statement_text": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations ",
        "statement_nums": [
            "More patients in the primary trial suffer from dysfunctions with"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%)"
        ]
    },
    {
        "id": "c330f152-c64e-47ab-8568-5129a1a2099e",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events ",
        "statement_nums": [
            "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) Cellulitis 0/3 (0.00%) Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion 1/64 (1.56%) Tachycardia 1/64 (1.56%) Nausea 2/64 (3.13%) Vomiting 2/64 (3.13%) Abdominal pain 2/64 (3.13%) Colitis 1/64 (1.56%) ",
            "Diarrhoea 1/64 (1.56%)Gastritis 1/64 (1.56%) Ileus 1/64 (1.56%) Fatigue 1/64 (1.56%) Pyrexia 1/64 (1.56%) Pain 1/64 (1.56%) Hepatic cirrhosis 1/64 (1.56%) Cellulitis 3/64 (4.69%) "
        ],
        "premise_nums": [
            "(0.00%) Cellulitis 0/3 (0.00%) Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion 1/64 (1.56%) Tachycardia 1/64 (1.56%) Nausea 2/64",
            "(3.13%) Vomiting 2/64 (3.13%) Abdominal pain 2/64 (3.13%) Colitis 1/64 (1.56%) Pain 1/64 (1.56%) Hepatic cirrhosis 1/64 (1.56%) Cellulitis 3/64 (4.69%)",
            "1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) Cellulitis 0/3 (0.00%)",
            "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%)",
            "1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Cellulitis 0/3 (0.00%) Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion",
            "Tachycardia 1/64 (1.56%) Nausea 2/64 (3.13%) Vomiting 2/64 (3.13%) Abdominal pain 2/64 (3.13%) Colitis 1/64 (1.56%)",
            "Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion 1/64 (1.56%) Tachycardia 1/64 (1.56%) Nausea 2/64 (3.13%) Vomiting 2/64 (3.13%) Abdominal pain",
            "(0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Cellulitis 0/3 (0.00%) Adverse Events 2: Total: 22/64 (34.38%) Pericardial effusion"
        ]
    },
    {
        "id": "e621f354-dea0-4d0f-a252-5480028c1712",
        "primaryId": "NCT00022516",
        "statement_text": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event ",
        "statement_nums": [
            "At least 1 patient in the primary trial suffered from a radiotherapy"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%) "
        ],
        "premise_nums": [
            "1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis",
            "Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT",
            "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia",
            "(0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%)",
            "0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total:",
            "Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473",
            "0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse",
            "Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis",
            "(0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%)"
        ]
    },
    {
        "id": "ee209156-74dc-475e-87af-ae51160982ef",
        "primaryId": "NCT00244881",
        "statement_text": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment ",
        "statement_nums": [
            "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Fraction of Patients With Increased Levels of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated for the CEC response rate  With 26 patients  this CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate) Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage of participants 30 "
        ],
        "premise_nums": [
            "patients respond  the CI is 30% to 70%). Time frame: After 3 weeks of treatment Results 1: Arm/Group Title: Treatment (Cediranib Maleate)",
            "or unacceptable toxicity  Overall Number of Participants Analyzed: 26 Measure Type: Number Unit of Measure: percentage",
            "Description: Patients receive oral AZD2171 once daily for 42 days  Courses repeat every 42 days in the absence of disease progression",
            "of Circulating Endothelial Cells An exact 95% confidence interval (CI) will be calculated",
            "CI will be no wider than 40% (e.g.  if 13 of 26 patients respond  the CI",
            "40% (e.g.  if 13 of 26 patients respond  the CI is 30% to 70%). Time frame: After 3"
        ]
    },
    {
        "id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
        "primaryId": "NCT01519700",
        "statement_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial ",
        "statement_nums": [
            "of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title: EP2006 + EP2006 & Neupogen Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean (Standard Deviation) Unit of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to receive Neupogen in Cycle 1 Overall Number of Participants Analyzed: 103 Mean (Standard Deviation) Unit of Measure: Days 1.2 (1.02) "
        ],
        "premise_nums": [
            "either EP2006 in Cycle 1 Overall Number of Participants Analyzed: 101 Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean",
            "Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1 Overall Number of Participants",
            "Outcome Measurement: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy Mean duration of severe neutropenia",
            "Grade 4 neutropenia (ANC less than 0.5*10^9 cells/L) Time frame: 21 days (Cycle 1 of chemotherapy treatment) Results 1: Arm/Group Title:",
            "of Measure: Days 1.17 (1.11) Results 2: Arm/Group Title: Neupogen + Neupogen & EP2006 Arm/Group Description: All subjects randomized to"
        ]
    },
    {
        "id": "c7c745d6-03ee-4740-9ef4-641fb6546e46",
        "primaryId": "NCT00544167",
        "statement_text": "Every adverse event in the primary trial occurred more than 8 times ",
        "statement_nums": [
            "adverse event in the primary trial occurred more than 8 times"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI 1/45 (2.22%) Pancreatitis 1/45 (2.22%) Infection - pneumonia 1/45 (2.22%) Infection - Streptococcus 1/45 (2.22%) Abcess of Bartholin's cyst 1/45 (2.22%) "
        ],
        "premise_nums": [
            "arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%) Hemmorhage - GI",
            "Adverse Events 1: Total: 7/45 (15.56%) Febrile neutropenia 1/45 (2.22%) Cardiac ischemia/infarction 1/45 (2.22%) Ventricular"
        ]
    },
    {
        "id": "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0",
        "primaryId": "NCT00617942",
        "secondaryId": "NCT00388726",
        "statement_text": "the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial ",
        "statement_nums": [
            "the primary trial had a lower total",
            "events compared to the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 7/37 (18.92%) Adverse Events 1: Total: 130/503 (25.84%)"
        ]
    },
    {
        "id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
        "primaryId": "NCT01827787",
        "statement_text": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin ",
        "statement_nums": [
            "Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Response Rate (ORR) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  Time frame: Disease was evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Title: Cohort 1: HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 45 Measure Type: Number ",
            "Unit of Measure: percentage of participants 35.6 (24 to 49)Results 2: Arm/Group Title: Cohort 2: TNBC Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on single agent eribulin until disease progression or withdrawal for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage of participants 13.2 (5 to 26) "
        ],
        "premise_nums": [
            "days 1 and 8 of each 21 day cycle Participants remained on treatment  Per RECIST 1.1 for target lesions: CR is complete disappearance",
            "Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle Participants remained on",
            "evaluated radiologically at baseline and every 9 weeks on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months",
            "for other reasons  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage",
            "lesions and PR is at least a 30% decrease in the sum of longest",
            "HR+/HER2- Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle",
            "months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days",
            "on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and 17 cycles/12 months (Cohort 2) Results 1: Arm/Group Title:",
            "Outcome Measurement: Overall Response Rate (ORR) ORR was",
            "Number of Participants Analyzed: 45 Measure Type: Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: percentage",
            "on treatment; Maximum treatment duration was 38 cycles/26 months (Cohort 1) and PR is at least a 30% decrease in the sum of"
        ]
    },
    {
        "id": "8f1959e4-b93a-4112-9726-27a4034f0e07",
        "primaryId": "NCT00191854",
        "statement_text": "Patients must have a one bi-dimensional  measurable indicator lesion to be included in the primary trial",
        "statement_nums": [
            "be included in the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female patients with histological or cytological proven diagnosis of breast cancer Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease Adequate organ function Exclusion Criteria: Prior chemotherapy for metastatic disease Previous radiation therapy is allowed but must not have included whole pelvis radiation Known or suspected brain metastasis  Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study  at the discretion of the investigator Concurrent administration of any other tumor therapy  including cytotoxic chemotherapy  hormonal therapy and immunotherapy (including trastuzumab (Herceptin)) Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder  including seizures or dementia "
        ],
        "premise_nums": [
            "Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or",
            "Stage IV disease Performance Status of 0 or 1 on the Eastern Cooperative Oncology",
            "Previous radiation therapy is allowed but must not have"
        ]
    },
    {
        "id": "e1782960-8d44-4acc-aaae-bfa4f8e38de0",
        "primaryId": "NCT00254592",
        "statement_text": "Patients must have an ECOG score below 3 to participate in the primary trial ",
        "statement_nums": [
            "must have an ECOG score below 3 to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must have a performance status of 0-2 by Zubrod criteria "
        ],
        "premise_nums": [
            "must have a performance status of 0-2 by Zubrod criteria"
        ]
    },
    {
        "id": "61bd93b2-b38f-496d-acd9-f8b188d28a39",
        "primaryId": "NCT00365599",
        "secondaryId": "NCT01771666",
        "statement_text": "Black men with and ECOG smaller than =2, with ANC greater than 1.5 x 10^9/L,Bilirubin greater than 2.0 mg/dl  PLT greater than 100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "statement_nums": [
            "than 1.5 x 10^9/L,Bilirubin greater than 2.0 mg/dl  PLT greater than 1.5 x 10^9/L,Bilirubin greater than 2.0 mg/dl  PLT",
            "than =2, with ANC greater than 1.5 x 10^9/L,Bilirubin greater than 2.0 mg/dl  PLT greater than 100",
            "are eligible for the primary trial but excluded from the secondary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Patients must have acceptable organ function  as defined by the following laboratory parameters: white blood count (WBC) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)  Creatinine smaller than 1.8 mg/dl (Creatinine clearance greater than 60 ml/min)  Both men and women of all races and ethnic groups are eligible for this trial  Patient with a history of blood clots are not eligible  Inclusion Criteria: ",
            "Women of 18 years of age or older "
        ],
        "premise_nums": [
            "Cooperative Oncology Group (ECOG) performance status 0-2. Patients must have acceptable organ function",
            "aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)  Creatinine smaller than 1.8 mg/dl (Creatinine clearance greater than 60",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than",
            "than 10.0g/dL; platelets (PLT) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT)",
            "Women of 18 years of age or older",
            "100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl  aspartate aminotransferase/alanine aminotransferase (AST/ALT) smaller than 2.5 X upper limit of normal (ULN)",
            "greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 100 x 10^9/L, Bilirubin smaller than 2.0 mg/dl",
            "absolute neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than",
            "x 10^9/L; hemoglobin (Hgb) greater than 10.0g/dL; platelets (PLT) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than",
            "neutrophil count (ANC) greater than 1.5 x 10^9/L; hemoglobin (Hgb) greater than 3.0 x 10^9/L; absolute neutrophil count (ANC) greater than"
        ]
    },
    {
        "id": "741c95c7-825c-4321-8d12-9037bb701ab8",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women ",
        "statement_nums": [
            "the primary trial is testing a web-based",
            "educational tool and the secondary trial is testing the effects"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders "
        ],
        "premise_nums": [
            "reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants",
            "reminders  At completion of the 24 weeks of follow up  they will",
            "prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship"
        ]
    },
    {
        "id": "6ce047b6-c18f-4f63-90ec-8643f5145efe",
        "primaryId": "NCT00305448",
        "statement_text": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "At least 11 patients in both cohorts of the primary trial achieved either complete response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR)  A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST  ORR is defined as percentage of patients with objective response  Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off  RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 11.1 Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number ",
            "Unit of Measure: percentage of participants 17.6"
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 51 Measure Type: Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization",
            "mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage",
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: percentage of participants 17."
        ]
    },
    {
        "id": "d647aad0-47f7-4b77-a265-e77dcf5e0983",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  in contrast a full year of daily physical exercise is explicitly required for the secondary trial ",
        "statement_nums": [
            "explicitly required for the secondary trial requires participants to exercise for 12 weeks while wearing a fitbit"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  INTERVENTION 1: CMRM vs UMRM [Not Specified] "
        ],
        "premise_nums": [
            "Active Living counseling program consists of 12 weekly group educational sessions  These sessions",
            "a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects"
        ]
    },
    {
        "id": "74fed085-3389-49c6-bdd2-a95c97071f2d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "statement_text": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "All cohorts in the primary trial had lower percentage of",
            "participants with pCR compared to cohort 1 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab ",
            "Drug plus BiologicalEpirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cycles Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
            "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% "
        ],
        "premise_nums": [
            "to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was",
            "Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm",
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0%",
            "days for 4 cycles) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in",
            "8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients",
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T",
            "by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes",
            "patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC",
            "to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression",
            "chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on days for 4 cycles) Overall Number of Participants Analyzed: 51",
            "in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks",
            "than Docetaxel (D) + Trastuzumab each 21 days for 4 cycles Overall Number of Participants Analyzed: 48",
            "840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "+ Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles) Overall",
            "run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on days for 4 cycles) Overall Number of Participants Analyzed: 51",
            "by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is",
            "treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV",
            "progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of"
        ]
    },
    {
        "id": "986ffe33-8e8b-4cbf-8408-eb9489fb2314",
        "primaryId": "NCT00450723",
        "statement_text": "There are several types of surgical and therapeutic treatments  such as Appendectomies and radiotherapy  which are banned for patients wanting to take part in the primary trial ",
        "statement_nums": [
            "take part in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically confirmed breast cancer Stage I or II disease (T1-T2, N0, M0/MX disease) No chest wall invasion by tumor (T3 disease) Medially or centrally located lesion No multicentric disease Multifocal disease allowed No clinically positive axillary nodes No enlarged internal mammary nodes by CT scan Hormone receptor status not specified PATIENT CHARACTERISTICS: Male or female Menopausal status not specified American Society of Anesthesiologists (ASA) physical status classification 1-2 Not pregnant or nursing Negative pregnancy test No other concurrent known  invasive malignancy No known chronic pulmonary disease No known allergy to methylene blue or isosulfan blue PRIOR CONCURRENT THERAPY: No prior thoracic or cardiac surgery No prior ipsilateral chest tube placement Contralateral chest tube placement allowed No prior neoadjuvant chemotherapy No prior radiotherapy to the mediastinum "
        ],
        "premise_nums": [
            "of Anesthesiologists (ASA) physical status classification 1-2 Not pregnant or nursing Negative pregnancy test",
            "I or II disease (T1-T2, N0, M0/MX disease) No chest wall invasion",
            "DISEASE CHARACTERISTICS: Histologically confirmed breast cancer Stage"
        ]
    },
    {
        "id": "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e",
        "primaryId": "NCT00483223",
        "secondaryId": "NCT00811135",
        "statement_text": "There are more cases of Intestinal perforation  Chest pain  death  Hyperglycemia and Pneumonia in the secondary trial than in the primary trial",
        "statement_nums": [
            "and Pneumonia in the secondary trial than in the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%) Hypertension 1/86 (1.16%) Adverse Events 1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%) Death * 1/88 (1.14%) Erysipelas * 1/88 (1.14%) Pneumonia * 1/88 (1.14%) "
        ],
        "premise_nums": [
            "8/86 (9.30%) Hypersensitivity reaction to Cisplatin 1/86 (1.16%) Infection with normal ANC 4/86 (4.65%) Neutrophil Count 1/86 (1.16%) Hyperglycemia 1/86 (1.16%)",
            "1: Intestinal perforation * 1/88 (1.14%) Chest pain * 1/88 (1.14%)"
        ]
    },
    {
        "id": "3f98cd71-ec28-4fd1-9ca0-2184eef3390a",
        "primaryId": "NCT02455453",
        "statement_text": "Patients with tumors that are HER2 +  PR and ER -  are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-. "
        ],
        "premise_nums": [
            "types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-."
        ]
    },
    {
        "id": "11138479-1666-4973-84c2-c6779b5444f5",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the same intervention ",
        "statement_nums": [
            "the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the",
            "In the primary trial only 1 cohort is administered the intervention  whereas"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  "
        ],
        "premise_nums": [
            "receive 30 mg duloxetine orally for 7 days  then 60 mg daily x 4 weeks  then 30 mg",
            "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and",
            "tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "1 week  then 60 mg daily x 4 weeks  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "INTERVENTION 2: Monotherapy: Alobresib 1.4 mg Participants with advanced solid tumors and"
        ]
    },
    {
        "id": "35c62055-2832-4119-9080-5603beea1934",
        "primaryId": "NCT02402764",
        "secondaryId": "NCT00490646",
        "statement_text": "There were no cases of Pneumopathy in either the primary trial or the secondary trial ",
        "statement_nums": [
            "Pneumopathy in either the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Memory impairment * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%) NAUSEA 0/24 (0.00%) PYREXIA 1/24 (4.17%) EXTRAVASATION 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%) ",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%) NAUSEA 1/24 (4.17%) PYREXIA 0/24 (0.00%) EXTRAVASATION 1/24 (4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) "
        ],
        "premise_nums": [
            "(0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2: Total: 6/24 (25.00%)",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24",
            "FEBRILE NEUTROPENIA 0/24 (0.00%)HAEMATOTOXICITY 1/24 (4.17%) NEUTROPENIA 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%)",
            "(0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24 (0.00%) APLASIA 1/24 (4.17%)",
            "Adverse Events 1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) LYMPHADENOPATHY 1/24 (4.17%) PERICARDIAL EFFUSION 0/24 (0.00%) ATRIAL FIBRILLATION 0/24",
            "Adverse Events 1: Total: 3/10 (30.00%) Sinus tachycardia * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24",
            "1: Total: 13/24 (54.17%) FEBRILE NEUTROPENIA 5/24 (20.83%) HAEMATOTOXICITY 0/24 (0.00%) CHOLECYSTITIS 1/24 (4.17%) PATHOLOGICAL FRACTURE 1/24 (4.17%) Adverse Events 2:",
            "(4.17%) CHOLECYSTITIS 0/24 (0.00%) PATHOLOGICAL FRACTURE 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA",
            "(30.00%) Sinus tachycardia * 1/10 (10.00%) Blurred vision * 1/10 (10.00%) Dyspnea * 2/10 (20.00%) Adverse Events 1: Total: 13/24",
            "HAEMATOTOXICITY 0/24 (0.00%) NEUTROPENIA 3/24 (12.50%) LYMPHADENOPATHY 0/24 (0.00%) PERICARDIAL EFFUSION 1/24 (4.17%) ATRIAL FIBRILLATION 1/24 (4.17%) APLASIA 0/24 (0.00%)"
        ]
    },
    {
        "id": "59ff0501-f6af-4739-bd07-71e12e8cd8a7",
        "primaryId": "NCT02244580",
        "secondaryId": "NCT01901146",
        "statement_text": "Patients with undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial ",
        "statement_nums": [
            "undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Estrogen receptor (ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease "
        ],
        "premise_nums": [
            "(ER)  PgR and HER2 expression have been determined Inclusion Criteria: HER2 positive disease"
        ]
    },
    {
        "id": "ab52c559-5712-44ff-becd-1c491e107472",
        "primaryId": "NCT00605267",
        "statement_text": "Men are not eligible for the primary trial ",
        "statement_nums": [
            "not eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  "
        ],
        "premise_nums": [
            "positive women  aged 20 years and over  with operable and"
        ]
    },
    {
        "id": "4619b957-3368-47b9-b949-01ec91208f96",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [
            "the secondary trial recorded more cardiac related",
            "adverse events than the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%) Anorexia 1/50 (2.00%) Hyperglycemia 2/50 (4.00%) Nervous system disorders - Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%) ",
            "Cardiac failure congestive 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%) "
        ],
        "premise_nums": [
            "Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)",
            "(0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93",
            "Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash",
            "Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94",
            "(1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%)",
            "0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93",
            "- Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1:",
            "Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93",
            "fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%)",
            "(34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%)",
            "(1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94",
            "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased",
            "Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia",
            "Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93",
            "Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93",
            "Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93",
            "(28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)"
        ]
    },
    {
        "id": "5bb09d7b-622f-4bdd-8dfd-809ea014a278",
        "primaryId": "NCT00559754",
        "secondaryId": "NCT02924883",
        "statement_text": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "cohort 1 of the primary trial",
            "higher percent of patients in cohort 1 of the secondary trial experienced adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 13/72 (18.06%) Adverse Events 1: Total: 52/133 (39.10%)"
        ]
    },
    {
        "id": "07327b61-973b-48bb-b42b-dfde1efcfb7d",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "statement_text": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial ",
        "statement_nums": [
            "PFS was in the primary trial",
            "PFS was in the secondary trial and the longest recorded"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurs first  If tumor progression data include more than 1 date  the first date will be used  PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib + Capecitabine Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen  Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.5 (4.5 to 6.0) Investigator's assessment: 5.4 (4.4 to 5.8) Results 2: Arm/Group Title: Capecitabine ",
            "Arm/Group Description: Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time of progression  participants could have been eligible to crossover to single agent sunitinib  administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.9 (5.4 to 7.6) Investigator's assessment: 5.5 (4.3 to 6.8) Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  Time frame: Baseline up to Week 16 Results 1: ",
            "Arm/Group Title: BosutinibArm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease progression  unacceptable toxicity or withdrawal of consent occurred  Overall Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8)",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous",
            "event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Week 16 Results 1:",
            "Independent radiology assessment: 5.5 (4.5 to 6.0) Investigator's assessment: 5.4 (4.4 to 5.8) Results 2: Arm/Group Title: Capecitabine",
            "orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time",
            "disease progression (up to 3 years from first dose) Results 1: Arm/Group Title: BosutinibArm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent",
            "event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until",
            "Arm/Group Title: BosutinibArm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48",
            "experienced progression or death by Week 16 is reported  Time frame: Baseline up to Week 16 Results 1:",
            "mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of study treatment to first documentation of objective tumor progression",
            "orally at a starting dose of 37.5 mg once a day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks",
            "first dose of study medication plus 1) divided by 7. Tumor progression was determined from",
            "milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease",
            "of study treatment to first documentation of objective tumor progression data include more than 1 date  the first date",
            "Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group",
            "orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days",
            "mg bosutinib orally once daily for 48 weeks  or until disease progression (up to 3 years from first dose) Results 1: Arm/Group"
        ]
    },
    {
        "id": "3307a083-0c8a-47b8-94cb-0bf4095b9c3b",
        "primaryId": "NCT00633750",
        "statement_text": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial ",
        "statement_nums": [
            "Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed axillary lymph node metastases (N2) "
        ],
        "premise_nums": [
            "stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma Exclusion Criteria: Fixed"
        ]
    },
    {
        "id": "bda2752e-082e-4d06-926a-04ade3f61c26",
        "primaryId": "NCT03165955",
        "secondaryId": "NCT00912340",
        "statement_text": "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial ",
        "statement_nums": [
            "11 patients in the primary trial suffer from a liver disease  0 in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Hepatitis acute 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other cardiac disorder *0/24 (0.00%) Ejection fraction decrease *0/24 (0.00%) Hypertension *0/24 (0.00%) Salivary gland infection *0/24 (0.00%) Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%) Ejection fraction decrease *1/30 (3.33%) Hypertension *1/30 (3.33%) Salivary gland infection *1/30 (3.33%) Pleural effusion *2/30 (6.67%) "
        ],
        "premise_nums": [
            "Hepatitis acute 1/28 (3.57%) Adverse Events 1: Total: 1/24 (4.17%) Pericardial effusion *1/24 (4.17%) Other",
            "Pleural effusion *0/24 (0.00%) Adverse Events 2: Total: 6/30 (20.00%) Pericardial effusion *1/30 (3.33%) Other cardiac disorder *1/30 (3.33%)"
        ]
    },
    {
        "id": "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3",
        "primaryId": "NCT00118157",
        "statement_text": "Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response ",
        "statement_nums": [
            "Only one the primary trial patient treated with oral"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) [Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally Overall Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 17 Measure Type: Number Unit of Measure: participants 1 (1 to 27)",
            "[Not Specified] Time frame: 4 weeks Results 1: Arm/Group Title: Arm 1 Arm/Group Description: Patients receive oral lapatinib",
            "oral tamoxifen once daily on days 1-28. lapatinib ditosylate: Given orally tamoxifen citrate: Given orally"
        ]
    },
    {
        "id": "f418c027-439a-4b19-bfb0-e1c1241886d8",
        "primaryId": "NCT01127763",
        "statement_text": "There were 4 more cases of Dyspnea than Dehydration in the primary trial ",
        "statement_nums": [
            "There were 4 more cases of Dyspnea than Dehydration in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%) "
        ],
        "premise_nums": [
            "Dehydration 1/25 (4.00%) Dyspnea (Shortness Of Breath) 2/25 (8.00%)"
        ]
    },
    {
        "id": "4805e49a-b99e-46d8-b937-13ac2501c4a4",
        "primaryId": "NCT00009945",
        "statement_text": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Eligibility Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy  If any sentinel node is histologically positive by H & E  or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC)  then the patient must have a completion axillary dissection  "
        ],
        "premise_nums": [
            "any sentinel node is histologically positive by H &"
        ]
    },
    {
        "id": "9a3cb836-66a8-4c68-980c-97e5841f331f",
        "primaryId": "NCT01091428",
        "statement_text": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel  supported by the primary trial results  is 40 mg orally  twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "statement_nums": [
            "supported by the primary trial results  is 40 mg orally  twice daily (BID) on",
            "twice daily (BID) on Days 1-3, 8-10 and 15-17",
            "Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel",
            "trial results  is 40 mg orally  twice daily (BID) on Days 1-3, 8-10 and 15-"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel ",
            "The MTD is defined as the dose range at which 1 of 6 evaluable participants experience dose limiting toxicities (DLT)  DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count smaller than 10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade 3 nausea/emesis  Grade 3 diarrhoea  Grade 3 fatigue  Grade 3 nonhematological toxicity that could be controlled to Grade 2 with appropriate treatment; 6. Other alisertib-related nonhematologic toxicities Grade 2 that  in opinion of investigator  required a dose reduction or discontinuation of therapy with alisertib Time frame: Cycle 1 (Up to 28 days) Results 1: ",
            "Arm/Group Title: Alisertib + Paclitaxel (Phase 1)Arm/Group Description: Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles)  Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: mg 40 "
        ],
        "premise_nums": [
            "than 10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade",
            "weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles)  Overall Number of",
            "weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly (Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or",
            "as the dose range at which 1 of 6 evaluable participants experience dose limiting",
            "alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID) on Days 1-3, 8-10 and 15-17, combined",
            "Time frame: Cycle 1 (Up to 28 days) Results 1:",
            "ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg  orally  twice daily (BID)",
            "neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4 neutropenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following",
            "5. Any other Grade 3 nonhematologic toxicity  with following exceptions: Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days; 2. Grade 4",
            "with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following events: 1. Grade 4 neutropenia and thrombocytopenia lasting 7 consecutive days;",
            "Adverse Events (NCI CTCAE) version 4.02 and was defined as any of the",
            "daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly (Days 1, 8, 15) in 28-day cycles in Phase 1",
            "cycles in Phase 1 (Up to 37 cycles)  Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: mg",
            "combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion  weekly (Days 1, 8, 15) in 28-day cycles in Phase 1",
            "Platelet count smaller than 10,000/mm^3; 4. Grade 3 thrombocytopenia with bleeding; 5. Any other Grade 3 nonhematologic toxicity  with following",
            "Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel"
        ]
    },
    {
        "id": "45d4f78f-04d4-434c-9679-fd92291e97b6",
        "primaryId": "NCT00553410",
        "statement_text": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up ",
        "statement_nums": [
            "A 55 year old postmenopausal patient with sarcoidosis would",
            "be excluded from the primary trial as it would prevent"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Confirmed diagnosis of prior operable  noninflammatory breast cancer meeting the following criteria: Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor)  determined by immunohistochemistry  after primary surgery and before commencement of prior endocrine therapy Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease Following primary surgery  eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes  but not supraclavicular nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs)  aromatase inhibitors (AIs)  or a sequential combination of both When calculating 4-6 years  neoadjuvant endocrine therapy should not be included No evidence of recurrent disease or distant metastatic disease No prior bilateral breast cancer PATIENT CHARACTERISTICS: Female Must be postmenopausal by any of the following criteria: Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for greater than 3 months) ",
            "Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol  luteinizing hormone [LH]  and follicle-stimulating hormone [FSH] in the postmenopausal range)Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol  LH  and FSH in the postmenopausal range) Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above Clinically adequate hepatic function No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin  in situ carcinoma of the cervix or bladder  or contra- or ipsilateral in situ breast carcinoma No other nonmalignant systemic diseases (cardiovascular  renal  lung  etc.) that would prevent prolonged follow-up ",
            "No psychiatric  addictive  or any other disorder that compromises compliance with protocol requirementsPRIOR CONCURRENT THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent endocrine SERM/AI therapy Any type of prior adjuvant therapy allowed including  but not limited to  any of the following: Neoadjuvant chemotherapy Neoadjuvant endocrine therapy Adjuvant chemotherapy Trastuzumab (Herceptin®) Ovarian ablation Gonadotropin releasing hormone analogues Lapatinib ditosylate No concurrent hormone-replacement therapy  bisphosphonates (except for treatment of bone loss)  or any other investigational agent "
        ],
        "premise_nums": [
            "Patients 56 years old or older with any evidence",
            "THERAPY: See Disease Characteristics More than 12 months since prior and no other concurrent",
            "sequential combination of both When calculating 4-6 years  neoadjuvant endocrine",
            "nodes Clinically disease-free Must have completed 4-6 years of prior adjuvant therapy allowed including  but not",
            "by immunohistochemistry  after primary surgery and before commencement of",
            "osteoporosis at any time during the 4-6 years of prior therapy No prior or",
            "in the postmenopausal range)Patients 55 years old or younger must have biochemical",
            "castration AND amenorrheic for greater than 3 months)",
            "(LHRH) analogues within the last year are eligible if they",
            "status as defined above Clinically adequate hepatic function No"
        ]
    },
    {
        "id": "2cebae78-f4a3-4e09-ac54-cd2388670274",
        "primaryId": "NCT01953003",
        "statement_text": "Patients receiving intervention 1 of the primary trial  will be administered medication topically and intraveinously ",
        "statement_nums": [
            "Patients receiving intervention 1 of the primary trial  will be administered medication topically and intraveinously"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest Capecitabine: Arm A : 1650 mg/m² Arm B : 2500 mg/m² "
        ],
        "premise_nums": [
            "day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day",
            "mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B : Capecitabine 1250 mg/m² twice daily orally for 14",
            "3 weeks  Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of",
            "vinflunine: intraveinous administration day 1 once every 3 weeks  280 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B :",
            "Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle followed by 1 week of rest  vinflunine: intraveinous administration",
            "iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each cycle followed by 1 week of rest  vinflunine:",
            "day 1 of each cycle every 3 weeks  Capecitabine 825 mg/m² Arm B : 2500 mg/m² INTERVENTION 2: Arm B :",
            "twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest  vinflunine:",
            "INTERVENTION 1: Arm A : iv Vinflunine Plus Capecitabine Vinflunine dose 280 mg/m² on day 1 of each"
        ]
    },
    {
        "id": "d8a98ace-009c-47e4-a812-3bc0df91ed2b",
        "primaryId": "NCT01516736",
        "secondaryId": "NCT00733408",
        "statement_text": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different ",
        "statement_nums": [
            "the primary trial and the secondary trial have non comparable results"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia  defined as number of consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4 neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Kaplan-Meier survival curves will be used  A 95% confidence interval for the median PFS will be calculated  A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab  However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results  ",
            "Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause  assessed up to 8 years"
        ],
        "premise_nums": [
            "A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel-",
            "any cause  assessed up to 8",
            "consecutive days with ANC smaller than 0.5 × 10^9/l (grade 4",
            "neutropenia)  Time frame: 21 days (Cycle 1 of chemotherapy treatment) Outcome Measurement: Progression-free Survival",
            "be used  A 95% confidence interval for the median PFS",
            "However  a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median",
            "registration to date of first documentation of progression or symptomatic",
            "of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy Mean duration of severe neutropenia",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "c8cfd67e-5fac-4bff-9296-6e42dcb09f80",
        "primaryId": "NCT00300781",
        "statement_text": "Participants of the primary trial are assigned an intervention depending on their hormone recpetor status ",
        "statement_nums": [
            "Participants of the primary trial are assigned an intervention"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment  INTERVENTION 2: Neratinib 240, No Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 240, Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally",
            "40mg coated tablets taken orally in prescribed dose of 240mg daily  as long as",
            "Prior Trastuzumab Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily  as long"
        ]
    },
    {
        "id": "57cf3760-1692-439f-bbe2-82a6bc8862ce",
        "primaryId": "NCT01376349",
        "secondaryId": "NCT01912612",
        "statement_text": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily ",
        "statement_nums": [
            "subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects  of the two",
            "two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I Low Dose DHEA Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD)  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 2: Arm II High Dose DHEA Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD  at bed time  for 12 weeks  Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study  INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  "
        ],
        "premise_nums": [
            "receive 30 mg duloxetine orally for 7 days  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "1 week  then 60 mg daily x 4 weeks  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days"
        ]
    },
    {
        "id": "7db1447c-b4e8-49c6-a125-8161bcd98560",
        "primaryId": "NCT00364611",
        "statement_text": "Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial ",
        "statement_nums": [
            "are ineligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Presence of any non-healing wound  fracture  or ulcer  or the presence of clinically significant (greater than /= Grade 2) peripheral vascular disease "
        ],
        "premise_nums": [
            "or the presence of clinically significant (greater than /="
        ]
    },
    {
        "id": "626a05e9-2caf-4e73-a132-5432a5b2c7d9",
        "primaryId": "NCT00550771",
        "secondaryId": "NCT00143390",
        "statement_text": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia  with the majority of those coming from the secondary trial ",
        "statement_nums": [
            "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks  Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
            "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen ",
            "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants 11 Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  ",
            "Time frame: Up to 2008 days of the treatmentResults 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of Measure: months 11.1 (10.8 to 16.6) "
        ],
        "premise_nums": [
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed:",
            "IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed:",
            "2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes",
            "IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed:",
            "2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of",
            "2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants",
            "IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by",
            "600 mg/m^2 IV over 30-90 minutes given every 21 days for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59",
            "over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of",
            "2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59",
            "over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants",
            "every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg",
            "IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by",
            "Time frame: Up to 2008 days of the treatmentResults 1: Arm/Group Title: Exemestane Arm/Group Description:",
            "from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks  Time frame:",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given",
            "Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen",
            "(first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of",
            "60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80",
            "given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over",
            "80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg",
            "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes given every 21 days for 4 courses (12 weeks) followed by",
            "80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of",
            "IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes",
            "expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the",
            "IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over",
            "IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over",
            "Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab",
            "as sudden  unexpected death within 24 hours of a definite or probable cardiac",
            "600 mg/m^2 IV over 30-90 minutes given every 21 days for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120",
            "bone metastasis only  at least 25% increase in the measurable lesion according",
            "by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4",
            "Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole",
            "Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package",
            "IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 145 Median (95% Confidence Interval) Unit of",
            "Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4",
            "2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes",
            "30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with",
            "IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given every 21 days for 4 courses (12 weeks) followed by",
            "Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered",
            "push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80",
            "minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months",
            "to 2008 days of the treatmentResults 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Measure: months 11.1 (10.8 to 16.6)",
            "IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes) given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed:",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Measure: months 13.8 (10.8 to 16.5) Results 2: Arm/Group Title: Anastrozole",
            "Number of Participants Analyzed: 59 Measure Type: Number Unit of Measure: Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months",
            "2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 30-90 minutes given every 21 days for 4 courses (12",
            "fraction (LVEF) drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was",
            "Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1:",
            "Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 11 Outcome Measurement: Time to Progression (TTP) -",
            "60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12",
            "Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: Participants 11 Outcome Measurement: Time to Progression (TTP) -"
        ]
    },
    {
        "id": "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "statement_text": "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial ",
        "statement_nums": [
            "There were 0 cases of night blindness in the primary trial  and 1 in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) Ocular - Other 1/3761 (0.03%) Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) ",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) Ocular - Other 0/3759 (0.00%) Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) "
        ],
        "premise_nums": [
            "0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy",
            "Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth",
            "0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial",
            "(4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial",
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48",
            "Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%)",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%)"
        ]
    },
    {
        "id": "b1cd4818-9623-45e5-a2b3-4c80016e3c82",
        "primaryId": "NCT00186121",
        "statement_text": "Patients with E2 outside the premenopausal range are ineligible for the primary trial ",
        "statement_nums": [
            "Patients with E2 outside the premenopausal range are ineligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "If tamoxifen administered within the past 3 months  plasma estradiol must be in the premenopausal range "
        ],
        "premise_nums": [
            "If tamoxifen administered within the past 3 months  plasma estradiol must"
        ]
    },
    {
        "id": "3050bca2-a8bc-412e-b679-5be1055e3749",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study ",
        "statement_nums": [
            "Cohort 1 of the secondary trial does not receive the",
            "of the study  whereas Cohort 1 of the primary trial recieves a consistent dose"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) "
        ],
        "premise_nums": [
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W",
            "CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) Triple-negative"
        ]
    },
    {
        "id": "a49666fd-f278-4dcf-b6bf-287ace3969aa",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Metastasis to the CNS were recorded in the primary trial ",
        "statement_nums": [
            "were recorded in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system 1/4 (25.00%) Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Dyspnoea 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain 0/3 (0.00%) Disease progression 0/3 (0.00%) Dehydration 0/3 (0.00%) Hyponatraemia 0/3 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3 (0.00%) Intracranial hypotension 0/3 (0.00%) ",
            "Pneumothorax 1/3 (33.33%)Dyspnoea 0/3 (0.00%) Hypoxia 0/3 (0.00%) "
        ],
        "premise_nums": [
            "2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system",
            "Pneumothorax 1/3 (33.33%)Dyspnoea 0/3 (0.00%) Hypoxia 0/3 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3",
            "Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain",
            "(0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%)",
            "Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system 1/4 (25.00%) Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4",
            "Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3"
        ]
    },
    {
        "id": "f6c014af-63db-4578-9b2d-74ea95901842",
        "primaryId": "NCT00445458",
        "secondaryId": "NCT00950742",
        "statement_text": "the primary trial and the secondary trial measure the DLT of their respective interventions  using the same time frame and the same unit of measure ",
        "statement_nums": [
            "the primary trial and the secondary trial measure the DLT of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel Dose Limiting Toxicity in subjects with solid tumors treated with neratinib  administered daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT) Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)  Important Limitations and Caveats are provided in the respective section  Time frame: 28 days "
        ],
        "premise_nums": [
            "Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants With Dose",
            "and 15 of a 28 day cycle  Time frame: From first dose date through day 28 Outcome Measurement: Number of Participants",
            "days 1, 8, and 15 of a 28 day cycle  Time frame: From first dose date through day 28",
            "daily  in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle  Time"
        ]
    },
    {
        "id": "c8ef1457-63a9-4eac-a98b-edb805afd35b",
        "primaryId": "NCT02660788",
        "secondaryId": "NCT01490892",
        "statement_text": "the primary trial is investigating different ways to communicate with women aged 51-73 years old   whereas the secondary trial is evaluating the impact of regular exercise and dieting ",
        "statement_nums": [
            "the primary trial is investigating different ways to communicate with women aged 51-73 years old",
            "communicate with women aged 51-73 years old   whereas the primary trial is investigating different ways"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Control Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm Mail Standard Reminder Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) "
        ],
        "premise_nums": [
            "Postcard Family Physician Reminder Letter INTERVENTION 1: 3D HI and SHI of",
            "Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging",
            "Arm Mail Standard Reminder Postcard INTERVENTION 2: Family Physician Reminder Letter Arm"
        ]
    },
    {
        "id": "515d0710-429b-4c28-b881-8a6531ee973e",
        "primaryId": "NCT03097653",
        "secondaryId": "NCT00662129",
        "statement_text": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial ",
        "statement_nums": [
            "included in either the secondary trial or the primary trial",
            "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Women aged 45-69, according to the target age of the screening centres involved; New invited women in mammography screening programme  Exclusion Criteria: None No non-measurable disease only  defined as all other lesions  including small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions  including any of the following: Bone lesions Leptomeningeal disease "
        ],
        "premise_nums": [
            "small lesions (longest diameter smaller than 2 cm) and truly non-measurable lesions",
            "Inclusion Criteria: Women aged 45-69, according to the target age of"
        ]
    },
    {
        "id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
        "primaryId": "NCT00633464",
        "statement_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial reported worse results than cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 ",
            "Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) "
        ],
        "premise_nums": [
            "progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly +",
            "non-target lesions  PR: At least 30% reduction from baseline in the sum",
            "cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeksOverall Number of Participants Analyzed: 39 Measure",
            "Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8)",
            "Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage",
            "method  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum",
            "percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2",
            "1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40",
            "cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40",
            "2: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2",
            "Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: Arm/Group Title: Cetuximab",
            "12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group",
            "progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2"
        ]
    },
    {
        "id": "c4a2ca0b-c4a7-4366-92c7-145dadd38af3",
        "primaryId": "NCT00629499",
        "statement_text": "Patients with peripheral neuropathy resulting in intolerable paresthesias  are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria  "
        ],
        "premise_nums": [
            "for Adverse Events (CTCAE) v3.0 criteria",
            "less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology"
        ]
    },
    {
        "id": "e591b3bb-0628-46e7-9d60-28989fd6a3d0",
        "primaryId": "NCT01674062",
        "statement_text": "One patient in the primary trial was observed vomiting blood ",
        "statement_nums": [
            "One patient in the primary trial was observed vomiting blood"
        ],
        "label": "Entailment",
        "premise_text": [
            "Haematemesis * 1/66 (1.52%) "
        ],
        "premise_nums": [
            "Haematemesis * 1/66 (1.52%)"
        ]
    },
    {
        "id": "75da6329-e8a1-4808-bb0f-78fd3a2dde9c",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity  Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
            "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) "
        ],
        "premise_nums": [
            "reported between day of first participant randomized  20 June 2007, until cut-off date  31 July",
            "percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatintravenous (IV) infusion administered on Day 1 until every 3 weeks with",
            "Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin",
            "Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV",
            "first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and",
            "Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable",
            "Evaluations were performed every 6 weeks until progression reported between day of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2",
            "disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly",
            "date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly",
            "Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June",
            "or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage",
            "Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab",
            "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin",
            "Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2)"
        ]
    },
    {
        "id": "dab9d582-eaf3-443f-bdb9-073aec304ee6",
        "primaryId": "NCT01629615",
        "secondaryId": "NCT00320541",
        "statement_text": "the secondary trial recorded more cardiac related adverse events than the primary trial ",
        "statement_nums": [
            "the secondary trial recorded more cardiac related",
            "adverse events than the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%) Anorexia 1/50 (2.00%) Hyperglycemia 2/50 (4.00%) Nervous system disorders - Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%) ",
            "Cardiac failure congestive 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%) "
        ],
        "premise_nums": [
            "Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)",
            "(0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93",
            "Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash",
            "Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Neutropenia 0/94 (0.00%) Thrombocytopenia 1/94 (1.06%) Arrhythmia 0/94",
            "(1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%)",
            "0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94 (0.00%) Tachycardia 0/94 (0.00%) Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93",
            "- Other 1/50 (2.00%) Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1:",
            "Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93",
            "fibrillation 1/93 (1.08%) Cardiac failure congestive 3/93 (3.23%) Cardiomyopathy 2/93 (2.15%) Pericardial effusion 1/93 (1.08%) Tachycardia 1/93 (1.08%)",
            "(34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased 4/50 (8.00%) Alkalosis 1/50 (2.00%)",
            "(1.08%) Arrhythmia 1/93 (1.08%) Atrial fibrillation 1/93 (1.08%) Cardiac failure congestive 0/94 (0.00%)Cardiomyopathy 0/94 (0.00%) Pericardial effusion 0/94",
            "Adverse Events 1: Total: 17/50 (34.00%) Fatigue 4/50 (8.00%) Papulopustular rash 1/50 (2.00%) Alanine aminotransferase increased 5/50 (10.00%) Aspartate aminotransferase increased",
            "Dry skin 1/50 (2.00%) Rash acneiform 1/50 (2.00%) Adverse Events 1: Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia",
            "Total: 27/94 (28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93",
            "Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93 (1.08%) Arrhythmia 1/93",
            "Adverse Events 2: Total: 36/93 (38.71%) Anaemia 2/93 (2.15%) Febrile neutropenia 9/93 (9.68%) Leukopenia 3/93 (3.23%) Neutropenia 4/93 (4.30%) Thrombocytopenia 1/93",
            "(28.72%) Anaemia 2/94 (2.13%) Febrile neutropenia 2/94 (2.13%) Leukopenia 1/94 (1.06%) Arrhythmia 0/94 (0.00%) Atrial fibrillation 0/94 (0.00%)"
        ]
    },
    {
        "id": "8b9bb672-1de3-4220-956c-9e86ed78063d",
        "primaryId": "NCT00265759",
        "secondaryId": "NCT00866905",
        "statement_text": "One case of hematolysis was recorded in the primary trial  none in the secondary trial ",
        "statement_nums": [
            "was recorded in the primary trial  none in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 9/157 (5.73%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Cataract 0/157 (0.00%) Diplopia 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%) ",
            "Tinnitus 1/157 (0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION 1/168 (0.60%) "
        ],
        "premise_nums": [
            "Tinnitus 1/157 (0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157",
            "(0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin",
            "Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%)",
            "Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS 1/168 (0.60%) PERIPHERAL NEUROPATHY 2/168 (1.19%) DEPRESSION",
            "Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157 (1.27%)",
            "decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157",
            "(0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA 3/168 (1.79%) ENTERITIS",
            "(0.64%)Cataract 1/157 (0.64%) Diplopia 0/157 (0.00%) Glaucoma 1/157 (0.64%) Vision blurred 1/157 (0.64%) Adverse Events 1: Total: 6/168 (3.57%) FEBRILE NEUTROPENIA",
            "Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157",
            "Blood disorder 1/157 (0.64%) Hemoglobin decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Glaucoma 0/157 (0.00%) Vision blurred 0/157 (0.00%) Adverse Events 2:",
            "Vision blurred 0/157 (0.00%) Adverse Events 2: Total: 14/157 (8.92%) Blood disorder 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%)",
            "Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Hemoglobin decreased 2/157 (1.27%) Hemolysis 1/157 (0.64%) Arrhythmia 0/157",
            "decreased 1/157 (0.64%) Hemolysis 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 0/157 (0.00%) Hearing impaired 2/157",
            "(0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%)",
            "Myocardial ischemia 1/157 (0.64%) Hearing impaired 0/157 (0.00%) Tinnitus 0/157 (0.00%) Arrhythmia 0/157 (0.00%) Cardiac disorder 0/157 (0.00%) Myocardial ischemia 1/157"
        ]
    },
    {
        "id": "3194a043-d156-49d6-97bb-81867ed188f0",
        "primaryId": "NCT00712985",
        "secondaryId": "NCT02038010",
        "statement_text": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV ",
        "statement_nums": [
            "Patients in the primary trial receive a lower dose",
            "trial patients receive of PI3K inhibitor BYL719 by IV than the secondary trial patients receive of PI3K"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx)  INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  PI3K inhibitor BYL719: Given PO Ado-trastuzumab emtansine: Given IV Pharmacological study: Correlative studies Laboratory biomarker analysis: Optional correlative studies "
        ],
        "premise_nums": [
            "250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1).",
            "-1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over",
            "INTERVENTION 1: Zoledronic Acid 5 mg IV Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time",
            "INTERVENTION 1: Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1) Patients receive 250 mg PO daily PI3K inhibitor BYL719 on",
            "time dose  Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone",
            "and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of disease progression",
            "PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat"
        ]
    },
    {
        "id": "aeac1009-91c3-40ad-8583-5b548e1f4b3b",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "statement_text": "the primary trial and the secondary trial only have test cohorts in their studies ",
        "statement_nums": [
            "the primary trial and the secondary trial only have test cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES) Patients receive a CES unit as in arm I  but the ear-lobe electrodes do not pass electrical current  Patients use their CES unit once daily in weeks 1-18. sham intervention: Given once a day for 18 weeks INTERVENTION 1: Treatment Gel + Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily  oral placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 weeks  INTERVENTION 2: Placebo Gel + Oral Treatment ",
            "Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  "
        ],
        "premise_nums": [
            "preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz",
            "CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified",
            "placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily",
            "Hz  and to automatically turn off at therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II",
            "CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES)",
            "Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily",
            "a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of",
            "Hz  and to automatically turn off at the end of 1 hour  Patients use their",
            "(2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel",
            "gel applied to breasts daily for 4-10 weeks"
        ]
    },
    {
        "id": "3058d104-172e-41be-b641-9f0f9cb172be",
        "primaryId": "NCT00240071",
        "statement_text": "At least one participant of the primary trial survived over 200 days without documented disease progression ",
        "statement_nums": [
            "one participant of the primary trial survived over 200 days without documented disease progression"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause  whichever occurs first  Time frame: From date of registration until disease progression or death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus Hormone Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256) "
        ],
        "premise_nums": [
            "previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days",
            "death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus",
            "patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well",
            "Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256)"
        ]
    },
    {
        "id": "bc845a3d-1f69-41a3-bf84-36a62e8127a4",
        "primaryId": "NCT01439282",
        "statement_text": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
        "statement_nums": [
            "the primary trial recorded more than 10 times the number of adverse events as cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 14/67 (20.90%) Adverse Events 2: Total: 1/10 (10.00%)"
        ]
    },
    {
        "id": "69ced998-f3c9-460a-a272-b2c95421b89d",
        "primaryId": "NCT00570323",
        "secondaryId": "NCT00193180",
        "statement_text": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial",
        "statement_nums": [
            "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: All subjects must be female  Postmenopausal status  defined as any one of the following criteria: Documented history of bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement  Exclusion Criteria: Pregnant or breast feeding females "
        ],
        "premise_nums": [
            "bilateral oophorectomy  Age 60 years or more  Age 45 to 59 and satisfying one or more",
            "following criteria: Amenorrhea for at least 12 months and intact uterus  Amenorrhea for less than 12 months and a follicle stimulating"
        ]
    },
    {
        "id": "45fb84a3-674c-40f5-ac8c-26a3c7844e7b",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole ",
        "statement_nums": [
            "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days "
        ],
        "premise_nums": [
            "laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days",
            "therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days",
            "pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD"
        ]
    },
    {
        "id": "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30",
        "primaryId": "NCT00146172",
        "statement_text": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb ",
        "statement_nums": [
            "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd "
        ],
        "premise_nums": [
            "INTERVENTION 1: Neratinib 40 mg Neratinb 40 mg qd INTERVENTION 2: Neratinib 80 mg Neratinib 80 mg qd"
        ]
    },
    {
        "id": "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9",
        "primaryId": "NCT00912340",
        "statement_text": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.",
        "statement_nums": [
            "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Pleural effusion *0/24 (0.00%) Adverse Events 2: Pleural effusion *2/30 (6.67%)"
        ]
    },
    {
        "id": "b3effb24-6ec0-4fa3-9c91-74a45bcc4602",
        "primaryId": "NCT01448447",
        "secondaryId": "NCT03252145",
        "statement_text": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device  which patients must use themselves to drain their lymph vessels ",
        "statement_nums": [
            "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Sole Method patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days INTERVENTION 2: Boost patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx) INTERVENTION 1: Manual Lymph Drainage Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb ",
            "Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid  resulting in reductions in interstitial fluid INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head  and gently pulls the underlying skin and subcutaneous tissue into the suction cup  This suction produces a stretch to the skin and in the subcutaneous tissue space  This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels  and mobilizes the superficial fascia  "
        ],
        "premise_nums": [
            "ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions",
            "(negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb PhysioTouch:",
            "at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx) INTERVENTION 1: Manual Lymph Drainage",
            "in reductions in interstitial fluid INTERVENTION 2: Negative Pressure PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to"
        ]
    },
    {
        "id": "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d",
        "primaryId": "NCT03106077",
        "statement_text": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks ",
        "statement_nums": [
            "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W "
        ],
        "premise_nums": [
            "Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W"
        ]
    },
    {
        "id": "341c0861-b9a3-491d-8d49-aa61a8501a4f",
        "primaryId": "NCT00083174",
        "secondaryId": "NCT00190671",
        "statement_text": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "statement_nums": [
            "event in both the primary trial and the secondary trial was 39."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%) Cardiac General - Other 2/2240 (0.09%) Endocrine - Other 1/2240 (0.04%) Ocular - Other 1/2240 (0.04%) Colitis 2/2240 (0.09%) Diarrhea 1/2240 (0.04%) Dysphagia 1/2240 (0.04%) Gastritis 1/2240 (0.04%) Adverse Events 1: Total: 6 Agranulocytosis 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%) Neutropenia 1/42 (2.38%) Thrombocytopenia 1/42 (2.38%) ",
            "Cardio-respiratory arrest 0/42 (0.00%)Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Fatigue 1/42 (2.38%) Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%) "
        ],
        "premise_nums": [
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%)",
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "Adverse Events 1: Total: 39/2240 (1.74%) Supraven.arrhyth  Atrial fibrillation 1/2240 (0.04%) Cardiac ischemia/infarction 2/2240 (0.09%) Valvular heart disease 1/2240 (0.04%)",
            "Multi-organ failure 0/42 (0.00%) Adverse Events 2: Total: 13 Agranulocytosis 1/61 (1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%)",
            "effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%) Anaemia 2/42 (4.76%) Febrile neutropenia 1/42 (2.38%) Leukopenia 0/42 (0.00%)",
            "effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "2: Total: 13 Agranulocytosis 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61",
            "effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%) Anaemia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%)",
            "(1.64%) Fatigue 1/61 (1.64%) Multi-organ failure 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "Cardio-respiratory arrest 0/42 (0.00%)Pericardial effusion 1/42 (2.38%) Gastric ulcer haemorrhage 0/42 (0.00%) Melaena 0/42 (0.00%)",
            "neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61",
            "neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61 (3.28%) Thrombocytopenia 1/61 (1.64%) Febrile neutropenia 0/61 (0.00%) Leukopenia 2/61 (3.28%) Neutropenia 2/61",
            "(3.28%) Thrombocytopenia 1/61 (1.64%) Cardio-respiratory arrest 1/61 (1.64%) Pericardial effusion 0/61 (0.00%) Gastric ulcer haemorrhage 1/61 (1.64%) Melaena 1/61 (1.64%)"
        ]
    },
    {
        "id": "16d6e554-a1df-42f9-b051-947d70595cbb",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of Leukopenia in the primary trial occurred in cohort 1.",
        "statement_nums": [
            "of Leukopenia in the primary trial occurred in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234 (0.43%) Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) ",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%) "
        ],
        "premise_nums": [
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%)",
            "ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234 (0.43%) Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234",
            "fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%)",
            "failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2:",
            "(0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240",
            "neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive",
            "Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234",
            "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240"
        ]
    },
    {
        "id": "8f0159ce-1044-4f31-94b7-e394cf91d4e1",
        "primaryId": "NCT00316199",
        "statement_text": "Any women with stage 4 or Unresectable  locally recurrent cancer breast cancer are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial",
            "Any women with stage 4 or Unresectable  locally recurrent cancer breast cancer"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer  Unresectable  locally recurrent breast cancer or stage IV disease  "
        ],
        "premise_nums": [
            "of Chinese origin with histologically or cytologically proven diagnosis"
        ]
    },
    {
        "id": "ccc5e420-dda4-4fb9-8d68-82551d69017f",
        "primaryId": "NCT00688909",
        "secondaryId": "NCT00129376",
        "statement_text": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms ",
        "statement_nums": [
            "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) Vomiting * [1]1/63 (1.59%) Acute Pharyngitis * 1/63 (1.59%) Infection * 3/63 (4.76%) Neutrophil count decreased * [1]1/63 (1.59%) Pneumonitis/pulmonary infiltrates * [3]1/63 (1.59%) "
        ],
        "premise_nums": [
            "leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1:",
            "(19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63 (1.59%) Cardiac-ischemia/infarction * 1/63 (1.59%) Vomiting",
            "(0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post",
            "Adverse Events 1: Total: 12/63 (19.05%) Febrile neutropenia * [1]4/63 (6.35%) Congestive heart failure * [2]1/63",
            "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis"
        ]
    },
    {
        "id": "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in the test group had better health outcomes than the control group ",
        "statement_nums": [
            "In the primary trial patients in the test"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips  (BMD)  Two X-ray beams with different energy levels are aimed at the patient's bones  When soft tissue absorption is subtracted out  the BMD can be determined from the absorption of each beam by bone  Time frame: baseline  month 24 Results 1: Arm/Group Title: Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36 Mean (Standard Deviation) Unit of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 34 Mean (Standard Deviation) ",
            "Unit of Measure: Z-score 0.037 (0.042)"
        ],
        "premise_nums": [
            "months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36",
            "Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)",
            "(DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at",
            "of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion",
            "period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36 Mean (Standard Deviation) Unit of Measure: Z-score",
            "frame: baseline  month 24 Results 1: Arm/Group Title: Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a"
        ]
    },
    {
        "id": "57e6f0e1-6157-43bc-8bdf-c3649ed49133",
        "primaryId": "NCT01129336",
        "secondaryId": "NCT01945775",
        "statement_text": "More than half the participants of the primary trial are considered to be censored  the secondary trial used the same outcome measurement  but had no censored patients ",
        "statement_nums": [
            "the participants of the primary trial are considered to be",
            "be censored  the secondary trial used the same outcome"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) Complete Response (CR): disappearance of all target lesions  Any pathological lymph nodes (target or non-target) must have exhibited a reduction in short axis to smaller than 10 mm  Partial Response (PR): at least a 30% decrease in sum of diameters of target lesions  taking as reference the baseline sum of diameters  Progressive Disease (PD): at least 20% increase in sum of diameters of target lesions taking as reference the smallest sum on study accompanied by an absolute increase of at least 5 mm or appearance of one or more new lesions  Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference smallest sum diameters  PFS is time from enrollment to date of first documented disease progression or death due to any cause  A participant is considered to be censored when data on time to event is missing due to a subject being lost to follow-up or non-occurrence of the outcome event before the completion of the trial  Time frame: up to 18 months Results 1: Arm/Group Title: Patients Without Bone Metastases ",
            "Arm/Group Description: Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Event: 9 Censor: 6 Results 2: Arm/Group Title: Patients With Bone Metastases Arm/Group Description: Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Event: 19 Censor: 10 Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment ",
            "IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause  whichever occurs first  As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements  compared to the smallest sum on study (including baseline)  the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions  evaluated as a whole  such that it is clear that treatment has failed and disease is progressing  regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions  The analysis was performed by Kaplan-Meier method Time frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Title: Talazoparib ",
            "Arm/Group Description: Participants received talazoparib 1 mg  orally  once daily until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or sponsor's decision to terminate the trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) Results 2: Arm/Group Title: Physician's Choice Treatment ",
            "Arm/Group Description: Participants received 1 of the following drugs in specified regimens  as per the physician's choice: 1) capecitabine 1250 mg/m^2 orally twice daily on Day 1 to 14 in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each cycle; until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or Sponsor's decision to terminate the trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months 5.6 (4.2 to 6.7) "
        ],
        "premise_nums": [
            "Zoledronic acid administration monthly during Months 1-18.Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "trial (up to a maximum of 70.2 months)  One cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion",
            "trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144",
            "cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Description: Participants received talazoparib 1 mg  orally  once",
            "enrollment to date of first documented disease progression or death",
            "trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144",
            "trial (up to a maximum of 45.3 months)  One cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day",
            "in solid tumors (RECIST) version 1.1 or death from any cause  whichever",
            "an absolute increase of at least 5 mm or appearance of one or more",
            "10 minute IV infusion on Day 1, 8, and 15 in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23",
            "trial (up to a maximum of 45.3 months)  One cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion",
            "compared to the smallest sum on study (including",
            "per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) Results 2: Arm/Group Title: Physician's",
            "sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal",
            "trial  Time frame: up to 18 months Results 1: Arm/Group Title: Patients Without Bone",
            "1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "Progressive Disease (PD): at least 20% increase in sum of diameters of",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 5.6 (4.2 to 6.7)",
            "trial (up to a maximum of 70.2 months)  One cyclesions: at least a 20% increase in the sum of target",
            "in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months)  One cycle was of 21 days Overall Number of Participants",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "each cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each",
            "trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Event: 9 Censor: 6 Results 2: Arm/Group Title: Patients With Bone",
            "cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day",
            "choice: 1) capecitabine 1250 mg/m^2 orally twice daily on Day 1 to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Event: 19 Censor: 10 Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological",
            "standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants"
        ]
    },
    {
        "id": "300dbe96-0be8-4ca0-aa3b-41bc059bac7f",
        "primaryId": "NCT02725801",
        "secondaryId": "NCT04030104",
        "statement_text": "Neither the primary trial or the secondary trial have control groups ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial have control groups"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: One-port intervention is placement of one-port tissue expander at time of reconstruction Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of two-port tissue expander at time of reconstruction AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging "
        ],
        "premise_nums": [
            "tissue expander for breast reconstruction INTERVENTION 2: Two-port intervention is placement of",
            "tissue expander for breast reconstruction INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging"
        ]
    },
    {
        "id": "f40c8d92-2921-45fd-8389-15048b08e229",
        "primaryId": "NCT00670982",
        "statement_text": "Neutropenia was the most prevalent adverse event in the primary trial ",
        "statement_nums": [
            "adverse event in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 9/29 (31.03%) Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29 (3.45%) "
        ],
        "premise_nums": [
            "Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis",
            "Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29"
        ]
    },
    {
        "id": "31387af4-aad1-4f3c-bd81-641340ad4096",
        "primaryId": "NCT00256698",
        "secondaryId": "NCT03573804",
        "statement_text": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial use completely different drugs"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Fulvestrant + Anastrozole Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented "
        ],
        "premise_nums": [
            "Dose Regimen + Anastrozole 1 mg INTERVENTION 2: Anastrozole Anastrozole 1 mg INTERVENTION 1: Prone to Supine MRI Evaluated",
            "number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated"
        ]
    },
    {
        "id": "eabe9a78-965e-4984-82c2-25598b6b35da",
        "primaryId": "NCT00534417",
        "statement_text": "The median TTP in cohort one of the primary trial is just under 27 months ",
        "statement_nums": [
            "cohort one of the primary trial is just under 27 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Time to Progression (TTP) Time to progression is defined as the time from treatment start until objective tumor progression  Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion  progression of existing non-target lesions  or the appearance of 1 or more new lesions  The median time to progression is the parameter used to describe TTP  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29 months  Results 1: Arm/Group Title: Capecitabine and Fulvestrant Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg  Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA) "
        ],
        "premise_nums": [
            "as 1000 mg po AM and 500 mg po PM in patients of body weight smaller than 80 kg  and at a",
            "as 1000 mg po AM and 500 mg po PM in patients with a body weight of 80 kg  Fulvestrant will be",
            "Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the",
            "basis at a total dose of 1500 mg  given as 1000 mg po AM and 500 mg po PM in patients",
            "lesions  or the appearance of 1 or more new lesions  The median",
            "will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28",
            "500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days",
            "mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days  Overall Number of",
            "frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks)  up to 29",
            "Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: Months 26.94 [1] (7.26 to NA)",
            "and at a total dose of 2000 mg given as 1000 mg po bid"
        ]
    },
    {
        "id": "006f6b4e-6245-4f09-9786-327bbed3d766",
        "primaryId": "NCT01328249",
        "statement_text": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Feasibility The regimen was considered feasible if the participant was able to complete the eribulin portion without dose delay or reduction  Dose delay was defined as a delay due to eribulin-related adverse event (AE) for more than 2 days for subsequent doses (cycles after the initiation of full dose of eribulin  except holidays  scheduling difficulties and nonclinical logistical issues)  If a participant had more than 1 dose omission  delay or reduction due to eribulin-related AE  these events were collectively counted as one entity in the same participant  Participants were followed for approximately 3 years after the last dose of the study treatment  Feasibility rates were calculated with or without growth factor support  In both cohorts  the percentage of participants who completed the eribulin portion of the regimen without a dose omission  delay or reduction due to eribulin-related AE was estimated via the observed completion rate and an exact 90% confidence interval (CI) was constructed  Time frame: From date of first dose  up to 3 years after the last dose of study treatment  or up to approximately 4 years 2 months Results 1: Arm/Group Title: Cohort 1: Eribulin Mesylate With Filgrastim as Needed ",
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors  subcutaneous pegfilgrastim (6 mg) or filgrastim  could be used with eribulin therapy at the physician's discretion if neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage of participants 70.4 (58.5 to 80.4) Results 2: Arm/Group Title: Cohort 2: Eribulin Mesylate With Prophylactic Filgrastim ",
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for 4 cycles  Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants greater than 60 kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle Overall Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage of participants 60.0 (41.7 to 76.4) "
        ],
        "premise_nums": [
            "Arm/Group Description: Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day",
            "Days 1 and 8 of a 21-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "(IV) on Day 1, of every 14-day cycle for 4 cycles (Cycles 5 to 8). In this Cohort growth factors",
            "observed completion rate and an exact 90% confidence interval (CI) was constructed",
            "of first dose  up to 3 years after the last dose of 300 micrograms for participants 60 kg or 480 micrograms for",
            "eribulin therapy at a dose of 300 micrograms for participants 60 kg  administered subcutaneously on Days 3 and 4 and Days 10",
            "cyclophosphamide regimen at a dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and",
            "dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle for 4 cycles",
            "neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage",
            "dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days 3 and 4 and Days 10 and 11 of each eribulin",
            "kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11 of each eribulin cycle Overall",
            "Participants were followed for approximately 3 years after the last dose of the study treatment",
            "dose of 300 micrograms for participants 60 kg or 480 micrograms for participants greater than 60 kg  administered subcutaneously on",
            "Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage of participants 60.0 (41.7 to 76.4)",
            "Participants were followed for approximately 3 years after the last dose of 1.4 mg/m^2 IV over 2 to 5 minutes on Days",
            "If a participant had more than 1 dose omission  delay or reduction due",
            "treatment  or up to approximately 4 years 2 months Results 1: Arm/Group Title: Cohort 1: Eribulin",
            "480 micrograms for participants greater than 60 kg  administered subcutaneously on Days 3 and 4 and Days 10 and 11",
            "neutropenia occurred that recovered to Grade 2.Overall Number of Participants Analyzed: 25 Measure Type: Number Unit of Measure: Percentage",
            "(60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles",
            "adverse event (AE) for more than 2 days for subsequent doses (cycles after the",
            "frame: From date of first dose  up to 3 years after the last dose",
            "Number of Participants Analyzed: 54 Measure Type: Number Unit of Measure: Percentage of participants 70.4 (58.5 to 80.4) Results 2: Arm/Group Title: Cohort",
            "cyclophosphamide (600 mg/m^2) IV on Day 1, of every 14-day cycle for up to approximately 4 years 2 months Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "88b13330-b937-4bbc-80ea-4bf8ccc17bd1",
        "primaryId": "NCT00699491",
        "statement_text": "3/4 participants in the primary trial suffered from Dose-limiting toxicities ",
        "statement_nums": [
            "3/4 participants in the primary trial suffered from Dose-limiting toxicities"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia) Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  ",
            "Overall Number of Participants Analyzed: 3Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 "
        ],
        "premise_nums": [
            "at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the",
            "Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and",
            "controlled with diabetic medication Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such",
            "IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8,",
            "1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression",
            "mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of",
            "Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the",
            "Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1",
            "at which at most one of 6 patients develops a dose limiting toxicity (DLT)",
            "of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably",
            "highest dose level has 2 or more DLTs  The number of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot",
            "Overall Number of Participants Analyzed: 3Measure",
            "Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the",
            "on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and",
            "22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the",
            "the next highest dose level has 2 or more DLTs  The number of"
        ]
    },
    {
        "id": "e90e2368-808d-454d-8080-30427235b89d",
        "primaryId": "NCT01009918",
        "secondaryId": "NCT01688609",
        "statement_text": "There are no racial criteria for entry into the primary trial  but there are for the secondary trial ",
        "statement_nums": [
            "for entry into the primary trial  but there are for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted)  Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up  Taxanes are permitted  Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy  Pertuzumab may be used in conjunction with trastuzumab  Left Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate renal function for administration of trastuzumab-containing chemotherapy regimen  Sitting systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute Not pregnant or breastfeeding Female patients of childbearing potential  who are sexually active  must have a negative pregnancy test before starting the study Both men and women must be willing to use effective contraception during the study  Teratogenicity is documented for both active study agents Able to swallow capsules EXCLUSION CRITERIA: Patients with metastatic disease Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen ",
            "Current treatment with angiotensin converting enzyme (ACE) inhibitors  angiotensin receptor blockers (ARBs)  such as losartan  β-blockers or digoxinKnown cardiac history: heart failure  myocardial infarction  radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors or β-blockers History of bronchial asthma or related bronchospastic conditions Hereditary or idiopathic angioedema History of severe hypersensitivity reactions to drugs or other causes  i.e  bee stings This protocol does not exclude patients who are participating on other investigational studies  Refer to the local IRB guidelines  Only Japanese women are eligible for the trial "
        ],
        "premise_nums": [
            "systolic blood pressure of greater than 90 mm Hg Pulse 60 beats/minute Not pregnant or breastfeeding Female patients",
            "given with or after primary chemotherapy  Pertuzumab may be",
            "Ventricular Ejection Fraction (LVEF) 50% by MUGA scan or echocardiogram Adequate",
            "radiation-induced cardiac dysfunction Known allergy to either ACE inhibitors",
            "INCLUSION CRITERIA Males and Females 18 years old diagnosed with HER2 positive breast cancer Scheduled to receive neoadjuvant",
            "potential  who are sexually active  must have"
        ]
    },
    {
        "id": "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e",
        "primaryId": "NCT00245219",
        "secondaryId": "NCT00038103",
        "statement_text": "the primary trial and the secondary trial only have test groups  so all patients are receiving novel (FDA approved) interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial only have test groups",
            "primary trial and the secondary trial only have test groups  so all patients are receiving novel (FDA"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Health Tracking (Control) Participants assigned to the health-tracking condition received usual care and did not attend any meetings  INTERVENTION 2: Peer Support The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another  Patients completed a weekly diary of critical experiences or current life problems as homework  and were then encouraged to share these experiences in the group meetings  The group facilitator encouraged participants to help one another with these issues  and share how they had dealt with similar problems  INTERVENTION 1: Exemestane (Exemestane Alone) oral dose exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination (Exemestane + Celecoxib) oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) "
        ],
        "premise_nums": [
            "exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)",
            "exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination"
        ]
    },
    {
        "id": "eea73ae4-0985-4f74-957d-e2aad7ab453c",
        "primaryId": "NCT00248170",
        "secondaryId": "NCT01299038",
        "statement_text": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer  she is too old to participate in both the secondary trial and the primary trial ",
        "statement_nums": [
            "Ae-Cha is a 32 year old Korean woman with an inoperable",
            "participate in both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Recent primary surgery for breast cancer Early stage breast cancer Postmenopausal Hormone receptor positive Positive lymph node involvement Exclusion Criteria: Metastatic disease Presence of contralateral breast cancer including DCIS Progression Other protocol-defined inclusion/exclusion criteria may apply  Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitors Conditions predisposing to renal failure secondary to rhabdomyolysis ",
            "Recent history of heavy alcohol use as judged by the treating physicianKnown to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements "
        ],
        "premise_nums": [
            "or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese",
            "Inclusion Criteria: Recent primary surgery for breast cancer Early",
            "predisposing to renal failure secondary to rhabdomyolysis",
            "receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1"
        ]
    },
    {
        "id": "6550c068-14e6-4e93-8f98-756338c91e35",
        "primaryId": "NCT00313170",
        "statement_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose ",
        "statement_nums": [
            "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response (ORR) Objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions)  All patients were to be followed up every 12 weeks for progression  defined by response evaluation criteria in solid tumors (RECIST v1.1). Time frame: The planned data cut-off for this study was when all patients  except withdrawals  had been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group Title: Fulvestrant 250 mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4) Results 2: Arm/Group Title: Fulvestrant 250 mg + Loading Dose Arm/Group Description: Fulvestrant 250 mg + Loading Dose Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 47 Measure Type: Number Unit of Measure: Percentage of patients 8.5 (2.4 to 20.4) Results 2: Arm/Group Title: Fulvestrant",
            "been followed up for at least 24 weeks  Patients received treatment up to approximately 2 years  Results 1: Arm/Group",
            "Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of patients 5.9 (1.2 to 16.2)",
            "mg Arm/Group Description: Fulvestrant 250 mg Overall Number of Participants Analyzed: 47 Measure Type: Number Unit of Measure: Percentage",
            "partial response (PR - at least 30% decrease in the sum of diameters",
            "were to be followed up every 12 weeks for progression  defined by response"
        ]
    },
    {
        "id": "0f5b81f0-b422-4000-8e0e-9f09c612ebc3",
        "primaryId": "NCT01293032",
        "secondaryId": "NCT00849472",
        "statement_text": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course ",
        "statement_nums": [
            "the patients in the primary trial or the secondary trial are required to undergo"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Group 2 (RS 11-25) Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or treatment Arm 2, neoadjuvant chemotherapy  INTERVENTION 1: AC  Followed by Weekly Paclitaxel and Concurrent Pazopanib Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same time each day  either 1 hour before or 2 hours after a meal) taken daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months  "
        ],
        "premise_nums": [
            "each day  either 1 hour before or 2 hours after a meal) taken daily and",
            "[mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles  This was followed",
            "the same oral dose 4-6 weeks after surgery and was continued daily and continuing until 7 days before surgery  Pazopanib was resumed",
            "every 28 days for 4 cycles given concurrently with oral pazopanib 800 mg (2 tablets taken at the same",
            "(AC) (600 mg/m^2) every 21 days for 4 cycles  This was then randomized to treatment Arm 1, neoadjuvant hormonal therapy  or",
            "with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for",
            "(WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given concurrently with oral pazopanib 800",
            "by weekly paclitaxel (WP) 80 mg/m^2 IV on Days 1, 8, and 15 every 28 days for 4 cycles given",
            "daily and continuing until 7 days before surgery  Pazopanib was resumed at the same oral dose 4-6 weeks after surgery and"
        ]
    },
    {
        "id": "f6bba549-3d18-4a53-8685-96b4e321b1a7",
        "primaryId": "NCT00645333",
        "secondaryId": "NCT00006110",
        "statement_text": "the primary trial records several immune system related adverse events in its patients  whereas the secondary trial does not ",
        "statement_nums": [
            "the primary trial records several immune system",
            "patients  whereas the secondary trial does not"
        ],
        "label": "Entailment",
        "premise_text": [
            "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) "
        ],
        "premise_nums": [
            "microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle",
            "of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%)",
            "Autoimmune disorder *1/30 (3.33%) Immune system disorder *1/30 (3.33%) Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia",
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe"
        ]
    },
    {
        "id": "1fe36432-40f8-4c53-ac2b-0f8e50e5743f",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "statement_text": "Several treatments in the secondary trial and the primary trial are administered by mouth ",
        "statement_nums": [
            "Several treatments in the secondary trial and the primary trial are administered by mouth"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Diagnostic FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had positive FES uptake at all disease sites on the baseline diagnostic FES PET scan  laboratory biomarker analysis: Correlative studies INTERVENTION 2: Diagnostic FES: Patients With FES Negative Sites of Disease Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  ",
            "This group represents patients who had some or all disease sites negative for FES uptake on the baseline diagnostic FES PET scan INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive",
            "or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression",
            "baseline diagnostic FES PET scan INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3",
            "(FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients",
            "FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients receive vorinostat PO 5 days a week for 3 weeks",
            "also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan",
            "who had some or all disease sites negative for FES",
            "determine response on the therapy for 6 months using clinical exams  tumor marker",
            "FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy",
            "tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative"
        ]
    },
    {
        "id": "3576f3e7-a1b9-4a75-934a-1ad2165b69dd",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "statement_text": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial ",
        "statement_nums": [
            "and vomiting in the primary trial than the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: Total: 28/39 (71.79%) Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%) Sinus Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%) ",
            "Eye tearing 1/39 (2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%) "
        ],
        "premise_nums": [
            "NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1:",
            "(2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%)",
            "Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia",
            "Total: 28/39 (71.79%) Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%)",
            "Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39",
            "(4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48",
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48"
        ]
    },
    {
        "id": "de71f285-4382-465f-9e7e-d163662f6d9c",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 66 patients in across both its cohorts ",
        "statement_nums": [
            "the primary trial only had a total of 66 patients in across both its cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%)"
        ]
    },
    {
        "id": "406247fb-003a-47b7-8fe4-b6b963b98f08",
        "primaryId": "NCT00281697",
        "statement_text": "the primary trial does not record any pain related adverse events ",
        "statement_nums": [
            "the primary trial does not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%) ",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%) "
        ],
        "premise_nums": [
            "Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia",
            "Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458",
            "Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction 2/221 (0.90%)",
            "39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221 (0.00%) Myocardial infarction",
            "2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458",
            "Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221",
            "Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia 5/221 (2.26%) Neutropenia 1/221 (0.45%) Anaemia 2/221 (0.90%) Thrombocytopenia 0/221 (0.00%) Pancytopenia 0/221",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 0/221 (0.00%) Atrial fibrillation 1/221 (0.45%)",
            "neutropenia 8/458 (1.75%) Neutropenia 6/458 (1.31%) Anaemia 3/458 (0.66%) Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial",
            "Tachycardia 0/458 (0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2: Total: 39/221 (17.65%) Febrile neutropenia",
            "Pericardial effusion 2/221 (0.90%)Tachycardia 2/221 (0.90%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 2:",
            "Thrombocytopenia 3/458 (0.66%) Pancytopenia 2/458 (0.44%) Myocardial infarction 0/458 (0.00%) Pericardial effusion 0/458 (0.00%) Tachycardia 0/458 (0.00%)",
            "(0.00%) Acute myocardial infarction 1/458 (0.22%) Atrial fibrillation 0/458 (0.00%) Adverse Events 1: Total: 112/458 (24.45%) Febrile neutropenia 8/458 (1.75%) Neutropenia"
        ]
    },
    {
        "id": "47553222-0aff-4394-bcfc-9f19c0863835",
        "primaryId": "NCT02441946",
        "secondaryId": "NCT00325598",
        "statement_text": "the secondary trial does not have a defined end date  whereas the primary trial lasted 2 weeks ",
        "statement_nums": [
            "date  whereas the primary trial lasted 2 weeks",
            "the secondary trial does not have a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration "
        ],
        "premise_nums": [
            "Time frame: Baseline  2 Weeks Outcome Measurement: Time frame: Within 1 year of protocol registration"
        ]
    },
    {
        "id": "e4756896-55c2-46e1-be19-14697ad3b39f",
        "primaryId": "NCT00201864",
        "statement_text": "One patient in the primary trial had blood calcium levels far above normal ",
        "statement_nums": [
            "One patient in the primary trial had blood calcium levels"
        ],
        "label": "Entailment",
        "premise_text": [
            "Hypercalcemia 1/40 (2.50%) "
        ],
        "premise_nums": [
            "Hypercalcemia 1/40 (2.50%)"
        ]
    },
    {
        "id": "594c9a79-d601-46b4-ae30-0b48a1117693",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "statement_text": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons ",
        "statement_nums": [
            "difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) ",
            "Elevated ALT or AST enzyme 0/537 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) "
        ],
        "premise_nums": [
            "Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "ALT or AST enzyme 0/537 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537",
            "Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "(0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%)",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537"
        ]
    },
    {
        "id": "99e8ee0e-d72d-4e19-9424-20e5891bb2b6",
        "primaryId": "NCT02447003",
        "secondaryId": "NCT00917735",
        "statement_text": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference in cohort size ",
        "statement_nums": [
            "to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial  despite the difference"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Total: 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Colitis 0/1 (0.00%) Constipation 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537 (0.00%) ",
            "Elevated ALT or AST enzyme 0/537 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537 (0.37%) "
        ],
        "premise_nums": [
            "Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall",
            "Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1 (0.00%) Myocarditis 0/1 (0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1",
            "ALT or AST enzyme 0/537 (0.00%)Diagnosis of Uterine Cancer 2/537 (0.37%) Motorcycle accident 1/537 (0.19%) Fall 1/537 (0.19%) Surgery 2/537",
            "Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "(0.00%) Diarrhoea 0/1 (0.00%) Gastroenteritis eosinophilic 0/1 (0.00%) Intestinal obstruction 0/1 (0.00%) Nausea 0/1 (0.00%)",
            "(0.00%) Myocarditis 0/1 (0.00%) Pericardial effusion 0/1 (0.00%) Pericarditis 0/1 (0.00%) Anaemia 0/1 (0.00%) Febrile neutropenia 0/1 (0.00%) Cardiac tamponade 0/1",
            "Adverse Events 2: Total: 8/537 (1.49%) Hypertension 1/537 (0.19%) Acoustic Neuroma 0/537 (0.00%) Diarrhea 1/537 (0.19%) Colitis 0/537"
        ]
    },
    {
        "id": "f1b0653f-b5ce-4558-b325-56244940c0cd",
        "primaryId": "NCT01273896",
        "statement_text": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial ",
        "statement_nums": [
            "as Cardiac adverse events in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Cardiac General  other1/22 (4.55%) Dyspnea (shortness of breath)2/22 (9.09%)"
        ]
    },
    {
        "id": "24b24d36-2500-4841-99a3-13cba905d77d",
        "primaryId": "NCT01234402",
        "statement_text": "the primary trial at least 8 different types of cardiac related adverse events ",
        "statement_nums": [
            "the primary trial at least 8 different types of cardiac related adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) "
        ],
        "premise_nums": [
            "1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations",
            "Adverse Events 1: Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations",
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%)",
            "2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%)",
            "ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "ventricular failure 1/52 (1.92%) Adverse Events 2: Acute myocardial infarction 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "2: Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%)"
        ]
    },
    {
        "id": "0797ff90-f847-4442-92fd-017c539bb38f",
        "primaryId": "NCT00546104",
        "statement_text": "1 patient in the primary trial suffered from a blood clot blocking their trachea ",
        "statement_nums": [
            "1 patient in the primary trial suffered from a blood"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) Dyspnea 2/31 (6.45%) "
        ],
        "premise_nums": [
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Anorexia 1/31 (3.23%) Dyspnea",
            "(3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%)",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain",
            "(3.23%) hyponatremia 1/31 (3.23%) fever1/31 (3.23%) AST 1/31 (3.23%) infection1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31",
            "Adverse Events 1: Total: 10/31 (32.26%) Edema  limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain",
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain",
            "limb 1/31 (3.23%) Thrombosis1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  extrimity limb",
            "back1/31 (3.23%) Pain  extrimity limb 1/31 (3.23%) Syncope 1/31 (3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain",
            "(3.23%) diarrhea1/31 (3.23%) Pain 2/31 (6.45%) Pain  back1/31 (3.23%) Pain  chest/thorax1/31 (3.23%) hyponatremia 1/31 (3.23%) fever1/31"
        ]
    },
    {
        "id": "e802b1f6-62fb-4759-b261-c69dbdc1d7ef",
        "primaryId": "NCT04080297",
        "secondaryId": "NCT02780713",
        "statement_text": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants ",
        "statement_nums": [
            "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days  INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  "
        ],
        "premise_nums": [
            "administered orally as two 50 mg capsules once daily for 28 days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant",
            "administered orally as two 50 mg capsules once daily for 28 days  INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg",
            "mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)",
            "INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days",
            "50 mg capsules once daily for 28 days  INTERVENTION 2: 200 mg Q-122 Dosage was 200 mg Q-122 administered orally as",
            "days  INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)"
        ]
    },
    {
        "id": "0a24a07e-2cb4-4591-aea4-a370f462cc49",
        "primaryId": "NCT00593346",
        "secondaryId": "NCT00902330",
        "statement_text": "the primary trial treament last for a shorter period of time than the secondary trial treatment ",
        "statement_nums": [
            "the primary trial treament last for a shorter period of",
            "of time than the secondary trial treatment"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks "
        ],
        "premise_nums": [
            "plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be",
            "CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified",
            "CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks",
            "Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  INTERVENTION 1:",
            "a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of",
            "Hz  and to automatically turn off at the end of 1 hour  Patients use their"
        ]
    },
    {
        "id": "97d0bbf0-c2c5-409b-820b-6e14a6326b06",
        "primaryId": "NCT02322814",
        "secondaryId": "NCT00356148",
        "statement_text": "A patient with Histologically confirmed estrogen receptor-negative  progesterone receptor-negative  and human epidermal growth factor 2 positive breast cancer  with no known Brain metastases and no prior history of cardiac dysfunction  could be eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "and human epidermal growth factor 2 positive breast cancer  with no known",
            "A patient with Histologically confirmed estrogen receptor-negative",
            "eligible for both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative  progesterone receptor (PR)-negative  and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease History of autoimmune disease Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously  are progressive  or require any type of therapy (e.g.  radiation  surgery  or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose History of clinically significant cardiac dysfunction Inclusion Criteria: Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II  Exclusion Criteria: Ductal carcinoma in situ (DCIS; stage 0 cancer)  Advanced or distant metastatic stage  Receiving any neoadjuvant therapy  History of receiving any antibiotics within prior 3 months  History of immunodeficiency  Having a remote infection  History of reaction to study antibiotics  ",
            "Denial of signing the consent form "
        ],
        "premise_nums": [
            "control symptoms from brain metastases within 30 days prior to first study treatment dose History of",
            "and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast",
            "Inclusion Criteria: Histologically confirmed estrogen receptor (ER)-negative",
            "of receiving any antibiotics within prior 3 months  History of immunodeficiency"
        ]
    },
    {
        "id": "bbb5ebc0-83c8-46cb-89b4-e1c67e042350",
        "primaryId": "NCT00859651",
        "statement_text": "Helen had stage III ovarian cancer 7 years prior  but has been disease-free for 5 years.  she is excluded from the primary trial ",
        "statement_nums": [
            "but has been disease-free for 5 years.  she is excluded from the primary trial",
            "Helen had stage III ovarian cancer 7 years prior  but has been disease-free for 5 years.  she is excluded"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Other prior malignancy  The following is allowed: adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  adequately treated stage I or II cancer from which the participant is currently in complete remission  or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years  "
        ],
        "premise_nums": [
            "the participant has been disease-free for 5 years",
            "The following is allowed: adequately treated basal cell"
        ]
    },
    {
        "id": "620106e8-2a7f-4078-80b6-d5f1840c66e1",
        "primaryId": "NCT00699491",
        "statement_text": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab ",
        "statement_nums": [
            "the primary trial results show that the",
            "(RPTD) (Phase I) is 3 mg/ks cixutumumab"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs  The number of patients in each cohort reporting a DLT is reported  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible  probably  or definite and fulfilling one of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably controlled with diabetic medication Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia  hypophosphatemia  and hypokalemia) Time frame: During first course Results 1: Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 ",
            "3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1 Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 1 "
        ],
        "premise_nums": [
            "at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the",
            "days 1, 8, 15, and 22 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses",
            "Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1",
            "controlled with diabetic medication Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such",
            "Arm/Group Title: Dose Level 1 Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22",
            "3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the",
            "mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of",
            "Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the",
            "Number of Participants Analyzed: 1 Measure Type: Number Unit of Measure: DLTs 2 Results 2: Arm/Group Title: Dose Level -1",
            "at which at most one of 6 patients develops a dose limiting toxicity (DLT)",
            "of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot be stably",
            "highest dose level has 2 or more DLTs  The number of the following criteria: Any grade 4 hematologic toxicity Hyperglycemia that cannot",
            "progression or unacceptable toxicity Overall Number of Participants Analyzed: 3 Measure Type: Number Unit of Measure: DLTs",
            "mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of",
            "the next highest dose level has 2 or more DLTs  The number of"
        ]
    },
    {
        "id": "94a7b007-0332-4d01-979e-9677e5da4316",
        "primaryId": "NCT00513292",
        "statement_text": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group ",
        "statement_nums": [
            "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: pCR Within the Breast  Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy Pathological complete response (pCR) rates will be based on institutional pathology reports  In the final analysis for publication  rates will be based on blinded central review of these institutional pathology reports  The Chi-squared test will be conducted at the two-sided 0.05 level  A 95% confidence interval will be computed for the difference in pCR rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab ",
            "Arm/Group Description: Patients receive Fluorouracil  epirubicin  and cyclophosphamide (FEC) comprising fluorouracil IV  epirubicin hydrochloride IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 138 Measure Type: Number ",
            "Unit of Measure: percentage of participants 56.5 (47.8 to 64.9)Results 2: Arm/Group Title: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 ",
            "Arm/Group Description: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and trastuzumab  patients receive FEC comprising fluorouracil IV  epirubicin IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive trastuzumab IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab as in arm I  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 142 Measure Type: Number Unit of Measure: percentage of participants 54.2 (45.7 to 62.6) "
        ],
        "premise_nums": [
            "and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and",
            "Number of Participants Analyzed: 138 Measure Type: Number of Participants Analyzed: 142 Measure Type: Number Unit of Measure: percentage",
            "12 weeks  Within 6 weeks after completion of FEC and trastuzumab IV once every 3 weeks for up to 52 weeks",
            "4 courses  Beginning 21 days after completion of FEC  patients receive trastuzumab IV once every 3 weeks for up to 52",
            "on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab",
            "rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once every 3 weeks for up to 52 weeks",
            "and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days",
            "0.05 level  A 95% confidence interval will be computed for",
            "laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 138 Measure Type: Number"
        ]
    },
    {
        "id": "2849d0ce-fed2-4c49-bec1-777c440caaeb",
        "primaryId": "NCT00127205",
        "statement_text": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole ",
        "statement_nums": [
            "More patients in the primary trial suffer from dysfunctions with"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Left ventricular diastolic dysfunction 3/2186 (0.14%) Left ventricular systolic dysfunction 1/2186 (0.05%)"
        ]
    },
    {
        "id": "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 12 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "Only 2 of the 12 adverse event types recorded in the primary trial  occurred more than"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33",
            "Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased"
        ]
    },
    {
        "id": "01a57096-0278-4c70-be43-acd57010cd6f",
        "primaryId": "NCT01332630",
        "secondaryId": "NCT00121134",
        "statement_text": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial  than in cohort 1 of the secondary trial ",
        "statement_nums": [
            "cohort 1 of the primary trial  than in cohort 1 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21 (9.52%) Headache 2/21 (9.52%) Dyspnea 2/21 (9.52%) Hypoxia 3/21 (14.29%) Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%) Headache 0/40 (0.00%) Dyspnea 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%) "
        ],
        "premise_nums": [
            "Total: 6/21 (28.57%) Hypertension 3/21 (14.29%) Edema 3/21 (14.29%) Nausea 2/21 (9.52%) Fracture 1/21 (4.76%) Dizziness 3/21 (14.29%) Syncope 2/21",
            "Adverse Events 1: Total: 1/40 (2.50%) Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%)",
            "Hypertension 0/40 (0.00%) Lower GI bleed 1/40 (2.50%) Death 0/40 (0.00%) Sinusitis 0/40 (0.00%) Wound Dehiscence 0/40 (0.00%)"
        ]
    },
    {
        "id": "49213077-0a5b-4368-a48a-282d2ca9d77a",
        "primaryId": "NCT02953860",
        "statement_text": "Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study ",
        "statement_nums": [
            "Patients in the primary trial receive more mg of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily  Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end treatment  "
        ],
        "premise_nums": [
            "at the start of treatment and 4 weeks after the start of treatment",
            "Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4",
            "start of treatment and 4 weeks after the start of treatment  with an optional 3rd biopsy at the end",
            "of care (SOC) and 160mg of Enzalutamide will be given IM on days 1, 15, 28, then every 4"
        ]
    },
    {
        "id": "426d3ecd-73e3-4226-83c6-cfcb9212ed62",
        "primaryId": "NCT00263588",
        "statement_text": "All the primary trial subjects either had Progressive disease  Complete CNS objective response rate or partial response rate ",
        "statement_nums": [
            "All the primary trial subjects either had Progressive"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: The Number of Participants With Central Nervous System (CNS) Best Overall Response Summary of CNS Objective Response (Lapatinib Monotherapy - MITT Population) Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was CNS objective response rate  A CNS objective response was defined as either a Complete response (CR) or Partial response (PR)  as assessed by volumetric analysis of brain Magnetic resonance imaging (MRI)  provided there was no progression of systemic disease outside of the CNS  increasing steroid requirements  or worsening of Neurological signs and symptoms (NSS) A CNS objective response rate was defined as a 50% volumetric reduction in sum of CNS target lesions  with no new or progressive CNS or non-CNS lesions  no increases in tumor-related steroid requirements and no worsening of neurological signs or symptoms Time frame: time from baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A ",
            "Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settingsOverall Number of Participants Analyzed: 94 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 6 6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings  Overall Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of Measure: Participants Complete response (CR): 0 0.0% Partial response (PR): 9 6.3% Stable disease (SD): 46 32.2% ",
            "Progressive disease (PD): 70 49.0%Unknown: 18 12.6% "
        ],
        "premise_nums": [
            "breast cancer  The primary indicator of drug efficacy was defined as a 50% volumetric reduction in sum of CNS",
            "progressive brain metastases from ErbB2-overexpressing breast cancer  The primary indicator of drug efficacy was",
            "0.0% Partial response (PR): 9 6.3% Stable disease (SD): 46 32.2%",
            "B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of",
            "Arm/Group Description: 750mg lapatinib administered orally twice daily  Cohort",
            "Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing",
            "baseline to data cutoff (25 Sept 2007); approximately 2 years Results 1: Arm/Group Title: Cohort A",
            "response rate was defined as a 50% volumetric reduction in sum of CNS",
            "6.4% Stable disease (SD): 40 42.6% Progressive disease (PD): 40 42.6% Unknown: 8 8.5% Results 2: Arm/Group Title: Cohort B",
            "Nervous System (CNS) Best Overall Response Summary of CNS Objective",
            "Number of Participants Analyzed: 143 Measure Type: Count of Participants Unit of"
        ]
    },
    {
        "id": "7c12676c-7973-4e9d-b1fc-3b14d241d0c8",
        "primaryId": "NCT00696072",
        "statement_text": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome  Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) Results 1: Arm/Group Title: Dasatinib Plus Letrozole Arm/Group Description: Dasatinib + Letrozole: Tablets  Oral  once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg ",
            "Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity  If the intolerable toxicity was determined to be related to dasatinib  dasatinib was discontinued and the patient continued on single-agent letrozole  Although drugs were taken daily  cycle length was 28-daysOverall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants CBR (CR+PR+SD): 40 CBR  DFI smaller than = 2 Years: 20 CBR  DFI greater than 2 Years: 20 "
        ],
        "premise_nums": [
            "lesions  PR= At least a 30% decrease in the sum of the",
            "20 CBR  DFI greater than 2 Years: 20",
            "once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg",
            "time greater than  equal to 6 months  CR= Disappearance of study drug to last dose plus 7 days",
            "of study drug to last dose plus 7 days  up to study",
            "Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population CBR=participants",
            "taken daily  cycle length was 28-daysOverall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants"
        ]
    },
    {
        "id": "3419e901-5880-488d-912c-023e8d1b51c7",
        "primaryId": "NCT01466972",
        "secondaryId": "NCT01446159",
        "statement_text": "the primary trial recorded one patient with congestive Cardiac failure  the secondary trial recorded more ",
        "statement_nums": [
            "Cardiac failure  the secondary trial recorded more",
            "the primary trial recorded one patient with"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Events 1: Heart Failure 1/30 (3.33%) Adverse Events 1: Cardiac failure 0/3 (0.00%) Adverse Events 2: Cardiac failure 0/3 (0.00%)"
        ]
    },
    {
        "id": "cd645637-0a31-4f54-bc75-4a52349cf100",
        "primaryId": "NCT00748553",
        "statement_text": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "statement_nums": [
            "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Phase 1 Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle "
        ],
        "premise_nums": [
            "(Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week",
            "cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week",
            "(Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-weekly for 3 weeks of each 4-week cycle"
        ]
    },
    {
        "id": "adfc79ba-2996-47ce-9986-7d287931df89",
        "primaryId": "NCT02115984",
        "statement_text": "A total of 3 patients in the primary trial experience a Herpes related adverse event ",
        "statement_nums": [
            "A total of 3 patients in the primary trial experience a Herpes related"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) "
        ],
        "premise_nums": [
            "0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn",
            "(45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before",
            "0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn",
            "day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%)",
            "Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after",
            "57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33",
            "Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia"
        ]
    },
    {
        "id": "414ae027-b420-4f01-afd5-164cd8146a30",
        "primaryId": "NCT01129336",
        "secondaryId": "NCT01945775",
        "statement_text": "16 participants of the primary trial are considered to be censored  the secondary trial used the same outcome measurement  but had no censored patients ",
        "statement_nums": [
            "16 participants of the primary trial are considered to be",
            "be censored  the secondary trial used the same outcome"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) Complete Response (CR): disappearance of all target lesions  Any pathological lymph nodes (target or non-target) must have exhibited a reduction in short axis to smaller than 10 mm  Partial Response (PR): at least a 30% decrease in sum of diameters of target lesions  taking as reference the baseline sum of diameters  Progressive Disease (PD): at least 20% increase in sum of diameters of target lesions taking as reference the smallest sum on study accompanied by an absolute increase of at least 5 mm or appearance of one or more new lesions  Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference smallest sum diameters  PFS is time from enrollment to date of first documented disease progression or death due to any cause  A participant is considered to be censored when data on time to event is missing due to a subject being lost to follow-up or non-occurrence of the outcome event before the completion of the trial  Time frame: up to 18 months Results 1: Arm/Group Title: Patients Without Bone Metastases ",
            "Arm/Group Description: Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Event: 9 Censor: 6 Results 2: Arm/Group Title: Patients With Bone Metastases Arm/Group Description: Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Event: 19 Censor: 10 Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment ",
            "IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause  whichever occurs first  As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements  compared to the smallest sum on study (including baseline)  the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions  evaluated as a whole  such that it is clear that treatment has failed and disease is progressing  regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions  The analysis was performed by Kaplan-Meier method Time frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Title: Talazoparib ",
            "Arm/Group Description: Participants received talazoparib 1 mg  orally  once daily until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or sponsor's decision to terminate the trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) Results 2: Arm/Group Title: Physician's Choice Treatment ",
            "Arm/Group Description: Participants received 1 of the following drugs in specified regimens  as per the physician's choice: 1) capecitabine 1250 mg/m^2 orally twice daily on Day 1 to 14 in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each cycle; until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or Sponsor's decision to terminate the trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months 5.6 (4.2 to 6.7) "
        ],
        "premise_nums": [
            "Zoledronic acid administration monthly during Months 1-18.Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "trial (up to a maximum of 70.2 months)  One cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion",
            "trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144",
            "cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months",
            "cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Description: Participants received talazoparib 1 mg  orally  once",
            "enrollment to date of first documented disease progression or death",
            "trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 144",
            "trial (up to a maximum of 45.3 months)  One cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day",
            "in solid tumors (RECIST) version 1.1 or death from any cause  whichever",
            "an absolute increase of at least 5 mm or appearance of one or more",
            "10 minute IV infusion on Day 1, 8, and 15 in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23",
            "trial (up to a maximum of 45.3 months)  One cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion",
            "compared to the smallest sum on study (including",
            "per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) Results 2: Arm/Group Title: Physician's",
            "sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal",
            "trial  Time frame: up to 18 months Results 1: Arm/Group Title: Patients Without Bone",
            "1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "Progressive Disease (PD): at least 20% increase in sum of diameters of",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 5.6 (4.2 to 6.7)",
            "trial (up to a maximum of 70.2 months)  One cyclesions: at least a 20% increase in the sum of target",
            "in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2",
            "Number of Participants Analyzed: 15 Measure Type: Number Unit of Measure: Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "Participants Analyzed: 144 Median (95% Confidence Interval) Unit of Measure: months)  One cycle was of 21 days Overall Number of Participants",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "each cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each",
            "trial (up to a maximum of 45.3 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287",
            "months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants Event: 9 Censor: 6 Results 2: Arm/Group Title: Patients With Bone",
            "cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine",
            "each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day",
            "choice: 1) capecitabine 1250 mg/m^2 orally twice daily on Day 1 to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: Participants Event: 19 Censor: 10 Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological",
            "standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy) Overall Number of Participants"
        ]
    },
    {
        "id": "45b2b9ec-ba58-4323-810a-4baed9c84a0e",
        "primaryId": "NCT00470847",
        "statement_text": "the primary trial participants will not receive any Lapatinib post WBRT ",
        "statement_nums": [
            "the primary trial participants will not receive"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lapatinib,Whole Brain Radiation,Herceptin Lapatinib before and during Whole Brain Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly "
        ],
        "premise_nums": [
            "Radiation Therapy (WBRT)  then Herceptin 4mg/kg IV weekly"
        ]
    },
    {
        "id": "72ffdfbf-aa72-4d44-814a-1d6ab8883898",
        "primaryId": "NCT00971945",
        "statement_text": "Patients must have already participated in a specific clinical study to participate in the primary trial ",
        "statement_nums": [
            "to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study "
        ],
        "premise_nums": [
            "a response after receiving at least two courses of weekly paclitaxel"
        ]
    },
    {
        "id": "db613a72-e300-41a7-987f-788c306d94a4",
        "primaryId": "NCT00403130",
        "statement_text": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial ",
        "statement_nums": [
            "patients participating in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral arterial ischemia * 1/26 (3.85%) Thrombosis * [1]1/26 (3.85%) Weakness * 1/26 (3.85%) Pain * [2]2/26 (7.69%) Febrile neutropenia * 1/26 (3.85%) Aspartate Aminotransferase * [3]1/26 (3.85%) Syncope * 1/26 (3.85%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 18/26 (69.23%) Thrombocytopenia * 4/26 (15.38%) Neutropenia * 3/26 (11.54%) Epitasis * 1/26 (3.85%) Peripheral"
        ]
    },
    {
        "id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
        "primaryId": "NCT00934856",
        "statement_text": "In total  across both cohorts of the primary trial  there was at least 2 fatigued patients ",
        "statement_nums": [
            "both cohorts of the primary trial  there was at least 2 fatigued patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 0/6 (0.00%) Thrombocytopenia * 1/6 (16.67%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) Thrombosis in device * 1/6 (16.67%) Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 1/6 (16.67%) Cholecystitis * 1/6 (16.67%) Adverse Events 2: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%) Neutropenia * 1/6 (16.67%) Thrombocytopenia * 0/6 (0.00%) Diarrhoea * 0/6 (0.00%) Pyrexia * 0/6 (0.00%) ",
            "Thrombosis in device * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%) Device deployment issue * 0/6 (0.00%) Hepatocellular injury * 0/6 (0.00%) Cholecystitis * 0/6 (0.00%) "
        ],
        "premise_nums": [
            "Thrombosis in device * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%)",
            "Adverse Events 1: Total: 2/6 (33.33%) Febrile neutropenia * 1/6 (16.67%)Fatigue * 0/6 (0.00%) Mucosal inflammation * 0/6 (0.00%)"
        ]
    },
    {
        "id": "f6f8a0d3-6288-44cf-9b34-27444110dd10",
        "primaryId": "NCT01581619",
        "secondaryId": "NCT01008150",
        "statement_text": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial  but not from the secondary trial ",
        "statement_nums": [
            "histologically confirmed extensive intraductal component of primary breast carcinoma would result in",
            "but not from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: No histologic evidence of EIC Inclusion Criteria: Patients should have a life expectancy of at least 10 years  excluding their diagnosis of breast cancer  Submission of a block from the diagnostic biopsy sample and from the surgical sample  if gross residual disease greater than or equal to 1.0 cm was removed at the time of surgery  is required for all patients Patients of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy and for at least 6 months after the last dose of study therapy  The Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1. Patients must have the ability to swallow oral medication  The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or by limited incisional biopsy  Patients must have ER analysis performed on the primary tumor prior to randomization  If ER analysis is negative  then progesterone receptor (PgR) analysis must also be performed  (Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.) Breast cancer must be determined to be HER2-positive prior to randomization  Assays using FISH or CISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  ",
            "Clinical staging  based on the assessment by physical exam  must be American Joint Committee on Cancer (AJCC) stage IIB  IIIA  IIIB  or IIIC: cT2 and cN1; cT3 and cN0 or cN1; Any cT and cN2 or cN3; or cT4The patient must have a mass in the breast or axilla measuring greater than or equal to 2.0 cm by physical exam  unless the patient has inflammatory breast cancer  in which case measurable disease by physical exam is not required  At the time of randomization  blood counts performed within 4 weeks prior to randomization must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL ",
            "The following criteria for evidence of adequate hepatic function performed within 4 weeks prior to randomization must be met: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and aspartate aminotransferase (AST) and ALT must be less than or equal to 1.5 x ULN for the lab Patients with alkaline phosphatase greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if liver imaging (CT  MRI  PET  or PET-CT scan) performed within 4 weeks prior to randomization does not demonstrate metastatic disease and the requirements for adequate hepatic function are met  ",
            "Patients with either unexplained skeletal pain or alkaline phosphatase that is greater than ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan  PET-CT scan  or PET scan performed within 4 weeks prior to randomization does not demonstrate metastatic disease  Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are determined to be benign by x-ray  MRI  or biopsy Serum creatinine performed within 4 weeks prior to randomization must be less than or equal to 1.5 x ULN for the lab  The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to 50% regardless of the facility's LLN  Exclusion Criteria: fine-needle aspiration (FNA) alone to diagnose the primary breast cancer  Excisional biopsy or lumpectomy performed prior to randomization  ",
            "Surgical axillary staging procedure prior to randomization  (Procedures that are permitted prior to study entry include: 1) FNA or core biopsy of an axillary node for any patient  and 2) although not recommended  a pre-neoadjuvant therapy SN biopsy for patients with clinically negative axillary nodes.)Definitive clinical or radiologic evidence of metastatic disease  (Note: Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 90 days prior to randomization.) History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in situ (DCIS) treated with radiation therapy (RT)  (Patients with a history of LCIS are eligible.) Contralateral invasive breast cancer at any time  (Patients with contralateral DCIS or lobular carcinoma in situ (LCIS) are eligible.) History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization  Known metastatic disease from any malignancy (solid tumor or hematologic)  ",
            "Previous therapy with anthracyclines  taxanes  cyclophosphamide  trastuzumab  or neratinib for any malignancy Treatment including RT  chemotherapy  and/or targeted therapy  administered for the currently diagnosed breast cancer prior to randomization  Continued endocrine therapy such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor  (Patients are eligible if these medications are discontinued prior to randomization.) Any continued sex hormonal therapy  e.g.  birth control pills and ovarian hormone replacement therapy  Patients are eligible if these medications are discontinued prior to randomization  Active hepatitis B or hepatitis C with abnormal liver function tests  Intrinsic lung disease resulting in dyspnea  Active infection or chronic infection requiring chronic suppressive antibiotics  Malabsorption syndrome  ulcerative colitis  inflammatory bowel disease  resection of the stomach or small bowel  or other disease or condition significantly affecting gastrointestinal function  Persistent greater than or equal to grade 2 diarrhea regardless of etiology  Sensory or motor neuropathy greater than or equal to grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0. ",
            "Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication Chronic daily treatment with corticosteroids with a dose of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)  Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg  with or without anti-hypertensive medications  (Patients with hypertension that is well-controlled on medication are eligible.) ",
            "Cardiac disease (history of and/or active disease) that would preclude the use of any of the drugs included in the treatment regimen  This includes but is not confined to: Active cardiac disease: symptomatic angina pectoris within the past 180 days that required the initiation of or increase in anti-anginal medication or other intervention; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis  History of cardiac disease: myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; history of documented congestive heart failure (CHF); and documented cardiomyopathy Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up  Pregnancy or lactation at the time of randomization  ",
            "The investigator should assess the patient to determine if she has any psychiatric or addictive disorder or other condition that  in the opinion of the investigator  would preclude her from meeting the study requirements Use of any investigational agent within 4 weeks prior to randomization  "
        ],
        "premise_nums": [
            "of the stomach or small bowel  or other disease greater than or equal to 1.0 cm was removed at",
            "than or equal to 1200/mm3; Platelet count must be greater than or equal to 1.0 cm was removed at the time of",
            "than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 1200/mm3; Platelet count must be greater than",
            "Group (ECOG) performance status must be 0 or 1. Patients must have the ability",
            "of greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)",
            "measuring greater than or equal to 2.0 cm by physical exam  unless the",
            "enzymes or persistent regional wall abnormalities on assessment of LV",
            "be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 1.0 cm was removed at the time of",
            "bilirubin elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or",
            "acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to 1200/mm3; Platelet count must be",
            "a life expectancy of at least 10 years  excluding their diagnosis required for all patients Patients of reproductive potential",
            "acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to 2.0 cm by physical exam  unless the",
            "ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scan performed within 90 days prior to randomization must",
            "than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 100,000/mm3; Hemoglobin must be greater",
            "than or equal to 1200/mm3; Platelet count must be greater than or equal to 2.0 cm by physical exam  unless the",
            "symptomatic angina pectoris within the past 180 days that required the initiation of or",
            "as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg  with or without",
            "during therapy and for at least 6 months after the last dose of study therapy",
            "require a strongly positive (3+) staining score",
            "than or equal to 1200/mm3; Platelet count must be greater than or equal to 50% regardless of the facility's LLN",
            "fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scand for at least 6 months after the last dose of study",
            "alone to diagnose the primary breast cancer  Excisional biopsy for patients with clinically negative axillary nodes.)Definitive clinical",
            "of the skin) within 5 years prior to randomization  Known metastatic",
            "acquisition(MUGA) scan performed within 90 days prior to randomization must be greater than or equal to grade 2, as defined by the NCI",
            "elevation greater than ULN to 1.5 x ULN due to Gilbert's disease or IIIC: cT2 and cN1; cT3 and cN0 or cN1; Any",
            "be determined to be HER2-positive prior to randomization  Assays using",
            "or equal to grade 2 diarrhea regardless of etiology  Sensory or",
            "cT3 and cN0 or cN1; Any cT and cN2 or cN3; or cT4The patient must have a mass",
            "cN1; Any cT and cN2 or cN3; or cT4The patient must have been performed within 90 days prior to randomization.) History of ipsilateral",
            "fraction (LVEF) assessment by 2-D echocardiogram or multiple gated acquisition(MUGA) scan performed within 90 days prior to randomization must be greater",
            "as a systolic BP greater than 150 mmHg or diastolic BP greater than or equal to 2.0 cm by physical exam  unless the",
            "but less than or equal to 2.5 x ULN are eligible for inclusion in",
            "than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)",
            "than or equal to 1200/mm3; Platelet count must be greater than or equal to 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)",
            "be less than or equal to 2.5 x ULN for the lab; and aspartate",
            "be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 50% regardless of the facility's LLN",
            "as a systolic BP greater than 150 mmHg or diastolic BP greater than or equal to grade 2, as defined by the NCI"
        ]
    },
    {
        "id": "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50",
        "primaryId": "NCT00572728",
        "secondaryId": "NCT02472964",
        "statement_text": "Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously ",
        "statement_nums": [
            "Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab)"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy  FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2), and post therapy (within 3 weeks prior to surgery  FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography: Undergo 18F-FLT PET/CT Computed Tomography: Undergo 18F-FLT PET/CT Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  ",
            "Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal  INTERVENTION 2: MYL-1401O Trastuzumab + Taxane Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If SD or PR  CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior PR  CR at cycle 9 (week 24) proceed to Herceptin©",
            "Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject",
            "weeks (investigators choice) for 8 cycles then evaluate for primary endpoint  Part 2: If",
            "1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice)",
            "Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice)",
            "and post therapy (within 3 weeks prior to surgery  FLT-3). Patients",
            "FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy  FLT-2),",
            "weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint",
            "9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once",
            "INTERVENTION 1: Herceptin© + Taxane Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously",
            "neoadjuvant chemotherapy  Fluorothymidine F-18: Undergo 18F-FLT PET/CT Positron Emission Tomography:",
            "or PR  CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject",
            "INTERVENTION 1: Diagnostic (18F-FLT) Patients undergo 18F-FLT PET/CT at baseline (prior to"
        ]
    },
    {
        "id": "878dcfeb-c3db-4077-9a3e-8098efa80a99",
        "primaryId": "NCT00836186",
        "statement_text": "Patients cannot be excluded from the primary trial on the basis of race or ethnicity ",
        "statement_nums": [
            "be excluded from the primary trial on the basis of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INCLUSION CRITERIA: Women of all races and ethnic groups are eligible for this trial "
        ],
        "premise_nums": [
            "INCLUSION CRITERIA: Women of all races and ethnic groups are"
        ]
    },
    {
        "id": "fc5dbfec-ba79-4c5d-9e38-3c97d0397570",
        "primaryId": "NCT04396665",
        "secondaryId": "NCT00493636",
        "statement_text": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet ",
        "statement_nums": [
            "can enter into the primary trial or the secondary trial; as long as they"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Informed consent signed Capability to use internet Exclusion Criteria: Breast cancer diagnosis duting the intervention Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma of the breast  Measurable or evaluable locally advanced or metastatic disease  Age 18 years  Disease progression during or after treatment with a bevacizumab-containing regimen in the adjuvant or first-line metastatic setting  Patients must have discontinued chemotherapy at least 3 weeks prior to randomization  No more than one prior chemotherapy regimen for locally advanced or metastatic disease  Prior hormonal therapy allowed provided it has been discontinued prior to randomization  Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomization  Previously radiated area(s) must not be the only site of disease  ECOG Performance Status of 0 or 1. Adequate bone marrow  liver  and renal function Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization  and must agree to use adequate contraception prior to study entry  for the duration of study participation and 28 days after the last study drug dosing  Patients must be able and willing to sign a written informed consent  Patients must be able to swallow and retain oral medication  Exclusion Criteria: ",
            "Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry)  Patients with unknown HER-2 status are not eligible Patients with active brain metastases  Major surgery  open biopsy  or significant traumatic injury within 4 weeks of randomization  Prior use of gemcitabine/capecitabine or sorafenib  Evidence or history of bleeding diathesis or coagulopathy  Serious  non-healing wound  ulcer  or bone fracture  Substance abuse  or medical  psychological  or social condition that may interfere with the patient's participation in the study or evaluation of the study results  Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed  Clinically significant cardiac disease Uncontrolled hypertension Thrombolic  embolic  venous  or arterial events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months  Pulmonary hemorrhage/bleeding event greater than NCI-CTCAE Grade 2 within 4 weeks of randomization  Any other hemorrhage/bleeding event NCI-CTCAE Grade 3 within 4 weeks of randomization  ",
            "Active clinically serious infection greater than NCI-CTCAE Grade 2.Known HIV infection or chronic hepatitis B or C (the safety and effectiveness of sorafenib in this patient population have not been studied)  Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ  treated basal cell carcinoma  superficial bladder tumors [Ta and Tis] or any cancer curatively treated greater than 5 years prior to randomization  Known or suspected allergy to sorafenib or gemcitabine/capecitabine  Prior or concurrent use of St  John's Wort or rifampin (rifampicin) within 3 weeks of randomization  Concurrent anti-cancer therapy other than gemcitabine/capecitabine and sorafenib/placebo  Prior treatment with any agent that targets VEGF or VEGFR (licensed or investigational)  except bevacizumab  Women who are pregnant or breast-feeding  Use of any investigational drug within 30 days or 5 half-lives  whichever is longer  preceding randomization  Inability to comply with protocol and/or not willing or not available for follow-up assessments  ",
            "Any condition which in the investigator's opinion makes the patient unsuitable for the study participation "
        ],
        "premise_nums": [
            "negative serum pregnancy test performed within 7 days prior to randomization  and must",
            "disease  ECOG Performance Status of 0 or 1. Adequate bone marrow  liver",
            "Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed  Clinically significant cardiac",
            "that is distinct in primary site or histology from breast",
            "pregnancy test performed within 7 days prior to randomization  and must have discontinued chemotherapy at least 3 weeks prior to randomization",
            "over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry)  Patients",
            "the intervention Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma",
            "28 days after the last study drug dosing  Patients with unknown HER-2 status are not eligible Patients with active",
            "or rifampin (rifampicin) within 3 weeks of randomization  Concurrent anti-cancer therapy",
            "hemorrhage/bleeding event greater than NCI-CTCAE Grade 2 within 4 weeks of randomization  Any",
            "the duration of study participation and 28 days after the last study drug dosing  Patients",
            "any cancer curatively treated greater than 5 years prior to randomization  Known or",
            "Use of any investigational drug within 30 days or 5 half-lives  whichever is longer",
            "Active clinically serious infection greater than NCI-CTCAE Grade 2.Known HIV infection or chronic"
        ]
    },
    {
        "id": "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce",
        "primaryId": "NCT01234337",
        "secondaryId": "NCT00217672",
        "statement_text": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial ",
        "statement_nums": [
            "occurred in either the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia * 0/260 (0.00%) Bundle branch block right * 0/260 (0.00%) Pericardial effusion * 0/260 (0.00%) Cardiopulmonary failure * 0/260 (0.00%) Aplasia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%) Adverse Events 2: Total: 71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle branch block right * 1/267 (0.37%) Pericardial effusion * 5/267 (1.87%) ",
            "Cardiopulmonary failure * 1/267 (0.37%)Aplasia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%) Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea  pain 1/74 (1.35%) hemorrhage/bleeding 2/74 (2.70%) "
        ],
        "premise_nums": [
            "Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) febrile neutropenia 3/74 (4.05%) speech impairment 1/74 (1.35%) dyspnea",
            "Adverse Events 1: Total: 80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Neutropenia * 2/260 (0.77%) Thrombocytopenia",
            "71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia * 1/267 (0.37%) Bundle",
            "and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%) febrile neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74",
            "80/260 (30.77%) Anaemia * 2/260 (0.77%) Febrile neutropenia * 0/260 (0.00%) Eye symptom * 1/260 (0.38%) Abdominal discomfort * 0/260 (0.00%)",
            "enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting and burning abdominal pain 2/74 (2.70%) Infection 1/74 (1.35%)",
            "discomfort * 1/267 (0.37%) Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74",
            "Adverse Events 1: Total: 13/74 (17.57%) neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia",
            "neutropenia 1/74 (1.35%) left ventricular dysfunction 1/74 (1.35%) fistula enterovesical 1/74 (1.35%) constipation and hypokalemia 1/74 (1.35%) nausea  vomiting",
            "Adverse Events 2: Total: 71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Neutropenia * 0/267 (0.00%) Thrombocytopenia",
            "71/267 (26.59%) Anaemia * 2/267 (0.75%) Febrile neutropenia * 1/267 (0.37%) Eye symptom * 0/267 (0.00%) Abdominal discomfort * 1/267 (0.37%)"
        ]
    },
    {
        "id": "64411610-090b-42d2-a176-d2b13ffef591",
        "primaryId": "NCT03210220",
        "secondaryId": "NCT00290745",
        "statement_text": "Unlike the primary trial  the secondary trial has no control group ",
        "statement_nums": [
            "Unlike the primary trial  the secondary trial has no control group"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Pecs Group Ultrasound guided pectoral nerve block is performed right after induction  before surgery  The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery  and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle   INTERVENTION 2: Control Group There is no block  INTERVENTION 1: Tamoxifen or Letrozole tamoxifen or letrozole work in treating women with ductal carcinoma in situ letrozole tamoxifen citrate conventional surgery neoadjuvant therapy "
        ],
        "premise_nums": [
            "a similar manner  20 mL is deposited at the level of the third rib between the pectoralis minor",
            "and 10 mL of 0.5% ropivacaine deposited  In a similar manner  20 mL is deposited at the level of"
        ]
    },
    {
        "id": "82bd50ac-9407-413b-9eb8-653cef49706c",
        "primaryId": "NCT02364388",
        "secondaryId": "NCT01425268",
        "statement_text": "warm saline solution is used in both the primary trial and the secondary trial ",
        "statement_nums": [
            "used in both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 2: Saline Tissue Expansion Saline Tissue Expansion inflated by needle injections of saline Saline Tissue Expansion: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline  "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "INTERVENTION 1: MAESTRO Baseline INTERVENTION 1: AeroForm Tissue Expansion AeroForm Tissue"
        ]
    },
    {
        "id": "470611af-16b2-4094-ae2a-c9c6155e2672",
        "primaryId": "NCT02122796",
        "secondaryId": "NCT01575522",
        "statement_text": "The intervention section for the primary trial does not detail the type or duration of the intervention  unlike the secondary trial ",
        "statement_nums": [
            "intervention  unlike the secondary trial",
            "intervention section for the primary trial does not detail the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Patients Undergoing Mastectomy Surgery Number of individuals having mastectomy surgery who were approached for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO "
        ],
        "premise_nums": [
            "PTEN loss  and PI3K mutation analysis by FISH and IHC",
            "collection at baseline and periodically during study for c-Met",
            "receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "for participation in the trial INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21"
        ]
    },
    {
        "id": "f3a03aec-194d-4538-9be3-cea8281d995c",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 3 different Adverse Events  ",
        "statement_nums": [
            "the primary trial recorded less than 3 different Adverse Events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31"
        ]
    },
    {
        "id": "14a5e557-b223-4649-9867-0ff0e9001f5e",
        "primaryId": "NCT00911898",
        "secondaryId": "NCT02352779",
        "statement_text": "the primary trial and the secondary trial do not explain their interventions in the intervention section ",
        "statement_nums": [
            "the primary trial and the secondary trial do not explain their"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: MM-111 All participants INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies "
        ],
        "premise_nums": [
            "1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo",
            "Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty",
            "INTERVENTION 1: MM-111 All participants INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty",
            "BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO"
        ]
    },
    {
        "id": "c8df3461-4063-4fb0-ae48-f57062eb0a68",
        "primaryId": "NCT03329937",
        "statement_text": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 3 cycles  after which all participants undergo neoadjuvant chemotherapy ",
        "statement_nums": [
            "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle  for 3 cycles",
            "once daily for a 28 day cycle  for 3 cycles  after which all participants undergo neoadjuvant chemotherapy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles  participants either underwent surgery  received additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy  at physician's discretion  A breast magnetic resonance imaging (MRI) was performed at the end of cycle 2 and breast ultrasounds were performed at the end of each cycle  including any additional cycles beyond cycle 2. After completion of all neoadjuvant therapy participants proceeded to surgery  at which time pathological complete response (pCR) was assessed  "
        ],
        "premise_nums": [
            "including any additional cycles beyond cycle 2. After completion of all neoadjuvant",
            "additional cycles of niraparib (maximum of 6 cycles total)  or received neoadjuvant chemotherapy",
            "the end of cycle 2 and breast ultrasounds were performed at the end of cycle 2 and breast ultrasounds were performed",
            "Niraparib 200 mg Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles  After 2 cycles",
            "performed at the end of cycle 2 and breast ultrasounds were performed at the"
        ]
    },
    {
        "id": "1cd7cf90-bf66-480b-9227-2f7d2eccd647",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments ",
        "statement_nums": [
            "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Topical Saline Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). INTERVENTION 2: ",
            "Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)Participants received eribulin mesilate 1.6 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). "
        ],
        "premise_nums": [
            "not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid",
            "not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate",
            "(Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously",
            "a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). INTERVENTION 2:",
            "not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulintravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets",
            "Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle",
            "orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as"
        ]
    },
    {
        "id": "15f9d033-ebf7-44b3-94e2-3b8ee90b862b",
        "primaryId": "NCT00370552",
        "statement_text": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial ",
        "statement_nums": [
            "or Complete Response (CR) between the 2 cohorts of the primary trial",
            "There over 20% difference in the Percentage of Participants"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions  Time frame: Baseline visit and then every 8 weeks to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity  Bevacizumab  10 mg/kg  administered after ixabepilone as IV infusion every 2 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity  ",
            "Overall Number of Participants Analyzed: 46Measure Type: Number Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone  40 mg/m^2 + Bevacizumab  15 mg/kg Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab  15 mg/kg  administered after ixabepilone as IV infusion every 3 weeks  Bevacizumab to be infused over 90 minutes for the first dose  and if well tolerated for 60 minutes  for the second dose  Then if still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was to be dosed until disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6) "
        ],
        "premise_nums": [
            "Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered",
            "still tolerated  over 30 minutes for subsequent infusions  Bevacizumab was",
            "to be infused over 90 minutes for the first dose  and 15 of a 28-day cycle until disease progression or unacceptable",
            "Number of Participants Analyzed: 46Measure Type: Number Unit of Measure: Percentage of participants 71.1 (55.7 to 83.6)",
            "1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable",
            "months  then every 3 months until disease progression Results 1: Arm/Group Description: Ixabepilone  40 mg/m^2, administered as a 3-hour IV",
            "evidence of target lesions; PR=At least 30% reduction in the sum of the",
            "90 minutes for the first dose  and if well tolerated for 60 minutes  for the second",
            "Bevacizumab to be infused over 90 minutes for the first dose reduction to 32 mg/m^2 implemented for all subsequent cycles  Bevacizumab",
            "mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 3-hour IV infusion on Day 1 of",
            "IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2",
            "While On-study CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of",
            "to be infused over 90 minutes for the first dose  and then every 8 weeks to 12 months  then every 3",
            "mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable",
            "Number of Participants Analyzed: 45 Measure Type: Number Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone",
            "progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 + Bevacizumab  10 mg/kg Arm/Group Description: Ixabepilone,16 mg/m^2, administered",
            "progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of",
            "to 12 months  then every 3 months until disease progression Results 1: Arm/Group Title: Ixabepilone  16",
            "Percentage of participants 47.8 (32.9 to 63.1) Results 2: Arm/Group Title: Ixabepilone  16 mg/m^2 + Bevacizumab  10 mg/kg",
            "Overall Number of Participants Analyzed: 46Measure Type: Number Unit of Measure:"
        ]
    },
    {
        "id": "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome ",
        "statement_nums": [
            "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) NAUSEA 0/98 (0.00%) "
        ],
        "premise_nums": [
            "ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%)",
            "TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%)",
            "FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%)"
        ]
    },
    {
        "id": "51cf1333-78b1-410a-82fe-aabfaa00a840",
        "primaryId": "NCT02995980",
        "statement_text": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial ",
        "statement_nums": [
            "patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category",
            "be eligilbe for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  Exclusion Criteria: History of iodinated contrast allergy "
        ],
        "premise_nums": [
            "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category",
            "History of iodinated contrast allergy"
        ]
    },
    {
        "id": "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d",
        "primaryId": "NCT00662025",
        "statement_text": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions ",
        "statement_nums": [
            "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Objective Response Based on Data Review Committee's Assessment Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST  Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE ",
            "Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity  and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance  Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study Overall Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants Total Number of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19 "
        ],
        "premise_nums": [
            "at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was administered orally",
            "defined as disappearance of all target and non-target lesions  PR is defined as 30% decrease in sum of the",
            "daily dosing schedule in 21-day cycles  Capecitabine was administered orally from Day 1 at the starting dose of 37.5 mg/day",
            "1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles  Capecitabine was",
            "those that persist on repeat evaluation 4 weeks after initial documentation of response",
            "of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR): 19",
            "of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8. Results 1: Arm/Group Title: SUNITINIB+CAPECITABINE",
            "administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for",
            "lesions  PR is defined as 30% decrease in sum of the longest",
            "Number of Participants Analyzed: 63 Measure Type: Number Unit of Measure: participants",
            "Evaluation Criteria in Solid Tumors version 1.0 (RECIST)  CR is",
            "Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of",
            "2, every 6 weeks after Cycle 2, and at the end of Participants with CR+PR: 19 Complete Response (CR): 0 Partial Response (PR):"
        ]
    },
    {
        "id": "aef2367d-78a5-4dc7-a6f7-d96415082362",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "case of Cardiopulmonary failure in cohort 2 of the secondary trial  but none in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure",
            "(0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%)",
            "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute"
        ]
    },
    {
        "id": "29ae75a2-d8d2-4427-bba3-ab2c411d5718",
        "primaryId": "NCT00201851",
        "statement_text": "There were no cases of Oesophageal spasming  Diastolic dysfunction or thrombosis observed in the primary trial ",
        "statement_nums": [
            "thrombosis observed in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer *0/244 (0.00%) Nosocomial pneumonia *0/244 (0.00%) Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Endocervical cancer *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/244 (0.00%) Pregnancy *0/244 (0.00%) Endocervical cancer",
            "Venous thrombosis *0/244 (0.00%) Adverse Events 2: Total: 5/255 (1.96%) Pregnancy *1/255 (0.39%) Nosocomial pneumonia *2/255 (0.78%) Venous thrombosis *1/255 (0.39%)"
        ]
    },
    {
        "id": "985c4cb3-2684-4a67-a479-998602044a0d",
        "primaryId": "NCT00475670",
        "statement_text": "compared to cohort 1 of the primary trial  other than sudden death  there are more cases of every observed adverse event in cohort 2.",
        "statement_nums": [
            "compared to cohort 1 of the primary trial  other than sudden",
            "every observed adverse event in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden Death * 1/41 (2.44%) Bacterial Infection * 1/41 (2.44%) Bronchitis * 1/41 (2.44%) Sepsis * 1/41 (2.44%) Lymphoedema * 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%)",
            "Lymphoedema * 0/3 (0.00%) Adverse Events 2: Total: 6/41 (14.63%) Febrile Neutropenia * 1/41 (2.44%) Neutropenia * 1/41 (2.44%) Sudden"
        ]
    },
    {
        "id": "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3",
        "primaryId": "NCT00107276",
        "secondaryId": "NCT00232505",
        "statement_text": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event  and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events ",
        "statement_nums": [
            "the intervention in the primary trial had adverse events  in comparison almost 10% patients in cohort 1 of",
            "cohort 1 of the secondary trial experienced an adverse event  and less than a 1/3 of those in cohort",
            "and less than a 1/3 of those in cohort 2 of the intervention in the primary trial had adverse events",
            "10% patients in cohort 1 of the secondary trial experienced an adverse events  in comparison almost 10% patients in cohort 1 of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 2: Total: 8/25 (32.00%)",
            "Adverse Events 1: Total: 4/95 (4.21%) Adverse Events 1: Total: 3/31 (9.68%) Adverse Events 2: Total: 8/25 (32.00%)"
        ]
    },
    {
        "id": "d695120e-db68-481d-9023-881e48654e29",
        "primaryId": "NCT00617539",
        "statement_text": "Patients with Extracranial metastases are still permited to enter in the primary trial ",
        "statement_nums": [
            "to enter in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain Extracranial metastases allowed "
        ],
        "premise_nums": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast"
        ]
    },
    {
        "id": "5319ac1a-07ae-4531-bf93-5fce83016c87",
        "primaryId": "NCT00941330",
        "statement_text": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan ",
        "statement_nums": [
            "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: A: Exemestane ARM A: Patients will be treated with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B: Docetaxel and Cytoxan ARM B: Patients will be treated with docetaxel and cytoxan  Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  "
        ],
        "premise_nums": [
            "with exemestane  Exemestane: 25 mg daily by mouth for 6 to 12 months  INTERVENTION 2: B:",
            "mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks)  Cytoxan: Cytoxan (600"
        ]
    },
    {
        "id": "087aba29-40c6-4453-a44b-e63c3867e5b4",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "A 75 year old female patient  with an ECOG of 3 and an estimated life expectancy of more",
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months"
        ]
    },
    {
        "id": "c679f426-b235-4ae9-ad6c-4f1a46a494d2",
        "primaryId": "NCT01390064",
        "secondaryId": "NCT00485953",
        "statement_text": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration ",
        "statement_nums": [
            "All Cohorts of the primary trial and the secondary trial receive their treatment via"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Initial Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly "
        ],
        "premise_nums": [
            "51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300",
            "(SC) injection following the schedule INTERVENTION 2: Escalation Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300",
            "of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms Vaccination",
            "Cohort Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51",
            "Subcutaneous administration of 5 doses of 500 micrograms Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms Vaccination",
            "(SC) injection following the schedule INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication"
        ]
    },
    {
        "id": "122b1aef-4506-464d-9852-47caa508b047",
        "primaryId": "NCT00879086",
        "statement_text": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia  but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial had the same number",
            "anaemia and Neutropenia  but Cohort 1 had 8 more cases of Leukopenia than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50 (0.00%) Neutropenia 1/50 (2.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Anaemia 1/51 (1.96%) Leukopenia 1/51 (1.96%) Neutropenia 1/51 (1.96%) Adverse Events 2: Anaemia 1/50 (2.00%) Leukopenia 0/50"
        ]
    },
    {
        "id": "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d",
        "primaryId": "NCT00841828",
        "secondaryId": "NCT01959490",
        "statement_text": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial ",
        "statement_nums": [
            "All cohorts in the primary trial had lower number of",
            "participants with pCR compared to cohort 1 of the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response  According to the Miller&Payne Criteria  pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC -greater than D + Lapatinib Arm/Group Description: EC -greater than D + Lapatinib Drugs plus Biological Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm 2: EC -greater than D + Trastuzumab Arm/Group Description: EC -greater than D + Trastuzumab ",
            "Drug plus BiologicalEpirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + Trastuzumab each 21 days for 4 cycles Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2 Positive) ",
            "Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  docetaxel IV  and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T (HER2 Positive) Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes  Docetaxel IV  and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0% "
        ],
        "premise_nums": [
            "to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last docetaxel dose the surgery was",
            "Measure: percentage of participants with pCR 23.5 (11.9 to 35.1) Results 2: Arm/Group Title: Arm",
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 6 100.0%",
            "days for 4 cycles) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: percentage",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in",
            "8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "Measure: percentage of participants with pCR 47.9 (33.8 to 62.0) Outcome Measurement: Number of Patients",
            "Number of Participants Analyzed: 6 Measure Type: Count of Participants Unit of Measure: Participants 4 80.0% Results 2: Arm/Group Title: Cohort 1T",
            "by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes",
            "patients is a grade 5-D. Time frame: Up to 16 weeks Results 1: Arm/Group Title: Arm 1: EC",
            "to the Miller&Payne Criteria (G5-A and G5-D). Within 3-4 weeks after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression",
            "chemotherapy  Time frame: Up to 30 days after last cycle of treatment Results 1: Arm/Group Title: Cohort 1P (HER2",
            "run-in Pertuzumab treatment of 840 mg IV over 60 minutes on days for 4 cycles) Overall Number of Participants Analyzed: 51",
            "in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D. Time frame: Up to 16 weeks",
            "than Docetaxel (D) + Trastuzumab each 21 days for 4 cycles Overall Number of Participants Analyzed: 48",
            "840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes",
            "+ Cyclophosphamide (EC) each 21 days for 4 cycles -greater than Docetaxel (D) + lapatinib each 21 days for 4 cycles) Overall",
            "run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on days for 4 cycles) Overall Number of Participants Analyzed: 51",
            "by genomically-derived molecular subtypes (HER2 positive or HER2 negative  pCR is",
            "treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV",
            "progression or unacceptable toxicity Overall Number of Participants Analyzed: 5 Measure Type: Count of Participants Unit of"
        ]
    },
    {
        "id": "9f7dc38b-1945-4035-a0ff-e08ead55145b",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "statement_text": "Patients who completed a trastuzumab regiment  to treat the current breast cancer greater than 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "the current breast cancer greater than 2 weeks before study entry are eligible for the primary trial but excluded from the",
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer "
        ],
        "premise_nums": [
            "therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any"
        ]
    },
    {
        "id": "b259774e-410a-49aa-b5d4-31b8d9505fc3",
        "primaryId": "NCT01525589",
        "statement_text": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial ",
        "statement_nums": [
            "variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1) "
        ],
        "premise_nums": [
            "deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)"
        ]
    },
    {
        "id": "e09a11e4-afc8-4351-a5bc-d847424c79ce",
        "primaryId": "NCT01565499",
        "secondaryId": "NCT01234402",
        "statement_text": "Some of the patients in the primary trial were recorded as having heart related adverse events  whereas many patients in the secondary trial experienced several different breathing related issues ",
        "statement_nums": [
            "many patients in the secondary trial experienced several different breathing"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1: Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%) ",
            "Anaemia 2/49 (4.08%)Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) "
        ],
        "premise_nums": [
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%)",
            "Adverse Events 1: Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%)",
            "(0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 1/52 (1.92%) Abdominal pain 0/52 (0.00%) Ascites 3/52 (5.77%)",
            "ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "(4.08%)Pancytopenia 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49",
            "(0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%)",
            "Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49",
            "Total: 20/52 (38.46%) Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52",
            "Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52 (1.92%) Palpitations 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure",
            "Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1:",
            "(0.00%) Palpitations 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%)",
            "Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Atrial fibrillation 0/52 (0.00%) Cardiac failure 1/52 (1.92%) Cardiogenic shock 1/52",
            "Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Local Infection Reservoir Area 1/81 (1.23%) Adverse Events 1:",
            "Total: 6/81 (7.41%) Colitis [1]1/81 (1.23%) Multiple Sclerosis Relapse 1/81 (1.23%) Neurotoxicity [2]2/81 (2.47%) Community-acquired pneumonia 1/81 (1.23%) Local Infection Reservoir",
            "(1.92%) Palpitations 0/52 (0.00%) Pericardial effusion 0/52 (0.00%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Ascites 0/49 (0.00%)",
            "effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Abdominal pain 1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%)",
            "1/49 (2.04%) Pericardial effusion 4/49 (8.16%) Right ventricular failure 0/49 (0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac",
            "Anaemia 0/52 (0.00%) Pancytopenia 1/52 (1.92%) Acute myocardial infarction 0/52 (0.00%) Ascites 3/52 (5.77%) Adverse Events 2: Total: 25/49 (51.02%)",
            "(0.00%) Acute myocardial infarction 1/49 (2.04%) Atrial fibrillation 1/49 (2.04%) Cardiac failure 0/49 (0.00%) Cardiogenic shock 0/49 (0.00%) Palpitations 1/49 (2.04%)"
        ]
    },
    {
        "id": "d22f01f0-b2be-45b9-8996-11727750b91e",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "statement_text": "the primary trial participants receive more anastrozole  Fulvestrant and exemestane than patients in the secondary trial ",
        "statement_nums": [
            "than patients in the secondary trial",
            "the primary trial participants receive more anastrozole"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive",
            "fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28",
            "mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in",
            "or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression",
            "16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib",
            "Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days"
        ]
    },
    {
        "id": "893d5684-03f8-4acd-86e4-6d38eea3ce16",
        "primaryId": "NCT00129935",
        "statement_text": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "statement_nums": [
            "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669 (0.00%) CNS cerebrovascular ischemia * [3]0/669 (0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) ",
            "CNS cerebrovascular ischemia * [3]1/715 (0.14%)Heart Failure * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%) "
        ],
        "premise_nums": [
            "[1]0/715 (0.00%) Hemoglobin * [2]1/715 (0.14%) CNS cerebrovascular ischemia * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%)",
            "Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes * [1]0/715 (0.00%) Hemoglobin * [1]0/715 (0.00%) Hemoglobin",
            "(0.00%) Heart Failure * [1]3/669 (0.45%) Thrombosis/embolism * [1]1/669 (0.15%) Thrombosis/embolism * [3]0/669 (0.00%) Adverse Events 2: Total: 138/715 (19.30%) Leukocytes *",
            "CNS cerebrovascular ischemia * [3]1/715 (0.14%)Heart Failure * [1]1/715 (0.14%) Thrombosis/embolism * [1]3/715 (0.42%) Thrombosis/embolism * [3]2/715 (0.28%)",
            "111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin * [2]0/669 (0.00%) CNS cerebrovascular ischemia * [1]0/669",
            "Adverse Events 1: Total: 111/669 (16.59%) Leukocytes * [1]1/669 (0.15%) Hemoglobin * [1]1/669 (0.15%) Hemoglobin"
        ]
    },
    {
        "id": "4b46164d-a4c2-4738-be36-588ab231ceb1",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "statement_text": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts ",
        "statement_nums": [
            "or Fever in the primary trial and the secondary trial cohorts",
            "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) Hypoxia 1/110 (0.91%) "
        ],
        "premise_nums": [
            "(0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110",
            "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110",
            "(0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)",
            "(0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)",
            "Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)"
        ]
    },
    {
        "id": "d9236874-7f3d-4402-9699-2889db9f5c61",
        "primaryId": "NCT00320541",
        "statement_text": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Leukopenia 1/94 (1.06%) Adverse Events 2: Leukopenia 3/93 (3.23%)"
        ]
    },
    {
        "id": "e33825f1-45df-41f5-ba07-e9059636a146",
        "primaryId": "NCT00057941",
        "secondaryId": "NCT01806259",
        "statement_text": "DLT occurence  used as the outcome measurement in the secondary trial and Clinical Benefit Rate  used in the primary trial are not synonymous  and represent entirely different patient characteristics ",
        "statement_nums": [
            "outcome measurement in the secondary trial and Clinical Benefit Rate",
            "used in the primary trial are not synonymous"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate Clinical benefit = complete response (CR)  partial response (PR)  or stable disease (SD) lasting for at least 6 months  assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions  PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions  with non-progressive disease in non-target lesions  SD= sum of the longest diameters of target lesions decrease smaller than 30% or increase smaller than 20%, with non-progressive disease in non-target lesions  141 eligible  treated patients were included  Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2 years  every 6 months between 2-3 years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause  whichever came first  assessed up to 5 years) Time frame: 5 years "
        ],
        "premise_nums": [
            "years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years  every 6 months between 2-3 years,no specific requirements after",
            "2 years for the primary analysis + 3 additional years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years",
            "Time frame: assessed every 3 cycles while on treatment  assessed every 6 months between 2-3 years,no specific requirements after 3 years",
            "PR= disappearance of or at least 30% decrease in the sum of the",
            "or stable disease (SD) lasting for at least 6 months  assessed per Response",
            "came first  assessed up to 5 years) Time frame: 5 years,no specific requirements after 3 years Outcome Measurement: Recurrence-free Survival 2 years",
            "included  Time frame: assessed every 3 cycles while on treatment  assessed every 3 months when follow up smaller than 2",
            "2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization",
            "in non-target lesions  141 eligible  treated patients were included  Time frame: assessed every 3 cycles while on treatment",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "5b0295e1-a322-40af-9acf-9cc1d55d3e64",
        "primaryId": "NCT00295620",
        "secondaryId": "NCT03366428",
        "statement_text": "the secondary trial and the primary trial use similar outcome measures  evaluating how long patients survive after treatment ",
        "statement_nums": [
            "the secondary trial and the primary trial use similar outcome measures"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Disease-free Survival After Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival  Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer "
        ],
        "premise_nums": [
            "Prolonged Endocrine Treatment To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after",
            "QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer"
        ]
    },
    {
        "id": "3658f2f7-a497-4abb-badb-c877036456f2",
        "primaryId": "NCT00077857",
        "statement_text": "Patients must be older than 18, female  have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial ",
        "statement_nums": [
            "Patients must be older than 18, female  have three or more",
            "must be older than 18, female  have three or more target lesions and more than 1 regiment of chemotherapy to participate"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2 regimens of chemotherapy for advanced/metastatic disease  "
        ],
        "premise_nums": [
            "Criteria: women greater than or equal 18 years of age; greater than or equal 1 target lesion; greater than or equal 2"
        ]
    },
    {
        "id": "37bc71d5-d9c0-4174-8da5-725d2d53a91b",
        "primaryId": "NCT00303108",
        "statement_text": "The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve  produced marginally better results than the other cohort ",
        "statement_nums": [
            "Taxane Na‚àö√òve  produced marginally better results than the",
            "The Cohort of the primary trial which received D+C and"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity  whichever came first  assessed up to 54 months  Results 1: Arm/Group Title: D+C and Taxane Naive Arm/Group Description: Doxil  Carboplatin and Taxane naive Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) Results 2: Arm/Group Title: D+C and Taxane Pretreated Arm/Group Description: Doxil  Carboplatin and Taxane pretreated Overall Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1)",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) Results 2: Arm/Group Title: D+C",
            "came first  assessed up to 54 months  Results 1: Arm/Group",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c",
        "primaryId": "NCT02781051",
        "secondaryId": "NCT01067976",
        "statement_text": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit  no physical activity is explicitly required for the secondary trial ",
        "statement_nums": [
            "explicitly required for the secondary trial requires participants to exercise for 12 weeks while wearing a fitbit"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  INTERVENTION 1: CMRM vs UMRM [Not Specified] "
        ],
        "premise_nums": [
            "Active Living counseling program consists of 12 weekly group educational sessions  These sessions",
            "a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects"
        ]
    },
    {
        "id": "8bcc9fa3-0317-471a-a5b5-b115b5b72dea",
        "primaryId": "NCT01302379",
        "statement_text": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.",
        "statement_nums": [
            "patient cohorts of the primary trial had a median Insulin"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Insulin Insulin measured as percent change from baseline Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle Intervention Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -21.8 (-29.7 to -13.0) Results 2: Arm/Group Title: Placebo + Lifestyle Intervention Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent change from baseline -17.7 (-25.9 to -8.6) "
        ],
        "premise_nums": [
            "dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500",
            "dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1",
            "for weight loss  Overall Number of Participants Analyzed: 83 Least Squares Mean (95% Confidence Interval) Unit of Measure: percent",
            "at dinner time Weeks 2-4: 2 pills at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500",
            "dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1",
            "Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning;",
            "500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner",
            "Time frame: change from baseline to 6 months Results 1: Arm/Group Title: Metformin + Lifestyle"
        ]
    },
    {
        "id": "52610141-321d-4e3d-8660-ebc14b9f1696",
        "primaryId": "NCT00082433",
        "statement_text": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine  triples patient OS  compared to Capecitabine alone ",
        "statement_nums": [
            "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) Overall survival was defined as the time in months from randomization until the date of death  For those patients who had not died  survival duration was censored at the last date the patient was known to be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method  Time frame: from date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine ",
            "Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2:",
            "date of randomization until death Results 1: Arm/Group Title: Ixabepilone + Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14",
            "Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine",
            "days  followed by 1 week of rest  Overall Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of",
            "a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall Number of",
            "Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine",
            "twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number",
            "cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days  followed",
            "Number of Participants Analyzed: 609 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02)",
            "be alive  Median OS with 95% CI estimated using the Kaplan-Meier Product",
            "a day (BID) (2000 mg/m2 daily dose) x 14 days  followed by 1 week of rest Overall Number of Participants",
            "Outcome Measurement: Overall Survival (OS) Overall survival was censored at the last date the patient was known",
            "Number of Participants Analyzed: 612 Median (95% Confidence Interval) Unit of Measure: months 15.64 (13.86 to 17.02)",
            "of Measure: months 16.39 (14.95 to 17.91) Results 2: Arm/Group Title: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14",
            "Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days  followed by 1 week of rest  Overall",
            "3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral capecitabine 1000 mg/m2 twice a day (BID)",
            "capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only  plus oral"
        ]
    },
    {
        "id": "90203158-6477-4486-b8d9-09dcaca63617",
        "primaryId": "NCT00570921",
        "secondaryId": "NCT00274456",
        "statement_text": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in cohort 1 of the primary trial ",
        "statement_nums": [
            "cohort 1 of the primary trial",
            "case of Cardiopulmonary failure in cohort 1 of the secondary trial  but none in"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute Cholecystitis * 1/33 (3.03%) Renal Failure * 1/33 (3.03%) Pneumonia * 1/33 (3.03%) Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) "
        ],
        "premise_nums": [
            "neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy",
            "(0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%)",
            "Adverse Events 1: Total: 5/33 (15.15%) Left Ventricular Thrombus * 1/33 (3.03%) Nausea * 1/33 (3.03%) Acute"
        ]
    },
    {
        "id": "03334f23-49ab-47e5-b420-a6753ce6e832",
        "primaryId": "NCT00574587",
        "secondaryId": "NCT00777049",
        "statement_text": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial ",
        "statement_nums": [
            "Myocardial ischaemia in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) ",
            "Vomiting 1/32 (3.13%)Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) Fatigue 0/20 (0.00%) "
        ],
        "premise_nums": [
            "pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23",
            "(3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32",
            "Adverse Events 1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "(0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive",
            "Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20",
            "fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%)",
            "Vomiting 1/32 (3.13%)Fatigue 1/32 (3.13%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive",
            "Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%)Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20",
            "Myocardial ischaemia 1/32 (3.13%) Abdominal discomfort 0/32 (0.00%) Ascites 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive",
            "(3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%)Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20",
            "Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20 (5.00%) Ascites 0/20 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse",
            "(3.13%) Constipation 0/32 (0.00%) Rectal haemorrhage 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive",
            "fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32 (3.13%)Fatigue 1/32 (3.13%) Adverse Events 2: Total: 8/20 (40.00%) Anaemia 1/20",
            "2/23 (8.70%) cardiac tamponade 0/23 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1:",
            "tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade",
            "Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32",
            "pulmonary emobolism 0/3 (0.00%) Adverse Events 2: Total: 2/23 (8.70%) cardiac tamponade 0/3 (0.00%) congestive heart failure 0/3 (0.00%) pulmonary emobolism 0/3",
            "(0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32",
            "1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure congestive 0/20 (0.00%) Myocardial ischaemia 0/20 (0.00%) Abdominal discomfort 1/20",
            "Adverse Events 1: Total: 12/32 (37.50%) Anaemia 0/32 (0.00%) Neutropenia 1/32 (3.13%) Thrombocytopenia 4/32 (12.50%) Atrial fibrillation 1/32 (3.13%) Cardiac",
            "1: Total: 0/3 (0.00%) cardiac tamponade 0/3 (0.00%) congestive heart failure 1/23 (4.35%) pulmonary emobolism 1/23 (4.35%) Adverse Events 1:",
            "Anaemia 1/20 (5.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 1/32 (3.13%) Cardiac failure congestive 1/32 (3.13%) Myocardial ischaemia 1/32",
            "(0.00%) Constipation 2/20 (10.00%) Rectal haemorrhage 0/20 (0.00%) Vomiting 0/20 (0.00%) Thrombocytopenia 1/20 (5.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive"
        ]
    },
    {
        "id": "a847cfc1-9556-4a55-9698-69c22696148f",
        "primaryId": "NCT02370238",
        "statement_text": "There were 2 cases of Angina in the primary trial ",
        "statement_nums": [
            "There were 2 cases of Angina in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%) ",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%) "
        ],
        "premise_nums": [
            "0/60 (0.00%) General physical health deterioration 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%)",
            "Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61",
            "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2:",
            "neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%)",
            "(20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%)",
            "0/60 (0.00%) General physical health deterioration 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%)",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%)",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) General physical health deterioration 1/60 (1.67%)",
            "Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General",
            "(21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%)",
            "(0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/60 (1.67%)",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%)",
            "chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60",
            "failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2:",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60"
        ]
    },
    {
        "id": "fcbb7e0f-d106-44bd-a252-9b57adc6f071",
        "primaryId": "NCT01075100",
        "statement_text": "No mental health issues were observed in the primary trial ",
        "statement_nums": [
            "were observed in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) ",
            "DEHYDRATION 0/53 (0.00%)DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) "
        ],
        "premise_nums": [
            "DEHYDRATION 0/53 (0.00%)DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53",
            "NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53",
            "(0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%)",
            "NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48",
            "(2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48",
            "BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%)DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53",
            "Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%)",
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53"
        ]
    },
    {
        "id": "f82d94fe-c633-4bae-b28d-074196a08577",
        "primaryId": "NCT03584009",
        "statement_text": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib ",
        "statement_nums": [
            "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a",
            "participants who were administered an additional 160 mg of Neratinib"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Defined as Complete Response (CR)  Partial Response (PR) or Stable Disease (SD) Lasting greater than or equal 24 Weeks  as Determined by the Investigator According to RECIST v1.1 Clinical Benefit was defined as CR  PR  or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline  as determined by the investigator according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or MRI: CR  Disappearance of all target lesions; PR  PR greater than or equal 30% decrease in the sum of diameters of target lesions (TL) taking as reference the baseline sum of diameters; SD  neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Disease Progression (PD)  PDgreater than or equal 20% increase in the sum of diameters of TL taking as reference the smallest sum on study(Nadir)  In addition to the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm. ",
            "Time frame: Randomization through till 6 months after the last participant is enrolled into the study (up to approximately 23 months)Results 1: Arm/Group Title: Venetoclax + Fulvestrant Arm/Group Description: Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days)  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 11.8 (4.44 to 23.87) Results 2: Arm/Group Title: Fulvestrant Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days)  Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 13.7 (5.70 to 26.26) "
        ],
        "premise_nums": [
            "addition to the relative increase of 20% sum must have demonstrate an absolute",
            "(PD)  PDgreater than or equal 20% increase in the sum of diameters",
            "Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent",
            "PR greater than or equal 30% decrease in the sum of diameters",
            "Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 11.8 (4.44 to 23.87) Results 2: Arm/Group Title: Fulvestrant",
            "the relative increase of 20% sum must have demonstrate an absolute increase of at least 5mm.",
            "(RECIST) v1.1. Per RECIST v1.1 for target lesions assessed by CT or",
            "Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: Percentage of Participants 13.7 (5.70 to 26.26)",
            "PR  or SD lasting more than equal to 24 weeks from randomization in participants with measurable",
            "6 months after the last participant is enrolled into the study (up to approximately 23 months)Results 1: Arm/Group Title: Venetoclax",
            "15 of Cycle 1 and Day 1 of subsequent cycles (Cycle lengthe relative increase of 20% sum must have demonstrate an absolute",
            "Investigator According to RECIST v1.1 Clinical Benefit was defined as CR  Disappearance of all target lesions; PR  PR",
            "Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent"
        ]
    },
    {
        "id": "e5379a89-f880-44c1-bee0-a0d8ad2abfce",
        "primaryId": "NCT00659373",
        "secondaryId": "NCT02202252",
        "statement_text": "the primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in the intervention section ",
        "statement_nums": [
            "primary trial has a 5 year long intervention  the duration of the secondary trial is not specified in",
            "the primary trial has a 5 year long intervention  the duration of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  INTERVENTION 1: Single Drain Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla  ",
            "Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography INTERVENTION 2: Double Drain Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  Insertion of double drains: Two drains will be inserted into the axilla and below the lower flap in the double drains group  Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography  "
        ],
        "premise_nums": [
            "Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg",
            "20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function",
            "orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen",
            "parent study  IBCSG 24-02 (SOFT)  The sample size",
            "25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for",
            "will be examined by ultrasonography INTERVENTION 2: Double Drain Insertion of double"
        ]
    },
    {
        "id": "d811aaec-b3bd-4376-a9d6-d14eacae875a",
        "primaryId": "NCT00717886",
        "statement_text": "Prior axillary surgery  axillary radiation  breast cancer and breast radiation are not permitted for entry to the primary trial  patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria ",
        "statement_nums": [
            "for entry to the primary trial  patients with prior",
            "enter if they satisfy all other inclusion criteria"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy  clinical examination  or fine-needle aspiration who are scheduled to undergo an ALND  Females greater than 21 years of age Exclusion Criteria: Prior ipsilateral axillary surgery Prior ipsilateral axillary radiation Prior ipsilateral breast cancer Prior ipsilateral breast radiation Allergy to isosulfan blue dye History of ipsilateral upper extremity lymphedema Prior history of surgical excision of the upper outer quadrant of the ipsilateral breast Prior history of neoadjuvant chemotherapy for current breast cancer Bulky axillary disease at presentation (N2) "
        ],
        "premise_nums": [
            "an ALND  Females greater than 21 years of age Exclusion Criteria: Prior ipsilateral"
        ]
    },
    {
        "id": "b02c99f3-70bd-4404-8d80-c57c6dfef7b7",
        "primaryId": "NCT02049957",
        "secondaryId": "NCT01506609",
        "statement_text": "There is are the same total number of patients in the primary trial as in the secondary trial ",
        "statement_nums": [
            "of patients in the primary trial as in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) Vomiting 0/6 (0.00%) Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) Gastritis 0/6 (0.00%) Nausea 0/6 (0.00%) ",
            "Vomiting 0/6 (0.00%)Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) NEUTROPENIA 0/2 (0.00%) PANCYTOPENIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) ",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) PANCYTOPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) "
        ],
        "premise_nums": [
            "Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER",
            "Vomiting 0/6 (0.00%)Fatigue 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "health deterioration 0/6 (0.00%) Generalised oedema 0/6 (0.00%) Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2",
            "Hepatic failure [1]0/6 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%)",
            "Hepatic failure [1]0/6 (0.00%) Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%)",
            "(0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) General physical health deterioration 0/6 (0.00%) Generalised oedema 0/6",
            "(0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%)",
            "CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "(0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2 (0.00%) PERICARDIAL EFFUSION 0/2 (0.00%) TACHYCARDIA 0/2 (0.00%)",
            "Adverse Events 1: Total: 0/2 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%)",
            "PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Angina pectoris 0/6 (0.00%) Pericardial",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/1 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "(0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "(0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "FEBRILE NEUTROPENIA 0/1 (0.00%)LYMPHADENOPATHY 0/1 (0.00%) NEUTROPENIA 0/1 (0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%)",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) THROMBOCYTOPENIA 0/2 (0.00%) ATRIAL FIBRILLATION 0/2 (0.00%) CARDIAC TAMPONADE 0/2",
            "Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1 (0.00%) TACHYCARDIA 0/2 (0.00%) ABDOMINAL PAIN 0/2 (0.00%) ABDOMINAL PAIN UPPER",
            "1/6 (16.67%) Angina pectoris 0/6 (0.00%) Pericardial effusion 0/6 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "CARDIAC TAMPONADE 0/1 (0.00%) PERICARDIAL EFFUSION 0/1 (0.00%) TACHYCARDIA 0/1 (0.00%) THROMBOCYTOPENIA 0/1 (0.00%) ATRIAL FIBRILLATION 0/1 (0.00%) CARDIAC TAMPONADE 0/1",
            "(0.00%) ANAEMIA 0/2 (0.00%) FEBRILE NEUTROPENIA 0/2 (0.00%) LYMPHADENOPATHY 0/2 (0.00%) Diplopia 0/6 (0.00%) Abdominal pain 0/6 (0.00%) Colitis 0/6 (0.00%)",
            "(0.00%) TACHYCARDIA 0/1 (0.00%) ABDOMINAL PAIN 0/1 (0.00%) ABDOMINAL PAIN UPPER 0/2 (0.00%) Adverse Events 2: Total: 0/1 (0.00%) ANAEMIA 0/1"
        ]
    },
    {
        "id": "3cbf2726-ddb0-460c-9dd2-082b8dda495d",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did experience adverse events ",
        "statement_nums": [
            "of patients in cohorts 1 in the primary trial experienced adverse events  but more than 45% of patients cohort 2 did",
            "adverse events  but more than 45% of patients cohort 2 did experience adverse events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6 (0.00%) "
        ],
        "premise_nums": [
            "5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11",
            "(9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6 (0.00%)",
            "to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6",
            "5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6",
            "(0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11"
        ]
    },
    {
        "id": "e7741151-2b2c-4e78-a4df-fe998c580714",
        "primaryId": "NCT01912612",
        "secondaryId": "NCT02392611",
        "statement_text": "In the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the dose of cohort 1.",
        "statement_nums": [
            "the primary trial only 1 cohort is administered the intervention  whereas in the secondary trial both cohorts receive the",
            "In the primary trial only 1 cohort is administered the intervention  whereas",
            "whereas in the secondary trial both cohorts receive the intervention  but cohort 2 recieves more than double the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm 1 (Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days  then 60 mg duloxetine orally for 28 days  then 30 mg duloxetine orally x 14 days  INTERVENTION 2: Arm 2 (Patients Without Pain -- Control) Patient reported pain and symptoms assessment for comparison at baseline  INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD  INTERVENTION 2: Monotherapy: Alobresib 1.4 mg ",
            "Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy  or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD "
        ],
        "premise_nums": [
            "receive 30 mg duloxetine orally for 7 days  then 60 mg daily x 4 weeks  then 30 mg",
            "INTERVENTION 1: Monotherapy: Alobresib 0.6 mg Participants with advanced solid tumors and",
            "tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg daily x 4 weeks  then 30 mg",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD",
            "(Patients With Pain) Duloxetine 30 mg daily x 1 week  then 30 mg daily x 2 weeks  Duloxetine: Subjects will",
            "1 week  then 60 mg daily x 4 weeks  then 60 mg duloxetine orally for 28 days  then 30 mg",
            "alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to",
            "then 30 mg daily x 2 weeks  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days"
        ]
    },
    {
        "id": "8cff36b0-a022-4469-8d14-7120be891cb1",
        "primaryId": "NCT00376688",
        "statement_text": "Less than 1/10 the primary trial subjects experienced a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks ",
        "statement_nums": [
            "stable disease (SD) for at least 24 weeks",
            "Less than 1/10 the primary trial subjects experienced a complete"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Clinical Benefit Rate (Complete Response  Partial Response  or Stable Disease) Response evaluation criteria in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR)  partial response (PR)  or stable disease (SD) for at least 24 weeks  Evaluation of target lesions: Complete Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the LD of target lesions  taking as reference the baseline sum LD; Stable Disease (SD)-- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD  taking as reference the smallest sum LD since the treatment started; Evaluation of non-target lesions: Complete Response (CR)-- Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/ Stable Disease (SD)-- Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits Time frame: Up to 24 months Results 1: Arm/Group Title: Treatment (Temsirolimus) ",
            "Arm/Group Description: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Temsirolimus: Given IV Overall Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7 "
        ],
        "premise_nums": [
            "stable disease (SD) for at least 24 weeks  Evaluation of target",
            "normal limits Time frame: Up to 24 months Results 1: Arm/Group Title: Treatment (Temsirolimus)",
            "Number of Participants Analyzed: 31 Measure Type: Number Unit of Measure: percentage of participants 9.7",
            "in solid tumors (RECIST) criteria version 1.0 was used for response evaluation  Clinical",
            "Response (CR)-- Disappearance of all target lesions; Partial Response (PR)-- At least a 30% decrease in the sum of the",
            "receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of"
        ]
    },
    {
        "id": "4ce24508-3d12-499f-ab7f-4b437ea51366",
        "primaryId": "NCT00304096",
        "secondaryId": "NCT00876395",
        "statement_text": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial ",
        "statement_nums": [
            "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Body weight greater than 110 lbs (without clothes) Inclusion Criteria: Adult Women ( 18 years old)  Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease  Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease  HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive)  Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued greater than 12 months prior to randomization  Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization  Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment  Documentation of negative pregnancy test  Organ functions at time of inclusion  Exclusion Criteria: Prior mTOR inhibitors for the treatment of cancer  Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy  Patients with only non-measurable lesions other than bone metastasis (e.g  pleural effusion  ascites  etc)  ",
            "Radiotherapy to 25% of the bone marrow within 4 weeks prior to randomizationHistory of central nervous system metastasis  Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract  Serious peripheral neuropathy  Cardiac disease or dysfunction  Uncontrolled hypertension  HIV  Pregnant  "
        ],
        "premise_nums": [
            "Body weight greater than 110 lbs (without clothes) Inclusion Criteria: Adult Women ( 18 years old)  Histologically or cytologically confirmed",
            "of measurable disease  HER2+ patients by local laboratory testing (IHC",
            "Criteria: Adult Women ( 18 years old)  Histologically or cytologically confirmed invasive",
            "disease  Must have at least one lesion that can be",
            "Radiotherapy to 25% of the bone marrow within 4 weeks prior to randomizationHistory of central nervous",
            "but should be discontinued greater than 12 months prior to randomization  Prior treatment"
        ]
    },
    {
        "id": "2514da19-b30a-44bb-8853-4545e97295da",
        "primaryId": "NCT00633464",
        "statement_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group ",
        "statement_nums": [
            "mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator  CR: Disappearance of all evidence of target and non-target lesions  PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions  Confidence interval (CI) was Computed using Clopper-Pearson method  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2: ",
            "Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 35.9 (21.2 to 52.8) "
        ],
        "premise_nums": [
            "non-target lesions  PR: At least 30% reduction from baseline in the sum",
            "40 mg/m^2Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 + Ixabepilone 40 mg/m^2Arm/Group Description: cetuximab 400 mg/m^2 loading",
            "progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Arm/Group Description:",
            "Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40 Measure Type: Number Unit of Measure: percentage",
            "Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants",
            "1: Arm/Group Title: Ixabepilone 40 mg/m^2 Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40",
            "cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 40",
            "Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective",
            "cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 39",
            "progression (maximum participant objective response of 18.3 weeks) Results 1: Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants",
            "weekly + ixabepilone 40 mg/m^2 every 3 weeks Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage",
            "Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.0 (16.6 to 46.5) Results 2:"
        ]
    },
    {
        "id": "cb9f8a52-b88e-4b04-bb28-a0eabead1439",
        "primaryId": "NCT00728949",
        "statement_text": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case ",
        "statement_nums": [
            "6 adverse event categories for cohort 1 of the primary trial which recorded at least one case"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "(0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%)",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%)",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%)",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction"
        ]
    },
    {
        "id": "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c",
        "primaryId": "NCT02806544",
        "secondaryId": "NCT00605267",
        "statement_text": "A patient with stage 2B   pathologically confirmed estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "elgible for both the primary trial and the secondary trial",
            "A patient with stage 2B   pathologically confirmed estrogen receptor-positive breast"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Clinical locally advance breast cancer (Stage IIB or III) Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria: Medical history of chemotherapy or endocrine therapy for breast cancer  or with treatment history of radiotherapy  Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT)  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Clinical locally advance breast cancer (Stage",
            "Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive women  aged 20 years and over  with operable and",
            "or PR Allred Score greater than 4 Inclusion Criteria: Premenopausal  estrogen receptor positive"
        ]
    },
    {
        "id": "358a1d3c-9ccc-48fc-badc-1644e326c8cb",
        "primaryId": "NCT02301988",
        "secondaryId": "NCT00728949",
        "statement_text": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain ",
        "statement_nums": [
            "recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection 0/75 (0.00%) Pneumonia 1/75 (1.33%) ",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Constipation 0/56 (0.00%) Diarrhoea 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) ",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) "
        ],
        "premise_nums": [
            "(1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%)",
            "Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites 1/56 (1.79%)",
            "(2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%)",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37",
            "(1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pyrexia 1/75",
            "(1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Pyrexia 1/75 (1.33%) Chest pain 0/75 (0.00%) Complication associated with",
            "1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction",
            "(1.79%) Pain 0/56 (0.00%) Adverse Events 2: Total: 11/37 (29.73%) Pancytopenia 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain",
            "(0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%)",
            "Ascites 0/37 (0.00%)Constipation 1/37 (2.70%) Diarrhoea 1/37 (2.70%) Vomiting 2/37 (5.41%) Disease progression 2/37 (5.41%) Infusion related reaction",
            "(1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Vomiting 0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Complication associated with device 1/76 (1.32%) General physical health",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37 (0.00%)",
            "0/75 (0.00%) Complication associated with device 0/75 (0.00%) General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%)",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell anaemia with crisis",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Pericarditis 1/37 (2.70%) Abdominal pain 2/37 (5.41%) Anal fissure 0/37",
            "General physical health deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%)",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 10/76 (13.16%) Sickle cell anaemia with crisis",
            "Atypical pneumonia 0/75 (0.00%)Dehydration 0/75 (0.00%) Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56",
            "Adverse Events 1: Total: 16/56 (28.57%) Pancytopenia 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56 (1.79%) Ascites",
            "0/56 (0.00%) Disease progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Nausea 0/56 (0.00%) Oesophageal pain 0/56 (0.00%) Vomiting 0/56 (0.00%)",
            "progression 2/56 (3.57%) Infusion related reaction 1/56 (1.79%) Pain 0/56 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "deterioration 0/76 (0.00%) Device related infection 2/76 (2.63%) Pneumonia 1/76 (1.32%) General physical health deterioration 0/76 (0.00%) Device related infection",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) Pericarditis 0/56 (0.00%) Abdominal pain 1/56 (1.79%) Anal fissure 1/56",
            "(13.16%) Sickle cell anaemia with crisis 1/76 (1.32%) Diarrhoea 1/76 (1.32%) Pyrexia 1/76 (1.32%) Chest pain 1/76 (1.32%) Complication associated with",
            "progression 2/37 (5.41%) Infusion related reaction 0/37 (0.00%) Pain 1/37 (2.70%) Nausea 2/37 (5.41%) Oesophageal pain 1/37 (2.70%) Vomiting 2/37 (5.41%)",
            "(2.63%) Pneumonia 1/76 (1.32%) Atypical pneumonia 1/76 (1.32%) Dehydration 1/76 (1.32%) Adverse Events 2: Total: 3/75 (4.00%) Sickle cell",
            "(4.00%) Sickle cell anaemia with crisis 0/75 (0.00%) Diarrhoea 0/75 (0.00%) General physical health deterioration 1/75 (1.33%) Device related infection"
        ]
    },
    {
        "id": "60a86c87-7387-4eae-b5dd-6245f8bf541e",
        "primaryId": "NCT00045032",
        "secondaryId": "NCT00416572",
        "statement_text": "WOCBP that refuse to use contraception are excluded from the primary trial  but may be eligible for the secondary trial if they are a UK resident ",
        "statement_nums": [
            "are excluded from the primary trial  but may be",
            "be eligible for the secondary trial if they are a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures INCLUSION CRITERIA (Disease Characteristics): Diagnosis of breast cancer Stage I or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within 30 miles of Magee Women's Hospital  Pittsburgh  Pennsylvania INCLUSION CRITERIA (Patient Characteristics): Female patients only Must be able to communicate EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer PRIOR CONCURRENT THERAPY: See Disease Characteristics "
        ],
        "premise_nums": [
            "or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment",
            "First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within",
            "of childbearing potential or less than 1 year post-menopause unwilling to use adequate"
        ]
    },
    {
        "id": "bd3055c6-09aa-47f0-89ed-67ad3798a580",
        "primaryId": "NCT00090857",
        "statement_text": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry  if the results from this are more than 2 standard deviations below normal  they must be excluded ",
        "statement_nums": [
            "this are more than 2 standard deviations below normal  they must have a bone density scan 1 month prior to study entry",
            "results from this are more than 2 standard deviations below normal  they must"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Bone density scan within 2 standard deviations from normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the study physician "
        ],
        "premise_nums": [
            "normal within the past 30 days Bone density scan 2 standard deviations below normal allowed if approved by the"
        ]
    },
    {
        "id": "21d7d726-8557-459f-a307-fae3e08f45d8",
        "primaryId": "NCT00656019",
        "secondaryId": "NCT00328783",
        "statement_text": "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial ",
        "statement_nums": [
            "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "EXCLUSION CRITERIA: History of parathyroid disease  hypercalcemia  or kidney stones  Inclusion Criteria: Requiring adjuvant or post mastectomy radiation therapy with tangential fields or 3-fields Adequate pulmonary function Presence of 5 cc of the heart or liver with the simulation fields Karnofsky Performance Status (KPS) equal to or greater than 70 Exclusion Criteria: Pregnant women Patients who have had previous ipsilateral breast or thoracic radiation therapy "
        ],
        "premise_nums": [
            "(KPS) equal to or greater than 70 Exclusion Criteria: Pregnant women Patients who have",
            "pulmonary function Presence of 5 cc of the heart or liver with tangential fields or 3-fields Adequate pulmonary function Presence of 5"
        ]
    },
    {
        "id": "9a8157a9-82fc-4d7e-9254-295123459430",
        "primaryId": "NCT00054132",
        "statement_text": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above ",
        "statement_nums": [
            "had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above",
            "of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Level of EGFR Expression Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive: faint immunoreactivity (weak staining) intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics  Time frame: Up to 12 years Results 1: Arm/Group Title: Treatment (Erlotinib Hydrochloride  Bevacizumab) Arm/Group Description: Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants EGFR 0: 24 EGFR 1+: 8 EGFR 2+: 4 ",
            "EGFR 3+: 0Insufficient tumor tissue: 2 "
        ],
        "premise_nums": [
            "the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics  Time frame: Up to 12 years Results 1: Arm/Group Title:",
            "days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of",
            "characteristics  Time frame: Up to 12 years Results 1: Arm/Group Title: Treatment (Erlotinib Hydrochloride",
            "or unacceptable toxicity  Overall Number of Participants Analyzed: 38 Measure Type: Number Unit of Measure: participants",
            "on a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+",
            "Number Unit of Measure: participants EGFR 0: 24 EGFR 1+: 8 EGFR 3+: 0Insufficient tumor tissue: 2",
            "1. Courses repeat every 21 days in the absence of disease progression a scale  ranging from 0-3+ 0=negative (no immunoreactivity) 1+"
        ]
    },
    {
        "id": "ff37494d-2c61-4c06-86c1-d6bcfbe9e360",
        "primaryId": "NCT01856543",
        "secondaryId": "NCT00365599",
        "statement_text": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis ",
        "statement_nums": [
            "Across all cohorts of the secondary trial and the primary trial there was only a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%) ",
            "Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%)Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%) Sodium  serum-low (hyponatremia) [1]1/43 (2.33%) Thrombosis/thrombus/embolism [6]2/43 (4.65%) "
        ],
        "premise_nums": [
            "Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70",
            "Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70 (0.00%) Ventricular tachycardia 0/70 (0.00%) Skin infection 2/70",
            "2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73",
            "Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Skin infection 2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea",
            "Adverse Events 1: Total: 4/43 (9.30%) Hemoglobin [1]1/43 (2.33%) Hemorrhage/Bleeding [2]1/43 (2.33%)",
            "Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea",
            "2/70 (2.86%) Dermatitis radiation 1/70 (1.43%) Dyspnea 0/70 (0.00%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70",
            "(0.00%) Dyspnea 1/73 (1.37%) Adverse Events 2: Total: 3/70 (4.29%) Chest Pain - cardiac 0/70 (0.00%) Myocarditis 0/70 (0.00%) Pericarditis 0/70",
            "Skin infection 0/73 (0.00%) Dermatitis radiation 0/73 (0.00%) Dyspnea 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73",
            "Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73 (1.37%) Ventricular tachycardia 1/73 (1.37%) Skin infection 0/73",
            "(hyponatremia) [1]1/43 (2.33%) Thrombosis/thrombus/embolism [6]2/43 (4.65%)",
            "Adverse Events 1: Total: 3/73 (4.11%) Chest Pain - cardiac 1/73 (1.37%) Myocarditis 1/73 (1.37%) Pericarditis 1/73",
            "Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%)Platelets [4]1/43 (2.33%) Anorexia [5]1/43 (2.33%)"
        ]
    },
    {
        "id": "eb00b609-f17b-4595-87bd-d0843ec9e39a",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "statement_text": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does ",
        "statement_nums": [
            "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its",
            "its patients than the primary trial does"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: ",
            "Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  "
        ],
        "premise_nums": [
            "tablet of magnesium oxide orally (PO) daily (QD) Week 3: Patients take two 400 mg tablet of magnesium oxide",
            "The decision support workshop will be 2 hours in duration on the morning of",
            "answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: Low Dose Magnesium Oxide (800",
            "mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week",
            "tablet of magnesium oxide orally (PO) daily (QD) Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide",
            "daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week"
        ]
    },
    {
        "id": "8bc9ea31-b731-4799-a1cc-a5ba63da00c1",
        "primaryId": "NCT00904033",
        "secondaryId": "NCT03592121",
        "statement_text": "Patients are not required to be sexually active to receive the primary trial intervention  this is however a requirement for the secondary trial where the intervention must be applied during sexual activity ",
        "statement_nums": [
            "not required to be sexually active to receive the primary trial intervention  this is",
            "a requirement for the secondary trial where the intervention must"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity "
        ],
        "premise_nums": [
            "hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply",
            "Apply to both nipple/areola regions approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola",
            "Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity",
            "pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting"
        ]
    },
    {
        "id": "0864493d-9f64-49d1-a585-21be71704c59",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia ",
        "statement_nums": [
            "Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the",
            "125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia",
            "In the primary trial there was no recorded"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 "
        ],
        "premise_nums": [
            "Limiting Toxicities (DLT): Part 1 Phase 1"
        ]
    },
    {
        "id": "c49428a7-cc55-474e-a773-88ff2019de1b",
        "primaryId": "NCT02780713",
        "statement_text": "Both cohorts of the primary trial are administered the same doses of their respective drugs  ",
        "statement_nums": [
            "Both cohorts of the primary trial are administered the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment Period 2 Participants received AZD9496 - Reference (100 mg)  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Treatment Period 1 Participants received AZD9496 - Variant A (100 mg)  INTERVENTION 2: Treatment"
        ]
    },
    {
        "id": "78136809-c8de-4c40-9a7e-1d61d879ba27",
        "primaryId": "NCT00611624",
        "secondaryId": "NCT00600340",
        "statement_text": "the primary trial and the secondary trial administer their interventions at different frequencies ",
        "statement_nums": [
            "the primary trial and the secondary trial administer their interventions at"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Five Days of Mammosite Therapy [Not Specified] INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks "
        ],
        "premise_nums": [
            "3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks",
            "8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every",
            "4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15",
            "mg/m² twice-daily  days 1-14, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every",
            "intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every"
        ]
    },
    {
        "id": "b430ea52-fa55-4280-9e23-8a7392afca58",
        "primaryId": "NCT00009945",
        "statement_text": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Eligibility Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy  If any sentinel node is histologically positive by H & E  or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC)  then the patient must have a completion axillary dissection  "
        ],
        "premise_nums": [
            "any sentinel node is histologically positive by H &"
        ]
    },
    {
        "id": "adfeff22-7bdd-4868-ab6e-90dd43d9621d",
        "primaryId": "NCT00038103",
        "statement_text": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial ",
        "statement_nums": [
            "alone cohort of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Subjects With Clinical Benefit Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation  Includes subjects with complete response (CR)  partial response (PR)  and long term disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV) Results 1: Arm/Group Title: Exemestane (Exemestane Alone) Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants 24 Results 2: Arm/Group Title: Combination (Exemestane + Celecoxib) Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants 24 "
        ],
        "premise_nums": [
            "exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 51 Measure Type: Number Unit of Measure: participants",
            "16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last",
            "Baseline  Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter",
            "exemestane taken with food (25 mg tablet once daily) Overall Number of Participants Analyzed: 49 Measure Type: Number Unit of Measure: participants",
            "disease stabilization (SD) for at least 24 weeks  Time frame: Baseline  Week 8, 16, 24, and every 12 weeks",
            "weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)",
            "exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) Overall Number"
        ]
    },
    {
        "id": "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "statement_text": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials ",
        "statement_nums": [
            "events obeserved in the primary trial and the secondary trial is the several case"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) ",
            "Lymphoedema * 0/3 (0.00%)"
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN",
            "(1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%)",
            "(2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70",
            "PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH",
            "Lymphoedema * 0/3 (0.00%)",
            "NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%)",
            "GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%)"
        ]
    },
    {
        "id": "276f5523-f45b-45b0-ad30-b737f2c1b1d0",
        "primaryId": "NCT00468585",
        "statement_text": "the primary trial recorded several skin infections in their patients ",
        "statement_nums": [
            "the primary trial recorded several skin infections"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/4 (50.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy  malaise) 1/4 (25.00%) Pain - Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation 0/3 (0.00%) Dehydration 0/3 (0.00%) Fatigue (asthenia  lethargy  malaise) 0/3 (0.00%) Pain - Back 0/3 (0.00%) Urinary tract infection 0/3 (0.00%) Dyspnea (shortness of breath) 0/3 (0.00%) ",
            "Pericardial effusion 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%) "
        ],
        "premise_nums": [
            "of breath) 0/4 (0.00%) Pericardial effusion 0/4 (0.00%) Thrombosis 0/4 (0.00%) Skin infection 0/4 (0.00%) Rash: hand-foot skin",
            "0/3 (0.00%) Rash: hand-foot skin reaction 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin",
            "skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation 0/4 (0.00%) Dehydration 1/4 (25.00%) Fatigue (asthenia  lethargy",
            "0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2: Total: 0/3 (0.00%) Atrial fibrillation",
            "Pericardial effusion 0/3 (0.00%)Thrombosis 0/3 (0.00%) Skin infection 0/3 (0.00%) Rash: hand-foot skin",
            "Back 1/4 (25.00%) Urinary tract infection 0/4 (0.00%) Dyspnea (shortness of"
        ]
    },
    {
        "id": "884ba067-d3fe-4837-ad2a-a802b671b53c",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with an ECOG score between 3-5 are eligible for the primary trial ",
        "statement_nums": [
            "Patients with an ECOG score between 3-5 are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria Women greater than 18 years of age with histologically or cytologically confirmed stage I  II or III breast cancer  If adjuvant chemotherapy is recommended  it must be completed before study start  Bone marrow aspirate positive by IC/FC assay a  Definition of positive: greater than 4 MM/ml b  Timing of bone marrow aspiration to determine study eligibility: i  If patient is to receive either no adjuvant therapy or hormonal therapy alone  the aspiration may be performed at diagnosis as part of the large MM study at University of California  San Francisco  or following diagnosis if the patient received initial surgery elsewhere  This is also true for patients who have surgery following neoadjuvant therapy for breast cancer  ii  If the patient is to receive adjuvant chemotherapy  the aspiration will be performed at least three weeks after chemotherapy has been completed  Adequate renal function as defined by: a  Creatinine must be smaller than upper limit of normal Normal liver function tests including total bilirubin  alkaline phosphatase  and aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) Ability to understand and sign informed consent  Concomitant hormonal therapy is allowed ",
            "Concomitant radiation therapy is allowedPatients who have had surgery following neoadjuvant chemotherapy or hormonal therapy are eligible to participate in this trial Exclusion Criteria History of allergy to bisphosphonates  Acute phase reactions occur in up to 24% of patients and disappear with subsequent dosing  An acute phase reaction does not qualify as an allergic reaction  History of renal insufficiency  Renal insufficiency is defined by a serum creatinine greater than the upper limit of normal or a creatinine clearance smaller than 50 mL/min due to any underlying cause  Karnofsky Performance status smaller than 90%. Any significant medical condition that might interfere with treatment  Women participating in this study are not allowed to receive other bisphosphonate therapy during the study period  either oral or intravenous  Patients who are pregnant "
        ],
        "premise_nums": [
            "phase reactions occur in up to 24% of patients and disappear with subsequent",
            "Definition of positive: greater than 4 MM/ml b  Timing of bone marrow",
            "Karnofsky Performance status smaller than 90%. Any significant medical condition",
            "aspiration will be performed at least three weeks after chemotherapy has",
            "Inclusion Criteria Women greater than 18 years of age with histologically or cytologically confirmed stage",
            "or a creatinine clearance smaller than 50 mL/min due to any underlying cause"
        ]
    },
    {
        "id": "6619c75a-4073-47e9-8586-5070be1b3d39",
        "primaryId": "NCT02222337",
        "statement_text": "Participants for the primary trial must be in pairs  a breast cancer survivor and a caregiver  both must either be fluent in english or spanish ",
        "statement_nums": [
            "Participants for the primary trial must be in pairs"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish "
        ],
        "premise_nums": [
            "participate  Caregivers: a primary caregiver for a Latina breast"
        ]
    },
    {
        "id": "d81fafa4-1196-407b-a8c2-27d7b5da2f4f",
        "primaryId": "NCT01816594",
        "secondaryId": "NCT02222337",
        "statement_text": "Patients with histologically confirmed  newly diagnosed stage 0 breast cancer cannot take part in the primary trial  or the secondary trial  unless they present LVEF below 50%",
        "statement_nums": [
            "trial  or the secondary trial  unless they present LVEF below 50%",
            "Patients with histologically confirmed  newly diagnosed stage 0 breast cancer cannot take part in the",
            "take part in the primary trial  or the secondary trial  unless they present"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish Exclusion Criteria: Inability to understand spoken English and/or Spanish and/or Cognitive impairment that precludes informed consent (determined by the PIs or Co-Investigators who are mental health professionals)  "
        ],
        "premise_nums": [
            "participate  Caregivers: a primary caregiver for a Latina breast"
        ]
    },
    {
        "id": "6d8b4720-e600-47d7-b6c5-3b8627f2358f",
        "primaryId": "NCT00320710",
        "statement_text": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients ",
        "statement_nums": [
            "was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202 (0.50%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Anaemia 3/202 (1.49%) Febrile neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202",
            "fibrillation 1/202 (0.50%) Cardiac failure congestive 1/202 (0.50%) Palpitations 1/202 (0.50%) Pericardial effusion 1/202 (0.50%) Supraventricular tachycardia 1/202",
            "neutropenia 2/202 (0.99%) Leukocytosis 0/202 (0.00%) Leukopenia 0/202 (0.00%) Neutropenia 0/202 (0.00%) Pancytopenia 1/202 (0.50%) Atrial fibrillation 1/202 (0.50%) Cardiac"
        ]
    },
    {
        "id": "1b84007d-0002-4ab6-8e05-609e7de58684",
        "primaryId": "NCT01646346",
        "secondaryId": "NCT03283553",
        "statement_text": "the secondary trial and the primary trial do not use topical medications in their studies ",
        "statement_nums": [
            "the secondary trial and the primary trial do not use topical"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: 4D Conformal Image-Guided Partial Breast RT This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  "
        ],
        "premise_nums": [
            "the breast twice a day for 5 days  INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda",
            "partial breast irradiation twice daily for 5 days  4D Conformal Image-Guided"
        ]
    },
    {
        "id": "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009",
        "primaryId": "NCT00213980",
        "secondaryId": "NCT02536339",
        "statement_text": "Adequate hematologic  renal  and hepatic function are required to participate in the secondary trial and the primary trial  however  patients with severe loss in cognitive function are still eligible ",
        "statement_nums": [
            "to participate in the secondary trial and the primary trial  however  patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Postmenopausal women  Stage III or axillary node positive Currently disease free of breast cancer and other invasive malignancies at the time of registration No concurrent use of bisphosphonates Exclusion Criteria: Metastatic disease Inclusion Criteria: Pathologically confirmed HER2-positive MBC Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment Stable systemic disease Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 LVEF at least 50% Adequate hematologic  renal  and hepatic function Life expectancy more than 12 weeks Exclusion Criteria: Progression of systemic disease at Screening Leptomeningeal disease History of intolerance or hypersensitivity to study drug Use of certain investigational therapies within 21 days prior to enrollment Current anthracycline use Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use Active infection Pregnant or lactating women Significant history or risk of cardiac disease Symptomatic intrinsic lung disease or lung involvement ",
            "History of other malignancy within the last 5 years"
        ],
        "premise_nums": [
            "Metastatic disease Inclusion Criteria: Pathologically confirmed HER2-positive MBC Progression of or new brain",
            "of other malignancy within the last 5",
            "Use of certain investigational therapies within 21 days prior to enrollment Current anthracycline use",
            "Oncology Group (ECOG) performance status of 0 or 1 LVEF at least 50% Adequate hematologic  renal  and",
            "radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment Stable systemic disease"
        ]
    },
    {
        "id": "dc7c4409-32e5-4211-83fe-0a97b6176ca0",
        "primaryId": "NCT01007942",
        "statement_text": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial  than in cohort 2.",
        "statement_nums": [
            "5 times more common in cohort 1 of the primary trial  than in cohort 2.",
            "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial  than in cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) Adverse Events 2: Febrile neutropenia 4/282 (1.42%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 30/280 (10.71%) Adverse Events 2: Febrile neutropenia 4/282 (1.42%)"
        ]
    },
    {
        "id": "73e7447b-a940-4126-a1d9-fffd7c56c900",
        "primaryId": "NCT00337103",
        "statement_text": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year ",
        "statement_nums": [
            "Mesylate group in the primary trial survived less than a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) OS was measured from the date of randomization until the date of death from any cause  or the last date the participant was known to be alive  Participants who were lost to follow-up or who were alive at the date of data cutoff were censored  The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff  the date of data cutoff was considered the end date  and 2) if the participant was lost to follow-up before data cutoff  the date they were last known to be alive was considered the end date  Participants who survived past the end of the study were counted as in the full study period  If death occurred after data cutoff  the end date was to be censored at the time of data cutoff  Time frame: From date of randomization until date of death from any cause  assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years Results 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  Overall Number of Participants Analyzed: 554 ",
            "Median (95% Confidence Interval)Unit of Measure: days 484 (462 to 536) "
        ],
        "premise_nums": [
            "Mar 2012, or up to approximately 6 years Results 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate",
            "cause  or the last date the participant was known",
            "Median (95% Confidence Interval)Unit of Measure: days 484 (462 to 536)",
            "Outcome Measurement: Overall Survival (OS) OS was measured",
            "mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  Overall Number of",
            "1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every"
        ]
    },
    {
        "id": "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2",
        "primaryId": "NCT00629499",
        "statement_text": "Patients with peripheral neuropathy  but no symptoms of neuropathy  are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria  "
        ],
        "premise_nums": [
            "for Adverse Events (CTCAE) v3.0 criteria",
            "less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology"
        ]
    },
    {
        "id": "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063",
        "primaryId": "NCT00129389",
        "secondaryId": "NCT00304096",
        "statement_text": "Patients with permanent sensory loss  interfering with daily activities are excluded from the primary trial and the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0. Histologically or cytologically confirmed adenocarcinoma of the breast Stage III or IV disease Primary or recurrent disease Invasive lobular carcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered from prior primary therapy Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including  but not limited to  surgery  chemotherapy  and radiotherapy within the past 36 months Must have at least one undissected axillary and/or inguinal lymph node basin No history of brain metastases Hormone receptor status Estrogen receptor-positive or -negative tumor PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal status not specified Absolute neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL Hemoglobin A1c smaller than 7% ",
            "AST and ALT 2.5 x upper limit of normal (ULN)Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN HIV negative Hepatitis C negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No known or suspected allergies to any component of the vaccine No active infection requiring antibiotics No New York Heart Association class III or IV heart disease No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement  except the following: Laboratory evidence of autoimmune disease (e.g.  positive ANA titer) without symptoms Clinical evidence of vitiligo Other forms of depigmenting illness Mild arthritis requiring nonsteroidal antiinflammatory drugs No medical contraindication or potential problem that would preclude study participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy More than 4 weeks since prior and no concurrent allergy desensitization injections More than 4 weeks since prior parenteral  oral  or inhaled corticosteroids ",
            "No concurrent inhaled steroids (e.g.  Advair® or triamcinolone acetonide)Prior or concurrent topical corticosteroids allowed More than 4 weeks since prior and no concurrent growth factors (e.g.  epoetin alfa  darbepoetin alfa  or pegfilgrastim) More than 4 weeks since prior and no concurrent other investigational medication More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents Prior and concurrent hormonal therapy (e.g.  tamoxifen  raloxifene  toremifene  fulvestrant  letrozole  anastrozole  or exemestane) allowed No prior vaccination with any synthetic peptides in this protocol Vaccines for infectious disease (e.g.  influenza) allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy for acute conditions not related to breast cancer allowed No concurrent illegal drugs "
        ],
        "premise_nums": [
            "carcinoma allowed HLA-A1, -A2, -A3, or -A31 positive Underwent and recovered from prior primary therapy Patients with no clinical",
            "or concurrent topical corticosteroids allowed More than 4 weeks prior to or 2 weeks after study vaccine Short term therapy",
            "must have undergone prior antineoplastic therapy including  but",
            "PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than or equal 2 motor or sensorial neurotoxicity by the National",
            "participation PRIOR CONCURRENT THERAPY: More than 4 weeks since prior surgery More than 4",
            "No known or suspected allergies to any component of",
            "upper limit of normal (ULN)Bilirubin 2.5 x ULN Alkaline phosphatase 2.5 x ULN Creatinine 1.5 x ULN HIV negative Hepatitis C negative",
            "and radiotherapy within the past 36 months Must have at least one undissected axillary and/or inguinal",
            "PATIENT CHARACTERISTICS: ECOG performance status of 0 or 1 Body weight greater than 110 lbs (without clothes) Male or female Menopausal",
            "neutrophil count greater than 1000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than or equal 2 motor or sensorial neurotoxicity by the National",
            "allowed  provided they are administered 2 weeks prior to or 2 weeks after study vaccine Short term therapy",
            "Pre-existing grade greater than or equal 2 motor or sensorial neurotoxicity by the National",
            "36 months Must have at least one undissected axillary and/or inguinallowed  provided they are administered 2 weeks prior to or 2"
        ]
    },
    {
        "id": "f4f50a05-9d63-4006-9680-b7ef68dbb5fe",
        "primaryId": "NCT00952731",
        "secondaryId": "NCT00956813",
        "statement_text": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO ",
        "statement_nums": [
            "Cohort 2 in the primary trial and the secondary trial but receive daily placebo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 2: Placebo Gel + Oral Treatment Placebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  INTERVENTION 2: Placebo Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily  "
        ],
        "premise_nums": [
            "gel applied to breasts daily for 4-10 weeks  INTERVENTION 2:",
            "(2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel"
        ]
    },
    {
        "id": "f34760f4-965e-4bbb-b88f-8b63a7045808",
        "primaryId": "NCT00741260",
        "statement_text": "Patients with HER2 positive tumors are ineligible for the primary trial ",
        "statement_nums": [
            "Patients with HER2 positive tumors are ineligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INCLUSION CRITERIA erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)  based on local testing  or based on centralized FISH testing prior to day 1. "
        ],
        "premise_nums": [
            "centralized FISH testing prior to day 1.",
            "(FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)"
        ]
    },
    {
        "id": "e7d00591-381f-45e2-abdb-2ae1e568b193",
        "primaryId": "NCT01421472",
        "statement_text": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells ",
        "statement_nums": [
            "More than 3 patients in the primary trial suffered from adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile Neutropenia * 5/67 (7.46%)"
        ]
    },
    {
        "id": "59da1fb5-2636-4ca8-8970-6cb45dedbed3",
        "primaryId": "NCT00885755",
        "secondaryId": "NCT01075100",
        "statement_text": "Patients' appetites were not affected in the primary trial or the secondary trial ",
        "statement_nums": [
            "not affected in the primary trial or the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%) Medical device complication * 1/33 (3.03%) Cellulitis * 1/33 (3.03%) Sepsis * 1/33 (3.03%) Hip fracture * 1/33 (3.03%) Back pain * 1/33 (3.03%) Menorrhagia * 1/33 (3.03%) Thrombosis * 1/33 (3.03%) Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) ",
            "DIARRHEA 4/48 (8.33%)NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) DEHYDRATION 0/53 (0.00%) DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) "
        ],
        "premise_nums": [
            "VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%)",
            "VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48",
            "(1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53",
            "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Cardiac failure * 1/33 (3.03%)",
            "ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%)NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48",
            "DIARRHEA 4/48 (8.33%)NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53",
            "Adverse Events 1: Total: 9/33 (27.27%) Febrile neutropenia * 1/33 (3.03%) Pyrexia * 2/33 (6.06%) Chest pain * 1/33 (3.03%)",
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48",
            "NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48",
            "(8.33%)NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%)",
            "FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD"
        ]
    },
    {
        "id": "f144c34b-9428-4836-bf01-5f7030eb579c",
        "primaryId": "NCT04030104",
        "secondaryId": "NCT02525718",
        "statement_text": "Intervention 1 for the secondary trial and the primary trial are for the control groups ",
        "statement_nums": [
            "Intervention 1 for the secondary trial and the primary trial are for the control"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly selected to receive saline (placebo)  administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  Saline: If randomized to this arm  subjects will receive an intraoperative injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone  The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue  Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery  ",
            "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If randomized to this arm  subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively  "
        ],
        "premise_nums": [
            "with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone",
            "with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone: If",
            "injection of saline  (2.5 mg/ml) INTERVENTION 2: 0.25 % Bupivacaine w/ Epinephrine & 4mg Dexamethasone",
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging INTERVENTION 1: Placebo Subjects will be randomly",
            "local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to"
        ]
    },
    {
        "id": "e7e87023-2227-4594-931a-0a3d89ec686e",
        "primaryId": "NCT02073487",
        "secondaryId": "NCT03371732",
        "statement_text": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "are eligible for the secondary trial and the primary trial",
            "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
            "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization  Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) ",
            "Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol Exclusion Criteria: Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix  Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; ",
            "Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded;Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing support for substance use  ",
            "An AUDIT-C score greater than 1 or more than one cigarette smoked per day "
        ],
        "premise_nums": [
            "An AUDIT-C score greater than 1 or more than one cigarette smoked per",
            "Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination",
            "CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin",
            "uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at",
            "count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at leastudy  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or",
            "for patients of childbearing potential within 2-weeks (preferably 7 days) prior",
            "of the stomach or small bowel  Subjects with ulcerative",
            "comply with the protocol Inclusion Criteria : women with primary breast cancer  without ongoing",
            "higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase",
            "study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina",
            "limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status:",
            "protocol Exclusion Criteria: Previous (less than 5 years) or current history of",
            "neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobinvasive component of the primary tumor and confirmed by a",
            "comply with the protocol Inclusion Criteria : women with primary breast cancer: Primary tumor greater than 1 cm diameter  measured by",
            "women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or",
            "Serum total bilirubin 2 x upper limit of normal (ULN)",
            "3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection"
        ]
    },
    {
        "id": "ca4a190a-9007-4f8f-a199-b8fe4064e55b",
        "primaryId": "NCT02149524",
        "statement_text": "Several adverse events which occurred in the primary trial were not heart related ",
        "statement_nums": [
            "which occurred in the primary trial were not heart related"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) ",
            "Cardiac failure congestive 3/437 (0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) "
        ],
        "premise_nums": [
            "(0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%)",
            "(0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438",
            "(0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%)",
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia",
            "neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "Adverse Events 1: Total: 58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Thrombocytopenia 0/438 (0.00%) Haemolytic anaemia",
            "(0.69%)Supraventricular tachycardia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia",
            "Leukopenia 1/438 (0.23%) Cardiac failure congestive 0/438 (0.00%) Supraventricular tachycardia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure",
            "Supraventricular tachycardia 0/438 (0.00%) Myocardial infarction 1/438 (0.23%) Vertigo 0/438 (0.00%) Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia",
            "Adverse Events 2: Total: 56/437 (12.81%) Febrile neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Haemolytic anaemia",
            "Cardiac failure congestive 3/437 (0.69%)Supraventricular tachycardia 1/437 (0.23%) Haemolytic anaemia 0/437 (0.00%) Leukopenia 0/437 (0.00%)",
            "neutropenia 10/437 (2.29%) Neutropenia 7/437 (1.60%) Anaemia 2/437 (0.46%) Thrombocytopenia 1/437 (0.23%) Myocardial infarction 0/437 (0.00%) Vertigo 1/437 (0.23%)",
            "58/438 (13.24%) Febrile neutropenia 13/438 (2.97%) Neutropenia 5/438 (1.14%) Anaemia 0/438 (0.00%) Haemolytic anaemia 1/438 (0.23%) Leukopenia 1/438 (0.23%) Cardiac failure"
        ]
    },
    {
        "id": "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c",
        "primaryId": "NCT00711529",
        "secondaryId": "NCT02835625",
        "statement_text": "the primary trial participants are treated with Cognitive behavioural therapy  this is not used at all in the secondary trial ",
        "statement_nums": [
            "is not used at all in the secondary trial",
            "the primary trial participants are treated with"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Hypnotherapy Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist  These sessions will be one week apart  Patients will also be instructed on the use of self-hypnosis techniques to use at home  INTERVENTION 2: Gabapentin Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)  INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  "
        ],
        "premise_nums": [
            "Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2:",
            "the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily)",
            "the study will undergo individually three one-hour sessions with"
        ]
    },
    {
        "id": "cb133915-dc40-4f93-a6a7-076e4d7f07a1",
        "primaryId": "NCT02685566",
        "secondaryId": "NCT03076190",
        "statement_text": "the primary trial and the secondary trial have the same number of study groups  but are testing different interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial have the same number"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 2: Full-Field Digital Mammography (FFDM) Breast Images with FFDM alone FFDM: FujiFilm Aspire Cristalle System  This endpoint will be evaluated qualitatively  The Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate)  INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group "
        ],
        "premise_nums": [
            "Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group",
            "Plus DBT: FujiFilm Aspire Cristalle System  This endpoint"
        ]
    },
    {
        "id": "1f0825b6-8e32-44ff-96b7-ab082e24b493",
        "primaryId": "NCT00045032",
        "secondaryId": "NCT00416572",
        "statement_text": "WOCBP that refuse to use contraception are excluded from the primary trial  but may be eligible for the secondary trial ",
        "statement_nums": [
            "be eligible for the secondary trial",
            "are excluded from the primary trial  but may be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures INCLUSION CRITERIA (Disease Characteristics): Diagnosis of breast cancer Stage I or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within 30 miles of Magee Women's Hospital  Pittsburgh  Pennsylvania INCLUSION CRITERIA (Patient Characteristics): Female patients only Must be able to communicate EXCLUSION CRITERIA (Patient Characteristics): Other prior malignancies except skin cancer PRIOR CONCURRENT THERAPY: See Disease Characteristics "
        ],
        "premise_nums": [
            "or II disease No more than 10 positive lymph nodes First-time diagnosis Under the age of 50 at diagnosis Finished active treatment",
            "First-time diagnosis Under the age of 50 at diagnosis Finished active treatment within the past 2 months English-speaking only Must live within",
            "of childbearing potential or less than 1 year post-menopause unwilling to use adequate"
        ]
    },
    {
        "id": "db96c4d6-ffcd-401a-8af3-807f665f16f7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "statement_text": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion criteria: Female patients 18 years of age  Written informed consent given  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed  Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology Group (ECOG) performance status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid (Zometa®)  Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry  Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) smaller than 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 Corrected (adjusted for serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)  ",
            "Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma  or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ)  of exposed bone in the mouth  or of slow healing after dental procedures Recent (within 6 weeks) or planned dental or jaw surgery (e.g  extraction  implants)  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients  Women of childbearing potential not using effective methods of birth control (e.g  abstinence  oral contraceptives or implants  IUD  vaginal diaphragm or sponge  or condom with spermicide)  History of non-compliance to medical regimens or potential unreliable behavior  Known sensitivity to study drug(s) or class of study drug(s)  Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study Use of any other investigational agent in the last 30 days  Exclusion Criteria: Prior history of osteoporosis or osteoporotic fracture  "
        ],
        "premise_nums": [
            "Inclusion criteria: Female patients 18 years of age  Written informed consent",
            "serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)",
            "serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 3 months since last infusion of Zoledronic Acid (Zometa®)",
            "Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology",
            "({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 Corrected (adjusted for serum albumin) serum calcium",
            "IV breast cancer with at least one bone metastasis radiologically confirmed",
            "other investigational agent in the last 30 days  Exclusion Criteria: Prior",
            "status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid",
            "entry  Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault"
        ]
    },
    {
        "id": "f078c722-b879-40f2-ac72-c733001b93dd",
        "primaryId": "NCT01740323",
        "secondaryId": "NCT00127205",
        "statement_text": "the secondary trial and the primary trial only accept 18 year olds ",
        "statement_nums": [
            "the secondary trial and the primary trial only accept 18 year olds"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female breast cancer patients over the age of 18 will be recruited for this study  Patients enrolled in the study will meet standard criteria for whole breast XRT  PATIENT CHARACTERISTICS: Age 18 and over "
        ],
        "premise_nums": [
            "cancer patients over the age of 18 will be recruited for this study",
            "PATIENT CHARACTERISTICS: Age 18 and over the age of 18 will be recruited for this study"
        ]
    },
    {
        "id": "c33d78e5-13be-4cde-b36e-7cc097f180a2",
        "primaryId": "NCT02041429",
        "secondaryId": "NCT00068588",
        "statement_text": "the primary trial and the secondary trial use the same outcome measurements  same drugs and the same cohort sizes ",
        "statement_nums": [
            "the primary trial and the secondary trial use the same outcome"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT)  See DLT primary outcome measure for definition Outcome Measurement: Maximum Tolerated Dose Determined by Dose-limiting Toxicities "
        ],
        "premise_nums": [
            "(DLT)  See DLT primary outcome measure for definition Outcome",
            "Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the"
        ]
    },
    {
        "id": "58dbc33b-d32c-4e91-a940-ca1148bbdae4",
        "primaryId": "NCT00075270",
        "secondaryId": "NCT01781299",
        "statement_text": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant ",
        "statement_nums": [
            "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 2: Placebo With Paclitaxel Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours  every 3 weeks  The treatment group was stratified by sites of metastatic disease and stage of disease  Participants were treated until disease progression  unacceptable toxicity  or consent withdrawal  INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS "
        ],
        "premise_nums": [
            "Lapatinib With Paclitaxel Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the",
            "expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this",
            "orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours  every 3 weeks"
        ]
    },
    {
        "id": "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e",
        "primaryId": "NCT00602043",
        "secondaryId": "NCT01720602",
        "statement_text": "Several treatments in the secondary trial are administered by mouth  none of the treatments in the primary trial are given via this route ",
        "statement_nums": [
            "Several treatments in the secondary trial are administered by mouth",
            "the treatments in the primary trial are given via this"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Diagnostic FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  This group represents patients who had positive FES uptake at all disease sites on the baseline diagnostic FES PET scan  laboratory biomarker analysis: Correlative studies INTERVENTION 2: Diagnostic FES: Patients With FES Negative Sites of Disease Patients undergo [^18F] FES PET scan  Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy  Patients are followed-up to determine response on the therapy for 6 months using clinical exams  tumor marker assays  conventional imaging and standard clinical FDG PET/CT  ",
            "This group represents patients who had some or all disease sites negative for FES uptake on the baseline diagnostic FES PET scan INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive",
            "or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression",
            "baseline diagnostic FES PET scan INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3",
            "(FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients",
            "FES: Average FES SUVmean greater than 1.5, no Negative Sites Patients receive vorinostat PO 5 days a week for 3 weeks",
            "also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan",
            "who had some or all disease sites negative for FES",
            "determine response on the therapy for 6 months using clinical exams  tumor marker",
            "FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan  Patients begin clinically indicated endocrine therapy",
            "tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative"
        ]
    },
    {
        "id": "2c462296-35f5-482a-9ece-3b4ed4c2f53a",
        "primaryId": "NCT01216176",
        "statement_text": "Urosepsis was the only recorded adverse event in the primary trial ",
        "statement_nums": [
            "adverse event in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive Heart Failure [2]0/12 (0.00%) Diverticulitis 0/12 (0.00%) Cholecystitis 0/12 (0.00%) Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive",
            "Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%)"
        ]
    },
    {
        "id": "6d4ecb16-6586-4ea8-a1dc-f825e951e060",
        "primaryId": "NCT00703326",
        "secondaryId": "NCT00274768",
        "statement_text": "Participants with HER2- primary liver tumors  confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "are eligible for the secondary trial and the primary trial",
            "Participants with HER2- primary liver tumors  confirmed by"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent  Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) DISEASE CHARACTERISTICS: Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast Hormone receptor status: Not specified "
        ],
        "premise_nums": [
            "confirmation of diagnosis Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization",
            "Inclusion Criteria: Participant has histologically or cytologically confirmed adenocarcinoma"
        ]
    },
    {
        "id": "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f",
        "primaryId": "NCT01252290",
        "secondaryId": "NCT00479674",
        "statement_text": "Unlike the secondary trial  the primary trial does not record any instances of Anemia  Dyspepsia  Nausea or vomiting ",
        "statement_nums": [
            "Unlike the secondary trial  the primary trial does not record any"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ * 1/35 (2.86%) Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%) Vomiting 1/41 (2.44%) Pain 3/41 (7.32%) Allergic reaction 1/41 (2.44%) Infections and infestations - Other  specify: [1]1/41 (2.44%) Vascular access complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%) "
        ],
        "premise_nums": [
            "specify: [1]1/41 (2.44%) Vascular access complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%)",
            "Adverse Events 1: Total: 22/41 (53.66%) Anemia 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%)",
            "complication 3/41 (7.32%) Alanine aminotransferase increased 1/41 (2.44%) Dyspepsia 1/41 (2.44%) Mucositis oral 1/41 (2.44%) Nausea 3/41 (7.32%)",
            "Adverse Events 1: Total: 2/35 (5.71%) Gastroesophageal reflux disease * 1/35 (2.86%) Ductal carcinoma in situ *"
        ]
    },
    {
        "id": "2731552d-195a-4f43-b6b5-02a3fbda81d9",
        "primaryId": "NCT01323530",
        "secondaryId": "NCT01106040",
        "statement_text": "the secondary trial and the primary trial do not have comparable Outcome Measurements ",
        "statement_nums": [
            "the secondary trial and the primary trial do not have comparable"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) ",
            "DLTs as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days  2) Neutropenia Grade 3 or 4 complicated by fever and/or infection (absolute neutrophil count [ANC] less than 1.0*10^9/liter [L]  fever of at least 38.5 degree celsius [°C])  3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated by bleeding and/or requiring platelet or blood transfusion  5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea  and Grade 3 or 4 vomiting or diarrhea in participants who had not received optimal treatment with antiemetic and/or antidiarrheal medication; excluding laboratory abnormalities without clinical symptoms)  6) Delayed recovery from treatment-related toxicity resulting in dose delay greater than 14 days  7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline Time frame: Cycle 1 (21 days) Outcome Measurement: Concordance of Blue Dye and Lymphoseek ",
            "The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek Time frame: Surgery after injections of Lymphoseek and blue dye "
        ],
        "premise_nums": [
            "increase of at least 2 grades from baseline Time frame: Cycle 1 as result of Grade 2 or higher treatment-related toxicity that",
            "7) Failure to administer at least 75 percent (%) of planned study drugs during Cycle 1 as result of Grade 2 or higher",
            "transfusion  5) Non-hematological toxicity Grade 3 or higher (excluding Grade 3 nausea  and Grade 3 or 4 vomiting or diarrhea",
            "as result of Grade 2 or higher treatment-related toxicity that constituted increase of at least 2 grades from baseline Time frame: Cycle 1",
            "[L]  fever of at least 38.5 degree celsius [°C])  3)Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated",
            "resulting in dose delay greater than 14 days  7) Failure to administer at least 75 percent (%) of planned study",
            "as per NCI CTCAE v3.0 were defined as:1) Neutropenia Grade 4 that lasted at least 7 days",
            "7 days  2) Neutropenia Grade 3 or 4 complicated by fever and/or infection",
            "defined as:1) Neutropenia Grade 4 that lasted at least 7 days  2) Neutropenia Grade 3 or 4 complicated by fever",
            "Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0)"
        ]
    },
    {
        "id": "8fee5ce4-3e46-4731-842e-a5b1df451c7d",
        "primaryId": "NCT01231659",
        "statement_text": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR) ",
        "statement_nums": [
            "Less than 40% of the primary trial participants achieved either complete"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Overall Response Rate (ORR) Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR)  disappearance of all target lesions for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR  Only descriptive statistics  Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol  Overall Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2 "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants 37.2",
            "Number of Participants Analyzed: 43 Measure Type: Number Unit of Measure: Percentage of Participants With Overall Response Rate (ORR) Overall Response",
            "for a period of at least one month; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole Arm/Group Description: All patients received 2 tablets (5 mg each) of",
            "each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until",
            "came first  assessed for approximately 15 months Results 1: Arm/Group Title: Everolimus + Letrozole",
            "partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT:",
            "the date of the first documented disease progression or date",
            "(PR)  greater than or equal 30% decrease in the sum of the"
        ]
    },
    {
        "id": "def4199f-a22d-4939-b15d-66fd073fb280",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group ",
        "statement_nums": [
            "Cohort 2 of the primary trial is the control group"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  "
        ],
        "premise_nums": [
            "chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks",
            "or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None"
        ]
    },
    {
        "id": "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2",
        "primaryId": "NCT00871858",
        "statement_text": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma ",
        "statement_nums": [
            "1 patient in the primary trial was diagnosed with a"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58 (1.72%) "
        ],
        "premise_nums": [
            "1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2:",
            "cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection",
            "Endometrial atrophy 0/60 (0.00%) Adverse Events 2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney",
            "0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60 (0.00%) Programmed peritoneal dialysis 1/60 (1.67%) Endometrial atrophy 0/60",
            "2: Total: 3/58 (5.17%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis",
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 0/60 (0.00%) Ankle fracture 1/60 (1.67%) Clear cell kidney cancer 0/60",
            "Adverse Events 1: Total: 2/60 (3.33%) Bronchial infection 1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney",
            "1/58 (1.72%) Ankle fracture 0/58 (0.00%) Clear cell kidney cancer 1/58 (1.72%) Programmed peritoneal dialysis 0/58 (0.00%) Endometrial atrophy 1/58"
        ]
    },
    {
        "id": "86c1430c-553b-4388-a034-b82f78afdc0d",
        "primaryId": "NCT01028352",
        "statement_text": "Patients with aromatase inhibitor associated musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy  are eligible for the primary trial ",
        "statement_nums": [
            "musculoskeletal symptoms  such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy  are eligible for the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: AI-associated musculoskeletal symptoms  defined as: Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy; "
        ],
        "premise_nums": [
            "that developed or worsened (6 or 7 on CGICS) during AI therapy or Grade 1 or higher sensory neuropathy that"
        ]
    },
    {
        "id": "b7cef0e1-7bd8-4c0e-a044-b11708cf927c",
        "primaryId": "NCT01905592",
        "statement_text": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies ",
        "statement_nums": [
            "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies (eribulin or vinorelbine or gemcitabine or capecitabine)  until progression or unacceptable toxicity develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops "
        ],
        "premise_nums": [
            "1: Physician's Choice Physician selection from 4 standard of care metastatic breast cancer chemotherapies",
            "develops  INTERVENTION 2: Niraparib Niraparib 300 mg (3x100 mg capsules) once daily until progression"
        ]
    },
    {
        "id": "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa",
        "primaryId": "NCT00444587",
        "statement_text": "A total of 2/93 patients in the primary trial were observed with either Leukopenia  Cardiopulmonary failure or Diarrhoea ",
        "statement_nums": [
            "A total of 2/93 patients in the primary trial were observed with either"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%) "
        ],
        "premise_nums": [
            "Leukopenia 2/93 (2.15%) Cardiopulmonary failure 2/93 (2.15%) Diarrhoea 3/93 (3.23%)"
        ]
    },
    {
        "id": "225f95a5-7c22-4cb7-a463-1c57d5b69d7a",
        "primaryId": "NCT01217385",
        "secondaryId": "NCT01202591",
        "statement_text": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial ",
        "statement_nums": [
            "for patients in the secondary trial or the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or estimated by physical exam; No contraindications for primary chemotherapy; Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; ",
            "If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation;Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines; Exclusion Criteria Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy; Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  Exclusion Criteria: Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa)  or any agent known to inhibit FGFRs  "
        ],
        "premise_nums": [
            "Inclusion Criteria Pathologically confirmed diagnosis of invasive",
            "normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional",
            "be a candidate for primary systemic (neoadjuvant) therapy and for",
            "study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy",
            "of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II);",
            "neoadjuvant therapy; Tumor size greater than 2cm, measured on imaging or",
            "been disease free for less than 5 years  Exclusion Criteria: Prior",
            "one year  OR surgically sterile  OR not",
            "function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits;"
        ]
    },
    {
        "id": "5464e8a7-159c-4e00-8710-45a44ceaeda3",
        "primaryId": "NCT03061175",
        "secondaryId": "NCT03098550",
        "statement_text": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study  whereas Cohort 1 of the primary trial has the same intervention for the full study ",
        "statement_nums": [
            "Cohort 1 of the secondary trial does not receive the",
            "of the study  whereas Cohort 1 of the primary trial has the same intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Web-Based CPM-DA) Patients receive a website address  a secure username and password  and instructions for using the web-based CPM-DA  Internet-Based Intervention: Receive web-based CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) "
        ],
        "premise_nums": [
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W",
            "CPM-DA Survey Administration: Ancillary studies INTERVENTION 1: Nivolumab + Daratumumab (TNBC) Triple-negative"
        ]
    },
    {
        "id": "98965d07-e2db-41bf-ac3e-a5c130513275",
        "primaryId": "NCT00382018",
        "secondaryId": "NCT03012477",
        "statement_text": "Between the patients in the primary trial and the secondary trial  only 1.56% suffered from sepsis ",
        "statement_nums": [
            "the patients in the primary trial and the secondary trial  only 1.56% suffered from sepsis"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161 (0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64 (1.56%) Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/161 (0.00%) Gastrointestinal-Other 0/161 (0.00%) Dehydration 0/161",
            "Renal/Genitourinary-Other 1/64 (1.56%) Sepsis 1/34 (2.94%)",
            "(0.00%) Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2: Total: 1/64 (1.56%) Gastrointestinal-Other 1/64 (1.56%) Dehydration 1/64"
        ]
    },
    {
        "id": "784cc905-937f-43fd-96a6-34ea8dce9e8d",
        "primaryId": "NCT00429104",
        "secondaryId": "NCT00878709",
        "statement_text": "Patients with end-stage liver disease are excluded from the primary trial and the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Chronic active hepatitis or cirrhosis  Inclusion Criteria: Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease  Been treated for early breast cancer with standard of care duration of trastuzumab  Could have been treated neoadjuvantly but have not reached pathologic complete response  Exclusion Criteria: Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry  History of heart disease  Corrected QT (QTc) interval greater than 0.45 seconds History of gastrointestinal disease with diarrhea as the major symptom  "
        ],
        "premise_nums": [
            "Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease",
            "Corrected QT (QTc) interval greater than 0.45 seconds History of gastrointestinal disease with diarrhea"
        ]
    },
    {
        "id": "2e3f2fde-569e-46ef-958d-710599fec9a1",
        "primaryId": "NCT00706030",
        "secondaryId": "NCT00171704",
        "statement_text": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density  the results from these two studies are therefore not directly comparable ",
        "statement_nums": [
            "target lesions and the secondary trial measures changes in Bone",
            "the primary trial studies the interventions impact"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Response Rate Overall Response Rate (ORR)  subjects with CR or PR by independent review in subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR)  disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions  and no new lesions  Time frame: From first dose date to progression or last tumor assessment  up to four years and six months  Outcome Measurement: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip  All DXA scans were evaluated by a central reader  ",
            "Time frame: Baseline  24 months"
        ],
        "premise_nums": [
            "was the lumbar spine (L2 to L4) and the secondary scanning site was the total",
            "Outcome Measurement: Overall Response Rate Overall Response Rate",
            "after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until",
            "randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment  The",
            "date to progression or last tumor assessment  up to",
            "review in subjects with ErbB-2-positive breast cancer treated at the MTD",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "of the Lumbar Spine (L2-l4) Lumbar spine (L2-L4) BMD measurements by dual energy X-ray"
        ]
    },
    {
        "id": "d1080199-2591-44bd-bdad-0dea3830e657",
        "primaryId": "NCT00106002",
        "statement_text": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression ",
        "statement_nums": [
            "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression "
        ],
        "premise_nums": [
            "INTERVENTION 1: Pemetrexed 600 mg/m2, intravenous (IV)  every 14 days until complete response or disease progression"
        ]
    },
    {
        "id": "c37c21f5-19a0-4fcc-af92-89690fb64091",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B ",
            "750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings "
        ],
        "premise_nums": [
            "1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo",
            "in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B",
            "B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of",
            "Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing",
            "BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO",
            "Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty",
            "Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A 750mg lapatinib administered orally twice daily  Cohort"
        ]
    },
    {
        "id": "bea7f10e-09d6-42c3-9e89-dfd1112a33d5",
        "primaryId": "NCT01276041",
        "secondaryId": "NCT00688909",
        "statement_text": "0 patients in the primary trial or the secondary trial died ",
        "statement_nums": [
            "0 patients in the primary trial or the secondary trial died"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70 (2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Mania 1/261 (0.38%) Pulmonary embolism 1/261 (0.38%) "
        ],
        "premise_nums": [
            "- Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) Diarrhea 2/70",
            "limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261",
            "leak 1/261 (0.38%) Spinal column stenosis 1/261 (0.38%) Depression 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis",
            "Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70",
            "(2.86%) Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) Adverse Events 1: Total: 5/261",
            "Adverse Events 1: Total: 5/261 (1.92%) Cholecystitis chronic 1/261 (0.38%) Post procedural bile leak 1/261 (0.38%) Spinal column stenosis"
        ]
    },
    {
        "id": "3d41d86b-f53f-4bf9-a4dd-eae2412c485e",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive letrozole  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "Only cohort 2 of the primary trial receive letrozole  but"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Bevacizumab Fulvestrant "
        ],
        "premise_nums": [
            "will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment",
            "the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab"
        ]
    },
    {
        "id": "0159bfb3-231e-4711-b3ee-2798c66f5f6a",
        "primaryId": "NCT01015131",
        "secondaryId": "NCT00312208",
        "statement_text": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts ",
        "statement_nums": [
            "Both the primary trial and the secondary trial record instances of Rectal"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) ",
            "Arrhythmia Ventricular 0/1634 (0.00%)Cardiomyopathy 1/1634 (0.06%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%)",
            "Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%)",
            "Arrhythmia Ventricular 0/1634 (0.00%)Cardiomyopathy 1/1634 (0.06%)",
            "Adverse Events 1: Total: 8/44 (18.18%) Febrile neutropenia4/44 (9.09%) Rectal bleeding1/44 (2.27%) Chest pain2/44 (4.55%) Fever1/44 (2.27%) Catheter site infection1/44",
            "infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders",
            "Fever1/44 (2.27%) Catheter site infection1/44 (2.27%) Neutrophil count decreased1/44 (2.27%) Dizziness1/44 (2.27%) Adverse Events 1: Total:"
        ]
    },
    {
        "id": "9e7628cd-931e-4b1f-b4c1-f03f0449ac27",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the cranial and foot area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [
            "the primary trial records two different types",
            "foot area  the secondary trial does not record any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%) Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29",
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%)",
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%)"
        ]
    },
    {
        "id": "f1108cbc-db27-431d-9154-1a267278bda4",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "Leukopenia were only observed in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) ",
            "Lymphedema 2/1635 (0.12%)Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "(0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635",
            "3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%)",
            "Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%)",
            "(0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%)",
            "(0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia",
            "Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%)"
        ]
    },
    {
        "id": "baf7e338-91fd-47d0-b766-a4e039efc5d7",
        "primaryId": "NCT01432886",
        "statement_text": "None of the patients in either cohort of the primary trial experienced DLT ",
        "statement_nums": [
            "either cohort of the primary trial experienced DLT"
        ],
        "label": "Entailment",
        "premise_text": [
            "Results 1: Arm/Group Title: E7389 With Weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously weekly  with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly Trastuzumab Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously tri-weekly  with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 "
        ],
        "premise_nums": [
            "the remaining doses  Overall Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants",
            "Number of Participants Analyzed: 6 Measure Type: Number Unit of Measure: Participants 0 Results 2: Arm/Group Title: E7389 With Tri-weekly",
            "(E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle  Trastuzumab was administered intravenously",
            "dose of 4 mg/kg followed by 2 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6",
            "dose of 8 mg/kg followed by 6 mg/kg for the remaining doses  Overall Number of Participants Analyzed: 6"
        ]
    },
    {
        "id": "9401b12d-3888-4a41-93a1-b2075930098b",
        "primaryId": "NCT00458237",
        "statement_text": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial ",
        "statement_nums": [
            "major surgery in the last two weeks are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients may have received prior radiation therapy Exclusion Criteria: Major surgery within 2 weeks before study entry "
        ],
        "premise_nums": [
            "therapy Exclusion Criteria: Major surgery within 2 weeks before study entry"
        ]
    },
    {
        "id": "c7aa030a-6b76-4bd7-a934-f02a4638a1ac",
        "primaryId": "NCT00908791",
        "secondaryId": "NCT00297596",
        "statement_text": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "ineligible for both the secondary trial and the primary trial",
            "Female patients over the age of 60, with Histologically confirmed breast cancer and"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded  Significant cardiac disease  including uncontrolled high blood pressure  unstable angina  and congestive heart failure  myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be excluded  Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded  Inclusion Criteria: Dementia or significantly altered mental status that would interfere with proper consenting  "
        ],
        "premise_nums": [
            "myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be"
        ]
    },
    {
        "id": "04fd88c2-cf92-468d-bbc4-567cae19948d",
        "primaryId": "NCT00087152",
        "secondaryId": "NCT00203502",
        "statement_text": "the primary trial recorded less patients with nausea than the secondary trial ",
        "statement_nums": [
            "the primary trial recorded less patients with nausea than the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Nausea 1/20 (5.00%) Adverse Events 1: Nausea/vomiting 4/39 (10.26%)"
        ]
    },
    {
        "id": "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd",
        "primaryId": "NCT00499122",
        "secondaryId": "NCT00454805",
        "statement_text": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial ",
        "statement_nums": [
            "of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41 (4.88%) Headache 1/41 (2.44%) Nausea 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) ",
            "Small Intestinal Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) "
        ],
        "premise_nums": [
            "Small Intestinal Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)",
            "embolism 1/41 (2.44%) Femoral Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Fatigue 2/41",
            "1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1:",
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41",
            "Adverse Events 1: Total: 27/41 (65.85%) Febrile Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41",
            "Obstruction 1/31 (3.23%)Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%)",
            "Artery occlusion 1/41 (2.44%) Abdominal Pain 2/41 (4.88%) Constipation 1/41 (2.44%) Cellulitis 1/41 (2.44%) Muscular Weakness 1/41 (2.44%) Adverse Events 1:",
            "27/41 (65.85%) Febrile Neutropenia 4/41 (9.76%) Neutropenia 1/41 (2.44%) Deep Vein Thrombosis 1/41 (2.44%) Pulmonary embolism 1/41 (2.44%) Femoral Artery occlusion",
            "Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)"
        ]
    },
    {
        "id": "8074c35f-b74c-4250-94f1-9ad22fa315d7",
        "primaryId": "NCT00375427",
        "secondaryId": "NCT00579826",
        "statement_text": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion criteria: Female patients 18 years of age  Written informed consent given  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed  Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology Group (ECOG) performance status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid (Zometa®)  Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry  Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) smaller than 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 Corrected (adjusted for serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)  ",
            "Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma  or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ)  of exposed bone in the mouth  or of slow healing after dental procedures Recent (within 6 weeks) or planned dental or jaw surgery (e.g  extraction  implants)  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients  Women of childbearing potential not using effective methods of birth control (e.g  abstinence  oral contraceptives or implants  IUD  vaginal diaphragm or sponge  or condom with spermicide)  History of non-compliance to medical regimens or potential unreliable behavior  Known sensitivity to study drug(s) or class of study drug(s)  Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study Use of any other investigational agent in the last 30 days  Exclusion Criteria: Prior history of osteoporosis or osteoporotic fracture  "
        ],
        "premise_nums": [
            "Inclusion criteria: Female patients 18 years of age  Written informed consent",
            "serum albumin) serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 12 mg/dL ( 3.0 mmol/L)",
            "serum calcium smaller than 8 mg/dl (2 mmol/L) or greater than 3 months since last infusion of Zoledronic Acid (Zometa®)",
            "Previous treatment with zoledronic acid every 3-4 weeks  for 9-12 infusions over no more than 15 months  Eastern Cooperative Oncology",
            "({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 Corrected (adjusted for serum albumin) serum calcium",
            "IV breast cancer with at least one bone metastasis radiologically confirmed",
            "other investigational agent in the last 30 days  Exclusion Criteria: Prior",
            "status 2   Life expectancy 1 year  Exclusion criteria: More than 3 months since last infusion of Zoledronic Acid",
            "entry  Serum creatinine greater than 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault"
        ]
    },
    {
        "id": "afc4a45b-6592-4ca8-b174-033fb6a0624a",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "statement_text": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial ",
        "statement_nums": [
            "have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases Brain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: Clinically or radiologically detectable metastasis (M1 disease) ",
            "Participants for whom surgery as primary intent procedure is the best option to treat their diseaseParticipants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease "
        ],
        "premise_nums": [
            "for whom surgery as primary intent procedure is the best",
            "for the treatment of locally advanced disease",
            "Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to",
            "control symptoms from brain metastasis within 2 months of the first study treatment  For LABC",
            "docetaxel History of disease progression within 3 months prior to study entry For LABC",
            "to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer",
            "Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of"
        ]
    },
    {
        "id": "2e1d4811-ae58-4b81-b53a-dbcb8c980a08",
        "primaryId": "NCT00033514",
        "statement_text": "Elizabeth has HER2 positive breast cancer  she is eligible for the primary trial ",
        "statement_nums": [
            "Elizabeth has HER2 positive breast cancer  she is eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) "
        ],
        "premise_nums": [
            "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH)"
        ]
    },
    {
        "id": "d4f738c5-c99a-4d8d-b335-5821ce97fbd5",
        "primaryId": "NCT00568022",
        "secondaryId": "NCT01120184",
        "statement_text": "Completely disabled patients  totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "Completely disabled patients  totally confined to bed or",
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast Exclusion Criteria: Number of prior chemotherapy lines of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 "
        ],
        "premise_nums": [
            "of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
            "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of"
        ]
    },
    {
        "id": "f27b25bd-c28e-4aac-8ad6-951fd7381ce4",
        "primaryId": "NCT01262027",
        "statement_text": "More than 1 patient in the primary trial suffered an adverse event ",
        "statement_nums": [
            "More than 1 patient in the primary trial suffered an adverse event"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/22 (4.55%) Blood bilirubin increased 1/22 (4.55%) Alkaline phosphatase increased 1/22 (4.55%)"
        ]
    },
    {
        "id": "5311216c-94e0-4d04-acd2-b95b932ddc02",
        "primaryId": "NCT00127933",
        "secondaryId": "NCT00191789",
        "statement_text": "the primary trial recorded at least one patient with an infection  whereas in the secondary trial none where observed ",
        "statement_nums": [
            "whereas in the secondary trial none where observed",
            "the primary trial recorded at least one patient with an infection"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%) Stomatitis 1/65 (1.54%) Vomiting 2/65 (3.08%) Fatigue 1/65 (1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%) "
        ],
        "premise_nums": [
            "Catheter site cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia",
            "Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65 (1.54%) Cardiac arrest 2/65 (3.08%) Myocardial infarction 1/65 (1.54%) Diarrhoea 5/65 (7.69%)",
            "(1.54%) Jaundice 1/65 (1.54%) Neutropenic infection 2/65 (3.08%)",
            "cellulitis 1/122 (0.82%) Catheter site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia",
            "site cellulitis 0/34 (0.00%) Adverse Events 1: Total: 17/65 (26.15%) Febrile neutropenia 3/65 (4.62%) Neutropenia 2/65 (3.08%) Pancytopenia 1/65 (1.54%) Thrombocytopenia 1/65"
        ]
    },
    {
        "id": "01dfa37b-ce65-4e90-addc-395241c92f5f",
        "primaryId": "NCT00191451",
        "statement_text": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events ",
        "statement_nums": [
            "Patients in the primary trial experienced a variety of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 10/50 (20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction 1/48 (2.08%) Tachycardia 1/48 (2.08%) ",
            "Intestinal obstruction 0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48 (2.08%) "
        ],
        "premise_nums": [
            "(20.00%) Anaemia 0/50 (0.00%) Febrile neutropenia 0/50 (0.00%) Neutropenia 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "(0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "(0.00%) Thrombocytopenia 0/50 (0.00%) Diastolic dysfunction 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "Intestinal obstruction 0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 1/48",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48",
            "(0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48",
            "(0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Retching 0/50 (0.00%) Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48",
            "(0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Nausea 1/50 (2.00%) Oesophageal spasm 0/50 (0.00%) Oesophagitis 0/50 (0.00%)",
            "0/48 (0.00%)Nausea 0/48 (0.00%) Oesophageal spasm 1/48 (2.08%) Oesophagitis 0/48 (0.00%) Tachycardia 0/50 (0.00%) Intestinal obstruction 0/50 (0.00%) Nausea 1/50 (2.00%)",
            "Adverse Events 2: Total: 11/48 (22.92%) Anaemia 4/48 (8.33%) Febrile neutropenia 0/48 (0.00%) Neutropenia 2/48 (4.17%) Thrombocytopenia 2/48 (4.17%) Diastolic dysfunction"
        ]
    },
    {
        "id": "43588c50-7dc4-4d46-a53d-e94576e8ab55",
        "primaryId": "NCT03197389",
        "statement_text": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception  for the course of the study through 120 days after receiving the study medication  Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject  Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception  until 120 after receiving the study therapy  "
        ],
        "premise_nums": [
            "the course of the study through 120 days after receiving the study medication",
            "5.7.1- Contraception  until 120 after receiving the study therapy",
            "of contraception as outlined in Section 5.7.2 - Contraception  for"
        ]
    },
    {
        "id": "630a8241-b776-4799-a7ca-b1fddf17686c",
        "primaryId": "NCT00206518",
        "statement_text": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "statement_nums": [
            "for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as: Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR) Presence of in situ carcinoma in the breast  No invasive tumor in breast and no tumor in LN (pCR) Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively greater than 75% therapeutic effect 3B: Subjectively between 50% - 75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4 No or few modification of tumoral appearance (pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel ",
            "Arm/Group Description: Chemotherapy In Arm A  patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will then be conducted  if operable  following completion of neoadjuvant treatment  This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles  For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity Taxotere/Docetaxel: Taxotere doxorubicin: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery  Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants 1: 3 2: 2 3A: 18 3B: 15 3C: 18 3D: 10 4: 3 N/A: 14 "
        ],
        "premise_nums": [
            "75% therapeutic effect 3C: Subjectively between 25% - 50% therapeutic effect 3D: Subjectively smaller than 25% therapeutic effect OR Grade 4",
            "mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery  Overall Number of Participants Analyzed: 83",
            "receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery  Primary surgery will",
            "standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles",
            "cycles before surgery  Overall Number of Participants Analyzed: 83 Measure Type: Number Unit of Measure: participants",
            "using BSA = 2.0 m2. This is done in order to",
            "18 3D: 10 4: 3 N/A: 14",
            "(pNR)  Time frame: 10 years Results 1: Arm/Group Title: A: Taxotere/Docetaxel",
            "patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated",
            "which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D,"
        ]
    },
    {
        "id": "8f3fddf2-97ab-4456-bff7-8f83b27e3849",
        "primaryId": "NCT00675259",
        "secondaryId": "NCT01875367",
        "statement_text": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial but included in the secondary trial",
            "with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion: HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: immuno-histochemistry (IHC) 3+ (greater than 10% of tumor cells with complete and intense membrane staining) "
        ],
        "premise_nums": [
            "Criteria: immuno-histochemistry (IHC) 3+ (greater than 10% of tumor cells with complete and",
            "HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: immuno-histochemistry (IHC) 3+ (greater than 10% of tumor cells with complete",
            "Exclusion: HER-2 neu overexpression either by IHC 3+ or FISH+ Inclusion Criteria: immuno-histochemistry"
        ]
    },
    {
        "id": "11617367-193f-4f6b-bc3e-e58ea76d1052",
        "primaryId": "NCT00485953",
        "secondaryId": "NCT00068601",
        "statement_text": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD ",
        "statement_nums": [
            "secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously "
        ],
        "premise_nums": [
            "INTERVENTION 1: Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication",
            "Active Medicine Group risedronate 35 mg weekly INTERVENTION 2: Placebo Group Received placebo medication once weekly INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing",
            "Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before"
        ]
    },
    {
        "id": "882f22f6-36d9-4c2f-8f49-52469d570977",
        "primaryId": "NCT01840163",
        "secondaryId": "NCT02005549",
        "statement_text": "the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer ",
        "statement_nums": [
            "the primary trial and the secondary trial do not exclude patients"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male Inclusion Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer  or in situ cancer of the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; prior or concurrent systemic antitumor therapy; clinically significant cardiac disease  "
        ],
        "premise_nums": [
            "Criteria: female patients  18-70years of age; histologically-proven invasive breast cancer; no",
            "the cervix; no distant disease/secondary cancer  Exclusion Criteria: pregnant",
            "Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability"
        ]
    },
    {
        "id": "8f5423c9-17b5-4f66-aa9f-1fc9763958b2",
        "primaryId": "NCT01250379",
        "statement_text": "None of the patients in the primary trial had Thrombocytopenia  heart failure  Pancytopenia  Acute coronary syndrome or Atrial fibrillation ",
        "statement_nums": [
            "the patients in the primary trial had Thrombocytopenia  heart"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Cardiac failure * 1/238 (0.42%) Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute coronary syndrome * 0/238 (0.00%) Atrial fibrillation * 0/238 (0.00%) Cardiac failure congestive * 0/238 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Cardiac failure * 1/238 (0.42%) Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute"
        ]
    },
    {
        "id": "0c45a782-1a3d-4e9b-a258-136ab080dbb6",
        "primaryId": "NCT00846027",
        "statement_text": "None of the adverse events recorded for the primary trial occurred less than twice ",
        "statement_nums": [
            "events recorded for the primary trial occurred less than twice"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Dehydration 1/82 (1.22%) Diarrhoea 1/82 (1.22%) "
        ],
        "premise_nums": [
            "1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%)",
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Supraventricular and nodal arrhythmia 1/82 (1.22%) Anorexia 1/82 (1.22%)",
            "Adverse Events 1: Total: 21/82 (25.61%) Neutrophils count decreased 1/82 (1.22%) Cardiac ischemia/infarction 1/82 (1.22%) Left",
            "(1.22%) Anorexia 1/82 (1.22%) Gastrointestinal perforation 1/82 (1.22%) Vomiting 1/82 (1.22%) Left ventricular systolic dysfunction 1/82 (1.22%) Hypertension 1/82 (1.22%)"
        ]
    },
    {
        "id": "4e42302d-2cd9-4a91-9338-8e3b0ffb9292",
        "primaryId": "NCT00654836",
        "statement_text": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial ",
        "statement_nums": [
            "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never",
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally recurrent or metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past No known CNS disease "
        ],
        "premise_nums": [
            "metastatic disease Must have HER-2-negative breast cancer or  if HER-2-positive, must be unable to receive trastuzumab",
            "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed primary adenocarcinoma of the breast Locally"
        ]
    },
    {
        "id": "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c",
        "primaryId": "NCT00270894",
        "statement_text": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule ",
        "statement_nums": [
            "60% of Subjects in the primary trial were able to Complete",
            "of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Subjects Able to Complete greater than 85% of the Planned Dose on Schedule Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with greater than 85% of the protocol-specified dose  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1: Arm/Group Title: Neoadjuvant Therapy Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments  Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage of participants 60 "
        ],
        "premise_nums": [
            "(6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks",
            "cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75",
            "Subjects Able to Complete greater than 85% of the Planned Dose on Schedule",
            "for 4 treatments  Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: percentage",
            "(100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 treatments  Overall Number of Participants Analyzed: 30"
        ]
    },
    {
        "id": "c77c8e02-7abb-4b63-8917-01babe5cd372",
        "primaryId": "NCT00863655",
        "statement_text": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "statement_nums": [
            "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in",
            "5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular coagulation 0/238 (0.00%) "
        ],
        "premise_nums": [
            "Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238 (0.84%) Disseminated intravascular",
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Adverse Events 2: Total: 37/238 (15.55%) Anaemia 2/238"
        ]
    },
    {
        "id": "f2b14720-6ff2-4ff7-a5bc-3841b93f647e",
        "primaryId": "NCT00911898",
        "statement_text": "the primary trial does not explain its intervention in the intervention section ",
        "statement_nums": [
            "the primary trial does not explain its"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: MM-111 All participants "
        ],
        "premise_nums": [
            "INTERVENTION 1: MM-111 All participants"
        ]
    },
    {
        "id": "03e9368b-18a7-4643-a38b-a7b002403bf1",
        "primaryId": "NCT00568022",
        "secondaryId": "NCT01120184",
        "statement_text": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "disabled patients below the age of 20, totally confined to bed or chair",
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast Exclusion Criteria: Number of prior chemotherapy lines of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 "
        ],
        "premise_nums": [
            "of treatment in the metastatic setting 3 Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
            "Inclusion Criteria: Women 20 years Histologically or cytologically confirmed diagnosis of"
        ]
    },
    {
        "id": "c5dbd52d-01d4-4919-bfe9-2b7885490d6a",
        "primaryId": "NCT00422903",
        "statement_text": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "statement_nums": [
            "Monitoring Committee was highest in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Clinical Objective Response (cOR) in the Breast  Evaluated by an Independent Radiological Evaluation Monitoring Committee cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST)  CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs)  PR for TLs is defined as a greater than or equal 30% decrease in the sum of the longest diameter (LD) of TLs  taking as a reference the Baseline sum LD  For non-TLs  it is defined as the persistence of greater than or equal 1 non-TL and no new TLs or non-TLs  Time frame: From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: Arm/Group Title: Letrozole + Placebo Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage of participants CR: 2 ",
            "PR: 58Results 2: Arm/Group Title: Letrozole + Lapatinib Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 41 Measure Type: Number Unit of Measure: percentage of participants CR: 12 PR: 54 "
        ],
        "premise_nums": [
            "From Baseline (Day 1) up to 6 months  evaluated every 12 weeks Results 1: Arm/Group Title: Letrozole + Placebo",
            "tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once",
            "as a greater than or equal 30% decrease in the sum of the",
            "orally once daily for 6 months prior to surgery  Overall Number of Participants Analyzed: 48 Measure Type: Number Unit of Measure: percentage",
            "persistence of greater than or equal 1 non-TL and no new TLs or non-TLs",
            "Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered",
            "PR: 58Results 2: Arm/Group Title: Letrozole +",
            "as the disappearance of all target lesions (TLs) and non-TLs"
        ]
    },
    {
        "id": "83115abd-1c07-4ee7-8ba5-b4575be2d50f",
        "primaryId": "NCT00630032",
        "secondaryId": "NCT00428922",
        "statement_text": "Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "Patients with radiologically confirmed bone metatases are",
            "excluded from both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion criteria: Clinically or radiologically detectable metastases (M0) Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ hybridization)+ Age 18 years No prior trastuzumab  except as given in the adjuvant or neoadjuvant setting  No prior chemotherapy in the metastatic setting  Exclusion Criteria: CNS (central nervous system) metastases Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating women Major surgical procedure  open biopsy  non-healing wounds  or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study  "
        ],
        "premise_nums": [
            "or radiologically detectable metastases (M0) Histologically confirmed breast cancer with evidence of metastatic disease HER2 3+ or FISH (fluorescent in situ",
            "Prior radiation therapy within the last 4 weeks Pregnant (positive pregnancy test) or lactating",
            "or significant traumatic injury within 28 days prior to starting study or anticipation",
            "needle aspirations or core biopsies within 7 days prior to start of study"
        ]
    },
    {
        "id": "784872db-8ccf-4ddc-a432-6ee00fd0b0cc",
        "primaryId": "NCT01857882",
        "secondaryId": "NCT01439945",
        "statement_text": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention ",
        "statement_nums": [
            "the secondary trial administers Magnesium Oxide to",
            "its patients whereas the primary trial tests an education intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Decision Support Workshop The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology  Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients  Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications  advantages / disadvantages  expected post-operative course  aesthetic result and complications with probabilities Registered nurse (30 mins): preparing for surgery  postoperative recovery and how to navigate the health care system Social worker (30 mins): values clarification exercise Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: Low Dose Magnesium Oxide (800 mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  INTERVENTION 2: High Dose Magnesium Oxide (1200 mg/Day) Week 2: ",
            "Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week 3: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD)  Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD)  "
        ],
        "premise_nums": [
            "tablet of magnesium oxide orally (PO) daily (QD) Week 3: Patients take two 400 mg tablet of magnesium oxide",
            "The decision support workshop will be 2 hours in duration on the morning of",
            "answers about her personal experience INTERVENTION 2: Standard Care Routine pre-consultation education INTERVENTION 1: Low Dose Magnesium Oxide (800",
            "mg/Day) Week 2: Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week",
            "tablet of magnesium oxide orally (PO) daily (QD) Weeks 4-9: Patients take three 400 mg tablet of magnesium oxide",
            "daily (QD)  Weeks 4-9: Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD) Week"
        ]
    },
    {
        "id": "adae7d81-bc8e-48e4-b966-27c2633eb72d",
        "primaryId": "NCT02131064",
        "statement_text": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples ",
        "statement_nums": [
            "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples tpCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy  tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer [AJCC] staging system  7th edition)  Percentage of participants with tpCR was reported  Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: Arm/Group Title: TCH + P ",
            "Arm/Group Description: Participants received pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion  trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles) Overall Number of Participants Analyzed: 221 Measure Type: Number ",
            "Unit of Measure: Percentage of Participants 56.1 (49.29 to 62.76)"
        ],
        "premise_nums": [
            "period (up to a total of 18 cycles) Overall Number of Participants Analyzed: 221 Measure Type: Number",
            "resected breast specimen and all sampled ipsilateral lymph nodes (",
            "3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance",
            "period (up to a total of 18 cycles) Overall Number of Participants 56.1 (49.29 to 62.76",
            "milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period  Participants received",
            "Time frame: Pre-surgery (within 6 weeks after neoadjuvant therapy; up to approximately 6 months) Results 1: Arm/Group Title:",
            "Participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion q3w for rest of the cycles (12",
            "(mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period",
            "the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg",
            "that is [i.e.]  ypT0/is, ypN0 in the American Joint Committee on Cancer",
            "Unit of Measure: Percentage of Participants 56.1 (49.29 to 62.76",
            "IV infusion  docetaxel 75 milligrams per square meter (mg/m^2) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period"
        ]
    },
    {
        "id": "4ee4061e-a532-459e-8d03-3055bd92419c",
        "primaryId": "NCT00082810",
        "statement_text": "Throughout the duration of the primary trial  pariticpants receive tipifarnib more often than Fulvestrant ",
        "statement_nums": [
            "the duration of the primary trial  pariticpants receive tipifarnib"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28",
            "mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in",
            "on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of"
        ]
    },
    {
        "id": "4cbb7f8f-ea60-453d-b4ab-e967944426d3",
        "primaryId": "NCT00992225",
        "statement_text": "Only 2 of the 16 adverse event types recorded in the primary trial  occurred more than once ",
        "statement_nums": [
            "Only 2 of the 16 adverse event types recorded in the primary trial  occurred more than"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33 (3.03%) Nausea 1/33 (3.03%) Vomiting 1/33 (3.03%) Fatigue 1/33 (3.03%) Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased 1/33 (3.03%) Dehydration 2/33 (6.06%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 10/33 (30.30%) Constipation 1/33 (3.03%) Dysphagia 1/33 (3.03%) Ileus 1/33",
            "Pain 1/33 (3.03%) Sepsis 2/33 (6.06%) Urinary tract infection 1/33 (3.03%) Alanine aminotransferase increased 1/33 (3.03%) Aspartate aminotransferase increased"
        ]
    },
    {
        "id": "47f11df7-6c82-4c50-9249-5085313a5064",
        "primaryId": "NCT00209092",
        "secondaryId": "NCT00631852",
        "statement_text": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial  but not for the secondary trial ",
        "statement_nums": [
            "be accepted for the primary trial  but not for the secondary trial",
            "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed breast carcinoma  Inclusion Criteria: Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging "
        ],
        "premise_nums": [
            "invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging",
            "Inclusion Criteria: Histologically or cytologically confirmed breast"
        ]
    },
    {
        "id": "3114ff0f-184c-48ba-b33d-631505cffeef",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Ascites  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "trial reported a combined total of 3 cases of Ascites  Asthenia and Gastritis in cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Ascites * 1/101 (0.99%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Ascites * 1/101 (0.99%) Gastritis * 1/101 (0.99%) Asthenia"
        ]
    },
    {
        "id": "edf31a43-a774-4f2a-8a02-89b84de941bb",
        "primaryId": "NCT02595372",
        "statement_text": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response ",
        "statement_nums": [
            "27.6% of Patients Who Have Fatty Acid",
            "(FASN) Expression in the primary trial treated with High Dose"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery  A patient is considered to have FASN expression if the positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression is evaluated using immunohistochemistry in core biopsy samples  The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: Arm/Group Title: High Dose Omeprazole Treatment Arm/Group Description: Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery  Overall Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3) "
        ],
        "premise_nums": [
            "Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until",
            "Number of Participants Analyzed: 29 Measure Type: Number Unit of Measure: percentage of participants 72.4 (52.8 to 87.3)",
            "positivity was greater than or equal 15% at the baseline or after 4-7 days of Omeprazole monotherapy  FASN expression",
            "will be calculated with an exact 95% confidence interval  Time frame: Up to 6 months Results 1: Arm/Group Title: High Dose Omeprazole"
        ]
    },
    {
        "id": "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109",
        "primaryId": "NCT01596751",
        "secondaryId": "NCT00193050",
        "statement_text": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts ",
        "statement_nums": [
            "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial",
            "or Fever between the primary trial and the secondary trial patient cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Nausea/Vomiting 1/110 (0.91%) Nausea 1/110 (0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%) Infection - Pneumonia 1/110 (0.91%) Dyspnea 2/110 (1.82%) Hypoxia 1/110 (0.91%) "
        ],
        "premise_nums": [
            "(0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110",
            "Dysphagia 0/5 (0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110",
            "(0.91%) Fever 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)",
            "(0.00%) Fever 0/5 (0.00%) Adverse Events 1: Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)",
            "Total: 17/110 (15.45%) Hemoglobin [1]1/110 (0.91%) Esophagitis 1/110 (0.91%) Dysphagia 1/110 (0.91%) Febrile Neutropenia 11/110 (10.00%) Infection - Other [2]1/110 (0.91%)"
        ]
    },
    {
        "id": "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with patients body weight ",
        "statement_nums": [
            "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib ",
            "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  "
        ],
        "premise_nums": [
            "With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be paired with LBH589 and will range in dose from 825",
            "will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days",
            "Treatment cycles will be 21 days in length  Once determined safety Lapatinib: Lapatinib  1000 mg PO daily will be added to",
            "825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once",
            "825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib",
            "be administered orally twice daily for 14 days out of every 21 days",
            "days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the"
        ]
    },
    {
        "id": "5a076708-c8d4-4341-9c1d-3ee762f57be5",
        "primaryId": "NCT03456427",
        "secondaryId": "NCT02685566",
        "statement_text": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial",
        "statement_nums": [
            "intervention sections of the primary trial and the secondary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: All Study Participants: Patient Assisted Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression  The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness  The technologist will then guide the subject to achieve appropriate compression level  sufficient but not excessive  and the image will be acquired  This will be done for both standard views CC & MLO  INTERVENTION 2: All Study Participants: Technologist Compression All subjects will undergo standard of care imaging on one breast  The other breast will be imaged using Patient-Assisted Compression (PAC)  followed by Technologist-controlled (TC) Compression  Technologist-Controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site  INTERVENTION 1: FFDM Plus DBT Breast Images with FFDM and DBT FFDM Plus DBT: FujiFilm Aspire Cristalle System  "
        ],
        "premise_nums": [
            "Plus DBT: FujiFilm Aspire Cristalle System"
        ]
    },
    {
        "id": "98a946b0-2be1-474c-b373-043f329ba261",
        "primaryId": "NCT02038010",
        "secondaryId": "NCT00764322",
        "statement_text": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib ",
        "statement_nums": [
            "primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration",
            "Neither the primary trial or the secondary trial are measuring Percentage of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)  A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication  Lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE Time frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes ",
            "Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM Time frame: 4 months "
        ],
        "premise_nums": [
            "following first dose of BYL719 that is determined to be at least possibly related to study medication",
            "Toxicity Criteria for adverse events version 4.0 (except for hyperglycemia)",
            "a dose interruption of more than 7 consecutive days of BYL719. In general adverse events (AEs) will",
            "Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes",
            "A DLT is described any grade 3 or higher  clinically significant toxicity (excluding alopecia)",
            "following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death",
            "is described any grade 3 or higher  clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of",
            "Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 DLTs of BYL719 in combination with T-DM1 will be assessed using National Cancer Institute's",
            "has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM",
            "experienced during the first 21 days following first dose of BYL719 that baseline and after 4 months of treatment; The most common CYP2D6",
            "4 Life-threatening or disabling AE Grade 5 Death related to AE Time frame: The 1st 21 days (Cycle 1) of treatment Outcome Measurement:"
        ]
    },
    {
        "id": "b82e6861-3908-43e9-8e54-cf60c7d96a4e",
        "primaryId": "NCT00721409",
        "secondaryId": "NCT02413320",
        "statement_text": "Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial ",
        "statement_nums": [
            "are eligible for the primary trial but not for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Inoperable estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients with newly diagnosed stage I (Tgreater than 1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy "
        ],
        "premise_nums": [
            "estrogen receptor positive and HER2 negative breast cancer  Inclusion Criteria: Patients",
            "newly diagnosed stage I (Tgreater than 1cm), II or III triple"
        ]
    },
    {
        "id": "b8e5baf7-ddc5-407f-84d3-4c93224477cd",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event ",
        "statement_nums": [
            "either cohort of the secondary trial that did not experience",
            "of patients in the primary trial experienced adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) ",
            "Alopecia 57/57 (100.00%)Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) "
        ],
        "premise_nums": [
            "1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation",
            "malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%)",
            "23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33",
            "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52",
            "Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%)",
            "2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%)",
            "Alopecia 57/57 (100.00%)Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after",
            "neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%)",
            "Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%)",
            "Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before",
            "Alopecia 57/57 (100.00%)Adverse Events 2: Total: 23/23 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before"
        ]
    },
    {
        "id": "79c34b71-a90f-4ddb-9aee-5f61f71f0846",
        "primaryId": "NCT01277757",
        "statement_text": "the primary trial is not testing a novel Physiotherapy or chemotherapy intervention ",
        "statement_nums": [
            "the primary trial is not testing a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28 days  "
        ],
        "premise_nums": [
            "orally once a week on days 1, 8, 15, and 22. Starting dose 200 mg  courses repeat every 28",
            "INTERVENTION 1: Akt Inhibitor MK-2206 Akt Inhibitor MK-2206 orally once a week on days 1, 8, 15, and 22. Starting"
        ]
    },
    {
        "id": "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62",
        "primaryId": "NCT02995980",
        "statement_text": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial ",
        "statement_nums": [
            "patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue",
            "be eligilbe for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category c or d)  "
        ],
        "premise_nums": [
            "Inclusion Criteria: Glomerular filtration rategreater than 60 Heterogeneously or extremely dense breasts (BI-RADS category"
        ]
    },
    {
        "id": "02d5fe7a-60e2-422f-98c0-92461b8fa13f",
        "primaryId": "NCT00438659",
        "secondaryId": "NCT01271725",
        "statement_text": "the primary trial and the secondary trial have a topical intervention  to be applied to the breast or face ",
        "statement_nums": [
            "the primary trial and the secondary trial have a topical intervention"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm A  INTERVENTION 1: Afatinib Monotherapy Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Afatinib and Paclitaxel or Vinorelbine Combination Therapy Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy "
        ],
        "premise_nums": [
            "area (breast or chest wall) for the duration of",
            "Patients could have dose reduced if 40 mg was not tolerated  INTERVENTION 2:",
            "once daily at a dose of 40 milligram (mg) film-coated tablets until progression of",
            "Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous",
            "INTERVENTION 1: Mometasone Patients apply 2.5 mL mometasone furoate cream once daily to",
            "have dose reduced if 40 mg was not tolerated  INTERVENTION 2: Placebo Patients apply 2.5 mL of an identical-appearing placebo cream to",
            "for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once daily at a dose of 40 milligram (mg) film-coated tablets until"
        ]
    },
    {
        "id": "869e413e-01c5-4a9e-8a4a-b6079f7ae300",
        "primaryId": "NCT00996632",
        "secondaryId": "NCT01644890",
        "statement_text": "Emily has an Inoperable non-metastatic breast cancer  she is eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Inoperable breast cancer Inclusion Criteria: Written informed consent of the patient signed by herself  Histologically confirmed metastatic or recurrent adenocarcinoma of the breast  Aged 20 to 74 at the time of informed consent  Exclusion Criteria: Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer  "
        ],
        "premise_nums": [
            "the breast  Aged 20 to 74 at the time of informed",
            "signed by herself  Histologically confirmed metastatic or recurrent"
        ]
    },
    {
        "id": "c0b528ef-ae9f-4c01-8915-b47856f07c95",
        "primaryId": "NCT01142661",
        "statement_text": "the primary trial accepts patients with grade 3 neuropathy ",
        "statement_nums": [
            "the primary trial accepts patients with grade 3 neuropathy"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol: Existing anti-cancer therapy-related toxicities of Grade greater than /= 2, except that alopecia and Grade 2 neuropathy are acceptable  "
        ],
        "premise_nums": [
            "2, except that alopecia and Grade 2 neuropathy are acceptable"
        ]
    },
    {
        "id": "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial the majority of patients had Stable Disease  none of them had complete or partial response ",
        "statement_nums": [
            "By week 48 of the primary trial the majority of patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o  Overall Number of Participants Analyzed: 49 Measure Type: Number ",
            "Unit of Measure: participants Patients with measurable disease at baseline: 39Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 "
        ],
        "premise_nums": [
            "Outcome Measurement: Best Overall Response of Everolimus and Exemestane",
            "confirmed CR or PR by week 48. Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane",
            "receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o  Overall",
            "- Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease",
            "two determinations of CR at least 4 weeks apart before progression are required",
            "measurable disease at baseline: 39Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0",
            "Number of Participants Analyzed: 49 Measure Type: Number"
        ]
    },
    {
        "id": "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff",
        "primaryId": "NCT02455453",
        "statement_text": "Patients with tumors that are HER2 negative  PR and ER positive are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-. "
        ],
        "premise_nums": [
            "types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-."
        ]
    },
    {
        "id": "01236718-14da-450c-8051-0207d31743a5",
        "primaryId": "NCT02555657",
        "statement_text": "The Median time from randomization to death due to any cause  was a month longer for patients in cohort 1 of the primary trial  compared to those in cohort 2.",
        "statement_nums": [
            "for patients in cohort 1 of the primary trial  compared to those in cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the time from randomization to death due to any cause  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall Number of Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: Arm/Group Title: Chemotherapy Arm/Group Description: Participants received capecitabine  eribulin  gemcitabine  or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice  TPC) in accordance with local regulations and guidelines  Overall Number of Participants Analyzed: 98 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7) "
        ],
        "premise_nums": [
            "Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 11.6 (8.3 to 13.7)",
            "Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10 Overall survival (OS) was defined as the",
            "Pembrolizumab Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)  Overall",
            "Participants Analyzed: 96 Median (95% Confidence Interval) Unit of Measure: Months 12.7 (9.9 to 16.3) Results 2: Arm/Group Title: Chemotherapy",
            "Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1: Arm/Group Title: Pembrolizumab Arm/Group"
        ]
    },
    {
        "id": "2048912d-9e9f-4cbc-89cc-19020f20a976",
        "primaryId": "NCT01966471",
        "secondaryId": "NCT00981812",
        "statement_text": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial ",
        "statement_nums": [
            "excluded from both the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Known hormone receptor status of the primary tumor Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy Exclusion Criteria: subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months "
        ],
        "premise_nums": [
            "receptor status of the primary tumor Adequately excised: participants must",
            "has had chemotherapy within the past 12 months"
        ]
    },
    {
        "id": "f5907902-d4d1-4d73-a196-7fbe0dcb44ad",
        "primaryId": "NCT00245219",
        "secondaryId": "NCT00038103",
        "statement_text": "the primary trial and the secondary trial both have control groups ",
        "statement_nums": [
            "the primary trial and the secondary trial both have control groups"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Health Tracking (Control) Participants assigned to the health-tracking condition received usual care and did not attend any meetings  INTERVENTION 2: Peer Support The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another  Patients completed a weekly diary of critical experiences or current life problems as homework  and were then encouraged to share these experiences in the group meetings  The group facilitator encouraged participants to help one another with these issues  and share how they had dealt with similar problems  INTERVENTION 1: Exemestane (Exemestane Alone) oral dose exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination (Exemestane + Celecoxib) oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily) "
        ],
        "premise_nums": [
            "exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)",
            "exemestane taken with food (25 mg tablet once daily) INTERVENTION 2: Combination"
        ]
    },
    {
        "id": "93a8e018-ac25-48b2-81d2-fd5b01be8f37",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "statement_text": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial ",
        "statement_nums": [
            "to those in the primary trial",
            "of patients in the secondary trial suffured from infection compared"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41 (2.44%) Hypokalemia 1/41 (2.44%) Bicarbonate 1/41 (2.44%) SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%) Hypoalbuminemia 1/41 (2.44%) Leukocytes 1/41 (2.44%) Hemoglobin 1/41 (2.44%) Neutrophils 1/41 (2.44%) INR 1/41 (2.44%) PTT 1/41 (2.44%) Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) ",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41",
            "Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%)",
            "Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)"
        ]
    },
    {
        "id": "d72c45e5-6654-4afe-91a0-1f47b0c13dc0",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast  with ipsilateral nodes pN2. She is eligible for the primary trial ",
        "statement_nums": [
            "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive",
            "with ipsilateral nodes pN2. She is eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. "
        ],
        "premise_nums": [
            "ipsilateral nodes must be pN2 or pN3.",
            "be determined to be HER2-positive prior to study entry  Assays",
            "than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive",
            "require a strongly positive (3+) staining score  By pathologic evaluation"
        ]
    },
    {
        "id": "e68b5690-11fd-4567-8dcc-dec91d1e4bb8",
        "primaryId": "NCT01033032",
        "statement_text": "The only adverse event recorded in the primary trial was one single case of spinal fracture ",
        "statement_nums": [
            "event recorded in the primary trial was one single case"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) "
        ],
        "premise_nums": [
            "(33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%)",
            "PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%)",
            "1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%)",
            "(0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%)",
            "1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) PLEURAL EFFUSION 1/3 (33.33%) PNEUMONITIS 0/3 (0.00%)"
        ]
    },
    {
        "id": "e1417a26-2f40-4dd6-b598-e66e57312595",
        "primaryId": "NCT01931163",
        "secondaryId": "NCT00274469",
        "statement_text": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were recorded as having LACRIMAL DISORDER ",
        "statement_nums": [
            "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER",
            "than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER  0% of the secondary trial patients were"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22 (4.55%) papilledema 1/22 (4.55%) Nausea 1/22 (4.55%) hyperglycemia 1/22 (4.55%) Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%) ",
            "Adverse Events 2:Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) "
        ],
        "premise_nums": [
            "21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%)",
            "1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE",
            "Adverse Events 1: Total: 6/22 (27.27%) Thrombocytopenia 1/22 (4.55%) leucocytopenia 1/22 (4.55%) neutropenia 1/22",
            "(0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101",
            "FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103 (0.97%) BLINDNESS 20/103 (0.00%)",
            "FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%)",
            "20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%)",
            "Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%)",
            "(0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101",
            "FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%)",
            "Adverse Events 2:Total: 22/103 (21.36%) LYMPHADENOPATHY 1/103 (0.97%) FEBRILE NEUTROPENIA 21/103 (0.97%) ATRIAL FIBRILLATION 1/103 (0.97%) ARRHYTHMIA 21/103 (0.97%)",
            "FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%) CARDIAC FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%)",
            "FAILURE 22/101 (1.98%) CARDIAC FAILURE CONGESTIVE 20/101 (0.00%) CORONARY OSTIAL STENOSIS 20/101 (0.00%) LACRIMAL DISORDER 0/101 (0.00%) BLINDNESS 21/101 (0.99%)",
            "21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE",
            "(0.97%) ARRHYTHMIA 21/103 (0.97%) CARDIAC FAILURE 20/103 (0.00%) CARDIAC FAILURE CONGESTIVE 21/103 (0.97%) CORONARY OSTIAL STENOSIS 21/103 (0.97%) LACRIMAL DISORDER 1/103",
            "Adverse Events 1: Total: 24/101 (23.76%) LYMPHADENOPATHY 0/101 (0.00%) FEBRILE NEUTROPENIA 20/101 (0.00%) ATRIAL FIBRILLATION 1/101 (0.99%) ARRHYTHMIA 20/101 (0.00%)",
            "(0.97%) BLINDNESS 20/103 (0.00%) GASTRIC ULCER 0/103 (0.00%) NAUSEA 0/103 (0.00%) BLINDNESS 21/101 (0.99%) GASTRIC ULCER 1/101 (0.99%) NAUSEA 1/101 (0.99%)"
        ]
    },
    {
        "id": "6ee89773-958b-4eb9-bc67-18fa98a70c2d",
        "primaryId": "NCT00365365",
        "statement_text": "the primary trial only recorded one type of acute adverse event ",
        "statement_nums": [
            "the primary trial only recorded one type"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 23/78 (29.49%) Febrile neutropenia * 4/78 (5.13%) Neutropenia * 1/78 (1.28%) Thrombocytopenia * 0/78 (0.00%) Acute coronary syndrome * 1/78 (1.28%) Cardiac failure congestive * 1/78 (1.28%) Myocardial infarction * 1/78 (1.28%) Cardiomyopathy * 0/78 (0.00%) Abdominal pain * 1/78 (1.28%) Diarrhoea * 1/78 (1.28%) Upper gastrointestinal haemorrhage * 1/78 (1.28%) "
        ],
        "premise_nums": [
            "(29.49%) Febrile neutropenia * 4/78 (5.13%) Neutropenia * 1/78 (1.28%) Thrombocytopenia * 0/78 (0.00%) Acute coronary syndrome * 1/78"
        ]
    },
    {
        "id": "4d776c28-8ed1-4f3f-9837-0821029d3775",
        "primaryId": "NCT00063570",
        "statement_text": "None of the patients in cohort 1 of the primary trial had a platlet deficiency  and none of the patients in cohort 2 were constipated ",
        "statement_nums": [
            "none of the patients in cohort 2 were constipated",
            "None of the patients in cohort 1 of the primary trial had a platlet deficiency"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Pyrexia 1/21 (4.76%) ",
            "Hepatic failure 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Sepsis 0/21 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%)",
            "Hepatic failure 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%)",
            "(0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21",
            "7 Anaemia 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)",
            "(3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)",
            "(1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain 1/52 (1.92%) Constipation 1/52 (1.92%)",
            "(1.92%) Pyrexia 2/52 (3.85%) Hepatic failure 1/52 (1.92%) Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%)",
            "Hyperbilirubinaemia 1/52 (1.92%) Device related infection 1/52 (1.92%) Pneumonia 2/52 (3.85%) Sepsis 1/52 (1.92%) Adverse Events 2: Total: 7 Anaemia 0/21 (0.00%)",
            "(0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%)Hyperbilirubinaemia 0/21 (0.00%) Device related infection 0/21 (0.00%) Pneumonia 0/21 (0.00%)",
            "(0.00%) Thrombocytopenia 1/21 (4.76%) Abdominal pain 0/21 (0.00%) Constipation 0/21 (0.00%) Febrile neutropenia 1/21 (4.76%) Pancytopenia 0/21 (0.00%) Thrombocytopenia 1/21",
            "Adverse Events 1: Total: 17 Anaemia 2/52 (3.85%) Febrile neutropenia 4/52 (7.69%) Pancytopenia 1/52 (1.92%) Thrombocytopenia 0/52 (0.00%) Abdominal pain"
        ]
    },
    {
        "id": "50e54a67-9cfb-4259-b810-2e9bc0b09b4c",
        "primaryId": "NCT00611624",
        "secondaryId": "NCT00600340",
        "statement_text": "the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy ",
        "statement_nums": [
            "the primary trial and the secondary trial require patients to undergo"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Five Days of Mammosite Therapy [Not Specified] INTERVENTION 1: Bevacizumab Plus Paclitaxel Bevacizumab 10 mg/kg intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks "
        ],
        "premise_nums": [
            "3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every 3 weeks",
            "8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15 mg/kg i.v.  day 1, every",
            "4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2: Bevacizumab Plus Capecitabine Bevacizumab 15",
            "mg/m² twice-daily  days 1-14, every 3 weeks  Capecitabine 1000 mg/m² twice-daily  days 1-14, every",
            "intravenous (i.v.)  days 1 and 15, every 4 weeks  Paclitaxel 90 mg/m2, days 1, 8 and 15, every"
        ]
    },
    {
        "id": "9f23f617-b8ec-4665-ad0b-9a9bc8b19691",
        "primaryId": "NCT00688740",
        "secondaryId": "NCT00191815",
        "statement_text": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts ",
        "statement_nums": [
            "primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts",
            "adverse events in the primary trial and the secondary trial is Neutropenia with a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 267/744 (35.89%) Neutropenia *2/744 (0.27%) Anaemia *1/744 (0.13%) Leukopenia *1/744 (0.13%) Thrombocytopenia *1/744 (0.13%) Thrombotic thrombocytopenic purpura *1/744 (0.13%) Atrial flutter *1/744 (0.13%) Cardiac arrest *1/744 (0.13%) Myocardial ischaemia *1/744 (0.13%) Arrhythmia *0/744 (0.00%) Cardiac failure congestive *0/744 (0.00%) Adverse Events 2: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736 (0.00%) Thrombocytopenia *0/736 (0.00%) ",
            "Thrombotic thrombocytopenic purpura *0/736 (0.00%)Atrial flutter *0/736 (0.00%) Cardiac arrest *0/736 (0.00%) Myocardial ischaemia *0/736 (0.00%) Arrhythmia *2/736 (0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) "
        ],
        "premise_nums": [
            "(1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%)",
            "(0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "ischaemia *0/736 (0.00%) Arrhythmia *2/736 (0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67",
            "failure congestive *1/736 (0.14%) Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "Thrombotic thrombocytopenic purpura *0/736 (0.00%)Atrial flutter *0/736 (0.00%) Cardiac arrest",
            "1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%)",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "(0.27%) Cardiac failure congestive *1/736 (0.14%) Adverse Events 1: Total: 67/736 (9.10%) Neutropenia *1/736 (0.14%) Anaemia *0/736 (0.00%) Leukopenia *0/736"
        ]
    },
    {
        "id": "b76c9c21-64f7-487b-bf08-e232a9da0174",
        "primaryId": "NCT01490892",
        "secondaryId": "NCT02364388",
        "statement_text": "The intervention in the primary trial requires an injection and two different imaging modalities  whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment ",
        "statement_nums": [
            "The intervention in the primary trial requires an injection and",
            "modalities  whereas the secondary trial firstly requires a consultation followed"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: 3D HI and SHI of UCA Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) 3D HI and SHI of UCA: Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) INTERVENTION 1: MAESTRO Baseline "
        ],
        "premise_nums": [
            "Perflutren injection  suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging"
        ]
    },
    {
        "id": "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb",
        "primaryId": "NCT00206427",
        "statement_text": "A patient in the primary trial had a fungal infection of the mouth ",
        "statement_nums": [
            "A patient in the primary trial had a fungal infection"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49 (2.04%) Febrile neutropenia *1/49 (2.04%) Left Ventricular Systolic Dysfunction *1/49 (2.04%) Constipation *1/49 (2.04%) Mucositis-oral *1/49 (2.04%) Infection-oral thrush *1/49 (2.04%) rash *1/49 (2.04%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49"
        ]
    },
    {
        "id": "d6b09c0f-979c-4151-87f9-830b964e275d",
        "primaryId": "NCT01216176",
        "statement_text": "Urosepsis was the most common adverse event in the primary trial ",
        "statement_nums": [
            "adverse event in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive Heart Failure [2]0/12 (0.00%) Diverticulitis 0/12 (0.00%) Cholecystitis 0/12 (0.00%) Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/12 (25.00%) Atrial fibrillation 0/12 (0.00%) Cardiac ischemia/infarction [1]0/12 (0.00%) Congestive",
            "Hyperbilirubinemia 0/12 (0.00%) Urosepsis 2/12 (16.67%) Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) Rash [3]0/12 (0.00%)"
        ]
    },
    {
        "id": "92da8d30-a7e9-4fb4-95e4-484b53279ad7",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "statement_text": "the primary trial and the secondary trial monitor the DFS of their patient cohorts  however the secondary trial reports the % of patients with DFS greater than or equal 5 years whereas the primary trial reports % of participants with DFS greater than or equal 2 years ",
        "statement_nums": [
            "with DFS greater than or equal 2 years",
            "with DFS greater than or equal 5 years whereas the primary trial and the secondary trial monitor the DFS of",
            "with DFS greater than or equal 5 years whereas the primary trial reports %"
        ],
        "label": "Entailment",
        "premise_text": [
            "Disease-free Survival (DFS) Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening  This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam  and laboratory and radiographic surveillance  The primary objective of the study is disease-free survival (DFS) at 24 months  Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years Disease Free Survival was defined as the interval from the date of randomization to the date of local  regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first  Disease free survival was estimated using the Kaplan-Meier method  Time frame: From randomization until relapse or death or up to 5 years "
        ],
        "premise_nums": [
            "relapse or death or up to 5 years",
            "every three months for the first 24 months after completion of primary therapies and every six months",
            "frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years Disease Free Survival was",
            "Participants With Disease Free Survival at 5 Years Disease Free Survival was defined as",
            "Disease-free survival (DFS) for all patients regardless of randomization will",
            "Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With"
        ]
    },
    {
        "id": "762c3b23-547a-40cb-86c9-767294f4a142",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial  due to her age ",
        "statement_nums": [
            "A 56 year old patient with a masectomy would",
            "be eligible for the primary trial  due to her"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) "
        ],
        "premise_nums": [
            "Criteria: Female  age 18 or older Intact breast (not surgically absent)"
        ]
    },
    {
        "id": "95a509d6-2990-49ac-b36c-aedf842f17ee",
        "primaryId": "NCT01111825",
        "statement_text": "There were no observed cases of Constipation  Diarrhoea  oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial ",
        "statement_nums": [
            "or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8 (0.00%) Nausea 0/8 (0.00%) Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia 0/6 (0.00%) Polycythaemia 0/6 (0.00%) ",
            "Acute coronary syndrome 0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Diarrhoea 0/6 (0.00%) Nausea 0/6 (0.00%) Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%) "
        ],
        "premise_nums": [
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "(37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:",
            "(0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2: Total: 2/6 (33.33%) Anaemia 0/6 (0.00%) Febrile neutropenia",
            "Stomatitis 0/6 (0.00%) Upper gastrointestinal haemorrhage 0/6 (0.00%) Vomiting 0/6 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%)",
            "0/6 (0.00%)Vertigo 0/6 (0.00%) Eyelid oedema 0/6 (0.00%) Constipation 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Total: 3/8 (37.50%) Anaemia 0/8 (0.00%) Febrile neutropenia 0/8 (0.00%) Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%)",
            "Polycythaemia 0/8 (0.00%) Acute coronary syndrome 0/8 (0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Diarrhoea 0/8",
            "(0.00%) Vertigo 0/8 (0.00%) Eyelid oedema 1/8 (12.50%) Constipation 0/8 (0.00%) Vomiting 0/6 (0.00%) Chest pain 1/6 (16.67%)",
            "Stomatitis 0/8 (0.00%) Upper gastrointestinal haemorrhage 0/8 (0.00%) Vomiting 0/8 (0.00%) Chest pain 0/8 (0.00%) Adverse Events 2:"
        ]
    },
    {
        "id": "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6",
        "primaryId": "NCT00258960",
        "statement_text": "One patient in the primary trial experienced a grade 4 adverse event ",
        "statement_nums": [
            "One patient in the primary trial experienced a grade 4 adverse event"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 16/48 (33.33%) Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%) "
        ],
        "premise_nums": [
            "grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Catheter - related",
            "Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%)",
            "cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis",
            "grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade",
            "grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48",
            "(2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis",
            "cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48",
            "(2.08%) Catheter - related infection grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade",
            "(6.25%) Neutropenia grade 3 1/48 (2.08%) Holocraneal cephalea 1/48 (2.08%) Hypersensibility reaction grade 3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis",
            "Febrile neutropenia grade 3 3/48 (6.25%) Neutropenia grade 3 1/48 (2.08%) Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48",
            "3 2/48 (4.17%) Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) Catheter - related infection grade 3 1/48 (2.08%)"
        ]
    },
    {
        "id": "19c2c2d7-4c33-4842-9ed4-02cfae663ce2",
        "primaryId": "NCT00066573",
        "secondaryId": "NCT01091454",
        "statement_text": "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial ",
        "statement_nums": [
            "There was 1 case of night blindness in the primary trial  and 0 in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy 1/3761 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%) Ocular - Other 1/3761 (0.03%) Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) ",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) Ocular - Other 0/3759 (0.00%) Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) "
        ],
        "premise_nums": [
            "0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Supraven.arrhyth  Atrial flutter 1/3761 (0.03%) Ventric.arrhyth  Trigeminy",
            "Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "Adverse Events 1: Total: 19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth",
            "0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "19/3761 (0.51%) Cardiac ischemia/infarction 3/3761 (0.08%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth  Atrial",
            "(4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Restrictive cardiomyopathy 0/3759 (0.00%) Supraven.arrhyth  Atrial",
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48",
            "Adverse Events 2: Total: 7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 1/3761 (0.03%) Restrictive cardiomyopathy 1/3761 (0.03%) Supraven.arrhyth",
            "7/3759 (0.19%) Cardiac ischemia/infarction 0/3759 (0.00%) Left ventricular systolic dysfunction 0/3759 (0.00%) Supraven.arrhyth  Atrial flutter 0/3759 (0.00%)",
            "Ventric.arrhyth  Trigeminy 0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%)",
            "0/3759 (0.00%)Hypothyroidism 1/3759 (0.03%) Blurred vision 0/3759 (0.00%) Nyctalopia 1/3759 (0.03%) Hypothyroidism 0/3761 (0.00%) Blurred vision 1/3761 (0.03%) Nyctalopia 0/3761 (0.00%)"
        ]
    },
    {
        "id": "1fdaafdc-766b-488e-9cc4-cbcad74ade97",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib ",
        "statement_nums": [
            "In the primary trial and the secondary trial the only drugs administered",
            "primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm 1 (Paclitaxel  Carboplatin) Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV INTERVENTION 2: Arm 2 (Veliparib  Paclitaxel  Carboplatin) ",
            "Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV Veliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  "
        ],
        "premise_nums": [
            "1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 21 days for 4 courses in the absence of disease progression",
            "receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and",
            "IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression",
            "saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression",
            "unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin",
            "Given IV Cyclophosphamide: Given IV INTERVENTION 2: Arm 2 (Veliparib  Paclitaxel",
            "Given IV Veliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients",
            "PO BID on days 1-5. Patients also receive paclitaxel IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days"
        ]
    },
    {
        "id": "0d75c493-58ce-4a45-8823-a9a1126751b3",
        "primaryId": "NCT00916578",
        "statement_text": "the primary trial is testing a combination of chemotherapy and radiotherapy ",
        "statement_nums": [
            "the primary trial is testing a combination"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  "
        ],
        "premise_nums": [
            "Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the",
            "Radiation therapy doses will be 50-57 Gy to the initial clinical target volume",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy doses will be 50-57 Gy to the initial clinical target volume"
        ]
    },
    {
        "id": "d0d4e184-0764-4c28-9af7-4535c7ed1aad",
        "primaryId": "NCT00303108",
        "statement_text": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "statement_nums": [
            "Cohort 2 of the primary trial produced marginally better results than cohort 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity  whichever came first  assessed up to 54 months  Results 1: Arm/Group Title: D+C and Taxane Naive Arm/Group Description: Doxil  Carboplatin and Taxane naive Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) Results 2: Arm/Group Title: D+C and Taxane Pretreated Arm/Group Description: Doxil  Carboplatin and Taxane pretreated Overall Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 42 Measure Type: Number Unit of Measure: percentage of participants 31.0 (17.6 to 47.1)",
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: percentage of participants 30.8 (17.0 to 47.6) Results 2: Arm/Group Title: D+C",
            "came first  assessed up to 54 months  Results 1: Arm/Group",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "until the date of first documented progression or date of"
        ]
    },
    {
        "id": "e45886af-1edd-4987-a280-2609a86fd3dd",
        "primaryId": "NCT02413320",
        "statement_text": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks   are eligible for the primary trial ",
        "statement_nums": [
            "have recieved chemotherapy in the last 4 weeks   are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: No prior chemotherapy  endocrine therapy or radiation therapy with therapeutic intent for this cancer Female subjects age 18 - 70 years "
        ],
        "premise_nums": [
            "for this cancer Female subjects age 18 - 70 years"
        ]
    },
    {
        "id": "c207ff16-b7d0-49e4-9177-0597044f3008",
        "primaryId": "NCT03374995",
        "statement_text": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks  others participants may have it administered by ubcutaneous injection ",
        "statement_nums": [
            "keratin are administered it topically twice daily for approximately 3-6 weeks  others participants may have"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies "
        ],
        "premise_nums": [
            "of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary",
            "studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care)",
            "receive topical keratin topically at least BID until the end of"
        ]
    },
    {
        "id": "35234f08-cf01-478f-b739-600b5a6ea3d9",
        "primaryId": "NCT00550771",
        "statement_text": "16/179 patients in the primary trial Experienced Cardiac Events  with the majority of those coming from cohort 2.",
        "statement_nums": [
            "majority of those coming from cohort 2.",
            "16/179 patients in the primary trial Experienced Cardiac Events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF)  myocardial infarction or arrhythmia  or probable cardiac death defined as sudden  unexpected death within 24 hours of a definite or probable cardiac event  or severe symptomatic HF  concomitant with a left ventricular ejection fraction (LVEF) drop of greater than 10 percentage points from baseline and to 50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks  Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin (PLD) Based Regimen ",
            "Arm/Group Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 120 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses) ",
            "Overall Number of Participants Analyzed: 59Measure Type: Number Unit of Measure: Participants 11 "
        ],
        "premise_nums": [
            "IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over",
            "Description: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab",
            "60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by",
            "IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by",
            "as sudden  unexpected death within 24 hours of a definite or probable cardiac",
            "from baseline and to smaller than 50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks  Time frame:",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given",
            "21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for",
            "600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose",
            "2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of",
            "Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package",
            "fraction (LVEF) drop of greater than 10 percentage points from baseline and to smaller than 50% LVEF; the LVEF drop was",
            "over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed: 59Measure Type: Number Unit of Measure:",
            "IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4",
            "60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80",
            "weeks  Time frame: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment Results 1: Arm/Group Title: Pegylated Liposomal Doxorubicin",
            "Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab",
            "Insert for a Total Duration of 1 Year Cardiac events defined as: Level 1:",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes given every 21 days for 4 courses (12 weeks) followed by",
            "courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes given weekly for 12 weeks (4 courses)Overall Number of Participants Analyzed:",
            "80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)Overall Number of",
            "Number of Participants Analyzed: 59Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen",
            "IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given every 21 days for 4 courses (12 weeks) followed by",
            "Unit of Measure: Participants 5 Results 2: Arm/Group Title: Doxorubicin Based Regimen Arm/Group Description: doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide"
        ]
    },
    {
        "id": "87adb323-6f56-4e1a-a04d-8437ac571eab",
        "primaryId": "NCT01805089",
        "statement_text": "Patients with Lactiferous duct carcinomas are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer "
        ],
        "premise_nums": [
            "lobular carcinoma in situ or stages 1-3 breast cancer"
        ]
    },
    {
        "id": "94410f2c-9c1c-4130-b479-738e343ba9f7",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "statement_text": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial ",
        "statement_nums": [
            "interventions used in the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days  "
        ],
        "premise_nums": [
            "laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules"
        ]
    },
    {
        "id": "f66f4c30-2d39-4e29-876a-487bca9a8ccf",
        "primaryId": "NCT02835625",
        "secondaryId": "NCT00486525",
        "statement_text": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions",
        "statement_nums": [
            "the primary trial and the secondary trial do not use any"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Digital Breast Tomosynthesis Digital Breast Tomosynthesis + Synthetic Mammography (DBT) The DBT was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2: Digital Mammography The digital mammograms was independently read by two radiologists  A consensus meeting decided whether to recall the woman or not  Women selected for further assessment (positive screening exam) was recalled  Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  "
        ],
        "premise_nums": [
            "Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis  INTERVENTION 2:",
            "in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also",
            "meeting decided whether to recall the woman or not"
        ]
    },
    {
        "id": "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6",
        "primaryId": "NCT00452673",
        "statement_text": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities ",
        "statement_nums": [
            "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population Safety was assessed from first dose of study drug through at least 30 days after the last dose  until resolution of drug-related toxicity or when toxicity was deemed irreversible  whichever was longer  An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade greater than or equal 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy  Time frame: Day 1 to 30 days post last dose Results 1: Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine ",
            "Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID  Participants were treated at each dose level (DL) for minimum of 21 days before accrual to the next DL  Rules for dose escalation: If 0 dose level toxicity (DLT) was observed in the first 3 participants in a cohort  the next higher cohort was opened to accrual  If 1 DLT was observed in the first 3 participants in a cohort  then 3 additional participants were studied  If 0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)  the next higher cohort was opened for accrual  If greater than or equal 2 DLT was observed in up to 6 subjects  then the maximum tolerated dose (MTD) was exceeded and the next lower DL was defined as the MTD  If 0 DLT was observed in 6 participants in a cohort and the next higher DL exceeded the MTD  then intermediate DLs would be studied  Once the MTD was determined  additional participants were enrolled into that dose group Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: participants 1 "
        ],
        "premise_nums": [
            "a cohort  then 3 additional participants were studied  If 0 DLT was observed in 6 participants in a cohort and",
            "(DLT) was observed in the first 3 participants in a cohort  then 3 additional participants were studied  If 0",
            "Time frame: Day 1 to 30 days post last dose Results 1: Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine",
            "of study drug through at least 30 days after the last dose level (DL) for minimum of 21 days before accrual to the",
            "were studied  If 0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)",
            "0 DLT was observed in those 3 (ie  1 DLT in 6 subjects at the DL)  the next",
            "Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily",
            "dose level (DL) for minimum of 21 days before accrual to the next DL",
            "study drugs and were: Clinically-evident toxicity of Grade greater than or equal 3, or of Grade 2 which",
            "Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral",
            "If 0 DLT was observed in 6 participants in a cohort and the next",
            "if it occurred in the first 21 days and was at least possibly related",
            "of study drug through at least 30 days after the last dose  until resolution of",
            "3, or of Grade 2 which required interruption of treatment for greater than or equal 2 DLT was observed in up to 6",
            "into that dose group Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: participants",
            "If greater than or equal 2 DLT was observed in up to 6 subjects  then the maximum",
            "3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which",
            "3, or of Grade 2 which required interruption of treatment for greater than or equal 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory"
        ]
    },
    {
        "id": "011991a5-724d-4b95-b9ab-9e1371d77368",
        "primaryId": "NCT00086957",
        "statement_text": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia ",
        "statement_nums": [
            "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Diarrhea * 0/2 (0.00%) Melaena * 0/2 (0.00%) Mucositis oral * 0/2 (0.00%) Nausea * 0/2 (0.00%) Vomiting * 0/2 (0.00%) Catheter related infection * 0/2 (0.00%) Infection NOS * 0/2 (0.00%) Leukopenia * 1/2 (50.00%) "
        ],
        "premise_nums": [
            "(100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%) Leukopenia * 1/2 (50.00%)",
            "Adverse Events 1: Total: 2/2 (100.00%) Febrile neutropenia * 2/2 (100.00%) Haemorrhage NOS * 0/2 (0.00%) Abdominal pain * 0/2 (0.00%)"
        ]
    },
    {
        "id": "8421197a-3a35-4738-b1c8-83cce0ac4115",
        "primaryId": "NCT02896855",
        "secondaryId": "NCT00171314",
        "statement_text": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial ",
        "statement_nums": [
            "the secondary trial recorded more total occurences",
            "adverse events than the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120 (0.00%) Large intestine polyp 0/120 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%) Oesophagitis 1/122 (0.82%) ",
            "Large intestine polyp 0/122 (0.00%)Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%) ",
            "Acute myocardial infarction 0/269 (0.00%)Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) "
        ],
        "premise_nums": [
            "Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%) Oesophagitis 1/122",
            "injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy",
            "(2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%)Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%)",
            "block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%)",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254",
            "(0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade",
            "1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%)",
            "(20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "(0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%)",
            "disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia",
            "(0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia",
            "artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%)",
            "0/254 (0.00%) Bundle branch block left 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis",
            "2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122 (7.38%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122",
            "Total: 47/254 (18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254",
            "(20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%)Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block",
            "Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular",
            "Adverse Events 1: Total: 23/120 (19.17%) Febrile neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular",
            "Acute myocardial infarction 0/269 (0.00%)Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%)",
            "disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "(20.82%) Anaemia 1/269 (0.37%) Febrile neutropenia 0/269 (0.00%) Lymphadenopathy 0/269 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)",
            "Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)",
            "Lymphadenopathy 1/254 (0.39%) Acute myocardial infarction 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%)",
            "injury 1/120 (0.83%) Pneumonia 3/120 (2.50%) Adverse Events 2: Total: 30/122 (24.59%) Febrile neutropenia 3/122 (2.46%) Leukopenia 3/122 (2.46%) Neutropenia 9/122",
            "failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Coronary artery stenosis 1/254 (0.39%) Adverse Events 2: Total: 56/269 (20.82%) Anaemia 1/269",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 0/120 (0.00%) Ventricular arrhythmia 1/120 (0.83%) Ascites 0/120 (0.00%) Oesophagitis 0/120",
            "(18.50%) Anaemia 1/254 (0.39%) Febrile neutropenia 1/254 (0.39%) Lymphadenopathy 1/254 (0.39%) Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle",
            "neutropenia 4/120 (3.33%) Leukopenia 2/120 (1.67%) Neutropenia 8/120 (6.67%) Cardiac tamponade 2/122 (1.64%) Ventricular arrhythmia 0/122 (0.00%) Ascites 1/122 (0.82%)",
            "Acute myocardial infarction 0/269 (0.00%)Angina pectoris 3/269 (1.12%) Angina unstable 1/269 (0.37%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269",
            "intestine polyp 0/122 (0.00%)Death 1/122 (0.82%) Liver injury 0/122 (0.00%) Pneumonia 5/122 (4.10%) Adverse Events 1: Total: 47/254 (18.50%) Anaemia 1/254",
            "disease 1/269 (0.37%) Coronary artery stenosis 0/269 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)",
            "Angina pectoris 0/254 (0.00%) Angina unstable 0/254 (0.00%) Bundle branch block left 1/269 (0.37%) Cardiac failure 1/269 (0.37%) Coronary artery disease",
            "0/254 (0.00%) Cardiac failure 4/254 (1.57%) Coronary artery disease 0/254 (0.00%) Death 1/120 (0.83%) Liver injury 1/120 (0.83%) Pneumonia 3/120 (2.50%)"
        ]
    },
    {
        "id": "d09091f1-3fc5-498b-8c59-4678590c8464",
        "primaryId": "NCT03176238",
        "secondaryId": "NCT01498458",
        "statement_text": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons can be made due to the significant differences in cohort sizes ",
        "statement_nums": [
            "with Enterocolitis in the secondary trial than in cohort 1 of the primary trial  no robust comparisons"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Acute myocardial infarction 0/199 (0.00%) Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac failure 1/199 (0.50%) Cardiopulmonary failure 1/199 (0.50%) Left ventricular failure 1/199 (0.50%) Supraventricular tachycardia 0/199 (0.00%) Ventricular tachycardia 1/199 (0.50%) Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8 (12.50%) Hepatotoxicity 3/8 (37.50%) Pancreatectomy * 1/8 (12.50%) "
        ],
        "premise_nums": [
            "0/199 (0.00%) Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac failure 1/199 (0.50%) Cardiopulmonary failure 1/199 (0.50%) Left ventricular failure",
            "Supraventricular tachycardia 0/199 (0.00%) Ventricular tachycardia 1/199 (0.50%) Adverse Events 1: Total: 6/8 (75.00%) Thrombocytopenia 1/8 (12.50%) Hypertension 1/8",
            "Supraventricular tachycardia 0/199 (0.00%) Ventricular tachycardia 1/199 (0.50%) Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199",
            "Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Acute myocardial infarction 0/199 (0.00%) Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac",
            "failure 1/199 (0.50%) Left ventricular failure 1/199 (0.50%) Supraventricular tachycardia 0/199 (0.00%) Ventricular tachycardia 1/199 (0.50%) Adverse Events 1:",
            "Atrial fibrillation 1/199 (0.50%) Cardiac arrest 1/199 (0.50%) Cardiac failure 1/199 (0.50%) Left ventricular failure 1/199 (0.50%) Supraventricular tachycardia 0/199",
            "Adverse Events 1: Total: 59/199 (29.65%) Anaemia 7/199 (3.52%) Thrombocytopenia 2/199 (1.01%) Acute myocardial infarction 0/199 (0.00%) Atrial fibrillation 1/199"
        ]
    },
    {
        "id": "fc7d8ffd-9896-4806-a095-d435cde83c88",
        "primaryId": "NCT00528567",
        "secondaryId": "NCT01196052",
        "statement_text": "The total number of patients affected by adverse events in cohort 2 the primary trial  is larger than the cohort size of the secondary trial ",
        "statement_nums": [
            "affected by adverse events in cohort 2 the primary trial  is larger than",
            "cohort size of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Pyrexia 2/148 (1.35%) Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%) "
        ],
        "premise_nums": [
            "related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea",
            "Cellulitis 1/148 (0.68%) Device related infection 2/148 (1.35%) Gastroenteritis viral 1/148 (0.68%) Gastrointestinal infection 1/148 (0.68%) Upper respiratory tract",
            "Adverse Events 2: Total: 250/1271 (19.67%) Adverse Events 1: Total: 15/148 (10.14%) Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal",
            "Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%)",
            "Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Diarrhoea",
            "Febrile neutropenia 1/148 (0.68%) Atrial fibrillation 2/148 (1.35%) Abdominal pain 1/148 (0.68%) Upper respiratory tract infection 1/148 (0.68%)"
        ]
    },
    {
        "id": "23116aca-0064-4426-b147-7af688a82443",
        "primaryId": "NCT00876395",
        "secondaryId": "NCT02287675",
        "statement_text": "Men suffering from Ulcerative colitis are excluded from the primary trial  but eligible for the secondary trial ",
        "statement_nums": [
            "are excluded from the primary trial  but eligible for the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract  Inclusion Criteria: The subject must be female and 18 years of age or older  The subject must be a preoperative clinical Tis  T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer The subject must have a diagnosis of primary breast cancer  The subject must be a candidate for surgical intervention  either with lumpectomy and SLNB or with mastectomy and SLNB  as the treatment of her breast cancer  The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2 The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study Exclusion Criteria: The subject has clinical or radiological or pathologic evidence of metastatic cancer  including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes  The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB  ",
            "The subject has a positive pregnancy test or is lactating The subject has had prior surgery to the indicated breast or axilla  "
        ],
        "premise_nums": [
            "Group (ECOG) performance status of Grade 0 - 2 The subject must provide written informed consent",
            "as well as clinical N0 and clinical M0 breast cancer The subject must be female and 18 years of age or older",
            "Tis  T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer The subject must have a"
        ]
    },
    {
        "id": "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4",
        "primaryId": "NCT00005879",
        "secondaryId": "NCT01217385",
        "statement_text": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female  over the age of 21 and british ",
        "statement_nums": [
            "for entry to the primary trial and the secondary trial is that patients must",
            "female  over the age of 21 and british"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Current random fine needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a BRCAPRO risk of at least 25% Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries  must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram ",
            "Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2No active cancer (e.g.  detectable disease) Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any Performance status: Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 1,000/mm^3 No deficiencies in protein C  protein S  or antithrombin III No activated protein C resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 1.5 mg/dL Cardiovascular: No history of deep venous thrombosis not related to trauma or pregnancy No severe coronary artery disease No history of prior stroke Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No other active cancer No retinal vein thrombosis No concurrent severe poorly controlled migraine ",
            "No factor V Leiden mutation carrierPRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration At least 12 months since prior chemotherapy Endocrine therapy: Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration At least 12 months since prior tamoxifen  raloxifene  or other antihormonal therapy Radiotherapy: At least 3 months since prior radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new medication that would be ingested for 1 or more months Inclusion Criteria Pathologically confirmed diagnosis of invasive breast cancer  determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy; ",
            "Tumor size greater than 2cm, measured on imaging or estimated by physical exam;No contraindications for primary chemotherapy; Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant therapy; Age 18 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II); Normal organ and marrow function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) 2.5 times the institutional upper limit of normal; creatinine within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; If female  postmenopausal for a minimum of one year  OR surgically sterile  OR not pregnant  confirmed by a pregnancy test as per institutional Standard of Care (SOC)  and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation; ",
            "Able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines;Exclusion Criteria Previous treatment (chemotherapy  radiation  or surgery) to involved breast; including hormone therapy; Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy  other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix  from which the patient has been disease free for less than 5 years  "
        ],
        "premise_nums": [
            "a known mutation in BRCA1 or BRCA2 Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine levels above institutional",
            "baseline aspiration Must continue all hormone replacement therapy and/or oral contraceptives within 6 months of baseline aspiration Must continue all",
            "Tumor size greater than 2cm, measured on imaging or",
            "neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients with creatinine",
            "100 U/L Alkaline phosphatase less than 200 U/L Renal: Creatinine less than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "12 months Hematopoietic: Hemoglobin greater than 10 g/dL Granulocyte count greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "resistance Hepatic: Albumin greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than 200 U/L",
            "be a candidate for primary systemic (neoadjuvant) therapy and for",
            "specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Any",
            "on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries",
            "must have been taken during days 1-14 of the menstrual cycle for premenopausal women",
            "modified Gail risk of at least 4% Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "modified Gail risk of at least 4% Hyperplasia without atypia but with a 10-year modified Gail risk of at least",
            "Hyperplasia without atypia but with a 10-year modified Gail risk of at least 25% Hyperplasia without atypia but with a",
            "Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% Hyperplasia without atypia but with a",
            "Not specified Life expectancy: At least 12 months Hematopoietic: Hemoglobin greater than 1.5 mg/dL AST less than 100 U/L Alkaline phosphatase less than",
            "normal institutional limits; OR creatinine clearance 30 mL/min/1.73 m2 for patients withan 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "medication that would be ingested for 1 or more months Inclusion Criteria Pathologically confirmed",
            "CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior immunotherapy Chemotherapy: At least 3 months between completion of prior KUMC phase",
            "use effective contraception during and for 3 months after study No other active cancer",
            "been disease free for less than 5 years or older; ECOG Performance Status 2 (Karnofsky 60%; see Appendix II);",
            "radiotherapy Surgery: At least 6 months between prior oophorectomy and baseline aspiration Other: At least 2 weeks since the start of other new",
            "pelvic sonogram within past 6 months showing endometrial thickening no greater than 3.0 g/dL Bilirubin less than 1.5 mg/dL AST less than",
            "atypia but with a 10-year modified Gail risk of at leastudy requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy",
            "physical exam;No contraindications for primary chemotherapy; Planned definitive breast surgery",
            "genetic testing performed for BRCA1 and BRCA2No active cancer (e.g.  detectable",
            "compliance with study requirements; Medically unstable; Under age 18; Pregnant or nursing; Previous malignancy",
            "a BRCAPRO risk of at least 25% Hyperplasia without atypia but with stepwedge within past 6 months If intact uterus and/or ovaries",
            "one year  OR surgically sterile  OR not",
            "function as follows: leukocytes 3,000/μl; absolute neutrophil count 1,500/μl; platelets 100,000/μl; total bilirubin within normal institutional limits;",
            "needle breast aspiration (FNA) evidence of 1 of the following: Hyperplasia with atypia Hyperplasia"
        ]
    },
    {
        "id": "98850daf-738c-4005-b476-8c5479ad3b79",
        "primaryId": "NCT00033514",
        "statement_text": "Mark has HER2 positive breast cancer  he is eligible for the primary trial ",
        "statement_nums": [
            "Mark has HER2 positive breast cancer  he is eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH) "
        ],
        "premise_nums": [
            "Inclusion Criteria: Women aged greater than 18 years Histologically documents metastatic breast cancer HER2 positive using Fluorescence In Situ Hybridization (FISH)"
        ]
    },
    {
        "id": "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c",
        "primaryId": "NCT00916578",
        "statement_text": "the primary trial is testing a combination of capecitabine once daily with radiotherapy ",
        "statement_nums": [
            "the primary trial is testing a combination"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Single Arm Institution  Open Label  Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will be administered when patients receives radiation therapy  Radiation therapy doses will be 50-57 Gy to the initial clinical target volume  "
        ],
        "premise_nums": [
            "Phase II Patients will received 825 mg/m2 bid of capecitabine  One of the",
            "Radiation therapy doses will be 50-57 Gy to the initial clinical target volume",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy  Capecitabine will",
            "doses of capecitabine will be taken 2 hours before receiving radiotherapy doses will be 50-57 Gy to the initial clinical target volume"
        ]
    },
    {
        "id": "a4ed4cc0-9444-4a5d-863c-578fd42b8794",
        "primaryId": "NCT00425854",
        "statement_text": "Intervention of Cohort B is described as Afatinib 50 mg  taken orally  bi-weekly ",
        "statement_nums": [
            "Cohort B is described as Afatinib 50 mg  taken orally  bi-weekly"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd "
        ],
        "premise_nums": [
            "Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd"
        ]
    },
    {
        "id": "be1c82e6-200d-4bef-b723-c78655fa40e5",
        "primaryId": "NCT00291694",
        "statement_text": "the primary trial does not specificy the route of administration of its intervention ",
        "statement_nums": [
            "the primary trial does not specificy the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months "
        ],
        "premise_nums": [
            "receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized"
        ]
    },
    {
        "id": "790047b1-43e3-486e-b41c-eaa89026eae7",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11.1% of patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients had Unexpected adverse events ",
        "statement_nums": [
            "In the primary trial 11.1% of patients had serious adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) Unexpected AE: 71.6 (60.5 to 81.1) Unexpected ADR: 24.7 (15.8 to 35.5) "
        ],
        "premise_nums": [
            "Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage",
            "South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to",
            "to end of the study about 6 months for each patient  Results 1:",
            "participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to",
            "20.1) Serious ADR: 0 (0 to 4.4) Unexpected AE: 71.6 (60.5 to 81.1) Unexpected ADR: 24.7 (15.8 to",
            "Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81.1) Unexpected ADR: 24.7 (15.8 to 35.5)"
        ]
    },
    {
        "id": "fc8ed290-e2b3-4eea-a837-d369dcd9b5da",
        "primaryId": "NCT00875979",
        "statement_text": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events ",
        "statement_nums": [
            "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Nausea 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%) Diarrhoea 0/3 (0.00%) Gastritis 0/3 (0.00%) Ileus 0/3 (0.00%) Fatigue 0/3 (0.00%) Pyrexia 0/3 (0.00%) Pain 0/3 (0.00%) Hepatic cirrhosis 0/3 (0.00%) Cellulitis 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%)",
            "1: Total: 0/3 (0.00%) Pericardial effusion 0/3 (0.00%) Tachycardia 0/3 (0.00%) Vomiting 0/3 (0.00%) Abdominal pain 0/3 (0.00%) Colitis 0/3 (0.00%)"
        ]
    },
    {
        "id": "207b0895-91de-4238-8d50-e2b8b7420fb0",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "statement_text": "In total there were more adverse events in the secondary trial than in the primary trial ",
        "statement_nums": [
            "adverse events in the secondary trial than in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: Total: 6/17 (35.29%) "
        ],
        "premise_nums": [
            "Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication",
            "Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: Total: 6/17 (35.29%)",
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%)"
        ]
    },
    {
        "id": "1340769c-b55c-480c-a4c4-130034e128ce",
        "primaryId": "NCT00317720",
        "statement_text": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial ",
        "statement_nums": [
            "Patients must have at least 1 prior treatment with trastuzumab to be eligible"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: History of trastuzumab resistance  defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer  Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy)for metastatic breast cancer  Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible  "
        ],
        "premise_nums": [
            "may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based"
        ]
    },
    {
        "id": "a4d6e27f-737b-4597-86e1-79b3f064cbee",
        "primaryId": "NCT02694029",
        "statement_text": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds ",
        "statement_nums": [
            "of holding their breath underwater for 30 seconds",
            "Candidates for the primary trial are expected to be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Women with diagnosis of breast malignancy Women whom requires left chest wall post-mastectomy radiation with or without bolus Age 18 years  Performance status ECOG smaller than /=3 Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry  for the duration of study participation  and for 90 days following completion of therapy  Should a woman become pregnant or suspect she is pregnant while participating in this study  she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent  Patient must be able to maintain a 30 second breath hold  Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with or without a boost (boost will not be evaluated for endpoints) Exclusion Criteria: Uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements  Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants  "
        ],
        "premise_nums": [
            "of study participation  and for 90 days following completion of therapy  Should",
            "must be able to maintain a 30 second breath hold  Conventional chest wall",
            "radiation with or without bolus Age 18 years  Performance status ECOG smaller than /=3 Women of child-bearing potential must agree to",
            "able to maintain a 30 second breath hold  Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with"
        ]
    },
    {
        "id": "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43",
        "primaryId": "NCT00887575",
        "secondaryId": "NCT01610284",
        "statement_text": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial ",
        "statement_nums": [
            "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/41 (7.32%) Adverse Events 1: Total: 146/573 (25.48%)"
        ]
    },
    {
        "id": "030eded8-6513-4028-b1fe-fefd6dd388ad",
        "primaryId": "NCT02429427",
        "statement_text": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial",
        "statement_nums": [
            "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin  white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit   Alkaline phosphatase less or equal to 1.5 x upper normal limit   Serum creatinine less than 1.5 x upper normal limit "
        ],
        "premise_nums": [
            "phosphatase less or equal to 1.5 x upper normal limit   Serum",
            "equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 100 x 109/l, Serum bilirubin less than",
            "cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal",
            "neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than",
            "blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or"
        ]
    },
    {
        "id": "d1d77877-9c85-41c8-9eca-6fd75b254a15",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial due to her age ",
        "statement_nums": [
            "take part in the primary trial due to her age",
            "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan "
        ],
        "premise_nums": [
            "skin ulceration Has known allergy or intolerance to triclosan",
            "Inclusion Criteria: 18 years of age or older with written"
        ]
    },
    {
        "id": "c32d1b74-07ab-4afb-9db6-878e20727661",
        "primaryId": "NCT02279108",
        "statement_text": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial",
            "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically proved infiltrating breast cancer (ductal  lobular carcinoma…) or a carcinoma in-situ with an elevated risk of micro-invasion  (High grade with necrosis  radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal or multifocal but in same quarter Size smaller than 5cm clinically palpable or not Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed informed consent by patient or legally responsable authority Patient registered to a social security system No surgical contra-indication Exclusion Criteria: Mammary carcinoma recurrence Previous same side mammary reduction Previous lumpectomy Contra-indication to surgery Pregnant or breast feeding patient Denial of participation "
        ],
        "premise_nums": [
            "Clinically or ultrasound axillary N0 Isotopic sentinel node detection Adult patient Signed",
            "in same quarter Size smaller than 5cm clinically palpable or not",
            "radiologically evaluated size more than 40mm, or immediate mastectomy…) Unifocal"
        ]
    },
    {
        "id": "ba0c0dc6-826b-426f-8738-eec23e47f6b0",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 2 months prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "had a hip replacement 2 months prior  she is not elgible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication "
        ],
        "premise_nums": [
            "study with investigational product during last 30 days Inability or unwillingness to comply with",
            "previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence",
            "of vascular access) within 4 weeks before study treatment Evidence of severe"
        ]
    },
    {
        "id": "77982c81-d147-48d9-909c-18b9a98224e9",
        "primaryId": "NCT01301729",
        "secondaryId": "NCT02129556",
        "statement_text": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial ",
        "statement_nums": [
            "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%) Retinal vein occlusion 0/6 (0.00%) Gastroenteritis 1/6 (16.67%) Vomiting 1/6 (16.67%) Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%) ",
            "Anemia 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) Gastroenteritis 0/52 (0.00%) Vomiting 0/52 (0.00%) Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/6 (66.67%) Anemia 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 1/6 (16.67%)",
            "tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32",
            "duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%)",
            "1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Adverse Events 1:",
            "Diarrhea 0/6 (0.00%) Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo",
            "0/6 (0.00%) Takotsubo cardiomyopathy 1/6 (16.67%) Pericardial effusion 0/6 (0.00%) Vertigo 0/52 (0.00%) Retinal vein occlusion 1/52 (1.92%) Gastroenteritis 0/52 (0.00%)",
            "Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%) Hepatic hemorrhage 1/52 (1.92%)",
            "Death 2/6 (33.33%) Bile duct dilatation 0/6 (0.00%) Hepatic hemorrhage 0/6 (0.00%) Adverse Events 2: Total: 25/52 (48.08%)",
            "Diarrhea 1/52 (1.92%) Death 9/52 (17.31%) Bile duct dilatation 1/52 (1.92%)Takotsubo cardiomyopathy 0/52 (0.00%) Pericardial effusion 2/52 (3.85%) Vertigo 0/52 (0.00%)",
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32"
        ]
    },
    {
        "id": "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec",
        "primaryId": "NCT00687440",
        "secondaryId": "NCT01307891",
        "statement_text": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx  Docetaxe and Trastuzumab ",
        "statement_nums": [
            "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants Who Had a Tumor Response  According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions  taking as reference the baseline sum LD) response  Time frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months after end of treatment  Results 1: Arm/Group Title: Caelyx  Docetaxel  Trastuzumab Arm/Group Description: Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end of this stage  based on the number of cardiac events  subjects will proceed to a second stage or restart with a lower dose of Caelyx  Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab  Overall Number of Participants Analyzed: 26 Measure Type: Number ",
            "Unit of Measure: Participants Participants who had a complete tumor response: 2Participants who had a partial tumor response: 13 Participants who did not have a tumor response: 11 Outcome Measurement: Objective Response Rate Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI  Responses include the following: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) best response from the start of treatment until disease progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients will be evaluated for response every 8 weeks  Patients with disease progression will be taken off the study  Overall Number of Participants Analyzed: 39 ",
            "Measure Type: NumberUnit of Measure: percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane Alone Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1) "
        ],
        "premise_nums": [
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will",
            "percentage of patients 28 (14.9 to 45.0) Results 2: Arm/Group Title: Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8,",
            "Time frame: Week 09, Week 18, at the end of each patient's",
            "will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered",
            "evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 26 Measure Type: Number",
            "docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles  At the end",
            "Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of patients 38 (18 to 61.1)",
            "either complete (disappearance of all target lesions) or partial (at 100 mg/m2 X 3 doses on Days 1, 8, and 15",
            "basis by an IV infusion over 30 minutes  Patients will be evaluated for response every 2 cycles (every 8 weeks)",
            "either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Abraxane at 100 mg/m2 X 3 doses on Days 1,",
            "will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to",
            "Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the",
            "frame: Week 09, Week 18, at the end of each patient's treatment  and at 3, 6, 9, and 12 months",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will be evaluated for response every 2 cycles (every 8 weeks)",
            "at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals  Abraxane will be administered",
            "will be evaluated for response every 2 cycles (every 8 weeks)  Overall Number of Participants Analyzed: 21",
            "progression  Time frame: Baseline to 6 months Results 1: Arm/Group Title: Abraxane + Tigatuzumab",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will receive Caelyx one day every 3 weeks in combination with docetaxel",
            "a partial tumor response: 13 Participants who did not have a tumor response: 11 Outcome Measurement: Objective Response Rate Patient response",
            "tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then",
            "5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles  Patients",
            "Days 1, 8, and 15 at 28-day intervals  Abraxane will be evaluated for response every 8 weeks  Patients with disease"
        ]
    },
    {
        "id": "2e03f6f1-0d4f-4ebf-8781-20918d70d78f",
        "primaryId": "NCT02165605",
        "statement_text": "A 56 year old patient with a masectomy would not be eligible for the primary trial",
        "statement_nums": [
            "be eligible for the primary",
            "A 56 year old patient with a masectomy would"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Female  age 18 or older Intact breast (not surgically absent) "
        ],
        "premise_nums": [
            "Criteria: Female  age 18 or older Intact breast (not surgically absent)"
        ]
    },
    {
        "id": "57e74ef2-f170-47bd-a908-2a7b3cec150d",
        "primaryId": "NCT00482391",
        "statement_text": "Patients with No QT prolongation are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "No QT prolongation (greater than 500 ms) "
        ],
        "premise_nums": [
            "No QT prolongation (greater than 500 ms)"
        ]
    },
    {
        "id": "b5957a75-140f-445b-99dc-199b8182b8ed",
        "primaryId": "NCT01805089",
        "statement_text": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial ",
        "statement_nums": [
            "are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: History of ductal carcinoma in situ  lobular carcinoma in situ or stages 1-3 breast cancer Postmenopausal "
        ],
        "premise_nums": [
            "lobular carcinoma in situ or stages 1-3 breast cancer Postmenopausal"
        ]
    },
    {
        "id": "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b",
        "primaryId": "NCT00486525",
        "statement_text": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently ",
        "statement_nums": [
            "two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Arm I: Yoga Therapy Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also encouraged to practice yoga at home  Patients recorded their total home/class practice time in weekly logs  INTERVENTION 2: Arm II: Wait-List Wait-listed women were told to continue performing their usual activities  and to refrain from beginning any yoga practice  After their final assessment they were offered the yoga classes  "
        ],
        "premise_nums": [
            "in a Hatha yoga session over 90 minutes twice weekly for 12 weeks  Patients were also"
        ]
    },
    {
        "id": "f57350c2-ac90-47ea-92b4-d903509bf07a",
        "primaryId": "NCT03252431",
        "statement_text": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time  There was no recorded difference whatsoever ",
        "statement_nums": [
            "both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle  Subjects remained in their assigned treatment arm throughout the study  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles)  Grade 4 (severe) neutropenia was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy  Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe  administered on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation) ",
            "Unit of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg fixed dose Neulasta   administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.45) "
        ],
        "premise_nums": [
            "were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each of 4 chemotherapy cycles  F-627: single dose pre-filled",
            "on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe Overall Number of Participants Analyzed: 196",
            "Eligible subjects were randomized in a 1:1 ratio  Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy",
            "Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) Results",
            "was defined as ANC smaller than 0.5 × 109/L within the first 12 days of chemotherapy  Time frame: The",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe",
            "Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group",
            "4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 197 Mean (Standard Deviation)",
            "(0.51)Results 2: Arm/Group Title: Neulasta Arm/Group Description: 6 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "Results 1: Arm/Group Title: F-627 Arm/Group Description: F-627, 20 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject",
            "4 chemotherapy cycles  F-627: single dose pre-filled syringe Overall Number of Participants Analyzed: 196 Mean (Standard Deviation) Unit of Measure: days",
            "(75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of Measure: days 0.2 (0.51)Results 2: Arm/Group Title: Neulasta Arm/Group",
            "Measurement: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 Eligible subjects were randomized in a 1:1"
        ]
    },
    {
        "id": "77c61307-567d-4ac2-a7f7-85feffd30473",
        "primaryId": "NCT00167414",
        "statement_text": "Patients do not need to have a known hormone receptor status to participate in the primary trial ",
        "statement_nums": [
            "to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Age: no limit Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different organs (liver  lung or bone)  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered  Concurrent therapy is allowed and recommended  The chemotherapy protocol type and schedule are at the discretion of the medical oncologist  Informed consent must be obtained  Pregnancy test must be negative for women of child bearing potential Exclusion Criteria: Inability of patient to be followed longitudinally as specified by protocol  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery  Women who are pregnant or nursing  Failure to meet requirements in Inclusion Criteria Contraindications to radiation  "
        ],
        "premise_nums": [
            "Concurrent therapy is allowed and recommended  The",
            "Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different"
        ]
    },
    {
        "id": "35dd977f-53d8-4400-b5cb-34caaa938e78",
        "primaryId": "NCT00764322",
        "statement_text": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months ",
        "statement_nums": [
            "Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes Measurements of plasma concentrations of the key active metabolite of tamoxifen  endoxifen  were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM)  extensive (EM)  intermediate (IM) or poor (PM) metabolism  A given patient has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM  UM/EM  EM/EM  etc.)  These diplotypes are collapsed into four phenotypes  UM  EM  IM or PM  Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers Arm/Group Description: Those with the highest transformation of the CYP2D6 genotype to allelic activity Overall Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59) ",
            "4-Month endoxifen concentration: 4 participants15.35 (5.48) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 5 Mean (Standard Deviation) Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants 8.4 (4.59)",
            "has two alleles  giving them 10 possible allelic combinations  or diplotypes (UM/UM",
            "4-Month endoxifen concentration: 4 participants15.35 (5.48)",
            "PM  Time frame: 4 months Results 1: Arm/Group Title: Ultra-rapid Metabolizers Arm/Group",
            "were measured at baseline and after 4 months of treatment; The most common CYP2D6 alleles have been grouped by functional activity"
        ]
    },
    {
        "id": "54554da5-e67f-4da5-819b-a85b7bc5d52c",
        "primaryId": "NCT00444535",
        "statement_text": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment ",
        "statement_nums": [
            "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Since there is no independent reviewer  only the investigator response was reported  Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks) Overall Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of Measure: Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12: 16 30.8% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 52 Measure Type: Count of Participants Unit of",
            "Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment The PFS rate",
            "frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab",
            "Bevacizumab Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg",
            "or death from any cause following 12 weeks of treatment  Disease progression is",
            "Time frame: up to week 12 Results 1: Arm/Group Title: Lapatinib + Bevacizumab",
            "Participants No disease progression by Week 12: 36 69.2% Disease progression or death by Week 12:",
            "Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the"
        ]
    },
    {
        "id": "592edd64-7841-4c19-ba75-583066308137",
        "primaryId": "NCT00343863",
        "statement_text": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV  oral cyclophosphamide  dexamethasone IV or orally and ondansetron IV ",
        "statement_nums": [
            "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV",
            "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloridexamethasone IV or orally and ondansetron IV"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Dexamethasone + Ondansetron IV All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)  "
        ],
        "premise_nums": [
            "receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Patients receive dexamethasone IV or orally"
        ]
    },
    {
        "id": "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial ",
        "statement_nums": [
            "of diarrhea and dyspepsia than cohort 1 of the primary trial",
            "Cohort 1 of the secondary trial recorded more cases of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%)",
            "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse",
            "Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia"
        ]
    },
    {
        "id": "3cd353ed-af0d-4356-8f45-efc1e91a2a0d",
        "primaryId": "NCT02878057",
        "statement_text": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities  are excluded from the primary trial ",
        "statement_nums": [
            "ambulatory and capable of all selfcare but unable to carry",
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) performance status of 0-1."
        ]
    },
    {
        "id": "b8473ae8-11c9-4578-aab8-ee96e6287715",
        "primaryId": "NCT00580333",
        "secondaryId": "NCT00934856",
        "statement_text": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no mimimum life expectancy define for the secondary trial ",
        "statement_nums": [
            "expectancy define for the secondary trial",
            "must have a life expectancy exceeding 3 months to particpate in the primary trial  there is no"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer For MBC participants: Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease  amenable for treatment with docetaxel History of disease progression within 3 months prior to study entry For LABC participants: Newly diagnosed locally advanced breast cancer  Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system) Exclusion Criteria: Significant cardiac disease Inadequate bone marrow  liver or renal function For MBC participants: Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases Brain metastases that are untreated  symptomatic or require therapy to control symptoms; or any radiation  surgery  or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment  For LABC participants: ",
            "Clinically or radiologically detectable metastasis (M1 disease)Participants for whom surgery as primary intent procedure is the best option to treat their disease Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease "
        ],
        "premise_nums": [
            "for whom surgery as primary intent procedure is the best",
            "Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to",
            "control symptoms from brain metastasis within 2 months of the first study treatment  For LABC",
            "Clinically or radiologically detectable metastasis",
            "docetaxel History of disease progression within 3 months prior to study entry For LABC",
            "to debilitating bone disease) HER2-positive metastatic or locally advanced breast cancer",
            "Criteria: Life expectancy of less than 12 weeks Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of"
        ]
    },
    {
        "id": "4243dc45-5a64-486d-ae2a-11448db00dcf",
        "primaryId": "NCT00246090",
        "secondaryId": "NCT00266799",
        "statement_text": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial ",
        "statement_nums": [
            "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 88/291 (30.24%) Adverse Events 2: Total: 46/102 (45.10%)"
        ]
    },
    {
        "id": "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "statement_text": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial ",
        "statement_nums": [
            "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator PFS is defined as the time from randomization until the earliest date of disease progression (PD) or death due to any cause  if sooner  The date of documented PD is defined as the date of radiological PD as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression  Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0), PD is defined as a 20% increase in the sum of the longest diameter (LD) of target lesions  taking as a reference the smallest sum LD recorded since the treatment started  or the appearance of 1 or more new lesions  Time frame: From the date of randomization until the date of the first documented progression or date of death from any cause  whichever came first  assessed for up to 46 months Results 1: Arm/Group Title: Placebo + Letrozole 2.5 mg ",
            "Arm/Group Description: Participants received 6 tablets of placebo  identical in appearance to lapatinib tablets  orally daily (approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 milligrams (mg) orally daily  preferably with the daily dose of lapatinib Overall Number of Participants Analyzed: 108 Measure Type: Count of Participants Unit of Measure: Participants 89 82.4% Results 2: Arm/Group Title: Lapatinib 1500 mg + Letrozole 2.5 mg Arm/Group Description: Participants received 6 tablets of Lapatinib orally daily (250 mg lapatinib/tablet for a total of 1500 mg of lapatinib/day; approximately at the same time each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast  Participants also received 1 tablet of letrozole 2.5 mg orally daily  preferably with the daily dose of lapatinib  Overall Number of Participants Analyzed: 111 Measure Type: Count of Participants Unit of Measure: Participants 88 79.3% Outcome Measurement: Time to Disease Progression (Initial Treatment) ",
            "Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study  whichever came first  TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months) Results 1: Arm/Group Title: Gemcitabine Plus Docetaxel Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until progression of disease at which time crossover treatment begins  Overall Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: Participants 88 79.3% Outcome Measurement: Time to Disease Progression",
            "Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79)",
            "1.0), PD is defined as a 20% increase in the sum of the",
            "Number of Participants Analyzed: 239 Median (95% Confidence Interval) Unit of Measure: Participants 89 82.4% Results 2: Arm/Group Title: Lapatinib 1500",
            "started  or the appearance of 1 or more new lesions  Time frame:",
            "1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous  day 1 every 21 days  Treatment continues until",
            "received 1 tablet of letrozole 2.5 mg orally daily  preferably with the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast",
            "first  assessed for up to 46 months Results 1: Arm/Group Title: Placebo + Letrozole",
            "each day)  either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast",
            "after breakfast  Participants also received 1 tablet of letrozole 2.5 milligrams (mg) orally daily  preferably with",
            "Docetaxel Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel",
            "of Lapatinib orally daily (250 mg lapatinib/tablet for a total of 1500 mg of lapatinib/day; approximately at the same",
            "1.0), PD is defined as a 20% increase in the sum of Lapatinib orally daily (250 mg lapatinib/tablet for a total of",
            "as a reference the smallest sum LD recorded since",
            "Unit of Measure: Participants 89 82.4% Results 2: Arm/Group Title: Lapatinib 1500 mg + Letrozole 2.5 mg Arm/Group Description: Participants received 6",
            "received 1 tablet of letrozole 2.5 mg orally daily  preferably with the date of the first documented progression or date of",
            "milligrams per meter squared (mg/m2) intravenous  days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous",
            "or 2) date of last contact for participants alive without",
            "due to study disease (up to 82 months) Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "f616e3d8-6c1a-4b99-ac79-ea87895e37b7",
        "primaryId": "NCT00902330",
        "secondaryId": "NCT00952731",
        "statement_text": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial ",
        "statement_nums": [
            "Cohort 2 of the primary trial is the control group in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Cranial Microcurrent Electrical Stimulation [CES]) Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes  The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz  and to automatically turn off at the end of 1 hour  Patients use their CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES) Patients receive a CES unit as in arm I  but the ear-lobe electrodes do not pass electrical current  Patients use their CES unit once daily in weeks 1-18. sham intervention: Given once a day for 18 weeks INTERVENTION 1: Treatment Gel + Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily  oral placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 weeks  INTERVENTION 2: ",
            "Placebo Gel + Oral TreatmentPlacebo gel applied to the breasts daily  20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules)  tamoxifen citrate: 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel applied to breasts daily for 4-10 weeks  "
        ],
        "premise_nums": [
            "preset to provide 1 hour of 100 μA (sub-sensory level)  modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz",
            "CES unit is preset to provide 1 hour of 100 μA (sub-sensory level)  modified",
            "placebo: Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily",
            "Hz  and to automatically turn off at therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II",
            "CES unit once daily in weeks 1-18. energy-based therapy: Given once a day for 18 weeks INTERVENTION 2: Arm II (Sham CES)",
            "Oral Placebo 4-hydroxytamoxifen gel 2mg/breast applied daily  Oral placebo taken daily for 4-10 weeks  afimoxifene: 2mg/breast applied daily",
            "a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of",
            "Hz  and to automatically turn off at the end of 1 hour  Patients use their",
            "(2) 10mg capsules) for 4-10 weeks  placebo gel: Placebo gel",
            "gel applied to breasts daily for 4-10 weeks"
        ]
    },
    {
        "id": "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710",
        "primaryId": "NCT01073865",
        "statement_text": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial ",
        "statement_nums": [
            "of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation  "
        ],
        "premise_nums": [
            "and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of randomisation",
            "Inclusion Criteria: Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation  and 2) E2",
            "1) last menses within 1 year of randomisation  and 2) E2 10 pg/mL and FSH 30 mIU/mL within 4 weeks of"
        ]
    },
    {
        "id": "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5",
        "primaryId": "NCT02187744",
        "statement_text": "sepsis  due to the presence of an implanted device was a common adverse event in the primary trial",
        "statement_nums": [
            "adverse event in the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Device related sepsis 1/113 (0.88%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Device related sepsis 1/113 (0.88%)"
        ]
    },
    {
        "id": "af677d94-a376-42ea-93fe-91963a071199",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "statement_text": "Patients with dysphagia cannot participate in the secondary trial  but may be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial",
            "cannot participate in the secondary trial  but may be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer requiring additional surgical resection Stage I  II or III disease Patient has ability to give signed informed consent Normal hepatic and renal function (creatininesmaller than 1.5, transaminases smaller than 1.5 times upper limit of normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy for breast cancer Abnormal liver function test Liver or kidney problems that would interfere with metabolism of study drug Any condition that would hamper informed consent or ability to comply with study protocol Participation in another research study in the last three months Known malignancy at any site other than breast Recent consumption of green tea (5 or more cups per day  within one week prior to biopsy) Allergy or intolerance to any component of green tea Inability or refusal to comply with definitive surgical therapy Inclusion Criteria: Able to swallow and retain oral medication  "
        ],
        "premise_nums": [
            "consumption of green tea (5 or more cups per day  within",
            "normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy",
            "0 or 1. Age 21 years and less than 75 Exclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer",
            "research study in the last three months Known malignancy at"
        ]
    },
    {
        "id": "6579e25e-8dcf-44b5-a50d-7c84672cba89",
        "primaryId": "NCT00981305",
        "statement_text": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial  as long as they are over the age of 20.",
        "statement_nums": [
            "ongoing treatment for their primary tumor are eliglbe for the",
            "they are over the age of 20."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: breast cancer survivors over 20 years-old "
        ],
        "premise_nums": [
            "Inclusion Criteria: breast cancer survivors over 20 years-old"
        ]
    },
    {
        "id": "1ac9c526-91e6-4e0d-8570-0a78e3ec78db",
        "primaryId": "NCT00451555",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events ",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial recorded exactly the same"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 17/94 (18.09%) Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94 (1.06%) Nausea 1/94 (1.06%) Vomiting 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94 (1.06%) Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic cardiomyopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%) ",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Vomiting 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Myocardial infarction 1/39 (2.56%)",
            "Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Asthenia 1/94 (1.06%) Disease progression 0/94 (0.00%) Oedema peripheral 1/94",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Asthenia 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39",
            "Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94",
            "Anaemia 2/94 (2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%)",
            "(2.13%) Lymphadenopathy 0/94 (0.00%) Angina pectoris 0/94 (0.00%) Ischaemic cardiomyopathy 0/94 (0.00%) Myocardial infarction 1/94 (1.06%) Haemorrhoids 1/94 (1.06%) Ileus 1/94",
            "Haemorrhoids 1/39 (2.56%)Ileus 1/39 (2.56%) Nausea 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%)",
            "0/39 (0.00%) Myocardial infarction 1/39 (2.56%) Disease progression 0/39 (0.00%) Oedema peripheral 1/39 (2.56%)",
            "Oedema peripheral 1/94 (1.06%) Adverse Events 2: Total: 9/39 (23.08%) Anaemia 2/39 (5.13%) Lymphadenopathy 0/39 (0.00%) Angina pectoris 0/39 (0.00%) Ischaemic"
        ]
    },
    {
        "id": "79c07f36-daf9-4844-ad8a-f362fbbaaf81",
        "primaryId": "NCT00767520",
        "statement_text": "Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial ",
        "statement_nums": [
            "Both cohorts of the primary trial reported the same precentage"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%)"
        ]
    },
    {
        "id": "bced9c90-5ce0-416c-a168-f9e74359b332",
        "primaryId": "NCT01381874",
        "statement_text": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group  however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group ",
        "statement_nums": [
            "Exemestane group in the primary trial had a better median"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS) Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical)  or death from any cause  PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI)  Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI  such as when the disease site is skin  bone marrow  or central nervous system  Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone Acetate + Prednisone ",
            "Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression  unacceptable toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59) "
        ],
        "premise_nums": [
            "exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression",
            "Time frame: Approximately 2 years Results 1: Arm/Group Title: Exemestane Arm/Group Description:",
            "Participants Analyzed: 89 Median (95% Confidence Interval) Unit of Measure: Months 3.65 (2.73 to 5.59)",
            "toxicity  or death (up to 3 years)  Overall Number of Measure: Months 3.65 (2.73 to 5.59)",
            "toxicity  or death (up to 3 years) Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months",
            "to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of Measure: Months",
            "toxicity  or death (up to 3 years)  Overall Number of Participants Analyzed: 102 Median (95% Confidence Interval) Unit of",
            "time from randomization to first occurrence of disease progression (either",
            "at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in",
            "toxicity  or death (up to 3 years)  Overall Number of Measure: Months 3.68 (1.94 to 5.26) Results 2: Arm/Group Title: Abiraterone"
        ]
    },
    {
        "id": "ce88c763-0062-48dc-b5e1-f81af32f2628",
        "primaryId": "NCT00593827",
        "secondaryId": "NCT00478257",
        "statement_text": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion Criteria: stage I-III breast cancer adjuvant or neoadjuvant anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast cancer confounding underlying medical illnesses history of mania history of other axis-I psychiatric disorder other physical or psychological impairments - "
        ],
        "premise_nums": [
            "anthracycline-based chemotherapy Exclusion Criteria: under age 18 pregnancy metastatic or inoperable (including inflammatory) breast",
            "nonmeasurable disease with serum CA27.29 (or CA15.3) 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Inclusion"
        ]
    },
    {
        "id": "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625",
        "primaryId": "NCT00334802",
        "secondaryId": "NCT00167414",
        "statement_text": "There is no age limit for either the secondary trial or the primary trial ",
        "statement_nums": [
            "limit for either the secondary trial or the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically and/or cytologically confirmed breast cancer Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen To have at least one measurable region Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow  liver and renal function) Exclusion Criteria: To have interstitial pneumonia or pulmonary fibrosis To have inflammatory breast cancer Within 28 days after the latest chemotherapy or radiotherapy  14 days after the latest hormonal/immunotherapy or 7 days after surgery To have brain metastases with symptoms To have severe complication (cardiac infarction  infection  drug hypersensitivity or diabetes) Inclusion Criteria: Age: no limit "
        ],
        "premise_nums": [
            "anthracycline regimen To have at least one measurable region Eastern Cooperative",
            "Group (ECOG) Performance Status: 0-1 To have adequate organ function (bone marrow",
            "Inclusion Criteria: Histologically and/or cytologically confirmed breast",
            "days after the latest hormonal/immunotherapy or 7 days after surgery To have inflammatory breast cancer Within 28 days after the latest chemotherapy"
        ]
    },
    {
        "id": "e6901a45-4c97-4618-bfcb-6f6dd046ef0c",
        "primaryId": "NCT00143390",
        "statement_text": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group ",
        "statement_nums": [
            "In the primary trial There was less than 3 months difference between the maximum and minimum"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Time to Progression (TTP) - Expert Evaluation Committee Assessment Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer  whichever comes first  Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started  For participants with bone metastasis only  at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition)  Time frame: Up to 2008 days of the treatment Results 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal  The study treatment was continued until the disease progression or other discontinuation criteria were met  Overall Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months 13.8 (10.8 to 16.5) "
        ],
        "premise_nums": [
            "bone metastasis only  at least 25% increase in the measurable lesions compared to the smallest SLD since the study",
            "2008 days of the treatment Results 1: Arm/Group Title: Exemestane Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were",
            "Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered",
            "Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months from randomization to first documentation of objective tumor progression",
            "Number of Participants Analyzed: 147 Median (95% Confidence Interval) Unit of Measure: months",
            "expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the"
        ]
    },
    {
        "id": "e94ea1b1-1816-4bac-b1ca-f6d66b95702a",
        "primaryId": "NCT00004888",
        "statement_text": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study ",
        "statement_nums": [
            "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event This table summarizes the cardiotoxicity events of different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline of LVEF greater than or equal 20% of baseline value  Grade 3 is congestive heart failure responsive to treatment  Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants  Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or more days after last cycle of induction therapy Results 1: Arm/Group Title: Arm I: Doxorubicin and Taxotere ",
            "Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered the day before  the day of  and the day following docetaxel  The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx  168 days): 4 Grade 1 After 30 days or more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 1 Grade 3 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 0 "
        ],
        "premise_nums": [
            "dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while",
            "after cycle 8 (~168 days)  and 30 or equal 10% but smaller than 20% of baseline value  Grade",
            "of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx  168 days): 4",
            "PLD completion  every 3 weeks for a total of 8 cycles  Dexamthasone 8 mg orally twice a day was administered",
            "8 (approx 168 days): 4 Grade 2 After 30 days or more days after last cycle of induction therapy Results",
            "4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168 days): 4 Grade 2 After 30 days or more",
            "(approx  168 days): 4 Grade 1 After 30 days or more days after last cycle of induction therapy Results",
            "of LVEF greater than or equal 20% of baseline value  Grade 2 is LVEF below LLN (50%) or decline",
            "Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour after",
            "different grades  Grade 1 is a decline of left ventricular ejection fraction(LVEF) greater than or equal 10% but smaller than 20% of",
            "more after last cycle: 1 Grade 2 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168",
            "Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  168 days): 4 Grade 1 After 30 days or more",
            "IV followed by docetaxel 60 mg/m^2 IV  one hour after cycle 8 (~168 days)  and 30 or",
            "was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was",
            "8 (approx 168 days): 4 Grade 2 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84",
            "more after last cycle: 1 Grade 3 After Cycle 4 (approx 84 days): 3 Grade 2 After Cycle 8 (approx 168",
            "8 (approx 168 days): 0 Grade 3 After 30 days or more after last cycle: 1 Grade 3 After Cycle 4 (approx 84",
            "is LVEF below LLN (50%) or decline of LVEF greater than or equal 10% but smaller than 20% of baseline",
            "Time frame: Baseline  after cycle 4 (~84 days)  after cycle 8 (~168 days)  and 30 or",
            "(approx  84 days): 2 Grade 1 After Cycle 8 (approx 168 days): 0 Grade 3 After 30 days or more",
            "4 (~84 days)  after cycle 8 (~168 days)  and 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV  one hour",
            "Number Unit of Measure: participants Grade 1 After Cycle 4 (approx  84 days): 2 Grade 1 After Cycle 8 (approx"
        ]
    },
    {
        "id": "0e3c62f7-a152-4370-9d09-b69a715c0a21",
        "primaryId": "NCT01216319",
        "secondaryId": "NCT03346161",
        "statement_text": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies ",
        "statement_nums": [
            "the secondary trial and the primary trial are evaluating surgical interventions"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Nipple Reconstruction Cylinder Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool) Investigators recruited patients scheduled for a plastic/reconstruction consult  Investigators identified patients who completed a mastectomy  or were scheduled for one  and considering reconstruction  but didn't have an appointment with a plastic/reconstructive surgeon  A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home  Patients randomized using computer random assignment  If the patient didn't have an appointment  she scheduled a convenient time to complete study procedures with research staff  Patients interacted with the decision tool  They were asked to answer a survey  After the appointment  the team collected information consult duration  decision process quality  and measures of shared decision making  Patient participation was approximately 30 minutes  "
        ],
        "premise_nums": [
            "to come to their scheduled appointment 30 minutes early to meet a coordinator or",
            "reconstruction: Biodesign® Nipple Reconstruction Cylinder INTERVENTION 1: Arm 1: BREASTChoice (Decision Tool)",
            "patients scheduled for a plastic/reconstruction consult  Investigators identified",
            "A study team member called the patient to determine",
            "making  Patient participation was approximately 30 minutes"
        ]
    },
    {
        "id": "7191b5e9-4f29-4261-8a64-51653ee151fe",
        "primaryId": "NCT00410813",
        "statement_text": "In the primary trial  Dasatinib  70 mg  Twice Daily results in a better median PFS than Dasatinib  100 mg  Daily ",
        "statement_nums": [
            "In the primary trial  Dasatinib  70",
            "PFS than Dasatinib  100 mg  Daily"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed  unequivocal progression of non-measurable disease  the appearance of any new lesion/site  death due to disease without prior documentation of progression and without symptomatic deterioration  development of one or more new bone lesions from baseline  or symptomatic deterioration related to disease progression  Time from date of registration to date of first documentation of progression or symptomatic deterioration  or death due to any cause  Patients last known to be alive and progression-free are censored at last date of contact  Time frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100 mg  Daily Arm/Group Description: Dasatinib  100 mg PO daily until progression of disease Overall Number of Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 10.3 (8.4 to 16.7) Results 2: Arm/Group Title: Dasatinib  70 mg  Twice Daily Arm/Group Description: Dasatinib  70 mg PO twice daily until progression of disease Overall Number of Participants Analyzed: 38 Median (95% Confidence Interval) ",
            "Unit of Measure: weeks 15.3 (8.7 to 20.1)"
        ],
        "premise_nums": [
            "measurable lesions over the smallest sum observed  unequivocal",
            "Arm/Group Description: Dasatinib  70 mg PO twice daily until progression of Measure: weeks 15.3 (8.7 to 20.",
            "Progression-free Survival RECIST progression defined as 20% increase in the sum of longest",
            "any cause  Patients last known to be alive and",
            "registration to date of first documentation of progression or symptomatic",
            "contact  Time frame: Up to 2 years Results 1: Arm/Group Title: Dasatinib  100",
            "Participants Analyzed: 41 Median (95% Confidence Interval) Unit of Measure: weeks 15.3 (8.7 to 20."
        ]
    },
    {
        "id": "639ccada-370d-4709-bdd7-1b29bbcc8769",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG greater than 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "ECOG greater than 1 and a life expectancy over 12 weeks are necessary to participate in the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months "
        ],
        "premise_nums": [
            "Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months"
        ]
    },
    {
        "id": "8c6e6c06-c409-4c42-b195-e9d2a1065b97",
        "primaryId": "NCT02069093",
        "statement_text": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet ",
        "statement_nums": [
            "the patients in the primary trial had minimal Stomatitis symptoms"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 = minimal symptoms  normal diet; grade 2 = symptomatic  but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without food or drink (NPO) for one hour after administration of the mouthwash  Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations  Overall Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants Stomatitis grade greater than or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 Stomatitis grade greater than or equal 2: Not evaluable: 1 "
        ],
        "premise_nums": [
            "or equal 2: Yes: 2 Stomatitis grade greater than or equal 2: No: 83 Stomatitis grade greater than or equal 2:",
            "Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was",
            "consequences  Time frame: 56 days Results 1: Arm/Group Title: Dexamethasone Based Mouthwash",
            "Number of Participants With Stomatitis Grade 2 The incidence of grade 2 stomatitis was reported  Grade 1 =",
            "Number of Participants Analyzed: 86 Measure Type: Number Unit of Measure: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational",
            "Also  participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations",
            "aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening",
            "steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks  Participants remained without"
        ]
    },
    {
        "id": "b5183c1c-adb5-4877-b061-50a16d6a5b52",
        "primaryId": "NCT00191815",
        "secondaryId": "NCT01301729",
        "statement_text": "None of the patients in the primary trial committed suicide  however there was one such case in the secondary trial ",
        "statement_nums": [
            "such case in the secondary trial",
            "the patients in the primary trial committed suicide  however"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute 1/67 (1.49%) Pleurisy 1/67 (1.49%) Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32 (3.13%) Infection 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) "
        ],
        "premise_nums": [
            "Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Adverse Events 1: Total: 6 Atrial fibrillation 1/67 (1.49%) Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%)",
            "1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67 (1.49%) Pneumonia 1/67 (1.49%)",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) General physical health deterioration 1/67 (1.49%) Escherichia sepsis 1/67",
            "Ventricular fibrillation 1/67 (1.49%) Gastrointestinal perforation 1/67 (1.49%) Periproctitis 1/67 (1.49%) Pneumonia 1/67 (1.49%) Tumour pain 1/67 (1.49%) Renal failure acute",
            "tract infection 1/32 (3.13%) Completed suicide 1/32 (3.13%) Upper respiratory tract infection 1/32 (3.13%) Completed suicide 1/32",
            "Adverse Events 1: Total: 5/32 (15.63%) Leukopenia 1/32 (3.13%) Neutropenia 1/32 (3.13%) Cataract 1/32"
        ]
    },
    {
        "id": "69f57cdb-22e9-4a3a-8f19-6095c66c6497",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "statement_text": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [
            "is used for the primary trial",
            "the secondary trial uses Clinical Benefit (CBR)"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Proportion of Participants With a Pathologic Complete Response Rate To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will assess pCR rates separately in ER+ and ER- cancers  Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen  Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen  Time frame: 20 weeks Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
            "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) "
        ],
        "premise_nums": [
            "cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study drug to last dose plus 7 days  up to study",
            "lesions  PR= At least a 30% decrease in the sum of the",
            "time greater than  equal to 6 months  CR= Disappearance of study drug to last dose plus 7 days",
            "of study drug to last dose plus 7 days  up to study",
            "Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population",
            "tumor cells at the primary tumor site and axillary lymph",
            "specimen  Time frame: 20 weeks Outcome Measurement: Number of Participants With",
            "weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will"
        ]
    },
    {
        "id": "ea505463-c509-416e-ad88-11576764b734",
        "primaryId": "NCT01771666",
        "secondaryId": "NCT01256567",
        "statement_text": "Japanese participants with an ECOG smaller than =1 are eligible for the secondary trial and the primary trial ",
        "statement_nums": [
            "participants with an ECOG smaller than =1 are eligible for the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) performance status of 0 or 1",
            "Group (ECOG) or Karnofsky Performance Status 0,1,2. Inclusion Criteria: The participant is Japanese"
        ]
    },
    {
        "id": "81669281-db01-4493-a797-0d60f448f706",
        "primaryId": "NCT00930930",
        "statement_text": "The overall most frequent adverse event in the primary trial was Dehydration ",
        "statement_nums": [
            "The overall most frequent adverse event in the primary trial was Dehydration"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96 (5.21%) ileus 1/96 (1.04%) nausea 2/96 (2.08%) vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) fatigue 2/96 (2.08%) Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) colitis 0/49 (0.00%) ",
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%) fatigue 0/49 (0.00%) "
        ],
        "premise_nums": [
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small",
            "1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small",
            "cardiac ischemia/infarction 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96 (1.04%) diarrhea 5/96",
            "diarrhea 0/49 (0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "(1.04%) fatigue 2/96 (2.08%) Adverse Events 2: Total: 6/49 (12.24%) Anemia 0/49 (0.00%) lymphopenia 0/49 (0.00%) cardiac ischemia/infarction",
            "(0.00%)ileus 0/49 (0.00%) nausea 1/49 (2.04%) vomiting 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "cardiac ischemia/infarction 0/49 (0.00%) sinus tachycardia 0/49 (0.00%) Dehydration 1/49 (2.04%) distal small bowel obstruction 0/49 (0.00%) edema 0/49 (0.00%)",
            "1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96",
            "vomiting 1/96 (1.04%) distal small bowel obstruction 1/96 (1.04%) edema 1/96 (1.04%)",
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) cardiac ischemia/infarction",
            "Adverse Events 1: Total: 22/96 (22.92%) Anemia 1/96 (1.04%) lymphopenia 1/96 (1.04%) sinus tachycardia 2/96 (2.08%) Dehydration 5/96 (5.21%) colitis 1/96"
        ]
    },
    {
        "id": "40dbf023-ead5-45fc-bdce-bf40e1955578",
        "primaryId": "NCT00382785",
        "secondaryId": "NCT00784849",
        "statement_text": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide  High Dose Magnesium Oxide or Mometasone in their intervention ",
        "statement_nums": [
            "Neither the primary trial or the secondary trial use Low Dose Magnesium"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support in a peer-led format INTERVENTION 1: Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel lymph nodes "
        ],
        "premise_nums": [
            "Methylene Blue One arm diagnostic using 1 mCi of 125-I Methylene blue dye to find sentinel",
            "INTERVENTION 1: Moderated Group one 12-week online support group led by a",
            "1: Moderated Group one 12-week online support group led by a professional healthcare provider INTERVENTION 2: Non-facilitated (Peer-led) 12-week online support"
        ]
    },
    {
        "id": "b64ae9c9-956a-421e-a41f-1886408fec2a",
        "primaryId": "NCT00003782",
        "statement_text": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "the cohorts in the primary trial had more than 5% of patients experiencing side effects"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%)"
        ]
    },
    {
        "id": "e0980234-0611-44de-9165-54bdd086663d",
        "primaryId": "NCT01539317",
        "secondaryId": "NCT01323530",
        "statement_text": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments ",
        "statement_nums": [
            "the primary trial uses a topical intervention and the secondary trial uses a combination of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Topical Saline Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). INTERVENTION 2: ",
            "Phase 1b (Schedule 1): Eribulin Mesilate (1.6 mg/m^2)Participants received eribulin mesilate 1.6 mg/m^2, injection  intravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD  undue toxicity  the presence of other medical conditions that prohibit continuation of therapy  pregnancy  a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). "
        ],
        "premise_nums": [
            "not reverse the local tenderness INTERVENTION 2: Topical Liquid Lidocaine Topical liquid",
            "not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate",
            "(Schedule 1): Eribulin Mesilate (1.2 mg/m^2) Participants received eribulin mesilate 1.2 mg/m^2, injection  intravenously",
            "a delay of more than 14 days in starting the next cycle during Phase 1b (Schedule 1). INTERVENTION 2:",
            "not reverse the local tenderness INTERVENTION 1: Phase 1b (Schedule 1): Eribulintravenously  once  on Day 1 and capecitabine 1000 mg/m^2, tablets",
            "Day 1 and capecitabine 1000 mg/m^2, tablets  orally  twice daily from Day 1 to 14 in each 21-day treatment cycle",
            "orally  twice daily from Day 1 to 14 in each 21-day treatment cycle for as long as"
        ]
    },
    {
        "id": "3366c10a-3d41-48ae-bfa8-26b9e655761e",
        "primaryId": "NCT00005908",
        "statement_text": "There were 8 cases of pharyngitis in cohort 2 of the primary trial ",
        "statement_nums": [
            "There were 8 cases of pharyngitis in cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Dehydration 1/30 (3.33%) Nausea 1/30 (3.33%) Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2: "
        ],
        "premise_nums": [
            "neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%)",
            "Adverse Events 1: Total: 29/30 (96.67%) Febrile neutropenia [1]3/30 (10.00%) Lymphatics 1/30 (3.33%) Diarrhea (without colostomy) 5/30 (16.67%)",
            "5/30 (16.67%) Abdominal pain or cramping 2/30 (6.67%) Colitis 1/30 (3.33%) Vomiting 1/30 (3.33%) Adverse Events 2:"
        ]
    },
    {
        "id": "be29030a-98e8-40ad-9138-90076fdb50d3",
        "primaryId": "NCT01572727",
        "statement_text": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial recorded more white blood",
            "cell related adversse events than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) ",
            "CATARACT 1/201 (0.50%)OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%) DIARRHOEA 3/201 (1.49%) "
        ],
        "premise_nums": [
            "CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%)OPTIC NEUROPATHY 1/201 (0.50%) ABDOMINAL PAIN 1/201 (0.50%) CONSTIPATION 1/201 (0.50%)",
            "2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202",
            "NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%)",
            "NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202",
            "61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202",
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE",
            "Adverse Events 1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 0/202 (0.00%) CARDIO-RESPIRATORY ARREST 1/202",
            "(0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202 (0.00%) CONSTIPATION 0/202 (0.00%)",
            "NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201",
            "CONSTIPATION 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA 0/201 (0.00%) LEUKOPENIA 1/201 (0.50%) NEUTROPENIA 0/201",
            "NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) NEUTROPENIA 2/202 (0.99%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201",
            "CARDIO-RESPIRATORY ARREST 1/202 (0.50%) PERICARDIAL EFFUSION 1/202 (0.50%) CATARACT 1/202 (0.50%) OPTIC NEUROPATHY 0/202 (0.00%) ABDOMINAL PAIN 0/202",
            "NEUTROPENIA 0/201 (0.00%) CARDIAC FAILURE CONGESTIVE 1/201 (0.50%) CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%)",
            "CARDIO-RESPIRATORY ARREST 0/201 (0.00%) PERICARDIAL EFFUSION 0/201 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA",
            "1: Total: 61/202 (30.20%) FEBRILE NEUTROPENIA 1/202 (0.50%) LEUKOPENIA 0/202 (0.00%) DIARRHOEA 5/202 (2.48%) Adverse Events 2: Total: 42/201 (20.90%) FEBRILE NEUTROPENIA"
        ]
    },
    {
        "id": "a31298d5-20ae-4a3d-a57b-e97288fff6c0",
        "primaryId": "NCT01097460",
        "statement_text": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years ",
        "statement_nums": [
            "the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Incidence of Treatment-emergent AE's [Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and Herceptin: For Phase 1: Dose escalation cohorts  MM-111 and Herceptin are administered weekly or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants 16 "
        ],
        "premise_nums": [
            "[Not Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin",
            "Specified] Time frame: 2 years Results 1: Arm/Group Title: MM-111 + Herceptin Arm/Group Description: MM-111 will be combined with Herceptin MM-111 and",
            "or bi-weekly via IV Overall Number of Participants Analyzed: 16 Measure Type: Number Unit of Measure: participants"
        ]
    },
    {
        "id": "54e93334-0f21-4ea2-b0f2-34473385da53",
        "primaryId": "NCT00003830",
        "statement_text": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients ",
        "statement_nums": [
            "both cohorts of the primary trial was Anaphylaxis  which affected less than 1% of patients"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 2/2788 (0.07%) Nervous system disorders - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal disorders - Other  specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%) "
        ],
        "premise_nums": [
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse",
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 2/2788 (0.07%) Nervous system disorders - Other",
            "Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other",
            "- Other  specify 0/2800 (0.00%) Nervous system disorders - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal",
            "Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 1/2800 (0.04%) Respiratory  thoracic and mediastinal",
            "Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2788 (0.00%) Respiratory  thoracic and mediastinal",
            "Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse",
            "Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and infestations - Other",
            "- Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 2: Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and",
            "specify 1/2800 (0.04%) Thromboembolic event 2/2800 (0.07%)",
            "Total: 8/2800 (0.29%) Anaphylaxis 5/2800 (0.18%) Infections and infestations - Other  specify 0/2800 (0.00%) Nervous system disorders - Other",
            "- Other  specify 1/2788 (0.04%) Thromboembolic event 1/2788 (0.04%) Adverse Events 1: Total: 9/2788 (0.32%) Anaphylaxis 5/2788 (0.18%) Infections and"
        ]
    },
    {
        "id": "4bd9f061-6420-443d-8f84-b703733644ac",
        "primaryId": "NCT01202591",
        "statement_text": "100% of patients in the primary trial suffered life threatening adverse events ",
        "statement_nums": [
            "100% of patients in the primary trial suffered life threatening adverse"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious) [Not Specified] Time frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 "
        ],
        "premise_nums": [
            "Results 2: Arm/Group Title: AZD4547 40mg Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg",
            "Ex 25mg Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane Overall Number of Participants Analyzed: 5",
            "Number of Participants Analyzed: 5 Measure Type: Number Unit of Measure: Participants 5 Results 2: Arm/Group Title: AZD4547 40mg Cont",
            "Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg",
            "from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg",
            "frame: 3 years  10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group",
            "screening to discontinuation plus 28 days safety follow-up)  Results 1: Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane"
        ]
    },
    {
        "id": "e6d3354b-b36a-42b9-b406-61a9af594686",
        "primaryId": "NCT00046891",
        "statement_text": "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily ",
        "statement_nums": [
            "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Ginkgo Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID) "
        ],
        "premise_nums": [
            "Biloba Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)"
        ]
    },
    {
        "id": "62b3d09e-6b2a-4827-8ceb-96ccafca18d4",
        "primaryId": "NCT00896649",
        "statement_text": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial ",
        "statement_nums": [
            "for patients in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion criteria: DISEASE CHARACTERISTICS: Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue At high-risk for breast cancer PATIENT CHARACTERISTICS: Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth: Hispanic Haitian Creole African American Caucasian PRIOR CONCURRENT THERAPY: None specified Exclusion criteria: No history of breast cancer  palpable breast mass  abnormal nipple discharge  or other focal complaints warranting diagnostic mammogram "
        ],
        "premise_nums": [
            "the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue"
        ]
    },
    {
        "id": "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3",
        "primaryId": "NCT00317603",
        "statement_text": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer  ECOGsmaller than 2 and a life expectancy exceeding 6 months ",
        "statement_nums": [
            "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer",
            "have histologically confirmed stage 3 or above breast cancer  ECOGsmaller than 18, have histologically confirmed stage 3 or above breast cancer"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater than or equal to 6 months 18 years of age or older "
        ],
        "premise_nums": [
            "of greater than or equal to 6 months 18 years of age or older",
            "Inclusion Criteria: Histologically confirmed Stage IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy",
            "IV breast cancer ECOG performance status 0 or 1 Estimated life expectancy of greater"
        ]
    },
    {
        "id": "85c315e5-7ae4-4764-8b02-87d36f67a159",
        "primaryId": "NCT00278109",
        "secondaryId": "NCT01881230",
        "statement_text": "Gemcitabine is not used in the primary trial  and used in only one of the arms of the secondary trial ",
        "statement_nums": [
            "the arms of the secondary trial",
            "not used in the primary trial  and used in"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Experimental cyclophosphamide: chemotherapy doxorubicin hydrochloride: chemotherapy adjuvant therapy: chemotherapy radiation therapy: chemotherapy INTERVENTION 1: Arm A: Nab-Paclitaxel + Gemcitabine Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment INTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin ",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment "
        ],
        "premise_nums": [
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment",
            "Gemcitabine Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment",
            "Days 1 and 8 in each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "unacceptable toxicity  required palliative radiotherapy or surgical intervention",
            "participant to continue on treatment INTERVENTION 2: Arm B: Nab-Paclitaxel + Carboplatin",
            "by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants",
            "8 by IV administration of each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and",
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8"
        ]
    },
    {
        "id": "497188e0-9d88-406f-b163-c154516cb12c",
        "primaryId": "NCT01560416",
        "statement_text": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial ",
        "statement_nums": [
            "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 2/15 (13.33%) Adverse Events 2: Total: 11/35 (31.43%)"
        ]
    },
    {
        "id": "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3",
        "primaryId": "NCT00438100",
        "secondaryId": "NCT00662025",
        "statement_text": "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "Patients with BUN smaller than 20 mg/dL  Platelet count: smaller than 90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Biopsy-diagnosed breast cancer with metastasis in multiple organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater than 1.5 mg/dL AST(GOT): within twice a normal upper value in an institution AST(GPT): within twice a normal upper value in an institution BUN: smaller than 25 mg/dL Creatinine: within a normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria: ",
            "Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery  radiation  or combined modality therapy with curative intentMeasurable disease as per RECIST  Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy  Prior treatment with an anthracycline and a taxane in the neoadjuvant  adjuvant or metastatic disease settings  Exclusion Criteria: Histology of inflammatory carcinoma with no other measurable disease  Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease  Brain metastases  spinal cord compression  or carcinomatous meningitis  or leptomeningeal disease  ",
            "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur)  UFT/UFT-E (tegafur/uracil)  TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting"
        ],
        "premise_nums": [
            "normal upper value in the institution 24 hours creatinine clearance: greater than 50 mL/min (using the Cockcroft-Gault formula) Women's",
            "Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater than 9.5 g/dL Total bilirubin: greater",
            "Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 or more Platelet count: smaller than 100,000/mm3 or more Hemoglobin: greater",
            "(World Health Organization :WHO) 0-2 Functions below are maintained in major organs: Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than",
            "Leukocyte count: 4,000/mm3 to 12,000/mm3 Neutrophil count: greater than 2,000/mm3 organs Performance Status (World Health Organization :WHO) 0-2 Functions below are",
            "Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/",
            "= Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 Inclusion Criteria:",
            "organs Performance Status (World Health Organization :WHO) 0-2 Functions below are maintained in major organs:",
            "Histologically- or cytologically-proven diagnosis of"
        ]
    },
    {
        "id": "f26fb90b-a9a5-4614-9680-2e9f6f0ba649",
        "primaryId": "NCT01828021",
        "secondaryId": "NCT01326481",
        "statement_text": "Patients in the primary trial and the secondary trial did not have any of the same adverse events  except Supraventricular extrasystoles which was the most common event in both trials ",
        "statement_nums": [
            "Patients in the primary trial and the secondary trial did not have any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%) Diarrhea 1/25 (4.00%) Nausea 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19 (5.26%) Fracture [1]1/19 (5.26%) Hip Fracture [1]1/19 (5.26%) Headache [2]1/19 (5.26%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue [1]1/19 (5.26%) Pyrexia [1]1/19",
            "Vomiting 1/25 (4.00%) Bile duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1:",
            "duct obstruction 1/25 (4.00%) Portal hypertension 1/25 (4.00%) Adverse Events 1: Total: 6/19 (31.58%) Febrile neutropenia [1]1/19 (5.26%) Fatigue",
            "Adverse Events 1: Total: 6/25 (24.00%) Supraventricular extrasystoles 1/25 (4.00%) Ventricular extrasystoles 1/25 (4.00%) Ascites 2/25 (8.00%)",
            "Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting 1/25 (4.00%) Pancreatitis 1/25 (4.00%) Small intestinal obstruction 1/25 (4.00%) Vomiting"
        ]
    },
    {
        "id": "90dd042b-c16c-4ea7-b360-625bd5e64590",
        "primaryId": "NCT00388726",
        "statement_text": "A 75 year old female patient  with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial ",
        "statement_nums": [
            "be eligible for the primary trial",
            "A 75 year old female patient  with an ECOG of 1 and an estimated life expectancy of more"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Age greater than or equal 18 years  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months  "
        ],
        "premise_nums": [
            "Oncology Group (ECOG) Performance Status of 0 to 2. Life expectancy of greater than or equal 3 months"
        ]
    },
    {
        "id": "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7",
        "primaryId": "NCT01271725",
        "statement_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group ",
        "statement_nums": [
            "In the primary trial The Percentage of Participants",
            "(OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 Objective response according to RECIST v1.1. Best overall response of confirmed complete response (CR) or confirmed partial response (PR) recorded since first administration of trial medication and until the earliest of disease progression  death or start of next treatment in each part separately  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by Magnetic resonance imaging (MRI): Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR  Percentage of participants with OR along with exact 95% Confidence Interval by Clopper and Pearson is presented  Time frame: From the initial dose of study drug until 28 days after end of the treatment period  up to 1562 days Results 1: Arm/Group Title: Afatinib Monotherapy ",
            "Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal  Patients could have dose reduced if 40 mg was not tolerated Overall Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage of participants 18 (10 to 28) Results 2: Arm/Group Title: Afatinib and Paclitaxel or Vinorelbine Combination Therapy Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease  unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy Overall Number of Participants Analyzed: 39 Measure Type: Number Unit of Measure: Percentage of participants 31 (17 to 48) "
        ],
        "premise_nums": [
            "of study drug until 28 days after end of the treatment period  up to 1562 days Results 1: Arm/Group Title: Afatinib Monotherapy",
            "Patient received Afatinib monotherapy orally once daily at a dose of 40 milligram (mg) film-coated tablets until progression of",
            "Patients could have dose reduced if 40 mg was not tolerated Overall Number of",
            "Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of",
            "have dose reduced if 40 mg was not tolerated Overall Number of study drug until 28 days after end of the treatment period",
            "Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage of participants 31 (17 to 48)",
            "have dose reduced if 40 mg was not tolerated Overall Number of Participants Analyzed: 74 Measure Type: Number Unit of Measure: Percentage",
            "participants with OR along with exact 95% Confidence Interval by Clopper and Pearson",
            "initial dose of study drug until 28 days after end of the treatment period",
            "Solid Tumours Version (RECIST) 1.1 Objective response according to RECIST v1.1. Best overall response of confirmed complete response",
            "(PR)  greater than or equal 30% decrease in the sum of the",
            "for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once daily at a dose of 40 milligram (mg) film-coated tablets until",
            "participants 18 (10 to 28) Results 2: Arm/Group Title: Afatinib and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or"
        ]
    },
    {
        "id": "20cc98f8-a71a-466d-a39c-735899791613",
        "primaryId": "NCT00915603",
        "secondaryId": "NCT02511730",
        "statement_text": "INR equal to or above 1.5 is mandatory for participation in the primary trial  it is not necessary for the secondary trial ",
        "statement_nums": [
            "not necessary for the secondary trial",
            "INR equal to or above 1.5 is mandatory for participation in the primary trial  it is not"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion Criteria: Subjects with unknown clinical status not participating in FMSU004A protocol  "
        ],
        "premise_nums": [
            "ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female subjects participating in FMSU004A protocol with known clinical status Exclusion",
            "International normalized ratio (INR) smaller than =1.5 or prothrombin time (PT)/partial Inclusion Criteria: Female"
        ]
    },
    {
        "id": "fa1c6f63-ae37-4c18-918b-7b9ba445fd81",
        "primaryId": "NCT00391092",
        "statement_text": "In total there were 32 cases of Febrile neutropenia in the primary trial ",
        "statement_nums": [
            "In total there were 32 cases of Febrile neutropenia in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia * 14/206 (6.80%) Adverse Events 2: Febrile neutropenia * 18/215 (8.37%)"
        ]
    },
    {
        "id": "6d0b2acc-11f4-479f-9a86-004e2f5f7599",
        "primaryId": "NCT00194779",
        "secondaryId": "NCT04080297",
        "statement_text": "IV is used as route of administration by the interventions in the primary trial and the secondary trial ",
        "statement_nums": [
            "the interventions in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days  "
        ],
        "premise_nums": [
            "laboratory biomarker analysis: Correlative studies INTERVENTION 1: 100 mg Q-122 Dosage was 100 mg Q-122 administered orally as two 50 mg capsules"
        ]
    },
    {
        "id": "7e9c3980-9f12-40c7-920e-76594db26fd1",
        "primaryId": "NCT02352779",
        "secondaryId": "NCT00263588",
        "statement_text": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics ",
        "statement_nums": [
            "and the other Low-dose Omega-3 Fatty Acid  in contrast the difference in the secondary trial is patient characteristics",
            "between cohorts in the primary trial is once cohort recieves"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty Acid) Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Questionnaire Administration: Ancillary studies Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A 750mg lapatinib administered orally twice daily  Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens  in total  for treatment of breast cancer in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B ",
            "750mg lapatinib administered orally twice daily  Cohort B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of breast cancer in the adjuvant and/or metastatic settings "
        ],
        "premise_nums": [
            "1: Arm I (Low-dose Omega-3 Fatty Acid) Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo",
            "in adjuvant and/or metastatic settings INTERVENTION 2: Cohort B",
            "B subjects had ECOG performance status 2 and/or more than 2 prior trastuzumab-containing regimens for treatment of",
            "Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing",
            "BID and placebo PO BID for 6 weeks  Omega-3 Fatty Acid: Given PO Placebo: Given PO",
            "Laboratory Biomarker Analysis: Correlative studies INTERVENTION 2: Arm II (High-dose Omega-3 Fatty",
            "Laboratory Biomarker Analysis: Correlative studies INTERVENTION 1: Cohort A 750mg lapatinib administered orally twice daily  Cohort"
        ]
    },
    {
        "id": "c83e003d-d12d-4f72-ab1f-c39f3a13326b",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 negative breast cancer ",
        "statement_nums": [
            "female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 negative breast cancer",
            "eligible for both the secondary trial and the primary trial  patients must be"
        ],
        "label": "Entailment",
        "premise_text": [
            "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: - Female 18 years  70 years  ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed breast cancer(IHC:ER 60% and PR 60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection At least one evaluative focus according to RECIST creterion or non-measurable disease but only bone metastasis Adequate bone marrow and organ function Progressive disease whilst receiving endocrine therapy for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving endocrine therapy Radiological or objective clinical evidence of recurrence or progression on or after last systemic therapy prior to enrolment "
        ],
        "premise_nums": [
            "confirmation of metastatic or locally advanced disease not amenable",
            "metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at",
            "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: - Female 18 years",
            "progression on or after last systemic therapy prior to enrolment",
            "receptor-high expressed breast cancer(IHC:ER 60% and PR 60%) on primary tumour at diagnosis/on biopsy of",
            "70 years  ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed",
            "of relapsed patients is more than 12 months Once received standard hormone treatment and"
        ]
    },
    {
        "id": "cae58656-76e7-447a-940e-dfcc78159173",
        "primaryId": "NCT00244933",
        "statement_text": "the primary trial monitors the occurrence of anemia in its adverse events ",
        "statement_nums": [
            "the primary trial monitors the occurrence of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19 (26.32%) Platelets 3/19 (15.79%) Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%) Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%) Dyspnea 3/19 (15.79%) "
        ],
        "premise_nums": [
            "Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19 (26.32%) Hemoglobin (Hgb) 1/19 (5.26%) Absolute neutrophil count (ANC) 5/19",
            "Adverse Events 1: Total: 5/19 (26.32%) Pain 3/19 (15.79%) White blood cells (WBC) 5/19"
        ]
    },
    {
        "id": "94c4c3fc-7bcb-407b-86b5-6699305d3dbd",
        "primaryId": "NCT02481050",
        "statement_text": "There are no adverse events in the primary trial that occurred more than once ",
        "statement_nums": [
            "adverse events in the primary trial that occurred more than"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/58 (24.14%) Constipation 1/58 (1.72%) Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Hypovolaemia 1/58 (1.72%) "
        ],
        "premise_nums": [
            "Vomiting 1/58 (1.72%) Upper gastrointestinal haemorrhage 1/58 (1.72%) Asthenia 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture",
            "Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture 1/58 (1.72%) Neutrophil count decreased",
            "fracture 1/58 (1.72%) Neutrophil count decreased 1/58 (1.72%) Dehydration 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture",
            "(1.72%) Asthenia 1/58 (1.72%) Chest pain 1/58 (1.72%) Pain 1/58 (1.72%) Sepsis 2/58 (3.45%) Fall 1/58 (1.72%) Spinal compression fracture"
        ]
    },
    {
        "id": "103fbaa8-1852-402a-9368-36bbf6c747b2",
        "primaryId": "NCT00022516",
        "statement_text": "At most 3 patients in the primary trial suffered from Neutropenia ",
        "statement_nums": [
            "At most 3 patients in the primary trial suffered from Neutropenia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%) "
        ],
        "premise_nums": [
            "1: Total: 0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis",
            "Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT",
            "Adverse Events 1: Total: 0/0 Leukopenia 0/0 Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 1/473 (0.21%) Arthralgia",
            "(0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%)",
            "0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total:",
            "Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse Events 2: Total: 11/473 (2.33%) Leukopenia 2/473",
            "0/0 Leukopenia 0/0 Neutropenia 0/0 Ocular-other 0/0 Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis 0/0 Adverse",
            "Leukopenia 2/473 (0.42%) Neutropenia 5/473 (1.06%) Ocular-other 1/473 (0.21%) Elevated SGPT 0/0 Arthralgia 0/0 CNS hemorrhage 0/0 Neurologic-other 0/0 Radiation dermatitis",
            "(0.21%) Neurologic-other 1/473 (0.21%) Radiation dermatitis 1/473 (0.21%) Arthralgia 1/473 (0.21%) CNS hemorrhage 1/473 (0.21%) Neurologic-other 1/473 (0.21%)"
        ]
    },
    {
        "id": "731dc36f-983d-4d4c-97ac-6e3eeee23a40",
        "primaryId": "NCT00581256",
        "statement_text": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial ",
        "statement_nums": [
            "breast cancer and an ECOG of 3 are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: All patients must have left-sided breast cancer  Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria "
        ],
        "premise_nums": [
            "Performance status should be 0-2 by ECOG criteria  Exclusion Criteria: Performance status greater than 2 by ECOG criteria"
        ]
    },
    {
        "id": "b2883781-f4e9-405e-9231-7a07e46c35b0",
        "primaryId": "NCT00429299",
        "statement_text": "Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram ",
        "statement_nums": [
            "one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: CT Plus Trastuzumab Participants received chemotherapy (CT)  which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks  followed by intravenous (IV) fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration  The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first paclitaxel course  Subsequent administrations were given weekly at 2 mg/kg IV for 30 minutes  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2: CT Plus Lapatinib 1500 mg ",
            "Participants received CT  which included paclitaxel 80 mg/m^2 weekly for 12 weeks  followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty stomach throughout the course of the CT and for three weeks after the last CT administration  Treatments were administered for 26 weeks prior to surgery Following Independent Data Monitoring Committee (IDMC) recommendations  lapatinib doses were reduced to 1250 mg/day orally on an empty stomach  "
        ],
        "premise_nums": [
            "two weeks after the last CT administration  The first dose of trastuzumab was administered",
            "weeks  followed by IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days",
            "three weeks after the last CT administration  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2:",
            "lapatinib doses were reduced to 1250 mg/day orally on an empty stomach",
            "chemotherapy (CT)  which included paclitaxel 80 milligrams per meters squared (mg/m^2) weekly for 12 weeks  followed by intravenous",
            "IV fluorouracil 600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses",
            "were given weekly at 2 mg/kg IV for 30 minutes  Treatments were administered for 26 weeks prior to surgery  INTERVENTION 2:",
            "CT administration  The first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60",
            "600 mg/m^2, IV epidoxorubicin 75 mg/m^2, and IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants",
            "dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes on the day of the first",
            "IV cyclophosphamide 600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty",
            "600 mg/m^2, once every 21 days for four treatment courses  Participants received lapatinib 1500 mg/day orally on an empty stomach throughout"
        ]
    },
    {
        "id": "932c2135-381a-4675-a782-e683eca8d935",
        "primaryId": "NCT00791037",
        "secondaryId": "NCT00606931",
        "statement_text": "the primary trial and the secondary trial both use vaccine based interventions  however this is done in different intervals and for a different duration of time ",
        "statement_nums": [
            "the primary trial and the secondary trial both use vaccine based"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Vaccine Therapy+ex Vivo-expanded T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later  patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion  Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations  Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals  HER-2/neu peptide vaccine: Given ID leukapheresis: Undergo leukapheresis ex vivo-expanded HER2-specific T cells: Given IV cyclophosphamide: Given IV sargramostim: Given ID laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy No comparison group  All enrolled participants were expected to undergo PET guided biopsy  "
        ],
        "premise_nums": [
            "booster HER2/neu peptide vaccine 1 month after the final T-cell infusion  followed by 2 additional booster vaccines at 2-month intervals",
            "T Cells) Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2",
            "laboratory biomarker analysis: Correlative study INTERVENTION 1: PET Guided Biopsy No comparison day 1. Treatment repeats every 7-10 days for up to",
            "IV over 30 minutes on day 1. Treatment repeats every 7-10 days 1, 8, and 15. Beginning 2 weeks later  patients",
            "and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days"
        ]
    },
    {
        "id": "6461007d-fc18-43e2-a797-11cb0a4512ce",
        "primaryId": "NCT01648322",
        "secondaryId": "NCT00436566",
        "statement_text": "the primary trial has a shorter time frame than the secondary trial ",
        "statement_nums": [
            "the primary trial has a shorter time frame than the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Duration of Moderate Neurtopenia Post First Chemotherapy Administration Number of days In which the patient has had an absolute neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Outcome Measurement: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment [Not Specified] Time frame: 6 months "
        ],
        "premise_nums": [
            "chemotherapy Time frame: The first of 4, 21 Day Chemotherapy Cycles Outcome Measurement: Number of",
            "neutrophil count (ANC) Level smaller than 2.0 x 10^9/L after first cycle of chemotherapy Time"
        ]
    },
    {
        "id": "819e85b0-2d4e-4535-b920-4e18868da883",
        "primaryId": "NCT00630032",
        "secondaryId": "NCT00428922",
        "statement_text": "Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial ",
        "statement_nums": [
            "Patients with radiologically confirmed metatases in the",
            "excluded from both the secondary trial and the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion criteria: Clinically or radiologically detectable metastases (M0) Exclusion Criteria: CNS (central nervous system) metastases "
        ],
        "premise_nums": [
            "Exclusion criteria: Clinically or radiologically detectable metastases (M0) Exclusion Criteria: CNS (central nervous system)"
        ]
    },
    {
        "id": "cc0d6fe8-69c4-49d3-b321-00e47c155db6",
        "primaryId": "NCT03098550",
        "statement_text": "There results from cohort 3 of the primary trial were inconclusive ",
        "statement_nums": [
            "There results from cohort 3 of the primary trial were inconclusive"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Adverse Events (AEs) Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title: Nivolumab + Daratumumab (TNBC) Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab + Daratumumab (NSCLC) ",
            "Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0% "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of Measure: Participants 41 100.0% Results 2: Arm/Group Title: Nivolumab +",
            "Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of Measure: Participants 21 100.0%",
            "Daratumumab Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1: Arm/Group Title:",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41",
            "16 mg/kg Q2W (weeks 9-24) Overall Number of Participants Analyzed: 41 Measure Type: Count of Participants Unit of",
            "16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure Type: Count of Participants Unit of",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W",
            "240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q2W (weeks 9-24)Overall Number of Participants Analyzed: 21 Measure",
            "cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 30 days post last dose (up to 34 months)"
        ]
    },
    {
        "id": "0fbb4fb4-620b-4ee9-aaa8-956992026cef",
        "primaryId": "NCT00454532",
        "statement_text": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events ",
        "statement_nums": [
            "than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11 (0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6 (0.00%) "
        ],
        "premise_nums": [
            "5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Infection-ulcer 20/11 (0.00%) Hemoglobin 20/11 (0.00%) Hypoglycemia 20/11",
            "(9.09%) Pain-breast 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6 (0.00%)",
            "to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6",
            "5/11 (45.45%) Hemorrhage  GI-abdomen NOS 21/11 (9.09%) Pain-liver 21/11 (9.09%) Pleural effusion 22/11 (18.18%) Adverse Events 2: Total: 0/6",
            "(0.00%) Pain-rib cage due to vomiting 20/11 (0.00%) Obstruction-gu ureter 1/11 (9.09%) Hemorrhage gu-bladder 21/11"
        ]
    },
    {
        "id": "69b12ff4-6bb4-4207-b400-67795709c3c8",
        "primaryId": "NCT02679755",
        "statement_text": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events ",
        "statement_nums": [
            "Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment  All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs)  AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs  Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs  Each AE was counted once for the participant in the most severe severity  A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly  Time frame: Baseline up to 28 days after last dose of study treatment  an average of 14 months Results 2: ",
            "Arm/Group Title: Palbociclib+Letrozole Australia CohortArm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information Overall Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants Participants with adverse events: 152 100.0% Participants with serious adverse events: 45 29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants discontinued due to adverse events: 9 5.9% "
        ],
        "premise_nums": [
            "with serious adverse events: 45 29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7",
            "for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs",
            "Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of",
            "29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing",
            "events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants with adverse events: 152 100.0% Participants with serious adverse events: 45 29.6%",
            "Time frame: Baseline up to 28 days after last dose of study treatment",
            "severe AEs  Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs",
            "Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle",
            "are moderate AEs; Grade 3 AEs are severe AEs  Grade 4 AEs are life-threatening consequences and Grade 5",
            "events: 45 29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants",
            "frame: Baseline up to 28 days after last dose of study treatment  an average of 14 months Results 2:"
        ]
    },
    {
        "id": "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial ",
        "statement_nums": [
            "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 "
        ],
        "premise_nums": [
            "Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria"
        ]
    },
    {
        "id": "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c",
        "primaryId": "NCT00464646",
        "statement_text": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast  IHC results were 1+. She is eligible for the primary trial ",
        "statement_nums": [
            "the breast  IHC results were 1+. She is eligible for the primary trial",
            "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients must be female  The patient must be greater than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive adenocarcinoma of the breast on histologic examination  The breast cancer must be determined to be HER2-positive prior to study entry  Assays performed using FISH require gene amplification  Assays using IHC require a strongly positive (3+) staining score  By pathologic evaluation  ipsilateral nodes must be pN2 or pN3. "
        ],
        "premise_nums": [
            "ipsilateral nodes must be pN2 or pN3.",
            "be determined to be HER2-positive prior to study entry  Assays",
            "than or equal to 18 years old  The patient's ECOG performance status must be 0 or 1. The tumor must be invasive",
            "require a strongly positive (3+) staining score  By pathologic evaluation"
        ]
    },
    {
        "id": "efc15257-5e19-4b7e-8b51-da94840784d8",
        "primaryId": "NCT00623233",
        "secondaryId": "NCT01525589",
        "statement_text": "the primary trial recorded 1 patient with a deficiency of platelets in the blood  whereas a total of 6 patients with a platelet deficiency where found in the secondary trial ",
        "statement_nums": [
            "whereas a total of 6 patients with a platelet deficiency where found in the secondary trial",
            "the primary trial recorded 1 patient with a deficiency of platelets in"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%) Neutropenia 1/52 (1.92%) Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%) Diarrhoea 1/52 (1.92%) Adverse Events 1: Total: 14/54 (25.93%) anaemia 2/54 (3.70%) Febrile neutropenia 7/54 (12.96%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%) ",
            "Cardiac failure congestive 1/54 (1.85%)Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Vomiting 0/20 (0.00%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%) "
        ],
        "premise_nums": [
            "Thrombocytopenia 1/52 (1.92%) Cardiac Failure Congestive 1/52 (1.92%) Cardio-Respiratory Arrest 1/52 (1.92%) Abdominal Pain 1/52 (1.92%) Constipation 1/52 (1.92%)",
            "failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive",
            "effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%) Chest discomfort 1/54 (1.85%) Adverse Events 2:",
            "Cardiac failure congestive 1/54 (1.85%)Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 1/54 (1.85%)",
            "failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20",
            "(0.00%) Thrombocytopenia 0/20 (0.00%) Atrial fibrillation 0/20 (0.00%) Cardiac failure congestive 0/20 (0.00%) Pericardial effusion 0/20 (0.00%) Nausea 0/20 (0.00%)",
            "Cardiac failure congestive 1/54 (1.85%)Pericardial effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%)",
            "Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%)",
            "Chest discomfort 1/54 (1.85%) Adverse Events 2: Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 0/20 (0.00%) Thrombocytopenia 0/20",
            "Adverse Events 1: Total: 18/52 (34.62%) Anaemia 2/52 (3.85%) Febrile Neutropenia 1/52 (1.92%) Haemolytic Uraemic Syndrome 1/52 (1.92%) Leukopenia 1/52 (1.92%)",
            "Total: 5/20 (25.00%) anaemia 0/20 (0.00%) Febrile neutropenia 2/20 (10.00%) Neutropenia 2/54 (3.70%) Thrombocytopenia 6/54 (11.11%) Atrial fibrillation 1/54 (1.85%)",
            "effusion 1/54 (1.85%) Nausea 2/54 (3.70%) Vomiting 3/54 (5.56%) Catheter site erythema 0/20 (0.00%) Chest discomfort 0/20 (0.00%)"
        ]
    },
    {
        "id": "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1",
        "primaryId": "NCT01310231",
        "secondaryId": "NCT00093808",
        "statement_text": "19.57% of patients in the secondary trial developed an eating disorder  there were no cases of this happening in the primary trial ",
        "statement_nums": [
            "this happening in the primary trial",
            "19.57% of patients in the secondary trial developed an eating disorder"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%) hypoxia 0/22 (0.00%) thromboembolism 0/22 (0.00%) Adverse Events 2: Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%) hypoxia 1/17 (5.88%) thromboembolism 1/17 (5.88%) Adverse Events 1: ",
            "Total: 9/46 (19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%) Anorexia 1/46 (2.17%) Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) "
        ],
        "premise_nums": [
            "Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia",
            "Total: 9/46 (19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46",
            "Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "(19.57%)Febrile neutropenia 1/46 (2.17%) Cardiac disorder 1/46 (2.17%) Diarrhea 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)",
            "Diarrhea 1/46 (2.17%) Upper gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%)",
            "neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia with urinary tract infection 1/17 (5.88%) dyspnoea 0/17 (0.00%)",
            "Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%) febrile neutropenia",
            "Total: 4/17 (23.53%) ascites with hyponatraemia 1/17 (5.88%) febrile neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia",
            "Adverse Events 1: Total: 3/22 (13.64%) ascites with hyponatraemia 0/22 (0.00%) febrile neutropenia with respiratory infection 1/22 (4.55%) urosepsis 1/22 (4.55%)",
            "gastrointestinal hemorrhage 1/46 (2.17%) Chest pain 1/46 (2.17%) Fatigue 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)",
            "neutropenia with respiratory infection 0/17 (0.00%) urosepsis 0/17 (0.00%) febrile neutropenia with urinary tract infection 0/22 (0.00%) dyspnoea 1/22 (4.55%)",
            "Dehydration 1/46 (2.17%) Serum potassium increased 1/46 (2.17%) Neutrophil count decreased 2/46 (4.35%) Platelet count decreased 1/46 (2.17%)"
        ]
    },
    {
        "id": "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%)"
        ]
    },
    {
        "id": "e4961c1a-83e2-40ed-93ac-64d5cef1f84a",
        "primaryId": "NCT01819233",
        "statement_text": "All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study ",
        "statement_nums": [
            "All the primary trial participants must reduce the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients receive food diaries to complete for 7-10 days  Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet  Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo radiation therapy QD 5 days a week for 6 weeks  Behavioral dietary intervention: Receive caloric restricted dietary intervention Therapeutic conventional surgery: Undergo definitive lumpectomy Radiation therapy: Undergo radiation therapy Counseling intervention: Receive dietary counseling Quality-of-life assessment: Ancillary studies "
        ],
        "premise_nums": [
            "INTERVENTION 1: Behavioral Dietary Intervention Beginning 2-4 weeks after completion of lumpectomy  patients",
            "receive food diaries to complete for 7-10 days  Dietary counselors then give",
            "reduce caloric intake by 25% of their normal diet  Patients undergo radiation therapy QD 5 days a week for 6",
            "caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy  and at least 2 weeks after radiation therapy)",
            "modifications to reduce caloric intake by 25% of their normal diet  Patients",
            "radiation therapy  during 6 weeks of radiation therapy  and at least 2 weeks after radiation therapy)  Patients undergo"
        ]
    },
    {
        "id": "9cb1c975-0d49-4437-af56-1a4f97e30aef",
        "primaryId": "NCT01663727",
        "secondaryId": "NCT00072293",
        "statement_text": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial ",
        "statement_nums": [
            "for participation in the primary trial or the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death PATIENT CHARACTERISTICS: ",
            "AgeAny age "
        ],
        "premise_nums": [
            "intent  ECOG performance status of 0 or 1 For women of childbearing potential",
            "lactation History of other malignancies within 5 years prior to screening  except for",
            "disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or",
            "or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with",
            "have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent",
            "Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical",
            "conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life"
        ]
    },
    {
        "id": "51699ae8-d297-4635-95c1-4ed38c8706c3",
        "primaryId": "NCT02732119",
        "statement_text": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial ",
        "statement_nums": [
            "fibrillation twice in the last month he is therefore excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Clinically significant  uncontrolled heart disease and/or recent cardiac events  "
        ],
        "premise_nums": [
            "Exclusion Criteria: Clinically significant  uncontrolled heart"
        ]
    },
    {
        "id": "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7",
        "primaryId": "NCT02129556",
        "statement_text": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Death 2/6 (33.33%) Adverse Events 2: Death 9/52 (17.31%)"
        ]
    },
    {
        "id": "949ac54b-a871-4134-a507-c98a4de55720",
        "primaryId": "NCT00394082",
        "secondaryId": "NCT01033032",
        "statement_text": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture  neither of these were observed in the secondary trial ",
        "statement_nums": [
            "the primary trial recorded cases of Anaphylaxis",
            "were observed in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50 (2.00%) Cholelithiasis 1/50 (2.00%) Anaphylactic reaction [1]1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%) ",
            "PLEURAL EFFUSION 1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) "
        ],
        "premise_nums": [
            "1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1:",
            "PLEURAL EFFUSION 1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%)",
            "(2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH",
            "Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia 1/50 (2.00%) Pancreatitis 1/50 (2.00%) Cholangitis 1/50",
            "1: Total: 1/3 (33.33%) FEBRILE NEUTROPENIA 0/3 (0.00%) LYMPH NODE PAIN 0/3 (0.00%) NEUTROPHIL COUNT DECREASED 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%)",
            "(2.00%) Dehydration 1/50 (2.00%) Electrolyte imbalance 1/50 (2.00%) Adverse Events 1: Total: 13/50 (26.00%) Febrile neutropenia 3/50 (6.00%) Neutropenia",
            "chemical 1/50 (2.00%) Spinal compression fracture 1/50 (2.00%) Dehydration 1/50 (2.00%) Pneumonia 1/50 (2.00%) Pneumonitis chemical 1/50 (2.00%) Spinal compression fracture",
            "1/3 (33.33%)PNEUMONITIS 0/3 (0.00%) PULMONARY INFILTERATES 0/3 (0.00%) ALOPECIA 0/3 (0.00%) THROMBOCYTOPENIA 0/3 (0.00%) CHEST PAIN 0/3 (0.00%) DEHYDRATION 0/3 (0.00%)"
        ]
    },
    {
        "id": "02407f87-235d-4240-98fe-498b352cce75",
        "primaryId": "NCT00167414",
        "statement_text": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial ",
        "statement_nums": [
            "have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Age: no limit Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different organs (liver  lung or bone)  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered  Concurrent therapy is allowed and recommended  The chemotherapy protocol type and schedule are at the discretion of the medical oncologist  Informed consent must be obtained  Pregnancy test must be negative for women of child bearing potential Exclusion Criteria: Inability of patient to be followed longitudinally as specified by protocol  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery  Women who are pregnant or nursing  Failure to meet requirements in Inclusion Criteria Contraindications to radiation  "
        ],
        "premise_nums": [
            "Concurrent therapy is allowed and recommended  The",
            "Karnofsky performance status (KPS) 70 No more than 5 metastatic sites involving one or more different"
        ]
    },
    {
        "id": "304977b6-9742-4c3b-84fd-e5ef1737a143",
        "primaryId": "NCT01597193",
        "statement_text": "ECOG smaller than 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial ",
        "statement_nums": [
            "ECOG smaller than 2 and a life expectancy over 12 weeks are necessary to participate in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months "
        ],
        "premise_nums": [
            "Oncology Group performance (ECOG) status of 0 or 1; Estimated life expectancy of at least 3 months"
        ]
    },
    {
        "id": "87c65217-85d9-4f05-87aa-f4dfacd9f25a",
        "primaryId": "NCT01790932",
        "statement_text": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial",
        "statement_nums": [
            "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Have received previous treatment with PI3K inhibitors "
        ],
        "premise_nums": [
            "received previous treatment with PI3K inhibitors"
        ]
    },
    {
        "id": "19e89ebc-a417-47a8-bfa7-1778baead178",
        "primaryId": "NCT01385137",
        "secondaryId": "NCT00593346",
        "statement_text": "Placebo treatment is used in the secondary trial  but there is only a test group in the primary trial ",
        "statement_nums": [
            "test group in the primary trial",
            "is used in the secondary trial  but there is"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 2: Arm II (Placebo) Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each patient will receive accelerated partial breast brachytherapy with multiple plane implant  Patients will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions  "
        ],
        "premise_nums": [
            "times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity INTERVENTION 1: Accelerated Partial Breast Brachytherapy Each",
            "oral placebo BID or TID for 24 weeks in the absence of",
            "3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum of 6 hours",
            "INTERVENTION 1: Arm I (Omega-3-fatty Acid) Patients receive oral omega-3-fatty acid twice daily (BID) or three",
            "will receive 3400 cGy delivered in 10 twice-daily fractions  Treatment is to be given over 5-7 days with a minimum"
        ]
    },
    {
        "id": "561a0631-1eb3-48d1-baa2-81eb3fa79b98",
        "primaryId": "NCT00950300",
        "secondaryId": "NCT00615901",
        "statement_text": "the primary trial recorded a patient with chest pain  whereas the secondary trial observed a patient with abdominal pain ",
        "statement_nums": [
            "the primary trial recorded a patient with",
            "pain  whereas the secondary trial observed a patient with"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Angina pectoris * 1/298 (0.34%) Adverse Events 1: Abdominal pain 1/38 (2.63%)"
        ]
    },
    {
        "id": "bc617e84-a0c1-400b-9ad5-88b56d1805e8",
        "primaryId": "NCT01671319",
        "statement_text": "1/42 patients in cohort 1 of the primary trial fainted ",
        "statement_nums": [
            "1/42 patients in cohort 1 of the primary trial fainted"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%) Rash/desquamation 1/42 (2.38%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/42 (9.52%) Perforation  GI 1/42 (2.38%) Febrile neutropenia 1/42 (2.38%) Syncope 1/42 (2.38%)"
        ]
    },
    {
        "id": "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5",
        "primaryId": "NCT01097642",
        "statement_text": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial ",
        "statement_nums": [
            "breast carcinoma (T3 N1 M0) are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients with histologic confirmation of invasive breast carcinoma  Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast cancer are eligible  "
        ],
        "premise_nums": [
            "Patients greater than or equal to 18 years  Patients should have T1N1-3M0 or T2-4 N0-3M0. Patients with bilateral breast"
        ]
    },
    {
        "id": "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe",
        "primaryId": "NCT00354640",
        "statement_text": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin ",
        "statement_nums": [
            "Patients taking Intervention 1 of the primary trial receive higher doses of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Anastrozole and Simvastatin adjuvant therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days "
        ],
        "premise_nums": [
            "laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD for 14 days",
            "therapy : laboratory analysis pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days",
            "pharmacological study : laboratory analysis simvastatin : 40 milligram tablet PO QD for 14 days anastrozole : 1 milligram tablet PO QD"
        ]
    },
    {
        "id": "b059e44b-9830-4c45-858e-ebd007fbaf69",
        "primaryId": "NCT00148668",
        "statement_text": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia ",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial recorded the same number"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%) "
        ],
        "premise_nums": [
            "0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT",
            "SGPT (ALT) 1/41 (2.44%) Adverse Events 2: Total: 5/40 (12.50%) Neutropenia 4/40 (10.00%) Febrile Neutropenia 1/40 (2.50%) SGPT (ALT) 0/40 (0.00%)",
            "Adverse Events 1: Total: 5/41 (12.20%) Neutropenia 4/41 (9.76%) Febrile Neutropenia 0/41 (0.00%) SGPT (ALT) 1/41 (2.44%) Adverse"
        ]
    },
    {
        "id": "fec065ca-fbde-476d-ab0d-7e7054e29858",
        "primaryId": "NCT00436917",
        "statement_text": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or with a prior surgery at the lumbosacral spine are excluded from the primary trial  as these would interfere with the necessary CT and MRI scans for the study ",
        "statement_nums": [
            "are excluded from the primary trial  as these would",
            "Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine  or"
        ],
        "label": "Contradiction",
        "premise_text": [
            "No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following: History of surgery at the lumbosacral spine  with or without implantable devices Scoliosis with a Cobb angle greater than 15 degrees at the lumbar spine "
        ],
        "premise_nums": [
            "with a Cobb angle greater than 15 degrees at the lumbar spine"
        ]
    },
    {
        "id": "ea3bd229-001c-487f-9cda-edf2e699dbb2",
        "primaryId": "NCT01153672",
        "secondaryId": "NCT01432145",
        "statement_text": "Patients in the primary trial receive vorinostat at the same frequency  dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "statement_nums": [
            "Patients in the primary trial receive vorinostat at the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy  AI Sensitization Therapy) Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD  letrozole PO QD  OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity  vorinostat: Given PO laboratory biomarker analysis: Correlative studies biopsy: Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography: Correlative studies anastrozole: Given PO letrozole: Given PO exemestane: Given PO gene expression analysis: Correlative studies INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO) once a day (od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given continuously until disease progression  ",
            "Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week  in the morning  One cycle is 28 days  Treatment is given continuously until disease progression Update: These original doses were reduced following an Urgent Safety Measure in August 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day  and 15mg/m2 of Methotrexate orally once a week  "
        ],
        "premise_nums": [
            "gene expression analysis: Correlative studies INTERVENTION 1: 6-Mercaptopurine and Methotrexate (6MP/MTX) 6-Mercaptopurine: 6MP 75mg/m2 body surface area  administered orally (PO)",
            "Methotrexate: Methotrexate 20mg/m2 will be taken orally  once a week",
            "an Urgent Safety Measure in August 2012 due to a large proportion of patients",
            "Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole",
            "myelo-suppression  The reduced doses were 55mg/m2 of 6MP orally once a day",
            "a day (od) in the morning 1 hour after eating  on a continuous",
            "(od) in the morning 1 hour after eating  on a continuous schedule  One cycle is 28 days  Treatment is given",
            "Optional correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies positron emission tomography:",
            "OR exemestane PO QD for 6 weeks  Courses repeat every 8 weeks in the absence of disease progression",
            "the morning  One cycle is 28 days  Treatment is given",
            "surface area  administered orally (PO) once a day  and 15mg/m2 of Methotrexate orally once a week"
        ]
    },
    {
        "id": "576e519a-1ef3-43e5-a13c-6058ad71f388",
        "primaryId": "NCT00297596",
        "secondaryId": "NCT00580333",
        "statement_text": "Patients have received prior radiation treatment  to treat the current breast cancer  in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial ",
        "statement_nums": [
            "cancer  in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the",
            "are eligible for the primary trial but excluded from the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab  All prior chemotherapy  trastuzumab and radiation therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any prior cytotoxic chemotherapy or radiation for the current breast cancer "
        ],
        "premise_nums": [
            "therapy should be completed greater than 2 weeks before enrollment  Exclusion Criteria: Any"
        ]
    },
    {
        "id": "699d0cb5-1ebb-441d-aa7e-041a48923b00",
        "primaryId": "NCT03374995",
        "statement_text": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks ",
        "statement_nums": [
            "keratin are administered it topically twice daily for approximately 3-6 weeks",
            "the primary trial subjects receiving keratin are administered it topically twice daily for approximately"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Group I (Topical Keratin) Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care) Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks)  Best Practice: Receive standard of care Quality-of-Life Assessment: Ancillary studies "
        ],
        "premise_nums": [
            "of radiation therapy (approximately 3-6 weeks)  Quality-of-Life Assessment: Ancillary",
            "studies Topical Keratin: Given topically INTERVENTION 2: Group II (Standard of Care)",
            "receive topical keratin topically at least BID until the end of"
        ]
    },
    {
        "id": "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b",
        "primaryId": "NCT01127373",
        "statement_text": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial ",
        "statement_nums": [
            "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Pathologic confirmation of metastatic disease in at least one regional lymph node  Regional lymph nodes are defined as the ipsilateral axillary lymph nodes  ipsilateral supraclavicular lymph nodes  and ipsilateral internal mammary lymph nodes  Thus  any T stage is allowed as long as the N stage is 1 and M stage is 0. "
        ],
        "premise_nums": [
            "of metastatic disease in at least one regional lymph node",
            "any T stage is allowed as long as the N stage is 1 and M stage is 0."
        ]
    },
    {
        "id": "6e882de6-e55f-40a4-95a1-bdb176e68a18",
        "primaryId": "NCT00266799",
        "statement_text": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome ",
        "statement_nums": [
            "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 30/98 (30.61%) NEUTROPENIA 1/98 (1.02%) ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%) ILEUS 0/98 (0.00%) NAUSEA 0/98 (0.00%) "
        ],
        "premise_nums": [
            "ATRIAL FIBRILLATION 1/98 (1.02%) CARDIAC FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%)",
            "TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) DIARRHOEA 2/98 (2.04%) FEMORAL HERNIA 0/98 (0.00%) HAEMATEMESIS 0/98 (0.00%)",
            "FAILURE 1/98 (1.02%) TACHYCARDIA 0/98 (0.00%) ACUTE VESTIBULAR SYNDROME 1/98 (1.02%) VERTIGO 0/98 (0.00%) ABDOMINAL PAIN 0/98 (0.00%) COLITIS 0/98 (0.00%)"
        ]
    },
    {
        "id": "233d2ec1-1383-4088-90af-c5a948847631",
        "primaryId": "NCT00110084",
        "secondaryId": "NCT01961544",
        "statement_text": "the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients ",
        "statement_nums": [
            "the primary trial and the secondary trial both reported cases of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Sepsis 1/50 (2.00%) Adverse Events 1: Pseudomonal sepsis * 1/101 (0.99%)"
        ]
    },
    {
        "id": "8e3fe244-d47d-48ce-ab29-4a5226024aad",
        "primaryId": "NCT00426556",
        "statement_text": "There were an equal number of cases of Febrile neutropenia  Leukopenia and Neutropenia across cohorts in the primary trial ",
        "statement_nums": [
            "across cohorts in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia 0/17 (0.00%) Leukopenia 0/17 (0.00%) Neutropenia 0/17 (0.00%) "
        ],
        "premise_nums": [
            "1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6 (0.00%) Adverse Events 2: Total: 6/17 (35.29%) Febrile neutropenia",
            "Adverse Events 1: Total: 3/6 (50.00%) Febrile neutropenia 0/6 (0.00%) Leukopenia 0/6 (0.00%) Neutropenia 0/6"
        ]
    },
    {
        "id": "670443b0-89bf-4af4-a9ab-4cdff26d09a8",
        "primaryId": "NCT00005957",
        "statement_text": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial ",
        "statement_nums": [
            "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of the breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or high-risk node negative "
        ],
        "premise_nums": [
            "breast No evidence of T4, N2-3, or M1 disease prior to surgery Node positive or",
            "DISEASE CHARACTERISTICS: Histologically proven invasive carcinoma of"
        ]
    },
    {
        "id": "455748bf-8e12-4834-8126-ab77cab16200",
        "primaryId": "NCT00332709",
        "secondaryId": "NCT00659373",
        "statement_text": "All the primary trial participants receive the same dose of Letrozole  only certain patients in the secondary trial are administered Exemestane ",
        "statement_nums": [
            "certain patients in the secondary trial are administered Exemestane",
            "All the primary trial participants receive the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation) Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study  IBCSG 24-02 (SOFT)  The sample size for this Co-SOFT substudy was small  so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS  "
        ],
        "premise_nums": [
            "Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally",
            "20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function",
            "for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane",
            "parent study  IBCSG 24-02 (SOFT)  The sample size",
            "2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid",
            "Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen 20mg orally daily or Exemestane",
            "Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily for 5 years INTERVENTION 2: Ovarian Function Suppression Tamoxifen",
            "(OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or",
            "Acid Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION 1: Tamoxifen Tamoxifen 20mg orally daily",
            "INTERVENTION 1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole",
            "(OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 3 years plus Zoledronic acid 4mg every 6 months INTERVENTION",
            "1: Letrozole Letrozole 2.5 mg/day for 3 years INTERVENTION 2: Letrozole + Zoledronic Acid Letrozole 2.5mg/day for 3 years plus Zoledronic"
        ]
    },
    {
        "id": "d29bd9dd-b52e-4b18-82ea-e2914dfb9579",
        "primaryId": "NCT01808573",
        "statement_text": "the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine ",
        "statement_nums": [
            "Capecitabine had a Mean (95% Confidence Interval) Progression Free Survival more than 2 months longer than patients administered with Lapatinib",
            "the primary trial Patients receiving Neratinib Plus"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Centrally Assessed Progression Free Survival Progression Free Survival (PFS)  Measured in Months  for Randomized Subjects of the Central Assessment  The time interval from the date of randomization until the first date on which recurrence  progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause  is documented  For subjects without recurrence  progression or death  it is censored at the last valid tumor assessment  Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or a measurable increase in a non-target lesion  or the appearance of new lesions  Here  the time to event was reported as the restricted mean survival time  The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months  Time frame: From randomization date to recurrence  progression or death  assessed up to 38 months  The result is based on primary analysis data cut  Results 1: Arm/Group Title: Neratinib Plus Capecitabine ",
            "Arm/Group Description: neratinib 240 mg orally  once daily with food  continuously in 21 day cycles  and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle Overall Number of Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months 8.8 (7.8 to 9.8) Results 2: Arm/Group Title: Lapatinib Plus Capecitabine Arm/Group Description: lapatinib 1250 mg orally  once daily  continuously in 21 day cycles  and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle  Overall Number of Participants Analyzed: 314 Mean (95% Confidence Interval) Unit of Measure: months 6.6 (5.9 to 7.4) "
        ],
        "premise_nums": [
            "(RECIST v1.1), as a 20% increase in the sum of the survival function up to 24 months  Time frame: From",
            "Outcome Measurement: Centrally Assessed Progression Free Survival",
            "Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the",
            "daily with food  continuously in 21 day cycles  and capecitabine 2000 mg/m^2 daily in 2 evenly divided",
            "and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses  orally with water within 30 minutes after a meal  taken on",
            "a meal  taken on days 1 to 14 of each 21 day cycle Overall Number of",
            "of randomization until the first date on which recurrence",
            "is censored at the last valid tumor assessment  Progression",
            "taken on days 1 to 14 of each 21 day cycles  and capecitabine 1500 mg/m^2 daily in 2 evenly divided",
            "or death  assessed up to 38 months  The result is based on primary analysis data cut  Results",
            "Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months 8.8 (7.8 to 9.8) Results 2: Arm/Group Title: Lapatinib",
            "orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21 day cycle",
            "doses  orally with water within 30 minutes after a meal  taken on days 1 to 14 of each 21",
            "days 1 to 14 of each 21 day cycle Overall Number of Participants Analyzed: 314 Mean (95% Confidence Interval) Unit of",
            "Capecitabine Arm/Group Description: lapatinib 1250 mg orally  once daily  continuously",
            "Number of Participants Analyzed: 307 Mean (95% Confidence Interval) Unit of Measure: months"
        ]
    },
    {
        "id": "2649c857-f98d-4529-9a4a-4f8b17813cb8",
        "primaryId": "NCT00337103",
        "statement_text": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Overall Survival (OS) OS was measured from the date of randomization until the date of death from any cause  or the last date the participant was known to be alive  Participants who were lost to follow-up or who were alive at the date of data cutoff were censored  The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff  the date of data cutoff was considered the end date  and 2) if the participant was lost to follow-up before data cutoff  the date they were last known to be alive was considered the end date  Participants who survived past the end of the study were counted as in the full study period  If death occurred after data cutoff  the end date was to be censored at the time of data cutoff  Time frame: From date of randomization until date of death from any cause  assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years Results 1: Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days  ",
            "Overall Number of Participants Analyzed: 554Median (95% Confidence Interval) Unit of Measure: days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5 g/m^2/Day Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days  Overall Number of Participants Analyzed: 548 Median (95% Confidence Interval) Unit of Measure: days 440 (400 to 487) "
        ],
        "premise_nums": [
            "in two equal doses on Days 1 to 14 every 21 days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5",
            "Results 2: Arm/Group Title: Capecitabine 2.5 g/m^2/Day Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two",
            "equal doses on Days 1 to 14 every 21 days  Overall Number of Participants Analyzed: 554Median",
            "1.4 mg/m^2 Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every",
            "up to data cutoff date of 12 Mar 2012, or up to approximately 6 years Results 1: Arm/Group Title: Eribulin Mesylate 1.4",
            "in two equal doses on Days 1 to 14 every 21 days  Overall Number of",
            "of Measure: days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5 g/m^2/Day Arm/Group Description: Capecitabine : Capecitabine 2.5",
            "given over 2-5 minutes on Days 1 and 8 every 21 days 484 (462 to 536) Results 2: Arm/Group Title: Capecitabine 2.5",
            "of Participants Analyzed: 554Median (95% Confidence Interval) Unit of Measure: days 440 (400 to 487)",
            "cause  or the last date the participant was known",
            "Outcome Measurement: Overall Survival (OS) OS was measured",
            "Mar 2012, or up to approximately 6 years Results 1: Arm/Group Title: Capecitabine 2.5 g/m^2/Day Arm/Group Description: Capecitabine : Capecitabine 2.5",
            "Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days"
        ]
    },
    {
        "id": "0a6e8720-ea47-4520-bd02-e0eb8fcd880f",
        "primaryId": "NCT00399802",
        "statement_text": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "statement_nums": [
            "Type I Collagen than the Odanacatib 5 mg group",
            "Collagen than the Odanacatib 5 mg group of the primary trial had a smaller Percentage",
            "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone resorption  Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame: Baseline and Week 4 Results 1: Arm/Group Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) Unit of Measure: Percentage change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment  Overall Number of Participants Analyzed: 27 Mean (95% Confidence Interval) ",
            "Unit of Measure: Percentage change -77 (-82 to -71)"
        ],
        "premise_nums": [
            "Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of",
            "5 mg tablet for 4 weeks and a single IV infusion of ZA 4 mg at the start of treatment and",
            "Participants provided urine specimens on Day 1 (baseline) and at Week 4 for measurement of u-NTx  Time frame:",
            "for 4 weeks  Overall Number of Participants Analyzed: 14 Mean (95% Confidence Interval) Unit of Measure: Percentage",
            "change -73 (-80 to -62) Results 2: Arm/Group Title: Once-daily Odanacatib 5 mg Arm/Group Description: Participants received a",
            "Type I Collagen (u-NTx) at Week 4 u-NTx is a biochemical index of bone",
            "Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks  Overall Number of Participants Analyzed: 14",
            "Title: Single IV Infusion of ZA 4 mg Arm/Group Description: Participants received a once-daily odanacatib 5 mg tablet for 4 weeks and a"
        ]
    },
    {
        "id": "ce6630d3-d3b7-4870-a486-9b6284a454f0",
        "primaryId": "NCT02679755",
        "statement_text": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort ",
        "statement_nums": [
            "Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Results 1: Arm/Group Title: Palbociclib+Letrozole India Cohort Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information Overall Number of Participants Analyzed: 100 Measure Type: Count of Participants Unit of Measure: Participants Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0% Participants with grade 3 or 4 adverse events: 69 69.0% Participants with grade 5 adverse events: 3 3.0% Participants discontinued due to adverse events: 2 2.0% Results 2: Arm/Group Title: Palbociclib+Letrozole Australia Cohort ",
            "Arm/Group Description: Participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing informationOverall Number of Participants Analyzed: 152 Measure Type: Count of Participants Unit of Measure: Participants Participants with adverse events: 152 100.0% Participants with serious adverse events: 45 29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants discontinued due to adverse events: 9 5.9% "
        ],
        "premise_nums": [
            "29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with adverse events: 152 100.0% Participants with serious adverse events: 45 29.6%",
            "a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle  Participants received",
            "a day at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received",
            "18.0% Participants with grade 3 or 4 adverse events: 69 69.0% Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing",
            "18.0% Participants with grade 3 or 4 adverse events: 69 69.0% Participants with grade 5 adverse events: 3 3.0% Participants discontinued due",
            "at 125 mg for 21 days followed by 7 days off treatment for each 28-day cycle  Participants received Letrozole orally",
            "or 4 adverse events: 69 69.0% Participants with grade 5 adverse events: 3 3.0% Participants discontinued due to adverse events: 2",
            "or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants discontinued due to adverse events: 9",
            "29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0%",
            "Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle",
            "events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0%",
            "events: 69 69.0% Participants with grade 5 adverse events: 3 3.0% Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0%",
            "18.0% Participants with grade 3 or 4 adverse events: 69 69.0% Participants with adverse events: 92 92.0% Participants with serious adverse events: 18 18.0%",
            "with serious adverse events: 18 18.0% Participants with grade 3 or 4 adverse events: 69 69.0% Participants with grade 5 adverse events: 3",
            "Number of Participants Analyzed: 100 Measure Type: Count of Participants Unit of",
            "7 days off treatment for each 28-day cycle  Participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing",
            "29.6% Participants with grade 3 or 4 adverse events: 124 81.6% Participants with grade 5 adverse events: 7 4.6% Participants discontinued due"
        ]
    },
    {
        "id": "27e31574-5a73-4a68-997d-daa84797a65a",
        "primaryId": "NCT00054028",
        "secondaryId": "NCT02162719",
        "statement_text": "Both the primary trial and the secondary trial at least partly administer their interventions intravenously ",
        "statement_nums": [
            "Both the primary trial and the secondary trial at least partly administer their interventions intravenously"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Suramin and Paclitaxel Suramin will be infused weekly over 30 minutes  Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin  INTERVENTION 1: Ipatasertib and Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity  elective withdrawal from the study  or study completion or termination  "
        ],
        "premise_nums": [
            "completion of the suramin infusion the 1 hour infusion of paclitaxel will begin",
            "Paclitaxel Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg  orally",
            "orally  once daily from Days 1-21 in each cycle of 28 days until disease progression  intolerable toxicity",
            "Suramin will be infused weekly over 30 minutes  Four hours after",
            "Days 1, 8, and 15 along with ipatasertib 400 mg  orally  once daily from Days 1-21 in each cycle of"
        ]
    },
    {
        "id": "e21171de-ad49-4fc5-9c5d-aa362ca61c8a",
        "primaryId": "NCT00014222",
        "statement_text": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas cohort two recorded 41.",
        "statement_nums": [
            "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events  whereas"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Adverse Events 2: Total: 86/688 (12.50%) Hemoglobin 15/688 (2.18%) Transfusion: Platelets 1/688 (0.15%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%) ",
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%) "
        ],
        "premise_nums": [
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%)",
            "Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "Ischemia/infarction 0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "(0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680",
            "neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680 (0.00%) Palpitations 0/680 (0.00%) Pericardial effusion 0/680 (0.00%) Keratitis 1/680 (0.15%)",
            "(0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Keratitis 0/688 (0.00%) Double vision 0/688 (0.00%) Colitis 0/688 (0.00%)",
            "Adverse Events 1: Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile",
            "11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 0/680 (0.00%) Febrile neutropenia 49/680 (7.21%) Edema 1/680 (0.15%) Ischemia/infarction 0/680",
            "Total: 83/680 (12.21%) Hemoglobin 11/680 (1.62%) Transfusion: Platelets 0/680 (0.00%) Transfusion: pRBCs 1/688 (0.15%) Febrile neutropenia 41/688 (5.96%) Edema 0/688 (0.00%)",
            "0/688 (0.00%)Palpitations 1/688 (0.15%) Pericardial effusion 1/688 (0.15%) Keratitis 0/688 (0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%)",
            "(0.00%) Keratitis 1/680 (0.15%) Double vision 1/680 (0.15%) Colitis 1/680 (0.15%) Adverse Events 2: Total: 86/688 (12.50%) Hemoglobin 15/688"
        ]
    },
    {
        "id": "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32",
        "primaryId": "NCT02518191",
        "statement_text": "Cohort 2 of the primary trial is the control group  as the Eligible patients with breast cancer treated with GnRHa every 28 days ",
        "statement_nums": [
            "Cohort 2 of the primary trial is the control group",
            "breast cancer treated with GnRHa every 28 days"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy  "
        ],
        "premise_nums": [
            "chemotherapy  Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks",
            "or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy  INTERVENTION 2: None"
        ]
    },
    {
        "id": "38f47a03-f71d-4072-a005-b954fb6069da",
        "primaryId": "NCT00684983",
        "statement_text": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year ",
        "statement_nums": [
            "Arm A of the primary trial lived with the disease"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression-free Survival (PFS) Analysis of the primary endpoint  PFS  will be performed using Cox regression with treatment group as a single covariate  Time frame: From randomization to the earliest date of documentation of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group Description: Patients receive oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  lapatinib ditosylate: Given PO and capecitabine: Given PO Overall Number of Participants Analyzed: 19 Median (95% Confidence Interval) Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6) "
        ],
        "premise_nums": [
            "of disease progression  up to 5 years Results 1: Arm/Group Title: Arm A Arm/Group",
            "(PFS) Analysis of the primary endpoint  PFS  will",
            "once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Participants Analyzed: 19 Median (95% Confidence Interval) Unit of Measure: Median survival and CI in months 6.0 (4.3 to 8.6)",
            "oral capecitabine twice daily on days 1-14 and oral lapatinib ditosylate once daily on"
        ]
    },
    {
        "id": "e41917b8-d921-4797-b845-0121a75104a4",
        "primaryId": "NCT00129376",
        "statement_text": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat ",
        "statement_nums": [
            "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Acute Pharyngitis * 1/63 (1.59%)"
        ]
    },
    {
        "id": "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541",
        "primaryId": "NCT02513472",
        "statement_text": "Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.",
        "statement_nums": [
            "Cohort 1 patients in the primary trial surivied almost twice as"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) ORR was defined as percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) using independent imaging review (IIR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. BOR of CR and PR was confirmed by a subsequent CR assessment and CR or PR assessment  respectively at least 4 weeks later  CR: disappearance of all measurable  non-measurable lesions and no unequivocal new lesions  Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (smaller than ) 10 millimeter (mm)  PR: at least a 30 percent (%) decrease in sum of diameters (SOD) of target lesions  taking as reference the baseline SOD and there are no unequivocal new lesions  and no progression of non-target disease  The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson method  As planned  data up to the primary completion date only were analyzed  Time frame: From date of first dose of study drug administration to date of first documentation of disease progression or death  whichever occurred first (up to 3 years 11 months) Results 1: ",
            "Arm/Group Title: Stratum 1: Eribulin Mesylate + PembrolizumabArm/Group Description: Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression  development of unacceptable toxicity  participant request  withdrawal of consent  or study termination by the sponsor in Phase 2 in the Stratum 1. Overall Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum 2: Eribulin Mesylate + Pembrolizumab ",
            "Arm/Group Description: Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression  development of unacceptable toxicity  participant request  withdrawal of consent  or study termination by the sponsor in Phase 2 in the Stratum 2.Overall Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 21.8 (14.2 to 31.1) "
        ],
        "premise_nums": [
            "than (smaller than ) 10 millimeter (mm)  PR: at least a 30 percent (%) decrease in sum",
            "metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on",
            "data up to the primary completion date only were analyzed",
            "and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b)",
            "Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum",
            "1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day",
            "non-target disease  The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson",
            "termination by the sponsor in Phase 2 in the Stratum 2.Overall Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage",
            "1b) and then continued in each 21-days Treatment Cycles in the presence of",
            "Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy",
            "Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 21.8 (14.2 to 31.1)",
            "participants with confirmed best overall response (BOR) of complete response",
            "PR assessment  respectively at least 4 weeks later  CR: disappearance of all",
            "whichever occurred first (up to 3 years 11 months) Results 1:",
            "Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum",
            "Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in"
        ]
    },
    {
        "id": "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7",
        "primaryId": "NCT02491892",
        "secondaryId": "NCT00887575",
        "statement_text": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial  this is due to the significant difference in cohort size ",
        "statement_nums": [
            "Cohort 1 of the secondary trial recorded more cases of",
            "of diarrhea and dyspepsia than cohort 1 of the primary trial  this is due"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: DIARRHEA 1/41 (2.44%) DYSPEPSIA 1/41 (2.44%)",
            "Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse",
            "Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia * 0/41 (0.00%) Adverse Events 1: Diarrhoea * 0/41 (0.00%) Dysphagia"
        ]
    },
    {
        "id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
        "primaryId": "NCT01881230",
        "statement_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "statement_nums": [
            "Gemcitabine group of the primary trial had a median Kaplan-Meier",
            "Estimate of Progression-Free Survival more than 83% less than the Carboplatin"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment  PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis  whichever occurred earlier  Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir  Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A  34 months for Arm B and 35 months for Arm C Results 1: Arm/Group Title: Arm A: Nab-Paclitaxel + Gemcitabine ",
            "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatmentOverall Number of Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months 5.5 (4.1 to 7.0) Results 2: Arm/Group Title: Arm B: Nab-Paclitaxel + Carboplatin ",
            "Arm/Group Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment until progressive disease (PD)  unacceptable toxicity  required palliative radiotherapy or surgical intervention of lesion(s)  withdrawal from study treatment  withdrawal of study consent  participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment Overall Number of Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 8.3 (5.7 to 10.6) "
        ],
        "premise_nums": [
            "Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months 8.3 (5.7 to 10.6)",
            "Tumor responses were assessed every 6 weeks using  Response Evaluation Criteria in",
            "8 by IV administration of each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "Days 1 and 8 in each 21-day treatment cycle  Participants Analyzed: 64 Median (95% Confidence Interval) Unit of Measure: months",
            "Days 1 and 8 in each 21-day treatment cycle  Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous",
            "by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle  Participants",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by",
            "8 by IV administration of each 21-day treatment cycle  Participants Analyzed: 61 Median (95% Confidence Interval) Unit of Measure: months",
            "unacceptable toxicity  required palliative radiotherapy or surgical intervention",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 in each 21-day treatment cycle  Participants continued treatment",
            "length of time on study was 31 months for Arm A  34 months for Arm B and 35 months",
            "randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A",
            "received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle  Participants continued treatment",
            "Description: Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed",
            "for Arm A  34 months for Arm B and 35 months for Arm C Results 1: Arm/Group Title: Arm A: Nab-Paclitaxel",
            "is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of",
            "Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and",
            "Progressive Disease- is at least a 20% increase in the sum of diameters"
        ]
    },
    {
        "id": "6214280f-f665-48d3-b33f-9d798deff71f",
        "primaryId": "NCT01855828",
        "secondaryId": "NCT00696072",
        "statement_text": "the secondary trial uses Overall Survival (OS) as outcome measurement  which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial ",
        "statement_nums": [
            "is used for the primary trial",
            "the secondary trial uses Overall Survival (OS) as outcome measurement"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Proportion of Participants With a Pathologic Complete Response Rate To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will assess pCR rates separately in ER+ and ER- cancers  Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen  Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen  Time frame: 20 weeks Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population ",
            "CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) "
        ],
        "premise_nums": [
            "cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study drug to last dose plus 7 days  up to study",
            "lesions  PR= At least a 30% decrease in the sum of the",
            "time greater than  equal to 6 months  CR= Disappearance of study drug to last dose plus 7 days",
            "of study drug to last dose plus 7 days  up to study",
            "Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population",
            "tumor cells at the primary tumor site and axillary lymph",
            "specimen  Time frame: 20 weeks Outcome Measurement: Number of Participants With",
            "weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer  This study will"
        ]
    },
    {
        "id": "108b54a9-b5cc-4f31-956f-e4e2e653d756",
        "primaryId": "NCT00089999",
        "statement_text": "In total more participants in the primary trial had no tumor Response  than partial response  and 0 participants had a complete response ",
        "statement_nums": [
            "more participants in the primary trial had no tumor Response",
            "partial response  and 0 participants had a complete response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR)  as Assessed by the Independent Review Committee (IRC) OR is defined as the number of participants achieving either a confirmed CR or PR  per Response Evaluation Criteria in Solid Tumors (RECIST  v 1.0). Best OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence  CR is defined as the disappearance of all target lesions (TLs) and non-TLs  PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs  taking as a reference the Baseline sum LD and no PD  or complete resolution of TLs and the persistence of one or more non-TL(s)  as assessed by the IRC  PD is defined as at least a 20% increase in the sum of the LD of TLs  taking as a reference the smallest sum LD recorded since the treatment started or the appearance of greater than or equal 1 new lesions or unequivocal progression of existing non-TLs  Responses were confirmed at subsequent assessments made greater than or equal 28 days after the original response  Participants with an unknown or missing response are treated as non-responders  ",
            "Time frame: From the date of the first dose of investigational product to the first documented evidence of a confirmed CR or PR (up to Study Week 103)Results 1: Arm/Group Title: Lapatinib 1500 mg QD Arm/Group Description: Participants received lapatinib 1500 mg orally QD  Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason  After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule  until disease progression  provided the treatment was tolerated  Overall Number of Participants Analyzed: 69 Measure Type: Number Unit of Measure: Participants CR: 0 PR: 15 Results 2: Arm/Group Title: Lapatinib 500 mg BID Arm/Group Description: Participants received lapatinib 500 mg orally BID  Treatment was continued for 12 weeks or until disease progression or withdrawal from treatment for another reason  After Week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule  until disease progression  provided the treatment was tolerated  Overall Number of Participants Analyzed: 69 Measure Type: Number Unit of Measure: Participants CR: 0 PR: 18 "
        ],
        "premise_nums": [
            "QD Arm/Group Description: Participants received lapatinib 1500 mg orally QD  Treatment was continued for 12 weeks or until disease progression or withdrawal",
            "assessments made greater than or equal 28 days after the original response  Participants",
            "appearance of greater than or equal 1 new lesions or unequivocal progression of existing",
            "BID Arm/Group Description: Participants received lapatinib 500 mg orally BID  Treatment was continued for 12 weeks or until disease progression or withdrawal",
            "PR is defined as at least a 30% decrease in the sum of the",
            "PR is defined as at least a 30% decrease in the date of the first dose of investigational product to",
            "Number of Participants Analyzed: 69 Measure Type: Number Unit of Measure: Participants With a Best Overall Response (OR) of Confirmed Complete",
            "1: Arm/Group Title: Lapatinib 1500 mg QD Arm/Group Description: Participants received lapatinib 1500 mg orally QD  Treatment was continued",
            "for another reason  After Week 12, participants with clinical benefit had the",
            "greater than or equal 28 days after the original response  Participants CR: 0 PR: 15 Results 2: Arm/Group Title: Lapatinib 500 mg"
        ]
    },
    {
        "id": "662f4992-0155-4a82-926f-b1821539aab7",
        "primaryId": "NCT00723125",
        "secondaryId": "NCT00617942",
        "statement_text": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery  compared to 60% in cohort 1 of the secondary trial ",
        "statement_nums": [
            "57% of patients in cohort 1 of the secondary trial",
            "Rates at Surgery  compared to 60% in cohort 1 of the secondary trial",
            "57% of patients in cohort 1 of the primary trial had Pathological Complete Response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Pathological Complete Response Rates at Surgery [Not Specified] Time frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks ",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Patients With Complete Pathologic Response Rate  Observed Following Treatment With q3week Carboplatin  Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC; These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden  Time frame: 1 year Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants 12 "
        ],
        "premise_nums": [
            "over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x",
            "mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV",
            "over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort",
            "frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: [Not Specified] Overall Number",
            "Observed Following Treatment With q3week Carboplatin  Weekly Abraxane and",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30-60 minutes q2weeks x 34 weeks",
            "frame: at surgery approximately 5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV",
            "and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over",
            "min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on",
            "minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x",
            "over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10",
            "1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV",
            "Time frame: 1 year Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14",
            "over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV",
            "x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x",
            "with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV",
            "over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed:",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes",
            "1: Arm/Group Title: Cohort 1 Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV",
            "omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28 Measure Type: Number Unit of Measure: participants",
            "5 months after initial treatment Results 1: Arm/Group Title: Cohort 1 Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14",
            "omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC",
            "15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over",
            "12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7,",
            "weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)Overall Number of Participants Analyzed: 28",
            "Number of Participants Analyzed: 37 Measure Type: Number Unit of Measure: participants 16 Outcome Measurement: Number of Patients With Complete",
            "60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes",
            "x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes",
            "30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes",
            "100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15",
            "Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV"
        ]
    },
    {
        "id": "398f744b-97cf-4f95-b162-99ec6652d327",
        "primaryId": "NCT01091454",
        "secondaryId": "NCT00054275",
        "statement_text": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial ",
        "statement_nums": [
            "and Leukopenia in the primary trial than the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48 (2.08%) Sinus bradycardia 1/48 (2.08%) Nausea 2/48 (4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: Total: 28/39 (71.79%) Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%) Sinus Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%) ",
            "Eye tearing 1/39 (2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%) "
        ],
        "premise_nums": [
            "NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1:",
            "(2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39 (2.56%) Fatigue 6/39 (15.38%)",
            "Lung infection 1/48 (2.08%) Mucosal infection 1/48 (2.08%) Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia",
            "Total: 28/39 (71.79%) Anemia 1/39 (2.56%) Leukopenia 4/39 (10.26%) Neutropenia 4/39 (10.26%) Chest Pain 1/39 (2.56%) Pericarditis 1/39 (2.56%)",
            "Tach  1/39 (2.56%) Sinus Tachycardia 1/39 (2.56%)Diarrhea 7/39 (17.95%) Mucositis 3/39 (7.69%) Nausea 2/39 (5.13%) Vomiting [1]1/39",
            "(4.17%) Vomiting 2/48 (4.17%) Death NOS 1/48 (2.08%) Fatigue 3/48 (6.25%) Allergic reaction 1/48 (2.08%) Lung infection 1/48",
            "Adverse Events 1: Total: 29/48 (60.42%) Anemia 4/48 (8.33%) Febrile neutropenia 7/48 (14.58%) Atrial fibrillation 1/48 (2.08%) Pericardial effusion 1/48"
        ]
    },
    {
        "id": "43421f19-878e-46f7-b456-8031835af649",
        "primaryId": "NCT00632489",
        "statement_text": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas the dose of Capecitabine changes with Body surface area ",
        "statement_nums": [
            "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib  whereas"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: LBH589 With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety  Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib ",
            "LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg  30 mg  45 mg  and 60 mg  Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the determined MTD to further assess safety Lapatinib: Lapatinib  1000 mg PO daily will be added to this combination  "
        ],
        "premise_nums": [
            "With Capecitabine MTD  LBH589 with Capecitabine LBH589: LBH589 will be paired with LBH589 and will range in dose from 825",
            "will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days",
            "Treatment cycles will be 21 days in length  Once determined safety Lapatinib: Lapatinib  1000 mg PO daily will be added to",
            "825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  Treatment cycles will be 21 days in length  Once",
            "825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days  INTERVENTION 2: LBH589 and Lapatinib LBH589 and Lapatinib",
            "be administered orally twice daily for 14 days out of every 21 days",
            "days  Treatment cycles will be 21 days in length  Once determined safe  10 additional patients will be treated at the"
        ]
    },
    {
        "id": "13fa44e7-38be-48fb-a0eb-6b212549f526",
        "primaryId": "NCT02260531",
        "statement_text": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group ",
        "statement_nums": [
            "much lower in the HER2-positive group in the primary trial,than in the ER+ and/or"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: CNS Objective Response Rate (ORR) The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions  taking as reference baseline sum LD  PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions  Time frame: Disease assessments occurred every 6 cycles  Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated up to 25 months  Results 1: Arm/Group Title: Cohort 1 - Cabozantinib  Trastuzumab for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily per treatment cycle Trastuzumab- IV administered once per cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles ",
            "Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1,Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Trastuzumab: For HER2-Positive participants only  Administered by IV on day 1 of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+ Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+) Cabozantinib- orally administered daily per treatment cycle MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )  Baseline  Cycle 2 Day 1, Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until progression or unacceptable toxicity develops  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 14 (.4 to 58) "
        ],
        "premise_nums": [
            "partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on",
            "by IV on day 1 of each 21 day cycle  Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage",
            "Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort 2",
            "lesions and PR is at least a 30% decrease in the sum of longest",
            "Baseline  Cycle 2 Day 1,Cabozantinib: One  60 mg tablet daily of each 21 day cycle  Number of Cycles: until",
            "is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of",
            "60 mg tablet daily of each 21 day cycle  Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage",
            "MRI- Baseline  Cycle 2 Day 1, and every 2 cyclesions and PR is at least a 30% decrease in the",
            "for HER2+ Arm/Group Description: HER2-positive Cabozantinib- orally administered daily percentage of participants 14 (.4 to 58)",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: percentage of participants 5 (.2 to 24) Results 2: Arm/Group Title: Cohort",
            "by IV on day 1 of each 21 day cycle  Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: percentage",
            "or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles  Response was evaluated",
            "MRI- Baseline  Cycle 2 Day 1, and every 2 cycles Magnetic Resonance Angiography (MRA )"
        ]
    },
    {
        "id": "12ae2315-cc50-43ac-a595-762c85c1ec58",
        "primaryId": "NCT02308020",
        "statement_text": "There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria ",
        "statement_nums": [
            "There were no participants in cohort 1 of the primary trial with a (CR) or"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) ",
            "OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria  CR is measurable target lesions  the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically  PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions  taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically  Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions  Stable disease (SD) is less than (smaller than )30% decrease relative to baseline but smaller than 20% increase in sum LD relative to nadir  Progressive disease (PD) is greater than or equal to ( ) 20% increase in sum LD relative to nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm) ",
            "Time frame: Baseline to Objective Disease Progression (Up to 36 Months)Results 1: Arm/Group Title: Part A Abemaciclib: HR+  HER2+ Breast Cancer Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET)  Participants with hormone receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle  Participants may continue to receive treatment until discontinuation criteria are met  Overall Number of Participants Analyzed: 23 Measure Type: Number Unit of Measure: percentage of participants 0 "
        ],
        "premise_nums": [
            "relative to baseline but smaller than 20% increase in sum LD relative increase of 20%, 1 lesion must increase by absolute value of",
            "relative to baseline but smaller than 20% increase in sum LD relative to",
            "A Abemaciclib: HR+  HER2+ Breast Cancer Arm/Group Description: Abemaciclib 200 mg was administered orally once every 12 hours",
            "(CNS) target lesions for at least 4 weeks; no new lesions; no",
            "PR is at least a 30% decrease in the sum longest duration",
            "to Objective Disease Progression (Up to 36 Months)Results 1: Arm/Group Title: Part",
            "Number of Participants Analyzed: 23 Measure Type: Number Unit of Measure: percentage of participants 0",
            "nadir and a relative increase of 20%, 1 lesion must increase by absolute value of 5 millimeter (mm)",
            "receptor positive HR+  HER2+ breast cancer receiving concurrent trastuzumab  150 mg abemaciclib was given orally once every"
        ]
    },
    {
        "id": "11403f92-661b-4334-8dfb-098586610ec6",
        "primaryId": "NCT02536339",
        "secondaryId": "NCT00371345",
        "statement_text": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial ",
        "statement_nums": [
            "the patients in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/39 (17.95%) Gastroenteritis viral 1/39 (2.56%) Parainfluenzae virus infection 1/39 (2.56%) Seizure 4/39 (10.26%) Headache 1/39 (2.56%) Hydrocephalus 1/39 (2.56%) Hypertension 1/39 (2.56%) Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN",
            "(2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70",
            "PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH",
            "NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%)",
            "Adverse Events 1: Total: 7/39 (17.95%) Gastroenteritis viral 1/39 (2.56%) Parainfluenzae virus infection 1/39 (2.56%) Seizure 4/39 (10.26%)",
            "(1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%)"
        ]
    },
    {
        "id": "2823adfc-b3a4-4626-9690-0c292aa8da04",
        "primaryId": "NCT01422408",
        "statement_text": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks ",
        "statement_nums": [
            "II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks",
            "the primary trial is a phase II"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Supportive Care (Fluocinonide Cream) This is a single-arm  single-stage  open-label phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All subjects will receive topical fluocinonide 0.05% cream to apply twice daily for two weeks and then once daily for two weeks to the vagina  The duration of treatment will be 4 weeks  "
        ],
        "premise_nums": [
            "The duration of treatment will be 4 weeks",
            "phase II trial of topical fluocinonide 0.05% cream to improve vaginal symptoms  All"
        ]
    },
    {
        "id": "1cda051f-27d0-4027-94cf-7b5340173ca2",
        "primaryId": "NCT02504424",
        "secondaryId": "NCT03708393",
        "statement_text": "the primary trial and the secondary trial do not have the same number of study groups ",
        "statement_nums": [
            "the primary trial and the secondary trial do not have the"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging"
        ]
    },
    {
        "id": "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3",
        "primaryId": "NCT00435409",
        "secondaryId": "NCT00319254",
        "statement_text": "The patient with the shortest PFS was in the secondary trial  at only 5 days  and the longest recorded PFS was in the primary trial at 78 months ",
        "statement_nums": [
            "PFS was in the secondary trial  at only 5 days  and the longest",
            "PFS was in the primary trial at 78 months"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause  whichever occurs first  If tumor progression data include more than 1 date  the first date will be used  PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group Title: Sunitinib + Capecitabine Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen  Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.5 (4.5 to 6.0) Investigator's assessment: 5.4 (4.4 to 5.8) Results 2: Arm/Group Title: Capecitabine ",
            "Arm/Group Description: Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time of progression  participants could have been eligible to crossover to single agent sunitinib  administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months Independent radiology assessment: 5.9 (5.4 to 7.6) Investigator's assessment: 5.5 (4.3 to 6.8) Outcome Measurement: Progression-Free Survival (PFS) Rate PFS was based on Kaplan-Meier estimates  PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause  PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])  or from death case report forms (CRFs)  Percentage of participants who had not experienced progression or death by Week 16 is reported  Time frame: Baseline up to Week 16 ",
            "Results 1:Arm/Group Title: Bosutinib Arm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease progression  unacceptable toxicity or withdrawal of consent occurred  Overall Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8) "
        ],
        "premise_nums": [
            "Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage of participants 39.6 (28.1 to 50.8)",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg daily continuously Overall Number of Participants",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous",
            "at a starting dose of 37.5 mg daily continuously Overall Number of Participants Analyzed: 221 Median (95% Confidence Interval) Unit of Measure: months",
            "Independent radiology assessment: 5.9 (5.4 to 7.6) Investigator's assessment: 5.5 (4.3 to 6.8) Outcome Measurement: Progression-Free Survival (PFS)",
            "the date of the first documentation of objective tumor progression data include more than 1 date  the first date",
            "event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline until",
            "orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days 1-14 every 3 weeks  At the time",
            "experienced progression or death by Week 16 is reported  Time frame: Baseline up to Week 16",
            "Arm/Group Description: Sunitinib administered orally at a starting dose of 2500 mg/m^2 per day (1250 mg/m^2 BID) from Days",
            "mg/m^2 BID) from Days 1-14 every 3 weeks  At the date of the first documentation of objective tumor progression",
            "first dose of study medication plus 1) divided by 7. Tumor progression was determined from",
            "milligram (mg) capsules  equivalent to 400 mg bosutinib orally once daily for 48 weeks  or until disease",
            "of study treatment to first documentation of objective tumor progression data include more than 1 date  the first date",
            "event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Week 16",
            "Baseline until disease progression (up to 3 years from first dose) Results 1: Arm/Group",
            "Results 1:Arm/Group Title: Bosutinib Arm/Group Description: Four bosutinib 100 milligram (mg) capsules  equivalent to 400",
            "orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of",
            "mg/m^2 BID) from Days 1-14 every 3 weeks  Overall Number of Participants Analyzed: 73 Measure Type: Number Unit of Measure: percentage",
            "Baseline until disease progression (up to 3 years from first dose) Results 1:Arm/Group Title: Bosutinib Arm/Group Description: Four bosutinib",
            "mg bosutinib orally once daily for 48 weeks  or until disease progression (up to 3 years from first dose) Results 1: Arm/Group"
        ]
    },
    {
        "id": "1e91c023-96e8-459b-9070-02df13339617",
        "primaryId": "NCT00513292",
        "statement_text": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group ",
        "statement_nums": [
            "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: pCR Within the Breast  Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy Pathological complete response (pCR) rates will be based on institutional pathology reports  In the final analysis for publication  rates will be based on blinded central review of these institutional pathology reports  The Chi-squared test will be conducted at the two-sided 0.05 level  A 95% confidence interval will be computed for the difference in pCR rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab ",
            "Arm/Group Description: Patients receive Fluorouracil  epirubicin  and cyclophosphamide (FEC) comprising fluorouracil IV  epirubicin hydrochloride IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 138 Measure Type: Number ",
            "Unit of Measure: percentage of participants 56.5 (47.8 to 64.9)Results 2: Arm/Group Title: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 ",
            "Arm/Group Description: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and trastuzumab  patients receive FEC comprising fluorouracil IV  epirubicin IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive trastuzumab IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab as in arm I  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 142 Measure Type: Number ",
            "Unit of Measure: percentage of participants 54.2 (45.7 to 62.6)"
        ],
        "premise_nums": [
            "and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and",
            "IV once weekly for an additional 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of FEC and trastuzumab",
            "4 courses  Beginning 21 days after completion of FEC  patients receive trastuzumab IV once every 3 weeks for up to 52",
            "on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients",
            "IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab",
            "Number of Participants Analyzed: 138 Measure Type: Number of Participants Analyzed: 142 Measure Type: Number",
            "rates  Time frame: Up to 5 years Results 1: Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once every 3 weeks for up to 52 weeks",
            "and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days",
            "Unit of Measure: percentage of participants 54.2 (45.7 to 62.",
            "laboratory biomarker analysis: Correlative studiesOverall Number of Participants Analyzed: 142 Measure Type: Number",
            "0.05 level  A 95% confidence interval will be computed for",
            "Unit of Measure: percentage of participants 56.5 (47.8 to 64.9)Results 2: Arm/Group Title: Paclitaxel/Trastuzumab Then"
        ]
    },
    {
        "id": "a15b4c0c-232b-4209-bf60-35d160e41d2c",
        "primaryId": "NCT03012477",
        "statement_text": "One patient in the primary trial experienced a thromboembolic event  a condition associated with a high degree of morbidity and mortality  However  the most common adverse event was Anemia ",
        "statement_nums": [
            "One patient in the primary trial experienced a thromboembolic event"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased 2/34 (5.88%) Dehydration 1/34 (2.94%) Headache 1/34 (2.94%) Thromboembolic event 1/34 (2.94%) "
        ],
        "premise_nums": [
            "Total: 13/34 (38.24%) Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%)",
            "Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased 1/34 (2.94%) Neutrophil count decreased",
            "Anemia 3/34 (8.82%) Diarrhea 7/34 (20.59%) Nausea 2/34 (5.88%) Sepsis 1/34 (2.94%) Urinary tract infection 1/34 (2.94%) Alkaline phosphatase increased"
        ]
    },
    {
        "id": "795d634a-9f9c-49a2-a4e7-ec99bd3600f2",
        "primaryId": "NCT02667626",
        "statement_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women ",
        "statement_nums": [
            "the primary trial is testing a web-based",
            "educational tool and the secondary trial is testing a medical"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: SCPR Intervention Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information  including resource lists of helpful websites  followed by regular reproductive health prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes  fertility concerns  contraception practices  and sexual function  The intervention also includes additional web-based information and resource lists  text-based reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders  At completion of the 24 weeks of follow up  they will have access to their SCPR  Control: Web-based resource lists and text-based study adherence reminders "
        ],
        "premise_nums": [
            "reproductive health and study adherence INTERVENTION 2: Control Young breast cancer participants",
            "reminders  At completion of the 24 weeks of follow up  they will",
            "prompts and study adherence reminders for 24 weeks  Reproductive Health Survivorship"
        ]
    },
    {
        "id": "e2d4c56c-a68f-4751-907d-9c2355c9528b",
        "primaryId": "NCT01463007",
        "secondaryId": "NCT00965523",
        "statement_text": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial ",
        "statement_nums": [
            "of patients in the secondary trial suffured from infection compared to the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41 (2.44%) Hypokalemia 1/41 (2.44%) Bicarbonate 1/41 (2.44%) SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%) Hypoalbuminemia 1/41 (2.44%) Leukocytes 1/41 (2.44%) Hemoglobin 1/41 (2.44%) Neutrophils 1/41 (2.44%) INR 1/41 (2.44%) PTT 1/41 (2.44%) Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) ",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 1/41 (2.44%) Infection 1/41 (2.44%) Creatinine 1/41",
            "Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "SGOT 1/41 (2.44%) Alkaline Phosphatase value 1/41 (2.44%) Hyperbilirubineamia 1/41 (2.44%)",
            "Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)",
            "Stomatitis2/81 (2.47%)Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%)"
        ]
    },
    {
        "id": "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9",
        "primaryId": "NCT00193050",
        "secondaryId": "NCT00232479",
        "statement_text": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial ",
        "statement_nums": [
            "must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Female Patients greater than 18 years of age Exclusion Criteria: Life expectancy of smaller than than 6 months Inclusion Criteria: HER-2 overexpressing breast cancer Clinical stage 2-3B Normal ejection fraction Exclusion Criteria: Metastatic disease Low ejection fraction "
        ],
        "premise_nums": [
            "of smaller than than 6 months Inclusion Criteria: HER-2 overexpressing breast cancer Clinical stage 2-3B Normal ejection fraction Exclusion Criteria: Metastatic",
            "Criteria: Life expectancy of smaller than than 6 months Inclusion Criteria: HER-2 overexpressing breast cancer Clinical stage 2-3B Normal"
        ]
    },
    {
        "id": "9ad3444c-143d-4c28-a08a-e0c9cda44900",
        "primaryId": "NCT00243503",
        "secondaryId": "NCT00448279",
        "statement_text": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients ",
        "statement_nums": [
            "the primary trial and the secondary trial did not observe any"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 25/60 (41.67%) Febrile neutropenia * 2/60 (3.33%) Adverse Events 1: Febrile neutropenia * 1/26 (3.85%) "
        ],
        "premise_nums": [
            "(41.67%) Febrile neutropenia * 2/60 (3.33%) Adverse Events 1: Febrile neutropenia * 1/26 (3.85%)"
        ]
    },
    {
        "id": "43061a8b-c1b2-4b5e-b935-73733d674fb4",
        "primaryId": "NCT01401959",
        "secondaryId": "NCT00852930",
        "statement_text": "the primary trial designates specific interventions to its patients depending on their tumour response  patients with complete response go to cohort A and all other in cohort B  in contrast the secondary trial assigns interventions randomly ",
        "statement_nums": [
            "to cohort A and all other in cohort B",
            "in contrast the secondary trial assigns interventions randomly"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cohort A: Triple-negative Breast Cancer Patients Patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients Patients with hormone receptor positive (ER and/or PR positive)  HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route  INTERVENTION 1: Laser Therapy Alone therapist administered laser treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual lymphatic drainage manual lymphatic drainage: therapist administered massage therapy "
        ],
        "premise_nums": [
            "treatment laser: therapist administered laser INTERVENTION 2: Mld Alone therapist administered manual",
            "2: Cohort B: ER/PR Positive/HER2-negative Breast Cancer Patients Patients with hormone",
            "therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via"
        ]
    },
    {
        "id": "25ec56f0-e472-4423-92ae-8d4840b067b5",
        "primaryId": "NCT03475992",
        "secondaryId": "NCT03106077",
        "statement_text": "Participants in the primary trial receive different interventions depending on their pre-diagnosis  whereas all patients in the secondary trial took the same intervention ",
        "statement_nums": [
            "Participants in the primary trial receive different interventions depending",
            "their pre-diagnosis  whereas all patients in the secondary trial took the same intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Pre-diagnosed Breast Cancer - Biopsy Confirmed Low-power microwave breast imaging system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave breast imaging system  No prior biopsy Low-power microwave breast imaging system: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W "
        ],
        "premise_nums": [
            "characterise diagnosed palpable breast lump INTERVENTION 2: Pre-diagnosed Breast Cyst Low-power microwave",
            "characterise diagnosed palpable breast lump INTERVENTION 1: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) 6 mg/kg IMGN853 IV Q3W",
            "system  Core needle biopsy performed 14 days before the microwave breast investigation Low-power"
        ]
    },
    {
        "id": "2c9e9407-e990-41bd-a87b-9d294c78f727",
        "primaryId": "NCT02286843",
        "statement_text": "the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions ",
        "statement_nums": [
            "the primary trial is testing a novel radiotracer called PET/CT to evaluate its",
            "use for visualization of HER2+ lesions"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions  PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions  rather than evaluation of only single lesions by biopsy  "
        ],
        "premise_nums": [
            "INTERVENTION 1: HER2-targeted PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT",
            "allows excellent visualization of HER2+ lesions  89Zr-pertuzumab is a novel radiotracer which allows excellent visualization of HER2+",
            "PET/CT Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT  89Zr-trastuzumab is a novel radiotracer which allows"
        ]
    },
    {
        "id": "f3cebdf7-be0c-45ad-85bd-bde827524e20",
        "primaryId": "NCT00693719",
        "statement_text": "the primary trial recorded less than 5 different Adverse Events  ",
        "statement_nums": [
            "the primary trial recorded less than 5 different Adverse Events"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31 (3.23%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 4/31 (12.90%) Bleeding 1/31 (3.23%) Pain 2/31 (6.45%) Dehydration 1/31 (3.23%) Dyspnea 1/31"
        ]
    },
    {
        "id": "53c62057-d6ea-4639-adaf-98cb1544a394",
        "primaryId": "NCT00425672",
        "statement_text": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle  up to a total of 6 times  but will stop earlier if they suffer disease progression or unacceptable toxicity occurs ",
        "statement_nums": [
            "of the primary trial undergo a 21 day treatment cycle  up to a total of 6 times  but will stop",
            "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle  up to a"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity  ONTAK: Given IV flow cytometry: Correlative studies immunohistochemistry staining method: Correlative studies enzyme-linked immunosorbent assay: Correlative studies laboratory biomarker analysis: Correlative studies protein expression analysis: Correlative studies "
        ],
        "premise_nums": [
            "receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of"
        ]
    },
    {
        "id": "599b37cd-f380-48ac-864d-e766a7af963e",
        "primaryId": "NCT01570036",
        "secondaryId": "NCT00021255",
        "statement_text": "the primary trial and the secondary trial monitor the % of their patient cohorts with DFS smaller than 6years.",
        "statement_nums": [
            "the primary trial and the secondary trial monitor the % of",
            "patient cohorts with DFS smaller than 6y"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Disease-free Survival (DFS) Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening  This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam  and laboratory and radiographic surveillance  The primary objective of the study is disease-free survival (DFS) at 24 months  Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years Disease Free Survival was defined as the interval from the date of randomization to the date of local  regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first  Disease free survival was estimated using the Kaplan-Meier method  Time frame: From randomization until relapse or death or up to 5 years "
        ],
        "premise_nums": [
            "relapse or death or up to 5 years",
            "every three months for the first 24 months after completion of primary therapies and every six months",
            "frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With Disease Free Survival at 5 Years Disease Free Survival was",
            "Participants With Disease Free Survival at 5 Years Disease Free Survival was defined as",
            "Disease-free survival (DFS) for all patients regardless of randomization will",
            "Time frame: Disease-free survival at 24 months Outcome Measurement: Percentage of Participants With"
        ]
    },
    {
        "id": "c428ec76-4d22-4d2d-8c06-1675bd431d41",
        "primaryId": "NCT02222337",
        "statement_text": "Participants for the primary trial must be in pairs  a breast cancer survivor and a caregiver  both must be ethnically Hispanic ",
        "statement_nums": [
            "both must be ethnically Hispanic",
            "Participants for the primary trial must be in pairs"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Survivors: Latina  has been diagnosed with breast cancer  speaks English or Spanish  has a Caregiver who is willing to participate  Caregivers: a primary caregiver for a Latina breast cancer survivor  speak English or Spanish "
        ],
        "premise_nums": [
            "participate  Caregivers: a primary caregiver for a Latina breast"
        ]
    },
    {
        "id": "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38",
        "primaryId": "NCT03283553",
        "statement_text": "the primary trial has two cohorts ",
        "statement_nums": [
            "the primary trial has two cohorts"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider  and to stimulate discussion about the role of the companion in the visit  2.) facilitated registration for the patient portal (for patient and family member  as desired by the patient)  and 3.) education (as relevant) on access to doctor's electronic visit notes  INTERVENTION 2: Usual Care Care as usual with the medical oncologist  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Multicomponent Intervention 1.) A one-page paper-pencil agenda"
        ]
    },
    {
        "id": "a9d5c664-896f-4bb1-95e7-1deaa88848ef",
        "primaryId": "NCT00089479",
        "secondaryId": "NCT02964234",
        "statement_text": "Agatha had her 53rd birthday last week  she has a histologically confirmed adenocarcinoma of the breast  with no evidence of metastatic disease  Agatha is of white british origin  she is eligible for the primary trial but not the secondary trial  due to her age ",
        "statement_nums": [
            "Agatha had her 53rd birthday last week  she has a",
            "had her 53rd birthday last week  she has a histologically confirmed adenocarcinoma of the",
            "is eligible for the primary trial but not the secondary trial  due to her"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: female patients 18-70 years of age; adenocarcinoma of the breast; previous invasive breast cancer if diagnosed greater than 5 years before entering study; no evidence of metastatic disease  Exclusion Criteria: history of severe hypersensitivity reaction to Taxotere; previous treatment with anthracycline  anthracenedione (mitoxantrone)  or taxane; treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years  Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female; "
        ],
        "premise_nums": [
            "taxane; treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years  Inclusion Criteria: Age",
            "with fluoropyrimidine (5-fluorouracil) within the last 5 years  Inclusion Criteria: Age 52-75 years old; Identification as Latina/Hispanic/Chicana female;",
            "Inclusion Criteria: female patients 18-70 years of age; adenocarcinoma of the breast;",
            "breast cancer if diagnosed greater than 5 years before entering study; no evidence of"
        ]
    },
    {
        "id": "62b5fe62-470d-46e3-82a6-d57cd6cab452",
        "primaryId": "NCT00471276",
        "secondaryId": "NCT00951665",
        "statement_text": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial ",
        "statement_nums": [
            "more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%) Nausea 1/26 (3.85%) ",
            "Abdominal pain 0/26 (0.00%)Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%) "
        ],
        "premise_nums": [
            "Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%)Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown",
            "0/26 (0.00%)Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%)",
            "(1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 1:",
            "7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Thrombocytopenia 0/26 (0.00%) Cardiac failure congestive 0/26 (0.00%) Extrasystoles 0/26 (0.00%)",
            "1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%)Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown",
            "Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 1:",
            "Death - unknown cause 1/26 (3.85%) Thrombosis in device 0/26 (0.00%)Constipation 0/26 (0.00%) Gastrointestinal haemorrhage 0/26 (0.00%) Death - unknown",
            "Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83 (1.20%) Gastrointestinal Haemorrhage 1/83 (1.20%) Asthenia 1/83 (1.20%)",
            "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hyperbilirubinaemia 1/83 (1.20%) Anal abscess 1/83 (1.20%) Dehydration 3/83 (3.61%)",
            "Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Hypothyroidism 1/83 (1.20%) Nausea 2/83 (2.41%) Vomiting 2/83 (2.41%) Diarrhea 1/83",
            "1: Total: 7/26 (26.92%) Febrile neutropenia 1/26 (3.85%) Neutropenia 0/26 (0.00%) Death - unknown cause 1/26 (3.85%) Thrombosis in device",
            "Adverse Events 1: Total: 13/83 (15.66%) Cardiac failure congestive 1/83 (1.20%) Dehydration 3/83 (3.61%) Decreased appetite 1/83 (1.20%) Adverse Events 1:"
        ]
    },
    {
        "id": "de349a2d-80ee-4c34-ab9f-38eb467c77d7",
        "primaryId": "NCT01106040",
        "secondaryId": "NCT01441596",
        "statement_text": "the primary trial and the secondary trial are not studying patient PFS  ORR or DLTs ",
        "statement_nums": [
            "the primary trial and the secondary trial are not studying patient"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Concordance of Blue Dye and Lymphoseek The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek  Time frame: Surgery after injections of Lymphoseek and blue dye Outcome Measurement: Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS)  no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation "
        ],
        "premise_nums": [
            "in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of",
            "Patient Benefit Rate at 12 Weeks Percentage of patients with patient benefit at week 12. Patient benefit was defined by the",
            "extra CNS disease according to RECIST 1.1 Time frame: 12 weeks from randomisation"
        ]
    },
    {
        "id": "0d37bf26-bc74-4a01-9bc9-61e2fa3051da",
        "primaryId": "NCT00446030",
        "secondaryId": "NCT00975676",
        "statement_text": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial have no overlap in"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Stratum 1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel  doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum 2: TCH + Bevacizumab HER2 positive participants were administered chemotherapy with docetaxel  carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  INTERVENTION 1: Triptorelin Plus Tamoxifen Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin Plus Exemestane Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years  "
        ],
        "premise_nums": [
            "treated with triptorelin plus tamoxifen for 5 years  INTERVENTION 2: Triptorelin",
            "treated with triptorelin plus exemestane for 5 years",
            "and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles  and maintenance therapy",
            "+ bevacizumab every 3 weeks for 6 cycles  and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of",
            "1: TAC + Bevacizumab HER2 negative participants were administered chemotherapy with docetaxel",
            "therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks  INTERVENTION 2: Stratum"
        ]
    },
    {
        "id": "69f7a93d-7134-40ec-aff3-50acd7119d2c",
        "primaryId": "NCT02425891",
        "secondaryId": "NCT00593827",
        "statement_text": "the secondary trial and the primary trial both measure PFS of their patient cohorts ",
        "statement_nums": [
            "the secondary trial and the primary trial both measure PFS of"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants PFS was defined as the time from randomization to the occurrence of disease progression  as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause  whichever occurred first  Time frame: Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months  Computed using Kaplan-Meier estimates  Time frame: From the date of randomization to 6-months on study "
        ],
        "premise_nums": [
            "From the date of randomization to 6-months on study",
            "Proportion of Participants Progression Free at 6 Months PFS at 6 months was defined as proportion of participants",
            "Baseline up to approximately 34 months Outcome Measurement: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression",
            "who neither progressed nor died before 6 months  Computed using Kaplan-Meier"
        ]
    },
    {
        "id": "8de31b0f-7127-4c8b-b5e0-060e7a83fae5",
        "primaryId": "NCT01299038",
        "statement_text": "Joe has a known history of Hepatitis  However as he is over the age of 18 is still eligible for the primary trial ",
        "statement_nums": [
            "he is over the age of 18 is still eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Metastatic adenocarcinoma of the breast (Stage IV) Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1 or 2 Normal organ and marrow function as defined in the protocol Exclusion Criteria: Participants may not be receiving any other study agents Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese  Japanese  Korean  Vietnamese or Asian-Indian origin) Concomitant use of the following drugs: cyclosporine  fibrates  niacin  gemfibrozil  ketaconazole  spironolactone  cimetidine  warfarin  erythromycin  or protease inhibitors Conditions predisposing to renal failure secondary to rhabdomyolysis Recent history of heavy alcohol use as judged by the treating physician Known to be pregnant (testing not required) or nursing History of rhabdomyolysis on statin therapy Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ",
            "Uncontrolled intercurrent illness including  but not limited to ongoing or active infection  hepatitis  symptomatic congestive heart failure  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements"
        ],
        "premise_nums": [
            "or HER2 therapy ) within last 5 weeks Any statin therapy within the last 3 weeks Asian decent (including Filipino  Chinese",
            "receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy) Minimum age 18 years ECOG Performance status of 0, 1",
            "predisposing to renal failure secondary to rhabdomyolysis Recent history of"
        ]
    },
    {
        "id": "207a1d82-a61b-4b5f-bebf-0706def6729d",
        "primaryId": "NCT01008150",
        "secondaryId": "NCT00375427",
        "statement_text": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial ",
        "statement_nums": [
            "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) Vomiting 0/42 (0.00%) Pyrexia 0/42 (0.00%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/42 (0.00%) ",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%) ",
            "Thrombocytopenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) "
        ],
        "premise_nums": [
            "Thrombocytopenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%)",
            "myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%)",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 1/42 (2.38%) Diarrhoea 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia",
            "(0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%) Oral pain 2/216 (0.93%) Vomiting 2/216 (0.93%)",
            "Total: 29/216 (13.43%) Anaemia 2/216 (0.93%) Febrile neutropenia 2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia",
            "Adverse Events 1: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 0/42 (0.00%) Oedema peripheral 0/42",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "Thrombocytopenia 0/209 (0.00%) Acute myocardial infarction 0/209 (0.00%) Cardiac failure 0/209 (0.00%) Diplopia 0/209 (0.00%)",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Vomiting 1/209 (0.48%) Mucosal inflammation 0/209 (0.00%) Pain 1/209 (0.48%)",
            "(2.38%) Diarrhoea 0/42 (0.00%) Abdominal pain 1/42 (2.38%) Colitis 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "2/216 (0.93%)Acute myocardial infarction 1/216 (0.46%) Cardiac failure 1/216 (0.46%) Diplopia 1/216 (0.46%) Gastric haemorrhage 1/216 (0.46%) Nausea 1/216 (0.46%)",
            "(0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209",
            "(10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "2: Total: 7/42 (16.67%) Febrile neutropenia 0/42 (0.00%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%)",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "(0.93%) Vomiting 2/216 (0.93%) Mucosal inflammation 1/216 (0.46%) Pain 0/216 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "(0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%) Nausea 0/209 (0.00%) Oral pain 0/209 (0.00%) Vomiting 1/209 (0.48%)",
            "dysfunction 1/42 (2.38%) Cardiac valve disease 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Pain 1/209 (0.48%) Adverse Events 2: Total: 29/216 (13.43%) Anaemia 2/216",
            "(0.00%) Fatigue 0/42 (0.00%) Adverse Events 1: Total: 21/209 (10.05%) Anaemia 0/209 (0.00%) Febrile neutropenia 0/209 (0.00%) Thrombocytopenia 0/209 (0.00%)",
            "like illness 0/42 (0.00%) Oedema peripheral 0/42 (0.00%) Fatigue 0/42 (0.00%) Diplopia 0/209 (0.00%) Gastric haemorrhage 0/209 (0.00%) Nausea 0/209 (0.00%)",
            "(2.38%) Fatigue 0/42 (0.00%) Adverse Events 2: Total: 7/42 (16.67%) Febrile neutropenia 1/42 (2.38%) Left venrticular dysfunction 1/42 (2.38%) Cardiac valve disease",
            "like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%) Diarrhoea 0/42 (0.00%) Abdominal pain 0/42 (0.00%) Colitis 0/42 (0.00%)",
            "Vomiting 0/42 (0.00%)Pyrexia 2/42 (4.76%) Influenza like illness 1/42 (2.38%) Oedema peripheral 1/42 (2.38%) Fatigue 0/42 (0.00%)"
        ]
    },
    {
        "id": "968aeaf1-44b9-4454-8c99-e3c207037485",
        "primaryId": "NCT01491737",
        "statement_text": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial ",
        "statement_nums": [
            "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Febrile neutropenia 4/127 (3.15%) Cardiac failure 0/127 (0.00%)"
        ]
    },
    {
        "id": "2b79f9cc-4262-4353-ad28-91cda07a9b9a",
        "primaryId": "NCT02988986",
        "statement_text": "Patients must have AST  ALP and ALT smaller than 1.5 ULN to participate in the primary trial ",
        "statement_nums": [
            "ALP and ALT smaller than 1.5 ULN to participate in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome  a higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN; "
        ],
        "premise_nums": [
            "aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5 x ULN;",
            "higher serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase",
            "Criteria: Hepatic status: Serum total bilirubin 1 x upper limit of normal (ULN; in",
            "serum total bilirubin [smaller than 1.5 x ULN] is allowed)  aspartate aminotransferase and alanine aminotransferase 1.5 x ULN  and alkaline phosphatase 1.5"
        ]
    },
    {
        "id": "d56ffd81-4007-477b-b3c3-0fdb89806931",
        "primaryId": "NCT00723398",
        "statement_text": "Patients with diabetes insipidusare not suitable for the primary trial ",
        "statement_nums": [
            "not suitable for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Postmenopausal status defined as history of at least 12 months without spontaneous menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy Breast density greater than 25% No hormone replacement therapy for at least six months prior to entry into this study Non-smokers  Exclusion Criteria: History of stroke  pulmonary embolism or deep vein thrombosis History of atherosclerotic heart disease Presence of any known hypercoagulable state either congenital (e.g.  protein S deficiency) or acquired (e.g.  corticosteroid treatment) Diabetes mellitus Uncontrolled hypertension (BP 140/90) Presence of a psychiatric condition that would interfere with adherence to the protocol  "
        ],
        "premise_nums": [
            "mellitus Uncontrolled hypertension (BP 140/90) Presence of a psychiatric condition that",
            "salpingo oophorectomy Breast density greater than 25% No hormone replacement therapy for at",
            "defined as history of at least 12 months without spontaneous menstrual bleeding or a"
        ]
    },
    {
        "id": "f62e6c20-862b-4ce3-9121-0d93ff050839",
        "primaryId": "NCT01373671",
        "secondaryId": "NCT00686127",
        "statement_text": "Lidoderm products are used in a intervention arm 1 of the secondary trial  and an FFDM product is used in arm 1 of the primary trial",
        "statement_nums": [
            "arm 1 of the secondary trial  and an FFDM product is used in arm 1 of the primary"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: FFDM and DBT FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day  "
        ],
        "premise_nums": [
            "Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day",
            "scan on Siemens MAMMOMAT Inspiration INTERVENTION 1: Lidocaine Patch Lidocaine patch 5% (Lidoderm®  Endo Pharmaceuticals Inc.):"
        ]
    },
    {
        "id": "833eeb4b-4921-468a-947d-bacfc7816ae6",
        "primaryId": "NCT02162719",
        "secondaryId": "NCT02131064",
        "statement_text": "the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR ",
        "statement_nums": [
            "the primary trial and the secondary trial investigate the effects of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS was defined as the time from randomization to the first occurrence of disease progression  as determined by investigator review of tumor assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study treatment regimen) from any cause  whichever occurred first  Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016) Outcome Measurement: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples "
        ],
        "premise_nums": [
            "(Clinical Cut Off Date: 07 June 2016) Outcome Measurement: Percentage of Participants With",
            "from randomization to the first occurrence of disease progression",
            "Time frame: Baseline up to 30 days after the last dose",
            "assessments by RECIST  v1.1 or death on study (smaller than =30 days after the last dose of study"
        ]
    },
    {
        "id": "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "statement_text": "the secondary trial records several gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [
            "the secondary trial records several gastrointestinal adverse",
            "events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%) Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle weakness upper limb * 0/30 (0.00%) Dizziness * 0/30 (0.00%) Seizure * 0/30 (0.00%) ",
            "Nervous system disorders - Other  specify * [1]0/30 (0.00%)Adverse Events 1: Hemorrhage  GI - stomach 0/76 (0.00%) Perforation  GI - colon 1/76 (1.32%) Ulcer  GI - stomach 0/76 (0.00%) "
        ],
        "premise_nums": [
            "Other  specify * [1]0/30 (0.00%)Adverse Events 1: Hemorrhage  GI - stomach",
            "specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) Febrile neutropenia (fever of unknown",
            "of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%)",
            "GI - colon 1/76 (1.32%) Ulcer  GI - stomach 0/76 (0.00%) Perforation  GI - colon",
            "microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle",
            "specify * [1]0/30 (0.00%)Adverse Events 1: Hemorrhage  GI - stomach 0/76 (0.00%) Perforation  GI - colon",
            "(3.33%) Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle",
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe"
        ]
    },
    {
        "id": "c317750d-6ef7-494d-8040-2c7fa3d777fb",
        "primaryId": "NCT01129622",
        "secondaryId": "NCT01156987",
        "statement_text": "the secondary trial and the primary trial both used MRI for their interventions ",
        "statement_nums": [
            "the secondary trial and the primary trial both used MRI for"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Letrozole  Breast Enhancement  Safety Single arm of healthy postmenopausal women to have two breast MRI (baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI  INTERVENTION 1: Healthy Volunteers Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications  and then undergo contrast injection  and SWIFT acquisition  Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications  The SWIFT MRI workflow will be performed as follows: "
        ],
        "premise_nums": [
            "healthy volunteers will be first screened for MRI contraindications",
            "(baseline and post-treatment)  Letrozole of 12.5 mg/day is given for three successive"
        ]
    },
    {
        "id": "87eca8d2-72fe-4285-9884-6d2ec7bae6df",
        "primaryId": "NCT00567190",
        "statement_text": "There was exactly the same proportion of anemic patinets in both cohorts of the primary trial ",
        "statement_nums": [
            "both cohorts of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Anaemia 3/396 (0.76%) Adverse Events 2: Anaemia 3/408 (0.74%)"
        ]
    },
    {
        "id": "7a87c605-fc41-4d0a-9291-85e88f6eb510",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "statement_text": "the secondary trial is testing a Gel which is applied inside the vagina  and the primary trial is testing an intervention which requires daily radiation of the breast(s) ",
        "statement_nums": [
            "the secondary trial is testing a Gel",
            "vagina  and the primary trial is testing an intervention"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: 0.005% Estriol Vaginal Gel ",
            "Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration"
        ],
        "premise_nums": [
            "Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: 0.005% Estriol Vaginal Gel",
            "40.5 Gy to the breast and 48.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "40.5 Gy to the breast and 46.5 gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks",
            "(2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor",
            "breast with a Friday boost of 2.0 Gy to the tumor bed  for",
            "for a total daily dose of 3.2 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "The overall dose will be 40.5 Gy to the breast with a Friday boost of 2.0 Gy to the tumor",
            "inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3:",
            "with a daily concomitant boost of 0.5 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm",
            "breast with a Friday boost of 2.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0"
        ]
    },
    {
        "id": "fbb853c9-bed4-4cde-a283-2d91b23d35bf",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "statement_text": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions  using different outcome measurements ",
        "statement_nums": [
            "the primary trial and the secondary trial both report results on"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR)  Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy ",
            "A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel Time frame: Week 26 "
        ],
        "premise_nums": [
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With",
            "(RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib",
            "Complete Response (pCR) After 26 Weeks of Therapy",
            "greater than or equal 30% decrease in the sum of therapy comprised the 2-week run-in phase  12 weeks of",
            "(PR)  greater than or equal 30% decrease in the sum of the"
        ]
    },
    {
        "id": "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5",
        "primaryId": "NCT00482391",
        "statement_text": "Patients with a QT interval longer than half a second are excluded from the primary trial ",
        "statement_nums": [
            "are excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "No QT prolongation (greater than 500 ms) "
        ],
        "premise_nums": [
            "No QT prolongation (greater than 500 ms)"
        ]
    },
    {
        "id": "84aa97cf-efce-484e-825e-5af509e5988f",
        "primaryId": "NCT01441596",
        "statement_text": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy  up to 160% of the starting dose ",
        "statement_nums": [
            "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Afatinib Mono Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated  the dose may be escalated to 50 mg  "
        ],
        "premise_nums": [
            "the dose may be escalated to 50 mg",
            "Afatinib monotherapy administered orally: starting dose 40 mg per day  continuous treatment in a 3-weekly course  If well tolerated"
        ]
    },
    {
        "id": "a40e172a-8839-499d-896d-be71a7ca4905",
        "primaryId": "NCT03076190",
        "secondaryId": "NCT03196635",
        "statement_text": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions  however all participants taking part in these studies will need to receive stem cell transplants ",
        "statement_nums": [
            "applied in either the primary trial or the secondary trial interventions  however all participants taking part in these"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Active Control Group Health Education Active Control Group INTERVENTION 2: My Surgical Success Treatment Group My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  "
        ],
        "premise_nums": [
            "evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study",
            "Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two",
            "My Surgical Success Intervention Group INTERVENTION 1: All Study Participants  PA"
        ]
    },
    {
        "id": "f29768ba-5d79-4528-839f-933ab13faaa1",
        "primaryId": "NCT01943916",
        "secondaryId": "NCT01653964",
        "statement_text": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging ",
        "statement_nums": [
            "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  INTERVENTION 1: Molecular Breast Imaging Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Overall Population Each subject served as",
            "breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi"
        ]
    },
    {
        "id": "343e0a32-aebe-4bbb-97c0-b2c597c36802",
        "primaryId": "NCT00392392",
        "secondaryId": "NCT00503906",
        "statement_text": "the primary trial records two different types of pain in its adverse events  in the abdomen and chest area  the secondary trial does not record any types of pain in its participants ",
        "statement_nums": [
            "chest area  the secondary trial does not record any",
            "the primary trial records two different types"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%) Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%) Neutropenic Fever [2]1/29 (3.45%) Peripheral Neuropathy [1]1/29 (3.45%) Seizure/Syncope [1]1/29 (3.45%) Hematuria [1]1/29 (3.45%) UTI [1]1/29 (3.45%) Shortness of breath [1]1/29 (3.45%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/29 (27.59%) Leukopenia [1]1/29 (3.45%) Thrombocytopenia [1]1/29",
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Abscess [1]1/29 (3.45%) Breast Abscess 1/29 (3.45%) Fever/Sepsis [1]1/29 (3.45%)",
            "Adverse Events 1: Pain - Abdomen 1/29 (3.45%) Pain - Chest 1/29 (3.45%)"
        ]
    },
    {
        "id": "4d51608c-b0d8-4019-9b9a-34cf1c3d5087",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg ",
        "statement_nums": [
            "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  "
        ],
        "premise_nums": [
            "Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching",
            "lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD"
        ]
    },
    {
        "id": "7bb88699-1536-4fdc-9cb2-c5ef350d559b",
        "primaryId": "NCT00331552",
        "secondaryId": "NCT01306942",
        "statement_text": "trastuzumab was used for the interventions in the primary trial and the secondary trial ",
        "statement_nums": [
            "the interventions in the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Phase I: Cyclophosphamide  Doxil  Trastuzumab Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity  Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician  pegylated liposomal doxorubicin hydrochloride: Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 ",
            "Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days "
        ],
        "premise_nums": [
            "followed by a rest period of 7 days  Dasatinib 100mg was repeated on Day 1 of a 28-day cycle until radiographic or",
            "Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression",
            "Given IV cyclophosphamide: Given orally trastuzumab: Given IV INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel",
            "treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and",
            "pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment was repeated on Day 1 of a 28-day cycle until",
            "a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest",
            "Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at",
            "followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)",
            "once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks",
            "phase I  the first cycle lasted 38 days",
            "patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose"
        ]
    },
    {
        "id": "c86ef61b-7565-465a-82ba-25e7ac050ccc",
        "primaryId": "NCT02139358",
        "secondaryId": "NCT02574455",
        "statement_text": "There was one case of hemorrhaging in the primary trial  and no recorded cases in the secondary trial ",
        "statement_nums": [
            "of hemorrhaging in the primary trial  and no recorded cases in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac * 1/15 (6.67%) Diarrhea * 1/15 (6.67%) Duodenal hemorrhage * 1/15 (6.67%) Fatigue * 1/15 (6.67%) Fever * 1/15 (6.67%) Sudden death NOS * 1/15 (6.67%) Sepsis * 1/15 (6.67%) Skin infection * 1/15 (6.67%) Neutrophil count decreased * 1/15 (6.67%) Platelet count decreased * 1/15 (6.67%) Adverse Events 1: Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) ",
            "Pericardial effusion 0/258 (0.00%)Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%) "
        ],
        "premise_nums": [
            "Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral",
            "(1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224",
            "pain 3/258 (1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%)",
            "(0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224",
            "Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral",
            "Adverse Events 1: Total: 7/15 (46.67%) Cardiac arrest * 1/15 (6.67%) Chest pain - cardiac *",
            "(1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 1: Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia",
            "neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224",
            "(26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence",
            "(0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224 (0.89%) Sinus tachycardia 1/224",
            "Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Thrombocytopenia 0/224 (0.00%) Atrial fibrillation",
            "neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 1/224 (0.45%) Mitral valve incompetence 0/224 (0.00%) Pericardial effusion 2/224",
            "(28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 4/224 (1.79%) Neutropenia 1/224 (0.45%) Abdominal pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%)",
            "pain 3/224 (1.34%) Abdominal pain upper 0/224 (0.00%) Colitis 0/224 (0.00%)Sinus tachycardia 0/258 (0.00%) Abdominal pain 3/258 (1.16%) Abdominal pain upper",
            "Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation",
            "Total: 69/258 (26.74%) Anaemia 3/258 (1.16%) Febrile neutropenia 13/258 (5.04%) Neutropenia 5/258 (1.94%) Thrombocytopenia 1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral",
            "(1.16%) Abdominal pain upper 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224 (0.89%) Febrile neutropenia",
            "1/258 (0.39%) Atrial fibrillation 0/258 (0.00%) Mitral valve incompetence 1/258 (0.39%) Colitis 1/258 (0.39%) Adverse Events 2: Total: 64/224 (28.57%) Anaemia 2/224"
        ]
    },
    {
        "id": "58dec898-e0af-41c1-96f9-7163d3e3e855",
        "primaryId": "NCT02019277",
        "secondaryId": "NCT00863655",
        "statement_text": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "statement_nums": [
            "the primary trial and the secondary trial recorded three of the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac failure * 1/50 (2.00%) Diarrhoea * 1/50 (2.00%) Gastritis * 1/50 (2.00%) Nausea * 1/50 (2.00%) Oesophagitis * 1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Drug hypersensitivity * 1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482 (0.00%) Thrombocytopenia 2/482 (0.41%) ",
            "Anaemia 28/482 (1.66%)Disseminated intravascular coagulation 21/482 (0.21%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) Neutropenia 20/482 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%) Lymphadenopathy 0/482 (0.00%) Neutropenia 0/482",
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia * 4/50 (8.00%) Anaemia * 1/50 (2.00%) Neutropenia * 1/50 (2.00%) Cardiac",
            "Adverse Events 1: Total: 27/50 (54.00%) Febrile neutropenia 21/482 (0.21%) Lymphadenopathy 20/482 (0.00%) Neutropenia 20/482 (0.00%)",
            "1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482 (32.78%) Anaemia 7/482 (1.45%) Disseminated intravascular coagulation 1/482 (0.21%)",
            "1/50 (2.00%) Pyrexia * 7/50 (14.00%) Mucosal inflammation * 1/50 (2.00%) Cellulitis * 2/50 (4.00%) Adverse Events 1: Total: 158/482"
        ]
    },
    {
        "id": "5cf74526-9f91-498d-a13a-6393dcd45b7b",
        "primaryId": "NCT02291913",
        "statement_text": "One patient in the primary trial suffered from an inflammation of the liver ",
        "statement_nums": [
            "One patient in the primary trial suffered from an inflammation"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal hemorrhage * 1/48 (2.08%) Non-Cardiac chest pain * 1/48 (2.08%) Pain * 1/48 (2.08%) Cholecystitis * 1/48 (2.08%) Diverticulitis * 1/48 (2.08%) Cellulitis * 1/48 (2.08%) Gastroenteritis * 1/48 (2.08%) "
        ],
        "premise_nums": [
            "15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48 (2.08%) Constipation * 2/48 (4.17%) Esophagitis * 1/48 (2.08%) Gastrointestinal",
            "Adverse Events 1: Total: 15/48 (31.25%) Anemia * 1/48 (2.08%) Cardiac failure congestive * 1/48"
        ]
    },
    {
        "id": "c40d8532-4e66-4eef-9644-91f20a02066d",
        "primaryId": "NCT02001974",
        "statement_text": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial ",
        "statement_nums": [
            "were recorded in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system 1/4 (25.00%) Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Dyspnoea 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain 0/3 (0.00%) Disease progression 0/3 (0.00%) Dehydration 0/3 (0.00%) Hyponatraemia 0/3 (0.00%) Metastasis to central nervous system 0/3 (0.00%) Oesophageal adenocarcinoma 0/3 (0.00%) ",
            "Intracranial hypotension 0/3 (0.00%)Pneumothorax 1/3 (33.33%) Dyspnoea 0/3 (0.00%) Hypoxia 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Intracranial hypotension 0/3 (0.00%)Pneumothorax 1/3 (33.33%) Dyspnoea 0/3 (0.00%) Hypoxia 0/3",
            "2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Hyponatraemia 1/4 (25.00%) Metastasis to central nervous system",
            "(0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain 0/3 (0.00%) Disease progression 0/3 (0.00%) Dehydration",
            "Oesophageal adenocarcinoma 0/4 (0.00%) Intracranial hypotension 0/4 (0.00%) Pneumothorax 0/4 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain",
            "(0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%)",
            "Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration 2/4 (50.00%) Abdominal pain 0/4 (0.00%) Disease progression 0/4 (0.00%) Dehydration",
            "Intracranial hypotension 0/3 (0.00%)Pneumothorax 1/3 (33.33%) Dyspnoea 0/3 (0.00%) Hypoxia 0/4 (0.00%) Adverse Events 2: Total: 1/3 (33.33%) Abdominal pain"
        ]
    },
    {
        "id": "3d450be5-4587-48e5-ae2e-745623606631",
        "primaryId": "NCT01289353",
        "secondaryId": "NCT00429182",
        "statement_text": "the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups ",
        "statement_nums": [
            "the primary trial and the secondary trial both administer bi-weekly oral"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Carboplatin: IV  weekly for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion  "
        ],
        "premise_nums": [
            "Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6,",
            "20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion",
            "for 6 weeks  AUC of 2.0 INTERVENTION 1: Carboplatin + Cyclophosphamide + Thiotepa Carboplatin : Target AUC of 20, then"
        ]
    },
    {
        "id": "fa28753a-aa3b-4642-9fd4-a2414fd8a472",
        "primaryId": "NCT00943670",
        "statement_text": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1 intravenous (IV) infusion ",
        "statement_nums": [
            "for patients in the primary trial was at its highest on Day 1 of the third cycle  post T-DM1"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Change From Baseline in Mean Duration of the QTc Interval The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle  The corrected QT interval was calculated using Fridericia's correction (QTcF) from electrocardiogram (ECG) data  Each participant had triplicate QTcF intervals measured at each timepoint and the average was calculated for each patient at each timepoint  For each timepoint  a participant's corresponding baseline QTcF interval was subtracted from the average QTcF intervals to create a baseline-adjusted average QTcF interval  Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose  Results 1: Arm/Group Title: T-DM1 ",
            "Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg Overall Number of Participants Analyzed: 51 Mean (Standard Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1, Day 8 [N=43]: -4.0 (13.4) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 3, Day 1, 15 minutes post-dose [N=37]: 4.7 (9.6) Cycle 3, Day 1, 60 minutes post-dose [N=37]: 4.7 (10.9) "
        ],
        "premise_nums": [
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60",
            "Arm/Group Description: Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle",
            "Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle",
            "Number of Participants Analyzed: 51 Mean (Standard Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose",
            "by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg Overall Number of Participants Analyzed:",
            "Day 1, 15 minutes pre-dose and 15 and 60 minutes post-dose of 3.6 mg/kg Overall Number of Participants Analyzed: 51",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle",
            "Time frame: Cycle 1 Day 1, pre-dose (Baseline); Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 1 Day 8; and Cycle 3 Day 1, 15 minutes pre-dose",
            "Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3) Cycle 3 Day 1, 15 minutes pre-dose and 15 and 60",
            "Deviation) Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle",
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1 Day 1, 15 and 60 minutes post-dose; Cycle 1 Day",
            "Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1) Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3) Cycle"
        ]
    },
    {
        "id": "5e700303-cd26-4024-a260-62f6a1c297ed",
        "primaryId": "NCT01000662",
        "secondaryId": "NCT02413008",
        "statement_text": "the secondary trial is testing a Gel which is applied to the breast  whereas the primary trial is testing an intervention which requires daily radiation of the breast ",
        "statement_nums": [
            "the secondary trial is testing a Gel",
            "breast  whereas the primary trial is testing an intervention"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy  Monday to Friday for 3 weeks  to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed  for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed  Arm 2= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed  for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: 0.005% Estriol Vaginal Gel ",
            "Route: Vaginal  Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration"
        ],
        "premise_nums": [
            "Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: 0.005% Estriol Vaginal Gel",
            "40.5 Gy to the breast and 48.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "40.5 Gy to the breast and 46.5 gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy)",
            "Radiation Therapy: Arm 1= 15 daily radiation fractions of 2.7 Gy Monday to friday for three weeks",
            "(2.7Gy+0.5 Gy)  The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor",
            "breast with a Friday boost of 2.0 Gy to the tumor bed  for",
            "for a total daily dose of 3.2 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "The overall dose will be 40.5 Gy to the breast with a Friday boost of 2.0 Gy to the tumor",
            "inside the vagina Dose: 1 g of gel  containing 50 Mcg of estriol Dosage schedule: Weeks 1-3:",
            "with a daily concomitant boost of 0.5 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0",
            "Gy to the breast and 46.5 gy to the tumor bed  INTERVENTION 1: ARM 1 Daily Boost Radiation Therapy Radiation Therapy: Arm",
            "breast with a Friday boost of 2.0 Gy to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0"
        ]
    },
    {
        "id": "4c4c191c-de68-44c8-a23c-2455acc43d46",
        "primaryId": "NCT00371345",
        "secondaryId": "NCT00475670",
        "statement_text": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial ",
        "statement_nums": [
            "events obeserved in the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%) Neutropenia * 0/3 (0.00%) Sudden Death * 0/3 (0.00%) Bacterial Infection * 0/3 (0.00%) Bronchitis * 0/3 (0.00%) Sepsis * 0/3 (0.00%) Lymphoedema * 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 20/70 (28.57%) NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN",
            "(1.43%) SINUSITIS 1/70 (1.43%) LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 1: Total: 0/3 (0.00%) Febrile Neutropenia * 0/3 (0.00%)",
            "(2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70",
            "PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%) PYREXIA 1/70 (1.43%) OEDEMA PERIPHERAL 1/70 (1.43%) GENERAL PHYSICAL HEALTH",
            "NAUSEA 2/70 (2.86%) VOMITING 1/70 (1.43%) DIARRHOEA 2/70 (2.86%) ABDOMINAL PAIN 1/70 (1.43%) ABDOMINAL PAIN LOWER 1/70 (1.43%) FATIGUE 2/70 (2.86%)",
            "GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%) SINUSITIS 1/70 (1.43%) GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%) PNEUMONIA 1/70 (1.43%)"
        ]
    },
    {
        "id": "e5a4cb11-2a00-4144-93ba-f5462d7efbf0",
        "primaryId": "NCT01818063",
        "secondaryId": "NCT00559507",
        "statement_text": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib ",
        "statement_nums": [
            "In the primary trial and the secondary trial the only drugs administered",
            "primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm 1 (Paclitaxel  Carboplatin) Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity  Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV INTERVENTION 2: Arm 2 (Veliparib  Paclitaxel  Carboplatin) ",
            "Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity Paclitaxel: Given IV Carboplatin: Given IV Doxorubicin: Given IV Cyclophosphamide: Given IV Veliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  "
        ],
        "premise_nums": [
            "1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 21 days for 4 courses in the absence of disease progression",
            "receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and",
            "IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression",
            "saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression",
            "unacceptable toxicity  Beginning 21 days after the last course  patients receive doxorubicin",
            "Given IV Cyclophosphamide: Given IV INTERVENTION 2: Arm 2 (Veliparib  Paclitaxel",
            "Given IV Veliparib: Given PO INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients",
            "PO BID on days 1-5. Patients also receive paclitaxel IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days"
        ]
    },
    {
        "id": "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c",
        "primaryId": "NCT01720602",
        "secondaryId": "NCT00082810",
        "statement_text": "the primary trial participants receive more anastrozole  letrozole and exemestane than patients in the secondary trial ",
        "statement_nums": [
            "than patients in the secondary trial",
            "the primary trial participants receive more anastrozole"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Vorinostat  AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive AI therapy comprising either anastrozole PO daily  letrozole PO daily  or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity  vorinostat: Given PO anastrozole: Given PO letrozole: Given PO exemestane: Given PO positron emission tomography: Correlative studies F-18 16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity "
        ],
        "premise_nums": [
            "AI Therapy) Patients receive vorinostat PO 5 days a week for 3 weeks  Patients also receive",
            "fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28",
            "mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in",
            "or exemestane PO daily for 4 weeks  Courses repeat every 28 days in the absence of disease progression",
            "16 alpha-fluoroestradiol: Correlative studies fludeoxyglucose F 18: Correlative studies laboratory biomarker analysis: Correlative studies INTERVENTION 1: Fulvestrant 250 mg + Tipifarnib",
            "Tipifarnib 300 mg Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days"
        ]
    },
    {
        "id": "27a4d1a8-185b-4483-85ce-0fbb3d323b99",
        "primaryId": "NCT01945775",
        "statement_text": "The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration ",
        "statement_nums": [
            "Talazoparib group of the primary trial was over a month"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause  whichever occurs first  As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements  compared to the smallest sum on study (including baseline)  the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions  evaluated as a whole  such that it is clear that treatment has failed and disease is progressing  regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions  The analysis was performed by Kaplan-Meier method  Time frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Title: Talazoparib ",
            "Arm/Group Description: Participants received talazoparib 1 mg  orally  once daily until radiographic disease progression as determined by the central IRF  unacceptable toxicity  consent withdrawal  physician's decision to terminate treatment  or sponsor's decision to terminate the trial (up to a maximum of 70.2 months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3) "
        ],
        "premise_nums": [
            "compared to the smallest sum on study (including",
            "per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target",
            "cause (up to maximum duration of 36.9 months) Results 1: Arm/Group Description: Participants received talazoparib 1 mg  orally  once",
            "months)  One cycle was of 21 days Overall Number of Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months",
            "sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal",
            "Participants Analyzed: 287 Median (95% Confidence Interval) Unit of Measure: months 8.6 (7.2 to 9.3)",
            "in solid tumors (RECIST) version 1.1 or death from any cause  whichever",
            "trial (up to a maximum of 70.2 months)  One cyclesions: at least a 20% increase in the sum of target",
            "until the date of first documented radiologic progressive disease per"
        ]
    },
    {
        "id": "ff797dd4-0b4d-42fc-808d-27c439563ce2",
        "primaryId": "NCT01743560",
        "statement_text": "By week 48 of the primary trial none of the patients had Complete Response  7 had partial response and 15 had progressive disease ",
        "statement_nums": [
            "By week 48 of the primary trial none of the patients",
            "had Complete Response  7 had partial response and 15 had progressive disease"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required  To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o  Overall Number of Participants Analyzed: 49 Measure Type: Number ",
            "Unit of Measure: participants Patients with measurable disease at baseline: 39Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0 Best at WK 48 - Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease (PD): 15 Unknown: 1 Missing: 8 "
        ],
        "premise_nums": [
            "Outcome Measurement: Best Overall Response of Everolimus and Exemestane",
            "confirmed CR or PR by week 48. Time frame: At 48 weeks Results 1: Arm/Group Title: Everolimus and Exemestane",
            "receive everolimus at a dose of 10mg daily p.o  and exemestane 25mg daily p.o  Overall",
            "- Partial Response (PR): 7 Best at WK 48 - Stable Disease (SD): 18 Best at WK 48 - Progressive Disease",
            "two determinations of CR at least 4 weeks apart before progression are required",
            "measurable disease at baseline: 39Patients with non-measurable disease at baseline: 10 Best at WK 48 - Complete Response (CR): 0",
            "Number of Participants Analyzed: 49 Measure Type: Number"
        ]
    },
    {
        "id": "9f666667-0fde-4d79-b53c-33c0ffbbed90",
        "primaryId": "NCT00494481",
        "statement_text": "Paula recently had fell down a flight of stairs and fractured her hip  she is excluded from the primary trial ",
        "statement_nums": [
            "is excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Females with histological/cytological confirmation of breast cancer  Subjects with a measurable lesion or bone lesions Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or other cardiac conditions "
        ],
        "premise_nums": [
            "lesions Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or"
        ]
    },
    {
        "id": "47084742-d031-4e59-865c-d8687282c782",
        "primaryId": "NCT00494481",
        "statement_text": "Paula recently had a heart attack  she is excluded from the primary trial ",
        "statement_nums": [
            "is excluded from the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or other cardiac conditions "
        ],
        "premise_nums": [
            "Exclusion Criteria: Previous radiotherapy within 6 weeks Significant cardiac events  arrhythmias or"
        ]
    },
    {
        "id": "ae583ea3-36a5-472c-acda-825cd7d513b6",
        "primaryId": "NCT00454805",
        "statement_text": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "statement_nums": [
            "In the primary trial there were no cases",
            "of subendocardial myocardial infarction in cohort 1 or 2"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31 (6.45%) Ascites 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%) Hypokalaemia 0/31 (0.00%) Adverse Events 2: Total: 4/31 (12.90%) Intracardiac Thrombus 0/31 (0.00%) Diarrhoea 0/31 (0.00%) Nausea 0/31 (0.00%) Vomiting 0/31 (0.00%) Ascites 1/31 (3.23%) Ileus 0/31 (0.00%) ",
            "Small Intestinal Obstruction 0/31 (0.00%)Multi-Organ Failure 1/31 (3.23%) Sepsis 0/31 (0.00%) Weight Decreased 0/31 (0.00%) Dehydration 0/31 (0.00%) Hypokalaemia 1/31 (3.23%) "
        ],
        "premise_nums": [
            "2: Total: 4/31 (12.90%) Intracardiac Thrombus 0/31 (0.00%) Diarrhoea 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ",
            "Adverse Events 1: Total: 15/31 (48.39%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31",
            "Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Sepsis 0/31 (0.00%) Weight Decreased 0/31 (0.00%) Dehydration 0/31 (0.00%)",
            "(6.45%) Hypokalaemia 0/31 (0.00%) Adverse Events 2: Total: 4/31 (12.90%) Intracardiac Thrombus 0/31 (0.00%) Diarrhoea 0/31 (0.00%)",
            "Small Intestinal Obstruction 0/31 (0.00%)Multi-Organ Failure 1/31 (3.23%) Sepsis 0/31 (0.00%) Ileus 1/31 (3.23%) Small Intestinal Obstruction 1/31 (3.23%) Multi-Organ",
            "(6.45%) Hypokalaemia 0/31 (0.00%) Adverse Events 2: Total: 4/31 (12.90%) Intracardiac Thrombus 1/31 (3.23%) Diarrhoea 2/31 (6.45%) Nausea 2/31 (6.45%) Vomiting 2/31",
            "(3.23%) Sepsis 0/31 (0.00%) Weight Decreased 0/31 (0.00%) Dehydration 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)",
            "Intestinal Obstruction 1/31 (3.23%) Multi-Organ Failure 0/31 (0.00%) Sepsis 1/31 (3.23%) Weight Decreased 1/31 (3.23%) Dehydration 2/31 (6.45%)"
        ]
    },
    {
        "id": "a18c447b-de08-48ef-8e65-0ecaa775c2b0",
        "primaryId": "NCT00206427",
        "statement_text": "A patient in the primary trial had a vaginal fungal infection ",
        "statement_nums": [
            "A patient in the primary trial had a vaginal fungal"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49 (2.04%) Febrile neutropenia *1/49 (2.04%) Left Ventricular Systolic Dysfunction *1/49 (2.04%) Constipation *1/49 (2.04%) Mucositis-oral *1/49 (2.04%) Infection-oral thrush *1/49 (2.04%) rash *1/49 (2.04%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 3/49 (6.12%) Neutrophils/ANC *1/49 (2.04%) Leukocytes *1/49 (2.04%) Hypocalcemia *1/49"
        ]
    },
    {
        "id": "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf",
        "primaryId": "NCT00932373",
        "statement_text": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial ",
        "statement_nums": [
            "from participation in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Grade 2 peripheral neuropathy "
        ],
        "premise_nums": [
            "Exclusion Criteria: Grade 2 peripheral neuropathy"
        ]
    },
    {
        "id": "d56745c3-ba0b-4b42-b3cf-ac060f658d83",
        "primaryId": "NCT00670982",
        "statement_text": "Acute coronary syndrome was the most prevalent adverse event in the primary trial  other than Thrombocytopenia  ",
        "statement_nums": [
            "adverse event in the primary trial  other than Thrombocytopenia"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 9/29 (31.03%) Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29 (3.45%) "
        ],
        "premise_nums": [
            "Neutropenia 5/29 (17.24%) Cataracts 1/29 (3.45%) Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis",
            "Abdominal Pain 1/29 (3.45%) Perforated Appendix 1/29 (3.45%) Surgical Intervention 1/29 (3.45%) Deep Vein Thrombosis 1/29 (3.45%) Cerebrovascular Ischemia 1/29"
        ]
    },
    {
        "id": "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f",
        "primaryId": "NCT01446159",
        "statement_text": "the primary trial only had a total of 6 patients in across both its cohorts ",
        "statement_nums": [
            "the primary trial only had a total of 6 patients in across both its cohorts"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 2/3 (66.67%) Adverse Events 2: Total: 0/3 (0.00%)"
        ]
    },
    {
        "id": "03c7f31f-788c-4edb-a885-b6cb0fca05da",
        "primaryId": "NCT00375505",
        "statement_text": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score ",
        "statement_nums": [
            "control group had a Z-score of 0.037, higher than the test group score",
            "In the primary trial patients in control group had a Z-score of 0.037, higher than the test"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at lumbar spine (L2-L4); DXA assessments of the BMD at dual hips  (BMD)  Two X-ray beams with different energy levels are aimed at the patient's bones  When soft tissue absorption is subtracted out  the BMD can be determined from the absorption of each beam by bone  Time frame: baseline  month 24 Results 1: Arm/Group Title: Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36 Mean (Standard Deviation) Unit of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 34 ",
            "Mean (Standard Deviation)Unit of Measure: Z-score 0.037 (0.042) "
        ],
        "premise_nums": [
            "months for a treatment period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36",
            "Placebo Arm/Group Description: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions)",
            "(DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 Bone mineral density (BMD) by DXA at",
            "of Measure: Z-score -0.075 (0.041) Results 2: Arm/Group Title: Zometa Arm/Group Description: Zoledronic Acid 4mg as a 15-minute infusion",
            "period of 24 months (total of 8 infusions)  Overall Number of Participants Analyzed: 36 Mean (Standard Deviation) Unit of Measure: Z-score"
        ]
    },
    {
        "id": "e43c01e9-20a2-4435-a32b-224d5f460d7c",
        "primaryId": "NCT01997333",
        "statement_text": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months ",
        "statement_nums": [
            "Free Survival for patients in cohort 1 the primary trial was 1.6 months"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause  Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions  or progression in a non-target lesion  or the appearance of new lesions  The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee  blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression  discontinuation due to toxicity  withdrawal of consent  or end of study  Overall Number of Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2) "
        ],
        "premise_nums": [
            "Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the",
            "and investigator assessments according to RECIST 1.1 criteria  Time frame: Evaluated every 6 - 9 weeks following treatment",
            "new lesions  The primary analysis of PFS was based",
            "Participants Analyzed: 109 Median (95% Confidence Interval) Unit of Measure: months 2.8 (1.6 to 3.2)",
            "9 weeks following treatment initiation Results 1: Arm/Group Title: Capecitabine Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21"
        ]
    },
    {
        "id": "c55f34ab-b883-465e-89dc-75bbeb8afa77",
        "primaryId": "NCT00369655",
        "secondaryId": "NCT00091832",
        "statement_text": "One patient in the primary trial had a Confirmed tumor partial response  No patients in the secondary trial were evaluated for tumor response ",
        "statement_nums": [
            "One patient in the primary trial had a Confirmed tumor",
            "No patients in the secondary trial were evaluated for tumor"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Proportion of Patients With Confirmed Tumor Response Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants Confirmed tumor partial response: 1 No Confirmed reponse: 20 Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100. Time frame: Baseline and Week 13 "
        ],
        "premise_nums": [
            "or unacceptable toxicity  Overall Number of Participants Analyzed: 21 Measure Type: Number Unit of Measure: Participants",
            "from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr)",
            "on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to 5 years Results 1: Arm/Group Title: Treatment (Ziv-afibercept) Arm/Group",
            "Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression",
            "1 No Confirmed reponse: 20 Outcome Measurement: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) Percent",
            "in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart  Time frame: Up to",
            "Baseline value ) x 100. Time frame: Baseline and Week 13"
        ]
    },
    {
        "id": "0ee36ceb-5790-440e-b6ad-10a0b7a23f43",
        "primaryId": "NCT01925170",
        "secondaryId": "NCT00324259",
        "statement_text": "Participant in cohort 1 of the primary trial undergo a Mammography  whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol  and no Mammography ",
        "statement_nums": [
            "cohort 1 of the secondary trial receive 6 mg Estradiol  and no Mammography"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Mammography Only For this reporting arm  the interpretation and analysis was done with mammography only  INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Arm 1 (6 mg Estradiol) 6 mg of estradiol daily (2 mg tid)"
        ]
    },
    {
        "id": "2535da13-e0f7-44df-aa02-89765d8d51cb",
        "primaryId": "NCT02419807",
        "secondaryId": "NCT00777101",
        "statement_text": "Patients with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial ",
        "statement_nums": [
            "with HER2 + breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage IIIB  IIIC  or IV erbB2 (HER2) positive breast cancer "
        ],
        "premise_nums": [
            "or IV erbB2 (HER2) positive breast cancer",
            "a confirmed diagnosis of clinical stage 1 or 2 breast cancer Inclusion Criteria: Stage"
        ]
    },
    {
        "id": "94fc6e05-8a73-43d9-a48c-531d36dfbbcd",
        "primaryId": "NCT00548184",
        "statement_text": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response  or better  after 12 weeks ",
        "statement_nums": [
            "cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Pathologic Assessment After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy  Pathologic complete response: no invasive cancer in the residual breast  Near pathologic complete response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants Analyzed: 64 Measure Type: Number Unit of Measure: participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic response: 30 "
        ],
        "premise_nums": [
            "response: residual disease of less than 1 cm in breast  Time frame: 12 weeks Results 1: Arm/Group Title: Lapatinib + Trastuzumab",
            "After Study Treatment Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or",
            "Number of Participants Analyzed: 64 Measure Type: Number Unit of Measure: participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic",
            "participants Complete Pathologic Response: 18 Near Complete Pathologic Response: 16 Not Pathologic response: 30",
            "study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week Overall Number of Participants"
        ]
    },
    {
        "id": "0057172f-d019-401b-a516-993a7b46a67b",
        "primaryId": "NCT01306942",
        "statement_text": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "statement_nums": [
            "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Phase I: Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days  INTERVENTION 2: Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 ",
            "Cohort 2: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was administered orally once daily (QD)  Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occured  Only in the phase I  the first cycle lasted 38 days "
        ],
        "premise_nums": [
            "followed by a rest period of 7 days  Dasatinib 100mg was repeated on Day 1 of a 28-day cycle until radiographic or",
            "I  the first cycle lasted 38 days  INTERVENTION 2: Phase I: Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2",
            "Treatment was repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression",
            "treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and",
            "phase I  the first cycle lasted 38 days  INTERVENTION 2: Phase",
            "dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of",
            "a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest",
            "cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days  Dasatinib 140mg was",
            "followed by a rest period of 7 days  Dasatinib 100mg was administered orally once daily (QD)",
            "weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a"
        ]
    },
    {
        "id": "bb23e8b8-c7d6-4e58-80a2-0555db5645e9",
        "primaryId": "NCT03096847",
        "secondaryId": "NCT01840163",
        "statement_text": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial  but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english ",
        "statement_nums": [
            "be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and",
            "not eligible for the primary trial  but may be"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability to read English Exclusion Criteria: Male "
        ],
        "premise_nums": [
            "Patient who received any CDK4/6 inhibitor or any mTOR inhibitor  Inclusion Criteria: Stage 1-2 invasive breast cancer diagnosis  DCIS Ability"
        ]
    },
    {
        "id": "c4588d2c-b0d4-428d-a958-29787b9d4ec5",
        "primaryId": "NCT00545077",
        "statement_text": "Only cohort 2 of the primary trial receive Bevacizumab  but both cohorts undergo Endocrine Therapy  ",
        "statement_nums": [
            "Only cohort 2 of the primary trial receive Bevacizumab  but"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm A: Endocrine Therapy (ET) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab (ET-B) Endocrine treatment consisting of either letrozole or fulvestrant  Patients will be randomized to receive bevacizumab 15mg/kg i.v  on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent  The patients will receive the assigned treatment until the progression of the disease  unacceptable toxicity or withdrawal of the consent  Letrozole Bevacizumab Fulvestrant "
        ],
        "premise_nums": [
            "will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment",
            "the consent  Letrozole Fulvestrant INTERVENTION 2: Arm B: ET With Bevacizumab"
        ]
    },
    {
        "id": "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6",
        "primaryId": "NCT00364611",
        "statement_text": "Patients with clinically significant grade 3 PVD are eligible for the primary trial ",
        "statement_nums": [
            "Patients with clinically significant grade 3 PVD are eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Presence of any non-healing wound  fracture  or ulcer  or the presence of clinically significant (greater than /= Grade 2) peripheral vascular disease "
        ],
        "premise_nums": [
            "or the presence of clinically significant (greater than /="
        ]
    },
    {
        "id": "00466f98-52b8-41f3-9bf1-2edaad950be9",
        "primaryId": "NCT02504424",
        "secondaryId": "NCT03708393",
        "statement_text": "the primary trial and the secondary trial both require the patients to activate the interventions by remote control ",
        "statement_nums": [
            "the primary trial and the secondary trial both require the patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: AeroForm Tissue Expander AeroForm Tissue Expansion inflation with carbon dioxide by remote control AeroForm Tissue Expander: The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander  INTERVENTION 1: IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging "
        ],
        "premise_nums": [
            "remote control to release small doses of carbon dioxide from",
            "IUS Alone IUS alone imaging INTERVENTION 2: Imagio (IUS+OA) IUS+OA imaging"
        ]
    },
    {
        "id": "50a524ae-2135-45f7-ae9b-515fd4e2e404",
        "primaryId": "NCT02445586",
        "secondaryId": "NCT02115984",
        "statement_text": "More than half of patients in the primary trial experienced adverse events  and 100% of patients in the secondary trial did not experience an adverse event ",
        "statement_nums": [
            "adverse events  and 100% of patients in the secondary trial did not experience an"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) Adverse Events 1: Total: 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2: ",
            "Total: 23/23 (100.00%)Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) "
        ],
        "premise_nums": [
            "malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%)",
            "Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52",
            "57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events 2:",
            "Total: 23/23 (100.00%)Dry eyes 2/11 (18.18%) Heartburn 2/11 (18.18%) Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11",
            "Nausea after the CT (before day 7) 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%)",
            "2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%)",
            "Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia 23/23 (100.00%) Herpetic eruption 3/11 (27.27%) Dry skin 9/11 (81.82%) Alopecia",
            "(1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%)",
            "31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%)",
            "Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Dry eyes 13/33 (39.39%) Heartburn 9/33 (27.27%) Nausea after",
            "Nausea after the CT (before day 7) 57/57 (100.00%) Herpetic eruption 0/33 (0.00%) Dry skin 15/33 (45.45%) Alopecia 57/57 (100.00%) Adverse Events"
        ]
    },
    {
        "id": "b2062e01-0ea6-4ee8-94a1-b59dc40901d3",
        "primaryId": "NCT01688609",
        "statement_text": "Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter to participate in the primary trial ",
        "statement_nums": [
            "with Primary tumor greater than 2 cm in diameter to participate in the primary trial",
            "Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer  with Primary",
            "histologically or cytologically confirmed ERBB2+ invasive breast cancer  with Primary tumor greater than 2 cm in diameter to participate in the"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+ "
        ],
        "premise_nums": [
            "Criteria: Patients must have histologically or cytologically confirmed primary invasive breast cancer Primary tumor",
            "cancer Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound",
            "Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or",
            "situ hybridization (FISH) + when IHC 2+"
        ]
    },
    {
        "id": "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af",
        "primaryId": "NCT00826267",
        "statement_text": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs ",
        "statement_nums": [
            "Cohort 1 and 2 of the primary trial receive different quantities of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day"
        ]
    },
    {
        "id": "43a9cc96-4020-459c-8fa4-4bbde7173f7a",
        "primaryId": "NCT02447328",
        "statement_text": "In the primary trial 11 patients had serious adverse events  no patients had serious Adverse Drug Reactions  and over half of patients passed away from Unexpected adverse events ",
        "statement_nums": [
            "In the primary trial 11 patients had serious adverse events  no"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) Percentage of patients with AEs  Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient  Results 1: Arm/Group Title: Single Arm Arm/Group Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage of participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to 4.4) Unexpected AE: 71.6 (60.5 to 81.1) Unexpected ADR: 24.7 (15.8 to 35.5) "
        ],
        "premise_nums": [
            "Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81 Measure Type: Number Unit of Measure: Percentage",
            "South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to 20.1) Serious ADR: 0 (0 to",
            "to end of the study about 6 months for each patient  Results 1:",
            "participants Adverse Events(AE): 81.5 (71.3 to 89.3) ADR; based on current South Korea label.: 38.3 (27.7 to 49.7) Serious AE: 11.1 (5.2 to",
            "20.1) Serious ADR: 0 (0 to 4.4) Unexpected AE: 71.6 (60.5 to 81.1) Unexpected ADR: 24.7 (15.8 to",
            "Description: fulvestrant (Faslodex ) Overall Number of Participants Analyzed: 81.1) Unexpected ADR: 24.7 (15.8 to 35.5)"
        ]
    },
    {
        "id": "ff319fa6-89b6-4f1a-871d-456edb91b69b",
        "primaryId": "NCT03045653",
        "statement_text": "Sharone had a hip replacement 3 weeks prior  she is not elgible for the primary trial ",
        "statement_nums": [
            "had a hip replacement 3 weeks prior  she is not elgible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases  including uncontrolled hypertension  active bleeding diatheses  or active infection including hepatitis B  hepatitis C and HIV With the exception of alopecia  any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia  altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures  including inability to take regular oral medication "
        ],
        "premise_nums": [
            "study with investigational product during last 30 days Inability or unwillingness to comply with",
            "previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence",
            "of vascular access) within 4 weeks before study treatment Evidence of severe"
        ]
    },
    {
        "id": "a321acf0-2296-4588-bf96-85b22bf1420f",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts ",
        "statement_nums": [
            "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) ",
            "Optic ischaemic neuropathy 1/76 (1.32%)Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) "
        ],
        "premise_nums": [
            "(18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%)",
            "Optic ischaemic neuropathy 1/76 (1.32%)Bowel peristalsis increased 0/76 (0.00%) Colitis 1/76 (1.32%) Diarrhoea 0/76",
            "neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%)",
            "neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased",
            "neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76",
            "(18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy",
            "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure"
        ]
    },
    {
        "id": "b841dfd8-4676-4d3c-a57d-6ba1055b8597",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "patient was treated with Pertuzumab for 6 months  and this treatment was discontinued 2 months prior to study entry and the",
            "is eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  "
        ],
        "premise_nums": [
            "therapy (e.g  antibodies) 4 weeks prior to starting study drug or"
        ]
    },
    {
        "id": "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4",
        "primaryId": "NCT01042535",
        "statement_text": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg ",
        "statement_nums": [
            "Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg) MTD of 1-methyl-d-tryptophan (indoximod) given by mouth (PO)  twice a day (BID)  with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) (100 mg  200 mg  400 mg  800 mg daily (QD) then 800 mg  1,200 mg  and 1,600 mg PO BID +up to 6 fixed dose Ad.p53 DC vaccinations q2wks. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. The MTD is the highest dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients  that is  0 or 1 out of 6 patients experiences a dose limiting toxicity (DLT)  Time frame: Up to 4 weeks Results 1: ",
            "Arm/Group Title: Treatment (Vaccine Therapy  1-methyl-d-tryptophan)Arm/Group Description: Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses  Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity  adenovirus-p53 transduced dendritic cell (DC) vaccine: Given intradermally (ID) 1-methyl-d-tryptophan: Given orally (PO) Laboratory biomarker analysis: Correlative studies Overall Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: indoximod dose in mg 1600 "
        ],
        "premise_nums": [
            "to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design with 7 indoximod",
            "200 mg  400 mg  800 mg daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days",
            "indoximod dose levels (DL) (100 mg  200 mg  400 mg  800 mg daily (QD) then 800 mg",
            "1,200 mg  and 1,600 mg PO BID +up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1",
            "vaccine: Given intradermally (ID) 1-methyl-d-tryptophan: Given orally (PO) Laboratory biomarker analysis:",
            "dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients  that is",
            "day (BID)  with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used",
            "(MTD) in Milligrams (mg) MTD of 1-methyl-d-tryptophan (indoximod) given by mouth",
            "Number of Participants Analyzed: 30 Measure Type: Number Unit of Measure: indoximod dose levels (DL) (100 mg  200 mg  400",
            "with up to 6 fixed doses Ad.p53 DC vaccinations every 200 mg  400 mg  800 mg daily (QD)",
            "Treatment (Vaccine Therapy  1-methyl-d-tryptophan)Arm/Group Description: Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3,",
            "with up to 6 fixed doses Ad.p53 DC vaccinations every 2 weeks (q2wks). This phase 1 study used a 3+3 design",
            "adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks (q2wks). This phase 1 study used a 3+3 design with 7",
            "1, 3, 5, and 10, and then every 3 weeks forally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats",
            "(MAD) that is safely tolerated among 6 treated patients  that is  0 or 1 out of 6 patients experiences",
            "5, and 10, and then every 3 weeks for 6 total doses  Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily",
            "days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with up to 6 fixed doses Ad.p53 DC vaccinations every 2",
            "400 mg  800 mg daily (QD) then 800 mg  1,200 mg  and 1,600 mg PO",
            "then 800 mg  1,200 mg  and 1,600 mg PO BID +up to 6 fixed",
            "that is  0 or 1 out of 6 patients experiences a dose limiting toxicity (DLT)",
            "and then every 3 weeks for 6 total doses  Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on"
        ]
    },
    {
        "id": "48d40c7e-3514-43c3-a31a-7b391727f012",
        "primaryId": "NCT01209195",
        "statement_text": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts ",
        "statement_nums": [
            "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV "
        ],
        "premise_nums": [
            "Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel -",
            "1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly",
            "1: Dose Escalation: Cohort 2 MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly",
            "Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort 1 MM-121 - 20 mg/kg loading dose followed by 12 mg/kg",
            "20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV INTERVENTION 2: Part 1: Dose Escalation: Cohort"
        ]
    },
    {
        "id": "dd98fca1-27a7-41c2-ba0c-3ff90aceab54",
        "primaryId": "NCT01305941",
        "statement_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial  meaning their cancer is Histologically-confirmed as being HER2-positive.",
        "statement_nums": [
            "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial  meaning their cancer",
            "meaning their cancer is Histologically-confirmed as being HER2-positive",
            "to participate in the primary trial  meaning their cancer is Histologically-confirmed as being"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (greater than /=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy  stereotactic radiosurgery  gamma knife  or equivalent)  Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible  "
        ],
        "premise_nums": [
            "brain lesion (greater than /=5 mm on radiographic imaging) after receipt of",
            "of the breast with at least one progressive and/or new metastatic",
            "Inclusion Criteria Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in",
            "clinical assay on either primary or metastatic tumor) adenocarcinoma of"
        ]
    },
    {
        "id": "b975dc12-757e-4ef5-af33-83dfce12e6cc",
        "primaryId": "NCT01989676",
        "statement_text": "the primary trial only records GI adverse events ",
        "statement_nums": [
            "the primary trial only records GI adverse"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia * 1/349 (0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349 (0.00%) Cardio-respiratory arrest * 2/349 (0.57%) Cardiovascular insufficiency * 0/349 (0.00%) "
        ],
        "premise_nums": [
            "(0.29%) Atrial fibrillation * 2/349 (0.57%) Cardiac arrest * 1/349 (0.29%) Cardiac failure * 0/349 (0.00%) Cardiac failure acute * 0/349",
            "Adverse Events 1: Total: 67/349 (19.20%) Anaemia * 3/349 (0.86%) Leukopenia * 1/349 (0.29%) Neutropenia * 3/349 (0.86%) Thrombocytopenia"
        ]
    },
    {
        "id": "2c4254c9-9c40-492f-aa45-2a9ab47579b3",
        "primaryId": "NCT02658734",
        "secondaryId": "NCT02073487",
        "statement_text": "Female Patients with LVEF greater than 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial ",
        "statement_nums": [
            "still eligible for the secondary trial but are excluded from the primary trial",
            "Female Patients with LVEF greater than 50%, who have previously undergone"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria: Prior treatment with trastuzumab emtansine Prior treatment with lapatinib or lapatinib with capecitabine or non-comparable biologic or biosimilar of trastuzumab Inclusion Criteria: Female gender; Age 18 years; Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination and mammography or ultrasound  Any N  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization  Known hormone receptor status  Hematopoietic status: CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status: ",
            "Serum total bilirubin 2 x upper limit of normal (ULN)  In the case of known Gilbert's syndrome  a higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization  Fertile patients must use effective contraception (barrier method - condoms  diaphragm - also in conjunction with spermicidal jelly  or total abstinence  Oral  injectable  or implant hormonal contraceptives are not allowed) Signed informed consent form (ICF) ",
            "Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol Exclusion Criteria: Previous (less than 5 years) or current history of malignant neoplasms  except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix  Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina  clinically significant arrhythmias  congestive heart failure  transmural myocardial infarction  uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at rest  or chronic therapy with oxygen; Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety; Unresolved or unstable  serious adverse events from prior administration of another investigational drug; Dementia  altered mental status  or any psychiatric condition that would prevent the understanding or rendering of ICF; ",
            "Malabsorption syndrome  disease significantly affecting gastrointestinal function  or resection of the stomach or small bowel  Subjects with ulcerative colitis are also excluded;Concurrent neoadjuvant cancer therapy (chemotherapy  radiation therapy  immunotherapy  biologic therapy other than the trial therapies); Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine  trastuzumab  lapatinib  paclitaxel  abraxane or their components; Pregnant or lactating women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g  active or uncontrolled infection  uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol Patients have an active infection and require IV or oral antibiotics  Pregnant or breast-feeding women Patients unwilling or unable to comply with the protocol "
        ],
        "premise_nums": [
            "Cooperative Oncology Group (ECOG) 0-1 Histologically confirmed invasive breast cancer: Primary tumor greater than 1 cm diameter  measured by clinical examination",
            "CBC not less than .75 of institutional lower limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin",
            "uncontrolled hypertension ( 180/110), unstable diabetes mellitus  dyspnea at",
            "count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at leastudy  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or",
            "for patients of childbearing potential within 2-weeks (preferably 7 days) prior",
            "of the stomach or small bowel  Subjects with ulcerative",
            "higher serum total bilirubin (smaller than 1.5 x ULN) is allowed  Aspartate Aminotransferase",
            "study  Preexisting peripheral neuropathy grade 2 Known history of uncontrolled or symptomatic angina",
            "limit  Absolute neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobin at least 9 g/dl  Hepatic status:",
            "protocol Exclusion Criteria: Previous (less than 5 years) or current history of",
            "neutrophil count 1,5 x 10^9/L, Platelet count 100 x 10^9/L, Hemoglobinvasive component of the primary tumor and confirmed by a",
            "women; Concomitant use of CYP3A4 inhibitors or inducers Other concurrent severe and/or",
            "Serum total bilirubin 2 x upper limit of normal (ULN)",
            "3.5 times ULN  Alkaline phosphatase 2.5 times ULN  Renal status: Creatinine 1.5mg/dL,Cardiovascular: Baseline left ventricular ejection"
        ]
    },
    {
        "id": "e140b055-b7fc-4802-a79b-9dfe7d136876",
        "primaryId": "NCT01575522",
        "secondaryId": "NCT00181363",
        "statement_text": "the primary trial and the secondary trial are testing completely different modalities of interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial are testing completely different"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Treatment (Tivantinib) Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity  Patients undergo blood sample collection at baseline and periodically during study for c-Met expression  relevant markers (HGF and VEGF)  PTEN loss  and PI3K mutation analysis by FISH and IHC  Archived tumor tissue samples are also analyzed  Laboratory Biomarker Analysis: Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position "
        ],
        "premise_nums": [
            "PTEN loss  and PI3K mutation analysis by FISH and IHC",
            "collection at baseline and periodically during study for c-Met",
            "receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression",
            "Correlative studies Tivantinib: Given PO INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position"
        ]
    },
    {
        "id": "0a6418c8-63a6-4900-bfc9-1659acbe1ad7",
        "primaryId": "NCT02581839",
        "statement_text": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) greater than or equal 3 months ",
        "statement_nums": [
            "Survival (PFS) greater than or equal 3 months",
            "At least 8 participants in the primary trial had a Central Nervous"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS) The study team will assess the percent of participants without CNS progression at 3 months  The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS  Response and progression by MR were evaluated using WHO/modified McDonald's criteria  Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate Eribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate ",
            "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the discretion of the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at the discretion of the treating physician Overall Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7) "
        ],
        "premise_nums": [
            "subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and",
            "Pre-Medication: Zofran: Zofran at 8mg orally  Given at the",
            "Time frame: At 12 weeks Results 1: Arm/Group Title: Eribulin Mesylate Arm/Group",
            "the treating physicianPre-Medication: Decadron: decadron at 8mg orally  Given at",
            "and every 12 weeks after cycles 4+ while on study eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes",
            "MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate",
            "PFS and estimate the PFS and 95% confidence interval (CI) of the PFS",
            "Days 1 and 8 of a 21-day cycle  An MRI will be completed at week 1, week 12 and every 12",
            "dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day",
            "Number of Participants Analyzed: 9 Measure Type: Number Unit of Measure: percentage of participants 88.9 (51 to 99.7)",
            "is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle  An MRI",
            "of participants without CNS progression at 3 months  The study team"
        ]
    },
    {
        "id": "2db9e0c7-d94b-47d2-a61f-55a0896d714e",
        "primaryId": "NCT00789581",
        "secondaryId": "NCT02445586",
        "statement_text": "the secondary trial reported more cases of Haematemesis  but the primary trial had more cases of Sinus tachycardia ",
        "statement_nums": [
            "Haematemesis  but the primary trial had more cases of",
            "the secondary trial reported more cases of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 58/305 (19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA * 1/305 (0.33%) DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%) DIASTOLIC DYSFUNCTION * 1/305 (0.33%) PERICARDIAL EFFUSION * 1/305 (0.33%) Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA * 0/304 (0.00%) ",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%) DIASTOLIC DYSFUNCTION * 0/304 (0.00%) PERICARDIAL EFFUSION * 0/304 (0.00%) Adverse Events 1: Total: 31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%) Stomatitis 1/52 (1.92%) Haematemesis 1/52 (1.92%) "
        ],
        "premise_nums": [
            "(19.02%) FEBRILE NEUTROPENIA * 12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA",
            "neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%)",
            "DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%) ATRIAL FIBRILLATION * 1/305 (0.33%)",
            "ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Diarrhoea 5/52 (9.62%) Salivary hypersecretion 1/52 (1.92%) Enteritis",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ATRIAL FIBRILLATION * 1/304 (0.33%)",
            "THROMBOCYTOPENIA * 0/304 (0.00%)DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA * 0/304 (0.00%) PANCYTOPENIA",
            "12/305 (3.93%) NEUTROPENIA * 4/305 (1.31%) ANAEMIA * 2/305 (0.66%) LEUKOPENIA * 1/305 (0.33%) PANCYTOPENIA * 1/305 (0.33%) THROMBOCYTOPENIA",
            "Adverse Events 2: Total: 50/304 (16.45%) FEBRILE NEUTROPENIA * 12/304 (3.95%) NEUTROPENIA * 1/304 (0.33%) ANAEMIA * 0/304 (0.00%) LEUKOPENIA",
            "31/52 (59.62%) Febrile neutropenia 2/52 (3.85%) Left ventricular dysfunction 2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%)",
            "2/52 (3.85%) Sinus tachycardia 1/52 (1.92%) Congenital arterial malformation 1/52 (1.92%) Enteritis 1/52 (1.92%) Abdominal pain 1/52 (1.92%) Vomiting 1/52 (1.92%)"
        ]
    },
    {
        "id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
        "primaryId": "NCT01644890",
        "statement_text": "Throughout the primary trial  one patient in cohort 1 developed issues with their vision ",
        "statement_nums": [
            "Throughout the primary trial  one patient in cohort 1 developed issues with their vision"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Ileus 1/214 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) ",
            "Diarrhoea 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) "
        ],
        "premise_nums": [
            "0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214",
            "Adverse Events 1: Total: 34/214 (15.89%) Leukocytosis 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "Diarrhoea 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%)",
            "Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%)",
            "(12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 1/213 (0.47%) Cardiac failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%)",
            "failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%)",
            "failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)",
            "fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213 (0.47%) Atrial fibrillation 0/214 (0.00%) Cardiac failure congestive 0/214 (0.00%) Pericardial effusion 1/214",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis",
            "(0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%)",
            "(0.47%)Enterocolitis 1/213 (0.47%) Ileus 0/213 (0.00%) Nausea 0/213 (0.00%) Cataract 1/213 (0.47%) Macular fibrosis 1/213 (0.47%) Constipation 1/213 (0.47%)",
            "fibrosis 0/214 (0.00%) Constipation 2/214 (0.93%) Diarrhoea 2/214 (0.93%) Enterocolitis 0/214 (0.00%) Pericardial effusion 1/214 (0.47%) Cataract 0/214 (0.00%) Macular fibrosis",
            "failure congestive 1/213 (0.47%) Pericardial effusion 0/213 (0.00%) Cataract 1/213 (0.47%) Nausea 3/214 (1.40%) Adverse Events 2: Total: 27/213 (12.68%) Leukocytosis 1/213"
        ]
    },
    {
        "id": "7be7cecb-d265-4098-9969-a40555702573",
        "primaryId": "NCT00679211",
        "statement_text": "1 patient in the primary trial was diangosed with Influenza ",
        "statement_nums": [
            "1 patient in the primary trial was diangosed with Influenza"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Influenza like illness 1/110 (0.91%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Influenza like illness 1/110 (0.91%)"
        ]
    },
    {
        "id": "5b0d3709-7879-4dea-96c3-29178cd9f162",
        "primaryId": "NCT00767520",
        "statement_text": "Both cohorts of the primary trial reported the same number of patients vomiting during the trial ",
        "statement_nums": [
            "Both cohorts of the primary trial reported the same number"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Vomiting 2/79 (2.53%) Adverse Events 2: Vomiting 2/76 (2.63%)"
        ]
    },
    {
        "id": "af70a3a9-d2d0-4d65-81fe-15a1becb5e95",
        "primaryId": "NCT01420146",
        "secondaryId": "NCT00077376",
        "statement_text": "the primary trial and the secondary trial both have a control arm  and several test arms ",
        "statement_nums": [
            "the primary trial and the secondary trial both have a control"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase  patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone  ",
            "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab were given at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity "
        ],
        "premise_nums": [
            "therapy) beginning one week after the 24th weekly dose  Trastuzumab were repeated every 21 days until disease progression or prohibitive toxicity",
            "1. Routine premedication included H1 blocker (diphenhydramine 50 mg orally (PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50",
            "at a dose of 6 mg/kg IV every 3 weeks (maintenance therapy) beginning one week after the 24th weekly dose  Trastuzumab",
            "(PO) or IV)  H2 blocker (ranitidine 150 mg PO or 50 mg IV or another equivalent H2 blocker)",
            "After completion of 24 weekly trastuzumab doses (induction therapy)  trastuzumab",
            "PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1: Trastuzumab/Ixabepilone/Carboplatin During the induction phase",
            "administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. Routine premedication included H1 blocker",
            "28-day cycle for a maximum of 6 cycles  Trastuzumab was administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day",
            "were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV)",
            "150 mg PO or 50 mg IV or another equivalent H2 blocker)  and at least a 5-HT3 antagonist and dexamethasone",
            "by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6",
            "INTERVENTION 1: Zr89-trastuzumab PET/CT Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm INTERVENTION 1:"
        ]
    },
    {
        "id": "a378f448-eef0-465a-abc0-8b4dd1156bb5",
        "primaryId": "NCT00372424",
        "secondaryId": "NCT00041067",
        "statement_text": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: Breast cancer with evidence of unresectable  locally recurrent  or metastatic disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting "
        ],
        "premise_nums": [
            "evidence of unresectable  locally recurrent  or metastatic",
            "disease  Tumors over-expressing Her-2 Candidate for treatment with docetaxel/trastuzumab HER2-positive by fluorescence in situ hybridization (FISH)"
        ]
    },
    {
        "id": "f30182a1-b82a-497c-885c-9bd2e805db62",
        "primaryId": "NCT01487954",
        "statement_text": "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water or Distilled  depending on which cohort they are in ",
        "statement_nums": [
            "All patients in the primary trial had to drink 237 ml of water  either Alkaline Water"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Arm I: Alkaline Water Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  INTERVENTION 2: Arm II: Distilled Water Patients undergo external beam radiation therapy as in arm I  Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy  external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD  5 days a week for 6 weeks  "
        ],
        "premise_nums": [
            "for 6 weeks  Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing",
            "arm I  Patients also drink 8 ounces of distilled water within"
        ]
    },
    {
        "id": "ae87e5a3-fdd8-4003-ae80-4b370cade158",
        "primaryId": "NCT01106898",
        "statement_text": "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years ",
        "statement_nums": [
            "2% of the primary trial patients had Recurrence-free Survival smaller than 3 years"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Recurrence-free Survival Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease  Time frame: Time from the start of treatment to recurrence  second malignancy  or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With or Without Maintenance Therapy) Arm/Group Description: SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity  MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity  cyclophosphamide  paclitaxel  trastuzumab: Given IV Overall Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5) "
        ],
        "premise_nums": [
            "patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of",
            "Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression",
            "or death as a first event  assessed up to 3 years Results 1: Arm/Group Title: Treatment (Chemotherapy With",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression",
            "Number of Participants Analyzed: 100 Measure Type: Number Unit of Measure: percentage of subjects 98 (92.2 to 99.5)",
            "receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 14 courses in the absence of disease progression"
        ]
    },
    {
        "id": "9f3062db-16fb-41b8-ac10-f205f66070c8",
        "primaryId": "NCT00696072",
        "statement_text": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years ",
        "statement_nums": [
            "and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than  equal to 6 months  CR= Disappearance of all target lesions  No new lesions  PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD  SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started  Physical examination,radiological assessment  and bone scans (if applicable) were used to assess outcome  Time frame: First dose of study drug to last dose plus 7 days  up to study completion (approximately 6 years) Results 1: Arm/Group Title: Dasatinib Plus Letrozole Arm/Group Description: Dasatinib + Letrozole: Tablets  Oral  once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg ",
            "Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity  If the intolerable toxicity was determined to be related to dasatinib  dasatinib was discontinued and the patient continued on single-agent letrozole  Although drugs were taken daily  cycle length was 28-daysOverall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants CBR (CR+PR+SD): 40 CBR  DFI smaller than = 2 Years: 20 CBR  DFI greater than 2 Years: 20 "
        ],
        "premise_nums": [
            "lesions  PR= At least a 30% decrease in the sum of the",
            "20 CBR  DFI greater than 2 Years: 20",
            "once daily  up to 2 years Dasatinib 100 mg + Letrozole 2.5 mg",
            "time greater than  equal to 6 months  CR= Disappearance of study drug to last dose plus 7 days",
            "of study drug to last dose plus 7 days  up to study",
            "Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population CBR=participants",
            "taken daily  cycle length was 28-daysOverall Number of Participants Analyzed: 56 Measure Type: Number Unit of Measure: participants"
        ]
    },
    {
        "id": "a1c5685a-8e6e-4733-aa8b-7040bac1a397",
        "primaryId": "NCT00022672",
        "statement_text": "There were no patients in either cohort of the primary trial with a PFS exceeding 6 months ",
        "statement_nums": [
            "either cohort of the primary trial with a PFS exceeding 6 months"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations  Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion  For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required  PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death  Kaplan Meier estimates of PFS are presented  Time frame: 24 Months  End of Study (Up to 5 years) Results 1: Arm/Group Title: Trastuzumab + Anastrozole ",
            "Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes  followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase Overall Number of Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 4.8 (3.7 to 7) End of Study: 5.8 (4.6 to 8.3) Results 2: Arm/Group Title: Anastrozole Arm/Group Description: 1 mg oral dose of anastrozole every day for 24 Months in the Main phase  In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes  followed by weekly doses of 2 mg/kg iv over 30 minutes  Overall Number of Participants Analyzed: 104 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1 to 4.5) "
        ],
        "premise_nums": [
            "in the Extension Phase Overall Number of Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months",
            "Number of Participants Analyzed: 104 Median (95% Confidence Interval) Unit of",
            "Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90",
            "identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions",
            "followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day",
            "could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over",
            "Months 24 Months: 4.8 (3.7 to 7) End of Study: 5.8 (4.6 to 8.3) Results 2: Arm/Group Title: Anastrozole",
            "an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions",
            "End of Study (Up to 5 years) Results 1: Arm/Group Title:",
            "Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1 to 4.5)",
            "Participants Analyzed: 103 Median (95% Confidence Interval) Unit of Measure: Months 24 Months: 2.4 (2 to 4.6) End of Study: 2.9 (2.1",
            "centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an"
        ]
    },
    {
        "id": "d58683e2-d276-4184-a8e9-c9df6ffd8047",
        "primaryId": "NCT00559507",
        "statement_text": "the primary trial participants are given saracatinib PO for a maximum of 28 days ",
        "statement_nums": [
            "the primary trial participants are given saracatinib PO for a maximum of 28 days"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Treatment (Enzyme Inhibitor Therapy) Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity  "
        ],
        "premise_nums": [
            "Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression"
        ]
    },
    {
        "id": "28d8f88a-e8cb-40c0-a12b-ef555f83ff59",
        "primaryId": "NCT01904903",
        "secondaryId": "NCT01663727",
        "statement_text": "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial ",
        "statement_nums": [
            "Patients must have LVEF smaller than 50% to be eligible for the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed  HER2-negative adenocarcinoma of the breast  with measurable or non-measurable locally recurrent or metastatic disease  Locally recurrent disease must not be amenable to resection with curative intent  ECOG performance status of 0 or 1 For women of childbearing potential  use of an acceptable and effective method of non-hormonal contraception For patients who have received recent radiotherapy  recovery prior to randomization from any significant acute toxicity  and radiation treatments have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent or metastatic disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or neo-adjuvant chemotherapy is allowed  provided its conclusion has been for at least 12 months prior to randomization Investigational therapy within 28 days of randomization General Medical Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical or psychiatric illness Active infection requiring intravenous (IV) antibiotics at screening Pregnancy or lactation ",
            "History of other malignancies within 5 years prior to screening  except for tumors with a negligible risk for metastasis or death"
        ],
        "premise_nums": [
            "intent  ECOG performance status of 0 or 1 For women of childbearing potential",
            "be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled",
            "disease Prior hormonal therapy smaller than 2 weeks prior to randomization Prior adjuvant or",
            "have to be completed more than 3 weeks from randomization Exclusion Criteria: Disease-Specific Exclusions: HER2-positive status Prior chemotherapy for locally recurrent",
            "History of other malignancies within 5 years prior to screening  except for",
            "Exclusions: Life expectancy of smaller than 12 weeks Inadequate organ function Uncontrolled serious medical",
            "LVEF smaller than 50% and 40% documented in echocardiogram done within the last 30 days Inclusion Criteria: Histologically or cytologically confirmed"
        ]
    },
    {
        "id": "0ee4c935-18bd-4807-a2af-041a3d84e125",
        "primaryId": "NCT02721147",
        "statement_text": "Stephanie has been living with her boyfriend for 2 months  she is eligible for the primary trial ",
        "statement_nums": [
            "been living with her boyfriend for 2 months  she is eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Has a partner or spouse who is greater than 21 Lives with a romantic partner greater than 6 months "
        ],
        "premise_nums": [
            "or spouse who is greater than 21 Lives with a romantic partner greater than 6 months"
        ]
    },
    {
        "id": "355fb813-cbe0-44f5-b04a-87813e060d54",
        "primaryId": "NCT00371254",
        "statement_text": "Patients must have eceptorsestrogen receptor (ER) -  progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer  aswell as not having Dysphagia ",
        "statement_nums": [
            "and human epidermal growth factor receptor 2 (HER2) - breast cancer"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: recurrent or progressive locally advanced  or 'triple negative' metastatic breast cancer Exclusion Criteria: Unable to take oral medication "
        ],
        "premise_nums": [
            "Criteria: recurrent or progressive locally advanced  or 'triple"
        ]
    },
    {
        "id": "274d9d2b-9227-4496-a525-d5477b0003ce",
        "primaryId": "NCT00796978",
        "secondaryId": "NCT01276041",
        "statement_text": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs  compared to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "More patients in cohort 1 of the secondary trial suffered from oedema in",
            "compared to patients in cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%) Left ventricular systolic dysfunction * 1/56 (1.79%) Dehydration * 1/56 (1.79%) Diarrhea * 1/56 (1.79%) Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%) Sodium  serum-low (hyponatremia) * 1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear pain 1/70 (1.43%) Blurred vision 1/70 (1.43%) Eye disorders - Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%) ",
            "Diarrhea 2/70 (2.86%)Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 8/56 (14.29%) Platelets * 1/56 (1.79%) Heart failure * 1/56 (1.79%)",
            "Diarrhea 2/70 (2.86%)Nausea 2/70 (2.86%) Death NOS 1/70 (1.43%) Edema limbs 1/70 (1.43%) Fatigue 3/70 (4.29%)",
            "- Other  specify 2/70 (2.86%) Abdominal Pain 5/70 (7.14%) Colitis 1/70 (1.43%)",
            "1/56 (1.79%) Fracture * 2/56 (3.57%) Adverse Events 1: Total: 18/70 (25.71%) Cardiac arrest 1/70 (1.43%) Pericardial effusion 1/70 (1.43%) Ear",
            "Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) *"
        ]
    },
    {
        "id": "d39078d9-9bc3-4b91-a012-e95f14813c9a",
        "primaryId": "NCT01252277",
        "statement_text": "Fiona's step sister  who is 34 years old was diagnosed with a ductal carcinoma  therefore fiona may be eligible for the primary trial ",
        "statement_nums": [
            "Fiona's step sister  who is 34 years old was diagnosed with a ductal",
            "be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria A first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer  "
        ],
        "premise_nums": [
            "under the age of 60 or multiple second degree relatives with breast cancer under the age of 60 or multiple second degree relatives",
            "breast cancer under the age of 60 or multiple second degree relatives with breast"
        ]
    },
    {
        "id": "02538194-97ac-4749-9301-83f108927478",
        "primaryId": "NCT00041067",
        "secondaryId": "NCT01273896",
        "statement_text": "Patients with ER positive  PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial ",
        "statement_nums": [
            "PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast cancer Metastasis to the ipsilateral supraclavicular lymph nodes allowed HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting No effusions or ascites as only sites of disease No primary or metastatic brain or central nervous system tumor Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin normal aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal: Not specified Cardiovascular: left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy) ",
            "No clinical evidence or history of cardiomyopathyOther: No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80 No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer  carcinoma in situ of the cervix  or other adequately treated stage I or II cancer currently in complete remission No known sensitivity to E  coli-derived proteins Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior anthracycline as adjuvant therapy allowed No prior cumulative dose of doxorubicin more than 360 mg/m^2 No prior cumulative dose of epirubicin more than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease No prior docetaxel No prior vinorelbine Prior paclitaxel allowed Endocrine therapy: Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed ",
            "No concurrent hormonal therapyRadiotherapy: At least 3 weeks since prior radiotherapy Surgery: At least 2 weeks since prior surgery and recovered Inclusion Criteria: Male and Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast cancer Metastatic or advanced stage breast cancer Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy) Patients with HER2+ disease must have received prior treatment with Trastuzumab Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeks Measurable disease by RECIST 1.1 Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL ",
            "Adequate hepatic function as defined by:Serum bilirubin 1.5 X upper limit of normal (ULN); Adequate renal function as defined by a serum creatinine 1.5 x ULN AST  ALT  and alkaline phosphatase 3 × ULN except for: Patients with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN Patients with Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with scheduled visits  treatment plans  laboratory tests  and other study procedures Female subjects of childbearing potential and males must agree to use adequate contraception (e.g.  hormonal or barrier method of birth control; abstinence) for the duration of study treatment Female subjects of childbearing age must have a negative serum pregnancy test at study entry  Exclusion Criteria: Surgery  radiotherapy  or lesion ablative procedure to the only area of measurable disease Major surgery within 4 weeks prior to first dose of STA-9090 ",
            "Poor peripheral venous access for study drug administration  Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g.  Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 50% at baseline Treatment with chronic immunosuppressants (e.g.  cyclosporine following transplantation) Women who are pregnant or lactating Uncontrolled intercurrent illness including  but not limited to  human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy  ongoing or active infection  symptomatic congestive heart failure  unstable angina pectoris  ventricular arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements Other medications  or severe acute/chronic medical or psychiatric condition  or laboratory abnormality that may increase the risk associated with study participation or study drug administration  or may interfere with the interpretation of study results in the judgment of the investigator Seizure disorder or requirement for seizure medication ",
            "Prior treatment with an HSP90 inhibitorpersistent adverse events of prior therapies that are greater than 1 grade 1 in severity history of or current coronary artery disease  myocardial infarction  angina pectoris  angioplasty or coronary bypass surgery history of or current uncontrolled dysrhythmias  or requirement for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea  orthopnea  or edema that requires current treatment with angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  beta blockers or diuretics "
        ],
        "premise_nums": [
            "1 Life expectancy of at least 3 months Adequate hematologic function as defined by:Serum bilirubin 1.5 X upper limit of normal (ULN); Adequate",
            "Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to first dose of STA-9090 Eastern Cooperative Oncology Group (ECOG) Performance Status",
            "serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with hepatic metastases: ALT and AST 5 × ULN Patients with hepatic",
            "angina pectoris  angioplasty or coronary bypass surgery",
            "Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of measurable disease Major surgery within 4 weeks prior to first dose",
            "Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than",
            "Polyethylene glycol [PEG] 300 and Polysorbate 80) Baseline QTc greater than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy",
            "Female patients must be at least 18 years of age Pathologically confirmed diagnosis of breast",
            "hormonal therapyRadiotherapy: At least 3 weeks since prior radiotherapy Surgery: At least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin normal aspartate",
            "therapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior anthracycline as",
            "hormonal therapy) Patients with HER2+ disease must have received prior treatment",
            "Prior treatment with an HSP90 inhibitorpersistent adverse events of prior therapies that are greater than 1 grade 1 in severity history of or",
            "as defined by a serum creatinine 1.5 x ULN AST  ALT  and",
            "of doxorubicin more than 360 mg/m^2 No prior cumulative dose of doxorubicin more than 360 mg/m^2 No prior cumulative dose",
            "defined by a serum creatinine 1.5 x ULN AST  ALT  and alkaline phosphatase 3 × ULN except for: Patients",
            "Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal: Not specified Cardiovascular: left",
            "expectancy of at least 3 months Adequate hematologic function as defined by: Absolute neutrophil count 1,500 cells/μL Platelets 100,000/μL Hemoglobin 9.0g/dL",
            "or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN) Alkaline",
            "Gilbert's disease: serum bilirubin smaller than 5 mg/dL Willingness and ability to comply with",
            "History of severe (grade 3 or 4) allergic or hypersensitivity reactions to",
            "therapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior treatment with an HSP90 inhibitorpersistent adverse events of prior therapies that",
            "Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of at least 3 months Adequate hematologic function as defined by:",
            "history of cardiomyopathyOther: No pre-existing grade 2 or greater motor or sensory peripheral neuropathy",
            "for antiarrhythmic medications  or Grade 2 or greater left bundle branch block New",
            "Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Life expectancy of epirubicin more than 720 mg/m^2 No more than 1 prior",
            "No concurrent hormonal therapyRadiotherapy: At least 3 weeks since prior radiotherapy Surgery: At least 2 weeks since prior surgery and recovered Inclusion",
            "DISEASE CHARACTERISTICS: Histologically confirmed stage IV breast",
            "anthracycline as adjuvant therapy allowed No prior cumulative dose of epirubicin more than 720 mg/m^2 No more than 1",
            "Baseline QTc greater than 470 msec Ventricular ejection fraction (EF) smaller than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy",
            "specified PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not",
            "supraclavicular lymph nodes allowed HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant",
            "than 720 mg/m^2 No more than 1 prior adjuvant or neoadjuvant chemotherapy: Not specified Chemotherapy: At least 6 months since prior chemotherapy Prior",
            "hepatic function as defined by:Serum bilirubin 1.5 X upper limit of measurable disease Major surgery within 4 weeks prior to first dose",
            "sites of disease No primary or metastatic brain or central",
            "specified Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin",
            "Female patients must be at least 18 years of age Pathologically confirmedications  or Grade 2 or greater left bundle branch block New",
            "hepatic function as defined by:Serum bilirubin 1.5 X upper limit of normal (ULN); Adequate"
        ]
    },
    {
        "id": "6d9113b4-9d18-4a1b-bc78-cc3ac1150876",
        "primaryId": "NCT01572038",
        "secondaryId": "NCT00826267",
        "statement_text": "Each patient in the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs ",
        "statement_nums": [
            "the primary trial receives 3 different drugs  whereas in the secondary trial patients receive 1 of 2 possible drugs"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Pertuzumab + Trastuzumab + Taxane Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end  unacceptable toxicity  withdrawal of consent  disease progression  or death  whichever occurred first  Taxane chemotherapy was docetaxel  paclitaxel  or nab-paclitaxel  per the investigator's choice  INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course  2 treatment courses were to be given in the trial  "
        ],
        "premise_nums": [
            "death  whichever occurred first  Taxane chemotherapy was docetaxel",
            "Afatinib 50 mg orally from Day 1 to Day 21 of eachemotherapy once of every 3 weeks per treatment cycle until predefined study",
            "plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study",
            "INTERVENTION 2: Lapatinib 1500 mg Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day",
            "INTERVENTION 1: Afatinib 50 mg Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day"
        ]
    },
    {
        "id": "99599b71-85d7-4c15-8d23-4294732f87cf",
        "primaryId": "NCT00558103",
        "statement_text": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD ",
        "statement_nums": [
            "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD)  INTERVENTION 2: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD  "
        ],
        "premise_nums": [
            "Pazopanib Placebo Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching",
            "lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD"
        ]
    },
    {
        "id": "adbc193f-ffd6-49ce-9acd-7b1675adf0c0",
        "primaryId": "NCT00768222",
        "statement_text": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan  she cannot take part in the primary trial ",
        "statement_nums": [
            "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan",
            "take part in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: 18 years of age or older with written informed consent Exclusion Criteria: Has inflammatory cancers or skin ulceration Has known allergy or intolerance to triclosan "
        ],
        "premise_nums": [
            "skin ulceration Has known allergy or intolerance to triclosan",
            "Inclusion Criteria: 18 years of age or older with written"
        ]
    },
    {
        "id": "c476f92a-a450-4e5c-9688-6557ff3d822b",
        "primaryId": "NCT01617668",
        "statement_text": "Patients must have healthy kidneys  liver and ovaries to participate in the primary trial ",
        "statement_nums": [
            "to participate in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed diagnosis of invasive triple negative breast cancer Known status for the LCL161 predictive gene expression signature as determined during molecular pre-screening Candidates for mastectomy or breast-conserving surgery Primary tumor of greater than 20 mm and less than or equal to 50 mm diameter measured by imaging (previous Amendment #3 was tumor size greater than 10 mm) Regional nodes N0-N2 Absence of distant metastatic disease ECOG performance status 0-1 Adequate bone marrow function Adequate liver function and serum transaminases Adequate renal function Exclusion Criteria: Bilateral or inflammatory breast cancer (bilateral mammography is required during Screening/baseline); locally recurrent breast cancer Patients currently receiving systemic therapy for any other malignancy  or having received systemic therapy for a malignancy in the preceding 3 months Uncontrolled cardiac disease Patients who are currently receiving chronic treatment (greater than 3 months) with corticosteroids at a dose 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed)  or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug Impaired GI function that may affect the absorption of LCL161 Pregnant or breast feeding (lactating) women ",
            "Women of child-bearing potential  defined as all women physiologically capable of becoming pregnant  unless they are using highly effective methods of contraception during dosing and for 180 days after study treatmentOther protocol-defined inclusion/exclusion criteria may apply "
        ],
        "premise_nums": [
            "surgery Primary tumor of greater than 20 mm and less than or equal to 50 mm diameter measured by imaging (previous Amendment",
            "10 mm) Regional nodes N0-N2 Absence of distant metastatic disease ECOG performance status 0-1 Adequate bone marrow function Adequate liver function",
            "currently receiving chronic treatment (greater than 3 months) with corticosteroids at a dose 10 mg of prednisone (or its glucocorticoid equivalent)",
            "Known status for the LCL161 predictive gene expression signature as determined during dosing and for 180 days after study treatmentOther protocol-defined inclusion/exclusion criteria",
            "potential  defined as all women physiologically capable of becoming",
            "affect the absorption of LCL161 Pregnant or breast feeding (lactating) women",
            "Inclusion Criteria: Histologically confirmed diagnosis of invasive",
            "for a malignancy in the preceding 3 months Uncontrolled cardiac disease Patients who are",
            "of contraception during dosing and for 180 days after study treatmentOther protocol-defined inclusion/exclusion criteria"
        ]
    },
    {
        "id": "39d685a4-b179-4687-a273-2a44e675f2c6",
        "primaryId": "NCT00900627",
        "statement_text": "The two groups in the primary trial receive the same drug treatment  but group 2 gets double the dose ",
        "statement_nums": [
            "two groups in the primary trial receive the same drug treatment  but group 2 gets double the dose"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle "
        ],
        "premise_nums": [
            "mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each",
            "weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931 120 mg bd Part",
            "INTERVENTION 1: AZD8931 160 mg bd Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8",
            "160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle INTERVENTION 2: AZD8931"
        ]
    },
    {
        "id": "c66963b9-19e0-4c0f-bb65-2fec15e60b8f",
        "primaryId": "NCT00965523",
        "statement_text": "The most common adverse events in the primary trial where Infection and Stomatitis  affecting a total of 14 patients ",
        "statement_nums": [
            "adverse events in the primary trial where Infection and Stomatitis  affecting a total of 14 patients"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) "
        ],
        "premise_nums": [
            "1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "(1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%)",
            "Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "14/81 (17.28%) Neutropenia1/81 (1.23%) Cataract1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81",
            "Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "Adverse Events 1: Total: 14/81 (17.28%) Neutropenia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Pyrexia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "(1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)",
            "Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%) Oedema1/81 (1.23%) Pain1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%) Malaise1/81 (1.23%)",
            "Infection2/81 (2.47%) Upper Limb Fracture1/81 (1.23%) Dehydration1/81 (1.23%) Hypercalcemia1/81 (1.23%) Ascites1/81 (1.23%) Gastritis Hemorrhagic1/81 (1.23%) Nausea1/81 (1.23%) Stomatitis2/81 (2.47%)"
        ]
    },
    {
        "id": "f541ce25-c43e-496b-98e6-8470fe23f840",
        "primaryId": "NCT00559845",
        "secondaryId": "NCT00426556",
        "statement_text": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial ",
        "statement_nums": [
            "were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%) Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: Total: 6/17 (35.29%) "
        ],
        "premise_nums": [
            "Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Postoperative Wound Complication",
            "Infection 1/54 (1.85%) Postoperative Wound Complication 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Adverse Events 1: Total: 3/6 (50.00%) Adverse Events 2: Total: 6/17 (35.29%)",
            "Adverse Events 1: Total: 8/54 (14.81%) Anaemia 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Febrile Infection 1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54",
            "(14.81%) Anaemia 1/54 (1.85%) Febrile Neutropenia 1/54 (1.85%) Retinopathy Hypertensive 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Cardiac Imaging Procedure Abnormal 1/54 (1.85%) Malignant Melanoma In",
            "1/54 (1.85%) Malignant Melanoma In Situ 1/54 (1.85%) Suicide Attempt 1/54 (1.85%) Dyspnoea 1/54 (1.85%)"
        ]
    },
    {
        "id": "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b",
        "primaryId": "NCT01224678",
        "statement_text": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "statement_nums": [
            "Intervention 2 of the primary trial resulted in a lower",
            "percentage in Mammographic Density than intervention 1."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women  The percent change in breast density will be reported here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description: Patients receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent change -3.4 (7.1) Results 2: Arm/Group Title: Vitamin D Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 40 Mean (Standard Deviation) Unit of Measure: percent change -1.4 (11.9) "
        ],
        "premise_nums": [
            "Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd",
            "receive oral placebo once daily for 12 months  Overall Number of Participants Analyzed: 46 Mean (Standard Deviation) Unit of Measure: percent",
            "here  Time frame: 12 months Results 1: Arm/Group Title: Placebo Arm/Group Description:",
            "receive oral vitamin D (2000 IU) once daily for 12 months  Overall Number of Participants Analyzed: 46"
        ]
    },
    {
        "id": "24d81b18-ce9c-4927-9386-9ebef969a159",
        "primaryId": "NCT00291135",
        "secondaryId": "NCT00291694",
        "statement_text": "The duration of treatment in the primary trial is half as long as in the secondary trial ",
        "statement_nums": [
            "of treatment in the primary trial is half as long as in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo daily for 12 months "
        ],
        "premise_nums": [
            "1: Letrozole Letrozole  2.5 mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib",
            "mg daily for six months INTERVENTION 1: Celecoxib Randomized to receive celecoxib daily for 12 months INTERVENTION 2: Placebo Randomized to receive placebo"
        ]
    },
    {
        "id": "e90f7748-f4b4-4822-8768-586c3f2f9980",
        "primaryId": "NCT00499083",
        "secondaryId": "NCT03045653",
        "statement_text": "In order to be eligible for both the secondary trial and the primary trial  patients must be female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 + breast cancer ",
        "statement_nums": [
            "female  over the age of 18, ECOG smaller than 2 and have Histologically confirmed HER2 + breast",
            "eligible for both the secondary trial and the primary trial  patients must be"
        ],
        "label": "Contradiction",
        "premise_text": [
            "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: - Female 18 years  70 years  ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed breast cancer(IHC:ER 60% and PR 60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection At least one evaluative focus according to RECIST creterion or non-measurable disease but only bone metastasis Adequate bone marrow and organ function Progressive disease whilst receiving endocrine therapy for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving endocrine therapy Radiological or objective clinical evidence of recurrence or progression on or after last systemic therapy prior to enrolment "
        ],
        "premise_nums": [
            "confirmation of metastatic or locally advanced disease not amenable",
            "metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at",
            "HER2/neu-negative tumor by IHC Female ECOG performance status 0-1 Inclusion Criteria: - Female 18 years",
            "progression on or after last systemic therapy prior to enrolment",
            "receptor-high expressed breast cancer(IHC:ER 60% and PR 60%) on primary tumour at diagnosis/on biopsy of",
            "70 years  ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confirmation of hormone receptor-high expressed",
            "of relapsed patients is more than 12 months Once received standard hormone treatment and"
        ]
    },
    {
        "id": "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86",
        "primaryId": "NCT00429572",
        "secondaryId": "NCT02455453",
        "statement_text": "post-menopausal patients are excluded from the secondary trial  but eligible for the primary trial ",
        "statement_nums": [
            "are excluded from the secondary trial  but eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Recurrent or residual metastatic breast carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor  No major organ dysfunction or active infection Exclusion Criteria: None Inclusion Criteria: Patient must be postmenopausal defined as meeting one or more of the following: "
        ],
        "premise_nums": [
            "carcinoma Zubrod performance status less than 2 18-60 years old Related donor human leukocyte antigen",
            "performance status less than 2 18-60 years old Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible"
        ]
    },
    {
        "id": "3c3fb5e3-1994-455a-bae4-6d267c5c89d7",
        "primaryId": "NCT00932373",
        "statement_text": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial ",
        "statement_nums": [
            "from participation in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Grade 2 peripheral neuropathy "
        ],
        "premise_nums": [
            "Exclusion Criteria: Grade 2 peripheral neuropathy"
        ]
    },
    {
        "id": "2ecd62df-f5ea-417d-8783-2174a6d77087",
        "primaryId": "NCT03573804",
        "secondaryId": "NCT02781051",
        "statement_text": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment  whereas in the secondary trial patients must use a fitbit ",
        "statement_nums": [
            "Participants of the primary trial must undergo at least one MRI during the intervention",
            "whereas in the secondary trial patients must use a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Prone to Supine MRI Evaluated by Radiologist A Radiologist A  number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated by Radiologist B Radiologist B  number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects were given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors  Topics covered within the book include benefits of exercise; recommendations on type  duration  frequency and intensity of exercise; goal-setting; and advice on overcoming barriers  Fitbit: Subjects were provided with a Fitbit and instructed to wear the device daily  Active Living counseling: The Active Living counseling program consists of 12 weekly group educational sessions  These sessions involved discussion of topics related to increasing physical activity  including: identifying and overcoming barriers  setting goals  and time management  Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills  stationary bikes  etc.)  "
        ],
        "premise_nums": [
            "Active Living counseling program consists of 12 weekly group educational sessions  These sessions",
            "number of participants successfully segmented INTERVENTION 1: Physical Activity Intervention Participants will",
            "a multi-component physical activity intervention for 12 weeks with a 6 month follow up  Print-based education: Subjects",
            "number of participants successfully segmented INTERVENTION 2: Prone to Supine MRI Evaluated"
        ]
    },
    {
        "id": "b43c02bf-c4b0-495f-b7ba-879f409cb685",
        "primaryId": "NCT01781299",
        "statement_text": "all subjects in the primary trial must commit to a regular exercise schedule ",
        "statement_nums": [
            "all subjects in the primary trial must commit to a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: AlloDerm RTU Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement  SurgiMend PRS "
        ],
        "premise_nums": [
            "expander placement  AlloDerm RTU INTERVENTION 2: SurgiMend PRS Participants within this"
        ]
    },
    {
        "id": "5ca02204-6120-4b02-bf3b-fba94d6fac4f",
        "primaryId": "NCT00274469",
        "statement_text": "No more than 1% of either cohorts of the primary trial felt nauseous ",
        "statement_nums": [
            "No more than 1% of either cohorts of the primary trial felt nauseous"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: NAUSEA 1/101 (0.99%) Adverse Events 2: NAUSEA 0/103 (0.00%)"
        ]
    },
    {
        "id": "625c2690-ec9e-4ecc-85c0-9b5ca8467848",
        "primaryId": "NCT00836186",
        "statement_text": "Patients cannot be excluded from the primary trial on the basis of gender or ethnicity ",
        "statement_nums": [
            "be excluded from the primary trial on the basis of"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INCLUSION CRITERIA: Women of all races and ethnic groups are eligible for this trial "
        ],
        "premise_nums": [
            "INCLUSION CRITERIA: Women of all races and ethnic groups are"
        ]
    },
    {
        "id": "c28ad685-4c91-492a-85ab-180f37d9cef5",
        "primaryId": "NCT00290758",
        "statement_text": "There was one GU and three GI adverse events recorded in the primary trial ",
        "statement_nums": [
            "events recorded in the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) renal - Other * 0/64 (0.00%) Obstruction  GU: Uterus * 0/64 (0.00%) Sexual * 1/64 (1.56%) Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) Ulceration * 0/64 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62"
        ]
    },
    {
        "id": "52e8d676-1744-4fdb-bab4-a553874329bd",
        "primaryId": "NCT00829166",
        "statement_text": "Female patients with Peripheral neuropathy greater than 0 are excluded from the primary trial ",
        "statement_nums": [
            "patients with Peripheral neuropathy greater than 0 are excluded from the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Peripheral neuropathy of Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)  Version 3.0 "
        ],
        "premise_nums": [
            "Grade greater than /= 3 per National Cancer Institute Common Terminology Criteria"
        ]
    },
    {
        "id": "beff8878-9405-412d-af3a-0f2720275bf3",
        "primaryId": "NCT00068601",
        "secondaryId": "NCT01684215",
        "statement_text": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions ",
        "statement_nums": [
            "the primary trial and the secondary trial both use subcutaneous injections"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Standard Chemotherapy Patients receive cyclophosphamide-containing chemotherapy alone  cyclophosphamide: Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy  Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity  cyclophosphamide: Part of planned chemotherapy regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent  INTERVENTION 2: PD-0332991 125 mg: Dose Escalation Cohort ",
            "In Phase 1-Part 1, participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of 28 days  unless participants experienced disease progression or unacceptable toxicity or withdrew consent "
        ],
        "premise_nums": [
            "oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg",
            "oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg",
            "regimen goserelin acetate: Given subcutaneously INTERVENTION 1: PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single oral dose",
            "period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily continuously for",
            "oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg",
            "Part of planned chemotherapy regimen INTERVENTION 2: Chemotherapy Plus Goserelin Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before",
            "capsule orally once daily continuously for 21 days followed by 7 days off treatment in each cycle of",
            "days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single",
            "PD-0332991 100 mg capsule orally once daily continuously for 21 days followed by 7 days off treatment in each",
            "days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg: Dose Escalation Cohort In Phase 1-Part 1, participants received single",
            "oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 125 mg"
        ]
    },
    {
        "id": "96f41881-6ba5-4688-8471-9462fc727919",
        "primaryId": "NCT00089661",
        "statement_text": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density  whereas those in cohort 2 lost mineral density ",
        "statement_nums": [
            "Density  whereas those in cohort 2 lost mineral density",
            "On average cohort 1 participants in the primary trial had an increased Lumbar"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry  Time frame: 12 months Results 1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1) "
        ],
        "premise_nums": [
            "Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent",
            "of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results 2: Arm/Group Title: Placebo",
            "1: Arm/Group Title: Denosumab 60 mg Q6M Arm/Group Description: [Not Specified] Overall Number of Participants Analyzed: 123",
            "Number of Participants Analyzed: 122 Least Squares Mean (95% Confidence Interval) Unit",
            "123 Least Squares Mean (95% Confidence Interval) Unit of Measure: Percent Change from Baseline 4.8 (4.3 to 5.4) Results",
            "Percent Change From Baseline at Month 12 Bone Mineral Density Assessed by Dual Energy"
        ]
    },
    {
        "id": "9dbf55d5-6af3-4250-b5cb-97799cdf778a",
        "primaryId": "NCT02370238",
        "statement_text": "There were no cases of Intracranial hemorrhage in the primary trial ",
        "statement_nums": [
            "Intracranial hemorrhage in the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%) ",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%) "
        ],
        "premise_nums": [
            "0/60 (0.00%) General physical health deterioration 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%)",
            "Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 0/61 (0.00%) Pericardial effusion 0/61",
            "Adverse Events 1: Total: 13/61 (21.31%) Anaemia 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2:",
            "neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%)",
            "(20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%)",
            "0/60 (0.00%) General physical health deterioration 1/60 (1.67%) Constipation 0/60 (0.00%) Intestinal perforation 0/60 (0.00%) Stomatitis 1/60 (1.67%)",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/60 (1.67%)",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) General physical health deterioration 1/60 (1.67%)",
            "Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60 (1.67%) Febrile neutropenia 0/60 (0.00%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General",
            "(21.31%) Anaemia 1/61 (1.64%) Febrile neutropenia 1/61 (1.64%) Cardiac failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%)",
            "(0.00%) Non-cardiac chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/60 (1.67%)",
            "failure congestive 1/60 (1.67%) Pericardial effusion 1/60 (1.67%) Constipation 0/60 (0.00%) Constipation 1/61 (1.64%) Intestinal perforation 1/61 (1.64%) Stomatitis 0/61 (0.00%)",
            "chest pain 2/61 (3.28%) Condition aggravated 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60",
            "failure congestive 0/61 (0.00%) Pericardial effusion 0/61 (0.00%) Constipation 1/61 (1.64%) General physical health deterioration 1/61 (1.64%) Adverse Events 2:",
            "Non-cardiac chest pain 0/60 (0.00%)Condition aggravated 0/60 (0.00%) General physical health deterioration 1/61 (1.64%) Adverse Events 2: Total: 12/60 (20.00%) Anaemia 1/60"
        ]
    },
    {
        "id": "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec",
        "primaryId": "NCT00338728",
        "statement_text": "Participants of the primary trial higher doses of Imatinib mesylate than Letrozole  but are administered Letrozole twice as often ",
        "statement_nums": [
            "Participants of the primary trial higher doses of Imatinib"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Letrozole and Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle  "
        ],
        "premise_nums": [
            "for 28 days and Letrozole 2.5 mg once a day daily for 28 days and Letrozole 2.5 mg once a day",
            "Imatinib Mesylate Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day",
            "mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28"
        ]
    },
    {
        "id": "d72709fd-e94e-4c27-bf56-3f028c0bbd3f",
        "primaryId": "NCT01118624",
        "statement_text": "The majority of the primary trial participants achieved CR or PR ",
        "statement_nums": [
            "The majority of the primary trial participants achieved CR or"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) Tumor response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients achieving a CR or PR is considered in the overall response  Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks)  or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended  Results 1: Arm/Group Title: Pralatrexate Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants 1 "
        ],
        "premise_nums": [
            "is considered in the overall response  Time frame: Assessed",
            "response evaluation was performed using RECIST 1.0 using CT/MRI  Proportion of patients",
            "Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks and nor more than every 12 weeks (+/- 1 week) if",
            "drug 190 mg/m^2 for 2 to 4 weeks  Overall Number of Participants Analyzed: 22 Measure Type: Number Unit of Measure: participants",
            "of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if"
        ]
    },
    {
        "id": "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b",
        "primaryId": "NCT00463788",
        "statement_text": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "statement_nums": [
            "Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Best Overall Response (BOR) Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST)  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and Cetuximab Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly  Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity  Overall Number of Participants Analyzed: 115 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin ",
            "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable toxicity or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2) "
        ],
        "premise_nums": [
            "reported between day of first participant randomized  20 June 2007, until cut-off date  31 July",
            "percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatintravenous (IV) infusion administered on Day 1 until every 3 weeks with",
            "Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 20.0 (13.1 to 28.5) Results 2: Arm/Group Title: Cisplatin",
            "Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV",
            "first participant randomized  20 June 2007, until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and",
            "Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD  unacceptable",
            "Evaluations were performed every 6 weeks until progression reported between day of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2",
            "disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly",
            "date  31 July 2009 Results 1: Arm/Group Title: Cisplatin and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly",
            "Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized  20 June",
            "or withdrawal of consent Overall Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage",
            "Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab",
            "Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until cut-off date  31 July 2009 Results 1: Arm/Group Title: Cisplatin",
            "Number of Participants Analyzed: 58 Measure Type: Number Unit of Measure: percentage of participants 10.3 (3.9 to 21.2)"
        ]
    },
    {
        "id": "49f44497-2382-4658-b716-38e66c5c52b7",
        "primaryId": "NCT00425854",
        "statement_text": "Intervention of Cohort B is described as Afatinib 50 mg  taken orally  for every day of the study ",
        "statement_nums": [
            "Cohort B is described as Afatinib 50 mg  taken orally  for every day"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd "
        ],
        "premise_nums": [
            "Cohort B Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd"
        ]
    },
    {
        "id": "4a6dc84a-3afd-4060-b8c5-981895f31099",
        "primaryId": "NCT00312208",
        "statement_text": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial ",
        "statement_nums": [
            "disorders were only observed in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%) Lymphadenopathy 0/1634 (0.00%) Lymphedema 0/1634 (0.00%) Pancytopenia 0/1634 (0.00%) Thrombocytopenia 0/1634 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) ",
            "Lymphedema 2/1635 (0.12%)Pancytopenia 1/1635 (0.06%) Thrombocytopenia 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "Adverse Events 1: Total: 331/1634 (20.26%) Anemia 3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 18/1634 (1.10%)",
            "(0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635",
            "3/1634 (0.18%) Coagulation disorders 1/1634 (0.06%) Hemorrhage Vaginal 1/1634 (0.06%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%)",
            "Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%) Lymphadenopathy 1/1635 (0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%)",
            "(0.06%) Arrhythmia 3/1635 (0.18%) Arrhythmia Ventricular 1/1635 (0.06%) Cardiomyopathy 0/1635 (0.00%) Arrhythmia 3/1634 (0.18%) Arrhythmia Ventricular 0/1634 (0.00%) Cardiomyopathy 1/1634 (0.06%)",
            "(0.00%) Cardiomyopathy 1/1634 (0.06%) Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia",
            "Adverse Events 2: Total: 520/1635 (31.80%) Anemia 5/1635 (0.31%) Coagulation disorders 0/1635 (0.00%) Hemorrhage Vaginal 0/1635 (0.00%) Leukopenia 56/1635 (3.43%)"
        ]
    },
    {
        "id": "f1f2e066-a016-422f-8627-d0e477933352",
        "primaryId": "NCT00193063",
        "statement_text": "In the primary trial patient cohort  3 different types of infections are observed ",
        "statement_nums": [
            "In the primary trial patient cohort  3 different types of infections are observed"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia 2/41 (4.88%) Infection - port site 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41 (7.32%) Confusion 1/41 (2.44%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 14/41 (34.15%) Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41",
            "(4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41 (2.44%) Infection - pneumonia",
            "Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Fever 2/41 (4.88%) Death NOS 1/41 (2.44%) Liver failure 1/41",
            "Cardiac ischemia/infarction 2/41 (4.88%) Duodenal ulcer 1/41 (2.44%) Vomiting 2/41 (4.88%) Infection - urinary tract 1/41 (2.44%) Disease progression 3/41"
        ]
    },
    {
        "id": "efbd87d7-f8ac-42c6-ac9a-e3a35d354885",
        "primaryId": "NCT00295867",
        "statement_text": "Patients with a Karnofsky status of 94% are eligible for the primary trial ",
        "statement_nums": [
            "Patients with a Karnofsky status of 94% are eligible for the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Exclusion Criteria Karnofsky Performance status smaller than 90%. "
        ],
        "premise_nums": [
            "Criteria Karnofsky Performance status smaller than 90%."
        ]
    },
    {
        "id": "a604244f-789f-4c12-8c5a-96c86d1b976e",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline ",
        "statement_nums": [
            "was a patient in the AZD0530 175 mg group  with a -75.9 % change from baseline",
            "Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) "
        ],
        "premise_nums": [
            "4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) Unit of",
            "Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage",
            "frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg once daily Overall Number of Participants Analyzed: 46",
            "Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of",
            "4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of",
            "Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants",
            "Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants"
        ]
    },
    {
        "id": "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97",
        "primaryId": "NCT01565083",
        "statement_text": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial ",
        "statement_nums": [
            "tachycardia occurred to patients in cohort 2 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%) "
        ],
        "premise_nums": [
            "Adverse Events 2: Supraventricular tachycardia * 1/107 (0.93%) Tachycardia * 1/107 (0.93%)"
        ]
    },
    {
        "id": "987b1da5-0276-417d-a659-8e298529ccac",
        "primaryId": "NCT01684215",
        "statement_text": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "statement_nums": [
            "In the primary trial there was no recorded",
            "Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 "
        ],
        "premise_nums": [
            "Limiting Toxicities (DLT): Part 1 Phase 1"
        ]
    },
    {
        "id": "0151d1fa-05c8-45a0-b21e-f08478ea5110",
        "primaryId": "NCT01697345",
        "secondaryId": "NCT00513292",
        "statement_text": "Fluorouracil  testosterone  and cyclophosphamide (FEC) are used in both cohorts of the secondary trial  but not in cohort 1 of the primary trial ",
        "statement_nums": [
            "both cohorts of the secondary trial  but not in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: FSFI Total Score (Pretest) Administered to participants prior to starting vaginal testosterone therapy  INTERVENTION 1: FEC-75 Then Paclitaxel/Trastuzumab ",
            "Patients receive Fluorouracil  epirubicin  and cyclophosphamide (FEC) comprising fluorouracil IV  epirubicin hydrochloride IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Beginning 21 days after completion of FEC  patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studiesINTERVENTION 2: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 ",
            "Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks  Beginning 7 days after the completion of paclitaxel and trastuzumab  patients receive FEC comprising fluorouracil IV  epirubicin IV  and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive trastuzumab IV once weekly for an additional 12 weeks  Within 6 weeks after completion of FEC and trastuzumab  patients undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab as in arm I  epirubicin hydrochloride: Given IV  cyclophosphamide: Given IV  paclitaxel: Given IV  trastuzumab: Given IV  therapeutic conventional surgery: Undergo surgery  laboratory biomarker analysis: Correlative studies"
        ],
        "premise_nums": [
            "and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses  Patients also receive",
            "IV once weekly for an additional 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of FEC and trastuzumab",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once weekly for 12 weeks  Beginning 7 days",
            "trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab",
            "laboratory biomarker analysis: Correlative studiesINTERVENTION 2: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75",
            "undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab (Herceptin) IV once weekly for 12 weeks  Within 6 weeks",
            "12 weeks  Within 6 weeks after completion of paclitaxel and trastuzumab IV once every 3 weeks for up to 52 weeks",
            "undergo surgery  Beginning 3-4 weeks after surgery  patients receive trastuzumab IV once every 3 weeks for up to 52 weeks",
            "patients receive trastuzumab IV once every 3 weeks for up to 52 weeks  epirubicin hydrochloride: Given"
        ]
    },
    {
        "id": "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de",
        "primaryId": "NCT01075100",
        "secondaryId": "NCT00290758",
        "statement_text": "several different mental health issues were observed in the primary trial and the secondary trial ",
        "statement_nums": [
            "were observed in the primary trial and the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%) ",
            "DEHYDRATION 0/53 (0.00%)DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) VOMITING 1/53 (1.89%) FEVER 1/53 (1.89%) RIGORS 1/53 (1.89%) Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) renal - Other * 1/62 (1.61%) Obstruction  GU: Uterus * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64 (0.00%) renal - Other * 0/64 (0.00%) Obstruction  GU: Uterus * 0/64 (0.00%) Sexual * 1/64 (1.56%) ",
            "Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)Ulceration * 0/64 (0.00%) "
        ],
        "premise_nums": [
            "NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "(0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53 (1.89%)",
            "Adverse Events 1: Total: 10/48 (20.83%) NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48",
            "Ulceration * 1/62 (1.61%) Adverse Events 2: Total: 1/64 (1.56%) Musculoskeletal * 0/64 (0.00%) Mood Alteration: Depression * 0/64",
            "DEHYDRATION 0/53 (0.00%)DIARRHEA 0/53 (0.00%) NAUSEA 1/53 (1.89%) RIGORS 1/53 (1.89%) Adverse Events 1: Total: 6/62 (9.68%) Musculoskeletal *",
            "(2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD",
            "Total: 5/53 (9.43%) NEUTROPENIA 1/53 (1.89%) THROMBOCYTOPENIA 1/53 (1.89%) VOLUME BLOOD DECREASED 0/53 (0.00%) FIBRILLATION ATRIAL 0/53 (0.00%) HYPOTENSION 0/53 (0.00%)",
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) RIGORS 0/48 (0.00%) Adverse Events 2: Total: 5/53 (9.43%) NEUTROPENIA 1/53",
            "6/62 (9.68%) Musculoskeletal * 1/62 (1.61%) Mood Alteration: Depression * 1/62 (1.61%) Sexual * 0/62 (0.00%) Pulmonary/Upper Respiratory: Dyspnea * 1/62",
            "Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)Ulceration * 0/64 (0.00%) HYPOTENSION 0/53 (0.00%) ABDOMINAL PAIN 0/53 (0.00%) APPETITE DECREASED 1/53",
            "DECREASED 0/48 (0.00%) DEHYDRATION 4/48 (8.33%) DIARRHEA 4/48 (8.33%) NAUSEA 3/48 (6.25%) VOMITING 2/48 (4.17%) FEVER 1/48 (2.08%) RIGORS 0/48",
            "BLOOD DECREASED 1/48 (2.08%) FIBRILLATION ATRIAL 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48",
            "NEUTROPENIA 1/48 (2.08%) THROMBOCYTOPENIA 0/48 (0.00%) VOLUME BLOOD DECREASED 1/48 (2.08%) HYPOTENSION 1/48 (2.08%) ABDOMINAL PAIN 1/48 (2.08%) APPETITE DECREASED 0/48"
        ]
    },
    {
        "id": "b838a265-99e4-42f0-bd72-b4f72d7eb16e",
        "primaryId": "NCT02027376",
        "statement_text": "A patient was treated with Pertuzumab for 6 months  and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects  hence this patient is eligible for the primary trial ",
        "statement_nums": [
            "this treatment was discontinued less than 1 month prior to study entry and the",
            "is eligible for the primary trial",
            "patient was treated with Pertuzumab for 6 months  and this treatment was discontinued less than 1 month prior to study entry"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Exclusion Criteria: Patients who have received biologic therapy (e.g  antibodies) 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy  "
        ],
        "premise_nums": [
            "therapy (e.g  antibodies) 4 weeks prior to starting study drug or"
        ]
    },
    {
        "id": "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21",
        "primaryId": "NCT00676793",
        "secondaryId": "NCT01931163",
        "statement_text": "Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial ",
        "statement_nums": [
            "eligible for both the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer requiring additional surgical resection Stage I  II or III disease Patient has ability to give signed informed consent Normal hepatic and renal function (creatininesmaller than 1.5, transaminases smaller than 1.5 times upper limit of normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy for breast cancer Abnormal liver function test Liver or kidney problems that would interfere with metabolism of study drug Any condition that would hamper informed consent or ability to comply with study protocol Participation in another research study in the last three months Known malignancy at any site other than breast Recent consumption of green tea (5 or more cups per day  within one week prior to biopsy) Allergy or intolerance to any component of green tea Inability or refusal to comply with definitive surgical therapy Inclusion Criteria: Able to swallow and retain oral medication  "
        ],
        "premise_nums": [
            "consumption of green tea (5 or more cups per day  within",
            "normal)  ECOG Performance status of 0 or 1. Age 21 years and less than 75 Exclusion Criteria: Prior hormonal or surgical therapy",
            "0 or 1. Age 21 years and less than 75 Exclusion Criteria: Definitive biopsy demonstrating primary breast cancer Residual breast cancer",
            "research study in the last three months Known malignancy at"
        ]
    },
    {
        "id": "f20cd859-7159-457a-a1cb-56bdb01d521b",
        "primaryId": "NCT00274456",
        "statement_text": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts ",
        "statement_nums": [
            "There are a total of 7 cases of Gastritis in the primary trial across both cohorts"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 1/76 (1.32%) ",
            "Bowel peristalsis increased 0/76 (0.00%)Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76 (0.00%) Nausea 1/76 (1.32%) "
        ],
        "premise_nums": [
            "neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy",
            "(18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Nausea 0/76 (0.00%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76",
            "Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure",
            "(0.00%) Nausea 0/76 (0.00%) Adverse Events 2: Total: 12/76 (15.79%) Neutropenia 2/76 (2.63%) Febrile neutropenia 1/76 (1.32%) Anaemia",
            "(0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 1/76 (1.32%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 1/76 (1.32%) Colitis 0/76 (0.00%)",
            "failure 0/76 (0.00%) Optic ischaemic neuropathy 0/76 (0.00%) Bowel peristalsis increased 0/76 (0.00%)Colitis 1/76 (1.32%) Diarrhoea 0/76 (0.00%) Gastritis 0/76",
            "(18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure 0/76 (0.00%) Optic ischaemic neuropathy",
            "Adverse Events 1: Total: 14/76 (18.42%) Neutropenia 10/76 (13.16%) Febrile neutropenia 1/76 (1.32%) Anaemia 0/76 (0.00%) Thrombocytopenia 0/76 (0.00%) Cardiopulmonary failure"
        ]
    },
    {
        "id": "d33df923-6c12-4135-b339-5cefdd240985",
        "primaryId": "NCT00003782",
        "statement_text": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects ",
        "statement_nums": [
            "the cohorts in the primary trial had more than 5% of patients experiencing side effects"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 66/1748 (3.78%) Adverse Events 2: Total: 43/1748 (2.46%)"
        ]
    },
    {
        "id": "0f49a1ec-ed73-465b-be20-b70fe990b1f0",
        "primaryId": "NCT00333775",
        "secondaryId": "NCT00201864",
        "statement_text": "There are several coagulative adverse events recorded in the primary trial  but not a single one in the secondary trial ",
        "statement_nums": [
            "events recorded in the primary trial  but not a",
            "single one in the secondary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) ",
            "Arteriospasm coronary 1/252 (0.40%)Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) "
        ],
        "premise_nums": [
            "first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40",
            "Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217",
            "Arteriospasm coronary 1/252 (0.40%)Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2:",
            "82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Atrioventricular block first degree 0/217 (0.00%) Cardiac failure 0/217",
            "(0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation 1/252 (0.40%) Arrhythmia 0/252 (0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first",
            "(2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%)",
            "Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217",
            "106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252 (0.40%) Atrial fibrillation",
            "Adverse Events 1: Total: 82/217 (37.79%) Febrile neutropenia 21/217 (9.68%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252 (0.00%) Thrombocytopenia 1/252",
            "(0.00%) Arrhythmia 1/217 (0.46%) Arteriospasm coronary 0/217 (0.00%) Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1:",
            "first degree 0/217 (0.00%) Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%)",
            "coronary 1/252 (0.40%)Atrioventricular block first degree 1/252 (0.40%) Cardiac failure 1/252 (0.40%) Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40",
            "Neutropenia 4/217 (1.84%) Leukopenia 0/217 (0.00%) Anaemia 1/217 (0.46%) Thrombocytopenia 0/217 (0.00%) Atrial fibrillation 0/217 (0.00%) Arrhythmia 1/217 (0.46%)",
            "Cardiac failure 0/217 (0.00%) Adverse Events 2: Total: 106/252 (42.06%) Febrile neutropenia 29/252 (11.51%) Neutropenia 13/252 (5.16%) Leukopenia 3/252 (1.19%) Anaemia 0/252"
        ]
    },
    {
        "id": "7370c10d-f6e7-4153-9649-9d2598ce1ed7",
        "primaryId": "NCT03196635",
        "secondaryId": "NCT01943916",
        "statement_text": "the primary trial and the secondary trial are both evaluating imaging techniques ",
        "statement_nums": [
            "the primary trial and the secondary trial are both evaluating imaging"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: All Study Participants  PA Compression Image Sets All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study Participants  TC Compression Image Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 1: Overall Population Each subject served as her own control  with imaging of each mass by both the test and control modalities  Specificity difference is a single measure for the overall ITD population  "
        ],
        "premise_nums": [
            "Sets All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two",
            "evaluated for acceptability of overall clinical image quality by two (2) readers  INTERVENTION 2: All Study"
        ]
    },
    {
        "id": "3f89537a-479e-4314-b9de-4caf845850fc",
        "primaryId": "NCT00558272",
        "statement_text": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a -73.0 % change from baseline ",
        "statement_nums": [
            "Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in",
            "4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group  with a"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage of the result at baseline  based on log transformed data  Back transformation of the least squares (LS) mean  Time frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4) Results 2: Arm/Group Title: Zoledronic Acid 4 mg Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of Measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2) "
        ],
        "premise_nums": [
            "4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 46 Geometric Mean (95% Confidence Interval) Unit of",
            "Type I Collagen (betaCTX) at Week 4 Result at Week 4 minus result at baseline as a percentage",
            "frame: Baseline to Week 4 Results 1: Arm/Group Title: AZD0530 175 mg once daily Overall Number of Participants Analyzed: 46",
            "Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of",
            "4 mg on Day 1 of the 4-week treatment period Overall Number of Participants Analyzed: 65 Geometric Mean (95% Confidence Interval) Unit of",
            "Results 1: Arm/Group Title: AZD0530 175 mg Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily Overall Number of Participants",
            "Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period Overall Number of Participants"
        ]
    },
    {
        "id": "8ba451be-606a-4a57-a85e-82b5e5b286fc",
        "primaryId": "NCT03366428",
        "statement_text": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms ",
        "statement_nums": [
            "from baseline in QTcF of over 30 ms",
            "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants Unit of Measure: Participants Maximum change from baseline in QTcF: greater than 30 ms: 3 6.1% Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0% "
        ],
        "premise_nums": [
            "QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer The",
            "3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title: DS-8201a Arm/Group Description: Participants who received",
            "(IV) infusion once every 3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49",
            "Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days)",
            "3 weeks on Day 1 of each 21-day cycle  Overall Number of Participants Analyzed: 49 Measure Type: Count of Participants Unit of",
            "greater than 30 ms: 3 6.1% Maximum change from baseline in QTcF: greater than 60 ms: 0 0.0%",
            "days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1: Arm/Group Title:"
        ]
    },
    {
        "id": "46906361-5133-4db9-b9e5-b9b7f80a8666",
        "primaryId": "NCT00721630",
        "secondaryId": "NCT00364611",
        "statement_text": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea ",
        "statement_nums": [
            "the primary trial and the secondary trial recorded the same proportion"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Nausea 1/23 (4.35%) Adverse Events 1: Nausea * 1/52 (1.92%)"
        ]
    },
    {
        "id": "3320983d-55cb-49f9-9265-ca4e77acf62a",
        "primaryId": "NCT01094184",
        "statement_text": "A patient who had a Joint injection in the last month would not be eligible for the primary trial ",
        "statement_nums": [
            "Joint injection in the last month would not be eligible for the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Inclusion Criteria: Histologically confirmed triple-negative (estrogen  progesterone  and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease Participant who in the Investigator's opinion requires combination therapy for their disease Life expectancy of greater than or equal to (greater than /=)12 weeks Exclusion Criteria: Previous chemotherapy for metastatic breast cancer Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain) Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment "
        ],
        "premise_nums": [
            "equal to (greater than /=)12 weeks Exclusion Criteria: Previous chemotherapy for metastatic",
            "surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of",
            "progesterone  and HER-2 receptor negative) adenocarcinoma of the breast in",
            "Inclusion Criteria: Histologically confirmed triple-negative (estrogen"
        ]
    },
    {
        "id": "6c57e451-a706-4b32-ae71-254e9d0e04de",
        "primaryId": "NCT01250379",
        "statement_text": "None of the patients in the primary trial had Thrombocytopenia  congestive Cardiac failure  Pancytopenia  Acute coronary syndrome or Atrial fibrillation ",
        "statement_nums": [
            "the patients in the primary trial had Thrombocytopenia  congestive"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute coronary syndrome * 0/238 (0.00%) Atrial fibrillation * 0/238 (0.00%) Cardiac failure congestive * 0/238 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Thrombocytopenia * 0/238 (0.00%) Pancytopenia * 0/238 (0.00%) Acute"
        ]
    },
    {
        "id": "83883edd-ea16-4b20-8a97-2a545f957add",
        "primaryId": "NCT00006110",
        "secondaryId": "NCT00464646",
        "statement_text": "the secondary trial records only gastrointestinal adverse events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI adverse events ",
        "statement_nums": [
            "the secondary trial records only gastrointestinal adverse",
            "events  whereas the primary trial doesn‚Äö√Ñ√¥t record any GI"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle weakness upper limb * 1/52 (1.92%) Dizziness * 1/52 (1.92%) Seizure * 1/52 (1.92%) Nervous system disorders - Other  specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%) Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle weakness upper limb * 0/30 (0.00%) Dizziness * 0/30 (0.00%) Seizure * 0/30 (0.00%) ",
            "Nervous system disorders - Other  specify * [1]0/30 (0.00%)Adverse Events 1: Total: 16/76 (21.05%) Hemoglobin 0/76 (0.00%) Left ventricular systolic function 1/76 (1.32%) Hypertension 0/76 (0.00%) Dehydration 1/76 (1.32%) Diarrhea 1/76 (1.32%) Hemorrhage  GI - stomach 0/76 (0.00%) Perforation  GI - colon 1/76 (1.32%) Ulcer  GI - stomach 0/76 (0.00%) Pain- head/headache 3/76 (3.95%) Pain- back 2/76 (2.63%) "
        ],
        "premise_nums": [
            "0/76 (0.00%) Left ventricular systolic function 1/76 (1.32%) Hypertension 0/76 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle",
            "specify * [1]1/52 (1.92%) Adverse Events 2: Total: 1/30 (3.33%) Febrile neutropenia (fever of unknown",
            "of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%)",
            "microbiologically documented infe * 0/52 (0.00%) Atrial Fibrillation * 1/52 (1.92%) Sepsis * 1/52 (1.92%) Muscle",
            "Other  specify * [1]0/30 (0.00%)Adverse Events 1: Total: 16/76 (21.05%) Hemoglobin 0/76 (0.00%) Left ventricular systolic function 1/76",
            "(3.33%) Atrial Fibrillation * 0/30 (0.00%) Sepsis * 0/30 (0.00%) Muscle",
            "0/76 (0.00%) Left ventricular systolic function 1/76 (1.32%) Hypertension 0/76 (0.00%) Pain- head/headache 3/76 (3.95%) Pain- back 2/76 (2.63%)",
            "Adverse Events 1: Total: 7/52 (13.46%) Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe"
        ]
    },
    {
        "id": "42d6a15e-fa43-4ebc-b627-70f4dd0233f8",
        "primaryId": "NCT00322374",
        "statement_text": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin ",
        "statement_nums": [
            "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days  "
        ],
        "premise_nums": [
            "INTERVENTION 1: Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV",
            "25 mg^m2 + Epirubicin 75 mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to",
            "IV infusion of 75 mg/m^2 epirubicin every 21 days  INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants",
            "mg^m2 Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin",
            "INTERVENTION 2: Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2 Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV"
        ]
    },
    {
        "id": "fc60c272-ceeb-47b5-b25b-dca832a2a57e",
        "primaryId": "NCT02203565",
        "secondaryId": "NCT00194779",
        "statement_text": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial ",
        "statement_nums": [
            "are used in the secondary trial and the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "INTERVENTION 1: Supportive Care (Dakin's Solution  Radiation Therapy) Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied topically radiation therapy: Undergo radiation therapy questionnaire administration: Ancillary studies laboratory biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant Therapy) See Detailed Description  doxorubicin hydrochloride: Given IV cyclophosphamide: Given PO paclitaxel: Given IV filgrastim: Given SC capecitabine: Given PO methotrexate: Given IV vinorelbine tartrate: Given IV needle biopsy: Correlative studies therapeutic conventional surgery: Undergo definitive breast surgery immunohistochemistry staining method: Correlative studies trastuzumab: Given IV tamoxifen citrate: Given PO letrozole: Given PO laboratory biomarker analysis: Correlative studies "
        ],
        "premise_nums": [
            "biomarker analysis: Optional correlative studies INTERVENTION 1: Treatment (Neoadjuvant Therapy  Adjuvant",
            "solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks  Dakin's solution: Applied"
        ]
    },
    {
        "id": "dfe1236f-ac29-4c1c-a287-6f46abb7703d",
        "primaryId": "NCT00810797",
        "secondaryId": "NCT00828074",
        "statement_text": "Skin infections were more common in patients in cohort 2 of the secondary trial  than in cohort 1 of the primary trial ",
        "statement_nums": [
            "more common in patients in cohort 2 of the secondary trial  than in cohort 1 of the primary trial"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 2: Skin infection * 0/5 (0.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Skin infection * 1/36 (2.78%) Adverse Events 2: Skin infection * 0/5 (0.00%)"
        ]
    },
    {
        "id": "b1060434-0f7c-4c4a-bcff-53c3124bb51e",
        "primaryId": "NCT02513472",
        "statement_text": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.",
        "statement_nums": [
            "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2."
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR) ORR was defined as percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) using independent imaging review (IIR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. BOR of CR and PR was confirmed by a subsequent CR assessment and CR or PR assessment  respectively at least 4 weeks later  CR: disappearance of all measurable  non-measurable lesions and no unequivocal new lesions  Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (smaller than ) 10 millimeter (mm)  PR: at least a 30 percent (%) decrease in sum of diameters (SOD) of target lesions  taking as reference the baseline SOD and there are no unequivocal new lesions  and no progression of non-target disease  The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson method  As planned  data up to the primary completion date only were analyzed  Time frame: From date of first dose of study drug administration to date of first documentation of disease progression or death  whichever occurred first (up to 3 years 11 months) Results 1: ",
            "Arm/Group Title: Stratum 1: Eribulin Mesylate + PembrolizumabArm/Group Description: Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression  development of unacceptable toxicity  participant request  withdrawal of consent  or study termination by the sponsor in Phase 2 in the Stratum 1. Overall Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum 2: Eribulin Mesylate + Pembrolizumab ",
            "Arm/Group Description: Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression  development of unacceptable toxicity  participant request  withdrawal of consent  or study termination by the sponsor in Phase 2 in the Stratum 2.Overall Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 21.8 (14.2 to 31.1) "
        ],
        "premise_nums": [
            "than (smaller than ) 10 millimeter (mm)  PR: at least a 30 percent (%) decrease in sum",
            "metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on",
            "data up to the primary completion date only were analyzed",
            "and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in  Phase 1b)",
            "Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum",
            "1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day",
            "non-target disease  The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson",
            "termination by the sponsor in Phase 2 in the Stratum 2.Overall Number of Participants Analyzed: 66 Measure Type: Number Unit of Measure: percentage",
            "1b) and then continued in each 21-days Treatment Cycles in the presence of",
            "Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy",
            "Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 21.8 (14.2 to 31.1)",
            "participants with confirmed best overall response (BOR) of complete response",
            "PR assessment  respectively at least 4 weeks later  CR: disappearance of all",
            "whichever occurred first (up to 3 years 11 months) Results 1:",
            "Number of Participants Analyzed: 101 Measure Type: Number Unit of Measure: percentage of participant 25.8 (15.8 to 38.0) Results 2: Arm/Group Title: Stratum",
            "Days 1 and 8 and pembrolizumab 200 mg  intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in"
        ]
    },
    {
        "id": "aed75656-1594-4d99-be42-7097f7926c18",
        "primaryId": "NCT00240071",
        "statement_text": "At least one participant of the primary trial died in under a 100 days ",
        "statement_nums": [
            "one participant of the primary trial died in under a 100 days"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Progression Free Survival (PFS) Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause  whichever occurs first  Time frame: From date of registration until disease progression or death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus Hormone Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256) "
        ],
        "premise_nums": [
            "previously were taking  Overall Number of Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days",
            "death  whichever occurs first Results 1: Arm/Group Title: Avastin (Bevacizumab) Plus",
            "patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well",
            "Participants Analyzed: 30 Median (95% Confidence Interval) Unit of Measure: days 125.5 (90 to 256)"
        ]
    },
    {
        "id": "6ce5a9d7-5793-43b0-92ed-980cca3be02b",
        "primaryId": "NCT01961544",
        "statement_text": "the primary trial reported a combined total of 3 cases of Pericardial effusion  Asthenia and Gastritis in cohort 1.",
        "statement_nums": [
            "a combined total of 3 cases of Pericardial effusion  Asthenia and Gastritis in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Pericardial effusion * 2/101 (1.98%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Pericardial effusion * 2/101 (1.98%) Gastritis * 1/101 (0.99%) Asthenia * 1/101 (0.99%)"
        ]
    },
    {
        "id": "b2a4f905-c6b5-4977-95de-5aa6424a5bb6",
        "primaryId": "NCT00217399",
        "statement_text": "To be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  there are no size boundaries for eligibility ",
        "statement_nums": [
            "be included in the primary trial  patients must have at least 1 unidimensionally measurable lesion  there are no"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Measurable disease  defined as greater than or equal 1 unidimensionally measurable lesion  including greater than or equal 1 of the following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal 10 mm on physical exam "
        ],
        "premise_nums": [
            "mm on CT scan (5 mm sections) Lesion greater than or equal 10 mm on CT scan (5 mm sections)",
            "CT scan or MRI (10 mm sections) Lesion greater than or equal 1 unidimensionally measurable lesion  including greater than",
            "sections) Lesion greater than or equal 20 mm on CT scan or MRI (10 mm sections) Lesion greater than or equal",
            "greater than or equal 1 of the following: Lesion greater than or equal 1 unidimensionally measurable lesion  including greater than",
            "mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or MRI (10",
            "following: Lesion greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal",
            "greater than or equal 10 mm on CT scan (5 mm sections) Lesion greater than or equal 20 mm on CT scan or",
            "mm on CT scan (5 mm sections) Lesion greater than or equal 1 of the following: Lesion greater than or"
        ]
    },
    {
        "id": "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4",
        "primaryId": "NCT00591851",
        "statement_text": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial ",
        "statement_nums": [
            "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Abdominal Pain 2/70 (2.86%) Diarrhea 21/70 (1.43%) Lower gastrointestinal hemorrhage 21/70 (1.43%) Nausea 21/70 (1.43%)"
        ]
    },
    {
        "id": "4db02d9b-d96e-4ced-947c-71cebcccc933",
        "primaryId": "NCT00847171",
        "secondaryId": "NCT01764022",
        "statement_text": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial ",
        "statement_nums": [
            "be eligible for the secondary trial",
            "are excluded from the primary trial but may still be"
        ],
        "label": "Entailment",
        "premise_text": [
            "No prior or currently active autoimmune disease* requiring management with systemic immunosuppression  including any of the following: Systemic lupus erythematosus Inclusion Criteria: Written informed consent and ability to follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC); Metastatic BC (stage IV according to TNM classification version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ; Documented results of oestrogen and progesterone receptors expression analysis; Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy - 20 weeks or more from the moment of randomization; Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone metastasis as the only measurable tumour are not eligible for the trial; ",
            "Patients of childbearing potential must implement reliable contraceptive measures during the study treatment  starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug Exclusion Criteria: Previous anticancer therapy for metastatic BC  including cytotoxic chemotherapy  or previous anticancer therapy with signal transduction inhibitors (e.g  lapatinib)  biological drugs (e.g  trastuzumab  bevacizumab)  experimental (not approved for BC therapy) anticancer drugs  Any previous hormonal therapy is allowed; Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC therapy; Surgery  radiation therapy  use of any experimental medications within 4 weeks (28 days) prior to randomization; Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor oil  hypersensitivity to dexamethasone  diphenhydramine  ranitidine/cimetidine  recombinant murine proteins  contrast agents or excipients of study medications; ",
            "BC metastases in central nervous system  progressing or clinically manifested (e.g  cerebral oedema  spinal cord injury)  with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to New York Heart Association (NYHA) classification  unstable angina pectoris  myocardial infarction) within 12 months prior to randomization; Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet  physical exercise); Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper limit of normal (ULN); Bilirubin level 1.5 × ULN; ",
            "Asparagine transferase (AST) and alanine transferase (ALT) levels 2.5 × ULN (5 × ULN for patients with liver metastases);Alkaline phosphatase level 5 × ULN; Pregnancy or lactation; Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening  except curatively treated intraductal carcinoma in situ  curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma; Conditions limiting patient's adherence to protocol requirements (dementia  neurologic or psychiatric disorders  drug addiction  alcoholism and others); Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; Concomitant participation in other clinical trials  previous participation in other clinical trials within 30 days before entering into the trial  previous participation in the same trial; Acute or active chronic infections; Hepatitis C virus  hepatitis B virus  HIV or syphilis infections; Obstacles in intravenous administration of study drugs "
        ],
        "premise_nums": [
            "treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;Cardiovascular system pathology (congestive",
            "patients with liver metastases);Alkaline phosphatase level 5 × ULN; Pregnancy or lactation;",
            "including contralateral breast cancer revealed within 5 years prior to screening  except curatively",
            "participation in other clinical trials within 30 days before entering into the trial",
            "ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper",
            "by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in",
            "myocardial infarction) within 12 months prior to randomization; Uncontrolled hypertension comprising",
            "size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm)  Patients having bone",
            "previous hormonal therapy is allowed; Disease progression within 6 months after adjuvant and/or neoadjuvant",
            "000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5 × upper limit of normal (ULN); Bilirubin level 1.5 × ULN;",
            "use of any experimental medications within 4 weeks (28 days) prior to randomization; Hypersensitivity",
            "Group (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy -",
            "follow the Protocol procedures; Age from 18 years to 75 years inclusive; Female gender; Histologically confirmed breast cancer (BC);",
            "despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental",
            "1 or 2, not increasing within 2 weeks prior to randomization; Life expectancy - 20 weeks or more from the moment of",
            "version 6); Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed",
            "Left ventricular ejection fraction smaller than 50% according to electrocardiography; Neutrophils 1500/mm3; Platelets 100 000/mm3; Hemoglobin 90 g/L; Creatinine level 1.5",
            "other clinical trials within 30 days before entering into the trial and until 6 months after the last administration of the"
        ]
    },
    {
        "id": "cfb07772-e485-491c-8ae3-9009e3d04415",
        "primaryId": "NCT00201864",
        "statement_text": "One patient in the primary trial had a WBC count far below normal ",
        "statement_nums": [
            "One patient in the primary trial had a WBC count"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%) Thromboembolism 2/40 (5.00%) "
        ],
        "premise_nums": [
            "Adverse Events 1: Total: 6/40 (15.00%) Nausea 1/40 (2.50%) Vomiting 1/40 (2.50%) Chest pain 1/40 (2.50%) Hypercalcemia 1/40 (2.50%)"
        ]
    },
    {
        "id": "a283b69c-0f36-4773-a711-9e6088a8ee63",
        "primaryId": "NCT01712009",
        "secondaryId": "NCT00343382",
        "statement_text": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine ",
        "statement_nums": [
            "Cohort 2 patients in the primary trial receive naproxen at the",
            "2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles  beginning on the day of pegfilgrastim administration  INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks  "
        ],
        "premise_nums": [
            "INTERVENTION 2: Pilocarpine 2 Times Per Day Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks",
            "a day (BID) for 5 days in each of the 4 cycles  beginning on the",
            "pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles",
            "INTERVENTION 2: Naproxen 500 mg BID Participants received adjuvant or neoadjuvant"
        ]
    },
    {
        "id": "8d90d538-3b56-48dd-bd58-007d266c923c",
        "primaryId": "NCT00915018",
        "statement_text": "The only cases of cardiac problems in the primary trial occurred in cohort 1.",
        "statement_nums": [
            "cardiac problems in the primary trial occurred in cohort 1."
        ],
        "label": "Contradiction",
        "premise_text": [
            "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234 (0.43%) Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) ",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%) "
        ],
        "premise_nums": [
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234",
            "Cardiac tamponade 0/234 (0.00%)Cardio-respiratory arrest 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%)",
            "ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234 (0.43%) Febrile neutropenia 0/234 (0.00%) Leukopenia 0/234 (0.00%) Neutropenia 0/234",
            "fibrillation 1/234 (0.43%) Cardiac failure congestive 0/234 (0.00%) Left ventricular dysfunction 1/234 (0.43%)",
            "failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2:",
            "(0.00%) Thrombocytopenia 1/234 (0.43%) Atrial fibrillation 1/234 (0.43%) Cardiac failure congestive 2/240 (0.83%) Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240",
            "neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240 (0.00%) Atrial fibrillation 0/240 (0.00%) Cardiac failure congestive",
            "Cardiac tamponade 1/240 (0.42%) Cardio-respiratory arrest 1/240 (0.42%) Left ventricular dysfunction 0/240 (0.00%) Adverse Events 2: Total: 56/234 (23.93%) Anaemia 1/234",
            "Adverse Events 1: Total: 67/240 (27.92%) Anaemia 0/240 (0.00%) Febrile neutropenia 1/240 (0.42%) Leukopenia 2/240 (0.83%) Neutropenia 1/240 (0.42%) Thrombocytopenia 0/240"
        ]
    },
    {
        "id": "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421",
        "primaryId": "NCT00904033",
        "secondaryId": "NCT03592121",
        "statement_text": "Patients are not required to be sexually active to receive the primary trial intervention  this is however a requirement for the secondary trial ",
        "statement_nums": [
            "not required to be sexually active to receive the primary trial intervention  this is",
            "a requirement for the secondary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: No Exercise Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting of progressive walking and resistance band training Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise INTERVENTION 1: AB-101 Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity Placebo: Apply approximately 1 hour prior to sexual activity "
        ],
        "premise_nums": [
            "hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply",
            "Apply to both nipple/areola regions approximately 1 hour prior to sexual activity INTERVENTION 2: Placebo Apply to both nipple/areola",
            "Apply to both nipple/areola regions approximately 1 hour prior to sexual activity AB-101: Apply approximately 1 hour prior to sexual activity",
            "pill taken once per week INTERVENTION 2: Exercise Exercise Arm: Exercise consisting"
        ]
    },
    {
        "id": "f6c64bb3-1836-4685-8541-8856f003524b",
        "primaryId": "NCT01105312",
        "statement_text": "Patients with non-measurable diseases are only eligible for phase I of the primary trial ",
        "statement_nums": [
            "phase I of the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for phase II study "
        ],
        "premise_nums": [
            "study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for"
        ]
    },
    {
        "id": "79272218-91b9-4331-ba44-6a3709a13f62",
        "primaryId": "NCT00073528",
        "secondaryId": "NCT00191152",
        "statement_text": "the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants  however they use different Units of Measure ",
        "statement_nums": [
            "the secondary trial and the primary trial study the Progression Free"
        ],
        "label": "Entailment",
        "premise_text": [
            "Outcome Measurement: Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator Measure Type: Count of Participants Unit of Measure: Participants 89 82.4% Outcome Measurement: Time to Disease Progression (Initial Treatment) Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79) "
        ],
        "premise_nums": [
            "the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast",
            "Progression (Initial Treatment) Median (95% Confidence Interval) Unit of Measure: months 9.28 (7.73 to 10.79)",
            "Participants Unit of Measure: Participants 89 82.4% Outcome Measurement: Time to Disease Progression",
            "Unit of Measure: Participants 89 82.4% Outcome Measurement: Time to Disease Progression (Initial Treatment) Median (95% Confidence Interval) Unit of Measure: months"
        ]
    },
    {
        "id": "97e3b0d7-3320-4eb5-bc42-5031db87692e",
        "primaryId": "NCT01964924",
        "secondaryId": "NCT00524303",
        "statement_text": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients ",
        "statement_nums": [
            "the primary trial and the secondary trial both report Objective Response"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Objective Response Rate (ORR)  Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy ",
            "A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed)  A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus)  Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes  26 weeks of therapy comprised the 2-week run-in phase  12 weeks of treatment with FEC  and 12 weeks of treatment with Paclitaxel Time frame: Week 26 "
        ],
        "premise_nums": [
            "(CR)  Disappearance of all target lesions; Partial Response (PR)  greater than or equal 30% decrease in the sum of",
            "PR  Time frame: 6 months Outcome Measurement: Percentage of Participants With",
            "(RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib",
            "Complete Response (pCR) After 26 Weeks of Therapy",
            "greater than or equal 30% decrease in the sum of therapy comprised the 2-week run-in phase  12 weeks of",
            "(PR)  greater than or equal 30% decrease in the sum of the"
        ]
    },
    {
        "id": "83251670-803e-4fec-a5cf-50f052932752",
        "primaryId": "NCT00708214",
        "statement_text": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group ",
        "statement_nums": [
            "with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s) on bone scan or on magnetic resonance imaging; Progression or occurrence of new lesion(s) according to the Response Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at 2 consecutive examinations; occurrence of disease-related skeletal events  If a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD according to the Investigator  they were considered as having PD  Time frame: 16 weeks Results 1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole ",
            "Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression Overall Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71) "
        ],
        "premise_nums": [
            "Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New",
            "Progression Free Participants After 16 Weeks of Treatment Progression was defined according to 1 of the following criteria: New bone lesion(s)",
            "Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment",
            "Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib",
            "further disease progression  Overall Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage",
            "Number of Participants Analyzed: 13 Measure Type: Number Unit of Measure: Percentage of participants 0.00 (0.00 to 24.71)",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of Progression Free Participants After 16 Weeks of Treatment Progression was",
            "Evaluation Criteria In Solid Tumours version 1.0 (RECIST); an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline",
            "50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression  Overall Number of Participants Analyzed: 7",
            "1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 40 mg therapy with letrozole 2.5",
            "1: Arm/Group Title: Afatinib 50 mg With Letrozole Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5",
            "an increase in tumour marker CA 15.3 of more than 20 percent,compared with baseline  at",
            "Number of Participants Analyzed: 7 Measure Type: Number Unit of Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib",
            "Measure: Percentage of participants 28.57 (3.67 to 70.96) Results 2: Arm/Group Title: Afatinib 40 mg With Letrozole"
        ]
    },
    {
        "id": "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de",
        "primaryId": "NCT01610284",
        "statement_text": "1 patient in the primary trial had an abrupt loss of heart function ",
        "statement_nums": [
            "1 patient in the primary trial had an abrupt loss"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 146/573 (25.48%) Anaemia 4/573 (0.70%) Disseminated intravascular coagulation 0/573 (0.00%) Neutropenia 1/573 (0.17%) Thrombocytopenia 0/573 (0.00%) Acute coronary syndrome 1/573 (0.17%) Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 0/570 (0.00%) ",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) "
        ],
        "premise_nums": [
            "Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%)",
            "Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial",
            "(0.53%) Disseminated intravascular coagulation 1/570 (0.18%) Neutropenia 1/570 (0.18%) Thrombocytopenia 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570",
            "flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial",
            "Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570 (0.53%) Disseminated intravascular",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573",
            "Angina pectoris 1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573",
            "Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573 (0.17%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570",
            "1/573 (0.17%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial fibrillation 2/573 (0.35%) Atrial flutter 0/573 (0.00%) Cardiac arrest 1/573",
            "(0.18%) Acute coronary syndrome 0/570 (0.00%) Angina pectoris 1/570 (0.18%) Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 1/570 (0.18%)",
            "Atrial flutter 1/570 (0.18%)Cardiac arrest 0/570 (0.00%) Cardiac failure 0/573 (0.00%) Adverse Events 2: Total: 101/570 (17.72%) Anaemia 3/570"
        ]
    },
    {
        "id": "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a",
        "primaryId": "NCT01256567",
        "secondaryId": "NCT01926886",
        "statement_text": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "statement_nums": [
            "adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease"
        ],
        "label": "Entailment",
        "premise_text": [
            "Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected lymphocele * 1/101 (0.99%) Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%) "
        ],
        "premise_nums": [
            "Ejection fraction decreased * 5/101 (4.95%) Lymphoedema * 1/101 (0.99%)",
            "lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac",
            "lung disease 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101 (7.92%) Vertigo * 1/101 (0.99%) Infected",
            "1: Total: 7/7 (100.00%) Febrile neutropenia 3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Muscular weakness 1/7",
            "3/7 (42.86%) Cardiac failure 1/7 (14.29%) Neutrophil count decreased 1/7 (14.29%) Pleural effusion 2/7 (28.57%) Adverse Events 1: Total: 8/101",
            "count decreased 1/7 (14.29%) Muscular weakness 1/7 (14.29%) Epistaxis 1/7 (14.29%) Interstitial lung disease 1/7 (14.29%) Pleural effusion 2/7"
        ]
    },
    {
        "id": "97812fde-57f3-4299-be34-dd436757adde",
        "primaryId": "NCT00093795",
        "statement_text": "Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial ",
        "statement_nums": [
            "collarbone cannot enter the primary trial"
        ],
        "label": "Entailment",
        "premise_text": [
            "Inclusion Criteria: By pathologic evaluation  ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)  "
        ],
        "premise_nums": [
            "node dissection and with more than 3 positive axillary lymph nodes)"
        ]
    },
    {
        "id": "4fef4cdf-53bf-4239-9d31-4710fd3edc6f",
        "primaryId": "NCT01605396",
        "statement_text": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months ",
        "statement_nums": [
            "Exemestane group of the primary trial had a median PFS of over 38.43 months"
        ],
        "label": "Contradiction",
        "premise_text": [
            "Outcome Measurement: 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) PFS was defined as the time from randomization to progressive disease  or death  whichever occurs first  Response was assessed according to RECIST 1.1 by BICR  According to RECIST 1.1, progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions  taking as reference the nadir SOD and an absolute increase of greater than 5 mm in the SOD  or the appearance of new lesions  PFS was analyzed using the Kaplan-Meier method and median PFS (95% confidence interval [CI]) in weeks was reported for each treatment arm  Per protocol  participants remained on assigned treatment until disease progression  Participants who discontinued study treatment for reasons other than disease progression continued to be assessed by imaging until objective documentation of progression  All participants (including participants who discontinued study treatment) were followed for survival until investigator notification to discontinue  Time frame: From Day 1 through last post-study efficacy follow-up (up to ~19 months) Results 1: ",
            "Arm/Group Title: Ridaforolimus + Dalotuzumab + ExemestaneArm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity  Overall Number of Participants Analyzed: 40 Median (95% Confidence Interval) Unit of Measure: Weeks 23.29 (8.71 to 38.43) "
        ],
        "premise_nums": [
            "Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on",
            "an absolute increase of greater than 5 mm in the SOD  or the",
            "discontinue  Time frame: From Day 1 through last post-study efficacy follow-up (up to",
            "Participants Analyzed: 40 Median (95% Confidence Interval) Unit of Measure: Weeks 23.29 (8.71 to 38.43)",
            "(IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or",
            "mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus",
            "disease (PD) was defined as a 20% relative increase in the sum of",
            "death  whichever occurs first  Response was assessed according to RECIST 1.1 by BICR  According to RECIST 1.1,",
            "+ ExemestaneArm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously",
            "method and median PFS (95% confidence interval [CI]) in weeks was defined as a 20% relative increase in the sum of"
        ]
    },
    {
        "id": "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b",
        "primaryId": "NCT00181363",
        "statement_text": "The only difference between the interventions used in the primary trial is the patients position ",
        "statement_nums": [
            "interventions used in the primary trial is the patients position"
        ],
        "label": "Entailment",
        "premise_text": [
            "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position "
        ],
        "premise_nums": [
            "INTERVENTION 1: Prone Prone position INTERVENTION 2: Supine Supine position"
        ]
    }
]